UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)
x

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2018

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to
Commission file number 1-3619

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

13-5315170
(I.R.S. Employer Identification Number)

235 East 42nd Street New York, New York
(Address of principal executive offices)

10017
(Zip Code)

(212) 733-2323
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Stock, $.05 par value
Floating Rate Notes due 2019
0.000% Notes due 2020
0.250% Notes due 2022
1.000% Notes due 2027

Name of each exchange on which registered
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange
New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes   x
    No   o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes  o
     No   x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x
No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)    Yes   x
   No   o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to
the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   x

Accelerated filer   o

Non-accelerated filer   o

Smaller reporting company   o

Emerging growth company   o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   o
    No   x
The aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s
most recently completed second fiscal quarter, July 1, 2018 , was approximately $212 billion . This excludes shares of common stock held by directors and executive officers at
July 1, 2018 . Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the
direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting
common stock.
The number of shares outstanding of the registrant’s common stock as of February 26, 2019 was 5,551,804,790 shares of common stock, all of one class.

Portions of the 2018 Annual Report to Shareholders

Portions of the Proxy Statement for the 2019 Annual Meeting of Shareholders

Parts I, II and IV

Part III

DOCUMENTS INCORPORATED BY REFERENCE

TABLE OF CONTENTS

PART I

ITEM 1. BUSINESS

About Pfizer

Available Information and Pfizer Website

Commercial Operations

Innovative Health

Essential Health

Collaboration and Co-Promotion Agreements

Research and Development

International Operations

Marketing

Patents and Other Intellectual Property Rights

Competition

Raw Materials

Government Regulation and Price Constraints

Environmental Matters

Tax Matters

Employees

Disclosure Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012

ITEM 1A. RISK FACTORS

ITEM 1B. UNRESOLVED STAFF COMMENTS

ITEM 2. PROPERTIES

ITEM 3. LEGAL PROCEEDINGS

ITEM 4. MINE SAFETY DISCLOSURES

EXECUTIVE OFFICERS OF THE COMPANY

PART II

ITEM  5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES

ITEM 6. SELECTED FINANCIAL DATA

ITEM  7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9A. CONTROLS AND PROCEDURES

ITEM 9B. OTHER INFORMATION

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 11. EXECUTIVE COMPENSATION

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

15(a)(1) Financial Statements

15(a)(2) Financial Statement Schedules

15(a)(3) Exhibits

ITEM 16. FORM 10-K SUMMARY

Pfizer Inc. 2018 Form 10-K i

Page

1

1

1

1

2

3

3

4

4

4

5

6

6

8

8

8

8

9

9

10

25

25

25

25

26

27

27

27

27

27

27

28

28

28

29

29

29

29

29

29

30

30

30

30

30

33

DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2018 Form 10-K (defined below) refer to Pfizer Inc. and its
subsidiaries. We also have used several other terms in this 2018 Form 10-K, most of which are explained or defined below.

2018 Financial Report

Exhibit 13 to this 2018 Form 10-K

2018 Form 10-K

This Annual Report on Form 10-K for the fiscal year ended December 31, 2018

2019 Proxy Statement

Proxy Statement for the 2019 Annual Meeting of Shareholders

ACA

ACIP

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

Advisory Committee on Immunization Practices

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Anacor

ANDA

Astellas

Anacor Pharmaceuticals, Inc.

Abbreviated New Drug Application

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Bain Capital

Bain Capital Private Equity and Bain Capital Life Sciences

BLA

BMS

Cerevel

cGMPs

DEA

Biologics License Application

Bristol-Myers Squibb Company

Cerevel Therapeutics, LLC

current Good Manufacturing Practices

U.S. Drug Enforcement Agency

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New Zealand

EFPIA

EH

EMA

Emerging Markets

EU

Exchange Act

FCPA

FDA

FFDCA

GPD

GSK

HIS

Hospira

ICU Medical

IH

IPR&D

LIBOR

LOE

MCO

Medivation

NDA

NMPA

NYSE

OTC

PBM

PGS

PMDA

R&D

SEC

European Federation of Pharmaceutical Industries and Associations

Essential Health

European Medicines Agency

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe,
Africa, the Middle East, Central Europe and Turkey

European Union

Securities Exchange Act of 1934, as amended

U.S. Foreign Corrupt Practices Act

U.S. Food and Drug Administration

U.S. Federal Food, Drug and Cosmetic Act

Global Product Development organization

GlaxoSmithKline plc

Hospira Infusion Systems

Hospira, Inc.

ICU Medical, Inc.

Innovative Health

In-process Research and Development

London Interbank Offered Rate

Loss of Exclusivity

Managed Care Organization

Medivation, Inc.

New Drug Application

National Medical Product Administration (formerly known as China Food and Drug Administration or CFDA)

New York Stock Exchange

over-the-counter

Pharmacy Benefit Manager

Pfizer Global Supply

Pharmaceuticals and Medical Device Agency in Japan

Research and Development

U.S. Securities and Exchange Commission

Tax Cuts and Jobs Act

Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

U.K.

U.S.

VAI

WRD

United Kingdom

United States

Voluntary Action Indicated

Worldwide Research and Development

Pfizer Inc. 2018 Form 10-K ii

~$53.6 Billion   in Revenues in 2018

10   Products with Direct Product and/or Alliance Revenues of
Greater than $1 Billion in 2018

2  Distinct Business Segments in 2018 —

Pfizer Innovative Health ( ~$33.4 Billion 2018 Revenues ) / Pfizer Essential Health ( ~$20.2
Billion 2018 Revenues )

6  Primary Therapeutic Areas in Pfizer Innovative Health in 2018

—
Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and
Consumer Healthcare

4  Pfizer Essential Health Product Categories in 2018  —

Global Brands (Legacy Established Products & Peri-LOE Products) , Sterile Injectable
Pharmaceuticals, Biosimilars and Pfizer CentreOne

>125  Countries Where We Sell Our Products

100   Projects in Clinical Research & Development*

~$8 Billion  2018 R&D Expense

58  Manufacturing Sites Worldwide Operated by PGS

~92,400   Employees Globally

Unless indicated otherwise, the information contained in this summary is as of December 31, 2018 .
This summary does not include information that will be incorporated by reference into Part III of
this 2018 Form 10-K from our 2019 Proxy Statement.
* As of January 29, 2019

Pfizer Inc. 2018 Form 10-K iii

TABLE OF CONTENTS

ITEM 1.

BUSINESS

 ABOUT PFIZER

PART I

Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and
significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and
vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local
communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a
much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us . The majority of our
revenues come from the manufacture and sale of biopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June
2, 1942.

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also
from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We
continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat
disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and
contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our
company’s purpose: Breakthroughs that change patients’ lives . By doing so, we expect to create value for the patients we serve and for our shareholders.

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through
various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions,
mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance
shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities.

Our significant recent business development activities include:

•

•

•

•

•

On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our
respective consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer
Healthcare name. The joint venture is expected to be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health,
skin health and therapeutic oral health and will be the largest global OTC consumer healthcare business. In exchange for contributing our Consumer
Healthcare business, we will receive a 32% equity stake in the company and GSK will own the remaining 68%. The transaction is expected to close in
the second half of 2019, subject to customary closing conditions including GSK shareholder approval and required regulatory approvals.

On February 3, 2017, we completed the sale of Pfizer’s global infusion systems net assets, HIS, to ICU Medical for up to approximately $900 million ,
composed of cash and contingent cash consideration, ICU Medical common stock and seller financing . HIS, which was acquired as part of the Hospira
acquisition in September 2015, includes intravenous pumps, solutions and devices.

On December 22, 2016, for $1,040 million we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives
business, primarily outside the U.S. , which includes the marketed products Zavicefta™ (ceftazidime-avibactam), Merrem™/Meronem™ (meropenem)
and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam and ceftaroline fosamil-avibactam.

On September 28, 2016, we acquired Medivation for approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Medivation is a
biopharmaceutical company focused on developing and commercializing small molecules for oncology.

On June 24, 2016, we acquired Anacor for approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed.
Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform.

For a further discussion of our strategy and our business development initiatives, see the Notes to Consolidated Financial Statements— Note 2 . Acquisitions,
Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method
Investments and Privately Held Investment and the Overview of Our Performance, Operating Environment, Strategy and Outlook — Our Strategy and — Our
Business Development Initiatives sections in our 2018 Financial Report.

Our businesses are heavily regulated in most of the countries in which we operate. In the U.S., the principal authority regulating our operations is the FDA. The
FDA regulates the safety and efficacy of the products we offer and our research, quality, manufacturing processes, product promotion, advertising and product
labeling. Similar regulations exist in most other countries, and in many countries the government also regulates our prices. In the EU, the EMA conducts the
scientific evaluation, supervision and safety monitoring of our products, and employs a centralized procedure for approval of medicines for the EU and the
European Economic Area countries. In China, the NMPA (formerly CFDA) is the primary regulatory authority for approving and supervising medicines. In Japan,
the PMDA is involved in a wide range of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. Health
authorities in many middle and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of the FDA or
EMA) before they begin to conduct their application review process and/or issue their final approval. For additional information, see the Item 1. Business —
Government Regulation and Price Constraints section below.

Note: Some amounts in this 2018 Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts.

AVAILABLE INFORMATION AND PFIZER WEBSITE

Our website is located at www.pfizer.com . This 2018 Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments
to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format
and, where applicable, in interactive data file format , as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.

Throughout this 2018 Form 10-K, we “incorporate by reference” certain information from other documents filed or to be filed with the SEC, including our 2019
Proxy Statement and the 2018 Financial Report, portions of which are filed as Exhibit 13 to this 2018 Form 10-K, and which also will be contained in Appendix A
to our 2019 Proxy Statement. The SEC allows us to disclose important information by referring to it in that manner. Please refer to this information. Our 2018
Annual Report to Shareholders consists of the 2018 Financial Report and the Corporate and Shareholder Information attached to the 2019 Proxy Statement. Our
2018 Financial Report will be available on our website on or about February 28, 2019. Our 2019 Proxy Statement will be available on our website on or about
March 14, 2019.

We may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure
promulgated by the SEC. These disclosures are included on our website in the “Investors” or “News” sections. Accordingly, investors should monitor these
portions of our website, in addition to following Pfizer’s press releases, SEC filings, public conference calls and webcasts, as well as Pfizer’s social media
channels (Pfizer’s Facebook, YouTube and LinkedIn pages and Twitter accounts ( @Pfizer and @Pfizer_News )).

Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on
Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business
Conduct and Ethics for Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; Board
Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on our
website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New
York, NY 10017. We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief
Executive Officer, Chief Financial Officer and Controller on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules.
Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, is
also available on our website.

The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts does not, and shall not be deemed to, constitute
a part of this 2018 Form 10-K. Pfizer’s references to the URLs for websites are intended to be inactive textual references only.

Pfizer Inc. 2018 Form 10-K 1

TABLE OF CONTENTS

COMMERCIAL OPERATIONS

From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through two distinct business segments: Pfizer
Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments were each led by a single manager. Each operating segment had
responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that
generally have achieved proof-of-concept. Each business had a geographic footprint across developed and emerging markets.

At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each of
which is led by a single manager—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Consumer Healthcare. We designed this new global structure to
take advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets.

Some additional information about each business follows:

•

•

•

Pfizer Biopharmaceuticals Group - a science-based Innovative Medicines business that includes our Innovative Health business units (except Consumer
Healthcare) as well as a new Hospital business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We also
incorporated our biosimilar portfolio into our Oncology and Inflammation & Immunology therapeutic areas;

Upjohn - an off-patent branded and generic established medicines business headquartered in China that includes 20 of our off-patent solid oral dose legacy
brands, including Lyrica , Lipitor , Norvasc, Viagra and Celebrex , as well as certain generic medicines; and

Consumer Healthcare - an over-the-counter medicines business, which we announced on December 19, 2018 will be contributed to, and combined with,
GSK’s consumer healthcare business to form a new consumer healthcare joint venture.

Results for 2018 and prior periods in our 2018 Form 10-K are reported on the basis under which we managed our businesses in 2018 and do not reflect the
2019 reorganization. Beginning with our first-quarter 2019 financial results, our financial reporting will reflect the new organizational structure.

For additional information regarding our new global structure, as well as our Organizing for Growth initiative, see the Overview of Our Performance, Operating
Environment, Strategy and Outlook––Our Strategy––Organizing for Growth section in our 2018 Financial Report.

Some additional information about our business segments as of December 31, 2018 (prior to our new 2019 commercial organizational re-alignment) follows:

IH focused on developing and commercializing novel, value-creating
medicines and vaccines that significantly improve patients’ lives, as well as
products for consumer healthcare.

Key therapeutic areas included internal medicine, vaccines, oncology,
inflammation & immunology, rare disease and consumer healthcare.

EH included legacy brands that have lost or will soon lose market
exclusivity in both developed and emerging markets, branded generics,
generic sterile injectable products, biosimilars and select branded products
including anti-infectives. EH also included an R&D organization, as well as
our contract manufacturing business. Through February 2, 2017, EH also
included HIS.

Leading brands included:
- Prevnar 13/Prevenar 13
- Xeljanz
- Eliquis
- Lyrica (U.S., Japan and certain other markets)
- Enbrel (outside the U.S. and Canada)
- Ibrance
- Xtandi
- Chantix/Champix
- Several OTC consumer healthcare products
(e.g., Centrum  and Advil )

Leading brands included:
- Lipitor
- Norvasc
- Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries)
- Celebrex
- Viagra*
- Inflectra/Remsima
- Sulperazon
- Several sterile injectable products

* Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH

(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.

Pfizer Inc. 2018 Form 10-K 2

Vaccines

Oncology

Inflammation and
Immunology

Rare Disease

Consumer Healthcare*

TABLE OF CONTENTS

For a further discussion of these operating segments, see the Innovative Health and Essential Health sections below and the Notes to Consolidated Financial
Statements— Note 18. Segment, Geographic and Other Revenue Information , including the tables therein captioned Selected Income Statement Information ,
Geographic Information and Significant Product Revenues , the table captioned Revenues by Segment and Geography in the Analysis of the Consolidated
Statements of Income section, and the Analysis of Operating Segment Information section in our 2018 Financial Report, which are incorporated by reference.

INNOVATIVE HEALTH

The key therapeutic areas comprising our IH business segment included:

Therapeutic Area

Description

Key Products

Internal Medicine

Included innovative brands from two therapeutic areas,
Cardiovascular Metabolic and Pain, as well as regional brands.

Lyrica  (outside Europe, Russia, Turkey, Israel and Central
Asia countries), Chantix/Champix  and  Eliquis  (jointly
developed and commercialized with BMS)

Prevnar 13/Prevenar 13 (pediatric/adult), Trumenba and
FSME-IMMUN

Included innovative vaccines brands across all ages—infants,
adolescents and adults—in pneumococcal disease, meningitis
and tick-borne encephalitis, with a pipeline focus on healthcare-
acquired infections and maternal health.

Included innovative oncology brands of biologics, small
molecules and immunotherapies across a wide range of
cancers.

Ibrance, Sutent, Xalkori, Inlyta  and Xtandi (jointly
developed and commercialized with Astellas)

Included innovative brands for chronic immune and
inflammatory diseases.

Enbrel  (outside the U.S. and Canada), Xeljanz  and
Eucrisa

Included innovative brands for a number of rare diseases,
including hematology, neuroscience, and inherited metabolic
disorders.

Included over-the-counter (OTC) brands with a focus on dietary
supplements, pain management, gastrointestinal and
respiratory and personal care. In 2018, according to Nicholas
Hall’s retail sales data (based on moving annual total data
through the third quarter of 2018), Pfizer’s Consumer
Healthcare business was the fifth-largest branded multi-
national, OTC consumer healthcare business in the world and
produced two of the ten largest selling consumer healthcare
brands (Centrum and Advil) in the world.

BeneFix , Genotropin  and Refacto AF/Xyntha

Dietary Supplements: Centrum  brands, Caltrate  and
Emergen-C

Pain Management: Advil  brands and ThermaCare

Gastrointestinal: Nexium 24HR/Nexium Control  and
 Preparation H

Respiratory and Personal Care: Robitussin , Advil Cold &
Sinus and ChapStick

* On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer

healthcare businesses into a new consumer healthcare joint venture, which will operate globally under the GSK Consumer Healthcare name. Assets and liabilities
associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. We expect to complete
the transaction during the second half of 2019, subject to customary closing conditions, including GSK shareholder approval and required regulatory approvals. For
additional information, see the Notes to Consolidated Financial Statements— Note 2 C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing
Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Assets and Liabilities Held for Sale
.

We recorded direct product and/or alliance revenues of more than $1 billion for each of eight IH products in 2018 , and seven IH products in 2017 and 2016 :

2018

2017

2016

Prevnar 13/Prevenar 13

Prevnar 13/Prevenar 13

Prevnar 13/Prevenar 13

Innovative Health $1B+ Products

Lyrica IH

Ibrance

Eliquis*

Enbrel

Xeljanz

Chantix/Champix

Sutent

Lyrica IH

Ibrance

Eliquis*

Enbrel

Xeljanz

Sutent

Lyrica IH

Enbrel

Ibrance

Eliquis*

Viagra IH

Sutent

* Eliquis  includes alliance revenues and direct sales in 2018, 2017 and 2016.

For a discussion of certain IH products and additional information regarding the revenues of our IH business, including revenues by geography and of significant
IH products, see the Notes to Consolidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Information and the Analysis of the
Consolidated Statements of Income — Revenues — Overview, — Revenues by Segment and Geography and — Revenues—Selected Product Discussion
sections in our 2018 Financial Report; and for additional information on the key operational revenue drivers of our IH business, see the Analysis of Operating
Segment Information — Innovative Health Operating Segment section of our 2018 Financial Report. For a discussion of the risks associated with our
dependence on certain of our major products, see Item 1A. Risk Factors — Dependence on Key In-Line Products below.

ESSENTIAL HEALTH

The product categories in our EH business segment included:

Product Category

Description

Global Brands — Legacy
Established Products

Included products that have lost patent protection (excluding
Sterile Injectable Pharmaceuticals and Peri-LOE Products).

Global Brands —
Peri-LOE Products

Included products that have recently lost or are anticipated to
soon lose patent protection.

Sterile Injectable
Pharmaceuticals

Biosimilars

Included generic injectables and proprietary specialty
injectables (excluding Peri-LOE Products).

Included recombinant and monoclonal antibodies, primarily in
inflammation, oncology and supportive care.

Key Products

Lipitor , Premarin  family and Norvasc

Lyrica (Europe, Russia, Turkey, Israel and Central Asia),
Viagra* , Celebrex , Pristiq , Zyvox , Vfend , Revatio  and
Inspra

Medrol , Sulperazon , Fragmin  and Tygacil

Inflectra / Remsima  (biosimilar infliximab) (U.S., Canada,
the EU, Australia and certain international markets),
Nivestim/Nivestym  (biosimilar filgrastim) (U.S. and certain
European, Asian and Africa/Middle East markets), Retacrit
 (biosimilar epoetin alfa-epbx/epoetin zeta) (U.S. and
certain European and Africa/Middle East markets) and Ixifi
Infliximab BS for I.V. Infusion 100mg (Japan)

Pfizer CentreOne

Included revenues from our contract manufacturing and active
pharmaceutical ingredient sales operation, including sterile
injectables contract manufacturing, and revenues related to our
manufacturing and supply agreements, including with Zoetis
Inc.

--

* Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH

(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.

We recorded direct product revenues of more than $1 billion for two EH products in 2018 , one EH product in 2017 , and two EH products in 2016 :

2018

Lipitor

Norvasc

Essential Health $1B+ Products

2017

Lipitor

2016

Lipitor

Premarin family of products

For a discussion of certain EH products and additional information regarding the revenues of our EH business, including revenues by geography and of
significant EH products, see the Notes to Consolidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Information and the Analysis
of the Consolidated Statements of Income — Revenues — Overview, — Revenues by Segment and Geography and — Revenues—Selected Product
Discussion sections in our 2018 Financial Report; and for additional information on the key operational revenue drivers of our EH business, see the Analysis of
Operating Segment Information — Essential Health Operating Segment section of our 2018 Financial Report. For a discussion of the risks associated with our
dependence on certain of our major products, see Item 1A. Risk Factors — Dependence on Key In-Line Products below.

Pfizer Inc. 2018 Form 10-K 3

TABLE OF CONTENTS

COLLABORATION AND CO-PROMOTION AGREEMENTS

We are party to collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including, among others, Eliquis , Xtandi and
Bavencio . Revenues from Eliquis (except in certain markets where we have direct sales) , Xtandi and Bavencio are included in alliance revenues.

Eliquis has been jointly developed and is being commercialized in collaboration with BMS. Pfizer funds between 50% and 60% of all development costs
depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS
compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus
a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant market; the agents in this class were developed
as alternative treatment options to warfarin in appropriate patients.

Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to
U.S. net sales of Xtandi . Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market.
In addition, Pfizer and Astellas share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international
Xtandi net sales (recorded in Other (Income)/Deductions––Net ). Xtandi is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor
signaling pathway within tumor cells.

Bavencio (avelumab) is being developed and commercialized in collaboration with Merck KGaA. Both companies jointly fund the majority of development and
commercialization costs, and split equally any profits generated from selling any products containing avelumab from this collaboration. Bavencio is currently
approved in metastatic Merkel cell carcinoma and for patients with locally advanced or metastatic urothelial carcinoma in certain countries and in development
as a potential treatment for multiple other types of cancer.

RESEARCH AND DEVELOPMENT

Innovation is critical to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. Our goal is to
discover, develop and bring to market innovative products that address major unmet medical needs.

Our R&D Priorities and Strategy

Our R&D priorities include:
•

delivering a pipeline of differentiated therapies and vaccines with the greatest medical and commercial potential;

•
•

advancing our capabilities that can position Pfizer for long-term leadership; and
creating new models for biomedical collaboration that will expedite the pace of innovation and productivity.

To that end, our research and development primarily focuses on:
•

Inflammation and Immunology ;

•
•
•

•
•

Internal Medicine ;
Oncology ;
Rare Diseases ;

Vaccines ; and
Biosimilars.

In January 2018, we announced our decision to end internal neuroscience discovery and early development efforts and re-allocate funding to other areas where
we have stronger scientific leadership. The development of tanezumab and potential treatments for rare neuromuscular disorders is not impacted by this
decision. In June 2018, we announced our plan to invest up to $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, our
venture investment vehicle. In September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to
continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, including
Parkinson’s disease, epilepsy, Alzheimer’s disease, schizophrenia and addiction. For additional information on the transaction with Bain Capital, see the Notes
to Consolidated Financial Statements–– Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and
Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Divestitures in our 2018 Financial Report.

While a significant portion of R&D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies
developed by third parties to incorporate into our discovery and development processes or projects, as well as our product lines, by entering into collaboration,
alliance and license agreements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us
to co-develop, license or acquire promising compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees to
fund a portion of the development costs of one or more of our pipeline products in exchange for rights to receive potential milestone payments, revenue sharing
payments, profit sharing payments and/or royalties. Collaboration, alliance, license and funding agreements and equity- or debt-based investments allow us to
share risk and cost and to access external scientific and technological expertise, and provide us the opportunity to advance our own products as well as the in-
licensed or acquired products.

Our R&D Operations

We conduct R&D internally and also through contracts with third parties, through collaborations with universities and biotechnology companies and in
cooperation with other pharmaceutical firms. In 2018, we continued to strengthen our global R&D organization and pursue strategies intended to improve
innovation and overall productivity in R&D to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time.

Our R&D spending in 2018 was conducted through a number of matrix organizations:
•

Research Units within our WRD organization were generally responsible for research and early-stage development assets for our IH business (assets that
have not yet achieved proof-of-concept).

•

•

Our R&D organization within the EH business supported the large base of EH products and helped develop potential new sterile injectable drugs and
therapeutic solutions, as well as biosimilars.

Our Global Product Development organization, a unified center for late-stage development for our innovative products that was generally responsible for the
operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in the Innovative portfolio. For WRD

assets, GPD worked in close collaboration with the Early Clinical Development group, which has expertise in various disciplines such as Biostatistics,
Clinical Pharmacology and Digital Medicine.

•

Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurred, provided technical expertise and
other services to the various R&D projects, and were organized into science-based functions (which were part of our WRD organization), such as
Pharmaceutical Sciences, Medicine Design, Regulatory and Drug Safety, and non-science-based functions, such as Facilities, Business Technology and
Finance.

At the beginning of 2019, we reorganized our R&D operations as part of our Organizing for Growth reorganization:

• WRD is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical & Safety organization that

incorporates the former Chief Medical Office as well as the Worldwide Safety function;
The R&D organization within the EH business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars into
WRDM and GPD and realigning them with the relevant therapeutic areas (e.g., Oncology and Inflammation & Immunology);

The Regulatory function has been moved from the WRDM organization into the GPD organization; and

Late-stage portfolio spend has been moved from IH to GPD and from EH to GPD and Upjohn.

•

•

•

For discussion regarding these R&D matrix organizations and additional information on our R&D operations and expenses, see the Overview of Our
Performance, Operating Environment, Strategy and Outlook — Our Strategy — Description of Research and Development Operations and Costs and Expenses
— Research and Development (R&D) Expenses sections in our 2018 Financial Report.

Our R&D Pipeline and Competition

The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the
continued strength of our businesses. Drug candidates can fail at any stage of the process, and candidates may not receive regulatory approval even after many
years of research and development. The process from discovery to development to regulatory approval can take more than ten years.

As of January 29, 2019 , we had the following number of projects in various stages of R&D:

Development of a single compound is often pursued as part of multiple programs. While these drug candidates may or may not eventually receive regulatory
approval, new drug candidates entering clinical development phases are the foundation for future products. In addition to discovering and developing new
products, our R&D efforts seek to add value to our existing products by improving their effectiveness, enhancing ease of dosing and by discovering potential new
indications for them.

Information concerning several of our drug candidates in development, as well as supplemental filings for existing products, is set forth in the Analysis of the
Consolidated Statements of Income — Product Developments––Biopharmaceutical section in our 2018 Financial Report, which is incorporated by reference.

Our competitors also devote substantial funds and resources to R&D. We also compete against numerous small biotechnology companies in developing
potential drug candidates. The extent to which our competitors are successful in their research could result in erosion of the sales of our existing products and
potential sales of products in development, as well as unanticipated product obsolescence. In addition, several of our competitors operate without large R&D
expenses and make a regular practice of challenging our product patents before their expiration. For additional information, see the Competition and Item 1A.
Risk Factors — Competitive Products sections below.

INTERNATIONAL OPERATIONS

We have significant operations outside the U.S. In 2018, operations in developed and emerging markets were managed through our two business segments: IH
and EH. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics
and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets.
Urbanization in emerging markets, particularly in Asia, is creating additional access opportunities for our medicines.

We sell our products in over 125 countries. Revenues from operations outside the U.S. of $28.3 billion accounted for 53% of our total revenues in 2018 . By total
revenues, China and Japan are our two largest national markets outside the U.S. For a geographic breakdown of revenues, see the table captioned Geographic
Information in the Notes to Consolidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Information in our 2018 Financial Report,
and the Analysis of the Consolidated Statements of Income — Revenues — Overview and — Revenues by Segment and Geography sections in our 2018
Financial Report.

Pfizer Inc. 2018 Form 10-K 4

TABLE OF CONTENTS

Our international operations are subject, in varying degrees, to a number of risks inherent in carrying on business in other countries, including, among other
things, currency fluctuations, capital and exchange control regulations and expropriation and other restrictive government actions. See Item 1A. Risk Factors —
International Operations below. Our international businesses are also subject to government-imposed constraints, including laws and regulations on pricing,
reimbursement, and access to our products. See Item 1. Business — Government Regulation and Price Constraints — Outside the United States below for a
discussion of these matters.

Depending on the direction of change relative to the U.S. dollar, foreign currency values can increase or decrease the reported dollar value of our net assets and
results of operations. While we cannot predict with certainty future changes in foreign exchange rates or the effect they will have on us, we attempt to mitigate
their impact through operational means and by using various financial instruments, depending upon market conditions. For additional information, see the Notes
to Consolidated Financial Statements— Note 7 F . Financial Instruments : Derivative Financial Instruments and Hedging Activities in our 2018 Financial Report,
as well as the Forward-Looking Information and Factors That May Affect Future Results — Financial Risk Management section in our 2018 Financial Report.
Those sections of our 2018 Financial Report are incorporated by reference.

MARKETING

In our global biopharmaceutical businesses, we promote our products to healthcare providers and patients. Through our marketing organizations, we explain the
approved uses, benefits and risks of our products to healthcare providers, such as doctors, nurse practitioners, physician assistants and pharmacists; MCOs that
provide insurance coverage, such as hospitals, Integrated Delivery Systems, Pharmacy Benefit Managers and health plans; and employers and government
agencies who hire MCOs to provide health benefits to their employees. We also market directly to consumers in the U.S. through direct-to-consumer advertising
that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have meaningful conversations with their doctors. In
addition, we sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues, and our patient
assistance programs.

Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and
pharmacies, and, in the case of our vaccines products in the U.S., we primarily sell directly to the U.S. Centers for Disease Control and Prevention, wholesalers,
individual provider offices, retail pharmacies, and integrated delivery networks. We seek to gain access for our products on healthcare authority and PBM
formularies, which are lists of approved medicines available to members of the PBMs. PBMs use various benefit designs, such as tiered co-pays for formulary
products, to drive utilization of products in preferred formulary positions. We may also work with payers to assist them with disease management, patient
education and other tools that help their medical treatment routines.

In 2018 , our top three biopharmaceutical wholesalers accounted for approximately 37% of our total revenues (and approximately 76% of our total U.S.
revenues).

% of 2018 Total Revenues and U.S. Revenues from
Major Biopharmaceutical Wholesalers and Other Customers

Our global Consumer Healthcare business uses its own sales and marketing organizations to promote its products, and occasionally uses distributors and
agents, principally in smaller markets. The advertising and promotions for our Consumer Healthcare business are generally disseminated to consumers through
television, print, digital and other media advertising, as well as through in-store promotion. Consumer Healthcare products are sold through a wide variety of
channels, including distributors, pharmacies, retail chains and grocery and convenience stores. Our Consumer Healthcare business generates a significant
portion of its sales from several large customers, the loss of any one of which could have a material adverse effect on the Consumer Healthcare business.

Pfizer Inc. 2018 Form 10-K 5

TABLE OF CONTENTS

PATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS

Our products are sold around the world under brand-name, logo and certain product design trademarks that we consider, in the aggregate, to be of material
importance to Pfizer. Trademark protection continues in some countries for as long as the mark is used and, in other countries, for as long as it is registered.
Registrations generally are for fixed, but renewable, terms.

We own or license a number of U.S. and foreign patents. These patents cover pharmaceutical and other products and their uses, pharmaceutical formulations,
product manufacturing processes and intermediate chemical compounds used in manufacturing.

Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries
where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends upon the type of patent, the
scope of its coverage and the availability of legal remedies in the country. Further, patent term extension may be available in many major countries to
compensate for a regulatory delay in approval of the product. For additional information, see Item 1. Business — Government Regulation and Price Constraints
— Outside the United States — Intellectual Property below.

In various markets, a period of regulatory exclusivity may be provided to certain therapeutics upon approval. The scope and term of such exclusivity will vary but,
in general, the period of regulatory exclusivity will run concurrently with the term of any existing patent rights associated with the therapeutic.

In the aggregate, our patent and related rights are of material importance to our businesses in the U.S. and most other countries. Based on current product
sales, and considering the vigorous competition with products sold by our competitors, the patent rights we consider most significant in relation to our business
as a whole, together with the year in which the basic product patent expires (including, where applicable, the additional six-month pediatric exclusivity period
and/or the granted patent term extension), are those for the medicines set forth in the table below. Unless otherwise indicated, the years set forth in the table
below pertain to the basic product patent expiration for the respective products. Patent term extensions, supplementary protection certificates and pediatric
exclusivity periods are not reflected in the expiration dates listed in the table below, unless they have been granted by the issuing authority. In some instances,
there are later-expiring patents relating to our products directed to particular forms or compositions, to methods of manufacturing, or to use of the drug in the
treatment of particular diseases or conditions. However, in some cases, such patents may not protect our drug from generic or, as applicable, biosimilar
competition after the expiration of the basic patent.

Drug

Lyrica

Chantix/Champix

Sutent

Ibrance

Inlyta

Xeljanz

Prevnar 13/Prevenar 13

Eucrisa

Eliquis (7)

Xtandi (8)

Besponsa

Xalkori

Bavencio (10)

U.S. Basic Product Patent
Expiration Year

Major EU Basic Product Patent
Expiration Year

Japan Basic Product Patent
Expiration Year

2019 (1)

2020

2021

2023

2025

2025

2026

2026

2026

2027

2027

2029

2033

2014 (2)

2021

2021

2028

2025

2028 (4)

2026 (5)

N/A (6)

2026

* (8)

2023

2027

2032

2022 (3)

2022

2024

2028

2025

2025

2029

N/A (6)

2026

* (8)

2028 (9)

2028

2033

(1)   In November 2018, the FDA granted pediatric exclusivity for Lyrica in the U.S. for an additional six months to June 2019; pediatric exclusivity applies to both the basic

product patent for Lyrica and a method of treatment patent, both of which expired in the U.S. in December 2018.

(2)   Lyrica regulatory exclusivity in the EU expired in July 2014.
(3)   Lyrica is covered by a Japanese method-of-use patent which expires in 2022. The patent is currently subject to an invalidation action.
(4)   Xeljanz EU expiry is provided by regulatory exclusivity.
(5)   The EU patent that covers the combination of the 13 serotype conjugates of Prevenar 13 has been revoked following an opposition proceeding. This first instance decision
has been appealed. There are other EU patents and pending applications covering the formulation and various aspects of the manufacturing process of Prevenar 13 that
remain in force.

(6)   Eucrisa is not approved in the EU or Japan.
(7)   Eliquis was developed and is being commercialized in collaboration with BMS.
(8)   Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S.
(9)   Besponsa Japan expiry is provided by regulatory exclusivity.
(10)  Bavencio is being developed and commercialized in collaboration with Merck KGaA.

A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For
additional information, including further discussion of our products experiencing, or expected to experience in 2019 , patent expirations or loss of regulatory
exclusivity in the U.S., Europe or Japan, see the Overview of Our Performance, Operating Environment, Strategy and Outlook — Our Operating Environment —
Industry-Specific Challenges — Intellectual Property Rights and Collaboration/Licensing Rights section in our 2018 Financial Report and Item 1A. Risk Factors
— Dependence on Key In-Line Products below.

Companies have filed applications with the FDA seeking approval of product candidates that such companies claim do not infringe our patents; these include
candidates that would compete with, among other products, Eliquis , Xeljanz and Xtandi . We also are often involved in other proceedings, such as inter partes
review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign
counterparts relating to our intellectual property or the intellectual property rights of others. For additional information, see the Notes to Consolidated Financial
Statements— Note 17 A1 . Contingencies and Certain Commitments — Legal Proceedings––Patent Litigation in our 2018 Financial Report.

The expiration of a basic product patent or loss of patent protection resulting from a legal challenge normally results in significant competition from generic
products against the originally patented product and can result in a significant reduction in revenues for that product in a very short period of time. In some
cases, however, we can continue to obtain commercial benefits from product manufacturing trade secrets; patents on uses for products; patents on processes
and intermediates for the economical manufacture of the active ingredients; patents for special formulations of the product or delivery mechanisms; or
conversion of the active ingredient to OTC products.

Biologic Products

Our biologic products, including BeneFIX , ReFacto , Xyntha , Bavencio , Prevnar 13/Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada),
may face in the future, or already face, competition from biosimilars (also referred to as follow-on biologics). In the U.S., such biosimilars would reference our
originator biologic products approved under the U.S. Public Health Service Act. Additionally, the FDA has approved a follow-on recombinant human growth
hormone that referenced our biotechnology product, Genotropin , that was approved under the FFDCA.

Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacy
and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives to
biologic medicines. Abbreviated legal pathways for the approval of biosimilars exist in certain international markets and, since the passage of the ACA in 2010, a
framework for such approval exists in the U.S. In Europe, the European Commission grants marketing authorizations for biosimilars pursuant to a set of general
and product class-specific guidelines for biosimilar approvals.

As part of our business strategy, we are capitalizing on our expertise in biologics manufacturing, as well as our regulatory and commercial strengths, to develop
and commercialize biosimilar medicines. See Item 1A. Risk Factors — Biologic Products below.

We may face litigation with respect to the validity and/or scope of patents relating to our biologic products. Likewise, as we develop, manufacture and seek to
launch biosimilars, patents may be asserted against us.

International

One of the main limitations on our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products. Under
international and U.S. free trade agreements in recent years, we have seen some improvement in global protection of intellectual property rights. For additional
information, see Item 1. Business — Government Regulation and Price Constraints — Outside the United States — Intellectual Property below.

COMPETITION

Our businesses are conducted in intensely competitive and often highly regulated markets. Many of our prescription pharmaceutical products face competition in
the form of branded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of
use, and cost effectiveness. Though the means of competition vary among product categories and business groups, demonstrating the value of our products is a
critical factor for success in all of our principal businesses.

Our competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus,
generic and biosimilar drug manufacturers and consumer healthcare manufacturers. We compete with other companies that manufacture and sell products that
treat diseases or indications similar to those treated by our major products.

This competition affects our core product business, which is focused on applying innovative science to discover and market products that satisfy unmet medical
needs and provide therapeutic improvements. Our emphasis on innovation is underscored by our multi-billion-dollar investment in R&D, as well as our business
development transactions, both designed to result in a strong product pipeline. Our investment in research does not stop with drug approval; we continue to
invest in further understanding the value of our products for the conditions they treat, as well as potential new applications. We seek to protect the health and
well-being of patients by striving to ensure that medically sound knowledge of the benefits and risks of our medicines is understood and communicated to
patients, physicians, payers and global health authorities. We also seek to continually enhance the organizational effectiveness of all of our biopharmaceutical
functions, including coordinating support for our salespersons’ efforts to accurately and ethically launch and promote our products to our customers.

Operating conditions have become more challenging under mounting global pressures of competition, industry regulation and cost containment. We continue to
take measures to evaluate, adapt and improve our organization and business practices to better meet customer and public needs. We believe that we have
taken an industry-leading role in evolving our approaches to U.S. direct-to-consumer advertising; interactions with, and payments to, healthcare professionals;
and medical education grants. We also continue to sponsor programs to address patient affordability and access barriers, as we strive to advance fundamental
health system change through support for better healthcare solutions.

Our vaccines business may face competition from the introduction of alternative or next generation vaccines. For example, Prevnar 13 may face competition in
the form of alternative 13-valent or additional valent next-generation pneumococcal conjugate vaccines prior to the expiration of its patents, which may adversely
affect our future results.

Our generics and biosimilars businesses compete with branded products from competitors, as well as other generics and biosimilars manufacturers. Globally,
Pfizer sells generic versions of Pfizer’s, as well as certain competitors’, solid oral dose and sterile injectable pharmaceutical products, as well as biosimilars. We
seek to maximize the opportunity to establish a “first-to-

Pfizer Inc. 2018 Form 10-K 6

TABLE OF CONTENTS

market” or early market position for our generic injectable drugs and biosimilars, as a “first-to-market” position provides customers a lower-cost alternative
immediately when available and also may provide us with potentially higher levels of sales and profitability until other generic or biosimilar competitors enter the
market.

Our Consumer Healthcare business faces competition from OTC business units in other major pharmaceutical and consumer packaged goods companies, and
retailers who carry their own private label brands. Our competitive position is affected by several factors, including the amount and effectiveness of our and our
competitors’ promotional resources; customer acceptance; product quality; our and our competitors’ introduction of new products, ingredients, claims, dosage
forms, or other forms of innovation; and pricing, regulatory and legislative matters (such as product labeling, patient access and prescription to OTC switches).

Managed Care Organizations

The evolution of managed care in the U.S. has been a major factor in the competitive makeup of the healthcare marketplace. Approximately 298 million people
in the U.S. now have some form of health insurance coverage. Due to the expansion of health insurance coverage (see Item 1. Business — Government
Regulation and Price Constraints — In the United States below), the marketing of prescription drugs to both consumers and the entities that manage this
expanded coverage in the U.S. continues to grow in importance.

The influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, those
organizations have been consolidating into fewer, even larger entities. This consolidation enhances both their ability to negotiate, as well as their importance to
Pfizer.

The growth of MCOs has increased pressure on drug prices as well as revenues. One objective of MCOs is to contain and, where possible, reduce healthcare
expenditures. MCOs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to members
of the MCOs), clinical protocols (requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or
more generic products before permitting access to a branded medicine), volume purchasing, long-term contracts and their ability to influence volume and market
share of prescription drugs. In addition, by placing branded medicines on higher-tier status in their formularies (leading to higher patient co-pays) or non-
preferred tier status, MCOs transfer a portion of the cost of the medicine to the patient, resulting in significant out-of-pocket expenses for the patient, especially
for chronic treatments. This financial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. MCOs
also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing, “copay accumulator” programs and value-based
pricing/contracting to improve their cost containment efforts. We are closely monitoring these newer approaches and developing appropriate strategies to
respond to them.

Due to their generally lower cost, generic medicines typically are placed in lowest cost tiers of MCO formularies. The breadth of the products covered by
formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular
medical problems. MCOs are currently evaluating the appropriate placement of biosimilars on their formularies.

Exclusion of a product from a formulary or other MCO-implemented restrictions can significantly impact drug usage in the MCO patient population.
Consequently, pharmaceutical companies compete to gain access to formularies for their products. Unique product features, such as greater efficacy, better
patient ease of use, or fewer side effects, are generally beneficial to achieving access to formularies. However, lower overall cost of therapy is also an important
factor. We have been generally, although not universally, successful in having our major products included on MCO formularies. However, increasingly our
branded products are being placed on the higher tiers or in a non-preferred status.

MCOs also emphasize primary and preventive care, out-patient treatment and procedures performed at doctors’ offices and clinics as another way to manage
costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed. Since the use of certain drugs can reduce the need
for hospitalization, professional therapy, or even surgery, such drugs can become favored first-line treatments for certain diseases.

The ACA has accelerated payment reform by distributing risk across MCOs and other stakeholders in care delivery with the intent of improving quality while
reducing costs, which creates pressure on MCOs to tie reimbursement to defined outcomes. We anticipate continued Congressional interest in modifying
provisions of the ACA, particularly given the recent ruling in Texas v. Azar to invalidate the law as unconstitutional, though we believe it is unlikely Congress will
find bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. We are monitoring any such actions to see if any
changes to the ACA will be enacted that would impact our business.

Generic Products

One of the biggest competitive challenges that our branded products face is from generic pharmaceutical manufacturers. Upon the expiration or loss of patent
protection for a product, especially a small molecule product, we can lose the major portion of revenues for that product in a very short period of time. Several
competitors make a regular practice of challenging our product

Pfizer Inc. 2018 Form 10-K 7

TABLE OF CONTENTS

patents before their expiration. Generic competitors often operate without large R&D expenses, as well as without costs of conveying medical information about
products to the medical community. In addition, the FDA approval process exempts generics from costly and time-consuming clinical trials to demonstrate their
safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. Generic competitors can market a competing
version of our product after the expiration or loss of our patent and often charge much less. In China, for example, we are expected to face strong competition by
certain generic manufacturers in 2019, which may result in price cuts and volume loss of some of our products.

In addition, our patent-protected products can face competition in the form of generic versions of competitors’ branded products that lose their market exclusivity.

As noted above, MCOs that focus primarily on the immediate cost of drugs often favor generics over brand-name drugs. Many governments also encourage the
use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S. Laws in the U.S. generally allow, and in some
cases require, pharmacists to substitute, for brand-name drugs, generic drugs that have been rated under government procedures to be chemically and
therapeutically equivalent to brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. Favoring
generics may reduce sales of our branded products.

RAW MATERIALS

Raw materials essential to our businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are
available from multiple sources. In 2018 , we experienced periodic shortages of select materials due to constrained capacity or operational challenges with the
associated suppliers. Supplier management activities are ongoing to work to ensure the necessary supply to meet our requirements for these materials. No
significant impact to our operations is anticipated in 2019.

GOVERNMENT REGULATION AND PRICE CONSTRAINTS

Pharmaceutical companies are subject to extensive regulation by government authorities in the countries in which they do business. Certain laws and
regulations that govern Pfizer’s business are discussed below.

General . Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations, including
those governing the manufacture and marketing of our products, could subject us to administrative and legal proceedings and actions by various governmental
bodies. For additional information on these proceedings and actions, see the Notes to Consolidated Financial Statements— Note 17 A . Contingencies and
Certain Commitments — Legal Proceedings in our 2018 Financial Report. Criminal charges, substantial fines and/or civil penalties, warning letters and product
recalls or seizures, delays in product approvals, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from such
proceedings and actions.

In the United States

Drug Regulation . In the U.S., biopharmaceutical products are subject to extensive pre- and postmarket regulation by the FDA, including regulations that govern,
among other things, the safety and efficacy of our medicines, clinical trials, advertising and promotion, manufacturing, labeling and record keeping. Our products
are also subject to postmarket surveillance under the FFDCA and its implementing regulations with respect to drugs, as well as the Public Health Service Act
and its implementing regulations with respect to biologics. Our Consumer Healthcare products are also subject to FDA regulation.

Other U.S. federal agencies, including the DEA, also regulate certain of our products. The U.S. Federal Trade Commission has the authority to regulate the
advertising of consumer healthcare products, including OTC drugs and dietary supplements. Many of our activities also are subject to the jurisdiction of the SEC.

Biopharmaceutical companies seeking to market a product in the U.S. must first test the product to demonstrate that it is safe and effective for its intended use.
If, after evaluation, the FDA determines the product is safe (i.e., its benefits outweigh its known risks) and effective, then the FDA will approve the product for
marketing, issuing a NDA or BLA as appropriate. Companies seeking to market a generic prescription drug must scientifically demonstrate that the generic drug
is bioequivalent to the innovator drug. The ANDA, or generic drug application, must show, among other things, that the generic drug is pharmaceutically
equivalent to the brand, the manufacturer is capable of making the drug correctly, and the proposed label is the same as that of the innovator/brand drug’s label.

Even after a drug or biologic is approved for marketing, it may still be subject to postmarketing commitments or postmarketing requirements. Postmarketing
commitments are studies or clinical trials that the drug or biologic sponsor has agreed to conduct, but are not required by law and/or regulation. Postmarketing
requirements include studies and clinical trials that sponsors are required to conduct, by law and/or regulation, as a condition of approval. Postmarketing studies
or clinical trials can be required in order to assess a known risk or demonstrate clinical benefit for drugs or biologics approved pursuant to accelerated approval.
If a company fails to meet its postmarketing requirements, the FDA may assess a civil monetary penalty, issue a warning letter or deem the drug or biologic
misbranded. Once a drug or biologic is approved, any modifications to the product must be notified to the FDA and may also require a manufacturer to submit
additional studies or conduct clinical trials. In addition, we are also required to report adverse events and comply with cGMPs, as well as advertising and
promotion regulations. Failure to comply with the FFDCA may subject us to administrative and/or judicial sanctions, including warning letters, product recalls,
seizures, delays in product approvals, injunctions, fines, civil penalties and/or criminal prosecution.

Biosimilar Regulation. The ACA created a framework for the approval of biosimilars (also known as follow-on biologics) following the expiration of 12 years of
exclusivity for the innovator biologic, with a potential six-month pediatric extension. Under the ACA, biosimilar applications may not be submitted until four years
after the approval of the reference innovator biologic.

The FDA is responsible for implementation of the legislation and approval of new biosimilars. Through FDA approvals and the issuance of draft and final
guidance, the FDA has addressed a number of issues related to the biosimilars approval pathway, such as the labeling expectations for biosimilars. Over the
next several years, the FDA is expected to issue additional draft and final guidance documents impacting biosimilars, including updated draft or final guidance
regarding the standards for demonstrating interchangeability with a U.S.-licensed reference product. In addition, in 2017, the Biosimilar User Fee Act was
reauthorized for a five-year period, which should lead to a significant increase in the FDA’s biosimilar user fee revenues, thereby providing the FDA with
additional resources to process biosimilar applications. For example, in the first year under the newly authorized fee structure, the FDA estimates its revenues
from biosimilar user fees will increase by more than $10 million.

Sales and Marketing Laws and Regulations . The marketing practices of U.S. biopharmaceutical companies are generally subject to various federal and state
healthcare laws that are intended, among other things, to prevent fraud and abuse in the healthcare industry and to protect the integrity of government
healthcare programs. These laws include anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a biopharmaceutical company from
soliciting, offering, receiving, or paying anything of value to generate business, including purchasing or prescribing of a particular product. False claims laws
generally prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods (including drugs or biologics) or
services to third-party payers (including Medicare and Medicaid) that are false or fraudulent and generally treat claims generated through kickbacks as false or

fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions and/or exclusion from federal healthcare programs (including
Medicare and Medicaid). The federal government and various states also have enacted laws to regulate the sales and marketing practices of pharmaceutical
companies. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers, require disclosure to the federal or
state government and the public of such interactions, and/or require the adoption of compliance standards or programs. Many of these laws and regulations
contain ambiguous requirements or require administrative guidance for implementation. Individual states, acting through their attorneys general, have become
active as well, seeking to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. Given the lack of clarity in
laws and their implementation, our activities could be subject to the penalties under the pertinent laws and regulations.

Pricing and Reimbursement . Pricing and reimbursement for our pharmaceutical products depends in part on government regulation. Pfizer must offer
discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, such as the Medicaid Drug Rebate
Program, the “federal ceiling price” drug pricing program, the 340B drug pricing program and the Medicare Part D Program. Pfizer must also report specific
prices to government agencies under healthcare programs, such as the Medicaid Drug Rebate Program and Medicare Part B. The calculations necessary to
determine the prices reported are complex and the failure to report prices accurately may expose Pfizer to penalties. See the discussion regarding rebates in the
Analysis of the Consolidated Statements of Income — Revenues — Overview section in our 2018 Financial Report and in the Notes to Consolidated Financial
Statements— Note 1 G . Basis of Presentation and Significant Accounting Policies : Revenues and Trade Accounts Receivable in our 2018 Financial Report,
which are incorporated by reference.

Government and private third-party payers routinely seek to manage utilization and control the costs of our products. For example, the majority of states use
preferred drug lists to restrict access to certain pharmaceutical products under Medicaid. Restrictions exist for some Pfizer products under certain state Medicaid
programs. As another example, access to our products under the Medicaid managed care program is typically determined by the health plans with which state
Medicaid agencies contract to provide services to Medicaid beneficiaries. Given certain states’ current and potential ongoing fiscal crises, a growing number of
states are considering a variety of cost-control strategies, including capitated managed care plans that typically contain cost by restricting access to certain
treatments. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers, who are the primary purchasers of our pharmaceutical
products in the U.S., will increase pricing pressures on pharmaceutical manufacturers, including us.

Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug
importation, could adversely affect our business if implemented. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing
and proposals to address the perceived high cost of pharmaceuticals. At the federal level, for example, in May 2018, President Trump released his Blueprint to
Lower Drug Prices and Reduce Out-of-Pocket Costs (Blueprint). Certain proposals in the Blueprint, and related drug pricing measures proposed since the
Blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry. As another example, in October 2018, the Centers for
Medicare and Medicaid Services solicited public comments on potential changes to payment for certain Medicare Part B drugs, including reducing the Medicare
payment amount for selected Medicare Part B drugs to more closely align with international drug prices. In addition, in January 2019, the White House Office of
Management and Budget released the long awaited proposed rule submitted by the Office of Inspector General of the Department of Health and Human
Services to remove safe harbor protections for drug rebates paid to insurance plans and PBMs for Medicare Part D and Managed Medicaid and to create new
safe harbors. Among other changes, the proposed rule would explicitly exclude the reductions in price offered by drug manufacturers to PBMs in Medicare Part
D and Managed Medicaid plans from protection under the “discount” safe harbor. It would also create a new safe harbor designed specifically for price
reductions in pharmaceutical products, but only those that are fully reflected in the price to the patient at the pharmacy counter. Additionally, a new safe harbor
was proposed to protect administrative fees paid to PBMs, which must be at fair market value, a fixed fee and not based upon a percentage of volume or list
price. Manufacturers could continue to negotiate price reductions with PBMs and Medicare Part D and Managed Medicaid plans if their reductions meet that
criterion. The proposed rule represents a large step toward significantly altering the current rebate model in place with MCOs. We are in the process of
evaluating the implications of the proposed rule on our operations and processes, as well as the infrastructure that will be required in order to implement the rule
once it is finalized. There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around
drug costs or limiting drug prices. Certain state legislation has been subject to legal challenges. Adoption of new legislation regulating drug pricing at the federal
or state level could further affect demand for, or pricing of, our products.

We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We will
continue to work with lawmakers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and ensure
access to medicines within an efficient and affordable healthcare system.

Healthcare Reform. There have been significant efforts at the federal and state levels to reform the healthcare system by enhancing access to healthcare,
improving the delivery of healthcare and further rationalizing payment for healthcare. For example, we face uncertainties due to federal legislative and
administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. For example, tax reform legislation enacted at the end
of 2017 eliminates the tax penalty for individuals who do not maintain sufficient health insurance coverage beginning in 2019 (the so-called “individual
mandate”). We anticipate continued Congressional interest in modifying provisions of the ACA, particularly given the recent ruling in Texas v. Azar to invalidate
the law as unconstitutional. At this time, the law remains in effect pending appeals of the decision. Given the outcomes of the 2018 U.S. midterm elections with
Democrats taking over the U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we believe it is unlikely Congress will find
bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer by the health insurance
exchanges and Medicaid expansion under the ACA are not material, so the impact of the change in law and similar recent administration actions is expected to
be limited. Any future replacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislation
reduces incentives for employer-sponsored insurance coverage. As another example, the Bipartisan Budget Act of 2018, which increased the discount we pay in
the Medicare Part D “coverage gap” from 50% to 70%, will modestly increase our future Medicare Part D rebates. Any future healthcare reform efforts may
adversely affect our business and financial results.

Anti-Corruption. The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign
government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA
includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.

Outside the United States

We encounter similar regulatory and legislative issues in most other countries.

New Drug Approvals. In the EU, the approval of new drugs may be achieved using the Mutual Recognition Procedure, the Decentralized Procedure or the EU
Centralized Procedure. These procedures apply in the EU member states, plus the European Economic Area countries, Norway, Iceland and Liechtenstein. The
Centralized Procedure, managed by the EMA, results in one single authorization for the whole EU, which provides the most rapid and efficient means of gaining
approval across the EU and is the one most commonly used for new products.

In China, the regulatory system historically presented numerous challenges for the pharmaceutical industry, as its requirements for drug development and
registration were often inconsistent with U.S. or other international standards. In recent years, however, China has introduced reforms and draft reforms, which
are discussed in more detail below, that attempt to address these challenges. 2018 was another active year in this respect, with a number of reforms coming into
effect, and more proposals and drafts being issued for consultation. Also, in 2018, a significant government restructuring resulted in the creation of the National

Medical Product Administration (NMPA), replacing the former CFDA.

In Japan, the PMDA is the point of entry for businesses looking to sell drugs in the country. The PMDA, which is involved in a wide range of regulatory activities,
including clinical studies, approvals, postmarketing reviews and pharmaceuticals safety, must approve an application before a new drug product may be
marketed in Japan. The PMDA also offers consultations on clinical trials of new drugs and provides advice on product classifications and approvals.

Health authorities in many middle and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of the
FDA or the EMA) before they begin to conduct their application review process and/or issue their final approval. Many authorities also require local clinical data
in the country’s population in order to receive final marketing approval.

Pharmacovigilance. In the EU, detailed legislation and guidance on pharmacovigilance has increased and strengthened in recent years. The EMA’s
Pharmacovigilance Risk Assessment Committee has the responsibility for reviewing and making recommendations on product safety issues for the EU
authorities. EU regulators may require pharmaceutical companies to conduct post-authorization safety and efficacy studies at the time of approval, or at any time
afterwards in light of scientific developments. There are also additional extensive requirements regarding adverse drug reaction reporting and additional
monitoring of products. Outside developed markets such as the EU and Japan, pharmacovigilance requirements vary and are generally not as extensive, but
there is a trend toward increasing regulation.

Pricing and Reimbursement . In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low-to-
zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement
levels to control costs for the government-sponsored healthcare system, particularly under recent global economic pressures. Governments may use a variety of
cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a
condition of market access and international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries).
This international patchwork of price regulation and differing economic conditions and incomplete value assessments across countries has led to varying health
outcomes and some third-party trade in our products between countries.

In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price
variations, exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting
from this dynamic can be expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some
European countries.

In addition, several important multilateral organizations, such as the United Nations (UN), including the World Health Organization (WHO), and the Organization
for Economic Cooperation and Development (OECD), are increasing scrutiny of international pharmaceutical pricing through issuing reports and policy
recommendations (e.g., 2016 UN High Level Panel Report on Access to Medicines ). Late in 2018, two new reports critical of the pharmaceutical industry’s
pricing practices were published: OECD’s Pharmaceutical Innovation and Access to Medicines and WHO’s Pricing of Cancer Medicines and its Impacts . These
reports and upcoming public forums focused on their recommendations will continue to exert additional pricing pressures.

In China, pricing pressures have increased in recent years. Top Chinese government officials have consistently emphasized the importance of improved health
outcomes, the need for healthcare reform and decreased drug prices as a key indicator of progress towards reform. Even though the government provides basic
health insurance for the vast majority of Chinese citizens, the insurance is not adequate to cover innovative medicines. Alternative funding sources for innovative
medicines remain suboptimal, as private health insurance growth is restrained by issues with access to healthcare data, potential corruption concerns and
control over providers.

In 2017 and 2018, Chinese authorities entered into special negotiations with China’s National Medical Security Bureau to add approximately 60 high-value drugs
(mainly oncology medicines) to the National Reimbursement Drug List. Prices for drugs were reduced dramatically through these negotiations, some by as much
as 70 percent. While these negotiations included a path to access for companies, market access is not strictly assured. In addition, significant questions about
the processes and negotiations for provincial tendering remain. In addition, multi-layered negotiations are required across provincial, municipal and hospital
levels, and the linkage of price negotiations to reimbursement is inconsistent. In the off-patent space, in 2013, China began to implement a quality consistency
(QCE) process in order to improve the quality of domestically-manufactured generic drugs, primarily by requiring such drugs to pass a test to assess their
bioequivalence to a qualified reference drug (typically the originator drug). In 2018, numerous local generics were officially deemed bioequivalent under the
QCE. A pilot project for centralized procurement of 31 categories of drugs covering 11 major Chinese cities now drives patients to generics that have passed the
QCE, which has resulted in dramatic price cuts for off-patent drugs.

In Japan, the access environment for innovative medicines continued to deteriorate in 2018 with tighter restrictions around the criteria to gain a price
maintenance premium and a push by the Japanese government to adopt healthcare technology assessments based on rigid cost-effectiveness criteria for re-
pricing of reimbursed medicines. Additionally, the Japanese government has officially requested the Ministry of Health, Labour and Welfare to look into using
cost-effectiveness analyses to make reimbursement decisions at the launch of a drug.

EU Regulatory Changes . The EU adopted a new Clinical Trials Regulation in May 2014, which is expected to come into effect sometime in late 2019. This
regulation is aimed at simplifying and harmonizing the governance of clinical trials in the EU and will require increased public posting of clinical trial results.

Brexit . In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as “Brexit”. In March 2017, the U.K. government
formally notified the European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process
establishing the terms of the exit and outlining the future relationship between the U.K. and the EU. Formal negotiations officially started in June 2017. This
process continues to be highly complex and the end result of these negotiations may pose certain implications to our research, commercial and general
business operations in the U.K. and the EU, including the approval and supply of our products. The EMA will be relocating from London, U.K. to Amsterdam,
Netherlands by the scheduled date of Brexit at the end of March 2019. At present, it is still unclear whether and to what extent the U.K. will remain within or
aligned to the EU system of medicines regulation, and/or what separate requirements will be imposed in the U.K. after it leaves the EU. However, both the U.K.
and the EU have issued detailed guidance for the industry on how medicines, medical devices and clinical trials will be separately regulated in their respective
territories in the event of a ‘hard Brexit’, meaning an outcome where no negotiated settlement is reached. For additional information on Brexit, see the Overview
of Our Performance, Operating Environment, Strategy and Outlook — Our Operating Environment — The Global Economic Environment in our 2018 Financial
Report .

China Regulatory Changes . In an effort to encourage drug innovation and reduce backlogs for existing applications for drug approval, the NMPA has unveiled
numerous reform initiatives for China’s drug approval system, and engaged in significant efforts to build its capabilities. The NMPA now divides drugs into new
drugs and generics, with the definition for new drugs changed from “China New” to “Global New.” This means that drugs previously approved in other markets
(such as the U.S. or Europe) will not be considered new drugs under China’s regulatory regime. This change in definition creates more opportunities for China’s
domestic drug manufacturers than for multinational firms, because multinational firms have historically had significant competitive advantage in successfully
achieving regulatory approvals for drugs first approved outside of China. Revisions in 2017 made clear, however, that regulatory approval from the FDA or the
EMA would no longer be required for approval of imported drugs, though a notable exception persists for imported vaccines, which still require prior approval
from a relevant regulatory agency. The “marketing authorization holder” system, which will allow for more flexibility in contract manufacturing arrangements and

asset transfers, is now being piloted in ten Chinese provinces, but not yet for imported drugs.

While challenges remain, a number of other policy changes are streamlining and accelerating approvals of domestic and imported drugs in China. These
reforms, along with China’s June 2018 entry into the Management Committee of the International Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use, are expected to pave the way for integration of Chinese regulations with global practices. These changes include introducing
an umbrella clinical trial authorization for all three phases of registration studies (instead of the original phase-by-phase approvals), a filing/recordation system
for bioequivalence studies on generics (instead of the original review and approval system), admitting more categories of drugs as innovative drugs eligible for
the fast track/“green channel” approval pathway and ongoing implementation of previously announced regulatory reforms. In 2018, the review timeline for clinical
trial authorizations was shortened to 60 working days due to the introduction of a clinical trial notification system, and China’s Fast Track Policy was finalized, for
a specific group of products selected by the Center for Drug Evaluation, part of the NMPA.

In addition, China’s Human Genetic Resources Administrative Office strictly scrutinizes clinical trials involving the collection, storage, export and use of human
genetic resources and relevant deriving data from the Chinese population, adding an extra layer of review in addition to that of the NMPA.

Healthcare Provider Transparency and Disclosures. A number of countries have implemented laws requiring (or their industry associations have recommended)
disclosure of transfers of value made by pharmaceutical companies to healthcare providers. For example, the EFPIA’s disclosure code requires all members,
including Pfizer, to disclose transfers of value to healthcare professionals and healthcare organizations.

Intellectual Property . The World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) required participant
countries to amend their intellectual property laws to provide patent protection for pharmaceutical products by 2005, with an extension until 2033 for least-
developed countries. While we still face patent grant, enforcement and other intellectual property challenges around the world, some countries have made
improvements. We include stronger patent protection among the factors we consider for continued business expansion in other participant countries.

While the global intellectual property environment has generally improved following WTO-TRIPS and bilateral/multilateral trade agreements, our future business
growth depends on further progress in intellectual property protection. In emerging market countries in particular, governments have used intellectual property
policies as a tool for reducing the price of imported medicines, as well as to protect their local pharmaceutical industries. Considerable political and economic
pressure exists to weaken current intellectual property protection and resist implementation of any further protection, which has led to policies such as more
restrictive standards for obtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of
inventions (e.g., new medical treatment methods), revocation of patents, issuance (and threat of issuance) of compulsory licenses, weak intellectual property
enforcement and failure to implement effective regulatory data protection. Our industry advocacy efforts focus on seeking a more balanced business
environment for foreign manufacturers, as well as on underscoring the importance of strong intellectual property systems for local innovative industries. In
developed countries as well, including the EU, we are facing an increasingly challenging intellectual property environment.

Canada’s intellectual property regime for drugs provides some level of patent protection and data exclusivity (currently eight years plus six-month pediatric
extension), but it lacks the predictability and stability that otherwise comparable countries provide. Through intense negotiations as part of the Canada/EU
Comprehensive Economic & Trade Agreement (CETA), Canadian authorities have amended the Patent Medicines (Notice of Compliance) Regulations to
provide the innovator a right of appeal, and Canada now provides sui generis protection for patent term extensions of up to two years for basic patents.
Furthermore, the US-Mexico-Canada Agreement (USMCA), if ratified and implemented, would establish 10 years of data protection for biologics and patent term
adjustment for unreasonable or unnecessary delays in the grant of patents.

In China, the intellectual property environment has improved, although effective enforcement and adequate legal remedies remain areas of concern. The
government has taken steps to protect intellectual property rights in conformity with World Trade Organization provisions, and several companies, including
Pfizer, have established R&D centers in China due to increased confidence in China’s intellectual property environment. Despite this, China remained on the
U.S. Trade Representative’s Priority Watch List for 2018. Further, the standards for patentability in China remain more restrictive than in other major markets,
including the U.S., Europe and Japan. Also, while a framework exists for protecting patents for 20 years, enforcement mechanisms are often lacking or
inconsistent. For example, the absence of effective patent linkage mechanisms and preliminary injunctions, impractical evidentiary burdens, and heightened
sufficiency standards have been used to invalidate patents at the enforcement stage.

In Brazil and other Latin American countries, the role of health regulatory authorities in reviewing patents (e.g., National Health Surveillance Agency in Brazil),
restrictive patentability rules, ambiguity regarding the term of certain patents and backlogs at patent agencies may limit our ability to protect our products through
patents. The lack of regulatory data protection and difficulties in protecting certain types of inventions, such as new medical uses of drug products, may limit the
commercial lifespan of some pharmaceutical products. Additionally, an increased threat of issuance of compulsory licenses for biopharmaceutical products
exists, which adds to business uncertainty.

In India, we have seen some progress in terms of expediting patent approval processes to reduce pendency rates and implementing training programs to
enhance enforcement. Despite these positive steps, gaps remain in terms of addressing longstanding intellectual property concerns. For example, policies
favoring compulsory licensing of patents, the tendency of the Indian Patent Office to revoke pharmaceutical patents in opposition proceedings (both pre- and
post-grant), and restrictive standards for patentability of pharmaceutical products have made it difficult to safeguard many of our inventions and our investments
in innovation. These policies heighten the risk of additional patent challenges targeting innovative pharmaceutical products, especially in areas perceived as
being important to the public health of the population. Challenges against Pfizer patents in India are ongoing.

ENVIRONMENTAL MATTERS

Most of our operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures
necessary for compliance with applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. See the Notes
to Consolidated Financial Statements— Note 17 A3 . Contingencies and Certain Commitments — Legal Proceedings––Commercial and Other Matters in our
2018 Financial Report. As a result, we incurred capital and operational expenditures in 2018 for environmental compliance purposes and for the clean-up of
certain past industrial activity as follows:

•

•

environment-related capital expenditures— $33 million ; and

other environment-related expenses— $162 million .

While capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a
material effect on our capital expenditures or competitive position.

Climate change presents risks to our operations, including the potential for additional regulatory requirements and associated costs, and the potential for more
frequent and severe weather events and water availability challenges that may impact our facilities and those of our suppliers. For example, in 2017, our
manufacturing and commercial operations in Puerto Rico were impacted by hurricanes. For additional information, see the Overview of Our Performance,
Operating Environment, Strategy and Outlook — Our Business — Impact of Hurricanes in Puerto Rico section of the 2018 Financial Report. We cannot provide

assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future; however, we have a program for reviewing our
vulnerability to potential weather-related risks and we update our assessments periodically. To date, we have concluded that, because of our facility locations,
our existing distribution networks and our controls, we do not anticipate that these risks will have a material impact on Pfizer in the near term.

TAX MATTERS

The discussion of tax-related matters in the Notes to Consolidated Financial Statements— Note 5 . Tax Matters in our 2018 Financial Report is incorporated by
reference.

Pfizer Inc. 2018 Form 10-K 8

TABLE OF CONTENTS

EMPLOYEES

In our innovation-intensive business, our employees are vital to our success. We generally believe we have good relationships with our employees. As of
December 31, 2018 , we employed approximately 92,400 people in our operations throughout the world.

DISCLOSURE PURSUANT TO SECTION 219 OF THE IRAN THREAT REDUCTION AND SYRIA HUMAN RIGHTS ACT OF 2012

Section 219 of Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRSHRA) requires disclosure by public companies of certain transactions involving
the Government of Iran, as well as entities and individuals designated under Executive Order 13382 and Executive Order 13224 (the Executive Orders). In some
instances, ITRSHRA requires companies to disclose these types of transactions, even if they were permissible under U.S. law or were conducted by a non-U.S.
affiliate in accordance with the local law under which such entity operates.

As a global biopharmaceutical company, we conduct business in multiple jurisdictions throughout the world. During 2018 , our activities included supplying life-
saving medicines, medical products and consumer products (Pfizer products) for patient and consumer use in Iran. We ship Pfizer products to Iran, and conduct
related activities, in accordance with licenses issued by the U.S. Department of the Treasury’s Office of Foreign Assets Control and other U.S. and non-U.S.
governmental entities, and in line with our corporate policies. We will continue our global activities to improve the health and well-being of patients and
consumers in a manner consistent with applicable laws and our corporate policies. To our knowledge, none of our activities during 2018 are required to be
disclosed pursuant to ITRSHRA.

Pfizer Inc. 2018 Form 10-K 9

TABLE OF CONTENTS

ITEM 1A.

RISK FACTORS

The statements in this Section describe the major risks to our business and should be considered carefully. In addition, these statements constitute our
cautionary statements under the Private Securities Litigation Reform Act of 1995.

Our disclosure and analysis in this 2018 Form 10-K and in our 2018 Annual Report to Shareholders contain forward-looking statements. From time to time, we
also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such forward-looking statements
involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,”
“ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and
other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and
financial performance, business plans and prospects, in-line products and product candidates, including anticipated regulatory submissions, data read-outs,
study starts, approvals, performance, timing of exclusivity and potential benefits of Pfizer’s products and product candidates, strategic reviews, capital allocation,
business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our
2019 fiscal year, our acquisitions and other business development activities, our ability to successfully capitalize on growth opportunities or prospects,
manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions,
business plans and prospects, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective
consumer healthcare businesses into a new consumer healthcare joint venture, prospective products or product approvals, our product pipeline, future
performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such
as legal proceedings, plans relating to share repurchases and dividends, government regulation and financial results, including, in particular, the availability of
raw materials for 2019 set forth in Item 1. Business–– Raw Materials in this 2018 Form 10-K; the anticipated progress in remediation efforts at certain of our
Hospira manufacturing facilities and the expectations related to our supply issues set forth in the Overview of Our Performance, Operating Environment,
Strategy and Outlook –– Our Business –– Product Manufacturing section in our 2018 Financial Report; the benefits expected from the reorganization of our
commercial operations into three businesses effective at the beginning of our 2019 fiscal year and our expectations regarding growth set forth in the Overview of
Our Performance, Operating Environment, Strategy and Outlook –– Our Strategy –– Organizing for Growth section in our 2018 Financial Report; the expected
timing of completion and benefits of our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer
healthcare joint venture set forth in the Item 1. Business–– About Pfizer and –– Innovative Health , and Item 1A. Risk Factors sections in this 2018 Form 10-K
and in the Overview of Our Performance, Operating Environment, Strategy and Outlook –– Our Business , –– Our Strategy and –– Our Business Development
Initiatives sections in our 2018 Financial Report; the anticipated costs related to our preparations for Brexit set forth in the Overview of Our Performance,
Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment section in our 2018 Financial Report; our
anticipated liquidity position set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook –– Our Operating Environment — The
Global Economic Environment and the Analysis of Financial Condition, Liquidity and Capital Resources sections in our 2018 Financial Report; our plans for
increasing investment in the U.S. set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Capital
Allocation and Expense Management––Increasing Investment in the U.S. section in our 2018 Financial Report; the financial guidance set forth in the Overview
of Our Performance, Operating Environment, Strategy and Outlook — Our Financial Guidance for 2019 section in our 2018 Financial Report; the anticipated
costs and savings, including from our cost-reduction/productivity initiatives, as well as from our Organizing for Growth initiative, set forth in the Costs and
Expenses — Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives section in our 2018 Financial
Report and in the Notes to Consolidated Financial Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-
Reduction/Productivity Initiatives ; the benefits expected from our business development transactions; the planned capital spending set forth in the Analysis of
Financial Condition, Liquidity and Capital Resources — Selected Measures of Liquidity and Capital Resources — Contractual Obligations section in our 2018
Financial Report; and the contributions that we expect to make from our general assets to the Company’s pension, postretirement and deferred compensation
plans during 2019 set forth in the Analysis of Financial Condition, Liquidity and Capital Resources — Selected Measures of Liquidity and Capital Resources —
Contractual Obligations section and in the Notes to Consolidated Financial Statements— Note 11 . Pension and Postretirement Benefit Plans and Defined
Contribution Plans in our 2018 Financial Report.

We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and
inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could
vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and
you are cautioned not to put undue reliance on forward-looking statements.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects. Also note that we
provide the following cautionary discussion of risks, uncertainties and possibly inaccurate assumptions relevant to our businesses. These are factors that,
individually or in the aggregate, may cause our actual results to differ materially from expected, projected or historical results. We note these factors

Pfizer Inc. 2018 Form 10-K 10

TABLE OF CONTENTS

for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all such
factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties.

RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS :

MANAGED CARE TRENDS

Private third-party payers and other managed care entities, such as pharmacy benefit managers, continue to take action to manage the utilization of drugs and
control the cost of drugs. Consolidation among MCOs has increased the negotiating power of MCOs and other private third-party payers. Private third-party
payers, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary
inclusion or favorable formulary placement. Failure to obtain or maintain timely adequate pricing or favorable formulary placement for our products, or failure to
obtain such formulary placement at favorable pricing, could adversely impact revenue. Private third-party payers, including self-insured employers, often
implement formularies with copayment tiers to encourage utilization of certain drugs and have also been raising co-payments required from beneficiaries,
particularly for branded pharmaceuticals and biotechnology products. Private third-party payers are also implementing new initiatives like so-called “copay
accumulators” (policies that provide that the value of copay assistance does not count as out-of-pocket costs that are applied toward deductibles) that can shift
more of the cost burden to manufacturers and patients. This cost shifting has increased consumer interest and input in medication choices, as they pay for a
larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals. Private third-party
payers also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing, and value-based pricing/contracting to improve their
cost containment efforts. Private third-party payers also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior
authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access
to a branded medicine. As the U.S. payer market consolidates further and as more drugs become available in generic form, biopharmaceutical companies may
face greater pricing pressure from private third-party payers, who will continue to drive more of their patients to use lower cost generic alternatives.

GENERIC COMPETITION

Competition from manufacturers of generic drugs is a major challenge for our branded products around the world, and the loss or expiration of intellectual
property rights can have a significant adverse effect on our revenues. The date at which generic competition commences may be different from the date that the
patent or regulatory exclusivity expires. However, upon the loss or expiration of patent protection for one of our products, or upon the “at-risk” launch (despite
pending patent infringement litigation against the generic product) by a generic manufacturer of a generic version of one of our patented products, we can lose
the major portion of revenues for that product in a very short period of time, which can adversely affect our business. A number of our products are expected to
face significantly increased generic competition over the next few years. In China, for example, we are expected to face strong competition by certain generic
manufacturers in 2019, which may result in price cuts and volume loss of some of our products.

Also, generic manufacturers have filed applications with the FDA seeking approval of product candidates that such companies claim do not infringe our patents;
these include candidates that would compete with, among other products, Eliquis, Xeljanz and Xtandi . Our licensing and collaboration partners also face
challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. In addition, our patent-protected
products may face competition in the form of generic versions of competitors’ branded products that lose their market exclusivity.

COMPETITIVE PRODUCTS

We cannot predict with accuracy the timing or impact of the introduction of competitive products, including new product entrants, in-line branded products,
generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and
drug candidates. The introduction of competitive products can result in erosion of the sales of our existing products and potential sales of products in
development, as well as unanticipated product obsolescence. Competitive product launches have occurred in recent years, and certain potentially competitive
products are in various stages of development. Some of these have been filed for approval with the FDA and with regulatory authorities in other countries.

We also produce generic and biosimilar pharmaceutical products that compete with products from competitors, including other generic and biosimilar
manufacturers. The ability to launch a generic or biosimilar pharmaceutical product at or before the anticipated formation of the generic or biosimilar marketplace
is important to that product’s profitability. Prices for products typically decline, sometimes dramatically, following generic or biosimilar entry, and as additional
companies receive approvals to market that product, competition intensifies. If a company’s generic or biosimilar product can be “first-to-market” such that its
only competition is the branded drug for a period of time, higher levels of sales and profitability can be achieved until other generic or biosimilar competitors
enter the market. With increasing competition in the generic or biosimilar product market, the timeliness with which we can market new generic or biosimilar
products will increase in importance. Our success will depend on our ability to bring new products to market quickly. The FDA, along with other regulatory
agencies around the world, has been

Pfizer Inc. 2018 Form 10-K 11

TABLE OF CONTENTS

experiencing a backlog of generic drug applications, which may result in delayed approvals of new generic products. While the FDA is taking steps to address
the backlog of pending applications, continued approval delays may be experienced by generic drug applicants over the next few years. Also, we may face
access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to
the innovator product. For example, Inflectra/Remsima has experienced access challenges among commercial payers. In September 2017, Pfizer filed suit in the
U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J) alleging that J&J’s exclusionary contracts and other anticompetitive
practices concerning Remicade® (infliximab) violate federal antitrust laws.

DEPENDENCE ON KEY IN-LINE PRODUCTS

We recorded direct product and/or alliance revenues of more than $1 billion for each of ten biopharmaceutical products in 2018: Prevnar 13/Prevenar 13 , Lyrica
, Ibrance , Eliquis , Enbrel , Lipitor , Xeljanz , Chantix/Champix, Sutent and Norvasc . Those products accounted for 51% of our total revenues in 2018 . If these
products or any of our other major products were to become subject to problems such as loss of patent protection (if applicable), changes in prescription growth
rates, material product liability litigation, unexpected side effects, regulatory proceedings, publicity affecting doctor or patient confidence, pressure from existing
competitive products, changes in labeling, pricing and access pressures, supply shortages or, if a new, more effective treatment should be introduced, the
adverse impact on our revenues could be significant. A number of our current products have experienced patent-based expirations or loss of regulatory
exclusivity in certain markets in the last few years (including some of our billion-dollar and previously billion-dollar products), and patents covering a number of
our best-selling medicines are, or have been, the subject of pending legal challenges. For example, as a result of a patent litigation settlement, Teva
Pharmaceuticals USA, Inc. launched a generic version of Viagra in the U.S. in December 2017. In addition, the basic product patent for Lyrica in the U.S. will
expire in June 2019, which includes the FDA’s grant of pediatric exclusivity that extended the period of market exclusivity in the U.S. for Lyrica for an additional
six months from December 2018. In addition, our revenues could be significantly impacted by the timing and rate of commercial acceptance of key new
products. For additional information, see the Overview of Our Performance, Operating Environment, Strategy and Outlook –– Our Operating Environment —
Industry-Specific Challenges — Intellectual Property Rights and Collaboration/Licensing Rights — Recent Losses and Expected Losses of Product Exclusivity
section in our 2018 Financial Report. Further, our Alliance revenues will be adversely affected by the termination or expiration of collaboration and co-promotion
agreements that we have entered into and that we may enter into from time to time.

RESEARCH AND DEVELOPMENT INVESTMENT

The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the
continued strength of our businesses. Our product lines must be replenished over time in order to offset revenue losses when products lose their market
exclusivity, as well as to provide for earnings growth. Our growth potential depends in large part on our ability to identify and develop new products or new
indications for existing products that address unmet medical needs and receive reimbursement from payers, either through internal R&D or through
collaborations, acquisitions, joint ventures or licensing or other arrangements with third parties. However, balancing current growth, investment for future growth
and the delivery of shareholder return remains a major challenge. The average costs of product development continue to rise, as do the regulatory requirements
in many therapeutic areas, which may affect the number of candidates funded as well as the sustainability of the R&D portfolio. Our ongoing investments in new
product introductions and in R&D for new products and existing product extensions could exceed corresponding sales growth.

Additionally, our R&D investment plans and resources may not be correctly matched between science and markets, and failure to invest in the right technology
platforms, therapeutic segments, product classes, geographic markets and/or in-licensing and out-licensing opportunities could adversely impact the productivity
of our pipeline. Further, even if the areas with the greatest market attractiveness are identified, the scientific approach may not succeed for any given program
despite the significant investment required for R&D, and the commercial potential of the product may not be as competitive as expected because of the highly
dynamic market environment and the hurdles in terms of access and reimbursement.

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a
sustainable pipeline that is positioned to deliver value in the near-term and over time. These strategies may not deliver the desired result, which could affect
growth and profitability in the future.

BIOLOGIC PRODUCTS

Abbreviated legal pathways for the approval of biosimilars exist in many international markets and, since the passage of the ACA, a framework for such approval
exists in the U.S. If competitors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subject
to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. For example, Enbrel faces ongoing biosimilar
competition in most developed Europe markets. The expiration or successful challenge of applicable patent rights could trigger this competition, assuming any
relevant regulatory exclusivity period has expired. We may face litigation with respect to the validity and/or scope of patents relating to our biologic products.

Pfizer Inc. 2018 Form 10-K 12

TABLE OF CONTENTS

We are developing biosimilar medicines. Risks related to our development of biosimilars include the potential for steeper than anticipated price erosion due to
increased competitive intensity (or, as in the case of Inflectra/Remsima , exclusionary contracting by the originator that leads to a lack of payer coverage and
lower uptake), coupled with high costs associated with clinical development or intellectual property challenges that may preclude timely commercialization of our
potential biosimilar products. There is also a risk of lower uptake for biosimilars due to various factors that may vary for different biosimilars (e.g., anti-
competitive practices, physician reluctance to prescribe biosimilars for existing patients taking the originator product, or misaligned financial incentives). See also
the Competitive Products risk factor above.

RESEARCH STUDIES

Decisions about research studies made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing
strategy and payer reimbursement possibilities if it receives regulatory approval. For example, a wider range of studies can lead to approval for a broader set of
indications that may impact the marketing and payer reimbursement process. However, each additional indication must be balanced against the time and
resources required to demonstrate benefit, the increased complexity of development and manufacturing and the potential delays to approval of the lead
indication. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no guarantee that an optimal balance between
trial conduct, speed and desired outcome will be achieved each time. The degree to which such potential challenges are foreseen and adequately addressed
could affect our future results.

INTERNATIONAL OPERATIONS

Our international operations could be affected by currency fluctuations, capital and exchange controls, economic conditions, expropriation and other restrictive
government actions, changes in intellectual property legal protections and remedies, trade regulations and procedures and actions affecting approval,
production, pricing, and marketing of, reimbursement for and access to our products, as well as by political unrest, unstable governments and legal systems and
inter-governmental disputes. Any of these changes could adversely affect our business.

Many emerging markets have experienced growth rates in excess of developed markets, leading to an increased contribution to the industry’s global
performance. As a result, we have been employing strategies to grow in emerging markets. However, our strategies in emerging markets may not be successful
and these countries may not continue to sustain these growth rates. For example, even though China is growing faster than most emerging markets, we face
certain challenges in China due to government imposed pricing controls affecting certain Pfizer medicines. In addition, some emerging market countries may be
particularly vulnerable to periods of financial or political instability or significant currency fluctuations or may have limited resources for healthcare spending.
Even though we constantly monitor the evolving emerging markets for any unanticipated risk to Pfizer, certain financial or political events in such markets, as
discussed above, can adversely affect our results.

SPECIALTY PHARMACEUTICALS

Specialty pharmaceuticals are medicines that treat rare or life-threatening conditions that typically have smaller patient populations. The growing availability and
use of innovative specialty pharmaceuticals, combined with their relative higher cost as compared to other types of pharmaceutical products, has generated
payer interest in developing cost-containment strategies targeted to this sector. The impact of payers’ efforts to control access to and pricing of specialty
pharmaceuticals is increasing. For Pfizer to date, a number of factors create a more challenging paradigm given our growing specialty business portfolio. These
include formulary restrictions and increasing use of utilization management tools such as step edits, which can lead to higher negotiated rebates or discounts to
health plans and PBMs in the U.S., as well as the increasing use of health technology assessments in markets around the world.

CONSUMER HEALTHCARE

The Consumer Healthcare business may be impacted by economic volatility, the timing and severity of the cough, cold and flu season, generic or store brand
competition affecting consumer spending patterns and market share gains of competitors’ branded products or generic store brands. In addition, regulatory and
legislative outcomes regarding the safety, efficacy or unintended uses of specific ingredients in our Consumer Healthcare products may require withdrawal,
reformulation and/or relabeling of certain products (e.g., cough/cold products). See Consumer Healthcare Joint Venture with GSK and The Global Economic
Environment risk factors below.

PRODUCT MANUFACTURING, SALES AND MARKETING RISKS

Difficulties or delays in product manufacturing, sales or marketing could affect future results through regulatory actions, shut-downs, work stoppages or strikes,
approval delays, withdrawals, recalls, penalties, supply disruptions or shortages, reputational harm, product liability, unanticipated costs or otherwise. Examples
of such difficulties or delays include, but are not limited to, the inability to increase production capacity commensurate with demand; the failure to predict market
demand for, or to gain market acceptance of, approved products; the possibility that the supply of incoming materials may be delayed or become unavailable
and that the quality of incoming materials may be substandard and not detected; the possibility that we may fail to maintain appropriate quality standards
throughout the internal and external supply network and/or comply with cGMPs and

Pfizer Inc. 2018 Form 10-K 13

TABLE OF CONTENTS

other applicable regulations such as serialization (which allows for track and trace of products in the supply chain to enhance patient safety); risks to supply
chain continuity and commercial operations as a result of natural (including hurricanes, earthquakes and floods) or man-made disasters (including arson or
terrorist attacks) at our facilities or at a supplier or vendor, including those that may be related to climate change; or failure to maintain the integrity of our supply
chains against intentional and criminal acts such as economic adulteration, product diversion, product theft, counterfeit goods and cyberattacks.

Regulatory agencies periodically inspect our drug manufacturing facilities to evaluate compliance with applicable cGMP requirements. Failure to comply with
these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions,
debarment, voluntary recall of a product or failure to secure product approvals, any of which could have a material adverse effect on our business, financial
condition and results of operations. In February 2017, for example, we received a warning letter from the FDA communicating the FDA’s view that certain
violations of cGMP regulations exist at Hospira’s manufacturing facility in McPherson, Kansas. We are undertaking corrective actions to address the concerns
raised by the FDA. In January 2018, the FDA upgraded the status of Pfizer’s McPherson manufacturing facility to VAI based on an October 2017 inspection. The
change to VAI status lifted the compliance hold that the FDA placed on approval of pending applications. In June 2018, the FDA informed us that it had
completed an evaluation of corrective actions and closed out the February 2017 warning letter issued to our McPherson manufacturing facility after determining
that we had addressed the violations contained in the warning letter. In July-August 2018, the FDA conducted a follow-up inspection of our McPherson facility
and issued an inspection report noting several findings. Pfizer responded to the FDA’s findings, and is in the process of implementing a corrective and
preventive action plan to address the FDA’s concerns. On the basis of the July-August 2018 FDA inspection, the FDA changed the inspection classification
status of the McPherson site to Official Action Indicated (OAI). Future FDA inspections and regulatory activities will further assess the adequacy and
sustainability of these corrections. Communication with the FDA on the status of the McPherson site is ongoing. As a result of this status, the FDA has refused,
and may continue to refuse, to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured
at our McPherson site until the site status is upgraded, which will require a successful re-inspection by the FDA. The product shortages we have been
experiencing within our portfolio are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints, technical issues and
supplier quality concerns. We continue to remediate issues at legacy Hospira facilities manufacturing sterile injectables. Any continuing product shortage
interruption at these manufacturing facilities could negatively impact our financial results, specifically in our Sterile Injectable Pharmaceuticals portfolio.

In addition, in September 2017, Meridian Medical Technologies, Inc., a subsidiary of Pfizer Inc., received a warning letter from the FDA asserting the FDA’s view
that certain violations of cGMP and Quality System Regulations exist at Meridian’s manufacturing sites in St. Louis, Missouri. Meridian responded to the warning
letter and committed to making improvements across the sites. We are undertaking corrective actions to address the concerns raised by the FDA, and
communication with the FDA is ongoing. Until the corrective actions are implemented and confirmed by the FDA following a re-inspection, the FDA may refuse to
grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at our St. Louis sites.

OUTSOURCING

We outsource certain services to other parties, including transaction processing, accounting, information technology, manufacturing, clinical trial recruitment and
execution, clinical lab services, non-clinical research, safety services, integrated facilities management and other areas. Outsourcing of services to third parties
could expose us to suboptimal quality of service delivery or deliverables and potentially result in repercussions such as missed deadlines or other timeliness
issues, erroneous data, supply disruptions, non-compliance (including with applicable legal or regulatory requirements and industry standards) and/or
reputational harm, with potential negative effects on our results.

COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES

We depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and
product candidates and also enter into joint ventures and other business development transactions in connection with our business. To achieve expected longer
term benefits, we may make substantial upfront payments in such transactions, which may negatively impact our reported earnings. We rely heavily on these
parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities.
Third parties may not complete activities on schedule or in accordance with our expectations. Failure by one or more of these third parties to meet their
contractual or other obligations to Pfizer; failure of one or more of these parties to comply with applicable laws or regulations; or any disruption in the
relationships between Pfizer and one or more of these third parties, could delay or prevent the development, approval, manufacturing or commercialization of
our products and product candidates and could also result in non-compliance or reputational harm, all with potential negative implications for our product pipeline
and business.

BIOPHARMACEUTICAL WHOLESALERS

In 2018 , our largest biopharmaceutical wholesaler accounted for approximately 15% of our total revenues (and approximately 31% of our total U.S. revenues),
and our top three biopharmaceutical wholesalers accounted for approximately 37% of our total

Pfizer Inc. 2018 Form 10-K 14

TABLE OF CONTENTS

revenues (and approximately 76% of our total U.S. revenues). If one of our significant biopharmaceutical wholesalers should encounter financial or other
difficulties, such wholesaler might decrease the amount of business that it does with us, and we might be unable to collect all the amounts that the wholesaler
owes us on a timely basis or at all, which could negatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacy
chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us.

BUSINESS DEVELOPMENT ACTIVITIES

We expect to continue to enhance our in-line products and product pipeline through various forms of business development, which can include alliances,
licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. However, these enhancement
plans are subject to the availability and cost of appropriate opportunities, competition from other pharmaceutical companies that are seeking similar opportunities
and our ability to successfully identify, structure and execute transactions, including the ability to satisfy the conditions to closing of announced transactions in
the anticipated timeframes or at all, and successfully integrate acquisitions. Pursuing these opportunities may require us to obtain additional equity or debt
financing, and could result in increased leverage and/or a downgrade of our credit ratings. Where we acquire debt or equity securities as all or part of the
consideration for business development activities, such as in connection with our contribution agreement entered into with Allogene Therapeutics, Inc., the value
of those securities will fluctuate, and may depreciate in value. We may not control the company in which we acquire securities, such as in connection with a
divestiture or collaborative arrangement, and as a result, we will have limited ability to determine its management, operational decisions and policies. Further,
while we seek to mitigate risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due
diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Legal proceedings or regulatory issues often arise as a result of
activities that occurred at acquired companies, their partners and other third parties. In 2016, for example, we paid $784.6 million to resolve allegations related to
Wyeth’s reporting of prices to the government with respect to Protonix for activities that occurred prior to our acquisition of Wyeth. For these and other reasons,
we may not realize the anticipated benefits of such transactions, and expected synergies and accretion may not be realized within the expected timeframes, or
at all.

COUNTERFEIT PRODUCTS

A counterfeit medicine is one that has been deliberately and fraudulently mislabeled as to its identity and source. A counterfeit Pfizer medicine, therefore, is one
manufactured by someone other than Pfizer, but which appears to be the same as an authentic Pfizer medicine. The prevalence of counterfeit medicines is a
significant and growing industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the Internet, which has
greatly facilitated the ease by which counterfeit medicines can be advertised, purchased and delivered to individual patients; the availability of sophisticated
technology that makes it easier for counterfeiters to make counterfeit medicines; the growing involvement in the medicine supply chain of under-regulated
wholesalers and repackagers; the lack of adequate inspection at certain international postal facilities as counterfeit medicines are increasingly delivered direct to
customers in small parcel packages; the tendency to misuse and abuse medicines; and the relatively modest risk of penalties faced by counterfeiters compared
to the large profits that can be earned by them from the sale of counterfeit medicines. Further, laws against pharmaceutical counterfeiting vary greatly from
country to country, and the enforcement of existing law varies greatly from jurisdiction to jurisdiction. For example, in some countries, pharmaceutical
counterfeiting is not a crime; in others, it may result in only minimal sanctions. In addition, those involved in the distribution of counterfeit medicines use complex
transport routes in order to evade customs controls by disguising the true source of their products.

Pfizer’s global reputation makes its medicines prime targets for counterfeiting organizations. Counterfeit medicines pose a risk to patient health and safety
because of the conditions under which they are manufactured—often in unregulated, unlicensed, uninspected and unsanitary sites—as well as the lack of
regulation of their contents. Failure to mitigate the threat of counterfeit medicines, which is exacerbated by the complexity of the supply chain, could adversely
impact our business, by, among other things, causing the loss of patient confidence in the Pfizer name and in the integrity of our medicines, potentially resulting
in lost sales, product recalls, and an increased threat of litigation.

We undertake significant efforts to counteract the threats associated with counterfeit medicines, including, among other things, working with the FDA and other
regulatory authorities and multinational coalitions to combat the counterfeiting of medicines and supporting efforts by law enforcement authorities to prosecute
counterfeiters; assessing new and existing technologies to seek to make it more difficult for counterfeiters to copy our products and easier for patients and
healthcare providers to distinguish authentic from counterfeit medicines; implementing business practices designed to protect patient health; promoting public
policies intended to hinder counterfeiting; working diligently to raise public awareness about the dangers of counterfeit medicines; working collaboratively with
wholesalers, pharmacies, customs offices, and law enforcement agencies to increase inspection coverage, monitor distribution channels, and improve
surveillance of distributors and repackagers, and using data analytics and risk assessment tools to better target the factors that give rise to the counterfeiting
problem in the first place. However, our efforts and the efforts of others may not be entirely successful, and the presence of counterfeit medicines may continue
to increase.

Pfizer Inc. 2018 Form 10-K 15

TABLE OF CONTENTS

RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS :

PRICING AND REIMBURSEMENT

U.S. and international governmental regulations that mandate price controls and limitations on patient access to our products or establish prices paid by
government entities or programs for our products impact our business, and our future results could be adversely affected by changes in such regulations or
policies.

In the U.S., many of our products are subject to increasing pricing pressures. Pharmaceutical product pricing is subject to enhanced government and public
scrutiny and calls for reform. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under
the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-
eligible. There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs
or limiting drug prices. Efforts by government officials or legislators to implement measures to regulate prices or payments for pharmaceutical products, including
legislation on drug importation, could adversely affect our business if implemented. See the discussion regarding pricing and reimbursement in the Item 1.
Business — Government Regulation and Price Constraints — In the United States — Pricing and Reimbursement section of this 2018 Form 10-K. Private third-
party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a
reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare provider
purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review
processes.

We encounter similar regulatory and legislative issues in most other countries. In certain international markets, such as the different EU Member States, Japan,
China, Canada and South Korea, governments have significant power as large single payers to regulate prices, access criteria (e.g., through public or private
health technology assessments), or other means of cost control, particularly under recent global financing pressures. As a result, we expect that pressures on
the pricing component of operating results will continue.

The adoption of restrictive price controls in new jurisdictions or more restrictive ones in existing jurisdictions, failure to obtain or maintain timely or adequate
pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could also adversely impact
revenue. In our vaccines business, we participate in a tender process in many countries for participation in national immunization programs. Failure to secure
participation in national immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business.

U.S. HEALTHCARE REFORM

The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. For example, the ACA was enacted by Congress in March
2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect
on our expenses and profitability. See the discussion under the Overview of Our Performance, Operating Environment, Strategy and Outlook — Our Operating
Environment — Industry-Specific Challenges — Regulatory Environment/Pricing and Access––U.S. Healthcare Legislation section in our 2018 Financial Report
and in Item 1. Business — Government Regulation and Price Constraints — In the United States . We face uncertainties due to federal legislative and
administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. For example, tax reform legislation enacted at the end
of 2017 eliminates the tax penalty for individuals who do not maintain sufficient health insurance coverage beginning in 2019 (the so-called “individual
mandate”). We anticipate continued Congressional interest in modifying provisions of the ACA, particularly given the recent ruling in Texas v. Azar to invalidate
the law as unconstitutional. At this time, the law remains in effect pending appeals of the decision. Given the outcomes of the 2018 U.S. midterm elections with
Democrats taking over the U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we believe it is unlikely Congress will find
bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer by the health insurance
exchanges and Medicaid expansion under the ACA are not material, so the impact of the change in law and similar recent administration actions is expected to
be limited. Any future replacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislation
reduces incentives for employer-sponsored insurance coverage, and we cannot predict how other future federal or state legislative or administrative changes
relating to healthcare reform will affect our business.

Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget
control actions, changes in patent laws, the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign
countries (which is among the U.S. presidential administration’s policy proposals), revisions to reimbursement of biopharmaceuticals under government
programs (such as the implementation of international reference pricing for Medicare Part B drugs, or changes to protected class criteria for Part D drugs),
restrictions on U.S. direct-to-consumer advertising, limitations on interactions with healthcare professionals, or the use of comparative effectiveness
methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among
pharmaceutical products and restricts access to innovative medicines.

Pfizer Inc. 2018 Form 10-K 16

TABLE OF CONTENTS

U.S. ENTITLEMENT REFORM

In the U.S., government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or
services provided using our products. The Congressional Budget Office routinely releases options for reducing federal spending, and the December 2018
release includes proposals to cap federal Medicaid payments to the states, and to require manufacturers to pay a minimum rebate on drugs covered under
Medicare Part D for low-income beneficiaries. Significant Medicare reductions could also result if, for example, Congress proceeds with certain proposals to
convert the Medicare fee-for-service program into a premium support program, or Congress chooses to implement the recommendations made annually by the
Medicare Payment Advisory Commission, which are primarily intended to extend the fiscal solvency of the Medicare program. These and any other significant
spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have
an adverse impact on our results of operations.

SUBSTANTIAL REGULATION

We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the U.S., principally by the FDA and the
DEA, and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements may subject us to operating restrictions and criminal
prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension,
revocation of approvals, corporate integrity or deferred prosecution agreements or exclusion from future participation in government healthcare programs, as
well as reputational harm.

DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS

Innovation is critical to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. The outcome of the
lengthy and complex process of identifying new compounds and developing new products is inherently uncertain and involves a high degree of risk and cost.
The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years. Drug candidates can and
do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new clinical data and further
analyses of existing clinical data, including results that may not support further clinical development of the applicable product candidate or indication. We may
not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory
submission dates, regulatory approval dates and/or launch dates. Similarly, we may not be able to successfully address all of the comments received from
regulatory authorities such as the FDA and the EMA, or obtain approval from regulators. Regulatory approval of drug or biologic products depends on myriad
factors, including a regulator making a determination as to whether a product’s benefits outweigh its known risks and a determination of the product’s efficacy.
Additionally, clinical trial data are subject to differing interpretations and assessments by regulatory authorities. Even after a drug or biologic is approved, it could
be adversely affected by regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters. We may not be able to receive or
maintain favorable recommendations by technical or advisory committees, such as the Advisory Committee on Immunization Practices that may impact the use
of our vaccines. For example, during the October 2018 ACIP meeting, the U.S. Centers for Disease Control and Prevention presented initial data and indicated
formal evaluation of evidence (grading) and a potential vote on the maintenance of the 65 years and older recommendation for Prevnar 13 would likely happen
in 2019. A potential adverse change in the ACIP recommendation would negatively impact future Prevnar 13 revenues. For additional information, see the
Analysis of the Consolidated Statements of Income — Revenues — Selected Product Discussion section of our 2018 Financial Report. Further, claims and
concerns that may arise regarding the safety and efficacy of in-line products and product candidates can result in a negative impact on product sales, product
recalls or withdrawals, and/or consumer fraud, product liability and other litigation and claims. Increasing regulatory scrutiny of drug safety and efficacy, with
regulatory authorities increasingly focused on product safety and the risk/benefit profile of products as they relate to already-approved products, has resulted in a
more challenging, expensive and lengthy regulatory approval process due to requests for, among other things, additional or more extensive clinical trials prior to
granting approval or increased post-approval requirements. For these and other reasons discussed in Item 1A. Risk Factors , we may not obtain the approvals
we expect within the timeframe we anticipate, or at all.

POST-APPROVAL DATA

As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these
Phase 4 trials could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of a
product. Regulatory agencies in countries outside the U.S. often have similar authority and may impose comparable requirements. Postmarketing studies,
whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as
adverse event reports, may also adversely affect the availability or commercial potential of our products. Further, the discovery of significant problems with a
product similar to one of our products could implicate the entire class of products; and this, in turn, could have an adverse effect on the availability or commercial
viability of our product(s) as well as other products in the class.

Pfizer Inc. 2018 Form 10-K 17

TABLE OF CONTENTS

INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND GOVERNMENT OFFICIALS

Risks and uncertainties apply if we provide, offer, or promise something of value to a healthcare professional, other healthcare provider and/or government
official. Requirements or industry standards in the U.S. and certain jurisdictions abroad that require pharmaceutical manufacturers to track and disclose financial
interactions with healthcare professionals and healthcare providers increase government and public scrutiny of such financial interactions. If an interaction is
found to be improper, government enforcement actions and penalties could result. These risks may increase as both U.S. and foreign enforcement agencies
adopt or increase enforcement efforts in respect of existing and new laws and regulations governing product promotion, marketing, anti-bribery and kickbacks,
industry regulations, and codes of conduct.

CHANGES IN LAWS AND ACCOUNTING STANDARDS

Our future results could be adversely affected by changes in interpretations of existing laws and regulations, or changes in laws and regulations, including,
among others, changes in accounting standards, taxation requirements (including tax rate changes, new tax laws, changes to existing tax laws and revised tax
law and regulatory clarifications and/or interpretations, including changes affecting the taxation by the U.S. of income earned outside the U.S. that may result
from pending and possible future proposals, including further clarifications and/or interpretations of the Tax Cuts and Jobs Act), competition laws, privacy laws
and environmental laws in the U.S. and other countries. For additional information, see the Provision/(Benefit) for Taxes on Income — Changes in Tax Laws and
New Accounting Standards sections, and Notes to Consolidated Financial Statements— Note 1 B. Basis of Presentation and Significant Accounting Policies :
Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.

LEGAL PROCEEDINGS

We and certain of our subsidiaries are involved in various legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not
cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged
infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label
promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment, tax litigation and other legal
proceedings, including various means for resolving asbestos litigation, that arise from time to time in the ordinary course of our business. Litigation is inherently
unpredictable, and excessive verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we
could in the future incur judgments, enter into settlements of claims or revise our expectations regarding the outcomes of certain matters, and such
developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the
period in which the amounts are paid.

Claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have
substantial defenses to these challenges with respect to all of our material patents, there can be no assurance as to the outcome of these matters, and a loss in
any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could
materially affect future results of operations.

Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple
emerging markets in which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, substantial fines
and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as
reputational harm and increased public interest in the matter could result from government investigations. In addition, in a qui tam lawsuit in which the
government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.

Our activities relating to the sale and marketing and the pricing of our products are subject to extensive regulation under the FFDCA, the Medicaid Drug Rebate
Program, the FCPA and other federal and state statutes, including those discussed elsewhere in this 2018 Form 10-K, as well as anti-kickback and false claims
laws, and similar laws in international jurisdictions. Like many companies in our industry, we have from time to time received inquiries and subpoenas and other
types of information demands from government authorities, and been subject to claims and other actions related to our business activities brought by
governmental authorities, as well as by consumers and private payers. In some instances, we have incurred significant expense, civil payments, fines and other
adverse consequences as a result of these claims, actions and inquiries. For example, these claims, actions and inquiries may relate to alleged failures to
accurately interpret or identify or prevent non-compliance with the laws and regulations associated with the dissemination of product information (approved and
unapproved), potentially resulting in government enforcement and damage to our reputation. This risk may be heightened by digital marketing, including social
media, mobile applications and blogger outreach.

In connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to
Medicare patients, in May 2018, we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Health
and Human Services, which is effective for a period of five

Pfizer Inc. 2018 Form 10-K 18

TABLE OF CONTENTS

years. In the CIA, we agreed to implement and/or maintain certain compliance program elements to promote compliance with federal healthcare program
requirements. Breaches of the CIA could result in severe sanctions against us.

For additional information, including information regarding certain legal proceedings in which we are involved in, see Notes to Consolidated Financial Statements
— Note 17 A . Contingencies and Certain Commitments — Legal Proceedings in our 2018 Financial Report.

ENVIRONMENTAL CLAIMS AND PROCEEDINGS

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business relating to environmental claims and
proceedings. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties
and can rely heavily on estimates and assumptions. While we have accrued for worldwide environmental liabilities, there is no guarantee that additional costs
will not be incurred beyond the amounts accrued. If we fail to properly manage the safety of our facilities and the environmental risks associated therewith or if
we are required to increase our accruals for contingencies for environmental claims and proceedings in the future, it could potentially have an adverse effect on
our results of operations.

RISKS RELATED TO INTELLECTUAL PROPERTY :

PATENT PROTECTION

Our long-term success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of
intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license
agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be
able to prevent third parties from launching generic or biosimilar versions of our branded products, using our proprietary technologies or from marketing products
that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis.
Similarly, any term extensions that we seek may not be granted on a timely basis, if at all. In addition, our issued patents may not contain claims sufficiently
broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular
product area. The scope of our patent claims also may vary between countries, as individual countries have distinct patent laws. We may be subject to
challenges by third parties regarding our intellectual property, including, among others, claims regarding validity, enforceability, scope and effective term.

Our ability to enforce our patents also depends on the laws of individual countries and each country’s practice with respect to enforcement of intellectual property
rights, and the extent to which certain sovereigns may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., a policy
of routine compulsory licensing (or threat of compulsory licensing) of pharmaceutical intellectual property). In countries that provide some form of regulatory
exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the
expiration of such regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as “at risk” launches that challenge our
patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do
not cover the product of the generic drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights
with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we
bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers,
governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter
partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other
foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such
proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several
of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In June 2018, the
Patent Trial and Appeal Board ruled on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has
appealed the decision. Challenges to other patents remain pending before the U.S. Patent and Trademark Office. The invalidation of these patents could
potentially allow a competitor pneumococcal vaccine into the marketplace. Further, if we are unable to maintain our existing license agreements or other
agreements pursuant to which third parties grant us rights to intellectual property, including because such agreements expire or are terminated, our operating
results and financial condition could be materially adversely affected.

Likewise, in the U.S. and other countries, we currently hold issued trademark registrations and have trademark applications pending, any of which may be the
subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on
our trademarks and trade dress to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting,
registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, our business could be materially adversely
affected. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by

Pfizer Inc. 2018 Form 10-K 19

TABLE OF CONTENTS

requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the
commencement of their employment, engagement or other relationship. Despite these efforts and precautions, we may be unable to prevent a third party from
copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies in some countries may not
adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or
identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.

THIRD PARTY INTELLECTUAL PROPERTY CLAIMS

A properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of
other companies, but the patent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual
property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not always
be successful.

Part of our business depends upon successfully identifying generic pharmaceutical product and biosimilar opportunities and launching products to take
advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may
arise in situations where patent protection of equivalent branded products has expired, where patents have been declared invalid, or where products do not
infringe the patents of others. To achieve a “first-to-market” or early market position for generic pharmaceutical products and biosimilars, we may take action,
such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable.

Third parties may claim that our products infringe one or more patents owned or controlled by the third party. Claims of intellectual property infringement can be
costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant damages. We are involved in patent-related disputes
with third parties over our attempts to market generic pharmaceutical products and biosimilars. Once we have final regulatory approval of the related generic
pharmaceuticals products or biosimilars, we may decide to commercially market these products even though associated legal proceedings (including any
appeals) have not been resolved (i.e., “at-risk” launch). If one of our marketed products is found to infringe valid patent rights of a third party, such third party
may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the
event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Any of these adverse consequences
could have a material adverse effect on our profitability and financial condition.

RISK RELATED TO TECHNOLOGY :

INFORMATION TECHNOLOGY AND SECURITY

Significant disruptions of information technology systems or breaches of information security could adversely affect our businesses. We rely to a large extent
upon sophisticated information technology systems to operate our businesses. In the ordinary course of business, we collect, store and transmit large amounts
of confidential information (including, but not limited to, personal information and intellectual property), and we deploy and operate an array of technical and
procedural controls to maintain the confidentiality and integrity of such confidential information. We also have outsourced significant elements of our operations
to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor
relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and
information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on
them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or
vendors, or from attacks by malicious third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a
wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, “hacktivists,” nation states and
others. As a global pharmaceutical company, our systems are subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that they
may remain undetected for a period of time. While we have invested in the protection of data and information technology, our efforts may not prevent service
interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of
critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. We maintain cyber
liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption
or breach of our systems.

Pfizer Inc. 2018 Form 10-K 20

TABLE OF CONTENTS

RISKS RELATED TO OUR STRATEGIC TRANSACTIONS :

STRATEGIC ACQUISITIONS

The success of any of our strategic acquisitions will depend, in large part, on our ability to realize anticipated benefits from combining these businesses with
Pfizer. We, for example, may fail to achieve cost savings anticipated with certain of these acquisitions, or such cost savings within the expected time frame.
Similarly, the accretive impact anticipated from certain of these acquisitions may not be realized or may be delayed. Integration of these businesses may result
in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and
policies. We also may fail to generate the revenue growth for the acquired business that we expected at the time of entering into the transaction. Expected
revenue from acquired products and product candidates also may be constrained by developments outside of our control. Unsuccessful clinical trials, regulatory
hurdles and commercialization challenges may adversely impact revenue and income contribution from products and product candidates, including those
acquired in these acquisitions. Hospira, for example, has experienced manufacturing disruptions and substantial regulatory scrutiny due to quality issues.
Manufacturing problems, as well as any corrective actions and their operational implementation, could adversely impact the revenue we generate from products
acquired from Hospira and result in substantial unanticipated costs. For additional information, see the Overview of Our Performance, Operating Environment,
Strategy and Outlook –– Our Business — Product Manufacturing section in our 2018 Financial Report.

CONSUMER HEALTHCARE JOINT VENTURE WITH GSK

The required shareholder and regulatory approvals may not be obtained or the regulatory approvals may contain materially burdensome conditions
that could have an adverse effect on us or the joint venture or the other conditions to the completion of the proposed transaction may not be
satisfied in a timely manner or at all.

Completion of the proposed transaction is subject to a number of conditions, including, among others, the approval of GSK’s shareholders and the receipt of
certain governmental and regulatory approvals, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, and the receipt of all required approvals under the antitrust laws of certain other jurisdictions, including the EU.
Although Pfizer and GSK have agreed to do all things necessary under applicable antitrust laws to complete the proposed transaction as promptly as reasonably
practicable, there can be no assurance that these approvals will be obtained in a timely manner or at all or that the other conditions to closing will be satisfied. In
addition, in connection with obtaining the required regulatory approvals, governmental authorities may impose conditions on the completion of the proposed
transaction or require changes to the terms of the proposed transaction. If any such conditions or changes are imposed, they may jeopardize or delay
completion of the proposed transaction, reduce or delay the anticipated benefits of the proposed transaction or allow the parties to terminate the stock and asset
purchase agreement, which could negatively impact our stock price and our or the joint venture’s, as applicable, future business and financial results.

We may fail to realize all of the anticipated benefits of the proposed transaction.

The success of the proposed transaction will depend, in part, on the joint venture’s ability to realize the anticipated benefits and cost synergies from the
proposed transaction. These anticipated benefits and cost savings may not be realized or may not be realized within the expected time period. The joint
venture’s integration of Pfizer’s and GSK’s consumer healthcare businesses may result in material unanticipated problems, costs, expenses, liabilities,
competitive responses, and loss of customer and other business relationships. Any material unanticipated issues arising from the integration process could
negatively impact our stock price and our or the joint venture’s, as applicable, future business and financial results.

Moreover, uncertainty about the effect of the proposed transaction on employees, customers, suppliers, distributors and other business partners may have an
adverse effect on us and the joint venture. These uncertainties may impair our and/or the joint venture’s ability to attract, retain and motivate key personnel until
the transaction is consummated and for a period of time thereafter, and could cause customers, suppliers, distributors and others who deal with us and/or the
joint venture to seek to change or cancel existing business relationships with us and/or the joint venture or fail to renew existing relationships. Employee
retention may be challenging during the pendency of the proposed transaction, as certain employees may experience uncertainty about their future roles. If key
employees depart because of issues related to the uncertainty and difficulty of integration or a desire not to remain with the combined business, our business
and the business of the joint venture following the completion of the transaction could be adversely affected.

Following the integration of the combined business, GSK intends to separate the joint venture as an independent company via a demerger of its equity interest
to its shareholders and a listing of the combined business on the U.K. equity market. GSK will have the sole right to decide whether and when to initiate a
separation and listing for a period of five years from closing of the proposed transaction. GSK may also sell all or part of its stake in the joint venture in a
contemporaneous initial public offering. Should a separation and listing occur during the first five years after closing, Pfizer has the option to participate through
the distribution of some or all of its equity interest in the joint venture to its shareholders. Following a separation or listing, and subject to customary lock-up or
similar restrictions, Pfizer will also have the ability to sell its equity interest in the joint venture through the capital markets. After the fifth anniversary of the
closing of the proposed transaction, both GSK and Pfizer will have the right to decide whether and when to initiate a separation and public listing of the joint
venture. The planned separation and

Pfizer Inc. 2018 Form 10-K 21

TABLE OF CONTENTS

public listing transactions may not be initiated or completed within the expected time periods or at all, and both the timing and success of any separation and
public listing transaction, as well as the value generated for Pfizer or its shareholders in any such transaction, will be subject to prevailing market conditions and
other factors at the time of such transaction. Although Pfizer is entitled to participate in any separation and listing transaction initiated by GSK during the first five
years after closing, it is not required to do so, and any future distribution or sale of Pfizer’s equity stake in the joint venture will similarly be subject to prevailing
market conditions and other factors at the time of such transaction. Pfizer’s ability to complete any such future distribution or sale may also be impacted by the
size of Pfizer’s retained equity stake at the time. The uncertainty relating to the separation and public listing transactions, their implementation, their timing and
their yet to be determined effects on the joint venture’s business may subject us and the joint venture to risks and uncertainties that may adversely affect our
business and financial results.

The joint venture may be subject to additional risks beyond those associated with Pfizer’s consumer healthcare business.

After completion of the transaction, the joint venture will be subject to the risks associated with GSK’s consumer healthcare business in addition to the risks
associated with Pfizer’s consumer healthcare business, and the business, financial condition and results of operations of the joint venture may be affected by
factors that are different from or in addition to those currently affecting the independent business, financial condition and results of operations of Pfizer’s
consumer healthcare business. Many of these factors are outside of our and the joint venture’s control, and could materially impact the business, financial
condition and results of operations of the joint venture. Moreover, although we will have certain consent, board representation and other governance rights with
respect to the joint venture, Pfizer will be a minority owner of the joint venture following the completion of the proposed transaction. As a result, Pfizer will not
have control over the joint venture, its management or its policies and we may have business interests, strategies and goals that differ in certain respects from
those of GSK or the joint venture.

The market value of our common stock may be adversely affected as a result of expected and unexpected costs associated with the proposed
transaction and integration of the businesses.

We have incurred, and expect to incur, transaction- and integration-related costs in connection with the proposed transaction. We expect that a substantial
portion of these transaction- and integration-related costs will be comprised of non-recurring fees for professional services to complete the proposed transaction,
facilities and systems consolidation costs and employment-related costs, although certain unanticipated costs and expenses may be incurred as well. If the stock
and asset purchase agreement is terminated, we would have incurred many of these costs, fees and expenses without realizing the expected benefits of the
transaction. These costs, fees and expenses could adversely affect our financial results.

OTHER RISKS:

THE GLOBAL ECONOMIC ENVIRONMENT

Like all businesses of our size, we are exposed to both global and industry-specific economic conditions. Governments, corporations, and insurance companies,
which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to
switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. Government financing pressures can lead to negative
pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology
assessments), or other means of cost control. Examples include the different EU Member States, Japan, China, Canada, South Korea and a number of other
international markets. The U.S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growing
government influence as government programs continue to grow as a source of coverage.

The global economic environment has not had, nor do we anticipate that it will have, a material impact on our liquidity or capital resources. Due to our significant
operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we
have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving
economic conditions, but there can be no guarantee that changes in global financial markets and global economic conditions will not affect our liquidity or capital
resources or impact our ability to obtain financing in the future.

We continue to monitor credit, capital restrictions and economic situations in volatile regions and markets, especially where the ability to obtain U.S. dollars for
local currency is unpredictable and challenging. We cannot predict the likelihood of future changes in these economic conditions, or what impact they may have
on our results of operations, financial condition or business.

In addition, given that a significant portion of our business is conducted in the EU, including the U.K., the formal change in the relationship between the U.K. and
the EU caused by Brexit may pose certain implications for our research, commercial and general business operations in the U.K. and the EU, including the
approval and supply of our products. Details on how Brexit will be executed and the impact on the remaining EU countries will dictate how and whether the
broader EU will be impacted

Pfizer Inc. 2018 Form 10-K 22

TABLE OF CONTENTS

and what the resulting impact on our business may be. For additional information, see the see the Overview of Our Performance, Operating Environment,
Strategy and Outlook –– Our Operating Environment — The Global Economic Environment section in our 2018 Financial Report.

We also continue to monitor the global trade environment and potential trade conflicts and impediments. If trade restrictions or tariffs reduce global economic
activity, or if other factors lead to a general economic downturn, potential impacts could include declining sales; increased costs; volatility in foreign exchange
rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government
cost control efforts; delays or failures in the performance of customers, suppliers, and other third parties on whom we may depend for the performance of our
business; and the risk that our allowance for doubtful accounts may not be adequate.

FOREIGN EXCHANGE AND INTEREST RATE RISK

Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates.
53% of our total 2018 revenues were derived from international operations, including 21% from Europe and 22% from China, Japan and the rest of Asia. As we
operate in multiple foreign currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound, the Canadian dollar and approximately 100
other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken against
another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses
would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables
remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on
earnings. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.

The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and
Argentina, can impact our results and financial guidance . For additional information about our exposure to foreign currency risk, see the Overview of Our
Performance, Operating Environment, Strategy and Outlook –– Our Financial Guidance for 2019 and Analysis of Financial Condition, Liquidity and Capital
Resources sections in our 2018 Financial Report.

In addition, our interest-bearing investments and borrowings, and our pension benefit obligations, net, and our postretirement benefit obligations, net, are subject
to risk from changes in interest rates and foreign exchange rates. These risks related to interest-bearing investments and borrowings and the measures we have
taken to help contain them are discussed in the Forward-Looking Information and Factors That May Affect Future Results — Financial Risk Management section
in our 2018 Financial Report. For additional details, see the Notes to Consolidated Financial Statements— Note 7 F . Financial Instruments : Derivative Financial
Instruments and Hedging Activities and — Note 11 . Pension and Postretirement Benefit Plans and Defined Contribution Plans in our 2018 Financial Report and
the Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions ––Benefit Plans section in our 2018 Financial Report.
Those sections of our 2018 Financial Report are incorporated by reference.

From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. There is
currently uncertainty around whether LIBOR will continue to exist after 2021. If LIBOR ceases to exist, we may need to amend certain agreements and we
cannot predict what alternative index would be negotiated with our counterparties. As a result, our interest expense could increase and our available cash flow
for general corporate requirements may be adversely affected. Additionally, uncertainty as to the nature of a potential discontinuance, modification, alternative
reference rates or other reforms may materially adversely affect the trading market for securities linked to such benchmarks. For additional information, see
Analysis of Financial Condition, Liquidity and Capital Resources — Selected Measures of Liquidity and Capital Resources — LIBOR .

Notwithstanding our efforts to foresee and mitigate the effects of changes in external fiscal circumstances, we cannot predict with certainty changes in currency
and interest rates, inflation or other related factors affecting our businesses.

MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS

In the first quarter of 2018, we adopted a new accounting standard whereby certain equity investments are measured at fair value with changes in fair value now
recognized in net income. We expect the adoption of this new accounting standard may increase the volatility of our income in future periods due to changes in
the fair value of equity investments. For additional information, see Notes to Consolidated Financial Statements— Note 1 B. Basis of Presentation and
Significant Accounting Policies : Adoption of New Accounting Standards in 2018 and the Forward-Looking Information and Factors That May Affect Future
Results — Financial Risk Management sections in our 2018 Financial Report.

Pfizer Inc. 2018 Form 10-K 23

TABLE OF CONTENTS

Our pension benefit obligations and postretirement benefit obligations, net of our plan assets, are subject to volatility from changes in fair value of equity
investments and other investment risk. For additional information, see Notes to Consolidated Financial Statements— Note 11. Pension and Postretirement
Benefit Plans and Defined Contribution Plans and the Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions —
Benefit Plans section in our 2018 Financial Report.

COST AND EXPENSE CONTROL/UNUSUAL EVENTS/FAILURE TO REALIZE THE ANTICIPATED BENEFITS OF STRATEGIC INITIATIVES AND
ACQUISITIONS

Growth in costs and expenses, changes in product, segment and geographic mix and the impact of acquisitions, divestitures, restructurings, internal
reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and
organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of
(i) our cost-reduction and productivity initiatives; (ii) the reorganization of our commercial operations into three businesses effective at the beginning of the
company’s 2019 fiscal year; (iii) any other corporate strategic initiatives; and (iv) any acquisitions, divestitures or other initiatives, such as our proposed
transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture.

INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS

Our consolidated balance sheet contains significant amounts of intangible assets, including goodwill. For IPR&D assets, the risk of failure is significant, and
there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and requires that
we invest in a large number of projects in an effort to achieve a successful portfolio of approved products. Our ability to realize value on these significant
investments is often contingent upon, among other things, regulatory approvals and market acceptance. As such, we expect that many of these IPR&D assets
will become impaired and be written off at some time in the future. If the associated R&D effort is abandoned, the related IPR&D assets will likely be written-off,
and we will record an impairment charge. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge
(such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the
business climate and/or a failure to replace the contributions of products that lose exclusivity). Any such charge may be significant. Our other intangible assets,
including developed technology rights and brands, face similar risks for impairment and charges related to such assets may be significant as well. For additional
details, see the Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions section in our 2018 Financial Report.

We also regularly review our equity-method investments for impairment. An impairment charge may result from the occurrence of unexpected adverse events or
management decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a
result of a weak economic environment, events related to particular customers or asset types, challenging market conditions or decisions by management.

INTERNAL CONTROL OVER FINANCIAL REPORTING

The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. Internal control over financial reporting can
provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements.
Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could undermine the ability to provide
accurate disclosure (including with respect to financial information) on a timely basis, which could cause investors to lose confidence in our disclosures
(including with respect to financial information), require significant resources to remediate the lapse or deficiency, and expose us to legal or regulatory
proceedings.

TERRORIST ACTIVITY

Our future results could be adversely affected by changes in business, political and economic conditions, including the cost and availability of insurance, due to
the threat of terrorist activity in the U.S. and other parts of the world and related U.S. military action overseas.

Pfizer Inc. 2018 Form 10-K 24

TABLE OF CONTENTS

ITEM 1B.

UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2.

PROPERTIES

As of December 31, 2018 , we had 498 owned and leased properties, amounting to approximately 53 million square feet.

Pfizer continues to own and lease space around the world for sales and marketing, customer service, regulatory compliance, R&D, manufacturing and
distribution, and administrative support functions. In many locations, business lines and operations are co-located to achieve synergy and operational
efficiencies.

Pfizer’s corporate headquarters are in New York City and Pfizer’s properties extend internationally to over 90 countries.

In April 2018, we entered an agreement to lease space at the Spiral, an office building in the Hudson Yards neighborhood of New York City. We will relocate our
global headquarters to this property with occupancy expected beginning in 2022. In July 2018, we completed the sale of our current headquarters in New York
City. We are in a lease-back arrangement with the buyer while we complete our relocation. We continue to advance our global workplace strategy to provide
workplaces that enable collaboration and foster innovation.

We have numerous facilities across the world to support our R&D organizations, with a heavy concentration in North America. In 2019 , we will operationalize
the new R&D facilities in St. Louis, Missouri and Andover, Massachusetts.

Our PGS division is headquartered in various locations, with leadership teams primarily in New York City, New York and in Peapack, New Jersey. As of
December 31, 2018 , PGS had responsibility for 58 plants around the world, which manufacture products for our commercial divisions. Locations with major
manufacturing facilities include Belgium, China, Germany, India, Ireland, Italy, Japan, Puerto Rico, Singapore and the U.S. Our PGS division’s plant network
strategy is expected to result in the exit of four of these sites over the next several years. PGS also operates multiple distribution facilities around the world.

In general, we believe that our properties are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeable
future. See the Notes to Consolidated Financial Statements— Note 9 . Property, Plant and Equipment in our 2018 Financial Report, which provides amounts
invested in land, buildings and equipment and which is incorporated by reference. See also the discussion in the Notes to Consolidated Financial Statements—
Note 15 . Lease Commitments in our 2018 Financial Report, which is also incorporated by reference.

ITEM 3.

LEGAL PROCEEDINGS

Certain legal proceedings in which we are involved are discussed in the Notes to Consolidated Financial Statements— Note 17 A . Contingencies and Certain
Commitments — Legal Proceedings in our 2018 Financial Report, which is incorporated by reference.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

Pfizer Inc. 2018 Form 10-K 25

TABLE OF CONTENTS

EXECUTIVE OFFICERS OF THE COMPANY

The executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the
regular meeting of the Board of Directors to be held on the date of the 2019 Annual Meeting of Shareholders, or until his or her earlier death, resignation or
removal. Each of the executive officers is a member of the Pfizer Executive Leadership Team.

Name

Albert Bourla

Age

57

Frank A. D’Amelio

61

Mikael Dolsten

60

Lidia Fonseca

Michael Goettler

Angela Hwang

Rady A. Johnson

Douglas M. Lankler

50

51

53

57

53

Position

Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018;
Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global
Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from
February 2016 until June 2016. President and General Manager of Established Products Business Unit from
December 2010 until December 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Health
from 2009 until November 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from
2005 until 2009. Our Director since February 2018. Board member of Pharmaceutical Research and
Manufacturers of America (PhRMA). Board member of the Pfizer Foundation, which promotes access to quality
healthcare. Member of the Board of Directors of the Partnership for New York City and Catalyst, a global non-
profit organization accelerating progress for the advancement of women into leadership.

Chief Financial Officer, Executive Vice President, Business Operations and Global Supply since November
2018. Executive Vice President, Business Operations and Chief Financial Officer from December 2010 until
October 2018. Senior Vice President and Chief Financial Officer from September 2007 until December 2010.
Prior to joining Pfizer, he was Senior Executive Vice President of Integration and Chief Administrative Officer of
Alcatel-Lucent from November 2006 until August 2007. Prior to the Alcatel-Lucent merger, he was Chief
Operating Officer of Lucent and before that Chief Financial Officer of Lucent. Director of Zoetis Inc. and of
Humana Inc. and Chair of the Humana Audit Committee. Director of the Independent College Fund of New
Jersey.

Chief Scientific Officer, President, Worldwide Research, Development and Medical since January 2019.
President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice
President; President of Worldwide Research and Development from May 2010 until December 2010. Senior
Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until
May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until
October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008.
Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners
from 2016 to 2017.

Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer
and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of
Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Tegna, Inc.

Group President, Pfizer Upjohn since January 2019. Executive Vice President from July 2018 until December
2018. Global President of Pfizer Inflammation & Immunology from January 2018 until June 2018. Global
President of Pfizer Rare Disease from January 2016 until December 2017. Global Commercial Officer, Senior
Vice President for Pfizer’s Global Innovative Pharma Business from January 2014 until December 2015.
Regional President, Europe for Pfizer Specialty Care and the chair of the European Management Team from
June 2012 until December 2013. Regional President Asia - Pacific for Specialty Care from October 2009 until
June 2012. Member of the board of directors of PSI (Population Services International).

Group President, Pfizer Biopharmaceuticals Group since January 2019. Group President, Pfizer Essential
Health from January 2018 until December 2018. Global President, Pfizer Inflammation and Immunology from
January 2016 until December 2017. Regional Head, U.S. Vaccines from January 2014 until December 2015.
Vice President, Emerging Markets for the Primary Care business from September 2011 until December 2013.
Vice President, U.S. Brands business within Essential Health from October 2009 until August 2011.

Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice
President, Chief Compliance and Risk Officer from December 2013 until December 2018. Senior Vice
President and Associate General Counsel from October 2006 until December 2013.

General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014
until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until
December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011.
Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice
President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior
Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August
2009.

Freda C. Lewis-Hall

64

A. Rod MacKenzie

Dawn Rogers

Sally Susman

John D. Young

59

54

57

54

Chief Patient Officer, Executive Vice President since January 2019. Executive Vice President, Chief Medical
Officer from December 2010 until December 2018. Senior Vice President, Chief Medical Officer from May 2009
until December 2010. Previously, she was Chief Medical Officer and Executive Vice President, Medicines
Development at Vertex Pharmaceuticals from June 2008 until May 2009. Dr. Lewis-Hall was Senior Vice
President, U.S. Pharmaceuticals, Medical Affairs for Bristol-Myers Squibb Company from 2003 until May 2008.
Director of Tenet Healthcare Corporation from December 2014 to May 2017.

Chief Development Officer, Executive Vice President since June 2016. Senior Vice President, Chief
Development Officer from March 2016 until June 2016. Group Senior Vice President and Head, Pharma
Therapeutics Research and Development from 2010 until March 2016. Senior Vice President, Head of
Worldwide Research from 2007 until 2010. Dr. MacKenzie represents Pfizer as a member of the Board of
Directors of ViiV Healthcare Limited.

Chief Human Resources Officer, Executive Vice President since January 2019. Executive Vice President,
Worldwide Human Resources from June 2018 until December 2018. Senior Vice President, Human Resources
for the Chief Operating Officer from November 2017 until May 2018. Senior Vice President of Human
Resources for Pfizer Essential Health, Global Product Development, and the Legal and Compliance Divisions
from 2016 until November 2017. Senior Vice President of Human Resources for the Global Innovative Pharma
Business from 2013 until 2016. Senior Vice President of Human Resources for the Primary Care Business Unit
from 2011 until 2013. Senior Vice President of Human Resources for Worldwide Research and Development
from 2008 until 2011. Vice President of Human Resources for Pfizer's European Commercial Operations from
2006 to 2008.

Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President,
Corporate Affairs (formerly Policy, External Affairs and Communications) from December 2010 until December
2018. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December
2010. Senior Vice President and Chief Communications Officer from February 2008 until December 2009. Prior
to joining Pfizer, Ms. Susman held senior level positions at The Est é e Lauder Companies, including Executive
Vice President from 2004 to January 2008. Director of WPP plc.

Chief Business Officer, Group President since January 2019. Group President, Pfizer Innovative Health from
January 2018 until December 2018. Group President, Pfizer Essential Health from June 2016 until December
2017; Group President, Global Established Pharma Business from January 2014 until June 2016. President
and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Unit’s
Regional President for Europe and Canada from 2009 until June 2012. U.K. Country Manager from 2007 until
2009. Director of Johnson Controls International plc.

Pfizer Inc. 2018 Form 10-K 26

TABLE OF CONTENTS

PART II

ITEM 5.

MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES

The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol “PFE”. As of February 26, 2019 ,
there were 150,398 holders of record of our common stock. Additional information required by this item is incorporated by reference from the Selected Quarterly
Financial Data (Unaudited) and Peer Group Performance Graph sections in our 2018 Financial Report.

The following table provides certain information with respect to our purchases of shares of the Company’s common stock during the fourth fiscal quarter of 2018
:

Period

Issuer Purchases of Equity Securities (a)

Total Number
of Shares
Purchased (b)

Average Price
Paid per
    Share (b)

Total Number of
Shares Purchased as
Part of Publicly
    Announced Plan (a)

Approximate Dollar
Value of Shares
that May Yet Be
Purchased
    Under the Plan (a)

October 1, 2018 through October 28, 2018

October 29, 2018 through November 30, 2018

December 1, 2018 through December 31, 2018
Total

38,477,427   $
43,812,603   $
32,598,112   $
114,888,142   $
(a)   For additional information, see the Notes to Consolidated Financial Statements –– Note 12 . Equity in our 2018 Financial Report, which is incorporated by reference.
(b)   In addition to the amounts purchased under our share repurchase program, these columns represent (i) 118,667 shares, primarily representing common stock surrendered
to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by
the trustee of 4,410 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted
performance share awards and who deferred receipt of such awards.

38,410,129   $
43,795,856   $
32,559,080   $
114,765,065

44.25
43.50
43.77
43.83

14,157,881,147

7,487,879,989

5,582,880,460

On February 7, 2019 , we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. LLC. This agreement was entered into pursuant
to our previously announced share repurchase authorization. For additional information, see the Notes to Consolidated Financial Statements — Note 19.
Subsequent Event in our 2018 Financial Report, which is incorporated by reference .

ITEM 6.

SELECTED FINANCIAL DATA

Information required by this item is incorporated by reference from the discussion under the heading Financial Summary in our 2018 Financial Report.

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Information required by this item is incorporated by reference from the discussion under the heading Financial Review in our 2018 Financial Report.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Information required by this item is incorporated by reference from the discussion under the Forward-Looking Information and Factors That May Affect Future
Results — Financial Risk Management section in our 2018 Financial Report.

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Information required by this item is incorporated by reference from the Report of Independent Registered Public Accounting Firm on the Consolidated Financial
Statements in our 2018 Financial Report and from the consolidated financial statements, related notes and supplementary data in our 2018 Financial Report.

Pfizer Inc. 2018 Form 10-K 27

TABLE OF CONTENTS

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.

CONTROLS AND PROCEDURES

Disclosure Controls

As of the end of the period covered by this 2018 Form 10-K, we carried out an evaluation, under the supervision and with the participation of our principal
executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is
defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer
concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our
periodic reports filed with the SEC.

Internal Control over Financial Reporting

Management’s report on the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange
Act), and the related report of our independent registered public accounting firm, are included in our 2018 Financial Report under the headings Management’s
Report on Internal Control Over Financial Reporting and Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting ,
respectively, and are incorporated by reference.

Changes in Internal Controls

During our most recent fiscal quarter, there has not been any change in the Company’s internal control over financial reporting (as such term is defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting.

ITEM 9B.

OTHER INFORMATION

Not applicable.

Pfizer Inc. 2018 Form 10-K 28

TABLE OF CONTENTS

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

PART III

Information about our Directors is incorporated by reference from the discussion under the heading Item 1 — Election of Directors in our 2019 Proxy Statement.
Information about compliance with Section 16(a) of the Exchange Act is incorporated by reference from the discussion under the heading Securities Ownership
— Section 16(a) Beneficial Ownership Reporting Compliance in our 2019 Proxy Statement. Information about the Pfizer Policies on Business Conduct governing
our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business Conduct and Ethics for
Members of the Board of Directors, is incorporated by reference from the discussions under the headings Governance — Pfizer Policies on Business Conduct
and — Code of Conduct for Directors in our 2019 Proxy Statement. Information regarding the procedures by which our shareholders may recommend nominees
to our Board of Directors is incorporated by reference from the discussion under the headings Item 1 — Election of Directors — Criteria for Board Membership
and Submitting Proxy Proposals and Director Nominations for the 2020 Annual Meeting in our 2019 Proxy Statement. Information about our Audit Committee,
including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading
Governance — Board Information—Board and Committee Information — Board Committees—The Audit Committee in our 2019 Proxy Statement. The balance
of the information required by this item is contained in the discussion entitled Executive Officers of the Company in Part I of this 2018 Form 10-K.

ITEM 11.

EXECUTIVE COMPENSATION

Information about Director and executive compensation is incorporated by reference from the discussion under the headings Non-Employee Director
Compensation ; Executive Compensation ; and Governance—Board Information—Board and Committee Information—Board Committees — The Compensation
Committee — Compensation Committee Interlocks and Insider Participation in our 2019 Proxy Statement.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information required by this item is incorporated by reference from the discussion under the headings Executive Compensation — Compensation Tables—
Equity Compensation Plan Information and Securities Ownership in our 2019 Proxy Statement.

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information about certain relationships and transactions with related parties is incorporated by reference from the discussion under the headings Related Person
Transactions and Indemnification — Transactions with Related Persons in our 2019 Proxy Statement. Information about director independence is incorporated
by reference from the discussion under the heading Governance — Other Governance Practices and Policies — Director Independence in our 2019 Proxy
Statement.

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES

Information about the fees for professional services rendered by our independent registered public accounting firm in 2018 and 2017 is incorporated by
reference from the discussion under the heading Item 2 — Ratification of Selection of Independent Registered Public Accounting Firm — Audit and Non-Audit
Fees in our 2019 Proxy Statement. Our Audit Committee’s policy on pre-approval of audit and permissible non-audit services of our independent registered
public accounting firm is incorporated by reference from the discussion under the heading Item 2 — Ratification of Selection of Independent Registered Public
Accounting Firm — Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm in
our 2019 Proxy Statement.

Pfizer Inc. 2018 Form 10-K 29

TABLE OF CONTENTS

ITEM 15.

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

PART IV

15(a)(1) Financial Statements. The following consolidated financial statements, related notes, report of independent registered public accounting firm and
supplementary data from our 2018 Financial Report are incorporated by reference into Item 8 of Part II of this 2018 Form 10-K:

•

•

•

•

•

•

•

•

Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements

Consolidated Statements of Income

Consolidated Statements of Comprehensive Income

Consolidated Balance Sheets

Consolidated Statements of Equity

Consolidated Statements of Cash Flows

Notes to Consolidated Financial Statements

Selected Quarterly Financial Data (Unaudited)

15(a)(2) Financial Statement Schedules. Schedules are omitted because they are not required or because the information is provided elsewhere in the
financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a
significant subsidiary.

15(a)(3) Exhibits. These exhibits are available upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New
York, New York 10017. The exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this 2018 Form 10-K. All other exhibit numbers indicate
exhibits filed by incorporation by reference. Exhibit numbers 10.1 through 10.33 are management contracts or compensatory plans or arrangements.

2.1

*2.2

3.1

3.2

3.3

4.1

4.2

4.3

4.4

Agreement and Plan of Merger, dated as of August 20, 2016, among Pfizer Inc., Montreal, Inc. and Medivation, Inc. is incorporated by
reference from our Current Report on Form 8-K filed on August 22, 2016 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-
K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or
exhibit to the Merger Agreement.)

Stock and Asset Purchase Agreement, dated December 19, 2018, by and among Pfizer Inc., GlaxoSmithKline plc and GlaxoSmithKline
Consumer Healthcare Holdings Limited. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally
furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Stock and Asset Purchase
Agreement.) 1

Our Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our Quarterly Report on Form 10-Q for the
period ended March 28, 2004 (File No. 001-03619).

Amendment dated May 1, 2006 to Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our Quarterly
Report on Form 10-Q for the period ended July 2, 2006 (File No. 001-03619).

Our By-laws, as amended December 18, 2017, are incorporated by reference from our Current Report on Form 8-K filed on December 21,
2017 (File No. 001-03619).

Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Report
on Form 8-K filed on January 30, 2001 (File No. 001-03619).

First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase
Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,
is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2009 (File No. 001-03619).

Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase
Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,
is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2009 (File No. 001-03619).

Third Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan Chase
Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,
is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2013 (File No. 001-03619).

1 Application has been made to the Securities and Exchange Commission for confidential treatment of certain portions of this exhibit. Omitted material for which confidential
treatment has been requested has been separately filed with the Securities and Exchange Commission.

Pfizer Inc. 2018 Form 10-K 30

TABLE OF CONTENTS

4.5

4.6

4.7

4.8

4.9

4.10

4.11

4.12

4.13

4.14

4.15

4.16

4.17

4.18

4.19

4.20

Fourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase
Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,
is incorporated by reference from our Current Report on Form 8-K report filed on May 15, 2014 (File No. 001-03619).

Fifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan Chase
Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001,
is incorporated by reference from our Current Report on Form 8-K report filed on October 6, 2015 (File No. 001-03619).

Sixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York
(successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),
as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on June
3, 2016 (File No. 001-03619).

Seventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank of
New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National
Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K
report filed on November 21, 2016 (File No. 001-03619).

Eighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York
(successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the Chase
Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture
dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 17, 2017 (File No.
001-03619).

Ninth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York
(successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),
as trustee, and The Bank of New York Mellon, London Branch, as paying agent and calculation agent, to Indenture dated as of January 30,
2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 6, 2017 (File No. 001-03619).

Tenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York
(successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))),
as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated
by reference from our Current Report on Form 8-K report filed on December 19, 2017 (File No. 001-03619).

Indenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon
(as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3
(File No. 33-57339), filed on January 18, 1995.

Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan
Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Registration Statement on Form S-3 (File No. 33-57339), filed on
January 18, 1995.

Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to
JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s 2003 Annual Report on Form 10-K (File No. 001-
01225).

Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to
JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on November 15,
2005 (File No. 001-01225).

Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to
JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth’s Current Report on Form 8-K filed on March 28, 2007
(File No. 001-01225).

Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to
JPMorgan Chase Bank, formerly The Chase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October
13, 1992), is incorporated by reference from our Current Report on Form 8-K filed on November 3, 2009 (File No. 001-03619).

Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our
Current Report on Form 8-K filed on September 7, 2018 (File No. 001-03619).

First Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by
reference from our Current Report on Form 8-K filed on September 7, 2018 (File No. 001-03619).

Except as set forth in Exhibits 4.1-19 above, the instruments defining the rights of holders of long-term debt securities of the Company and
its subsidiaries have been omitted. 2

2 We agree to furnish to the Securities and Exchange Commission, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and
its subsidiaries.

Pfizer Inc. 2018 Form 10-K 31

TABLE OF CONTENTS

10.1

10.2

10.3

10.4

10.5

10.6

*10.7

10.8

10.9

10.10

10.11

*10.12

*10.13

10.14

10.15

10.16

10.17

10.18

10.19

10.20

10.21

10.22

10.23

10.24

10.25

2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders (File No.
001-03619).

Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 Annual Report on Form 10-K (File No.
001-03619).

Pfizer Inc. 2014 Stock Plan is incorporated by reference from our Proxy Statement for the 2014 Annual Meeting of Shareholders (File No.
001-03619).

Form of Acknowledgment and Consent and Summary of Key Terms for Stock Option Grants, RSUs and TSRUs is incorporated by reference
from our 2017 Annual Report on Form 10-K (File No. 001-03619).

  Form of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K (File No. 001-03619).

Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2017
Annual Report on Form 10-K (File No. 001-03619).

  Amendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees.

Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2016
(File No. 001-03619).

Amendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by reference
from our Quarterly Report on Form 10-Q for the period ended October 1, 2017 (File No. 001-03619).

Amendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K (File
No. 001-03619).

Amendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the
period ended September 30, 2018 (File No. 001-03619).

  Amendment No. 4 to the Pfizer Supplemental Savings Plan.

  Amendment No. 5 to the Pfizer Supplemental Savings Plan.

Pfizer Inc. Global Performance Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1,
2017 (File No. 001-03619).

  Executive Annual Incentive Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No. 001-03619).

Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No.
001-03619).

Amendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013
Annual Report on Form 10-K (File No. 001-03619).

Amendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from our
Quarterly Report on Form 10-Q for the period ended July 3, 2016 (File No. 001-03619).

Wyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with all material Amendments, is incorporated by
reference from our 2013 Annual Report on Form 10-K (File No. 001-03619).

Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012),
together with all material Amendments is incorporated by reference from our 2011 Annual Report on Form 10-K (File No. 001-03619).

Amendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by reference
from our 2013 Annual Report on Form 10-K (File No. 001-03619).

The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Report
on Form 10-K (File No. 001-03619).

The form of Indemnification Agreement with each of the Named Executive Officers identified in our 2018 Proxy Statement is incorporated by
reference from our 1997 Annual Report on Form 10-K (File No. 001-03619).

Letter to Frank A. D’Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our Current
Report on Form 8-K filed on August 22, 2007 (File No. 001-03619).

Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009 (File
No. 001-03619).

*10.26

  Amendment No. 1 to Pfizer Inc. Executive Severance Plan.

Pfizer Inc. 2018 Form 10-K 32

TABLE OF CONTENTS

10.27

10.28

10.29

10.30

10.31

10.32

Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from
our 2008 Annual Report on Form 10-K (File No. 001-03619).

Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our
Quarterly Report on Form 10-Q for the period ended September 28, 2014 (File No. 001-03619).

Form of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009 (File
No. 001-03619).

Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period
ended April 3, 2011 (File No. 001-03619).

Form of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (File
No. 001-03619).

Form of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (File
No. 001-03619).

* 10.33

  Time Sharing Agreement, dated December 17, 2018, by and between Pfizer Inc. and Ian C. Read.

* 13

* 21

* 23

* 24

*31.1

* 31.2

* 32.1

* 32.2

Portions of the 2018 Financial Report, which, except for those sections incorporated by reference, are furnished solely for the information of
the SEC and are not to be deemed “filed.”

  Subsidiaries of the Company.

  Consent of Independent Registered Public Accounting Firm.

  Power of Attorney (included as part of signature page).

  Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.

Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.

*101.INS

  XBRL Instance Document

*101.SCH

  XBRL Taxonomy Extension Schema

*101.CAL

  XBRL Taxonomy Extension Calculation Linkbase

*101.LAB

  XBRL Taxonomy Extension Label Linkbase

*101.PRE

  XBRL Taxonomy Extension Presentation Linkbase

*101.DEF

  XBRL Taxonomy Extension Definition Document

ITEM 16.

FORM 10-K SUMMARY

A Form 10-K summary is provided at the beginning of this 2018 Form 10-K, with hyperlinked cross-references. This allows users to easily locate the
corresponding items in this 2018 Form 10-K, where the disclosure is fully presented. The summary does not include certain Part III information that is
incorporated by reference from our 2019 Proxy Statement.

Pfizer Inc. 2018 Form 10-K 33

TABLE OF CONTENTS

SIGNATURES

Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the
authorized person named below.

Dated: February 28, 2019

By:

  /S/    MARGARET M. MADDEN

Pfizer Inc.

Margaret M. Madden
Senior Vice President and Corporate Secretary
Chief Governance Counsel

We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our
true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this
Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities
and on the date indicated.

Signature

   Title

/S/    ALBERT BOURLA
Albert Bourla

Chief Executive Officer and Director
(Principal Executive Officer)

  Date

February 27, 2019

/S/    FRANK A. D’AMELIO
Frank A. D’Amelio

Chief Financial Officer, Executive Vice President, Business Operations and Global
Supply   (Principal Financial Officer)

February 26, 2019

/S/    LORETTA V. CANGIALOSI
Loretta V. Cangialosi

Senior Vice President—Controller
(Principal Accounting Officer)

February 26, 2019

/S/    IAN C. READ
Ian C. Read

/S/    DENNIS A. AUSIELLO
Dennis A. Ausiello

/S/    RONALD E. BLAYLOCK
Ronald E. Blaylock

/S/    W. DON CORNWELL
W. Don Cornwell

/S/    JOSEPH J. ECHEVARRIA
Joseph J. Echevarria

/S/    HELEN H. HOBBS
Helen H. Hobbs

Executive Chairman of the Board

February 28, 2019

Director

Director

Director

Director

Director

February 26, 2019

  February 27, 2019

February 26, 2019

February 26, 2019

February 28, 2019

TABLE OF CONTENTS

Signature

   Title

/S/    JAMES M. KILTS
James M. Kilts

/S/    DAN R. LITTMAN
Dan R. Littman

/S/    SHANTANU NARAYEN
Shantanu Narayen

/S/    SUZANNE NORA JOHNSON
Suzanne Nora Johnson

/S/    JAMES C. SMITH
James C. Smith

Director

Director

Director

Director

Director

  Date

February 26, 2019

February 26, 2019

February 26, 2019

February 26, 2019

February 26, 2019

EXHIBIT 2.2

STOCK AND ASSET PURCHASE AGREEMENT

by and among

PFIZER INC.,

GLAXOSMITHKLINE PLC

and

GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED

DATED AS OF DECEMBER 19, 2018

Confidential Treatment Requested by Pfizer Inc.

Section 1.1
Section 1.2

Definitions
Interpretation

TABLE OF CONTENTS

ARTICLE I

DEFINITIONS AND TERMS

ARTICLE II

PURCHASE AND SALE

Section 2.1
Section 2.2
Section 2.3
Section 2.4
Section 2.5
Section 2.6
Section 2.7
Section 2.8
Section 2.9
Section 2.10

Purchase and Sale of Purchased Assets
Consents; Shared Contracts
Excluded Assets
Assumption of Assumed Liabilities
Retained Liabilities
Purchase Consideration
Delivery of the Purchase Consideration
Estimated Closing Statement; Estimated Adjustment Payments
Post-Closing Working Capital and Net Cash Adjustments
Withholding

ARTICLE III

CLOSING

Section 3.1
Section 3.2

Closing
Restated Purchaser Articles of Association

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF SELLER PARENT

Section 4.1
Section 4.2
Section 4.3
Section 4.4
Section 4.5

Organization
Authority; Binding Effect
Conveyed Subsidiaries; Capital Structure
No Conflicts; Consents
Governmental Authorization

Page

     2
   39

   40
   43
   47
   50
   51
   51
   52
   52
   53
   57

   57
   58

   58
   58
   59
   60
   61

Section 4.6
Section 4.7
Section 4.8
Section 4.9
Section 4.10

Section 4.11
Section 4.12
Section 4.13
Section 4.14
Section 4.15
Section 4.16
Section 4.17
Section 4.18
Section 4.19
Section 4.20

Financial Information
Absence of Material Changes
No Litigation
Compliance with Laws
Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and
Recalls
Environmental Matters
Material Contracts
Intellectual Property
Real Property
Assets
Taxes
Employee Benefits; Employees
Global Trade Controls; Anti-Corruption Matters
Brokers
No Other Representations or Warranties

   61
   62
   62
   63

   63
   64
   65
   66
   67
   68
   69
   71
   73
   74
   74

i

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF PURCHASER PARENT

Organization
Authority; Binding Effect
Purchaser; Purchaser Subsidiaries; Capital Structure
No Conflicts; Consents
Governmental Authorization
Financial Information
Absence of Material Changes
Securities Act
No Litigation
Compliance with Laws
Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and
Recalls
Environmental Matters
Material Contracts
Intellectual Property
Real Property
Assets
Taxes
Employee Benefits; Employees
Global Trade Controls; Anti-Corruption Matters
Brokers
No Other Representations or Warranties

ARTICLE VI

COVENANTS

Information and Documents
Conduct of Business
Regulatory Approvals
Reasonable Best Efforts; Further Assurances
Tax Matters
Employees and Employee Benefits
Intercompany Accounts and Arrangements
Access to Records and Information
Mail and Other Communications
Transfer of Business IP and Registrations
No Solicitation
Confidentiality
Guarantees; Letters of Credit
Certain Ancillary Agreements

   76
   76
   78
   79
   80
   80
   81
   81
   81
   81

   82
   83
   84
   85
   86
   87
   88
   90
   92
   93
   93

   96
   98
105
115
117
136
153
155
156
157
157
157
159
161

Section 5.1
Section 5.2
Section 5.3
Section 5.4
Section 5.5
Section 5.6
Section 5.7
Section 5.8
Section 5.9
Section 5.10
Section 5.11

Section 5.12
Section 5.13
Section 5.14
Section 5.15
Section 5.16
Section 5.17
Section 5.18
Section 5.19
Section 5.20
Section 5.21

Section 6.1
Section 6.2
Section 6.3
Section 6.4
Section 6.5
Section 6.6
Section 6.7
Section 6.8
Section 6.9
Section 6.10
Section 6.11
Section 6.12
Section 6.13
Section 6.14

Section 6.15
Section 6.16
Section 6.17
Section 6.18
Section 6.19
Section 6.20
Section 6.21
Section 6.22
Section 6.23

Retained and Transferred Names
Compliance with WARN
Litigation Support; Non-Indemnified Claims
Insurance
Trade Notification
Accounts; Products Received
Directors’ and Officers’ Indemnification
Return of Assets; Transfer of Purchased Assets
Bulk Transfer Laws

ii

162
163
164
165
167
167
167
168
169

Section 6.24
Section 6.25
Section 6.26
Section 6.27

Purchaser Parent Shareholder Meeting; Purchaser Parent Board Recommendation
Resignations
Remedial Action Access
Acknowledgements

ARTICLE VII

INDEMNIFICATION

Section 7.1
Section 7.2
Section 7.3
Section 7.4
Section 7.5
Section 7.6
Section 7.7
Section 7.8
Section 7.9
Section 7.10
Section 7.11

Indemnification by Seller Parent and Purchaser Parent
Indemnification by Purchaser
Indemnification Procedures
Expiration
Certain Limitations
Losses Net of Insurance, Etc.
No Right of Set-Off
Materiality
Mitigation; Other Limitations
Sole Remedy/Waiver
Indemnification Payments

ARTICLE VIII

CONDITIONS TO CLOSING

Section 8.1
Section 8.2
Section 8.3
Section 8.4

Conditions to the Obligations of the Parties
Conditions to the Obligations of Purchaser and Purchaser Parent
Conditions to the Obligations of Seller Parent
Frustration of Closing Conditions

Section 9.1
Section 9.2

Termination
Effect of Termination

ARTICLE IX

TERMINATION

ARTICLE X

MISCELLANEOUS

Section 10.1
Section 10.2
Section 10.3
Section 10.4
Section 10.5
Section 10.6
Section 10.7
Section 10.8

Notices
Amendment; Waiver
Assignment
Entire Agreement
Parties in Interest
Public Disclosure
Expenses
Disclosure Letters; Disclosures Modifying Other Sections of Agreement

170
173
173
173

174
175
175
177
178
178
178
178
179
180
181

181
181
182
182

183
184

186
187
187
188
188
188
188
188

Section 10.9
Section 10.10
Section 10.11
Section 10.12
Section 10.13
Section 10.14
Section 10.15

No Admission
Governing Law; Jurisdiction
Counterparts
Headings
Severability
Rules of Construction
Specific Performance

iii

189
189
190
190
190
190
190

Section 10.16
Section 10.17
Section 10.18

ANNEXES

ANNEX A
ANNEX B-1
ANNEX B-2
ANNEX B-3
ANNEX B-4
ANNEX C
ANNEX D
ANNEX E-1
ANNEX E-2
ANNEX F
ANNEX G

EXHIBITS

EXHIBIT A
EXHIBIT B
EXHIBIT C
EXHIBIT D
EXHIBIT E
EXHIBIT F
EXHIBIT G

Affiliate Status
Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege
Translation of Currencies

191
191
193

Index of Defined Terms
Accounting Principles
Sample Closing Statement
Purchaser Accounting Principles
Sample Purchaser Closing Statement
List of Antitrust Approvals
PCH Split Products
Business Key Products
Purchaser Key Products
PCH Switch Products
Purchaser Parent Retained Assets

List of instruments and documents to be delivered by Seller Parent
List of instruments and documents to be delivered by Purchaser and Purchaser Parent
Form of Purchaser Shareholders Agreement
Form of Structuring Considerations Agreement
Form of Restated Purchaser Articles of Association
Seller Parent Draft Ancillary Agreements
Purchaser Parent Draft Ancillary Agreements

Seller Disclosure Letter
Purchaser Parent Disclosure Letter

iv

STOCK AND ASSET PURCHASE AGREEMENT

This STOCK AND ASSET PURCHASE AGREEMENT, dated as of December 19, 2018 (this “ Agreement ”), is by
and  among  Pfizer  Inc.,  a  Delaware  corporation  (“  Seller  Parent  ”),  GlaxoSmithKline  Plc,  a  public  limited  company  incorporated
under the laws of England (“ Purchaser Parent ”, and together with Seller Parent, the “ Parents ”), and GlaxoSmithKline Consumer
Healthcare Holdings Limited, a company incorporated under the laws of England (“ Purchaser ,” and together with the Parents, the “
Parties ”).

W I T N E S S E T H :

WHEREAS,  in  addition  to  its  other  businesses,  Seller  Parent  is  engaged  through  certain  of  its  Subsidiaries  in  the

Business (as defined below);

WHEREAS,  in  addition  to  its  other  businesses,  Purchaser  Parent  is  engaged  through  Purchaser  in  the  Purchaser

Business (as defined below);

WHEREAS, the Parties desire that (a) the Sellers (as defined below) sell and transfer to Purchaser or the Purchaser
Designated Affiliates (as defined below), and that Purchaser or such Purchaser Designated Affiliates purchase from the Sellers, all of
Seller Parent’s and the other Sellers’ right, title and interest in the Purchased Assets; (b) Purchaser and such Purchaser Designated
Affiliates  assume  the  Assumed  Liabilities  (as  defined  below);  and  (c)  Purchaser  allot  and  issue  to  Seller  Parent  or  its  applicable
designee B Ordinary Shares in the capital of Purchaser, in the case of each of clauses (a) ,  (b) , and (c) , in the manner and upon the
terms and conditions set forth herein;

WHEREAS,  certain  Sellers,  Purchaser,  Purchaser  Parent  and  the  Purchaser  Designated  Affiliates,  at  or  prior  to  the

Closing, will execute each of the Ancillary Agreements; and

WHEREAS, the respective Boards of Directors of Seller Parent, Purchaser Parent and Purchaser have approved this
Agreement,  the  Structuring  Considerations  Agreement,  the  Purchaser  Shareholders  Agreement  and  the  transactions  contemplated
hereby and thereby.

NOW,  THEREFORE,  in  consideration  of  the  foregoing,  the  representations,  warranties,  covenants  and  agreements
contained  herein,  and  other  good  and  valuable  consideration,  the  adequacy  and  receipt  of  which  are  hereby  acknowledged,  the
Parties hereby agree as follows:

ARTICLE I

DEFINITIONS AND TERMS

Section  1.1            Definitions  .  As  used  in  this  Agreement,  the  following  terms  have  the  meanings  set  forth  or  as

referenced below:

“ A Ordinary Shares ” has the meaning set forth in Section 2.7 .

“ ABO ” has the meaning set forth in Section 6.6(e)(i) .

“ Accounting Principles ” has the meaning set forth in Section 2.8 .

“  Action  ”  means  any  action,  cause  of  action,  claim,  charge,  suit,  countersuit,  hearing,  complaint,  arbitration,

subpoena, audit, investigation, litigation or proceeding by or before any court, Governmental Authority or arbitration tribunal.

“ ADR ” means American Depositary Receipts of Purchaser Parent issued under the Deposit Agreement.

“ Affiliate ” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or
under common control with, such Person at any time during the period for which the determination of affiliation is being made. For
purposes  of  this  Agreement,  (a)  the  Conveyed  Subsidiaries  (and  their  Subsidiaries)  shall  be  deemed  to  be  (i)  Affiliates  of  Seller
Parent (and not Purchaser Parent or Purchaser) prior to the Closing, and (ii) Affiliates of Purchaser Parent and Purchaser (and not
Seller  Parent  or  any  other  Seller)  as  of  and  following  the  Closing  and  (b)  Purchaser  and  its  Subsidiaries  shall  be  deemed  to  be
Affiliates of Purchaser Parent (and not Seller Parent) prior to, as of and following the Closing.

“  Agreement  ”  has  the  meaning  set  forth  in  the  preamble  of  this  Agreement,  as  the  same  may  be  amended  or

supplemented from time to time in accordance with the terms hereof.

“ Amended Consignment  Selling Agreement ”  means  the  amended  consignment  selling  agreement,  substantially  in
the  form  provided  to  Seller  Parent  prior  to  the  date  hereof,  to  be  entered  into  between  Hindustan  Unilever  Limited  and  Leo  Asia
Private Limited on or around the time of completion of the divestiture of Horlicks and other consumer healthcare nutrition brands to
Unilever plc and the merger of Leo Consumer Healthcare Limited India with Hindustan Unilever Limited.

“  Ancillary  Agreements  ”  means,  collectively,  the  Transition  Services  Agreement,  Intellectual  Property  License
Agreement, Manufacturing and Supply Agreement (Seller Parent as Supplier), Manufacturing and Supply Agreement (Purchaser as
Supplier),  IP  Assignment  Agreements,  Transitional  Trademark  License  Agreement,  Safety  Data  Exchange  Agreement,  Lease
Agreement, Local Implementing Agreements, the Structuring Considerations Agreement and the Purchaser Shareholders Agreement.

2

“  Ancillary  Implementing  Agreements  ”  means,  collectively,  the  IP  Assignment  Agreements  and  the  Local

Implementing Agreements.

“ Anti-Corruption Laws ” means the U.S. Foreign Corrupt Practices Act of 1977, as amended; the U.K. Bribery Act
of  2010;  and  any  applicable  Law  related  to  anti-bribery  or  anti-corruption  in  any  other  jurisdiction  in  which  the  Business  or  the
Purchaser Business, as applicable, markets, commercializes, distributes and sells products as of the date of this Agreement or as of
the Closing.

“ Antitrust Laws ” means statutes, rules, regulations, orders, decrees, administrative and judicial doctrines, and other
Laws of any jurisdiction that are designed or intended to prohibit, restrict or regulate actions that may have the purpose or effect of
creating a monopoly, lessening competition or restraining trade.

“ Approvals ” means any consent, approval or authorization of, permit or license issued or granted by, Governmental
Order, waiver or exemption by, negative clearance from, or the expiration or early termination of any waiting period imposed by,
any Person (including any third party or Governmental Authority (including any Governmental Antitrust Authority)).

“ Assumed Contracts ” has the meaning set forth in Section 2.1(e) .

“ Assumed Liabilities ” has the meaning set forth in Section 2.4 .

“ B Ordinary Shares ” has the meaning set forth in Section 2.7 .

“ Balance Sheet Date ” has the meaning set forth in Section 4.6(a) .

“ Business ” means the worldwide business of researching, developing, manufacturing, marketing, commercializing,
distributing and selling (a) the products sold under the brand names set forth on Annex E-1 or variations or derivatives of such names
(including  translations  thereof)  (the  “ Business  Key  Products  ”,  and  such  brands,  the  “  Business  Key  Brands  ”),  as  conducted  by
Seller Parent (directly  and indirectly  through its Subsidiaries)  as of the date of this Agreement  and as of immediately  prior to the
Closing  and  (b)  any  over-the-counter  consumer  healthcare  or  medicine  products,  wellness  products  and  other  personal  care,  oral
care, nutrition, skin health, cosmetic and related products (other than the PCH Split Products), as conducted by Seller Parent (directly
and  indirectly  through  its  Subsidiaries)  through  its  Pfizer  Consumer  Healthcare  business  unit  (directly  or  indirectly  pursuant  to  a
contractual arrangement with any other Pfizer business unit, to the extent of the Pfizer Consumer Healthcare business unit’s rights
pursuant to such contractual arrangement) as of the date of this Agreement and as of immediately prior to the Closing.

“ Business Copyrights ” means all Copyrights, Copyright registrations and applications for Copyright registration that

both (a) are owned by Seller Parent or its Subsidiaries and (b) are Related to the Business.

“ Business Day ”  means  any  day  other  than  a  Saturday,  a  Sunday  or  a  day  on  which  banks  in  New  York  City  or

London are authorized or obligated by Law or executive order to close.

3

“ Business Employee ” means each individual who, immediately prior to the Closing (a) is employed by Seller Parent
or its Affiliates (other than the Conveyed Subsidiaries or their Subsidiaries) and devotes 70% or more of his or her services to the
Business, or (b) is employed by any of the Conveyed Subsidiaries (or their Subsidiaries), including, to the extent required by Law,
any  individual  described  in  clause (a) or (b)  who  is  not  actively  at  work  as  a  result  of  an  approved  leave  of  absence  (including
disability leave, military leave, or family medical leave).

“ Business Employee (non-U.S.) ” means a Business Employee based outside of the United States.

“ Business Employee (U.S.) ” means a Business Employee based in the United States.

“ Business IP ” means  (a)  all  Business  Copyrights,  Business  Patent  Rights  , Business  Trademark  Rights,  Business
Know-How  and  Business  Software,  (b)  all  other  Intellectual  Property  that  both  (i)  is  owned,  or  purported  to  be  owned,  by  Seller
Parent or its Subsidiaries and (ii) is Related to the Business, and (c) all Intellectual Property listed in the IP Schedules; provided that
the Business IP does not include any Registered IP that is not listed, or required to be listed, on the IP Schedules .

“ Business IT Systems ” means all Information Systems that both (a) are owned by Seller Parent or its Subsidiaries

and (b)(i) are solely related to, solely held for use with, or solely used in connection with the Business; or (ii) located at a Facility.

“ Business Key Brands ” has the meaning set forth in the definition of “Business.”

“ Business Key Products ” has the meaning set forth in the definition of “Business.”

“ Business Know-How ” means all Know-How that both (a) is owned by Seller Parent or its Subsidiaries and (b) is

Related to the Business.

“ Business Licensed IP ” has the meaning set forth in Section 4.13(c) .

“  Business  Net  Cash  ”  means  the  amount  (which  may  be  a  positive  or  negative  number)  equal  to  (a)  all  Cash
Equivalents minus
(b) all outstanding Funded Indebtedness, in each case, of the Conveyed Subsidiaries and their Subsidiaries, as of
12:01  a.m.  (New  York  time)  on  the  Closing  Date;  provided that  any  Cash  Equivalents  or  Funded  Indebtedness  of  the  Conveyed
Subsidiaries  or  their  Subsidiaries  as  of  12:01  a.m.  (New  York  time)  on  the  Closing  Date  that  will  not  be  Purchased  Assets  or
Assumed Liabilities (subject to the last sentence of Section 2.2(b) ) shall be excluded from the calculation of Business Net Cash.

“ Business Patent Rights ” means all Patent Rights that (a) both (i) are owned by Seller Parent or its Subsidiaries and
(ii) are solely related to, solely held for use with, or solely used in connection with the Business; or (b) are listed on the IP Schedules.

“ Business Software  ”  means  all  Software  that  both  (a)  is  owned  or  purported  to  be  owned  by  Seller  Parent  or  its

Subsidiaries and (b) is Related to the Business.

4

“  Business  Trademark  Rights  ”  means  all  of  the  following  that  are  owned  by  or  registered  to  Seller  Parent  or  its
Subsidiaries  (a)(i)  all  Trademarks  (including  Trademark  registrations  and  applications  for  Trademark  registrations)  that  are  (A)
solely related to, solely held for use with, or solely used in connection with the Business; or (B) listed in the IP Schedules; (b) all
Trademarks that contain, comprise, or include (but only to the extent they include) a Trademark described in the foregoing clause
(a); (c) all Trademarks that are confusingly similar to the Trademarks described in clauses (a) or (b) such that they could not be used
in commerce without infringing such Trademarks; (d) all Internet Identifiers and telephone numbers or other alphanumeric addresses
or mnemonics containing any of the foregoing; and (e) the goodwill of the Business symbolized by any of the foregoing.

“ Business Working Capital ” means the amount (which may be a positive or negative number) equal to (a) the sum of
the assets of the Business as of 12:01 a.m. (New York time) on the Closing Date represented in the line items shown on the Sample
Closing Statement for the Business as of such time, minus
(b) the sum of the liabilities of the Business as of 12:01 a.m. (New York
time) on the Closing Date represented in the liability line items shown on the Sample Closing Statement for the Business as of such
time, in each case calculated in a manner consistent with the Accounting Principles and the Sample Closing Statement; provided that
there  shall  be  excluded  from  such  calculation  the  Excluded  Assets,  the  Retained  Liabilities,  all  assets  or  Liabilities  in  respect  of
Income  Taxes  (whether  current,  deferred,  or  contingent),  any  amounts  included  in  the  calculation  of  Business  Net  Cash,  any
intercompany  accounts  or  Liabilities  to  be  repaid  or  extinguished  pursuant  to  this  Agreement  in  connection  with  the  Closing,
including pursuant to Section 6.7 , and any intercompany receivables and intercompany payables, and other intercompany Liabilities,
solely between or among any Conveyed Subsidiaries and any of their Subsidiaries.

“ Cash Equivalents  ”  means,  with  respect  to  any  Person  and  as  of  any  time,  all  cash  and  cash  equivalents,  checks,
money  orders,  marketable  securities,  short-term  instruments,  bank  and  other  depositary  accounts,  certificates  of  deposit,  time
deposits, negotiable instruments, securities and brokerage accounts, funds in time and demand deposits or similar accounts of such
Person as of such time, calculated, in the case of Seller Parent, in a manner consistent with the Accounting Principles and the Sample
Closing Statement, and in the case of Purchaser, in a manner consistent with the Purchaser Accounting Principles and the Purchaser
Sample Closing Statement, (a) excluding the value of outstanding checks and wire transfers that have been issued or transmitted by
such  Person  but  have  not  yet  cleared  as  of  such  time,  unless  a  corresponding  liability  is  included  in  the  calculation  of  Business
Working Capital or Purchaser Working Capital, as applicable, (b) including the value of uncollected bank deposits of such Person
and outstanding checks and wire transfers that have been issued or transmitted to such Person but have not yet cleared as of such
time  (  provided  that  such  outstanding  checks  and  wire  transfers  ultimately  clear),  unless  in  each  case  a  corresponding  asset  is
included  in  the  calculation  of  Business  Working  Capital  or  Purchaser  Working  Capital,  as  applicable,  and  (c)  including  (i)  with
respect to Purchaser, the value of any out-of-pocket costs or expenses incurred by either Purchaser or Purchaser Parent prior to the
Closing  pursuant  to  Section  2.2  ,  Section  6.3(d)  or  Section  6.3(i)  (in  each  case,  other  than  any  Purchaser  Parent  Transaction
Expenses) and (ii) with respect to the Conveyed Subsidiaries and their Subsidiaries, the value of any out-of-pocket costs or expenses
incurred by either Seller Parent or

5

its Affiliates prior to the Closing pursuant to Section 2.2 , Section 6.3(d) or Section 6.3(i) (in each case, other than any Seller Parent
Transaction Expenses).

“ China Entities ” has the meaning set forth in Section 6.5(g)(iii)(A) .

“ Clean Team Agreement ” means the Clean Team Confidentiality Agreement between Seller Parent and Purchaser

Parent, dated as of December 17, 2018, as amended or supplemented from time to time.

“ Closing ” means the closing of the transactions contemplated by this Agreement pursuant and subject to the terms of

this Agreement.

“ Closing Date ” has the meaning set forth in Section 3.1(a) .

“ Closing Statement Finalization Date ” has the meaning set forth in Section 2.9(f) .

“ Code ” means the Internal Revenue Code of 1986, as amended.

“ Collateral Source ” has the meaning set forth in Section 7.6 .

“  Collective  Bargaining  Agreement  ”  means  any  collective  bargaining  agreement,  labor  agreement,  work  rules  or
practices,  or  any  other  labor-related  agreements  or  arrangements  with  any  labor  union,  labor  organization,  works  council  or
consultation body.

“ Comparable Position ” has the meaning set forth in Section 6.6(b)(i) .

“ Compliance Requirements ” has the meaning set forth in Section 6.15(a) .

“ Confidential Information ” has the meaning set forth in Section 6.12(b) .

“  Confidentiality  Agreement  ”  means  the  Confidentiality  Agreement  between  Seller  Parent  and  Purchaser  Parent,

dated as of October 11, 2018, as amended or supplemented from time to time.

“ Continuation Period ” has the meaning set forth in Section 6.6(c)(i) .

“  Contract  ”  means  any  contract,  agreement,  lease  or  license  (other  than  any  Governmental  Authorization)  that  is
binding  on  any  Person  or  any  part  of  its  property  under  applicable  Law,  including  any  amendment  thereto,  other  than  any  Seller
Group Plan, Purchaser Group Plan, Foreign Seller Group Plan and Foreign Purchaser Group Plan.

“ Controlling Party ” has the meaning set forth in Section 6.5(e)(iii) .

“ Conveyed  Subsidiaries  ”  means  those  entities  set  forth  in  Section 1.1(A) of  the  Seller  Disclosure  Letter,  as  such
Section  may  be  amended  by  Seller  Parent  prior  to  the  Closing  Date  solely  to  reflect  any  changes  pursuant  to  the  Seller  Internal
Restructurings (including any steps Seller

6

Parent shall undertake to effect the Seller Internal Restructurings) made in accordance with Section 6.5(f)(i) .

“ Conveyed Subsidiary Excluded Asset ” has the meaning set forth in Section 2.1 .

“  Conveyed  Subsidiary  Plan  ”  means  each  Seller  Group  Plan  and  each  Foreign  Seller  Group  Plan  sponsored  and

maintained by any Conveyed Subsidiary or Subsidiary thereof.

“ Copyrights ” has the meaning set forth in the definition of “Intellectual Property.”

“ Counterparty ” has the meaning set forth in Section 6.3(d)(ii)(A) .

“ D&O Indemnitees ” has the meaning set forth in Section 6.21(a) .

“ DC Employees (non-U.S.) ” has the meaning set forth in Section 6.6(g)(i) .

“ DC Employees (U.S.) ” has the meaning set forth in Section 6.6(f)(i) .

“ DC Transfer Amounts ” has the meaning set forth in Section 6.6(g)(ii) .

“ Deductible ” has the meaning set forth in Section 7.5(a) .

“ De Minimis Claim Threshold ” has the meaning set forth in Section 7.5(a) .

“ Delayed Antitrust Approval ” has the meaning set forth in Section 6.3(e)(i) .

“ Delayed Business ” has the meaning set forth in Section 6.3(e)(i) .

“ Delayed Business Cut-Off Date ” has the meaning set forth in Section 6.3(e)(i) .

“ Delayed Business Notice ” has the meaning set forth in Section 6.3(e)(i) .

“ Delayed Business Purchaser ” has the meaning set forth in Section 6.3(e)(i) .

“ Delayed Employment Period ” has the meaning set forth in Section 6.6(b)(iii) .

“ Delayed Transfer Employee ” has the meaning set forth in Section 6.6(b)(iii) .

“  Deposit  Agreement  ”  means  the  deposit  agreement  dated  December  27,  2000,  as  amended  and  restated  as  of
December 21, 2007, between Purchaser Parent, the Bank of New York Mellon (as depositary thereunder) and the owners and holders
of ADRs issued thereunder.

“ Direct Transfer ” has the meaning set forth in Section 6.5(g)(iii)(A) .

“ Disability Employee ” has the meaning set forth in Section 6.6(b)(iv) .

“ Disputed Item ” has the meaning set forth in Section 2.9(b) .

7

“  Environmental  Law  ”  means  the  Resource  Conservation  and  Recovery  Act,  42  U.S.C.  Section  6901  et  seq.,  the
Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. Section 9601 et seq., and any applicable Law
of  any  jurisdiction,  as in  effect  on  or  prior  to  the  Closing  Date,  relating  to  pollution  or the  protection  of  the  environment,  natural
resources, wildlife or threatened or endangered species (including indoor and outdoor air, soil, sediment, surface water, groundwater,
drinking  water,  and  surface  or  subsurface  land),  public  or  worker  health  or  safety  with  respect  to  Hazardous  Materials,  or  the
exposure  to,  or  the  use,  storage,  recycling,  treatment,  generation,  transportation,  processing,  handling,  labeling,  Release,  disposal,
recycling, treatment or other management of Hazardous Materials.

“ Environmental Liability ” means any Liability arising under Environmental Laws.

“  Environmental  Permit  ”  means  any  Governmental  Authorization  held  by  either  a  Conveyed  Subsidiary  (or  a
Subsidiary thereof) for its then-current operations or a Seller for the then-current operation of any Real Property, each following the
consummation of any Seller Internal Restructurings and as of the Closing Date, and required pursuant to an Environmental Law.

“ Equipment ” has the meaning set forth in Section 2.1(d) .

“ Equipment Leases ” has the meaning set forth in Section 2.1(d) .

“ ERISA ” means the Employee Retirement Income Security Act of 1974, as amended.

“ ERISA Affiliate ” means any Person that would be treated at a relevant time as a single employer with any other

Person under Section 4001(b) of ERISA or Section 414 of the Code.

“ Estimated Business Deficit Adjustment ” has the meaning set forth in Section 2.8(c) .

“ Estimated Business Excess Adjustment ” has the meaning set forth in Section 2.8(b) .

“ Estimated Business Net Cash ” means Seller Parent’s good-faith estimate of the Business Net Cash as set forth on

the Estimated Closing Statement.

“ Estimated Business Working Capital ” means Seller Parent’s good-faith estimate of the Business Working Capital

as set forth on the Estimated Closing Statement.

“ Estimated Closing Statement ” means a written statement setting forth the Estimated Business Working Capital and
the Estimated Business Net Cash, prepared in a manner consistent with the Accounting Principles and the Sample Closing Statement.

“ Estimated Purchaser Closing Statement ” means a written statement setting forth the Estimated Purchaser Working
Capital  and the Estimated  Purchaser  Net Cash, prepared  in a manner consistent  with the Purchaser  Accounting  Principles  and the
Sample Purchaser Closing Statement.

“ Estimated Purchaser Deficit Adjustment ” has the meaning set forth in Section 2.8(e) .

8

“ Estimated Purchaser Excess Adjustment ” has the meaning set forth in Section 2.8(d) .

“ Estimated Purchaser Net Cash ” means Purchaser Parent’s good-faith estimate of the Purchaser Net Cash as set forth

on the Estimated Purchaser Closing Statement.

“  Estimated  Purchaser  Working  Capital  ”  means  Purchaser  Parent’s  good-faith  estimate  of  the  Purchaser  Working

Capital as set forth on the Estimated Purchaser Closing Statement.

“ Excluded Assets ” has the meaning set forth in Section 2.3(a) .

“ Facilities ” means the manufacturing and research and development facilities listed in Section 1.1(B) of the Seller

Disclosure Letter.

“ FCA ” means the United Kingdom Financial Conduct Authority.

“ FICA ” has the meaning set forth in Section 6.6(p) .

“  Filings  ”  means  any  registrations,  applications,  declarations,  reports,  submissions  or  other  filings  with,  or  any

notices to, any Person (including any third party or Governmental Authority (including any Governmental Antitrust Authority)).

“ Final Business Deficit Adjustment ” has the meaning set forth in Section 2.9(h) .

“ Final Business Excess Adjustment ” has the meaning set forth in Section 2.9(g) .

“ Final Business Net Cash ” has the meaning set forth in Section 2.9(e) .

“ Final Business Working Capital ” has the meaning set forth in Section 2.9(e) .

“ Final Closing Statement ” means (a) if no notice of Disputed Items with respect to the Proposed Closing Statement
is delivered by either Parent within the period provided in Section 2.9(b) , the Proposed Closing Statement as prepared by Purchaser,
or (b) if such a notice of Disputed Items with respect to the Proposed Closing Statement is timely delivered by a Parent, the Proposed
Closing  Statement  with  modifications  as  agreed  to  in  writing  by  the  Parties  and/or  as  directed  by  the  Independent  Accountant
pursuant to Section 2.9(d) , as applicable.

“  Final  Determination  ”  means  (a)  with  respect  to  U.S.  federal  Income  Taxes,  a  “determination”  as  defined  in
Section 1313(a) of the Code, and (b) with respect to Taxes other than U.S. federal Income Taxes, any final determination of Liability
in  respect  of  a  Tax  that,  under  applicable  Law,  is  not  subject  to  further  appeal,  review  or  modification  through  proceedings  or
otherwise, including the expiration of a statute of limitations or a period for the filing of claims for refunds, amended Tax Returns or
appeals from adverse determinations.

“ Final Pre-Closing Income Tax Amount ” has the meaning set forth in Section 6.5(d)(vi)(A) .

9

“ Final Purchaser Net Cash ” has the meaning set forth in Section 2.9(e) .

“ Final Purchaser Parent Deficit Adjustment ” has the meaning set forth in Section 2.9(j) .

“ Final Purchaser Parent Excess Adjustment ” has the meaning set forth in Section 2.9(i) .

“ Final Purchaser Working Capital ” has the meaning set forth in Section 2.9(e) .

“ Financial Statements ” has the meaning set forth in Section 4.6(a) .

“  Foreign  Purchaser  Group  Plan  ”  means  each  pension,  profit  sharing,  savings,  retirement,  health,  life,  disability,
deferred compensation, incentive, bonus, employment, retention, change in control, termination, severance and fringe benefit plan,
program, or arrangement maintained, or contributed to, by Purchaser Parent or any of its Affiliates in which any Purchaser Business
Employee (non-U.S.) or Former Purchaser Business Employee (non-U.S.) participates or is a party, other than plans, programs, or
arrangements required to be maintained or contributed to by the Laws of the relevant jurisdiction and other than the Purchaser Group
Plans.

“ Foreign Seller Group Plan ” means each pension, profit sharing, savings, retirement, health, life, disability, deferred
compensation, incentive, bonus, employment, retention, change in control, termination, severance and fringe benefit plan, program,
or arrangement maintained, or contributed to, by Seller Parent or any of its Affiliates in which any Business Employee (non-U.S.) or
Former  Business  Employee  (non-U.S.)  participates  or  is  a  party,  other  than  plans,  programs,  or  arrangements  required  to  be
maintained or contributed to by the Laws of the relevant jurisdiction and other than the Seller Group Plans.

“ Form Ancillary Agreement ” has the meaning set forth in Section 6.14(a) .

“ Former Business Employee ” means an employee of Seller Parent or its Affiliates who both (A) performed services
on behalf of or to the Business as of immediately prior to his or her termination of employment, and (B) would have been considered
a  Business  Employee  if  his  or  her  employment  had  not  terminated  prior  to  the  Closing.    The  term  “Former  Business  Employee”
when  followed  by  “(U.S.)”  means  a  Former  Business  Employee  who  was  employed  in  the  United  States  and  when  followed  by
“(non-U.S.)” means a Former Business Employee who was employed outside the United States.

“  Former  Purchaser  Business  Employee  ”  means  an  employee  of  Purchaser  Parent  or  its  Affiliates  who  both
(A) performed services on behalf of or to the Purchaser Business as of immediately prior to his or her termination of employment,
and  (B)  would  have  been  considered  a  Purchaser  Business  Employee  if  his  or  her  employment  had  not  terminated  prior  to  the
Closing.    The  term  “Former  Purchaser  Business  Employee”  when  followed  by  “(U.S.)”  means  a  Former  Purchaser  Business
Employee  who  was  employed  in  the  United  States  and  when  followed  by  “(non-U.S.)”  means  a  Former  Purchaser  Business
Employee who was employed outside the United States.

10

“ FSMA ” means the UK Financial Services and Markets Act 2000.

“  Fundamental  Purchaser  Parent  Representations  ”  means  the  representations  and  warranties  of  Purchaser  Parent

contained in Section 5.1 , Section 5.2 , Section 5.3(a) , Section 5.3(b) , Section 5.16 and Section 5.20 .

“ Fundamental Seller Parent Representations ” means the representations and warranties of Seller Parent contained in

Section 4.1 , Section 4.2 , Section 4.3(a) , Section 4.3(b) , Section 4.15 and Section 4.19 .

“ Funded Indebtedness  ”  means,  with  respect  to  any  Person  and  as  of  any  time,  without  duplication,  the  following
obligations of such Person as of such time (including in respect of principal, accrued and unpaid interest, premiums (including make-
whole  premiums),  prepayment  penalties,  breakage  costs  and  other  fees,  expenses  and  charges  that  would  arise  as  a  result  of  the
discharge of such amount owed and directly attributable to the consummation of the Closing), calculated, in the case of Seller Parent,
in a manner consistent with the Accounting Principles and the Sample Closing Statement, and in the case of Purchaser, in a manner
consistent  with  the  Purchaser  Accounting  Principles  and  the  Purchaser  Sample  Closing  Statement:  (a)  the  outstanding  principal
amount of any indebtedness for borrowed money; (b) all capitalized lease obligations that are classified by such Person as a balance
sheet  liability  in  accordance  with  the  Accounting  Principles  or  Purchaser  Accounting  Principles,  as  applicable;  (c)  all  direct
reimbursement obligations in respect of letters of credit, solely to the extent such letters of credit have actually been drawn; (d) all
obligations  evidenced  by  bonds,  notes,  debentures  or  debt  securities;  (e)  any  net  payment  obligations  under  any  interest  rate  or
currency  hedging  Contract  to  the  extent  classified  by  such  Person  as  a  balance  sheet  liability  in  accordance  with  the  Accounting
Principles or Purchaser Accounting Principles, as applicable, calculated as of such time as the net amount of payment that would be
required to be paid by such Person to the counterparty bank(s) upon the unwind or early termination of such Contract at such time;
(f) any amounts owing as deferred purchase price of, or a contingent payment for, any business, assets, property, goods or services
(other than ordinary course trade payables and those listed on Section 1.1(C) of the Seller Disclosure Letter); (g) all guarantees and
keepwell  arrangements  issued  by  such  Person  to  a  creditor  against  a  loss  with  respect  to  the  obligations  described  in  clauses  (a)
through (f) of another Person; and (h) in the case of the Conveyed Subsidiaries and their Subsidiaries, Seller Accrued Income Taxes
and, in the case of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries and their Subsidiaries), Purchaser Accrued
Income Taxes; provided that Funded Indebtedness shall not include (i) any intercompany payables, or other intercompany Liabilities,
solely between or among (A) any Conveyed Subsidiaries (or any of their Subsidiaries) and any of their Subsidiaries or (B) Purchaser
(or  any  of  its  Subsidiaries)  and  any  of  its  Subsidiaries,  (ii)  any  intercompany  accounts  or  other  Liabilities  to  be  repaid  or
extinguished pursuant to this Agreement in connection with the Closing, including pursuant to Section 6.7 , (iii) any Liabilities in
respect  of  Taxes  (other  than  Purchaser  Accrued  Income  Taxes  or  Seller  Accrued  Income  Taxes),  including  any  reserves  for
contingent Taxes, or (iv) any amounts included in the calculation of the Business Working Capital or Purchaser Working Capital.

“ FUTA ” has the meaning set forth in Section 6.6(p) .

“ GAAP ” means generally accepted accounting principles in the United States.

11

“ Global Trade Control Laws ” means U.S. Export Administration Regulations; the U.S. International Traffic in Arms
Regulations;  the  U.S.  economic  sanctions  rules  and  regulations  implemented  under  statutory  authority  and/or  the  President’s
Executive  Orders  and  administered  by  the  U.S.  Department  of  the  Treasury  Office  of  Foreign  Assets  Control;  European  Union
(E.U.)  Council  Regulations  on  export  controls,  including  Nos.  428/2009,  267/2012;  other  E.U.  Council  sanctions  regulations,  as
implemented in E.U. Member States; United Nations sanctions policies; and other relevant economic sanctions, export and import
control  Laws  in  any  other  jurisdiction  in  which  the  Business  or  the  Purchaser  Business,  as  applicable,  markets,  commercializes,
distributes and sells products as of the date of this Agreement or as of Closing.

“ Goods in Transit ” means Products that have left a facility of Seller Parent (or any Subsidiary of Seller Parent), were
recorded by Seller Parent (or the Subsidiary of Seller Parent) as sales in their accounting systems at or prior to 12:01 a.m. (New York
time) on the Closing Date, but have not been received by customers or Purchaser.

“ Governmental Antitrust Authority ” means any of the U.S. Federal Trade Commission, the Antitrust Division of the
U.S. Department of Justice, the attorneys general of the several states of the United States and any other Governmental Authority
having jurisdiction with respect to the transactions contemplated hereby pursuant to applicable Antitrust Laws.

“ Governmental Authority ” means any supra-national, transnational, national, state, municipal or local government,
any  federal,  state,  city,  municipality  or  other  political  subdivision  thereof  and  any  entity,  department,  bureau,  body,  agency,
commission,  authority  or  court  of  competent  jurisdiction,  whether  domestic,  foreign  or  multinational,  exercising  executive,
legislative, judicial, regulatory, taxing or administrative functions of or pertaining to government and any executive official thereof
or any arbitral body .

“ Governmental Authorizations ” means all licenses, permits, certificates, clearances, registrations, consents and other
authorizations  and  approvals  from  any  Governmental  Authority  required  to  carry  on  the  Business  or  the  Purchaser  Business,  as
applicable, under the applicable Laws of any Governmental Authority.

“  Governmental  Order  ”  means  any  order,  writ,  judgment,  injunction,  decree,  ruling,  stipulation,  determination  or

award entered by or with any Governmental Authority.

“  Hazardous  Materials  ”  means  all  pollutants,  contaminants,  wastes  or  chemicals  or  other  materials  or  substances
defined,  classified,  listed  or  regulated  as  “hazardous,”  “extremely  hazardous,”  “restricted  hazardous  wastes,”  “dangerous,”
“pollutants,”  “contaminants,”  “toxic,”  or  words  of  similar  import  under  any  Environmental  Law,  including  asbestos,  asbestos
containing materials, lead-based paint, toxic mold, petroleum, and petroleum products, or for which Liability may be imposed under
Environmental Law.

“ Hold-Back Termination Date ” has the meaning set forth in Section 6.3(e)(i) .

“  HSR  Act  ”  means  the  Hart-Scott-Rodino  Antitrust  Improvements  Act  of  1976,  as  amended,  and  the  rules  and

regulations promulgated thereunder.

12

“  IFRS  ”  means  the  body  of  pronouncements  issued  by  the  International  Accounting  Standards  Board  (IASB),
including International Financial Reporting Standards and interpretations approved by the IASB, International Accounting Standards
and Standing Interpretations Committee interpretations approved by the predecessor International Accounting Standards Committee
as  endorsed  under  the  EU  accounting  regulations  and  included  in  the  periodic  report  showing  the  status  of  endorsement  by  the
European Financial Reporting Advisory Group.

“ Income Tax ” means any U.S. federal, state, local or non-U.S. Taxes imposed on or calculated by reference to net

income or profits (however denominated), franchise Taxes and other similar Taxes.

“ Income Tax Return ” means any Tax Return in respect of Income Taxes.

“ Indebtedness ” means, with respect to any Person and as of any time, without duplication, the following obligations
as of such time: (a) all Funded Indebtedness of such Person and (b) all letters of credit or performance bonds issued for the account
of such Person (and reimbursement obligations in respect thereof).

“ Indemnified Party ” has the meaning set forth in Section 7.3(a) .

“ Indemnifying Party ” has the meaning set forth in Section 7.3(a) .

“  Independent  Accountant  ”  means  any  registered  independent  public  accounting  firm  of  international  standing  as

Seller Parent and Purchaser shall mutually agree upon.

“ Indirect Transfers ” has the meaning set forth in Section 6.5(g)(iii)(B) .

“  Information  Systems  ”  means  (a)  computer  systems,  servers,  workstations,  routers,  hubs,  switches,  data
communications  networks  (other  than  the  Internet)  and  other  information  technology  equipment  used  to  create,  store,  transmit,
exchange  or  receive  information,  voice  or  data  and  (b)  documentation,  user  manuals,  and  training  manuals  documenting  the
functionality or use of any of the foregoing.

“ Insurance Matter ” has the meaning set forth in Section 6.18(b) .

“ Insurance Policy ” has the meaning set forth in Section 6.18(b) .

“  Intellectual  Property  ”  means  all  intellectual  property  rights  throughout  the  world,  including:  (a)  Patent  Rights,
(b)  trademarks,  service  marks,  corporate  names,  trade  names,  Internet  Identifiers,  logos,  slogans,  trade  dress,  and  other  similar
designations of source or origin, together with the goodwill symbolized by any of the foregoing (“ Trademarks ”), (c) copyrights and
intellectual property rights in copyrightable and other works, moral rights, design rights and other sui generis rights (“ Copyrights ”),
(d)    trade  secrets  or  other  proprietary  rights  in  clinical,  technical,  scientific,  manufacturing,  regulatory  and  other  information,
inventions (whether or not patentable), discoveries, designs, results, techniques, database rights, data, databases, data collections and
other  know-how,  including  plans,  processes,  practices,  methods,  trade  secrets,  instructions,  formulae,  formulations,  recipes,
compositions, specifications, protocols, analytical and quality control

13

information and procedures, test data and results, reports, studies, and marketing, pricing, distribution, cost and sales information (“
Know-How ”), (e) intellectual property rights in Software and (f) applications and registrations and renewals for, and all associated
rights with respect to, any of the foregoing in any jurisdiction, including all rights to collect royalties, products and proceeds with
respect to any of the foregoing.

“ Intellectual Property License Agreement ” has the meaning set forth in Section 6.14(a) .

“ Intentional Breach ” means, with respect to any representation, warranty, covenant or agreement in this Agreement,
an action or omission taken or omitted to be taken on or after the date hereof that the breaching Person intentionally takes (or fails to
take) and knows would, or would reasonably be expected to, cause a material breach of such representation, warranty, covenant or
agreement.

“  Internet  Identifier  ”  means  any  Internet  domain  name  or  electronic  address,  Internet  domain  name  registration,
uniform resource locator, social media accounts, or social media account addresses or other identifiers, alpha-numeric designations
associated with any of the foregoing, and account names or identifiers, passwords or other credentials to access or modify the access
rights to any of the foregoing.

“ Inventory ” means (a) all raw material inventory, work-in-process inventory, Goods in Transit and finished Products
inventory, in each case, solely owned by Sellers or the Conveyed Subsidiaries (or any of their Subsidiaries) and solely used or held
for use in the Business (other than any raw material inventory, work-in-process inventory and finished products inventory subject to
a Manufacturing and Supply Agreement (Seller Parent as Supplier)) and (b) raw material inventory, work-in-process inventory and
finished products inventory, in each case, solely owned by Sellers or the Conveyed Subsidiaries (or any of their Subsidiaries) and
solely  used  or  held  for  use  in  a  Manufacturing  and  Supply  Agreement  (Purchaser  as  Supplier),  but  excluding  any  raw  material
inventory or work-in-process inventory (including any active pharmaceutical ingredients) that Seller Parent or any of its Affiliates
supplies  through  a  tolling  or  similar  arrangement  (including,  following  the  Closing,  any  Manufacturing  and  Supply  Agreement
(Purchaser as Supplier), and including all Customer-Supplied Materials (as defined therein)) to a Facility prior to, on or following
the Closing for the manufacture of products subject to a Manufacturing and Supply Agreement (Purchaser as Supplier) (which raw
material inventory and work-in-process inventory (including such Customer-Supplied Materials), for clarity, shall not be Inventory
or any other Purchased Asset and Purchaser shall acquire no right, title or interest therein).

“ IP Assignment Agreements ” has the meaning set forth in Section 6.14(a) .

“ IP Schedules ” has the meaning set forth in Section 4.13(a) .

“ IRS ” means the U.S. Internal Revenue Service.

“ Know-How ” has the meaning set forth in the definition of “Intellectual Property.”

14

“ Knowledge of Purchaser Parent ” means the actual knowledge of any of the individuals listed in Section 1.1(B) of

the Purchaser Parent Disclosure Letter.

“ Knowledge of Seller Parent ” means the actual knowledge of any of the individuals listed in Section 1.1(D) of the

Seller Disclosure Letter.

“ Laws ” means any law, act, statute, ordinance, rule, directive, regulation, code, treaty (including any Tax treaty) of

any Governmental Authority or any Governmental Order.

“ Lease Agreement ” has the meaning set forth in Section 6.14(d) .

“  Leased  Purchaser  Real  Property  ”  means  all  real  property  primarily  related  to,  held  for  use  with,  or  used  in

connection with the Purchaser Business, other than the Owned Purchaser Real Property.

“ Leased Real Property ” has the meaning set forth in Section 2.1(c) .

“  Liabilities  ”  means  any  and  all  Losses,  debts,  liabilities  and  obligations,  whether  accrued  or  unaccrued,  fixed  or

variable, known or unknown, absolute or contingent, matured or unmatured or determined or determinable.

“ Liens ” means any lien, security interest, mortgage, charge, pledge, license, easement or other similar encumbrance,
title  defect  or  material  use  or  transfer  restriction,  it  being  understood  and  agreed  that  “Lien”  does  not  include  any  non-exclusive
license or other non-exclusive grant of rights to Intellectual Property.

“ Listing Rules ” means the rules and regulations made by the FCA pursuant to Part 6, section 73A of the FSMA and

contained in the FCA’s publication of the same name.

“  Local  Implementing  Agreements  ”  means  the  various  Share  transfer  agreements,  Purchased  Asset  transfer
agreements  and  other  agreements  and  the  schedules  and  exhibits  thereto  to  be  entered  into  by  Purchaser  and  the  Purchaser
Designated  Affiliates  and  the  applicable  Sellers  for  purposes  of  implementing  the  sale,  transfer,  conveyance,  and  assignment,  as
applicable, of the applicable Sellers’ right, title and interest in the Shares and the other Purchased Assets to, and the employment of
the Business Employees consistent with Section 6.6 by, Purchaser and such Purchaser Designated Affiliates, and the assumption of
the Assumed Liabilities, as the case may be, in the appropriate jurisdictions, prepared and executed in accordance with Section 6.14 .
The Parties agree that the Local Implementing Agreements shall not expand or limit the rights and obligations of the Parties or their
Affiliates  beyond  those  provided  for  in  this  Agreement,  and  that  the  Local  Implementing  Agreements  shall  not  provide  for  any
additional rights, obligations or indemnities of the Parties or their Affiliates, that are not provided for in this Agreement. For clarity,
the Indirect Transfers shall be effected pursuant to a Local Implementing Agreement.

“ Loss ” means any and all damages, losses, Taxes, penalties, judgments, settlements, payments, fines, interest, costs
and expenses (including the reasonable out-of-pocket costs and expenses of attorneys and other professional advisors incurred in the
investigation, defense and/or

15

settlement thereof), but excluding any damages to the extent not reasonably foreseeable, loss of business reputation, or punitive or
exemplary  damages  (in  each  case,  other  than  to  the  extent  such  damages  are  awarded  to  any  third  party  by  Governmental  Order
against, and paid by, an Indemnified Party).

“ Make-Whole Award ” has the meaning set forth in Section 6.6(c)(vi) .

“ Manufacturing and Supply Agreement (Purchaser as Supplier) ” has the meaning set forth in Section 6.14(a) .

“ Manufacturing and Supply Agreement (Seller Parent as Supplier) ” has the meaning set forth in Section 6.14(a) .

“  Manufacturing  Registrations  ”  means  all  Governmental  Authorizations  granted  to  Seller  Parent  or  any  of  its

Affiliates by, or pending with, any Governmental Authority for manufacturing facilities that are Facilities.

“ Material Adverse Effect ” means any change, event, development, occurrence or effect that, individually or in the
aggregate,  has  had,  or  would  reasonably  be  expected  to  have,  a  material  adverse  effect  on  the  business,  results  of  operations  or
financial condition of the Business, taken as a whole; provided , however , that any change, event, development, occurrence or effect
to  the  extent  resulting  from  or  arising  out  of  any  of  the  following,  either  alone  or  in  combination,  shall  not  be  considered  in
determining  whether  there  has  been  or  may  be  a  Material  Adverse  Effect:  (i)  general  economic  conditions  (including  changes  in
(A) financial  or market  conditions,  (B)  currency  exchange  rates, (C)  prevailing  interest  rates  or credit  markets  or (D) the price  of
commodities  or  raw  materials)  applicable  in  countries,  jurisdictions  or  markets  in  which  there  are  Purchased  Assets  or  sales  of
Products (or the securities, syndicated loan, credit or financial markets globally or in any such economies, countries, jurisdictions or
markets); (ii) changes (or proposed changes) in the legal, Tax, regulatory or political conditions (including changes in Law or in the
interpretation or application of Law) applicable in countries, jurisdictions or markets in which there are Purchased Assets or sales of
Products;  (iii)  changes  (or  proposed  changes)  in  GAAP  or  other  applicable  accounting  standards  or  the  interpretations  thereof;
(iv)  conditions  in  or  affecting  the  industries  in  which  the  Business  operates;  (v)  conditions  resulting  from  natural  disasters,
earthquakes,  hurricanes,  tsunamis,  floods,  fires,  storms,  typhoons,  lightning,  hail  storms,  blizzards,  tornadoes,  droughts,  cyclones,
arctic frosts, mudslides, wildfires, manmade disasters, acts of God, pandemics or other weather-related or natural conditions, or the
commencement, occurrence, continuation or intensification of any war (whether or not declared), sabotage, armed hostilities, civil
unrest, military attacks or acts of terrorism or declaration of national emergency; (vi)  any failure by the Business to meet budgets,
plans, projections or forecasts (whether internal or otherwise) for any period (it being understood that the underlying causes of the
failure to meet such budgets, plans, projections or forecasts may be taken into account in determining whether a Material Adverse
Effect  has  occurred  unless  such  causes  are  otherwise  excepted  under  this  paragraph;  provided  that  this  clause  (vi)  shall  not  be
construed  as  implying  that  Seller  Parent  is  making  any  representation  or  warranty  herein  with  respect  to  any  budgets,  plans,
projections or forecasts, and no such representations or warranties are being made); (vii) any change in Seller Parent’s stock price or
trading volume (it being understood that the underlying causes of such change may be taken

16

into account in determining  whether a Material Adverse Effect has occurred unless such causes are otherwise excepted under this
paragraph);  (viii)  Seller  Parent’s  pursuit  of  strategic  alternatives  for  the  Business  or  the  negotiation,  execution,  announcement,
performance,  pendency  or  consummation  of  this  Agreement,  the  transactions  contemplated  hereby  or  by  any  of  the  Ancillary
Agreements  (it  being  understood  and  agreed  that  the  foregoing  shall  not  apply  to  the  representations  and  warranties  set  forth  in
Section  4.4  ),  the  identity  of  Purchaser  or  any  of  its  Affiliates  or  any  acts  or  omissions  of  Purchaser  or  its  Affiliates  or  any
communication  by  Purchaser  or  any  of  its  Affiliates,  including  in  respect  of  its  plans  or  intentions  (including  in  respect  of  the
Business  Employees)  with  respect  to  the  Business,  including  the  impact  thereof  on  relationships,  contractual  or  otherwise,  with
customers, suppliers, distributors, partners or employees; (ix) without limiting clause (viii) above, any action taken by Seller Parent
or its Affiliates (including any Conveyed Subsidiary and their Subsidiaries) as expressly required by this Agreement, including any
changes, events or effects arising out of the application of Antitrust Laws (including any action or judgment arising under Antitrust
Laws) to this Agreement or the transactions contemplated hereby or the effect of any action taken (or agreed to be taken) by Seller
Parent, Purchaser, or any of their respective Affiliates pursuant to Section 6.3 ; (x) any action taken, or failure to take action, or such
other  changes  or  events,  in  each  case,  to  which  Purchaser  has  consented  in  writing;  (xi)  any  labor  strike,  slow  down,  lockout  or
stoppage, pending or threatened, against the Business; or (xii) any Excluded Assets or Retained Liabilities; provided , further , that
any  change,  event,  development,  occurrence  or  effect  referred  to  in  clauses  (i)  ,  (ii)  ,  (iii)  ,  (iv)  and  (v)  may  be  considered  in
determining whether there has been or may be a Material Adverse Effect to the extent such change, event, development, occurrence
or effect has a disproportionate adverse impact on the business, results of operations or financial condition of the Business, taken as a
whole,  relative  to  the  other  businesses  in  the  industries  in  which  the  Business  operates  (in  which  case  only  such  incremental
disproportionate impact may be considered in determining whether there has been or may be a Material Adverse Effect).

“ Material Contract ” has the meaning set forth in Section 4.12(a) .

“ Most Cost-Effective Manner ” means a Remedial Action based upon (a) the least stringent clean-up standards that,
based on the use classification (industrial, commercial or residential) as of the Closing Date of the applicable real property subject to
the  Remedial  Action,  are  established  under  Environmental  Law  and  (b)  the  least-costly  methods  that  are  in  accordance  with
Environmental  Law,  in  each  case  of  (a)  and  (b)  that  are  approved  by  or  otherwise  acceptable  to  the  applicable  Governmental
Authorities, including the use of engineering and institutional controls to eliminate or minimize exposure pathways, and may also
include, in the reasonable discretion of the Party responsible for such Remedial Action, any other Remedial Action that is allowed
under applicable Environmental Law and approved by or otherwise acceptable to the applicable Governmental Authorities.

“ Name Change Date ” has the meaning set forth in Section 6.15(a) .

“ New Subsidiaries ” has the meaning set forth in Section 6.27 .

“ Non-Controlling Party ” has the meaning set forth in Section 6.5(e)(iii) .

“ Non-Indemnified Claims ” has the meaning set forth in Section 6.17(b) .

17

“ Notice 7 ” has the meaning set forth in Section 6.5(g)(iii)(B) .

“ Off-the-Shelf Software ” means software licensed from a third party on general commercial terms that continues to

be commonly available for license on such general commercial terms.

“ Ordinary Shares ” means the A Ordinary Shares and the B Ordinary Shares.

“ Outside Date ” has the meaning set forth in Section 9.1(b) .

“ Outstanding Antitrust Jurisdiction ” has the meaning set forth in Section 6.3(e)(i) .

“  Owned  Purchaser  Real  Property  ”  means  the  real  property  that  both  (a)  is  owned  by  Purchaser  Parent  or  its

Subsidiaries and (b) is primarily related to, held for use with, or used in connection with the Purchaser Business.

“ Owned Real Property ” has the meaning set forth in Section 2.1(b) .

“ Parent Indemnified Parties ” has the meaning set forth in Section 7.2 .

“ Parents ” has the meaning set forth in the preamble of this Agreement.

“ Parties ” has the meaning set forth in the preamble of this Agreement.

“ Patent Rights ” means (a) issued patents, (b) invention  disclosures,  and pending patent applications,  including  all
provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon,
(c)  patents-of-addition,  reissues,  reexaminations  and  extensions  or  restorations  by  existing  or  future  extension  or  restoration
mechanisms,  including  patent  term  adjustments,  patent  term  extensions,  supplementary  protection  certificates  or  the  equivalent
thereof, (d) inventor’s certificates, (e)  registered or other utility model rights, registered or other design rights and registered or other
industrial property rights and (f) United States and foreign counterparts of any of the foregoing.

“ PCH Split Products ” has the meaning set forth in the definition of “Retained Businesses.”

“ Pension Transfer Amounts ” has the meaning set forth in Section 6.6(e)(ii) .

“ Permitted Liens ” means (a) Liens approved in writing by Purchaser; (b) statutory Liens arising out of operation of
Law  with  respect  to  a  Liability  incurred  in  the  ordinary  course  of  business  for  amounts  which  are  not  yet  due  and  payable  or  for
which  an  adequate  reserve  has  been  established  in  the  Financial  Statements;  (c)  Liens  and  other  imperfections  of  title  that  do  not
materially detract from the value or materially impair the use of the property subject thereto or make such property unmarketable or
uninsurable; (d) with respect to real property, (i) easements, declarations, covenants, rights-of-way, restrictions and other charges,
instruments or encumbrances that are recorded against title to real estate which do not materially impair the use or occupancy of such
real property in the operation of the Business conducted thereon; (ii) zoning ordinances,

18

variances, conditional use permits and similar regulations, permits, approvals and conditions which are not violated by the current
use of the real property subject thereto in the operation of the Business conducted thereon; (iii) Liens not created by the Sellers that
affect  the  underlying  fee  interest  of  any  leased  real  property,  including  master  leases  or  ground  leases,  which  do  not  materially
impair the use or occupancy of such real property in the operation of the Business conducted thereon; and (iv) all matters of record
and any state of facts that an accurate survey or inspection of the property would disclose to the extent such matters or states of fact
do  not  materially  detract  from  the  value  or  materially  impair  the  use  or  occupancy  of  such  real  property  in  the  operation  of  the
Business  conducted  thereon;  (e)  Liens  for  Taxes,  assessments  or  other  governmental  charges  or  levies  (i)  that  are  not  yet  due  or
payable  or  (ii)  that  are  being  contested  in  good  faith  by  appropriate  proceedings  and  for  which  an  adequate  reserve  has  been
established  in  the  Financial  Statements;  (f)  mechanics’,  materialmen’s,  carriers’,  workmen’s,  warehousemen’s,  repairmen’s,
landlords’ or other similar Liens and security obligations arising in the ordinary course of business for amounts which are not yet due
and  payable  or  for  which  an  adequate  reserve  has  been  established  in  the  Financial  Statements;  (g)  Liens  arising  under  original
purchase  price  conditional  sales  contracts  and  equipment  leases  with  third  parties  entered  into  in  the  ordinary  course  of  business;
(h) Liens that will be released and, as appropriate, removed of record, at or prior to the Closing Date in accordance with the terms of
this Agreement; (i) Liens arising on assets and products sold in the ordinary course of business; (j) Liens arising in connection with
any  consignment  arrangement  entered  into  in  the  ordinary  course  of  business;  (k)  Liens  identified  in  the  Financial  Statements
(including in the notes thereto); (l) with respect to any equity of a Conveyed Subsidiary (or any of its Subsidiaries), any restrictions
under  applicable  securities  Laws  and  any  Lien  set  forth  in  the  governing  documents  of  such  Conveyed  Subsidiary  (or  any  of  its
Subsidiaries);  (m)  other  Liens  that  do  not  materially  detract  from  the  value  of,  or  materially  impair  the  current  use  of,  the  assets
subject thereto; and (n) Liens disclosed or set forth in the Seller Disclosure Letter.

“ Person ” means an individual, a limited liability company, joint venture, a corporation, a partnership, an association,

a trust, a division or operating group of any of the foregoing or other entity or organization, including a Governmental Authority.

“  Plan  Regulatory  or  Funding  Documents  ”  means  (to  the  extent  applicable)  (i)  the  most  recent  summary  plan
description with respect to each such plan, (ii) any related trust or other funding vehicle and any current administrative or service
contract  or  insurance  policy,  (iii)  the  most  recent  annual  report  on  IRS  Form  5500  and  the  most  recent  actuarial  report,  financial
statements or similar reports or statements, (iv) the most recent determination or opinion letter received from the IRS with respect to
each such plan intended to qualify under Section 401 of the Code and (v) any documents applicable to a Foreign Seller Group Plan
or Foreign Purchaser Group Plan (as applicable) that are analogous to those contemplated by clauses (i) through (iv) .

“ Post-Closing Representation ” has the meaning set forth in Section 10.17(a) .

“ Post-Closing Tax Period ” means any taxable period (or portion thereof) beginning after the Closing Date and, in the

case of any Straddle Period, the portion of such period beginning after the Closing Date.

19

“ PRC Taxing Authority ” means any Taxing Authority in the People’s Republic of China.

“ Pre-Closing Income Tax Amount ” has the meaning set forth in Section 6.5(d)(vi)(A) .

“ Pre-Closing Separate Tax Returns ” has the meaning set forth in Section 6.5(a)(i) .

“ Pre-Closing Tax Period ” means any taxable period (or portion thereof) ending on or before the Closing Date and, in

the case of any Straddle Period, the portion of such period ending on and including the Closing Date.

“ Preference  Shares  ” means non-voting,  irredeemable  preference  shares with a nominal value of £1.00 each in the
capital of Purchaser, having the rights and restrictions set out in the Restated Purchaser Articles of Association and the Purchaser
Shareholders Agreement.

“ Product Registrations ” means all Governmental Authorizations granted to a Conveyed Subsidiary or a Seller by, or
pending with, any Governmental Authority and Related to the Business, to market any Product, including FDA drug listings, FDA
Product  Marketing  Authorizations,  other  national  or  regional  marketing  authorizations  or  permits  and  CE  marks  anywhere  in  the
world. “Product Registrations” shall not include any Manufacturing Registrations.

“  Products  ”  means  (a)  the  products  researched,  developed,  manufactured,  marketed,  commercialized,  distributed
and/or sold under the brand names set forth on Annex E-1 or variations or derivatives of such names (including translations thereof)
that  are  researched,  developed,  manufactured,  marketed,  commercialized,  distributed  and/or  sold  by  or  on  behalf  of  Seller  Parent
(directly and indirectly through its Subsidiaries) as of the date hereof and as of immediately prior to the Closing, (b) any over-the-
counter  consumer  healthcare  or  medicine  products,  wellness  products  and  other  personal  care,  oral  care,  nutrition,  skin  health,
cosmetic  and  related  products  (other  than  the  PCH  Split  Products)  that  are  researched,  developed,  manufactured,  marketed,
commercialized, distributed and/or sold by or on behalf of Seller Parent (directly and indirectly through its Subsidiaries) through the
Pfizer Consumer Healthcare business unit (directly or indirectly pursuant to a contractual arrangement with any other Pfizer business
unit, to the extent of the Pfizer Consumer Healthcare business unit’s rights pursuant to such contractual arrangement) as of the date
hereof and as of immediately prior to the Closing and (c) with respect to each of the foregoing products (clauses (a) and (b)), any line
extensions or other developments with respect to such product that are in progress as of the date hereof or immediately prior to the
Closing Date.

“ Property Taxes ” means real, personal and intangible ad
valorem
property Taxes.

“ Proposed Closing Statement ” has the meaning set forth in Section 2.9(a) .

“ Proposed Divestiture ” has the meaning set forth in Section 6.3(d)(ii) .

“ Purchase Consideration ” has the meaning set forth in Section 2.7 .

“ Purchased Assets ” has the meaning set forth in Section 2.1 .

20

“ Purchaser ” has the meaning set forth in the preamble of this Agreement.

“ Purchaser Account ” means the bank account or accounts controlled solely by Purchaser specified by Purchaser in

writing to the other Parties at least two (2) Business Days before the Closing Date.

“ Purchaser Accrued Income Taxes ” means an amount (not less than zero) equal to the aggregate current Income Tax
liabilities  of  Purchaser  and  its  Subsidiaries  (other  than  the  Conveyed  Subsidiaries  and  their  Subsidiaries)  (which  shall  not  be  less
than zero in any jurisdiction) for all taxable periods (or portions thereof) ending on or before the Closing Date for which final Tax
Returns  have  not  been  filed.  The  calculation  of  Purchaser  Accrued  Income  Taxes  shall  (i)  exclude  any  deferred  Tax  liabilities  or
deferred  Tax  assets  and  any  amounts  in  respect  of  speculative  or  contingent  liabilities  for  Tax,  (ii)  include  estimated  (or  other
prepaid)  Income  Tax  payments  only  to  the  extent  that  such  payments  have  the  effect  of  reducing  (not  below  zero)  the  particular
current  Income  Tax  liability  in  respect  of  which  such  payments  were  made,  (iii)  include  Income  Tax  deductions  or  Tax  refunds
(including for overpayments of estimated Taxes), in each case, only to the extent such deductions or Tax refunds have the effect of
reducing (not below zero) a particular current Income Tax liability to which they are relevant, (iv) be prepared in accordance with
the past practice (including reporting positions and accounting methods) of Purchaser or its applicable Subsidiary in preparing Tax
Returns for Income Taxes and (v) in the case of a Straddle Period, be determined in accordance with Section 6.5(d)(iii) .

“ Purchaser Accounting Principles ” has the meaning set forth in Section 2.8(a) .

“ Purchaser Adverse Action ” has the meaning set forth in Section 6.3(f) .

“ Purchaser Ancillary Agreement ” has the meaning set forth in Section 6.7(b) .

“ Purchaser Assumed Employee Liabilities ” has the meaning set forth in Section 6.6(a)(i) .

“ Purchaser Assumed Severance Liabilities ” has the meaning set forth in Section 6.6(c)(ii) .

“  Purchaser  Business  ”  means  (a)  the  worldwide  business  of  researching,  developing,  manufacturing,  marketing,
commercializing, distributing and selling the products sold under the brand names set forth on Annex E-2 or variations or derivatives
of such names (including translations thereof) (the “ Purchaser Key Products ”, and such brands, the “ Purchaser Key Brands ”), as
conducted by Purchaser Parent (directly and indirectly through its Subsidiaries, including Purchaser and its Subsidiaries) as of the
date of this Agreement and as of immediately prior to the Closing, (b) the business reflected in the Purchaser Financial Statements,
including the assets, rights, properties, activities, operations and liabilities that comprise such business, (c) the business of marketing,
commercializing,  distributing  and  selling  any  over-the-counter  consumer  healthcare  or  medicine  products,  wellness  products  and
other  personal  care,  oral  care,  nutrition,  skin  health,  cosmetic  and  related  products  (the  “  Consumer  Healthcare  Products  ”)  as
conducted by Leo Asia Private Limited (including, for clarity, pursuant to the Amended Consignment Selling Agreement) as of the
date of

21

this Agreement and as of immediately prior to the Closing and (d) to the extent not otherwise reflected in the Purchaser Financial
Statements,  the  research  and  development  of  any  Consumer  Healthcare  Products,  as  conducted  by  Purchaser  Parent  (directly  and
indirectly through its Subsidiaries) through its GlaxoSmithKline Consumer Healthcare business (directly or indirectly pursuant to a
contractual  arrangement  with  any  other  GlaxoSmithKline  business,  to  the  extent  of  the  GlaxoSmithKline  Consumer  Healthcare
business’  rights  pursuant  to  such  contractual  arrangement)  as  of  the  date  of  this  Agreement  and  as  of  immediately  prior  to  the
Closing. Notwithstanding the foregoing, the following shall not be included in Purchaser Business: (x) the worldwide business of
researching, developing, manufacturing, marketing, commercializing, distributing and selling pharmaceutical products to the extent
such  business  and  the  economic  benefit  attendant  to  such  business  is  not  reflected  in  the  Purchaser  Financial  Statements  and  (y)
those assets listed in Annex G .

“ Purchaser Business Employee ” means each individual who, immediately prior to the Closing: (a) is employed by
Purchaser  Parent  or  its  Affiliates  (other  than  Purchaser  or  its  Subsidiaries)  and  devotes  70%  or  more  of his  or  her  services  to  the
Purchaser Business but excluding any individual who is based in France or employed by any French Affiliate of Purchaser Parent, or
(b) is employed by Purchaser (or its Subsidiaries).

“  Purchaser  Business  Employee  (non-U.S.)  ”  means  a  Purchaser  Business  Employee  based  outside  of  the  United

States.

“ Purchaser Business Employee (U.S.) ” means a Purchaser Business Employee based in the United States.

“ Purchaser Business Plan ” means each Purchaser Group Plan and each Foreign Purchaser Group Plan sponsored and

maintained by Purchaser or a Subsidiary of Purchaser.

“ Purchaser  Copyrights  ”  means  all  Copyrights,  Copyright  registrations  and  applications  for  Copyright  registration

that are owned by Purchaser or its Subsidiaries.

“ Purchaser Current Representation ” has the meaning set forth in Section 10.17(b) .

“ Purchaser DC Plans (non-U.S.) ” has the meaning set forth in Section 6.6(g)(i) .

“ Purchaser DC Plans (U.S.) ” has the meaning set forth in Section 6.6(f)(i) .

“ Purchaser Designated Affiliate ” has the meaning set forth in Section 10.3 (b).

“ Purchaser Designated Person ” has the meaning set forth in Section 10.17(b) .

“ Purchaser Environmental Permit ” means any Governmental Authorization held by Purchaser Parent or any of its
Subsidiaries  for  the  then-current  operations  of  the  Purchaser  Business  or  for  the  then-current  operation  of  any  Purchaser  Real
Property, as of the Closing Date, and required pursuant to an Environmental Law.

“ Purchaser Facilities ” has the meaning set forth in Section 5.15(d) .

22

“ Purchaser Financial Statements ” has the meaning set forth in Section 5.6(a) .

“ Purchaser FSA Plan ” has the meaning set forth in Section 6.6(i) .

“  Purchaser  Group  Plan  ”  means  any  employee  benefit  plan  as  defined  in  Section  3(3)  of  ERISA  and  any  other
material written fringe benefit, incentive, bonus, employment, retention, change in control, termination or severance plan, program,
fund, agreement or arrangement, whether or not subject to ERISA, maintained (or contributed to or required to be contributed to) by
Purchaser Parent or any of its Affiliates, in which any Purchaser Business Employee (U.S.) or Former Purchaser Business Employee
(U.S.) participates or is a party.

“ Purchaser Indemnified Parties ” has the meaning set forth in Section 7.1(a) .

“ Purchaser Internal Restructurings ” has the meaning set forth in Section 6.5(f)(ii) .

“  Purchaser  IP  ”  means  (a)  all  Purchaser  Copyrights,  Purchaser  Patent  Rights  ,  Purchaser  Trademark  Rights,
Purchaser Know-How and Purchaser Software, and (b) all other Intellectual Property that is owned, or purported to be owned, by
Purchaser or its Subsidiaries.

“ Purchaser IT Systems ” means all Information Systems that are owned by Purchaser or its Subsidiaries.

“ Purchaser Key Products ” has the meaning set forth in the definition of “Purchaser Business.”

“ Purchaser Key Brands ” has the meaning set forth in the definition of “Purchaser Business.”

“ Purchaser Know-How ” means all Know-How that is owned by Purchaser or its Subsidiaries.

“ Purchaser Liabilities ” means any and all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaser
and  its  Subsidiaries),  other  than  Liabilities  identified  as  Purchaser  Parent  Retained  Liabilities  in  clauses  (a)  through  (f)  of  the
definition of “Purchaser Parent Retained Liabilities”, whether arising prior to, on or after the Closing, to the extent resulting from or
arising out of the past, present or future ownership, operation, use or conduct of the Purchaser Business.

“ Purchaser Licensed IP ” means all Intellectual Property owned by Purchaser Parent or any of its Affiliates that has
been  licensed  to  Purchaser  or  its  Subsidiaries  pursuant  to  a  Purchaser  Ancillary  Agreement,  including  the  Purchaser  Licensed
Trademark Rights .

“ Purchaser Licensed Trademark Rights ” has the meaning set forth in Section 5.14(h) .

“ Purchaser Manufacturing Registrations ” means all Governmental Authorizations granted to Purchaser Parent or any

of its Affiliates by, or pending with, any Governmental Authority for manufacturing facilities that are Purchaser Facilities.

23

“ Purchaser Material Adverse Effect ” means any change, event, development, occurrence or effect that, individually
or in the aggregate, has had, or would reasonably be expected to have, a material adverse effect on the business, results of operations
or financial condition of the Purchaser Business, taken as a whole, or Purchaser and its Subsidiaries, taken as a whole; provided ,
however  ,  that  any  change,  event,  development,  occurrence  or  effect  to  the  extent  resulting  from  or  arising  out  of  any  of  the
following,  either  alone  or  in  combination,  shall  not  be  considered  in  determining  whether  there  has  been  or  may  be  a  Purchaser
Material  Adverse  Effect:  (i)  general  economic  conditions  (including  changes  in  (A)  financial  or  market  conditions,  (B)  currency
exchange  rates,  (C)  prevailing  interest  rates  or  credit  markets  or  (D)  the  price  of  commodities  or  raw  materials)  applicable  in
countries,  jurisdictions  or  markets  in  which  there  are  assets  of  the  Purchaser  Business  or  sales  of  Purchaser  Products  (or  the
securities,  syndicated  loan,  credit  or  financial  markets  globally  or  in  any  such  economies,  countries,  jurisdictions  or  markets);
(ii)  changes  (or  proposed  changes)  in  the  legal,  Tax,  regulatory  or  political  conditions  (including  changes  in  Law  or  in  the
interpretation  or  application  of  Law)  applicable  in  countries,  jurisdictions  or  markets  in  which  there  are  assets  of  the  Purchaser
Business or sales of Purchaser Products; (iii) changes (or proposed changes) in IFRS or other applicable accounting standards or the
interpretations  thereof;  (iv)  conditions  in  or  affecting  the  industries  in  which  the  Purchaser  Business  operates;  (v)  conditions
resulting from natural disasters, earthquakes, hurricanes, tsunamis, floods, fires, storms, typhoons, lightning, hail storms, blizzards,
tornadoes,  droughts,  cyclones,  arctic  frosts,  mudslides,  wildfires,  manmade  disasters,  acts  of  God,  pandemics  or  other  weather-
related or natural conditions, or the commencement, occurrence, continuation or intensification of any war (whether or not declared),
sabotage, armed hostilities, civil unrest, military attacks or acts of terrorism or declaration of national emergency; (vi) any failure by
the  Purchaser  Business  to  meet  budgets,  plans,  projections  or  forecasts  (whether  internal  or  otherwise)  for  any  period  (it  being
understood that the underlying causes of the failure to meet such budgets, plans, projections or forecasts may be taken into account
in  determining  whether  a  Purchaser  Material  Adverse  Effect  has  occurred  unless  such  causes  are  otherwise  excepted  under  this
paragraph; provided that this clause (vi) shall not be construed as implying that Purchaser Parent is making any representation or
warranty  herein  with  respect  to  any  budgets,  plans,  projections  or  forecasts,  and  no  such  representations  or  warranties  are  being
made); (vii) any change in Purchaser Parent’s stock price or trading volume (it being understood that the underlying causes of such
change may be taken into account in determining whether a Purchaser Material Adverse Effect has occurred unless such causes are
otherwise excepted under this paragraph); (viii) the negotiation, execution, announcement, performance, pendency or consummation
of this Agreement, the transactions contemplated hereby or by any of the Ancillary Agreements (it being understood and agreed that
the foregoing shall not apply to the representations and warranties set forth in Section 5.4 ); (ix) without limiting clause (viii) above,
any action  taken  by Purchaser  Parent,  Purchaser  or any of their Affiliates  as expressly  required  by this Agreement,  including  any
changes, events or effects arising out of the application of Antitrust Laws (including any action or judgment arising under Antitrust
Laws) to this Agreement or the transactions contemplated hereby or the effect of any action taken (or agreed to be taken) by Seller
Parent, Purchaser or any of their respective Affiliates pursuant to Section 6.3 ; (x) any action taken, or failure to take action, or such
other changes or events, in each case, to which Seller Parent has consented in writing; (xi) any labor strike, slow down, lockout or
stoppage, pending or threatened, against the Purchaser Business; or (xii) any Purchaser Parent Retained Liabilities; provided , further
, that any change, event, development, occurrence or effect referred to in clauses (i) , (ii) , (iii) , (iv) and (v)

24

may be considered in determining whether there has been or may be a Purchaser Material Adverse Effect to the extent such change,
event,  development,  occurrence  or  effect  has  a  disproportionate  adverse  impact  on  the  business,  results  of  operations  or  financial
condition  of  the  Purchaser  Business,  taken  as  a  whole,  relative  to  the  other  businesses  in  the  industries  in  which  the  Purchaser
Business operates (in which case only such incremental disproportionate impact may be considered in determining whether there has
been or may be a Purchaser Material Adverse Effect).

“ Purchaser Material Contract ” has the meaning set forth in Section 5.13(a) .

“  Purchaser  Net  Cash  ”  means  the  amount  (which  may  be  a  positive  or  negative  number)  equal  to  (a)  all  Cash
Equivalents minus
(b) all outstanding Funded Indebtedness, in each case, of Purchaser and its Subsidiaries (other than the Conveyed
Subsidiaries and their Subsidiaries), as of 12:01 a.m. (New York time) on the Closing Date; provided that all proceeds, payments or
consideration received by Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) as a result of any action
taken  (or  agreed  to  be  taken)  by  Seller  Parent,  Purchaser  Parent,  Purchaser  or  any  of  their  respective  Affiliates  pursuant  to
Section 6.3 shall be excluded from the calculation of Purchaser Net Cash.

“ Purchaser Parent ” has the meaning set forth in the preamble of this Agreement.

“ Purchaser  Parent  Account  ”  means  the  bank  account  or  accounts  specified  by  Purchaser  Parent  in  writing  to  the

other Parties hereto at least two (2) Business Days before the Closing Date.

“ Purchaser Parent Adverse Recommendation Change ” has the meaning set forth in Section 6.24(e) .

“ Purchaser Parent Board Recommendation ” has the meaning set forth in Section 5.2(a) .

“ Purchaser Parent Combined Tax Returns ” has the meaning set forth in Section 6.5(e)(v) .

“ Purchaser Parent Disclosure Letter ” means the disclosure letter that Purchaser Parent has delivered to Seller Parent

as of the date of this Agreement.

“ Purchaser  Parent  Estimated  Closing  Statement  ”  means  a  written  statement  setting  forth  the  Estimated  Purchaser
Working Capital and the Estimated Purchaser Net Cash, prepared in a manner consistent with the Purchaser Accounting Principles
and the Purchaser Sample Closing Statement.

“ Purchaser Parent Final Plan ” has the meaning set forth in Section 6.5(f)(iv) .

“ Purchaser Parent Indemnified Parties ” has the meaning set forth in Section 7.1(a) .

“ Purchaser Parent Indemnified Taxes ” has the meaning set forth in Section 6.5(d)(ii) .

25

“ Purchaser Parent Retained Businesses ” mean all businesses of Purchaser Parent or any of its Subsidiaries other than
the Purchaser Business, including the worldwide business of researching, developing, manufacturing, marketing, commercializing,
distributing and selling (i) any products not included in the definition of “Purchaser Business” and (ii) without limiting the foregoing
clause (i) , any pharmaceutical products or pharmaceutical products that have become or may in the future become, in whole or in
part, over-the-counter products (other than the products included in the definition of “Purchaser Business”).

“  Purchaser  Parent  Retained  Liabilities  ”  means  any  Liabilities  of  Purchaser  Parent  or  its  Affiliates  (including

Purchaser and its Subsidiaries) other than the Purchaser Liabilities. The Purchaser Parent Retained Liabilities shall include:

(a)           all  Liabilities  for  which  Purchaser  Parent  or  any  of  its  Affiliates  (other  than  Purchaser  and  its  Subsidiaries)

expressly has responsibility pursuant to the terms of this Agreement or any Purchaser Ancillary Agreement;

(b)      all Purchaser Parent Transaction Expenses;

(c)      all Liabilities, including Liabilities for Taxes, of Purchaser Parent or its Subsidiaries to the extent related to or
arising out of the assets, properties and rights of Purchaser Parent or its Affiliates (other than Purchaser and its Subsidiaries) or the
Purchaser  Parent  Retained  Businesses  (including  the assets listed  in Annex G ) (other than any Liabilities  for which Purchaser  or
Seller Parent expressly has responsibility pursuant to the terms of this Agreement or any Ancillary Agreement, and other than any
Liabilities  that  are  separately  allocated  pursuant  to  any  other  agreement  or  transaction  related  to  such  assets,  properties  or  rights
between  Seller  Parent  or  any  of  its  Affiliates,  on  the  one  hand,  and  Purchaser  Parent  or  any  of  its  Affiliates,  on  the  other  hand,
including  any  commercial  or  other  agreements  unrelated  to  this  Agreement),  including  Environmental  Liabilities,  whether  arising
prior to, on or after the Closing, to the extent arising out of or related to the ownership or occupancy of any manufacturing, office,
research  and  development,  or  warehouse  facilities  owned,  leased  or  operated  by  Purchaser  Parent  or  its  Affiliates  other  than  the
Purchaser Facilities;

(d)      all Indebtedness of Purchaser Parent and its Affiliates other than (i) Funded Indebtedness of Purchaser and its
Subsidiaries included in the calculation of Final Purchaser Net Cash and (ii) Indebtedness of Purchaser and its Subsidiaries that is not
Funded Indebtedness;

(e)      all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) (i) pursuant
to the Put Option Implementation Agreement, dated as of March 27, 2018, by and among Purchaser Parent, Purchaser and Novartis
AG (among others), or (ii) related to or arising out of the divestiture of Horlicks and other consumer healthcare nutrition brands to
Unilever plc or its Affiliates and the merger of GSK Consumer Healthcare Limited India with Hindustan Unilever Limited, and the
transactions  contemplated  thereby  and  any  related  Contracts  entered  into  in  connection  therewith  other  than  the  Amended
Consignment Selling Agreement; and

(f)      all Liabilities of Purchaser Parent or any of its Affiliates (including Purchaser and its Subsidiaries) set forth in

Section 1.1(C) of the Purchaser Parent Disclosure Letter.

26

“ Purchaser Parent Shareholder Approval ” has the meaning set forth in Section 5.2(a) .

“  Purchaser  Parent  Shareholder  Approval  Resolution  ”  means  the  ordinary  resolution  of  Purchaser  Parent’s

shareholders required to approve the arrangements as contemplated herein or by any of the Ancillary Agreements.

“ Purchaser  Parent  Shareholder  Circular  ”  means  the  related  party  (as  defined  in  Chapter  11  of  the  Listing  Rules)

circular to be prepared and published by Purchaser Parent in connection with the Purchaser Parent Shareholder Meeting.

“ Purchaser Parent Shareholder Meeting ” has the meaning set forth in Section 6.24(a) .

“ Purchaser Parent Termination Fee ” has the meaning set forth in Section 9.2(b) .

“  Purchaser  Parent  Transaction  Expenses  ”  means  any  outside  counsel,  investment  banking,  accounting,  financial
advisory and other advisory costs, fees and expenses incurred by Purchaser Parent or any of its Affiliates (including Purchaser and
its Subsidiaries) at or prior to the Closing specifically in connection with the evaluation and negotiation of a transaction involving
Seller  Parent  and  the  Business,  and  the  negotiation,  execution  and  performance  of  this  Agreement  and  the  consummation  of  the
transactions contemplated by this Agreement, including the Purchaser Internal Restructurings, in each case other than costs, fees and
expenses  for  which  Seller  Parent  or  its  Affiliates  expressly  has  responsibility  (including  pursuant  to  payment,  reimbursement,
indemnification or other similar obligations set forth herein) pursuant to the terms of this Agreement.

“ Purchaser Patent Rights ” means all Patent Rights that are owned by Purchaser or its Subsidiaries.

“ Purchaser Pension Plans ” has the meaning set forth in Section 6.6(e)(i) .

“ Purchaser Permitted Liens ” means (a) Liens approved in writing by Seller Parent; (b) statutory Liens arising out of
operation  of  Law  with  respect  to  a  Liability  incurred  in  the  ordinary  course  of  business  for  amounts  which  are  not  yet  due  and
payable  or  for  which  an  adequate  reserve  has  been  established  in  the  Purchaser  Financial  Statements;  (c)  Liens  and  other
imperfections of title that do not materially detract from the value or materially impair the use of the property subject thereto or make
such property unmarketable or uninsurable; (d) with respect to real property, (i) easements, declarations, covenants, rights-of-way,
restrictions  and  other  charges,  instruments  or  encumbrances  that  are  recorded  against  title  to  real  estate  which  do  not  materially
impair  the  use  or  occupancy  of  such  real  property  in  the  operation  of  the  Purchaser  Business  conducted  thereon;  (ii)  zoning
ordinances, variances, conditional use permits and similar regulations, permits, approvals and conditions which are not violated by
the  current  use  of  the  real  property  subject  thereto  in  the  operation  of  the  Purchaser  Business  conducted  thereon;  (iii)  Liens  not
created by Purchaser Parent or its Affiliates that affect the underlying fee interest of any leased real property, including master leases
or  ground  leases,  which  do  not  materially  impair  the  use  or  occupancy  of  such  real  property  in  the  operation  of  the  Purchaser
Business conducted thereon; and (iv)  all matters of record and any state of facts that an accurate survey or inspection of the property
would disclose to the extent such matters or states of fact do not materially detract from the value or materially impair the use

27

or occupancy of such real property in the operation of the Purchaser Business conducted thereon; (e) Liens for Taxes, assessments or
other governmental charges or levies (i) that are not yet due or payable or (ii) that are being contested in good faith by appropriate
proceedings  and  for  which  an  adequate  reserve  has  been  established  in  the  Purchaser  Financial  Statements;  (f)  mechanics’,
materialmen’s, carriers’, workmen’s, warehousemen’s, repairmen’s, landlords’ or other similar Liens and security obligations arising
in  the  ordinary  course  of  business  for  amounts  which  are  not  yet  due  and  payable  or  for  which  an  adequate  reserve  has  been
established  in  the  Purchaser  Financial  Statements;  (g)  Liens  arising  under  original  purchase  price  conditional  sales  contracts  and
equipment leases with third parties entered into in the ordinary course of business; (h) Liens that will be released and, as appropriate,
removed of record, at or prior to the Closing Date in accordance with the terms of this Agreement; (i) Liens arising on assets and
products sold in the ordinary course of business; (j) Liens arising in connection with any consignment arrangement entered into in
the ordinary course of business; (k) Liens identified in the Purchaser Financial Statements (including in the notes thereto); (l) with
respect to any equity of Purchaser or any of its Subsidiaries, any restrictions under applicable securities Laws and any Lien set forth
in the governing documents of Purchaser (or any of its Subsidiaries); (m) other Liens that do not materially detract from the value of,
or  materially  impair  the  current  use  of,  the  assets  subject  thereto;  and  (n)  Liens  disclosed  or  set  forth  in  the  Purchaser  Parent
Disclosure Letter.

“ Purchaser Privileged Communications ” has the meaning set forth in Section 10.17(d) .

“  Purchaser  Product  Registrations  ”  means  all  Governmental  Authorizations  granted  to  Purchaser  Parent  or  a
Subsidiary of Purchaser Parent by, or pending with, any Governmental Authority and Related to the Purchaser Business to market
any Purchaser Products, including FDA drug listings, FDA Product Marketing Authorizations, other national or regional marketing
authorizations or permits and CE marks anywhere in the world. “Purchaser Product Registrations” shall not include any Purchaser
Manufacturing Registrations.

“  Purchaser  Products  ”  means  the  products  researched,  developed,  manufactured,  marketed,  commercialized,
distributed and/or sold by the Purchaser Business, and any line extensions or other developments with respect to such products that
are in progress as of the date hereof or immediately prior to the Closing Date.

“ Purchaser Real Property ” means, collectively, the Leased Purchaser Real Property and the Owned Purchaser Real

Property.

“ Purchaser Real Property Leases ” means real property leases, subleases, licenses and occupancy arrangements with

respect to the Leased Purchaser Real Property.

“ Purchaser Related Party Contract ” means any Contract between Purchaser Parent and any of its Affiliates (other

than Purchaser and its Subsidiaries), on the one hand, and Purchaser or its Subsidiaries, on the other hand.

“ Purchaser Retiree Medical Plan ” has the meaning set forth in Section 6.6(h) .

28

“  Purchaser  Shared  Contract  ”  means  any  Contract,  sales  order,  purchase  order,  instrument  or  other  commitment,
obligation  or  arrangement  entered  into  prior  to  the  date  hereof  (or  entered  into  prior  to  the  Closing  in  accordance  with  this
Agreement) that is between Purchaser Parent or any of its Subsidiaries (including Purchaser and its Subsidiaries), on the one hand,
and  one  or  more  third  parties,  on  the  other  hand,  that  inures  to  the  benefit  or  burden  of  both  the  Purchaser  Business  and  any
Purchaser  Parent  Retained  Business,  other  than  any  enterprise-wide  Contracts,  Contracts  with  respect  to  Off-the-Shelf  Software,
Purchaser  Group  Plans,  Foreign  Purchaser  Group  Plans,  Collective  Bargaining  Agreements  and  any  agreement  or  grant  with  any
Taxing Authority; provided that any such Contract that provides only de
minimis
assets or services to the Purchaser Business or the
Purchaser Parent Retained Business, as the case may be, shall not be deemed to be a Purchaser Shared Contract for purposes hereof.

“ Purchaser Shareholders Agreement ” has the meaning set forth in Section 6.14(b) .

“  Purchaser  Software  ”  means  all  Software  (a)  that  is  owned  by  Purchaser  or  its  Subsidiaries  and  (b)  that  is

exclusively used by Purchaser or its Subsidiaries in the operation of the Purchaser Business.

“ Purchaser Tax Act ” has the meaning set forth in Section 6.5(d)(i) .

“ Purchaser Tax Indemnified Parties ” has the meaning set forth in Section 6.5(d)(i) .

“  Purchaser  Trademark  Rights  ”  means  all  Trademarks,  including  Trademark  registrations  and  applications  for
Trademark registrations, (a) that are owned by or registered to Purchaser or its Subsidiaries (including any Purchaser Key Brands);
or (b) containing, comprising, or including (but only to the extent they include) any of the foregoing clause (a), including, in each
case of clauses (a) and (b), (x) all Trademarks that are confusingly similar to the Trademarks described in clauses (a) and (b) (such
that they could not be used in commerce without infringing such Trademarks), (y) all Internet Identifiers and telephone numbers or
other  alphanumeric  addresses  or  mnemonics  containing  any  of  the  foregoing  and  (z)  the  goodwill  symbolized  by  any  of  the
foregoing.

“ Purchaser Working Capital ” means the amount (which may be a positive or negative number) equal to (a) the sum
of the assets of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries and their Subsidiaries), on a consolidated basis,
as of 12:01 a.m. (New York time) on the Closing Date represented in the asset line items shown on the Purchaser Sample Closing
Statement as of such time, minus
(b) the sum of the liabilities of Purchaser and its Subsidiaries (other than the Conveyed Subsidiaries
and their Subsidiaries), on a consolidated basis, as of 12:01 a.m. (New York time) on the Closing Date represented in the liability
line  items  shown  on  the  Purchaser  Sample  Closing  Statement  for  Purchaser  as  of  such  time,  in  each  case  calculated  in  a  manner
consistent  with  the  Purchaser  Accounting  Principles  and  the  Purchaser  Sample  Closing  Statement;  provided  that  there  shall  be
excluded  from  such  calculation  any  Purchased  Assets  (regardless  of  the  time  of  day  at  which  the  Closing  occurs),  the  Purchaser
Parent  Retained  Liabilities,  all  assets  or  Liabilities  in  respect  of  Income  Taxes  (whether  current,  deferred,  or  contingent),  any
amounts included  in the calculation  of Purchaser  Net Cash, the proceeds,  payments  or consideration  paid or payable to Purchaser
Parent or any of its Affiliates (including Purchaser and its Subsidiaries)

29

as  a  result  of  any  action  taken  (or  agreed  to  be  taken)  by  Seller  Parent,  Purchaser  Parent,  Purchaser  or  any  of  their  respective
Affiliates  pursuant  to  Section  6.3  ,  any  intercompany  accounts  or  other  Liabilities  to  be  repaid  or  extinguished  pursuant  to  this
Agreement in connection with the Closing, including pursuant to Section 6.7 , and any intercompany receivables and intercompany
payables,  and  other  intercompany  Liabilities,  solely  between  or  among  Purchaser  (or  any  of  its  Subsidiaries)  and  any  of  its
Subsidiaries.

“ Real Property ” means, collectively, the Leased Real Property and the Owned Real Property.

“ Real Property Leases ” has the meaning set forth in Section 2.1(c) .

“  Records  ”  means  (a)  all  current  and  historical  books,  records,  reports  and  other  documents  and  information  that
pertain to business plans, budgets, financial and accounting data, brand insights and research, Business IP, vendors, manufacturing,
customers,  research  and  development  of  the  Products,  invoices,  marketing  and  advertising  operations,  policies,  procedures,
techniques,  systems,  employee  handbooks  or  manuals,  training  materials,  operating  manuals  and  documentation,  and  production
manuals and documentation, in each case, in any form or medium, but in each case excluding personnel files and Seller Combined
Tax  Returns  and  (b)  Registration  Information  (including  in  relation  to  pending  applications  for  Product  Registrations  and
Manufacturing Registrations).

“ Registered IP ” has the meaning set forth in Section 4.13(a).

“ Registered Business IP ” has the meaning set forth in Section 4.13(a) .

“ Registered Purchaser IP ” has the meaning set forth in Section 5.14(a) .

“  Registration  Information  ”  means  copies  of  the  Product  Registrations  and  Manufacturing  Registrations  and  any

existing files Related to the Product Registrations and Manufacturing Registrations in the possession of the relevant Seller.

“ Regulatory Action ” has the meaning set forth in Section 6.3(c)(iv) .

“ Related to the Business ” or “ Relating to the Business ” means primarily relating to, primarily held for use with, or

primarily used in connection with the Business.

“ Related to the Purchaser Business ” or “ Relating to the Purchaser Business ” means primarily relating to, primarily

held for use with, or primarily used in connection with the Purchaser Business.

“  Release  ”  means  any  releasing,  spilling,  leaking,  pumping,  pouring,  emitting,  emptying,  injecting,  depositing,
disposing, discharging, dispersal, escaping, dumping, migrating or leaching into the environment, including ambient air, indoor air,
sediments,  drinking  water,  water,  surface  or  subsurface  strata  or  groundwater,  including  the  movement  of  Hazardous  Materials
through or in the indoor or outdoor air, soil, surface water, groundwater or property.

30

“ Remedial Action ” means any action required by a Governmental Authority or Governmental Order or pursuant to
Environmental Law to clean up or remediate soil, sediments, air, building materials, drinking water, surface water, groundwater or
other  environmental media  in response to a  Release or  presence of Hazardous  Materials, including  any associated action taken  to
investigate, monitor, assess and evaluate the extent and severity of any such Release, action taken to remediate any such Release,
post-remediation monitoring of any such Release, and preparation of all reports, studies, analyses or other documents relating to the
foregoing.  “Remedial  Action”  also  refers  to  any  Action  relating  to  any  of  the  above,  including  the  negotiation  and  execution  of
judicial or administrative consent decrees, or defending claims brought by any Governmental Authority or any other Person, whether
such  claims  are equitable  or legal  in nature,  relating  to the relevant  cleanup  or remediation  in  response  to the relevant  Release  or
presence of Hazardous Materials and associated actions.

“  Remediation  Completion  Date  ”  means  the  date  that  (a)  the  Governmental  Authority  with  jurisdiction  over  a
Remedial  Action  issues  a  written  notice  indicating  that  no  further  action,  other  than  operation  and  maintenance  of  institutional  or
engineering controls is required, or (b) if, after requesting in writing such a notice from such a Governmental Authority, despite the
Party responsible for such a Remedial Action having reasonably completed the requirements to obtain such a written notice, no such
written notice is issued within 90 days after such Governmental Authority’s receipt of such request or any longer time period granted
to such Governmental Authority under the relevant Environmental Law, then the Remediation Completion Date shall mean the date
that an engineering firm mutually selected by the Parties and consistently ranked on the list of the Top 200 Environmental Firms
published by the Engineering News-Record, and employing an Environmental Professional as defined in 40 CFR Part 312.10 and
ASTM  E1527-13,  concurs  that  no  further  action,  other  than  operation  and  maintenance  of  institutional  or  engineering  controls,  is
required.

“ Replacement Shared Contract ” has the meaning set forth in Section 2.2(d) .

“ Representatives ” means, with respect to any Person, such Person’s Affiliates and any of such Person’s or any of its
Affiliates’  directors,  officers,  managers,  partners,  employees,  counsel,  financial  advisors,  accountants,  consultants  and  other
advisors, representatives and agents.

“ Resolution Period ” has the meaning set forth in Section 2.9(c) .

“ Restated Purchaser Articles of Association ” has the meaning set forth in Section 3.2 .

“  Restricted  Market  ”  means,  as  applicable  under  Global  Trade  Control  Laws,  the  Crimean  Peninsula,  Cuba,  the

Donbass Region, Iran, North Korea, Sudan, and Syria.

“ Restricted  Party ” means any individual(s)  or entity(ies)  on any of the following  lists (such lists, the “ Restricted
Party  Lists  ”):  the  list  of  sanctioned  entities  maintained  by  the  United  Nations;  the  Specially  Designated  Nationals  List  and  the
Sectoral Sanctions Identifications List, as administered by the U.S. Department of the Treasury Office of Foreign Assets Control; the
U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce;
the entities subject to restrictive measures and the Consolidated List of

31

Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign & Security Policy;
the List of Excluded Individuals / Entities, as published by the U.S. Health and Human Services – Office of Inspector General; any
lists of prohibited or debarred parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of persons and entities
suspended  or  debarred  from  contracting  with  the  U.S.  government;  and  similar  lists  of  restricted  parties  maintained  by  a
Governmental  Authority  of  any  other  jurisdiction  in  which  the  Business  or  the  Purchaser  Business,  as  applicable,  markets,
commercializes, distributes and sells products as of the date of this Agreement or as of the Closing Date.

“ Restricted Party Lists ” has the meaning set forth in the definition of “Restricted Party.”

“ Retained Brands ” has the meaning set forth in Section 6.15(a) .

“  Retained  Businesses  ”  mean  all  businesses  of  Seller  Parent  or  any  of  its  Subsidiaries  (including  the  Conveyed
Subsidiaries  and  any  of  their  Subsidiaries)  other  than  the  Business,  including  the  worldwide  business  of  researching,  developing,
manufacturing, marketing, commercializing, distributing and selling (a) any products not included in the definition of “Business”,
(b) each of the products set forth on Annex D (the “ PCH Split Products ”), (c) without limiting the foregoing clauses (a) and (b) ,
any pharmaceutical products or pharmaceutical products that have become or may in the future become, in whole or in part, over-
the-counter products (other than the products included in the definition of “Business”) and (d) any products set forth on Annex F .

“ Retained Environmental Liabilities ” has the meaning set forth in Section 2.5(b) .

“ Retained Facilities ” means the manufacturing, office, research and development, and warehouse facilities owned,

leased or operated by Seller Parent or any of its Affiliates, other than the Facilities.

“ Retained Facilities Environmental Liabilities ” has the meaning set forth in Section 2.5(b) .

“ Retained Liabilities ” has the meaning set forth in Section 2.5 .

“  Retained  Names  ”  means  (a)  the  Pfizer  trademark,  name  and  brand,  (b)  the  Wyeth  trademark,  name  and  brand,
(c)  all  Trademarks  owned  or  used  by  Seller  Parent  or  any  of  its  Affiliates  other  than  the  Business  Trademark  Rights,  and  (d)  all
Trademarks containing, comprising, or related to any of the foregoing, including (i) all Trademarks that are variations or derivatives
thereof  or  confusingly  similar  thereto,  and  (ii)  all  Internet  Identifiers  and  telephone  numbers  or  other  alphanumeric  addresses  or
mnemonics containing any of the foregoing. Notwithstanding anything in this Agreement to the contrary, Retained Names expressly
includes those Trademarks set forth in Section 1.1(E) of the Seller Disclosure Letter.

“ Retained Real Property ” shall mean all real property owned, leased or used by Seller Parent or any of its Affiliates,

other than the Owned Real Property and the Leased Real Property.

32

“  Retained  Subsidiaries  ”  means  any  Subsidiary  of  Seller  Parent,  other  than  the  Conveyed  Subsidiaries  and  their

Subsidiaries.

“ Review Period ” has the meaning set forth in Section 2.9(b) .

“ Safety Data Exchange Agreement ” has the meaning set forth in Section 6.14(a) .

“ Sale ” has the meaning set forth in Section 2.6 .

“  Sample  Closing  Statement  ”  means  the  calculation  set  forth  on  Annex  B-2  ,  in  a  manner  consistent  with  the
Accounting Principles, for illustrative purposes only, of the Business Working Capital and the Business Net Cash, in each case, as of
December  31,  2017,  including  the  line  items  to  be  included  as  assets  and  liabilities  in  the  calculation  of  the  Business  Working
Capital.

“ Sample Purchaser Closing Statement ” means the calculation set forth on Annex B-4 , in a manner consistent with
the Purchaser Accounting Principles, for illustrative purposes only, of the Purchaser Working Capital and the Purchaser Net Cash, in
each case, as of December 31, 2017, including the line items to be included as assets and liabilities in the calculation of the Purchaser
Working Capital.

“  Securities  Act  ”  means  the  U.S.  Securities  Act  of  1933,  as  amended,  and  the  rules  and  regulations  promulgated

thereunder.

“ Seller Account ” means the bank account  or accounts  specified  by Seller  Parent  in writing  to the other Parties  at

least two (2) Business Days before the Closing Date.

“ Seller Accrued Income Taxes ” means an amount (not less than zero) equal to the aggregate  current Income Tax
liabilities of the Conveyed Subsidiaries and their Subsidiaries (which shall not be less than zero in any jurisdiction) for all taxable
periods (or portions thereof) ending on or before the Closing Date for which final Tax Returns have not been filed. The calculation
of Seller Accrued Income Taxes shall (i) exclude any deferred Tax liabilities or deferred Tax assets and any amounts in respect of
speculative or contingent liabilities for Tax, (ii) include estimated (or other prepaid) Income Tax payments only to the extent that
such  payments  have  the  effect  of  reducing  (not  below  zero)  the  particular  current  Income  Tax  liability  in  respect  of  which  such
payments were made, (iii) include Income Tax deductions or Tax refunds (including for overpayments of estimated Taxes), in each
case, only to the extent such deductions or Tax refunds have the effect of reducing (not below zero) a particular current Income Tax
liability  to  which  they  are  relevant,  (iv)  be  prepared  in  accordance  with  the  past  practice  (including  reporting  positions  and
accounting methods) of the applicable Conveyed Subsidiary or its applicable Subsidiary in preparing Tax Returns for Income Taxes
and (v) in the case of a Straddle Period, be determined in accordance with Section 6.5(d)(iii) .

“ Seller Cash Incentive Plan ” has the meaning set forth in Section 6.6(c)(v) .

“ Seller Closing Bonus ” has the meaning set forth in Section 6.6(c)(v) .

“ Seller Combined Tax Returns ” has the meaning set forth in Section 6.5(a)(i) .

33

“ Seller Current Representation ” has the meaning set forth in Section 10.17(a) .

“ Seller DC Plans (non-U.S.) ” has the meaning set forth in Section 6.6(g)(i) .

“ Seller DC Plans (U.S.) ” has the meaning set forth in Section 6.6(f)(i) .

“ Seller Designated Person ” has the meaning set forth in Section 10.17(a) .

“ Seller Disclosure Letter ” means the disclosure letter that Seller Parent has delivered to Purchaser as of the date of

this Agreement.

“ Seller Facilities ” has the meaning set forth in Section 4.14(d) .

“ Seller FSA Plan ” has the meaning set forth in Section 6.6(i) .

“ Seller Group Plan ” means any employee benefit plan as defined in Section 3(3) of ERISA and any other material
written  fringe  benefit,  incentive,  bonus,  employment,  retention,  change  in  control,  termination  or  severance  plan,  program,  fund,
agreement or arrangement, whether or not subject to ERISA, maintained (or contributed to or required to be contributed to) by any
Seller  or any Conveyed  Subsidiary  (or  Subsidiary  thereof),  or any of their respective  Affiliates,  in which  any Business  Employee
(U.S.) or Former Business Employee (U.S.) participates or is a party.

“ Seller Indemnifiable Tax Return ” has the meaning set forth in Section 6.5(a)(ii) .

“ Seller Indemnified Taxes ” has the meaning set forth in Section 6.5(d)(i) .

“ Seller Internal Restructurings ” has the meaning set forth in Section 6.5(f)(i) .

“ Seller LTD Plan ” has the meaning set forth in Section 6.6(b)(iv) .

“ Seller Parent ” has the meaning set forth in the preamble of this Agreement.

“ Seller Parent Equity Awards ” has the meaning set forth in Section 6.6(c)(vi) .

“ Seller Parent Final Plan ” has the meaning set forth in Section 6.5(f)(iii) .

“  Seller  Parent  Guarantees  ”  means  all  obligations  of  Seller  Parent  or  any  of  the  Retained  Subsidiaries  under  any
Contract, instrument or other commitment, obligation or arrangement (other than Seller Parent LCs) or other obligation in existence
as of the Closing Date to the extent related to the Business for which Seller Parent or any of the Retained Subsidiaries is or may be
liable,  as  guarantor,  indemnitor,  original  tenant,  primary  obligor,  Person  required  to  provide  financial  support  or  collateral  in  any
form whatsoever, or otherwise (including by reason of performance guarantees).

“ Seller Parent Indemnified Parties ” has the meaning set forth in Section 7.1(b) .

“  Seller  Parent  LCs  ”  means  all  letters  of  credit  issued  by  or  for  the  account  of  Seller  Parent  or  the  Retained

Subsidiaries on behalf of or in favor of any Conveyed Subsidiary, any of

34

their  Subsidiaries  or  the  Business,  and  all  obligations  (including  reimbursement  obligations)  of  Seller  Parent  or  the  Retained
Subsidiaries in respect of the foregoing.

“  Seller  Parent  Related  Party  Contract  ”  means  any  Contract  between  a  Conveyed  Subsidiary  or  any  of  their
Subsidiaries,  on  the  one  hand,  and  Seller  Parent  or  its  Subsidiaries  (other  than  the  Conveyed  Subsidiaries  or  any  of  their
Subsidiaries), on the other hand.

“ Seller Pension Plans ” has the meaning set forth in Section 6.6(e)(i) .

“ Seller Privileged Communications ” has the meaning set forth in Section 10.17(c) .

“  Seller  Retained  Plan  ”  means  each  Seller  Group  Plan  and  Foreign  Seller  Group  Plan  that  is  not  a  Conveyed

Subsidiary Plan.

“ Seller Retained Severance Liabilities ” has the meaning set forth in Section 6.6(c)(ii) .

“ Seller Retention Awards ” has the meaning set forth in Section 6.6(j) .

“ Seller Retiree Medical Plans ” has the meaning set forth in Section 6.6(h) .

“ Seller Tax Act ” has the meaning set forth in Section 6.5(d)(ii) .

“ Seller Transaction Expenses ” means any outside counsel, investment banking, accounting, financial advisory and
other advisory costs, fees and expenses incurred by Seller Parent or any of its Subsidiaries (including the Conveyed Subsidiaries and
any of their Subsidiaries) at or prior to the Closing specifically in connection with the Strategic Process conducted by Seller Parent
or  the  negotiation,  execution  and  performance  of  this  Agreement  and  the  consummation  of  the  transactions  contemplated  by  this
Agreement,  including  the  Seller  Internal  Restructurings,  other  than  costs,  fees  and  expenses  for  which  Purchaser  or  its  Affiliates
expressly  has  responsibility  (including  pursuant  to  payment,  reimbursement,  indemnification  or  other  similar  obligations  set  forth
herein) pursuant to the terms of this Agreement.

“ Sellers ” means (i) Seller Parent and (ii) all of the Subsidiaries of Seller Parent that, as of immediately prior to the

Closing, own any Purchased Assets.

“ Shared Contract ” means any Contract, sales order, purchase order, instrument or other commitment, obligation or
arrangement  entered  into  prior  to  the  date  hereof  (or  entered  into  prior  to  the  Closing  in  accordance  with  this  Agreement)  that  is
between Seller Parent or any of its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries), on the one hand, and
one or more third parties, on the other hand, that inures to the benefit or burden of both the Business and any Retained Business,
other than any enterprise-wide Contracts, Contracts with respect to Off-the-Shelf Software, Seller Group Plans, Foreign Seller Group
Plans, Collective Bargaining Agreements and any agreement or grant with any Taxing Authority; provided that any such Contract
that provides only de
minimis
assets or services to the Business or the Retained Businesses, as the case may be, shall not be deemed
to be a Shared Contract for purposes hereof.

35

“ Shared Contractual Liabilities ” means Liabilities in respect of Shared Contracts.

“ Shares ” has the meaning set forth in Section 2.1(a) .

“  Software  ”  means  (a)  computer  programs,  including  software  implementation  of  algorithms,  models  and
methodologies,  whether  in  source  code,  object  code,  human  readable  form  or  other  form,  (b)  user  interfaces,  report  formats,
firmware,  development  tools,  templates,  menus,  buttons  and  icons  and  (c)  documentation,  user  manuals,  and  training  manuals
documenting the functionality or use of any of the foregoing.

“ Specified Records ” has the meaning set forth in Section 2.1(j) .

“ Straddle Period ” has the meaning set forth in Section 6.5(a)(ii) .

“ Straddle Period Tax Returns ” has the meaning set forth in Section 6.5(a)(ii) .

“ Strategic Process ” means all matters, whether occurring before or after the date of this Agreement, relating to the
review of strategic alternatives with respect to the Business, including the potential sale or other separation of the Business, and all
activities  in  connection  therewith,  including  matters  relating  to  (a)  the  solicitation  of  proposals  from  and  negotiations  with  third
parties in connection with the potential sale of the Business or (b) the drafting, negotiation or interpretation of any of the provisions
of  this  Agreement  or  the  Ancillary  Agreements,  or  the  determination  of  the  allocation  of  any  assets  or  Liabilities  pursuant  to  the
foregoing agreements or the transactions contemplated thereby.

“ Subsequent Loss ” has the meaning set forth in Section 6.5(b) .

“ Subsidiary ” means an entity as to which Seller Parent, Purchaser Parent or Purchaser or any other relevant entity, as
the case may be, owns as of the date of determination, directly or indirectly, more than fifty percent (50%) of the voting power or
other similar interests. Any Person which comes within this definition as of the date of this Agreement but thereafter fails to meet
such definition shall from and after such time not be deemed to be a Subsidiary of Seller Parent, Purchaser Parent or Purchaser or
any other relevant entity, as the case may be. Similarly, any Person which does not come within such definition as of the date of this
Agreement but which thereafter meets such definition shall from and after such time be deemed to be a Subsidiary of Seller Parent,
Purchaser Parent or Purchaser or any other relevant entity, as the case may be.

“ Target Business Net Cash ” means [***].

“ Target Business Working Capital ” means [***].

“ Target Purchaser Net Cash ” means [***].

“ Target Purchaser Working Capital ” means [***].

Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions
have been omitted from this filing and have been filed separately with the SEC.

36

“ Tax Asset ”  means  any  Tax  Item  that  could  reduce  a  Tax  otherwise  payable,  including  a  net  operating  loss,  net
capital loss, general business credit, foreign Tax credit, investment credit, research or experimentation credit, charitable deduction or
credit related to alternative minimum Tax or other Tax credit.

“ Tax Benefit ” means the Tax effect  of any Tax Item that decreases  Taxes paid or payable,  including  any interest
with respect thereto or interest that would have been payable but for such item. For purposes of determining the amount and timing
of any Tax Benefit, the recipient of the Tax Benefit shall be deemed to realize or utilize any Tax Benefit as and when such recipient
actually receives such Tax Benefit in the form of a reduction in the amount of Taxes that would otherwise be payable, including as a
credit  against  estimated  Taxes,  or  actually  receives  such  Tax  Benefit  in  the  form  of  a  cash  refund,  with  the  amount  of  such  Tax
Benefit being determined on a “with and without” basis taking the Tax Item into account by treating it as the last item available in
computing taxable income and as having been used after any other Tax attribute, and such Tax Benefit shall be determined net of
any Tax detriments (including reduction of Tax basis of any asset) attributable to any Loss generating the Tax Item giving rise to
such Tax Benefit.

“ Tax Claim ” has the meaning set forth in Section 6.5(e)(i) .

“  Tax  Item  ”  means  any  item  of  income,  gain,  loss,  deduction,  credit,  recapture  of  credit  or  any  other  item  that
increases or decreases Taxes paid or payable, including an adjustment under Section 481 of the Code (or any similar provision of
state, local or foreign Law) resulting from a change in accounting method.

“ Tax Proceeding ” means any audit, inquiry, examination, contest, litigation or other Action by, with, or against any

Taxing Authority.

“  Tax  Return  ”  means  any  return,  report,  declaration,  information  return,  statement  or  other  document  filed  or
required  to  be  filed  with  any  Taxing  Authority  (including  any  schedule  or  attachment  thereto  and  any  amendment  thereof),  in
connection with the determination, assessment or collection of any Tax or the administration of any Laws relating to any Tax.

“  Taxes  ”  means  all  taxes,  charges,  duties,  imposts,  fees,  levies  and  other  assessments  of  any  kind  whatsoever,
whether or not disputed, including  income, alternative  or add-on minimum, gross receipts, estimated, capital stock, excise, real or
personal  property,  sales  or  use,  value  added,  goods  and  services,  registration,  windfall,  profits,  excess  profits,  documentary,  ad
valorem
 ,  intangibles,  license,  withholding  (with  respect  to  compensation  or  otherwise),  payroll,  employment,  workers’
compensation,  unemployment  compensation,  premium,  occupancy,  disability,  net  worth,  capital  gains,  transfer,  stamp,  social
security,  environmental,  occupation  and  franchise  taxes,  imposed  by  any  Governmental  Authority,  and  including  any  interest,
penalties and additions attributable thereto.

“  Taxing  Authority  ”  means  any  Governmental  Authority  responsible  for  the  imposition,  regulation,  collection  or

administration of any Taxes.

“ Termination Expenses ” has the meaning set forth in Section 6.6(c)(ii) .

37

“ Third Party Claim ” has the meaning set forth in Section 7.3(a) .

“ Trademarks ” has the meaning set forth in the definition of “Intellectual Property.”

“ Transfer of Undertakings Laws ” means (a) the Council of the European Union Directive 2001/23/EC of March 21,
2001  on  the  approximation  of  the  Laws  of  the  member  states  of  the  European  Union  relating  to  the  safeguarding  of  employees’
rights  in  the  event  of  transfers  of  undertakings,  businesses  or  parts  of  undertakings  or  businesses  and/or  local  implementing
legislation  both  as  amended  from  time  to  time  or  (b)  any  similar  or  equivalent  Laws  applicable  in  jurisdictions  outside  of  the
European Union providing for an automatic transfer of employment or employer substation.

“  Transfer  Taxes  ”  means  any  federal,  state,  county,  local,  foreign  and  other  sales,  bulk  sales,  use,  transfer,  real
property  transfer,  excise,  license,  privilege,  gross  receipts,  conveyance,  documentary  transfer,  stamp,  land,  customs,  recording,
registration  or  other  similar  Tax  (including  any  notarial  fee),  but  excluding  any  VAT,  imposed  in  connection  with,  or  otherwise
relating  to,  the  transactions  contemplated  by  this  Agreement  or  the  recording  of  any  sale,  transfer,  conveyance  or  assignment  of
property (or any interest therein) effected pursuant to or contemplated by this Agreement.

“ Transferred Employee (non-U.S.) ” has the meaning set forth in Section 6.6(b)(v) .

“ Transferred Employee (U.S.) ” has the meaning set forth in Section 6.6(b)(v) .

“ Transferred Employees ” has the meaning set forth in Section 6.6(b)(v) .

“ Transferred FSA Balances ” has the meaning set forth in Section 6.6(i) .

“ Transferred Pension Plan Employees ” has the meaning set forth in Section 6.6(e)(i) .

“ Transition Plan ” has the meaning set forth in Section 6.4(c) .

“ Transition Services Agreement ” has the meaning set forth in Section 6.14(a) .

“ Transition Team ” has the meaning set forth in Section 6.4(b) .

“ Transitional Trademark License Agreement ” has the meaning set forth in Section 6.14(a) .

“ Treasury Regulations ” means the United States Treasury regulations promulgated under the Code.

“ TUL Employee ” has the meaning set forth in Section 6.6(b)(ii) .

“ UKLA ” means the United Kingdom Listing Authority.

38

“ United States ” means the United States of America, including its territories and possessions.

“ VAT ” means goods and services Tax, value added Tax and other similar transactional indirect Taxes (but excluding

transfer Tax, stamp duty and other similar Taxes).

“ WARN ” means the Worker Adjustment and Retraining Notification Act of 1988, as amended or any similar Law.

Section 1.2      Interpretation . The words “hereof,” “herein,” “hereto” and “hereunder” and words of similar import
refer  to  this  Agreement  as  a  whole,  including  all  Annexes,  Exhibits  and  Schedules,  and  not  to  any  particular  provision  of  this
Agreement and the words “date hereof” refer to the date of this Agreement.  The terms defined in the singular have a comparable
meaning  when  used  in  the  plural,  and  vice  versa.  The  terms  “dollars”  and  “$”  mean  U.S.  dollars.  Wherever  the  words  “include,”
“includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” Unless
otherwise  specifically  provided  for  herein,  the  term  “or”  shall  not  be  deemed  to  be  exclusive.  When  a  reference  is  made  in  this
Agreement to an Article, a Section, an Annex, an Exhibit or a Schedule, such reference shall be to an Article or a Section of, or an
Annex, an Exhibit or a Schedule to, this Agreement unless otherwise indicated. Any Law defined or referred to in this Agreement or
in any agreement or instrument that is referred to herein means such Law as from time to time amended, modified or supplemented,
including (in the case of statutes) by succession of comparable successor Laws and the related regulations thereunder and published
interpretations thereof; provided that, for purposes of any representations and warranties contained in this Agreement that are made
as of a specific date or dates, references to any Law shall be deemed to refer to such Law, as amended, and the related regulations
thereunder and published interpretations thereof, in each case, as of such date. Any reference to “writing” or comparable expressions
includes  a  reference  to  facsimile  transmission,  e-mail  or  comparable  means  of  communication.  Where  used  with  respect  to
information, the phrases “delivered” or “made available” means that the information referred to has been physically or electronically
delivered  to  the  relevant  parties  or  their  respective  Representatives,  including  material  that  has  been  posted  in  the  “data  room”
(virtual or otherwise) established by a Party two (2) Business Days prior to the date hereof (or the Closing Date, but only in the case
of information required to be delivered or made available under this Agreement prior to the Closing Date) . The term “disclosed,”
when used in reference to information disclosed to Purchaser Parent or Purchaser, shall be understood to include (but not be limited
to) all disclosures contained in the Seller Disclosure Letter and all written information as shared over e-mail or otherwise included in
Seller Parent’s virtual data room made available to Purchaser Parent or its Affiliates or Representatives (including in any confidential
information memorandum) two (2) Business Days prior to the date hereof (or the Closing Date, but only in the case of information
required  to be disclosed  under  this  Agreement  prior  to the Closing  Date),  and  when used in reference  to information  disclosed  to
Seller  Parent,  shall  be  understood  to  include  (but  not  be  limited  to)  all  disclosures  contained  in  the  Purchaser  Parent  Disclosure
Letter and all written information as shared over e-mail or otherwise included in Purchaser Parent’s virtual data room made available
to Seller Parent or its Affiliates or Representatives (including in any confidential information memorandum) two (2) Business Days
prior to the date hereof (or the Closing Date, but only in the case of information required to be

39

disclosed under this Agreement prior to the Closing Date) . Reference to “day” or “days” are to calendar days. When calculating the
period  of  time  before  which,  within  which  or  following  which  any  act  is  to  be  done  or  step  taken  (or  not  taken)  pursuant  to  this
Agreement, the date that is the reference date in calculating such period shall be excluded, except that if the last day of such period is
a non-Business  Day, the period in question shall end on the next succeeding Business Day. Amounts used in any calculations for
purposes  of  this  Agreement,  the  Ancillary  Agreements  or  any  other  document  delivered  in  connection  herewith  may  be  either
positive or negative, it being understood that the addition of a negative number shall mean the subtraction of the absolute value of
such  negative  number  and  the  subtraction  of  a  negative  number  shall  mean  the  addition  of  the  absolute  value  of  such  negative
number.

ARTICLE II

PURCHASE AND SALE

Section 2.1      Purchase and Sale of Purchased Assets . Upon the terms and subject to the conditions set forth in this
Agreement, at the Closing, Seller Parent shall, and shall cause the other Sellers to, sell, convey, assign and transfer to Purchaser or
the applicable Purchaser Designated Affiliates, and Purchaser shall or shall cause the applicable Purchaser Designated Affiliates to
purchase, acquire and accept, all of Seller Parent’s and its Subsidiaries’ right, title and interest, free and clear of all Liens other than
Permitted Liens, as at the Closing in the following (collectively, the “ Purchased Assets ”):

(a)      the equity interests in the Conveyed Subsidiaries (collectively, the “ Shares ”);

(b)      the real property that is set forth in Section 2.1(b) of the Seller Disclosure Letter (collectively, the “ Owned
Real Property ”) and the Facilities (including the related improvements and fixtures), and all easements and other rights and interests
appurtenant thereto;

(c)      the real property leases, subleases, licenses and occupancy arrangements that are set forth in Section 2.1(c) of
the Seller Disclosure Letter (collectively, the “ Real Property Leases ” and the real property related to such Real Property Leases, the
“ Leased Real Property ”), including the right to all security deposits and other amounts and instruments deposited by or on behalf of
the Sellers thereunder;

(d)            (i)  other  than  Information  Systems  (which  are  the  subject  of  clauses  (ii)  and  (iii)),  the  owned  and  leased
furniture, equipment, fixtures, machinery, supplies, spare parts, tools, tangible personal property and other tangible property (A) that
is Related to the Business and located at a Facility, except as set forth on Section 2.3(a)(xx) of the Seller Disclosure Letter, or (B) set
forth on Section 2.1(d)(i)(B) of the Seller Disclosure Letter, (ii) personal computers and vehicles primarily used by the Transferred
Employees in respect of the Business (the assets described in the foregoing clauses (i) and (ii) , collectively, the “ Equipment ”), (iii)
Business IT Systems, and (iv) any leases relating to such Equipment or Business IT Systems (the “ Equipment Leases ”);

(e)      Contracts, sales orders, purchase orders, instruments and other commitments, obligations and arrangements (i)

to which Seller Parent or any of its Subsidiaries is a party and that

40

are related solely to the Business, a Purchased Asset or an Assumed Liability, or (ii) that constitute a Shared Contract, but only the
portion of such Shared Contract related to the Business (collectively, the “ Assumed Contracts ”);

(f)      all Inventory and samples of any Product;

(g)            all  Business  IP,  including  the  right  to  sue  and  recover  and  retain  damages  for  past,  present  and  future
infringement or misappropriation of or other violation of any Business IP and all corresponding rights that, now or hereafter, may be
secured throughout the world with respect to any Business IP, but for clarity excluding all Retained Names;

(h)            all  Registration  Information  (including  in  relation  to  pending  applications  for  Product  Registrations  and

Manufacturing Registrations) Related to the Business;

(i)            all  Governmental  Authorizations,  including  Product  Registrations,  Manufacturing  Registrations  and

Environmental Permits, that are owned, used or licensed (subject to the terms of such licenses) and Related to the Business;

(j)      without duplication, (A) all Records Relating to the Business (including any applicable attorney-client privilege,
attorney work product protection and expectation of client privilege attaching to any such Record), other than the Records set forth
on Section 2.1(j) of the Seller Disclosure Letter (the “ Specified Records ”); provided that the Sellers and their Affiliates may retain
one (1) copy of each of the foregoing pursuant to Section 6.8 and remove or redact the names of any customers or vendors from such
lists to the extent such customers or vendors relate solely to the Retained Businesses, (B) copies of (x) the portions of all Records
that relate  to, but  do not  primarily  relate  to, the Business  and (y) the Specified  Records,  and  (C) the corporate  books  and records
(including  Tax  Returns  other  than  any  Seller  Combined  Tax  Returns)  of  the  Conveyed  Subsidiaries  and  their  Subsidiaries  to  the
extent  related  to  the  Business;  provided  ,  further  ,  that  in  each  case  of  clauses  (A)-(C),  Seller  Parent  may  redact  or  remove  any
information not related to the Business;

(k)      all accounts receivable and all other assets, in each case included in the calculation of Final Business Working

Capital, and all Cash Equivalents included in the calculation of Final Business Net Cash;

(l)      the goodwill Relating to the Business, together with the right to represent to third parties that Purchaser is the

successor to the Business;

(m)      all claims, defenses, causes of action, counterclaims and rights of set-off against third parties (at any time or in
any manner arising or existing, whether choate or inchoate, known or unknown, contingent or non-contingent) relating primarily to
the Business, a Purchased Asset or an Assumed Liability;

(n)      all credits, prepaid expenses, rebates, deferred charges, advance payments, security deposits and other deposits

or amounts held as surety by third Persons and prepaid items,

41

in  each  case  Related  to  the  Business  or  primarily  related  to  a  Purchased  Asset  or  an  Assumed  Liability  and  included  in  the
calculation of Final Business Working Capital or Final Business Net Cash;

(o)      the amount of any insurance proceeds, recoveries or refunds (net of any reasonable costs of investigating and
pursuing the underlying claim and of collection and any Taxes imposed in respect thereof) received by Seller Parent or any of its
Affiliates under the Insurance Policies after the date hereof in respect of any Loss prior to the Closing in respect of any Purchased
Asset or Assumed Liability to the extent Purchaser does not otherwise receive the benefit thereof (including through application of
such proceeds) and except to the extent the related Liabilities are included in the calculation of Final Business Working Capital or
Final Business Net Cash;

(p)            the  assets  of  all  Conveyed  Subsidiary  Plans  and  the  assets  transferred  to  Purchaser  and  the  Purchaser

Designated Affiliates pursuant to Section 6.6 ;

(q)      the assets set forth in Section 2.1(q) of the Seller Disclosure Letter;

(r)           to  the  extent  legally  transferable,  all  third-party  warranties,  indemnities,  further  assurance  and  other  similar
covenants, and guarantees to the extent relating to any of the Equipment, Inventory, other Purchased Assets and Assumed Liabilities;
and

(s)      any other assets, properties or rights in each case Relating to the Business, other than those assets specifically

identified as Excluded Assets in clauses (i) through (xx) of Section 2.3(a) .

Notwithstanding anything else herein to the contrary, (i) any assets, properties or rights of any Conveyed Subsidiary (or Subsidiary
thereof) that constitute Purchased Assets hereunder shall be deemed Purchased Assets for all purposes of this Agreement (including
Article VII ), except to the extent any such asset, property or right otherwise would be an Excluded Asset had it not been an asset,
property or right of such Conveyed Subsidiary or Subsidiary (and instead an asset, right, or property of Seller Parent or any of its
Affiliates  (other  than  a  Conveyed  Subsidiary  (or  a  Subsidiary  thereof)))  (a  “  Conveyed  Subsidiary  Excluded  Asset  ”),  (ii)  any
Conveyed Subsidiary Excluded Asset shall be deemed an Excluded Asset for all purposes of this Agreement (including Article VII )
and  Seller  Parent  shall  use  commercially  reasonable  efforts  to  transfer  such  Conveyed  Subsidiary  Excluded  Asset,  subject  to
obtaining  required  consents  and  Approvals,  out  of  the  relevant  Conveyed  Subsidiary  (or  Subsidiary  thereof)  on  or  prior  to  the
Closing, or thereafter in accordance with Section 6.22 , and (iii) any Liability of any Conveyed Subsidiary (or Subsidiary thereof)
that otherwise would be a Retained Liability had it not been a Liability of such Conveyed Subsidiary or Subsidiary (and instead a
Liability  of  Seller  Parent  or  any  of  its  Affiliates  (other  than  a  Conveyed  Subsidiary  (or  a  Subsidiary  thereof)))  shall  be  deemed  a
Retained Liability for all purposes of this Agreement (including Article VII ) and Seller Parent shall use commercially reasonable
efforts to transfer such Retained Liability, subject to obtaining required consents and Approvals, out of such Conveyed Subsidiary
(or Subsidiary thereof) on or prior to the Closing, or thereafter in compliance with Section 6.22 . The transfer of assets, properties
and rights of any Conveyed Subsidiaries (or any Subsidiary thereof) deemed a Purchased Asset shall be effected solely by virtue of
the transfer of the Sellers’ right, title and interest in the Shares and not through the direct transfer of such assets, properties or rights,
and Seller Parent and its Subsidiaries shall not be required to transfer any such

42

assets, properties or rights of the Conveyed Subsidiaries and their Subsidiaries other than through the transfer of the Sellers’ right,
title and interest in the Shares.

Section 2.2      Consents; Shared Contracts .

(a)      Notwithstanding any other provision of this Agreement, neither this Agreement nor any Ancillary Agreement
shall constitute an agreement to, directly or indirectly, sell, convey, assign, transfer or deliver any interest in any Purchased Asset
(other than the Shares) or any right or benefit arising thereunder or resulting therefrom if such sale, conveyance, assignment, transfer
or  delivery,  or  the  purchase  or  assumption  thereof  by  Purchaser  or  the  applicable  Purchaser  Designated  Affiliates,  without  the
consent or Approval of any Person(s) (including consents or Approvals of any Governmental Authorities), or otherwise, (i) would
constitute a breach or other contravention of the rights of such Person(s), (ii) would be ineffective under, or contravene, applicable
Law or (iii) would result in the termination, cancellation or acceleration of any material right or obligation of, or result in the loss of
any  material  benefit  of,  or  otherwise  adversely  affect  in  any  material  respect  the  contractual  rights  of,  the  Sellers  or  any  of  their
Affiliates, or upon transfer, Purchaser or the applicable Purchaser Designated Affiliates; provided , however , that the Parties shall
treat Purchaser or the applicable Purchaser Designated Affiliate, as the case may be, as the owner of any such Purchased Asset (and
of (x) any portion of any Shared Contract that relates to and is allocated to the Business and the benefits and burdens of which are to
be transferred to Purchaser or a Purchaser Designated Affiliate, as the case may be, pursuant to Section 2.2(d) and (y) any Delayed
Business) to the fullest extent permitted by applicable Law for all purposes as of the Closing Date. Without limiting the foregoing, if
any direct or indirect sale, conveyance, assignment, transfer or delivery, or any agreement to do the same, by the Sellers of, or any
direct or indirect purchase or assumption by Purchaser or any Purchaser Designated Affiliate of, any interest in any Purchased Asset
or  any  right  or  benefit  arising  thereunder  or  resulting  therefrom,  requires  the  consent  or  Approval  of  any  Person(s)  (including
consents  or  Approvals  of  any  Governmental  Authorities),  then  such  sale,  conveyance,  assignment,  transfer,  delivery,  agreement,
purchase or assumption shall be made subject to (and shall only be effective upon) such consent or Approval being obtained and the
remainder of this Section.

(b)            Each  of  Seller  Parent,  Purchaser  Parent  and  Purchaser  shall,  and  shall  cause  its  Affiliates  to,  use  their
reasonable best efforts to obtain all consents or Approvals referred to in Section 2.2(a) (other than from Governmental Authorities
under applicable Law, which are the subject of Section 6.3 and Section 6.4 , and with respect to the Purchaser Parent Shareholder
Approval, which is the subject of Section 6.24 ), including by executing, acknowledging and delivering such assignments, transfers,
consents,  assumptions,  and  other  agreements,  documents  and  instruments  and  taking  such  other  actions  as  may  reasonably  be
requested by the other Party in order to carry out the intent of this Agreement and any Ancillary Agreements and in order to convey
and transfer to, and vest in, Purchaser and the applicable Purchaser Designated Affiliates, the Sellers’ right, title and interest in the
Purchased Assets and to effectuate the assumption by Purchaser of the Assumed Liabilities, as contemplated by this Agreement, the
Local Implementing Agreements and the transactions contemplated hereby and thereby; provided that except as otherwise expressly
provided  by  this  Agreement  or  any  Ancillary  Agreement,  none  of  Seller  Parent,  Purchaser  Parent  or  Purchaser  or  any  of  their
respective Affiliates shall be required to expend any money or

43

commence  any  litigation,  or  offer  or  grant  any  accommodation  (financial  or  otherwise)  to  obtain  any  such  consent  or  Approval.
Purchaser  Parent  and  Purchaser  agree  to  provide  such  reasonable  security  and  assurances  as  to  financial  capability,  resources  and
creditworthiness  as  may  be  reasonably  requested  by  any  Person(s)  whose  consent  or  Approval  is  sought  in  connection  with  the
transactions  contemplated  hereby.  If  any  consent  or  Approval  referred  to  in  Section  2.2(a)  is  not  obtained  prior  to  the  Closing,
subject to Article VIII , the Closing shall nonetheless take place, and (i) for a period of up to twenty-four (24) months following the
Closing Date or until such earlier time as such consent or Approval is obtained, in the case of consents or Approvals other than those
required from Governmental Authorities under applicable Law, and (ii) until (A) the earliest to occur of (x) thirty-six (36) months
following the Closing Date, (y) the completion of a Listing Transaction (as defined in the Purchaser Shareholders Agreement) or (z)
such  time  as  such  consent  or  Approval  is  obtained,  in  the  case  of  consents  or  Approvals  from  Governmental  Authorities  under
applicable Law other than Antitrust Laws or (B) the Delayed Business Cut-Off Date, in the case of any Delayed Business subject to
a Delayed Antitrust Approval, Seller Parent shall use reasonable best efforts to continue to perform its obligations under and comply
with the terms of any Purchased Asset, as applicable, upon the direction of Purchaser, in all material respects in the ordinary course
of business, and the Parties shall (and shall cause their Affiliates to) use reasonable best efforts to, at no cost to the Sellers or their
Affiliates, (x) in the case of consents or Approvals other than those required from Governmental Authorities under applicable Law
(which are the subject of Section 6.3 and Section 6.4) , obtain such consents or Approvals, subject to and in accordance with the first
sentence of this Section 2.2(b) and (y) obtain or structure an arrangement for Purchaser or such Purchaser Designated Affiliates to
receive  (or  for  the  Sellers  and  their  Affiliates  to  enforce  for  the  benefit  of  Purchaser  or  such  Purchaser  Designated  Affiliates),
whether  by  license,  sub-license,  sub-assignment,  or  by  other  means,  the  economic  and  operational  claims,  rights  and  benefits  of
ownership of such Purchased Assets (including any Delayed Business), including the net profits from the operation or subsequent
sale  of  such  Purchased  Assets  (including  any  Delayed  Business),  and  including  the  right  to  manage  and  control  such  Purchased
Assets and direct the exercise of voting rights associated with any Purchased Assets that are Shares or, if such arrangement is not
made, to agree to such other good faith equitable result; provided that the Sellers and their Affiliates shall not be required to take any
action that would, in the good-faith reasonable judgment of the Sellers, constitute a breach or other contravention of the rights of any
Person(s), be ineffective under, or contravene, applicable Law (but only to the extent enforceable against Seller Parent or any of its
Affiliates) or result in the termination, cancellation or acceleration of any material right or obligation of, or result in the loss of any
material  benefit  of,  or  otherwise  adversely  affect  in  any  material  respect  the  contractual  rights  of,  the  Sellers  or  any  of  their
Affiliates. To the extent Seller Parent is not permitted under applicable Law to obtain or structure an arrangement for Purchaser or
such Purchaser Designated Affiliates to receive (or for the Sellers and their Affiliates to enforce for the benefit of Purchaser or such
Purchaser  Designated  Affiliates)  the  economic  and  operational  claims,  rights  and  benefits  of  ownership  of  such  Purchased  Assets
(including  any  Delayed  Business),  Seller  Parent  shall  use  reasonable  best  efforts  to  segregate  any  net  profits  associated  with  the
ownership  of  such  Purchased  Assets  (including  any  Delayed  Business)  in  an  account  for  Purchaser’s  benefit,  such  funds  to  be
released as promptly as practicable once permitted under applicable Law. Purchaser shall indemnify and hold harmless the Sellers
and the Seller Parent Indemnified Parties for and against all burdens (including losses from the operation or subsequent sale of such
Purchased Assets (including any Delayed Business)) and Liabilities arising out of or relating to each such arrangement

44

or  the  ownership  of  the  underlying  Purchased  Asset  (including  any  Delayed  Business),  and  any  risk  of  loss  or  damage  to  such
Purchased Asset (including any Delayed Business), and shall be responsible for all Assumed Liabilities related thereto in accordance
with this Agreement (without limiting any express indemnification obligations of Seller Parent set forth in Section 7.1 ). Without
limiting Section 6.3(f) , upon obtaining the requisite consents and Approvals following the Closing, any such Purchased Asset shall
be  transferred  and  assigned  to,  and  accepted  and  assumed  by,  Purchaser  and  the  applicable  Purchaser  Designated  Affiliates
hereunder. The obligations of the Parties pursuant to Section 6.3 shall be in addition to this Section 2.2(b) , and in the event of any
conflict between this Section 2.2(b) and Section 6.3 , Section 6.3 shall control. Without limiting Section 2.2(a) or Section 6.3(f)(i) ,
notwithstanding the fact that any applicable consent or Approval referred to in Section 2.2(a) is not obtained  prior to the Closing
(including any consent or Approval required to transfer an interest in a Purchased Asset to which an Assumed Liability relates), each
of the assets, properties and rights described in Section 2.1 shall be deemed to be Purchased Assets under this Agreement and each of
the Liabilities described in Section 2.4 shall be deemed to be Assumed Liabilities under this Agreement.

(c)      Purchaser Parent and Purchaser acknowledge that certain consents or Approvals of or related to the transactions
contemplated  by  this  Agreement  may  be  required  from  certain  Persons  (including  Governmental  Authorities)  with  respect  to  the
Purchased Assets, and the sale, conveyance, assignment, transfer, delivery, purchase or assumption of any interest therein, and that
such consents and Approvals may not be obtained. Notwithstanding anything to the contrary set forth in this Agreement, Purchaser
Parent and Purchaser agree that the Sellers and their Affiliates shall not have any Liability whatsoever arising out of or relating to the
failure to obtain any consents or Approvals that may have been or may be required in connection with or related to the transactions
contemplated by this Agreement or because of any default under, or acceleration or termination of or loss of any benefit under, any
Real  Property  Lease,  Equipment  Lease,  Contract,  sales  order,  purchase  order,  instrument  or  other  commitment,  obligation  or
arrangement,  Product  Registration,  Manufacturing  Registration,  Environmental  Permit,  Governmental  Authorization  or  any  claim,
right or benefit arising under or from any Purchased Asset, as a result thereof, except in the case of a breach by Seller Parent of its
express  covenants,
 representations  or  warranties  set  forth  in  this  Agreement  related  thereto.
Notwithstanding anything to the contrary set forth in this Agreement, Purchaser Parent and Purchaser expressly acknowledge and
agree  that  (other  than  the  conditions  expressly  set  forth  in  Sections  8.1(a)  and  8.1(b)  )  in  no  event  shall  the  receipt  of  any  such
consents  and  Approvals  be  a  condition  to  the  obligations  of  Purchaser  Parent  or  Purchaser  to  consummate  the  Sale  and  the  other
transactions  contemplated  by  this  Agreement,  and  Purchaser  Parent  and  Purchaser  reaffirm  their  respective  obligations  to
consummate the Sale and the other transactions contemplated by this Agreement subject only to the express conditions set forth in
Sections 8.1 and 8.2 , irrespective and independent of whether any such consents or Approvals are obtained.

 agreements,

 obligations,

(d)      Except as otherwise agreed by Seller Parent and Purchaser Parent or as otherwise provided in this Agreement or
an Ancillary Agreement, and except with respect to any Shared Contracts that relate to services to be provided under the Transition
Services Agreement, and without limiting the other provisions of this Section 2.2 , to the extent reasonably requested by Purchaser
(i) Seller Parent, Purchaser Parent and Purchaser shall, and shall cause their respective

45

Affiliates to, reasonably cooperate and use their reasonable best efforts (at Purchaser’s cost) to obtain the consent and agreement of
the third party that is a counterparty to any Shared Contract to enter into a new Contract with Purchaser or the applicable Purchaser
Designated  Affiliate  (or  a  Conveyed  Subsidiary  or  its  Subsidiary)  or  to  assign  or  transfer,  to  the  extent  assignable  or  transferable
under the terms of such Shared Contract, to Purchaser or the applicable Purchaser Designated Affiliate (or a Conveyed Subsidiary or
its Subsidiary) the portion of such Shared Contract (and the rights, benefits, obligations and burdens thereunder) that relates to the
Business, pursuant to which Purchaser or the applicable Purchaser Designated Affiliate (or a Conveyed Subsidiary or its Subsidiary)
receives the rights and benefits, and bears the obligations and burdens, of such portion of any such Shared Contract that relates to
and is allocated to the Business, as reasonably agreed by Seller Parent and Purchaser, in each case effective as of the Closing Date
(each, a “ Replacement Shared Contract ”), unless such Shared Contract relates to a Delayed Business, in which case effective as of
the date of transfer of such Delayed Business to Purchaser or the applicable Purchaser Designated Affiliate; provided that the failure
to obtain such consent or agreement or such Replacement Shared Contract shall in no event be deemed a breach of this Agreement
by  Seller  Parent  or  any  of  its  Affiliates,  except  in  the  case  of  a  breach  by  Seller  Parent  of  its  express  covenants,  agreements,
obligations, representations or warranties set forth in this Agreement related thereto, and (ii) to the extent such a Replacement Shared
Contract is not obtained, until the earlier of twenty-four (24) months following the Closing Date and the expiration or termination
date of the applicable Shared Contract (assuming, for these purposes, that the then-current term in effect as of immediately prior to
the  Closing  is  not  renewed  or  extended),  the  Parties  shall  (and  shall  cause  their  Affiliates  to)  use  reasonable  best  efforts  to,  at
Purchaser’s cost, obtain or structure an arrangement for Purchaser or the applicable Purchaser Designated Affiliates to receive the
rights and benefits, and bear the obligations and burdens, of such portion of any such Shared Contract that relates to and is allocated
to the Business, as reasonably agreed by Seller Parent and Purchaser; provided that in the case of each of clauses (i) and (ii) , the
Sellers,  Purchaser  Parent  and  Purchaser  and  their  respective  Affiliates  shall  not  be  required  to  take  any  action  that  would,  in  the
good-faith reasonable judgment of the Sellers or Purchaser, constitute a breach or other contravention of the rights of any Person(s),
be  ineffective  under,  or  contravene,  applicable  Law  or  any  such  Shared  Contract  or  result  in  the  termination,  cancellation  or
acceleration of any material right or obligation of, or result in the loss of any material benefit of, or otherwise adversely affect in any
material respect the contractual rights of, the Sellers, Purchaser or any of their respective Affiliates. Purchaser shall indemnify and
hold  harmless  the  Sellers  and  the  Seller  Parent  Indemnified  Parties  for  and  against  all  burdens  and  Liabilities  arising  out  of  any
Replacement Shared Contract, each such arrangement referred to in this Section 2.2(d) and the portion of any Shared Contract that is
subject  to  any  such  arrangement  (other  than  Shared  Contractual  Liabilities  allocated  to  Seller  Parent  in  accordance  with  the
following  sentence).  With  respect  to  Shared  Contractual  Liabilities  pursuant  to,  under  or  relating  to  any  Shared  Contract,  such
Shared Contractual Liabilities shall be allocated between Seller Parent and Purchaser as follows: (i) if a Liability is incurred solely in
respect  of  the  Business  or  the  Retained  Businesses,  such  Liability  shall  be  allocated  to  Purchaser  (in  respect  of  the  Business)  or
Seller Parent (in respect of the Retained Businesses); and (ii) if a Liability cannot be so allocated under clause (i) , such Liability
shall be allocated to Seller Parent or Purchaser, as the case may be, based on the relative proportion of total benefit received by the
Business  and  the  Retained  Businesses  under  the  relevant  Shared  Contract,  as  reasonably  agreed  by  Seller  Parent  and  Purchaser.
Notwithstanding the foregoing, (A) each of Seller Parent and Purchaser shall be responsible for any or all Liabilities

46

arising from its (or its Affiliates’) direct or indirect breach of any Shared Contract and (B) Purchaser shall be solely responsible for
any or all Liabilities arising out of or relating to any Replacement Shared Contract.

(e)      To the extent an asset or liability that comprises the business as reflected in the Financial Statements is not a
Purchased  Asset  or  an  Assumed  Liability,  the  Parties  shall  work  together  in  good  faith  to  determine  whether,  consistent  with  the
terms of this Agreement, and if so how best to, transfer the benefit or detriment of such asset or liability to Purchaser.

Section 2.3      Excluded Assets .

(a)      Notwithstanding any provision in this Agreement, Purchaser and the Purchaser Designated Affiliates are not
purchasing or acquiring any of Seller Parent’s or its Affiliates’ (including the Conveyed Subsidiaries’ or their Subsidiaries’) right,
title or interest in any assets, properties or rights other than the Purchased Assets (the “ Excluded Assets ”), including:

(i)      all assets constituting ownership interests in, or that are used or held for use in, the Retained Businesses,

other than those assets identified as Purchased Assets in clauses (a) through (s) of Section 2.1 ;

(ii)      all Retained Real Property;

(iii)            (A)  the  Retained  Facilities,  (A)  any  owned  and  leased  furniture,  equipment,  fixtures,  machinery,
supplies, spare parts, tools, tangible personal property and other tangible property located at the Retained Facilities or
not  Related  to  the  Business,  except  as  set  forth  on  Section  2.1(d)(i)(B)  of  the  Seller  Disclosure  Letter,  and  any
personal computers and vehicles that are not primarily used by the Transferred Employees in respect of the Business,
(A)  the Information  Systems  of Seller  Parent  and its Subsidiaries,  other  than the  Business  IT Systems and (A) any
leases relating to the assets described in the foregoing clauses (B) through (D) ;

(iv)            all  legal  and  beneficial  interest  in  the  share  capital  or  equity  interest  of  any  Person  other  than  the
Conveyed  Subsidiaries  (and  their  Subsidiaries),  other  than  those  equity  interests  set  forth  on  Section  2.1(q)  of  the
Seller Disclosure Letter;

(v)            all  Shared  Contracts  and  all  other  Contracts,  sales  orders,  purchase  orders,  instruments  and  other
commitments, obligations and arrangements to which Seller Parent or any of its Affiliates is a party or by which any
of its or their properties, assets or rights is subject, in each case other than Assumed Contracts;

(vi)          all inventory (including all raw material inventory, work-in-process inventory, spare parts inventory

and finished products inventory) other than the Inventory and any samples of Products;

(vii)            the  Retained  Names  and  all  other  Intellectual  Property  that  is  not  Business  IP,  including  such

Intellectual Property licensed to Purchaser under an

47

Ancillary Agreement or otherwise, and including as set forth on Section  2.3(a)(vii) of the Seller Disclosure Letter,
and  including  the  right  to  sue  and  recover  and  retain  damages  for  past,  present  and  future  infringement  or
misappropriation or any other violation of any such Intellectual Property;

(viii)            all  Governmental  Authorizations,  including  product  registrations,  manufacturing  registrations  and
environmental  permits,  owned,  used  or  licensed  by  Seller  Parent  or  any  of  its  Affiliates  and  not  Related  to  the
Business;

(ix)      all customer and vendor lists, all advertising, marketing, sales and promotional materials, and business
and  financial  records,  books,  and  documents  and  other  Records,  in  each  case  not  Related  to  the  Business,  and  the
Specified Records;

(x)      all accounts receivable and other current assets and all cash and cash equivalents, checks, money orders,
marketable  securities,  short-term  instruments,  bank  and  other  depositary  accounts,  certificates  of  deposit,  time
deposits,  negotiable  instruments,  securities  and  brokerage  accounts,  funds  in  time  and  demand  deposits  or  similar
accounts  of Seller  Parent  or any of its Affiliates  (including  the Conveyed  Subsidiaries  or any of their Subsidiaries)
(other  than  the  accounts  receivable  and  other  assets,  in  each  case  included  in  the  calculation  of  the  Final  Business
Working Capital, and the Cash Equivalents included in the calculation of Final Business Net Cash);

(xi)      all Tax refunds, Tax credits or other Tax Assets of the Sellers and any refund or credit against Seller
Indemnified  Taxes  to  which  Seller  Parent  is  entitled  pursuant  to  Section  6.5(c)  ,  whether  or  not  derived  from  the
Business and whether or not existing prior to the Closing, but excluding any refunds or credits or other Tax Assets to
the  extent  reflected  as  an  asset  on  the  Final  Closing  Statement  and  taken  into  account  in  the  calculation  of  (a)  the
Final  Business  Working  Capital  or  (b)  Seller  Accrued  Income  Taxes  (to  the  extent,  with  respect  to  clause  (b)  ,
offsetting a Tax Liability in such calculation);

(xii)      all Seller Combined Tax Returns and all Tax Returns of the Sellers or any of their Affiliates (other than
the  Conveyed  Subsidiaries  and  their  Subsidiaries)  that  do  not  relate  solely  to  Purchased  Assets  or  Assumed
Liabilities, and in each case any books and records relating thereto;

(xiii)      all claims, defenses, causes of action, counterclaims and rights of set-off against third parties (at any
time  or  in  any  manner  arising  or  existing,  whether  choate  or  inchoate,  known  or  unknown,  contingent  or  non-
contingent) other than those identified as Purchased Assets in Section 2.1 ;

(xiv)      all rights of Seller Parent or any of its Affiliates (for clarity, other than, from and after the Closing, the

Conveyed Subsidiaries and their Subsidiaries) under

48

this  Agreement  or  the  Ancillary  Agreements  and  any  documents  delivered  or  received  in  connection  herewith  or
therewith;

(xv)      except as set forth in Section 2.1(o) and subject to Section 6.18 , all current and prior insurance policies
and  all  rights  of  any  nature  with  respect  thereto,  including  all  insurance  recoveries  thereunder  and  rights  to  assert
claims with respect to any such insurance recoveries;

(xvi)      except as expressly set forth in this Agreement (including Section 2.1(p) and Section 6.6 ), all assets of

any Seller Group Plan or Foreign Seller Group Plan that is not a Conveyed Subsidiary Plan;

(xvii)      all corporate-level services (but not the assets related to such services to the extent such assets are
Purchased Assets) of the type currently provided to the Business by Seller Parent or any of its Affiliates, and without
limiting Seller Parent’s obligations under the Transition Services Agreement;

(xviii)      all third-party warranties, indemnities, further assurances and similar covenants and guarantees other

than those identified as Purchased Assets in Section 2.1 ;

(xix)      all assets, properties and rights of any Person that are not Related to the Business, including all assets,
properties and rights constituting ownership interests in, or that are used or held for use in, or related to, the Retained
Businesses,  in  each  case  other  than  those  assets,  properties  or  rights  identified  as  Purchased  Assets  in  clauses  (a)
through (s) of Section 2.1 ; and

(xx)      the assets set forth in Section 2.3(a)(xx) of the Seller Disclosure Letter.

(b)      Notwithstanding anything in this Agreement to the contrary but subject to Section 6.5(f) , prior to the Closing,
Seller  Parent  shall  use  commercially  reasonable  efforts  to  take  (or  cause  one  or  more  of  its  Affiliates  to  take)  such  action  as  is
necessary,  advisable  or  desirable  to  transfer  the  Excluded  Assets  from  the  Conveyed  Subsidiaries  and  their  Subsidiaries  (and,  if
needed, from the Sellers) to Seller Parent or one or more of its Retained Subsidiaries for such consideration or for no consideration,
as may be determined by Seller Parent in its sole discretion, but in compliance with all applicable Laws and as would not result in
any  material  adverse  impact  to  the  Purchased  Assets  or  the  Business.  After  the  Closing  Date,  the  Parties  shall  continue  to  use
commercially reasonable efforts to take all actions (and shall cause their Affiliates (including the Conveyed Subsidiaries and their
Subsidiaries) to continue to use commercially reasonable efforts to take all actions) reasonably requested by the other Party to effect
the provisions  of this Section 2.3 , including the return of any Excluded Assets for no additional consideration. Any action taken
pursuant to this Section 2.3(b) after the Closing Date shall be deemed for purposes of calculating the Business Working Capital and
the Business Net Cash pursuant to Section 2.9 to have occurred as of 12:01 a.m. (New York time) on the Closing Date.

49

Section 2.4      Assumption of Assumed Liabilities . Upon the terms and subject to the conditions of this Agreement, at
the Closing, Purchaser shall (i) assume and, subject to Section 2.5 , Section 6.5 , Section 6.6 and Article VII , pay, perform, satisfy
and  discharge  any  and  all  Liabilities  of  the  Sellers  or  any  of  their  Affiliates  (including  the  Conveyed  Subsidiaries  and  their
Subsidiaries), whether arising prior to, on or after the Closing, to the extent resulting from or arising out of the past, present or future
ownership,  operation,  use  or  conduct  of  the  Business  or  the  Purchased  Assets  (including  the  Shares)  and  (ii)  cause  the  Conveyed
Subsidiaries and their Subsidiaries to pay, perform, satisfy and discharge any and all of their respective Liabilities, in each case of
the foregoing clauses (i) and (ii), other than Liabilities identified as Retained Liabilities in clauses (a) through (g) of Section 2.5 (all
of the foregoing Liabilities being collectively referred to herein as the “ Assumed Liabilities ”). The Assumed Liabilities shall also
include the following:

(a)          all Liabilities to the extent expressly assumed by, retained by or agreed to be performed by Purchaser or its
Subsidiaries  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries)  pursuant  to  the  terms  of  this  Agreement,  including  all
Liabilities  to  the  extent  transferred  to  or  assumed  or  retained  by  Purchaser  or  its  Subsidiaries  pursuant  to  Section  6.6  and
Section 6.13 ;

(b)          all Liabilities in respect of any Action, whether class, individual or otherwise in nature, in law or in equity,
whether or not presently threatened, asserted or pending, to the extent arising out of, or to the extent relating to, the Business or the
operation or conduct of the Business prior to, on or after the Closing;

(c)      all Liabilities for Taxes of the Conveyed Subsidiaries and their Subsidiaries and, without duplication, all other
Liabilities for Taxes imposed with respect to, arising out of or relating to the Purchased Assets or the Business, in each case, other
than Seller Indemnified Taxes for which Seller Parent is liable pursuant to this Agreement;

(d)            all  Liabilities  to  the  extent  arising  out  of,  or  to  the  extent  relating  to,  the  design,  manufacture,  testing,
marketing, distribution, use or sale of Products prior to, on or after the Closing, including warranty obligations and irrespective of the
legal theory asserted;

(e)      all Liabilities to suppliers and customers, in each case to the extent arising out of, or to the extent relating to, the

Business, including in respect of any Products returned prior to, on or after the Closing;

(f)      all accounts payable and all other Liabilities, in each case included in the calculation of Final Business Working
Capital, all Funded Indebtedness included in the calculation of Final Business Net Cash and all other Indebtedness of the Conveyed
Subsidiaries (or their Subsidiaries) that is not Funded Indebtedness;

(g)      all Environmental Liabilities of any nature whatsoever to the extent arising out of, or relating to, or in respect of
the Conveyed Subsidiaries (or their Subsidiaries), the Purchased Assets, the Business or the Facilities, whether arising prior to, on or
after the Closing, other than the Retained Facilities Environmental Liabilities or the Retained Environmental Liabilities;

50

(h)            all  Liabilities  to  the  extent  relating  to,  resulting  from  or  arising  out  of  the  Assumed  Contracts,  including
Purchaser’s  or  its  Affiliates’  (including  any  Conveyed  Subsidiary’s  or  its  Subsidiaries’)  portion  of  Shared  Contractual  Liabilities
pursuant to Section 2.2(d) ; and

(i)      the Liabilities set forth in Section 2.4(i) of the Seller Disclosure Letter.

Section 2.5      Retained Liabilities . Except as otherwise set forth in this Agreement, and subject to Article VII , the
Sellers shall retain, and none of Purchaser or any of its Affiliates shall assume or be responsible for pursuant to this Agreement, any
Liabilities of Sellers or any of their Affiliates other than the Assumed Liabilities (such Liabilities other than the Assumed Liabilities,
the “ Retained Liabilities ”). The Retained Liabilities shall include:

(a)      all Liabilities for which any Seller expressly has responsibility pursuant to the terms of this Agreement or any

Ancillary Implementing Agreement, including all Liabilities for which the Sellers have responsibility pursuant to Section 6.6 ;

(b)      all Liabilities of any Seller or Conveyed Subsidiary (or Subsidiaries thereof) to the extent related to or arising
out of (i) the Excluded Assets (other than any Liabilities for which Purchaser or its Affiliates expressly has responsibility pursuant to
the terms of this Agreement or any Ancillary Agreement, and other than any Liabilities that are separately allocated pursuant to any
other agreement or transaction related to such Excluded Assets between Seller Parent or any of its Affiliates, on the one hand, and
Purchaser or any of its Affiliates,  on the other hand, including any commercial  or other agreements  unrelated  to this Agreement),
including Environmental Liabilities, whether arising prior to, on or after the Closing, to the extent arising out of or related to the
ownership or occupancy of the Retained Facilities (the “ Retained Facilities Environmental Liabilities ”) or (ii) the matters set forth
on Section 2.5(b)(ii) of the Seller Disclosure Letter (the “ Retained Environmental Liabilities ”);

(c)      all Seller Indemnified Taxes;

(d)      all Seller Transaction Expenses;

(e)      Seller Parent’s portion of Shared Contractual Liabilities pursuant to Section 2.2(d) ;

(f)      all Indebtedness of Seller Parent and its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries)

that are not Assumed Liabilities under Section 2.4 ; and

(g)            all  Liabilities  of  Seller  Parent  or  any  of  its  Affiliates  (including  the  Conveyed  Subsidiaries  and  their

Subsidiaries) set forth in Section 2.5(g) of the Seller Disclosure Letter.

Section  2.6            Purchase  Consideration  .  In  consideration  of  the  sale  and  transfer  to  Purchaser  or  the  applicable
Purchaser  Designated  Affiliates  of the applicable  Sellers’ right, title and interest in the Purchased  Assets, including  the Shares, in
accordance with and subject to the terms of this Agreement (the “ Sale ”), and the other obligations of Seller Parent pursuant to this
Agreement, at the Closing, Purchaser shall, and Purchaser Parent shall cause Purchaser to, (a) allot, issue and

51

deliver the Purchase Consideration in accordance with Section 2.7 , and (b) assume the Assumed Liabilities.

Section 2.7      Delivery of the Purchase Consideration . At the Closing, Purchaser shall, and Purchaser Parent shall
cause Purchaser to, allot and issue to Seller Parent (and/or Seller Parent’s designee(s) (which shall be one or more Affiliates of Seller
Parent), in such allocations as may be directed by Seller Parent), free and clear of all Liens except for Liens arising under applicable
securities  Laws,  and  credited  as  fully  paid,  a  number  of  B  ordinary  shares  in  the  capital  of  Purchaser,  having  the  rights  and
restrictions  set  out  in  the  Restated  Purchaser  Articles  of  Association  (the  “  B  Ordinary  Shares  ”),  in  such  number  so  that,
immediately following Closing, (a) the B Ordinary Shares owned by Seller Parent (and/or Seller Parent’s designee(s)) will represent
32% of the Ordinary Shares (such B Ordinary Shares, the “ Purchase Consideration ”) and (b) the A ordinary shares in the capital of
Purchaser,  having  the  rights  and  restrictions  set  out  in  the  Restated  Purchaser  Articles  of  Association,  owned  by  a  wholly  owned
Subsidiary of Purchaser Parent (the “ A Ordinary Shares ”) will represent the remaining 68% of the Ordinary Shares, in each case of
the foregoing clauses (a) and (b), after giving effect to (and including) the issuance of the B Ordinary Shares, and, together with the
Preference Shares, such shares will represent all of the issued share capital of Purchaser.

Section 2.8      Estimated Closing Statement; Estimated Adjustment Payments .

(a)      No fewer than seven (7) Business Days before the Closing Date, (a) Seller Parent shall prepare in good faith and
deliver  to  Purchaser  Parent  the  Estimated  Closing  Statement,  which  shall  include  Seller  Parent’s  good  faith  calculation  of  the
Estimated  Business  Working  Capital,  Estimated  Business  Net  Cash  and  any  Estimated  Business  Excess  Adjustment  or  Estimated
Business  Deficit  Adjustment  to  be  paid  at  Closing,  prepared  in  a  manner  consistent  with  the  accounting  principles,  procedures,
policies and methods set forth in Annex B-1 (the “ Accounting Principles ”) and the Sample Closing Statement and (b) Purchaser
Parent  shall  prepare  in  good  faith  and  deliver  to  Seller  Parent  the  Purchaser  Estimated  Closing  Statement,  which  shall  include
Purchaser  Parent’s  good  faith  calculation  of  the  Estimated  Purchaser  Working  Capital,  Estimated  Purchaser  Net  Cash  and  any
Estimated Purchaser Parent Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment to be paid at Closing, prepared in
a  manner  consistent  with  the  accounting  principles,  procedures,  policies  and  methods  set  forth  in  Annex  B-3  (the  “  Purchaser
Accounting  Principles  ”)  and  the  Sample  Purchaser  Closing  Statement.  The  Parties  shall  have  the  right  to  review  the  Estimated
Closing Statement and the Purchaser Parent Estimated Closing Statement and the Parties shall cooperate in good faith in an effort to
agree to any required modification based on such review.

(b)          If (i) the amount equal to (A) the Estimated Business Working Capital plus
(B) the Estimated Business Net
Cash exceeds (ii) the amount equal to (A) the Target Business Working Capital plus
(B) the Target Business Net Cash (the amount
of  such  excess,  the  “  Estimated Business  Excess  Adjustment  ”),  at  the  Closing,  Purchaser  shall,  and  Purchaser  Parent  shall  cause
Purchaser to, pay to Seller Parent (and/or Seller Parent’s designee(s), in such allocations as may be directed by Seller Parent) by wire
transfer of immediately available funds to the Seller Account, an amount in cash equal to the Estimated Business Excess Adjustment.

52

(c)           If  (i)  the  amount  equal  to  (A)  the  Target  Business  Working  Capital  plus
(B)  the  Target  Business  Net  Cash
exceeds (ii) the amount equal to (A) the Estimated Business Working Capital plus
(B) the Estimated Business Net Cash (the amount
of such excess, the “ Estimated Business Deficit Adjustment ”), at the Closing, Seller Parent shall pay to Purchaser by wire transfer
of immediately available funds to the Purchaser Account, an amount in cash equal to the Estimated Business Deficit Adjustment.

(d)      If (i) the amount equal to (A) the Estimated Purchaser Working Capital plus
(B) the Estimated Purchaser Net
Cash exceeds (ii) the amount equal to (A) the Target Purchaser Working Capital plus
(B) the Target Purchaser Net Cash (the amount
of such excess, the “ Estimated Purchaser Parent Excess Adjustment ”), at the Closing, Purchaser shall, and Purchaser Parent shall
cause  Purchaser  to,  pay  to  Purchaser  Parent  (and/or  Purchaser  Parent’s  designee(s),  in  such  allocations  as  may  be  directed  by
Purchaser Parent) by wire transfer of immediately available funds to the Purchaser Parent Account, an amount in cash equal to the
Estimated Purchaser Parent Excess Adjustment.

(e)      If (i) the amount equal to (A) the Target Purchaser Working Capital plus
(B) the Target Purchaser Net Cash
exceeds  (ii)  the  amount  equal  to  (A)  the  Estimated  Purchaser  Working  Capital  plus
 (B)  the  Estimated  Purchaser  Net  Cash  (the
amount  of  such  excess,  the  “  Estimated  Purchaser  Parent  Deficit  Adjustment  ”),  at  the  Closing,  Purchaser  Parent  shall  pay  to
Purchaser  by  wire  transfer  of  immediately  available  funds  to  the  Purchaser  Account,  an  amount  in  cash  equal  to  the  Estimated
Purchaser Parent Deficit Adjustment.

(f)            Any  Estimated  Business  Excess  Adjustment,  Estimated  Business  Deficit  Adjustment,  Estimated  Purchaser
Parent Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment paid at the Closing shall be subject to the post-Closing
adjustment provisions of Section 2.9 .

Section 2.9      Post-Closing Working Capital and Net Cash Adjustments .

(a)      Within one hundred and twenty (120) days after the Closing Date, Purchaser shall deliver to Seller Parent and
Purchaser  Parent  a  statement  setting  forth  Purchaser’s  calculation  of  the  Business  Working  Capital,  the  Business  Net  Cash,
Purchaser Working Capital and Purchaser Net Cash (together with reasonable documentation, back-up and supporting detail for each
of  the  items  and  calculations  in  such  statement,  the  “  Proposed  Closing  Statement  ”).  The  Proposed  Closing  Statement  shall  be
unaudited  but  shall  be  prepared  in  a  manner  consistent  with  (i)  with  respect  to  the  calculation  of  Business  Working  Capital  and
Business Net Cash, the Accounting Principles and the Sample Closing Statement and (ii) with respect to the calculation of Purchaser
Working  Capital  and  Purchaser  Net  Cash,  the  Purchaser  Accounting  Principles  and  the  Sample  Purchaser  Closing  Statement,
including as to line items and the classification of asset and liability line items set forth thereon, and take into account any transfers
made pursuant to Section 2.3(b) , and to the extent the Proposed Closing Statement reflects amounts that are different from amounts
presented on the balance sheet included in the Financial Statements or the Purchaser Financial Statements, as applicable, as of the
Balance Sheet Date, such differences shall be based on facts or occurrences arising solely between the Balance Sheet Date and the
Closing.

53

(b)      Following the delivery of the Proposed Closing Statement until the date that is ninety (90) days thereafter (the “
Review Period ”), either or both Parents may, by delivering a written notice to the other Parties, dispute the amounts reflected on the
line items of the Proposed Closing Statement (any such disputed amount, a “ Disputed Item ”). A Parent’s written notice of Disputed
Items shall identify each Disputed Item and specify the nature of such Parent’s disagreement, the amount of each item in dispute and
the basis therefor, and the amount that such Parent believes is the correct amount of the Business Working Capital, the Business Net
Cash, Purchaser Working Capital or Purchaser Net Cash, as applicable, based on the disagreements set forth in its notice of Disputed
Items,  including  the  adjustments  applied  by  such  Parent  to  the  Proposed  Closing  Statement  in  calculating  any  such  amounts.  A
Parent shall be deemed to have agreed with all other items and amounts contained in the Proposed Closing Statement not so objected
to by it in a notice of Disputed Items within the Review Period in accordance with this Section 2.9(b) , and the failure by a Parent to
provide a notice of Disputed Items to the other Parties within the Review Period will constitute such Parent’s agreement with all of
the items in the Proposed Closing Statement,  and the Proposed Closing Statement shall be conclusive,  final and binding upon the
Parties as the Final Closing Statement with respect to the items thereon so agreed by both Parents.

(c)          If a notice  of Disputed  Items shall  be timely  delivered  in accordance  with Section 2.9(b) , the Parties shall,
during the forty-five (45) days following the date of such delivery (the “ Resolution Period ”), negotiate in good faith to resolve the
Disputed Items. During the Review Period and the Resolution Period, each Party and its Representatives (including its accountants)
shall be permitted to review the working papers of the other Parties and their accountants relating to the notice of Disputed Items and
the Proposed Closing Statement (subject to execution of customary working paper access letters). To the extent any Disputed Items
are so resolved in writing by mutual agreement of all Parties within the Resolution Period, then the Proposed Closing Statement, as
revised to incorporate such changes as have been agreed between all Parties, shall be conclusive, final and binding upon the Parties
as the Final Closing Statement with respect to the items thereon so agreed.

(d)      If during such Resolution Period the Parties are unable to reach agreement on all Disputed Items, the Parties
shall refer all unresolved Disputed Items to the Independent Accountant. The Independent Accountant shall make a determination
with  respect  to  each  unresolved  Disputed  Item  within  forty-five  (45)  days  after  its  engagement  by  the  Parties  to  resolve  such
Disputed Items, which determination shall be made in accordance with the rules set forth in this Section 2.9 . Except as the Parties
may otherwise agree, all communications between any of the Parties or any of their respective Representatives, on the one hand, and
the Independent Accountant, on the other hand, will be in writing with copies simultaneously delivered to the non-communicating
Parties.  The  Parties  shall  cooperate  with  the  Independent  Accountant  in  its  proceedings,  including  by  providing  such  accounting
books  and  records  and  working  papers  of  each  Party  and  its  accountants,  as  the  Independent  Accountant  may  reasonably  request
(subject to execution of customary working paper access letters). The Independent Accountant shall make its determination (i) based
solely on the documentation submitted by, and presentations made by, any of the Parties (any such documentation or presentation
must be provided to the other Parties at the same time as its submission or presentation to the Independent Accountant) and (ii) in a
manner consistent with (A) the Accounting Principles and the Sample Closing Statement and the definitions

54

of Business Working Capital and Business Net Cash, in the case of the calculation of Business Working Capital and Business Net
Cash, and (B) the Purchaser Accounting  Principles and the Sample Purchaser Closing Statement,  and the definitions  of Purchaser
Working Capital and Purchaser Net Cash, in the case of the calculation of Purchaser Working Capital and Purchaser Net Cash (and
in each case each of the defined terms used in each of those terms or in which those terms are used and the related provisions of this
Agreement). The Independent Accountant shall deliver to the Parties, within such forty-five (45)-day period, a written report setting
forth  its  adjustments,  if  any,  to  the  Proposed  Closing  Statement  and  the  calculations  supporting  such  adjustments,  and  any  such
adjustments must be within the range of values established for such Disputed Item by Purchaser in the Proposed Closing Statement
and by the applicable Parent(s) in the notice of Disputed Items delivered pursuant to Section 2.9(b) . Absent manifest errors, such
report shall be conclusive, final and binding on the Parties and enforceable in a court of law, effective as of the date the Independent
Accountant’s  written  determination  is  received  by  the  Parties,  and  the  Proposed  Closing  Statement,  as  revised  to  incorporate  the
Independent  Accountant’s  resolution  of  the  Disputed  Items,  shall  be  conclusive,  final  and  binding  upon  the  Parties  as  the  Final
Closing Statement. Purchaser shall pay the fees and expenses of the Independent Accountant, and the Independent Accountant shall
bill  Purchaser  accordingly.  The  Parties  acknowledge  that  they  have  discussed  their  past  contacts,  if  any,  with  the  Independent
Accountant, and that no Party shall have the right to object to the Independent Accountant’s service in such role by reason of non-
disclosure of past contacts, conflicts of interest or any other reason. If, before the Independent Accountant renders its determination
with  respect  to  the  Disputed  Items  in  accordance  with  this Section 2.9(d) ,  any  Disputed  Items  are  resolved  in  writing  by  mutual
agreement of all Parties, then in each case such items as so agreed will be conclusive, final and binding on the Parties immediately
upon such notice as the Final Closing Statement with respect to the items thereon so agreed.

(e)      As used herein, “ Final Business Working Capital ”, “ Final Business Net Cash ”, “ Final Purchaser Working
Capital ” and “ Final Purchaser Net Cash ” mean (i) if no notice of Disputed Items with respect to the Business Working Capital,
Business Net Cash, Purchaser Working Capital or Purchaser Net Cash, respectively, is delivered by either Parent within the period
provided in Section 2.9(b) , the Business Working Capital, Business Net Cash, Purchaser Working Capital or Purchaser Net Cash,
respectively, as shown in the Proposed Closing Statement as prepared by Purchaser, or (ii) if such a notice of Disputed Items with
respect  to  the  Business  Working  Capital,  Business  Net  Cash,  Purchaser  Working  Capital  or  Purchaser  Net  Cash,  respectively,  is
timely  delivered  by  either  Parent,  either  (A)  the  Business  Working  Capital,  Business  Net  Cash,  Purchaser  Working  Capital  or
Purchaser Net Cash, respectively, as mutually agreed to in writing by the Parties or (B) the Business Working Capital, Business Net
Cash,  Purchaser  Working  Capital  or  Purchaser  Net  Cash,  respectively,  as  shown  in  the  Independent  Accountant’s  calculation
delivered pursuant to Section 2.9(d) .

(f)           Until  the  date  on  which  the  Proposed  Closing  Statement  shall  become  conclusive,  final  and  binding  on  the
Parties pursuant to this Section 2.9 (the “ Closing Statement Finalization Date ”),  each  Party  agrees  that  following  the  Closing  it
shall,  and  shall  cause  its  Representatives  to,  preserve  the  accounting  books  and  records  of  the  Business  and  of  Purchaser  and  its
Affiliates  on  which  the  Proposed  Closing  Statement  is  to  be  based  and  shall  not  take  any  actions  with  respect  to  such  books  and
records that would obstruct or prevent the procedures set

55

forth in this Section 2.9 (including books and records related to the Business Working Capital, the Business Net Cash, the Purchaser
Working  Capital  and  the  Purchaser  Net  Cash  or  the  Proposed  Closing  Statement  or  the  preparation  of  the  Proposed  Closing
Statement).

(g)      If (i) the amount equal to (A) the Final Business Working Capital plus
(B) the Final Business Net Cash exceeds
(ii) the amount equal to (A) the Estimated Business Working Capital plus
(B) the Estimated Business Net Cash (the amount of such
excess, the “ Final Business Excess Adjustment ”), Purchaser shall, and Purchaser Parent shall cause Purchaser to, pay within five
(5) Business Days of the Closing Statement Finalization Date to Seller Parent (and/or Seller Parent’s designee(s), in such allocations
as may be directed by Seller Parent) by wire transfer of immediately available funds to the Seller Account, an amount in cash equal
to the amount of the Final Business Excess Adjustment.

(h)          If (i) the amount equal to (A) the Estimated Business Working Capital plus
(B) the Estimated Business Net
Cash exceeds (ii) the amount equal to (A) the Final Business Working Capital plus
(B) the Final Business Net Cash (the amount of
such  excess,  the  “  Final  Business  Deficit  Adjustment  ”),  Seller  Parent  shall  pay  within  five  (5)  Business  Days  of  the  Closing
Statement  Finalization  Date to Purchaser  by wire transfer of immediately  available  funds to the Purchaser  Account,  an amount in
cash equal to the amount of the Final Business Deficit Adjustment.

(i)            If  (i)  the  amount  equal  to  (A)  the  Final  Purchaser  Working  Capital  plus
 (B)  the  Final  Purchaser  Net  Cash
exceeds  (ii)  the  amount  equal  to  (A)  the  Estimated  Purchaser  Working  Capital  plus
 (B)  the  Estimated  Purchaser  Net  Cash  (the
amount  of  such  excess,  the  “  Final  Purchaser  Parent  Excess  Adjustment  ”),  Purchaser  shall,  and  Purchaser  Parent  shall  cause
Purchaser to, pay within five (5) Business Days of the Closing Statement Finalization  Date to Purchaser Parent (and/or Purchaser
Parent’s designee(s), in such allocations as may be directed by Purchaser Parent) by wire transfer of immediately available funds to
the Purchaser Parent Account, an amount in cash equal to the amount of the Final Purchaser Parent Excess Adjustment.

(j)      If (i) the amount equal to (A) the Estimated Purchaser Working Capital plus
(B) the Estimated Purchaser Net
Cash exceeds (ii) the amount equal to (A) the Final Purchaser Working Capital plus
(B) the Final Purchaser Net Cash (the amount of
such  excess,  the  “  Final Purchaser  Parent  Deficit  Adjustment  ”),  Purchaser  Parent  shall  pay  within  five  (5)  Business  Days  of  the
Closing  Statement  Finalization  Date  to  Purchaser  by  wire  transfer  of  immediately  available  funds  to  the  Purchaser  Account,  an
amount in cash equal to the amount of the Final Purchaser Parent Deficit Adjustment.

(k)           Until  the  date  on  which  the  Proposed  Closing  Statement  shall  become  conclusive,  final  and  binding  on  the
Parties pursuant to this Section 2.9 , each Party agrees that following the Closing it shall afford and cause to be afforded to the other
Parties and their Affiliates and the Representatives retained by the other Parties in connection with the preparation of the Proposed
Closing  Statement  and  any  adjustment  to  the  Estimated  Business  Excess  Adjustment,  Estimated  Business  Deficit  Adjustment,
Estimated Purchaser Parent Excess Adjustment or Estimated Purchaser Parent Deficit Adjustment contemplated by this Section 2.9 ,
reasonable access upon reasonable notice during normal business hours to the properties, books, contracts, personnel and records of
the Business and Purchaser and Purchaser Parent and such Party’s, its Affiliates’ and

56

their  respective  accountants’  working  papers  (subject  to  execution  of  customary  working  paper  access  letters)  relevant  to  the
preparation  of  the  Proposed  Closing  Statement  and  any  adjustment  contemplated  by  this  Section  2.9  ,  including  any  notice  of
Disputed  Items,  and  shall  provide  the  other  Parties  and  their  Affiliates  and  Representatives,  upon  the  other  Party’s  reasonable
request, with copies of any such books, contracts, records and work papers.

(l)      Except in cases of fraud with respect to the representations, warranties, covenants and agreements contained in
this  Agreement,  the  process  set  forth  in  this  Section  2.9  shall  be  the  sole  and  exclusive  remedy  of  any  of  the  Parties  and  their
respective  Affiliates  for any disputes  related  to the Final Business  Excess Adjustment,  the Final Business  Deficit  Adjustment,  the
Final Purchaser Parent Excess Adjustment and the Final Purchaser Parent Deficit Adjustment.

Section 2.10      Withholding . Absent any change in Law after the date hereof, Purchaser acknowledges and agrees
that  no  withholding  is  required  in  respect  of  the  payment  of  the  Purchase  Consideration  or  any  amounts  payable  to  Seller  Parent
pursuant  to  Section  2.8  or  Section  2.9  as  a  result  of  Purchaser’s  tax  residence  to  the  extent  Seller  Parent  satisfies  its  obligations
pursuant  to  Section  3.1(b)  .  In  the  event  that  any  deduction  or  withholding  for  Taxes  in  respect  of  the  payment  of  the  Purchase
Consideration or any amounts payable to Seller Parent pursuant to Section 2.8 or Section 2.9 is required by Law, Purchaser and the
Purchaser  Designated  Affiliates  shall  be entitled  to deduct  and withhold  such amounts  from  such  payments  to the  extent  required
under applicable Law; provided that Purchaser shall give Seller Parent written notice of any such requirement to deduct and withhold
any  Taxes  from  such  amounts  promptly  after  becoming  aware  of  such  requirement.  Purchaser  and  Seller  Parent  shall  reasonably
cooperate  with  each  other  to  minimize  the  amounts,  if  any,  required  to  be  deducted  and  withheld.  If  any  amount  is  withheld  in
accordance  with  the  foregoing  provisions  of  this  Section  2.10  ,  such  withheld  amount  shall  be  treated  for  all  purposes  of  this
Agreement as having been paid to the applicable recipient of such amount otherwise payable.

ARTICLE III

CLOSING

Section 3.1      Closing .

(a)      Subject to Section 3.1(d) , the Closing shall take place at the offices of Wachtell, Lipton, Rosen & Katz located
at 51 West 52nd Street, New York, New York 10019, at 10:00 a.m. (New York time) on the third (3rd) Business Day following the
satisfaction or waiver of all the conditions set forth in Article VIII (other than the conditions that by their nature are to be satisfied on
the Closing  Date,  but  subject  to  the  satisfaction  or waiver  of such conditions),  or at such other  time  and  place  as the  Parties  may
mutually agree. The date on which the Closing occurs is referred to as the “ Closing Date .” Unless the Parties agree otherwise, and
notwithstanding the actual occurrence of the Closing at any particular time on the Closing Date, the Closing shall be deemed to occur
and  be  effective  as  of  12:01  a.m.  (New  York  time)  on  the  Closing  Date.  In  addition  to  payment  of  the  amounts  set  forth  in
Section 2.8 :

57

(b)      At the Closing, Seller Parent shall deliver, or cause to be delivered, to Purchaser the instruments and documents

set forth in Exhibit A .

(c)      At the Closing, Purchaser shall, and Purchaser Parent shall cause Purchaser to, deliver to Seller Parent, as agent
for the Sellers, or its designee(s) the following: (i) customary and satisfactory evidence of the allotment and issuance of the Purchase
Consideration to Seller Parent or its designee(s), credited as fully paid and (ii) the instruments and documents set forth in Exhibit B .

(d)           Seller  Parent  and  Purchaser  Parent  hereby  agree  that  if  the  Closing  Date  does  not  fall  on  the  last  day  of  a
calendar month, the Parties shall cooperate in good faith and discuss designing a lock box construct to facilitate a month end closing
for accounting purposes pursuant to which each of Seller Parent and Purchaser Parent is put in the same economic position as if the
Closing  had  occurred  on  the  originally  contemplated  Closing  Date  and  so  that  neither  Party  bears  any  additional  closing
conditionality risk or value leakage risk during the interim period.

Section 3.2      Restated Purchaser Articles of Association . Purchaser Parent shall, in accordance with applicable Law
and the articles of association of Purchaser, cause the articles of association of Purchaser to be amended and restated, effective as of
immediately prior to the Closing, to be in the form set forth in Exhibit E (the “ Restated Purchaser Articles of Association ”).

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF SELLER PARENT

Except  as  set  forth  in  the  Seller  Disclosure  Letter  and  in  accordance  with  Section  10.8  ,  Seller  Parent  hereby

represents and warrants to Purchaser Parent and Purchaser as follows:

Section 4.1            Organization .  Seller  Parent  is  a  corporation  duly  organized,  validly  existing  and  in  good  standing
under the Laws of the State of Delaware. Each Seller is, or will be as of the Closing, a corporation, partnership or other legal entity
duly organized, validly existing and, where applicable, in good standing under the Laws of the jurisdiction of its organization, except
where the failure to be so organized, existing or in good standing would not, individually or in the aggregate, be materially adverse
to the Business or prevent or reasonably be expected to prevent the Sellers from consummating the Closing prior to the Outside Date.

Section 4.2      Authority; Binding Effect .

(a)      Seller Parent has all requisite corporate power and authority to execute and deliver this Agreement and each
Ancillary Agreement to which it will be a party and to perform its obligations hereunder and thereunder. The execution and delivery
by  Seller  Parent  of  this  Agreement  and  each  such  Ancillary  Agreement,  and  the  performance  by  Seller  Parent  of  its  obligations
hereunder  and  thereunder,  have  been,  or  will  have  been  as  of  the  Closing,  duly  authorized  by  all  requisite  corporate  action.  Each
Seller  has,  or  will  have  as  of  the  Closing,  all  requisite  corporate  or  other  similar  applicable  power  and  authority  to  execute  and
deliver each Ancillary Agreement

58

to which it will be a party and to perform its obligations thereunder. The execution and delivery by each Seller of each Ancillary
Agreement to which it will be a party, if applicable, and the performance by it of its obligations thereunder, have been, or will have
been as of the Closing, duly authorized by all requisite corporate or other similar applicable action.

(b)           Seller  Parent  has,  and  each  other  Seller  has,  or  will  have  as  of  the  Closing,  all  requisite  corporate  or  other
similar applicable power and authority to carry on its respective business as it pertains to the Business as currently conducted and to
own, lease and operate its properties and assets related to the Business, except where the failure to have such power and authority
would not, individually or in the aggregate, be materially adverse to the Business or prevent or reasonably be expected to prevent the
Sellers from consummating the Closing prior to the Outside Date.

(c)      This Agreement has been duly executed and delivered by Seller Parent and, assuming this Agreement has been
duly executed and delivered by Purchaser Parent and Purchaser, constitutes a legal, valid and binding obligation of Seller Parent, and
each Ancillary Agreement will be as of the Closing duly executed and delivered by each Seller that will be a party thereto and will,
assuming  such  Ancillary  Agreement  has  been  duly  executed  and  delivered  by  Purchaser  Parent,  Purchaser  or  the  applicable
Purchaser Designated Affiliate, constitute a legal, valid and binding obligation of such Seller, in each case enforceable against Seller
Parent  or  such  other  Seller  in  accordance  with  its  terms,  except  as  enforcement  may  be  limited  by  bankruptcy,  insolvency,
reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles of
equity (regardless of whether enforcement is sought in a proceeding in equity or law).

Section 4.3      Conveyed Subsidiaries; Capital Structure .

(a)          Each  of the Conveyed  Subsidiaries  is, or will  be as of the Closing,  a corporation,  partnership  or other  legal
entity duly organized and validly existing, with all requisite corporate or other similar applicable power and authority to own, lease
and operate its properties and assets related to the Business and to carry on its respective business as it pertains to the Business, as
currently  conducted,  except  where  the  failure  to  be  so  organized  or  existing  or  to  have  such  power  and  authority  would  not,
individually  or in the aggregate,  be materially  adverse to the Business. Each of the Conveyed  Subsidiaries  is, or will be as of the
Closing, duly qualified to do business and, where applicable, in good standing in each jurisdiction where the nature of its business or
properties makes such qualification necessary, except where the failure to be so qualified or in good standing would not, individually
or in the aggregate, be materially adverse to the Business.

(b)      Section 4.3(b) of the Seller Disclosure Letter sets forth, as of immediately prior to the Closing, (i) the name and
the jurisdiction of organization of each of the Conveyed Subsidiaries and (ii) the record owners of such outstanding equity interests.
All of the outstanding equity interests of each of the Conveyed Subsidiaries are, or will be as of the Closing, validly issued, fully
paid and, in the case of any Conveyed Subsidiary which is a corporation, non-assessable, and the Shares are not subject to, and were
not  issued  in  violation  of,  any  preemptive  right.  As  of  the  Closing,  there  will  be  no  outstanding  warrants,  options,  agreements,
subscriptions, convertible or exchangeable securities or other commitments pursuant to which any of the Conveyed Subsidiaries

59

is  or  may  become  obligated  to  issue,  sell,  purchase,  return,  redeem  or  otherwise  acquire  any  equity  interests  of  the  Conveyed
Subsidiaries, or any securities convertible into or exchangeable for the capital stock or voting securities of any Conveyed Subsidiary.
As of the Closing, there will be no rights of first refusal, rights of first offer, voting trusts, stockholder agreements, proxies or other
Contracts in effect with respect to the sale or voting of the equity interests of the Conveyed Subsidiaries. The Sellers own of record
and beneficially as of the date of this Agreement, or will own of record and beneficially as of immediately prior to the Closing, all of
the  issued  and  outstanding  Shares,  free  and  clear  of  all  material  Liens  except  for  Liens  arising  under  applicable  securities  Laws.
Except for the Shares and the equity interests of any Subsidiary of a Conveyed Subsidiary, the Purchased Assets do not include, and
the Conveyed Subsidiaries do not own, any other equity interests of any Person.

(c)      Section 4.3(c) of the Seller Disclosure Letter sets forth, as of immediately prior to the Closing, (i) the name and
the jurisdiction of organization of each Subsidiary of the Conveyed Subsidiaries and (ii) the record owners of the outstanding equity
interests of such Subsidiaries. Each such Subsidiary is, or will be as of the Closing, a corporation, partnership or other legal entity
duly organized and validly existing, with all requisite corporate or other similar applicable  power and authority  to own, lease and
operate  its  properties  and  assets  related  to  the  Business  and  to  carry  on  its  respective  business  as  it  pertains  to  the  Business,  as
currently  conducted,  except  where  the  failure  to  be  so  organized  or  existing  or  to  have  such  power  and  authority  would  not,
individually or in the aggregate, be materially adverse to the Business. Except as set forth in Section 4.3(c) of the Seller Disclosure
Letter, all of the outstanding equity interests of each Subsidiary of a Conveyed Subsidiary are owned of record and beneficially by
such Conveyed Subsidiary (or a Subsidiary thereof) as of the date of this Agreement, or will be owned of record and beneficially by
such  Conveyed  Subsidiary  (or  a  Subsidiary  thereof)  as of  immediately  prior  to  the  Closing,  free  and  clear  of  all  Liens  except  for
Liens arising under applicable securities Laws. All of the outstanding equity interests of each Subsidiary of a Conveyed Subsidiary
are,  or  will  be  as  of  the  Closing,  validly  issued,  fully  paid  and,  in  the  case  of  any  such  Subsidiary  which  is  a  corporation,  non-
assessable. As of the Closing, there will be no outstanding warrants, options, agreements, subscriptions, convertible or exchangeable
securities or other commitments pursuant to which any Subsidiary of a Conveyed Subsidiary is or may become obligated to issue,
sell,  purchase,  return,  redeem  or  otherwise  acquire  any  equity  interests  of  such  Subsidiary,  or  any  securities  convertible  into  or
exchangeable for the capital stock or voting securities of such Subsidiary. As of the Closing, there will be no rights of first refusal,
rights of first offer, voting trusts, stockholder agreements, proxies or other Contracts in effect with respect to the sale or voting of the
equity interests of any Subsidiary of a Conveyed Subsidiary.

Section 4.4      No Conflicts; Consents . The execution, delivery and performance of this Agreement by Seller Parent
and each Ancillary Implementing Agreement by a Seller party to such Ancillary Implementing Agreement, and the consummation of
the transactions contemplated hereby and thereby, by Seller Parent and such Seller do not and will not (a) violate any provision of
the certificate of incorporation or bylaws of Seller Parent or the comparable organizational documents of any of the other Sellers or
any of the Conveyed  Subsidiaries  (or any Subsidiary  thereof),  (b) subject to obtaining  the consents set forth in  Section 4.4 of the
Seller Disclosure Letter, result in a violation of, or require the consent of any Person pursuant to, or conflict with, constitute

60

a default under, or result in the breach or termination, cancellation or acceleration (whether with or without the giving of notice or
the lapse of time or both) of any right or obligation of the Sellers or the Conveyed Subsidiaries (or any Subsidiary thereof) under, or
to a loss of any benefit of the Business to which the Sellers or the Conveyed Subsidiaries (or their Subsidiaries) is entitled, under any
Material Contract or Real Property Lease, or result in the imposition of a Lien on any Purchased Assets, other than Permitted Liens,
and (c) assuming compliance with the matters set forth in Sections 4.5 and 5.5 , violate or result in a breach of or constitute a default
under any Law, Governmental Authorization or other restriction of any Governmental Authority to which any Seller or Conveyed
Subsidiary  (or  Subsidiary  thereof)  is  subject,  except,  with  respect  to  clauses  (b)  and  (c)  ,  as  would  not,  individually  or  in  the
aggregate, be materially adverse to the Business or prevent or reasonably be expected to prevent the Sellers from consummating the
Closing prior to the Outside Date.

Section 4.5      Governmental Authorization . The execution, delivery and performance of this Agreement by Seller
Parent and each Ancillary Implementing Agreement by a Seller party to such Ancillary Implementing Agreement does not require
any  Approval  of,  or  Filing  with,  any  Governmental  Authority,  except  for  (a)  the  expiration  or  early  termination  of  the  applicable
waiting  period  under  the  HSR  Act,  (b)  the  Approvals  and  Filings  set  forth  in  Section 4.5 of  the  Seller  Disclosure  Letter,  (c)  the
Approvals  and  Filings  which  if  not  obtained  or  made  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to  the
Business or prevent or reasonably be expected to prevent the Sellers from consummating the Closing prior to the Outside Date, and
(d) the Approvals and Filings required due to the regulatory obligations of Purchaser, Purchaser Parent or any of their Affiliates.

Section 4.6      Financial Information .

(a)      Section 4.6(a) of the Seller Disclosure Letter contains copies of the audited balance sheet of the Business as of
December  31,  2017  (the  “  Balance  Sheet  Date  ”),  December  31,  2016  and  December  31,  2015  and  the  related  audited  income
statement for the years ended December 31, 2017, December 31, 2016 and December 31, 2015 (together with any notes thereto, the “
Financial Statements ”). Section 4.6(a) of the Seller Disclosure Letter also sets forth the accounts of the Business as of March 31,
2018,  June  30,  2018,  and  September  30,  2018  corresponding  to  the  accounts  included  in  the  Sample  Closing  Statement  (the  “
Business  Working  Capital  Accounts  ”).  The  Business  Working  Capital  Accounts  were  prepared  using  principles,  procedures,
policies and methods consistent in all material respects with those used in the preparation of the balance sheet of the Business as of
the Balance Sheet Date included in the Financial Statements.

(b)      Except as set forth in Section 4.6(b) of the Seller Disclosure Letter or as noted in the Financial Statements, the
Financial Statements were prepared in accordance with GAAP, on a consistent basis for each period presented, and present fairly in
all  material  respects,  (i)  the  financial  condition,  assets  and  liabilities  of  the  Business  as  of  the  dates  therein  specified  and  (ii)  the
results  of  operations  of  the  Business  for  the  periods  indicated;  provided  that  the  Financial  Statements  and  the  foregoing
representations and warranties concerning the Financial Statements are qualified by the fact that the Business has not operated as a
separate standalone entity and has received certain

61

allocated charges and credits as stated therein which do not necessarily reflect amounts that would have resulted from arm’s-length
transactions or that the Business would incur on a standalone basis.

(c)            Except  as  set  forth  in  Section  4.6(c)  of  the  Seller  Disclosure  Letter,  the  Business  does  not  have  any
Indebtedness  or  other  Liabilities  of  any  nature  or  kind  whatsoever  (whether  accrued,  known  or  unknown,  absolute,  contingent  or
otherwise) that would be required to be reflected on a balance sheet of the Business prepared in accordance with GAAP except for (i)
Liabilities  accrued  for,  reflected  on,  disclosed  and/or  reserved  against  on  the  Financial  Statements,  (ii)  Liabilities  incurred
subsequent  to  the  Balance  Sheet  Date  in  the  ordinary  course  of  business,  (iii)  Liabilities  taken  into  account  in  the  Final  Closing
Statement,  Final  Business  Working  Capital  or  Final  Business  Net  Cash,  (iv)  the  Retained  Liabilities,  (v)  Liabilities  incurred  in
connection with or arising out of the transactions contemplated hereby, (vi) Liabilities disclosed or set forth in the Seller Disclosure
Letter and (vii) Liabilities which would not, individually or in the aggregate, be materially adverse to the Business.

(d)      All of the information supplied by Seller Parent or its Affiliates to Purchaser Parent expressly for inclusion, or
to  support  statements  made,  in  the  announcement  of  the  Sale  and  the  other  transactions  contemplated  by  this  Agreement  to  be
released immediately following execution of this Agreement in compliance with the Listing Rules, the Purchaser Parent Shareholder
Circular,  or  any  amendment  or  supplement  thereto,  or  any  announcement  to  any  regulatory  information  service  approved  by  the
UKLA  in  connection  with  the  Purchaser  Parent  Shareholder  Circular,  and  any  other  related  documents  required  to  be  filed  or
published in connection with the Sale and/or the other transactions contemplated by this Agreement, will have been prepared in good
faith  and  will  not  to  the  Knowledge  of  Seller  Parent,  in  the  case  of  the  Purchaser  Parent  Shareholder  Circular,  at  the  time  the
Purchaser Parent Shareholder Circular and any amendments or supplements thereto are first published in accordance with the Listing
Rules and at the time of the Purchaser Parent Shareholder Meeting, and in the case of any other such document, at the time it is first
published, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

Section  4.7            Absence  of  Material  Changes  .  Except  as  otherwise  contemplated  by  this  Agreement  and  the
transactions contemplated hereby (including the Strategic Process and the Seller Internal Restructurings), since December 31, 2017
(a)  there has not been any Material Adverse Effect and (a)  until the date of this Agreement, the Business has been operated, in all
material respects, in the ordinary course of business.

Section 4.8      No Litigation .

(a)            Except  as  set  forth  in  Section  4.8(a)  of  the  Seller  Disclosure  Letter,  there  is  no  Action  pending  or,  to  the
Knowledge of Seller Parent, threatened against a Conveyed Subsidiary or any Subsidiaries thereof or the Sellers or their Affiliates
relating to the Business or any properties or rights of a Conveyed Subsidiary or its Subsidiaries or any Purchased Asset, before any
Governmental Authority or arbitration tribunal other than Actions which would not, individually or in the aggregate, be materially
adverse to the Business.

62

(b)      Except as set forth in Section 4.8(b) of the Seller Disclosure Letter, none of the Conveyed Subsidiaries or any
Subsidiaries thereof or the Sellers is subject to any Governmental Order relating to the Business or any Purchased Asset other than
those which would not, individually or in the aggregate, be materially adverse to the Business.

Section 4.9      Compliance with Laws . Except as set forth in Section 4.9 of the Seller Disclosure Letter:

(a)      Each Seller and each Conveyed Subsidiary (and Subsidiary thereof) is, and for the last three (3) years has been,
in compliance with all Laws applicable to the ownership, lease or operation of the Purchased Assets and the Business, including (i)
the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq. and applicable binding implementing regulations issued by the
U.S.  Food  and  Drug  Administration,  (ii)  the  applicable  Laws  of  the  European  Union  and  applicable  binding  implementing
regulations  issued  by  applicable  Governmental  Authorities  in  those  jurisdictions  in  the  European  Union  in  which  the  Business
markets, commercializes, distributes and sells Products, or otherwise operates, or has marketed, commercialized, distributed or sold
Products,  or  otherwise  operated,  in  the  last  three  (3)  years  (including  European  Union’s  Directive  95/46/EC,  as  amended,  and
Regulation EU 2016/679 (the General Data Protection Regulation), and any national implementing legislation of the foregoing) and
as of the Closing and (iii) the applicable Laws of any other jurisdiction in which the Business markets, commercializes, distributes
and sells Products, or otherwise operates, or has marketed, commercialized, distributed or sold Products, or otherwise operated, in
the last three (3) years and as of the Closing, except in the case of each of the foregoing clauses (i) , (ii) and (iii) to the extent that the
failure to comply therewith would not, individually or in the aggregate, be materially adverse to the Business.

(b)      The Sellers and the Conveyed Subsidiaries (and Subsidiaries thereof) collectively possess, or will possess as of
the  Closing,  all  Governmental  Authorizations  necessary  for  the  conduct  of  the  Business,  as  currently  conducted,  and  each  such
Governmental Authorization is in full force and effect, except where the failure to possess any such Governmental Authorization or
the failure of such Governmental Authorization to be in full force and effect would not, individually or in the aggregate, materially
impair the operations of the Business, taken as a whole.

Section 4.10           Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and

Recalls .

(a)      Except with respect to Environmental Permits (which are the subject of Section 4.11 ):

(i)      Seller Parent and its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) own, possess
or validly have the right to use all Governmental Authorizations required to research, develop, manufacture, market,
commercialize, distribute, test, use, store and sell the Products, except where the failure to so own, possess or validly
have such right would not, individually or in the aggregate, materially impair the operations of the Business, taken as
a whole;

63

(ii)      All Products sold under the Product Registrations are manufactured and marketed in accordance with
the  specifications  and  standards  contained  in  such  Product  Registrations,  and  the  applicable  Manufacturing
Registrations, except where the failure to comply therewith would not, individually or in the aggregate, be materially
adverse to the Business; and

(iii)            Except  as  set  forth  in  Section  4.10(a)(iii)  of  the  Seller  Disclosure  Letter,  a  Seller  or  Conveyed
Subsidiary  (or  Subsidiary  thereof)  is,  or  will  be  as  of  the  Closing,  the  sole  and  exclusive  owner  of  each  Product
Registration and Manufacturing Registration.

(b)           Except  as  set  forth  in  Section 4.10(b) of  the Seller  Disclosure  Letter,  there  is no Action  pending,  or, to  the
Knowledge  of  Seller  Parent,  threatened,  relating  to  the  Business  or  Purchased  Assets  (i)  arising  from  complaints,  allegations  or
Actions relating to any injury to person or property or as a result of ownership, possession, provision or use of any of the Products
that  were  manufactured,  processed,  distributed,  shipped  or  sold  prior  to  the  date  of  this  Agreement  or  (ii)  relating  to  any  alleged
hazard  or  alleged  defect  in  design,  manufacture,  materials  or  workmanship,  including  any  failure  to  warn  or  alleged  breach  of
express or implied warranty or representation, relating to the Products, except in the case of each of the foregoing clauses (i) and (ii)
, for Actions which would not, individually or in the aggregate, be materially adverse to the Business.

(c)      Except as set forth in Section 4.10(c) of the Seller Disclosure Letter, since January 1, 2016, there have been no
recalls  or  market  withdrawals  of  Products  and,  to  the  Knowledge  of  Seller  Parent,  no  facts  or  circumstances  exist  that  would
reasonably  be  expected  to  result  in  recalls  or  market  withdrawals  of  Products  that  would,  individually  or  in  the  aggregate,  be
materially adverse to the Business.

(d)           Notwithstanding  any  other  provision  of  this  Agreement,  this  Section 4.10 sets  forth  the  sole  and  exclusive
representations  and  warranties  of  Seller  Parent  with  respect  to  Product  Registrations  and  Manufacturing  Registrations,  products
liability and product recalls, and the other regulatory matters described in this Section 4.10 .

Section 4.11      Environmental Matters . Except as set forth in Section 4.11 of the Seller Disclosure Letter:

(a)      (i) the Sellers (with respect to the Business), the Conveyed Subsidiaries and their Subsidiaries, the Business (as
currently  or  formerly  conducted),  the  Purchased  Assets  and  the  Facilities  are  and have  been  since  January  1,  2016  in compliance
with  all  applicable  Environmental  Laws  and  Governmental  Authorizations  required  under  Environmental  Law  (including
Environmental  Permits);  (ii)  none  of  the  Sellers  nor  their  Affiliates  (in  each  case,  with  respect  to  the  Business  or  the  Purchased
Assets) are undertaking or required to undertake any Remedial Action at the Real Property or any property formerly owned, leased
or operated by a Conveyed Subsidiary or their Subsidiaries (or any of their respective predecessors) or by the Business (as currently
or formerly conducted) ; and (iii)  since  January  1, 2016,  none  of  the Sellers  or their  Affiliates  has  received  written  notice  from  a
Governmental  Authority  or  other  Person  that  it  is  subject  to  any  unresolved  enforcement  action  or  Liability  with  respect  to  the
Conveyed Subsidiaries or their

64

Subsidiaries,  the  Business  (as  currently  or  formerly  conducted),  the  Purchased  Assets  or  the  Facilities  under  any  applicable
Environmental  Laws  or  Environmental  Permits,  except  for  such  noncompliance,  Remedial  Actions,  Liabilities  or  enforcement
actions that would not, individually or in the aggregate, be materially adverse to the Business;

(b)      all Governmental Authorizations (including Environmental Permits) required of the Sellers and their Affiliates
(in each case, with respect to the Business or the Purchased Assets) under all applicable Environmental Laws have been obtained and
are held by a Seller or Conveyed Subsidiary (or Subsidiary thereof), except for such failures to obtain as would not, individually or
in the aggregate, materially impair the operations of the Business, taken as a whole; and

(c)      no Actions or written claims are pending or, to the Knowledge of Seller Parent, threatened against any Seller or
their Affiliates (in each case, with respect to the Business or the Purchased Assets) arising from or as a result of, and there have been
no  (i)  exposures  to  Hazardous  Materials  ,  including  on,  in,  under,  about  or  from  the  Purchased  Assets  or  at  the  Facilities,
(ii) Releases of Hazardous Materials, including at , on, in, under, or from any Purchased Assets or from any Facilities, (iii) off-site
treatment, storage or disposal of Hazardous Materials generated by t he Business (as currently or formerly conducted), the Sellers
(with respect to the Business ) or any Conveyed Subsidiary or their Subsidiaries or (iv) any violations of any Environmental Laws
arising, directly or indirectly, in connection with the Business (as currently or formerly conducted) or any of the Purchased Assets or
Facilities, in each case that has resulted or would result in Environmental Liability , except for such claims, Actions, Environmental
Liabilities or investigations that would not, individually or in the aggregate, be materially adverse to the Business.

(d)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations  and  warranties  set  forth  in  this
Section  4.11  are  the  sole  and  exclusive  representations  and  warranties  of  Seller  Parent  with  respect  to  Environmental  Laws,
Environmental Permits, Environmental Liabilities, Hazardous Materials and other environmental matters.

Section 4.12      Material Contracts .

(a)      Except (x) for Contracts entered into after the date of this Agreement, (y) for intercompany agreements solely
between or among Conveyed Subsidiaries (or any of their Subsidiaries) or that shall be terminated as of or prior to the Closing Date
in  accordance  with  Section  6.7  or  (z)  as  set  forth  in  Section  4.12(a)  of  the  Seller  Disclosure  Letter,  none  of  the  Conveyed
Subsidiaries (or any Subsidiary thereof), Seller Parent or any of its Affiliates is a party to or bound by any Contract in effect as of the
date hereof that is material to the Business, taken as a whole (a “ Material Contract ”).

(b)      Except as set forth in Section 4.12(b) of the Seller Disclosure Letter, (i) except as would not, individually or in
the aggregate, be materially adverse to the Business, each Material Contract is legal, valid and binding on the Seller or Conveyed
Subsidiary (or Subsidiary thereof) that is a party thereto and, to the Knowledge of Seller Parent, each other party thereto, and is in
full  force  and  effect,  except  as  enforcement  may  be  limited  by  bankruptcy,  insolvency,  reorganization,  fraudulent  conveyance,
moratorium or similar Laws affecting creditors’ rights

65

generally  or  by  general  principles  of  equity  (regardless  of  whether  enforcement  is  sought  in  a  proceeding  in  equity  or  law),  and
(ii)  no  Seller  or Conveyed  Subsidiary  (or Subsidiary  thereof)  or, to the Knowledge  of Seller  Parent,  any  other  party  thereto,  is in
breach  of,  or  default  under,  any  such  Material  Contract,  except  for  such  breaches  or  defaults  as  would  not,  individually  or  in  the
aggregate, be materially adverse to the Business.

(c)      Section 4.12(c) of the Seller Disclosure Letter lists all material Seller Parent Related Party Contracts.

Section 4.13      Intellectual Property .

(a)            Seller  Parent  has  made  available  to  Purchaser  (at  least  two  (2)  Business  Days  prior  to  the  date  hereof  ),  a
complete and accurate listing (the “ IP Schedules ”) of all issued Patent Rights, pending applications for Patent Rights, registered
Trademarks,  pending  Trademark  registration  applications  and  registered  Copyrights  (collectively,  the  “  Registered  IP  ”)  that  are
Business IP (collectively, the “ Registered Business IP ”) which listing shall be incorporated by reference into Section 4.13(a) of the
Seller  Disclosure  Letter.  To  the  Knowledge  of  Seller  Parent  (but  only  as  to  validity  and  enforceability),  as  of  the  date  of  this
Agreement, except as would not, individually or in the aggregate, be materially adverse to the Business, the Registered Business IP
is  in  effect  and  subsisting  and,  if  registered,  is  not  invalid  or  unenforceable.  The  Business  Trademarks  Rights,  together  with
Trademarks that are licensed to the Sellers or the Conveyed Subsidiaries by a third party, include all of the Business Key Brands.

(b)      All material Business IP and Business Licensed IP shall be, following the Closing, transferable and licensable
(or  sublicensable,  as  the  case  may  be)  by  Purchaser  and  its  Subsidiaries,  without  payment  of  any  kind  to  Seller  Parent  or  any
Affiliate of Seller Parent, as may be needed in the ordinary course of the operation of the Business, and shall be fully transferable,
assignable  and  assumable,  as  the  case  may  be,  without  payment  of  any  kind  to  Seller  Parent  or  any  Affiliate  of  Seller  Parent,  in
connection  with  a  change  of  control  (that  constitutes  an  assignment)  of  Purchaser  or  any  Listing  Transaction  (as  defined  in  the
Purchaser  Shareholders  Agreement)  or the sale of substantially  all of the assets of a business unit of Purchaser  to the extent  such
Business IP or Business Licensed IP is related to such business unit.

(c)      Except as would not, individually or in the aggregate, be materially adverse to the Business, and taking into
account Section 6.22 , the Business IP, together with the Intellectual Property (i) licensed to Purchaser or its Subsidiaries by Seller
Parent or any of its Affiliates under the Ancillary Agreements (the “ Business Licensed IP ”), (ii) covered by the Assumed Contracts
or Shared  Contracts,  or (iii)  to which Purchaser  or its Affiliates  are provided  access under any Ancillary  Agreement,  including  in
connection with the services provided under the Transition Services Agreement, constitutes all of the Intellectual Property owned or
controlled  by  Seller  Parent  or  any  of  its  Subsidiaries  that  is  used  or  held  for  use  in,  or  that  is  necessary  for,  the  conduct  of  the
Business, as conducted as of the date of this Agreement. The operation of the Business immediately following the Closing will not
infringe any of Seller Parent’s or any of its Affiliates’ Intellectual Property.

(d)      Except as would not, individually or in the aggregate, be materially adverse to the Business, (x) the conduct of

the Business does not, to the Knowledge of Seller Parent, infringe,

66

misappropriate  or  otherwise  violate  the  Intellectual  Property  of  any  Person  and  (y)  as  of  the  date  of  this  Agreement,  there  is  no
Action  pending  or,  to  the  Knowledge  of  Seller  Parent,  threatened  in  writing  against  any  Conveyed  Subsidiary  or  any  Subsidiary
thereof  or  any  Seller  or  any  of  its  Affiliates  (i)  alleging  any  such  infringement,  misappropriation,  or  other  violation,  or  (ii)
challenging the validity, enforceability, ownership, use, registrability, or patentability of the Business IP, other than ordinary course
prosecution proceedings associated with the application for or registration of Registered IP.

(e)      Except as would not, individually or in the aggregate, be materially adverse to the Business, as of the date of
this Agreement, to the Knowledge of Seller Parent, no Person is infringing, misappropriating or otherwise violating any Business IP
and  as  of  the  date  of  this  Agreement,  no  such  Actions  are  pending  or,  to  the  Knowledge  of  Seller  Parent,  threatened  against  any
Person by Seller Parent, or any of its Affiliates (including any Conveyed Subsidiary or any Subsidiary thereof) or any other Seller.

(f)      Seller Parent or its Subsidiaries (including the Conveyed Subsidiaries), as applicable, are the sole legal owners
of  all  Registered  Business  IP  that  is  owned  or  purported  to  be  owned  by  Seller  Parent  or  its  Affiliates.  None  of  the  Registered
Business IP or any other material Business IP is subject to any Lien, other than Permitted Liens.

(g)      Since January 1, 2016, to the Knowledge of Seller Parent, there (i) have been no failures of the Business IT
Systems that have materially and adversely impacted the conduct of the Business and (ii) has been no unauthorized access, loss, use
or  breach  of  security  with  respect  to  the  Business  IT  Systems  or  any  material  sensitive,  confidential  or  proprietary  information
(including personally identifiable information) relating to the Business that have materially and adversely impacted the Business.

(h)            Notwithstanding  any  provision  of  this  Agreement  to  the  contrary,  except  with  respect  to  Section  4.7  ,
Section 4.12 , and this Section 4.13 sets forth the sole and exclusive representations and warranties of Seller Parent with respect to
Intellectual Property.

Section 4.14      Real Property .

(a)      The Sellers or the Conveyed Subsidiaries (or their Subsidiaries) have, or will have as of the Closing, insurable
title  in  fee  simple  to  the  Owned  Real  Property,  free  and  clear  of  any  Liens,  other  than  Permitted  Liens.  Except  as  set  forth  in
Section 4.14(a) of the Seller Disclosure Letter or as would not, individually or in the aggregate, materially impair the operations of
the Business, taken as a whole, neither Sellers nor the Conveyed Subsidiaries (or their Subsidiaries) is leasing or otherwise granting
to any third party the right to use or occupy any Owned Real Property or any portion thereof.

(b)      Except as set forth in Section 4.14(b)(i) of the Seller Disclosure Letter, Sellers or the Conveyed Subsidiaries (or
their  Subsidiaries)  has  a  valid  leasehold  interest  and  valid  and  continuing  right  to  use  and  occupy  each  Leased  Real  Property
pursuant to a Real Property Lease. Except (x) as set forth in Section 4.14(b)(ii) of the Seller Disclosure Letter, or (y) as would not,
individually or in the aggregate, materially impair the operations of the Business, taken as a whole,

67

(i) each Real Property Lease is legal, valid and binding on the Seller or Conveyed Subsidiary (or Subsidiary thereof) that is a party
thereto and, to the Knowledge of Seller Parent, each other party thereto and is in full force and effect, except as enforcement may be
limited  by  bankruptcy,  insolvency,  reorganization,  fraudulent  conveyance,  moratorium  or  similar  Laws  affecting  creditors’  rights
generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), (ii) no
Seller or Conveyed Subsidiary (or Subsidiary thereof) or, to the Knowledge of Seller Parent, any other party thereto, is in breach of,
or default under, any such Real Property Lease and (iii) neither the Sellers nor the Conveyed Subsidiaries (or their Subsidiaries) is
leasing or otherwise granting to any third party the right to use or occupy any Leased Real Property or any portion thereof.

(c)      Except as set forth in Section 4.14(c) of the Seller Disclosure Letter, (i) no certificate, permit or license from
any  Governmental  Authority  having  jurisdiction  over  any  of the  Real  Property,  or any  Contract,  easement  or other  right  which  is
necessary to permit the lawful occupancy of the buildings and improvements on any of the Real Property or which is necessary to
permit the lawful use of all driveways, roads and other means of egress and ingress to and from any of the Real Property, in each
case, with respect to the Business, has not been obtained or, to the Knowledge of Seller Parent, is not in full force and effect, which
would,  individually  or  in  the  aggregate,  materially  impair  the  operations  of  the  Business,  taken  as  a  whole,  and  (ii)  none  of  the
Sellers  (in  respect  of  the  Business)  or  the  Conveyed  Subsidiaries  or  their  Subsidiaries  has  received  any  written  notice  from  any
Governmental  Authority  that  the  Real  Property  is  currently  in  violation  of  any  applicable  Law  that  would,  individually  or  in  the
aggregate, materially impair the operations of the Business, taken as a whole.

(d)      Section 4.14(d)(i) of the Seller Disclosure Letter sets forth each manufacturing and research and development
facility at which Products are manufactured or developed that is owned or operated by Sellers or the Conveyed Subsidiaries (or their
Subsidiaries)  (the  “  Seller  Facilities  ”).  Except  as  set  forth  in  Section  4.14(d)(ii)  of  the  Seller  Disclosure  Letter,  Sellers  or  the
Conveyed  Subsidiaries  (or  their  Subsidiaries)  has  insurable  title  in  fee  simple  to,  or  a  valid  leasehold  interest  and  valid  and
continuing right to use and occupy, each Seller Facility.

Section 4.15      Assets .

(a)      Except as otherwise provided in this Agreement or as would not, individually or in the aggregate, materially
impair the operations of the Business, taken as a whole, the Sellers or the Conveyed Subsidiaries (or their Subsidiaries) have, or will
have  as  of  the  Closing,  good  and  valid  title  to,  or  other  legal  rights  to  possess  and  use,  all  of  the  assets  comprising  the  business
reflected in the Financial Statements (for clarity, excluding any assets sold or disposed of in the ordinary course of business after the
date thereof), free and clear of any Liens other than Permitted Liens.

(b)      Except (i) as set forth in Section 4.15(b) of the Seller Disclosure Letter (ii) for Excluded Services (as defined in
the Transition Services Agreement) and (iii) as would not, individually or in the aggregate, materially impair the operations of the
Business, taken as a whole, the Purchased Assets (assuming all consents and Approvals as may be required in connection with the
consummation of the transactions contemplated by this Agreement and the Ancillary Agreements

68

have  been  obtained;  provided  ,  that  no  such  assumption  shall  be  made  to  the  extent  Seller  Parent  is  not  in  compliance  with  its
obligations under Section 2.2 and Section 6.3 of this Agreement), together with the benefits, services, assets, licenses, sublicenses
and other rights and benefits to be provided to Purchaser and its Affiliates pursuant to this Agreement and the Ancillary Agreements,
will,  in  the  aggregate,  constitute  all  of  the  assets  either  used  in  or  necessary  for  Purchaser  and  its  Subsidiaries  (including  the
Conveyed Subsidiaries and their Subsidiaries) to conduct the Business as conducted as of the date of this Agreement and as of the
Closing.

(c)            After  giving  effect  to  the  Seller  Internal  Restructurings  and  the  other  transactions  contemplated  by  this
Agreement  and  the  Ancillary  Agreements  (assuming  all  consents  and  Approvals  as  may  be  required  in  connection  with  the
consummation of the transactions contemplated by this Agreement and the Ancillary Agreements have been obtained; provided , that
no  such  assumption  shall  be  made  to  the  extent  Seller  Parent  is  not  in  compliance  with  its  obligations  under  Section  2.2  and
Section  6.3  of  this  Agreement)  and  except  as  provided  for  in  the  Ancillary  Agreements,  the  Conveyed  Subsidiaries  (and  the
Subsidiaries  thereof)  will  not,  directly  or  indirectly,  be  engaged  in  any  Retained  Business,  or  hold  or  be  subject  to  any  Retained
Liability or Excluded Asset (other than non-material or ministerial liabilities, assets, rights or properties).

Section 4.16      Taxes .

(a)      All income and other material Tax Returns that are required to be filed in respect of the Purchased Assets or the
Business  or  by  or  on  behalf  of  any  Conveyed  Subsidiary  or  Subsidiary  thereof  have  been  timely  filed  (taking  into  account  any
applicable extensions), and all such Tax Returns are true, correct and complete in all material respects.

(b)      All income and other material Taxes required to be paid in respect of the Purchased Assets or the Business or
by or in respect of any Conveyed  Subsidiary or any Subsidiary thereof have been timely paid (taking into account any applicable
extensions).

(c)      The Conveyed Subsidiaries (and the Subsidiaries thereof), and the Sellers solely with respect to the Business,
have deducted or withheld and paid over to the applicable Taxing Authority all material Taxes required to have been deducted or
withheld and paid over in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder
or  other  third  party  and  each  such  Conveyed  Subsidiary  or  Subsidiary  thereof  has  (if  required  by  any  applicable  Laws  to  do  so)
provided appropriate certificates of deduction.

(d)            There  are  no  Liens  for  material  Taxes  upon  any  of  the  Purchased  Assets  or  the  assets  of  the  Conveyed

Subsidiaries or any of their Subsidiaries, except for Permitted Liens.

(e)      Within the past three (3) years, none of the Conveyed Subsidiaries and none of their Subsidiaries has been a

“distributing corporation” or a “controlled corporation” in a distribution intended to qualify under Section 355(a) of the Code.

(f)      There are no current or pending audits, examinations, contests or other Actions with respect to material Taxes of

any Conveyed Subsidiary or any Subsidiary thereof or of

69

any Seller with respect to any Purchased Assets or the Business, and no such audits, examinations, contests or other Actions have
been threatened in writing.

(g)      There are no outstanding powers of attorney granted by any of the Conveyed Subsidiaries or any Subsidiary
thereof with respect to material Taxes for any taxable period beginning after the Closing Date, other than powers of attorney granted
to other Conveyed Subsidiaries or Subsidiaries thereof.

(h)      None of the Conveyed Subsidiaries or any Subsidiary thereof is party to any Tax sharing, allocation, indemnity
or  similar  agreement  or  arrangement  (other  than  (x)  any  such  agreement  or  arrangement  solely  between  or  among  two  or  more
Conveyed  Subsidiaries  and/or  Subsidiaries  thereof  and  (y)  provisions  contained  in  commercial  agreements  or  arrangements  the
primary purpose of which is not Taxes (including employment agreements, credit agreements, leases and supply or manufacturing
agreements)).

(i)      None of the Conveyed Subsidiaries or Subsidiaries thereof is or has been party to any “listed transaction” as
defined in Section 6707A of the Code and Treasury Regulations Section 1.6011-4. No Conveyed Subsidiary or Subsidiary thereof
has at any time entered into or been engaged in or been a party to or promoter of any scheme, transaction or arrangement which was
required  by  Law  to  be  specifically  disclosed  to  a  Taxing  Authority  or  a  main  or  dominant  purpose  or  object  of  which  was  the
avoidance or deferral of or the obtaining of a reduction in or other advantage in respect of any Taxes.

(j)      In the last three (3) years, no claim has been made in writing by any Taxing Authority in any jurisdiction in
which any of the Conveyed Subsidiaries or Subsidiaries thereof, or any Seller with respect to the Business or any Purchased Assets,
does not file income or franchise Tax Returns to the effect that such entity is or may be subject to income or franchise taxation by
such jurisdiction.

(k)           None  of  the  Conveyed  Subsidiaries  or  Subsidiaries  thereof  will  be  required  to  include  any  material  item  of
income in, or exclude any material item of deduction from, taxable income for any taxable period beginning after the Closing Date
as  a  result  of:  (i)  change  in  method  of  accounting  for  a  taxable  period  ending  on  or  prior  to  the  Closing  Date  made  prior  to  the
Closing,  (ii) “closing  agreement”  executed  prior to the Closing,  (iii) intercompany  transaction  or excess loss account  described  in
Treasury Regulations under Section 1502 of the Code entered into or existing prior to the Closing, (iv) prepaid amount received on
or  prior  to  the  Closing,  (v)  election  under  Section  108(i)  of  the  Code  made  prior  to  the  Closing  or  (vi)  installment  sale  or  open
transaction disposition occurring on or before the Closing Date.

(l)          Neither  entering  into  this  Agreement  nor  consummating  the transactions  contemplated  hereby,  nor,  so far as
Seller  Parent  is  aware,  any  other  event,  transaction,  action  or  circumstance  will  give  rise  to  any  Liability  for  Tax  or  result  in  the
withdrawal or clawback of any Tax Benefit for any Conveyed Subsidiary or any Subsidiary of any Conveyed Subsidiary as a result
of any Conveyed Subsidiary or any Subsidiary of any Conveyed Subsidiary ceasing to be a member of a group with any other Person
for Tax purposes.

70

(m)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations and  warranties set  forth  in  this
Section 4.16 and Section 4.17 (to  the  extent  related  to  Taxes)  are  the  sole  and  exclusive  representations  and  warranties  of  Seller
Parent with respect to Taxes.

Section 4.17      Employee Benefits; Employees .

(a)      Set forth in Section 4.17(a) of the Seller Disclosure Letter is a true and complete list of each material Seller
Group  Plan  and  Foreign  Seller  Group  Plan  categorized  by  (i)  whether  the  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  is  a
Conveyed Subsidiary Plan and (ii) the country or countries for which such Seller Group Plan or Foreign Seller Group Plan provides
benefits. No Conveyed Subsidiary Plan provides benefits to, or otherwise covers, any individual who is not a Business Employee,
Former Business Employee, or the dependents or beneficiaries thereof.

(b)      With respect to each material Conveyed Subsidiary Plan (other than Foreign Seller Group Plans that are not
defined benefit pension plans), Seller Parent has made available to Purchaser Parent, prior to the date of this Agreement, true and
complete copies of (i) each such plan’s governing document and any amendments thereto (or a written summary of all material terms
if the plan has not been reduced to writing) and (ii) any applicable Plan Regulatory or Funding Documents. In addition, within thirty
(30) days following the date hereof, with respect to each (x) material Conveyed Subsidiary Plan that is a Foreign Seller Group Plan,
Seller  Parent  shall  make  available  to  Purchaser  true  and  complete  copies  of  the  documents  contemplated  by  the  immediately
preceding sentence, and (y) each other material Seller Group Plan or Foreign Seller Group Plan for which Purchaser, the Conveyed
Subsidiaries or their respective Affiliates have or will assume Liability following the Closing, Seller Parent shall make available to
Purchaser Parent summaries of the material terms of such plans, the most recent summary plan description (if any) and excerpts or
summaries  of  the  actuarial  reports  for  such  plans  to  the  extent  relevant  to  the  Liabilities  being  assumed.  Seller  Parent  has  made
available to Purchaser Parent, on or prior to the date of this Agreement, a summary that is accurate in all material respects of the
value of the assets and Liabilities of the Seller Pension Plans that relate to Business Employees and Former Business Employees as
of the end of the 2017 fiscal year of Seller Parent.

(c)      The IRS has issued a favorable determination letter, or for a prototype plan, opinion letter, with respect to each
Conveyed Subsidiary Plan intended to be qualified within the meaning of Section 401(a) of the Code or, if no such determination has
been made, either an application for such determination is pending with the IRS or the time within which such determination may be
sought  from  the  IRS  has  not  yet  expired,  and,  to  the  Knowledge  of  Seller  Parent,  nothing  has  occurred  since  the  date  of  such
determination  or  opinion  that  would  reasonably  be  expected  to  result  in  disqualification  of  such  Conveyed  Subsidiary  Plan.  Each
Conveyed Subsidiary Plan that is intended to qualify for any particular tax or regulatory treatment under the Laws of a country other
than the United States (i) has received documentation of such qualification from a Governmental Authority (if available), and, to the
Knowledge of Seller Parent, nothing has occurred since the date of such documentation that would reasonably be expected to result
in  disqualification  of  such  Conveyed  Subsidiary  Plan  or  (ii)  if  such  documentation  is  not  available,  to  the  Knowledge  of  Seller
Parent, so qualifies.

71

(d)      No Seller Group Plan is a “multiemployer plan,” as such term is defined in Section 3(37) of ERISA, nor is any
Conveyed Subsidiary Plan subject to Section 302 or Title IV of ERISA or Section 412 of the Code. None of the Purchased Assets is
subject  to  a  lien  under  Section  430(k)  of  the  Code  or  Section  4068  of  ERISA,  and  neither  Seller  Parent  nor  any  of  its  ERISA
Affiliates  has  incurred  any  liability  under  Title  IV  of  ERISA  (other  than  premium  payments  to  the  Pension  Benefit  Guaranty
Corporation  in the ordinary course) or Section 4971 of the Code which has not been and will not be fully paid as of the Closing.
None of the Conveyed Subsidiaries (or the Subsidiaries thereof) or the Business has as of the date of this Agreement, or will have as
of  the  Closing,  any  Liability  in  respect  of  post-employment  or  post-retirement  medical,  health  or  life  insurance  benefits  for  any
current or former employees, except as required by applicable Law or to avoid excise tax under Section 4980B of the Code. Except
as set forth on Section 4.17(d) of the Seller Disclosure Letter, no Seller Group Plan or Foreign Seller Group Plan is a defined benefit
pension plan.

(e)            Each  Seller  Group  Plan  and  Foreign  Seller  Group  Plan  (other  than  a  Conveyed  Subsidiary  Plan)  has  been
maintained,  operated,  funded  and  administered  in  compliance  in  all  respects  with  its  terms  and  applicable  Law,  except  for  such
instances of noncompliance that would not, individually or in the aggregate, be materially adverse to the Business. Each Conveyed
Subsidiary  Plan  has  been  established,  maintained,  funded  and  administered  in  compliance  in  all  material  respects  its  terms  and
applicable Law. All material contributions or premiums with respect to each Conveyed Subsidiary Plan have been paid or deducted
in a timely fashion and there are no material outstanding defaults or violations thereunder that have not been properly recorded in the
Financial Statements. Other than routine claims for benefits, there are no suits, claims, proceedings, actions, governmental audits or
investigations that are pending or threatened against or involving any Seller Group Plan or Foreign Seller Group Plan or asserting
any rights to or claims for benefits under any Seller Group Plan or Foreign Seller Group Plan, except for such actions that have not
had and would not, individually or in the aggregate, a be materially adverse to the Business.

(f)      Except as set forth in Section 4.17(f) of the Seller Disclosure Letter: (i) none of the Conveyed Subsidiaries (or
employers of Business Employees who are not as of Closing employed in a Conveyed Subsidiary) recognize a labor union (in the
case of employers that are not Conveyed Subsidiaries or Subsidiaries thereof, excluding any labor union that does not represent the
Business Employees) and none of the Business Employees are represented by any labor organization, works council or consultation
body  (other  than  industry-wide  or  national  labor  organizations)  or  subject  to,  or  covered  by,  the  terms  of  any  material  Collective
Bargaining  Agreement in  connection with  their services to the  Business, (ii) no  labor union,  labor organization,  works council  or
consultation body has made a demand for recognition or certification, and there are no representation or certification proceedings,
union elections or, to the Knowledge of Seller Parent, union organizing activities, pending or threatened in writing with respect to
the Business Employees, the Business or the Conveyed Subsidiaries or their Affiliates with respect to the Business, (iii)  there are no
pending or threatened in writing strikes, lockouts, work stoppages or slowdowns involving the Business Employees or against the
Business  or  the  Conveyed  Subsidiaries  or  their  Affiliates  with  respect  to  the  Business  and  (iv)  there  is  no  unfair  labor  practice
charge,  labor  arbitration  or  labor  grievance  proceeding  pending  or  threatened  in  writing  against  the  Business  or  the  Conveyed
Subsidiaries or their Affiliates with respect to the Business that would, in the case of

72

the foregoing clauses (iii)  and  (iv) , individually or in the aggregate, be materially adverse to the Business. As of the date hereof,
Seller Parent has provided copies to Purchaser of all material Collective Bargaining Agreements applicable to Business Employees,
the  Business  or  the  Conveyed  Subsidiaries  or  their  Subsidiaries.  Seller  Parent,  the  Conveyed  Subsidiaries  and  their  respective
Subsidiaries have satisfied any material pre-signing requirement to provide notice to, or enter into any information and consultation
procedure  with,  any  labor  union,  labor  organization,  works  council  or  consultation  body  in  connection  with  the  execution  of  this
Agreement or the transactions contemplated by this Agreement as required by any Contract or Laws.

(g)           As  of  the  Closing,  Seller  Parent  represents  that  each  Business  Employee  devotes,  and  has  devoted  seventy
percent (70%) or more of his or her working time in the last twelve (12) months (or such shorter period he or she has been employed
by Seller Parent and its Affiliates) to performing services on behalf of the Business.

(h)           As  at  the  date  hereof,  the  Seller  Internal  Restructurings  in  France  and  Netherlands  have  been  completed  in
accordance  with  applicable  Laws  (including  obtaining  requisite  opinions  from  applicable  works  councils  and  employee
representative  bodies)  such  that  there  are  no  Business  Employees  employed  in  the  Business  in  France  or  Netherlands  other  than
those employed by a Conveyed Subsidiary.

(i)      Except as required by plans, programs, or arrangements required to be maintained or contributed to by the Laws
of  a  non-U.S.  jurisdiction,  neither  the  execution  and  delivery  of  this  Agreement,  nor  the  consummation  of  the  transactions
contemplated hereby (either alone or in conjunction with any other event), will cause any (i) payments to become due or payable to
any Business Employee, Former Business Employee, current or former consultant or director, (ii) acceleration, vesting or increase in
any  compensation  or benefits  to  any  Business  Employee,  Former  Business  Employee,  current  or  former  consultant  or  director,  or
(iii)  Conveyed  Subsidiary  (or  a  Subsidiary  thereof)  to  transfer  or  set  aside  any  assets  to  fund  any  benefits  under  any  Conveyed
Subsidiary Plan, or limit or restrict in any material respect the right of Purchaser or any of its Affiliates or any Conveyed Subsidiary
(or  a  Subsidiary  thereof)  to  amend,  terminate  or  transfer  the  assets  of  any  Conveyed  Subsidiary  Plan.  Neither  the  execution  and
delivery of this Agreement, nor the consummation of the transactions contemplated herein, will constitute a “change in ownership or
control” or “change in effective control” of Seller Parent within the meaning of Section 280G of the Code. No Conveyed Subsidiary
(or any Subsidiary thereof) is party to any plan, program, policy or arrangement providing for the “gross-up” or other compensation
to any individual because of the imposition of any Tax on any payment to the individual related to Section 4999 or Section 409A of
the Code.

Section 4.18      Global Trade Controls; Anti-Corruption Matters .

(a)      The Sellers (with respect to the Business), the Conveyed Subsidiaries (and their Subsidiaries), as well as their
respective  directors,  officers,  and  employees,  are  in  compliance  with  all  Global  Trade  Control  Laws,  including  possession  of  and
compliance  with  Governmental  Authorizations  required  by  Global  Trade  Control  Laws,  except  for  such  noncompliance  as  would
not, individually or in the aggregate, be materially adverse to the Business.

73

(b)      The Sellers (with respect to the Business) and the Conveyed Subsidiaries (and their Subsidiaries) do not engage
in any business with, or use, directly or indirectly, any corporate funds to contribute to or finance the activities of, any Restricted
Party or in any Restricted Market except as permitted by Governmental Authorization, except as would not, individually or in the
aggregate, be materially adverse to the Business.

(c)      None of the Sellers (with respect to the Business), the Conveyed Subsidiaries (and their Subsidiaries), nor any

of their respective directors, officers, and employees, is a Restricted Party or owned or controlled by a Restricted Party.

(d)      To Seller Parent’s Knowledge, the Sellers (with respect to the Business), the Conveyed Subsidiaries (and their
Subsidiaries), as well as their respective directors, officers, and employees are in compliance with all Anti-Corruption Laws, except
for such noncompliance as would not, individually or in the aggregate, be materially adverse to the Business. For purposes of this
Section  4.18(d)  only,  “Seller  Parent’s  Knowledge”  means  that  the  conduct  giving  rise  to  the  noncompliance  with  or  violation  of
Anti-Corruption  Law  was  reported  to  the  Compliance  Division  of  Seller  Parent  and  such  conduct  is  or  was  the  subject  of  a
Compliance Division investigation on or prior to the Closing Date.

(e)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations  and  warranties  set  forth  in  this
Section 4.18 are the sole and exclusive representations and warranties of Seller Parent with respect to Global Trade Control Laws
and Anti-Corruption Laws.

Section 4.19      Brokers . No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or
commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of
Seller  Parent  for  which  Purchaser  or  any  of  its  Affiliates  (including,  after  the  Closing,  the  Conveyed  Subsidiaries  or  their
Subsidiaries)  would  be  liable.  Seller  Parent  is  solely  responsible  for  the  fees  and  expenses  of  Centerview  Partners,  LLC,
Guggenheim Securities, LLC and Morgan Stanley & Co. LLC.

Section 4.20      No Other Representations or Warranties .

(a)          Except for the representations and warranties contained in this Article IV or in any Ancillary Implementing
Agreement, neither Seller Parent, the other Sellers nor any of their respective Affiliates, Representatives or any other Person makes
any express or implied representation or warranty with respect to Seller Parent, the other Sellers, the Conveyed Subsidiaries or any
of their respective Subsidiaries or Affiliates, the Purchased Assets, the Business or with respect to any other information provided, or
made  available,  to  Purchaser  Parent,  Purchaser  or  any  of  their  Affiliates  or  Representatives  in  connection  with  the  transactions
contemplated  hereby.  Except  as  expressly  set  forth  in  the  representations  and  warranties  contained  in  this  Article  IV  or  in  any
Ancillary Implementing Agreement, neither Seller Parent nor any of its Affiliates, Representatives or any other Person has made any
representation or warranty, express or implied, as to the prospects of the Business or its profitability, or with respect to any forecasts,
projections or business plans or other information (including any Evaluation Material (as defined in the Confidentiality Agreement))
delivered  to  Purchaser  Parent,  Purchaser  or  any  of  their  Affiliates  or  Representatives  in  connection  with  Purchaser  Parent’s  and
Purchaser’s review of the Business and

74

the negotiation and execution of this Agreement, including as to the accuracy or completeness thereof or the reasonableness of any
assumptions  underlying  any  such  forecasts,  projections  or  business  plans  or  other  information.  Except  to  the  extent  expressly
provided  in  this  Agreement  with  respect  to  the  representations  and  warranties  contained  in  this  Article  IV  or  in  any  Ancillary
Implementing Agreement, neither Seller Parent, the other Sellers nor any of their respective Affiliates, Representatives or any other
Person will have, or be subject to, any Liability or other obligation to Purchaser Parent, Purchaser, their Affiliates or Representatives
or any other Person resulting from the sale and purchase of the Purchased Assets, or the Business to Purchaser Parent, Purchaser or
their  Affiliates  or  Purchaser  Parent’s  or  Purchaser’s  use  of,  or  the  use  by  any  of  their  Affiliates  or  Representatives  of,  any
information,  including  information,  documents,  projections,  forecasts,  business  plans  or  other  material  (including  any  Evaluation
Material  (as  defined  in  the  Confidentiality  Agreement))  made  available  to  Purchaser  Parent,  Purchaser,  their  Affiliates  or
Representatives  by  any  means,  including  in  any  virtual  data  room,  confidential  information  memorandum,  management
presentations, offering materials, site tours or visits, diligence calls or meetings or any documents prepared by, or on behalf of, Seller
Parent, the other Sellers or any of their respective Affiliates or Representatives, or Purchaser Parent, Purchaser or their Affiliates or
Representatives. Each of Seller Parent and the other Sellers and their respective Affiliates disclaims any and all representations and
warranties, whether express or implied, except for the representations and warranties contained in this Article IV or in any Ancillary
Implementing  Agreement.  Notwithstanding  anything  to  the  contrary  contained  in  this  Agreement,  neither  Seller  Parent,  the  other
Sellers  nor  any  of  their  respective  Affiliates  makes  any  express  or  implied  representation  or  warranty  with  respect  to  Excluded
Assets, Retained Businesses or Retained Liabilities.

(b)      Seller Parent acknowledges and agrees that, except for the representations and warranties contained in Article V
or  in  any  Ancillary  Implementing  Agreement,  neither  Purchaser  Parent,  Purchaser  nor  any  of  their  respective  Affiliates,
Representatives  or  any  other  Person  makes  any  express  or  implied  representation  or  warranty  with  respect  to  Purchaser  Parent,
Purchaser  or  any  of  their  respective  Subsidiaries  or  Affiliates,  the  Purchaser  Business  or  with  respect  to  any  other  information
provided,  or  made  available,  to  Seller  Parent  or  any  of  its  Affiliates  or  Representatives  in  connection  with  the  transactions
contemplated  hereby.  Seller  Parent  acknowledges  and agrees that, except to the extent  expressly  provided  in this Agreement  with
respect to the representations and warranties contained in Article V or in any Ancillary Implementing Agreement, neither Purchaser
Parent, Purchaser nor any of their respective Affiliates, Representatives or any other Person will have, or be subject to, any Liability
or other obligation to Seller Parent or any of its Affiliates or Representatives or any other Person resulting from Seller Parent’s use
of, or the use by any of its Affiliates or Representatives of any information, including information, documents, projections, forecasts,
business plans or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) made available to
Seller Parent or any of its Affiliates or Representatives by any means, including in any virtual data room, confidential information
memorandum,  management  presentations,  offering  materials,  site  tours  or  visits,  diligence  calls  or  meetings  or  any  documents
prepared  by,  or  on  behalf  of,  Purchaser  Parent,  Purchaser  or  any  of  their  respective  Affiliates  or  Representatives.  Seller  Parent
acknowledges  and  agrees  that  it  is  not  relying  on  any  representation  or  warranty  of  Purchaser  Parent,  Purchaser,  or  any  of  their
Affiliates or Representatives or any other Person, other than those representations and warranties specifically set forth in Article V or
in any Ancillary Implementing Agreement. Seller

75

Parent  acknowledges  and  agrees  that  each  of  Purchaser  Parent  and  Purchaser  and  their  respective  Affiliates  disclaims  any  and  all
representations and warranties, whether express or implied, except for the representations and warranties contained in Article V or in
any Ancillary Implementing Agreement. Seller Parent acknowledges and agrees that neither Purchaser Parent, Purchaser nor any of
their  respective  Affiliates  makes  any  express  or  implied  representation  or  warranty  with  respect  to  the  Purchaser  Parent  Retained
Businesses or Purchaser Parent Retained Liabilities.

(c)      Seller Parent acknowledges that it has conducted to its satisfaction an independent investigation of the financial
condition, results of operations and projected operations of Purchaser and the Purchaser Business and the nature and condition of its
properties, assets, liabilities and businesses and, in making the determination to proceed with the transactions contemplated hereby,
has relied solely on the results of its own independent investigation and the representations and warranties set forth in Article V or
any Ancillary Implementing Agreement. In light of these inspections and investigations and the representations and warranties made
to Seller Parent by Purchaser Parent in Article V or in any Ancillary  Implementing  Agreement,  Seller Parent is relinquishing  any
right to any claim based on any representations and warranties other than those specifically included in Article V or in any Ancillary
Implementing Agreement. Any claims Seller Parent may have for breach of representation or warranty shall be based solely on the
representations and warranties of Purchaser Parent set forth in Article V or in any Ancillary Implementing Agreement.

(d)      Seller Parent acknowledges that, except as explicitly set forth herein, neither Purchaser Parent, Purchaser nor
any of their Affiliates has made any warranty, express or implied, as to the prospects of Purchaser or the Purchaser Business or their
profitability, or with respect to any forecasts, projections or business plans or other information (including any Evaluation Material
(as  defined  in  the  Confidentiality  Agreement))  delivered  to  Seller  Parent  or  any  of  its  Affiliates  or  Representatives  in  connection
with  Seller  Parent’s  review  of  the  Purchaser  Business  and  the  negotiation  and  execution  of  this  Agreement,  including  as  to  the
accuracy or completeness thereof or the reasonableness of any assumptions underlying any such forecasts, projections or business
plans or other information.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF PURCHASER PARENT

Except as set forth in the Purchaser Parent Disclosure Letter and in accordance with Section 10.8 , Purchaser Parent

hereby represents and warrants to Seller Parent and Purchaser as follows:

Section  5.1            Organization  .  Each  of  Purchaser  Parent  and  Purchaser  is  validly  existing  and  is  a  company  duly

incorporated and registered under the laws of England.

Section 5.2      Authority; Binding Effect .

(a)      Purchaser Parent, Purchaser and each applicable Purchaser Designated Affiliate have all requisite corporate or

other similar applicable power and authority to execute and

76

deliver  this  Agreement  and  each  Ancillary  Agreement  to  which  it  will  be  a  party,  and,  subject  to  receipt  of  the  Purchaser  Parent
Shareholder Approval, to perform their obligations hereunder and thereunder. The execution and delivery by Purchaser Parent and
Purchaser  of  this  Agreement  and,  subject  to  receipt  of  the  Purchaser  Parent  Shareholder  Approval,  the  performance  by  Purchaser
Parent and Purchaser of their obligations hereunder have been, and the execution and delivery by Purchaser Parent, Purchaser and
each  Purchaser  Designated  Affiliate  of  each  Ancillary  Agreement  to  which  it  will  be  a  party  and  the  performance  by  Purchaser
Parent,  Purchaser  and  such  Purchaser  Designated  Affiliates  of  their  obligations  thereunder  have  been  or  will  have  been  as  of  the
Closing, duly authorized by all requisite corporate or other similar applicable action. At a meeting duly called and held, the Board of
Directors  of  Purchaser  Parent  has  unanimously  (i)  approved  this  Agreement  and  the  Sale  and  the  other  transactions  contemplated
hereby in accordance with applicable Law, (ii) directed that the Purchaser Parent Shareholder Circular be prepared and, subject to
the approval of that circular by the UKLA, published in accordance with the terms of this Agreement, (iii) subject to the publication
of  the  Purchaser  Parent  Shareholder  Circular  and  Section  6.24(f)  ,  resolved  that  the  Purchaser  Parent  Shareholder  Meeting  be
convened for the purpose of obtaining the Purchaser Parent Shareholder Approval and (iv) resolved, subject to Section 6.24(f) , to
(1) unanimously recommend approval by Purchaser Parent’s shareholders of the Purchaser Parent Shareholder Approval Resolution
to Purchaser Parent’s shareholders, including in the Purchaser Parent Shareholder Circular, without qualification, and (2) state in the
Purchaser Parent Shareholder Circular that the Sale and the other transactions contemplated by this Agreement are, in the Board of
Directors of the Purchaser Parent’s opinion, fair and reasonable so far as the Purchaser Parent shareholders are concerned and that
the  Board  of  Directors  have  been  so  advised  by  Citigroup  Global  Markets  Limited  and  J.P.  Morgan  Securities  plc  (such
recommendation and statement being together, the “ Purchaser Parent Board Recommendation ”). As of the date of this Agreement,
the Board of Directors of Purchaser Parent has not subsequently rescinded, modified or withdrawn any of the foregoing resolutions.
The approval of the Sale and the other transactions contemplated by this Agreement by the holders of ordinary shares of Purchaser
Parent, by way of approval of the Purchaser Parent Shareholder Approval Resolution at the Purchaser Parent Shareholder Meeting
(the  “  Purchaser  Parent  Shareholder  Approval  ”)  is  the  only  Approval  required  from  the  holders  of  Purchaser  Parent’s  ordinary
shares  or  other  securities  of  Purchaser  Parent  or  its  Affiliates  in  connection  with  the  consummation  of  the  Sale  and  the  other
transactions contemplated by this Agreement.

(b)      Purchaser Parent, Purchaser and each Subsidiary of Purchaser has, or will have as of the Closing, all requisite
corporate or other similar applicable power and authority to carry on its respective business as it pertains to the Purchaser Business
as currently conducted and to own, lease and operate its properties and assets related to the Purchaser Business, except where the
failure  to  have  such  power  and  authority  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to  Purchaser  or  the
Purchaser  Business  or  prevent  or  reasonably  be  expected  to  prevent  Purchaser  Parent,  Purchaser  or  any  Purchaser  Designated
Affiliate from consummating the Closing prior to the Outside Date. Purchaser is duly qualified to do business and, where applicable,
in good standing in each jurisdiction where the nature of its business or properties makes such qualification necessary, except where
the failure to be so qualified or in good standing would not, individually or in the aggregate, be materially adverse to Purchaser or
the Purchaser Business.

77

(c)      This Agreement has been duly executed and delivered by Purchaser Parent and Purchaser and, assuming this
Agreement  has  been  duly  executed  and  delivered  by  Seller  Parent,  constitutes  a  legal,  valid  and  binding  obligation  of  Purchaser
Parent  and  Purchaser,  and  each  Ancillary  Agreement  will  be  as  of  the  Closing  duly  executed  and  delivered  by  Purchaser  Parent,
Purchaser and each Purchaser Designated Affiliate which will be a party thereto and will, assuming such Ancillary Agreement has
been  duly  executed  and  delivered  by  each  Seller  that  will  be  a  party  thereto,  constitute  a  legal,  valid  and  binding  obligation  of
Purchaser Parent, Purchaser and such Purchaser Designated Affiliate, in each case enforceable against Purchaser Parent, Purchaser
and  such  Purchaser  Designated  Affiliate  (as  applicable)  in  accordance  with  its  terms,  except  as  enforcement  may  be  limited  by
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or
by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law).

Section 5.3      Purchaser; Purchaser Subsidiaries; Capital Structure .

(a)      As of the date hereof, the issued share capital of Purchaser is 63,500 ordinary shares. All of the issued ordinary
shares of Purchaser have been validly issued, fully paid and non-assessable, and are not subject to, and were not issued in violation
of, any preemptive right. The B Ordinary Shares, when issued in accordance with this Agreement at Closing, will be validly issued,
fully  paid  and  non-assessable,  and  will  not  be  issued  in  violation  of  any  preemptive  right.  As  of  the  Closing,  there  will  be  no
outstanding warrants, options, agreements, subscriptions, convertible or exchangeable securities or other commitments pursuant to
which  Purchaser  is  or  may  become  obliged  to  issue,  sell,  purchase,  return,  redeem  or  otherwise  acquire  any  of  its  shares,  or  any
securities convertible into or exchangeable for its shares. As of the Closing, there will be no rights of first refusal, rights of first offer,
voting trusts, shareholder agreements, proxies or other Contracts in effect with respect to the sale or voting of any of the shares of
Purchaser. A wholly owned Subsidiary of Purchaser Parent owns legally and beneficially as of the date of this Agreement, and will
own legally and beneficially as of immediately prior to the Closing, all of the issued shares in the capital of Purchaser, free and clear
of  all  Liens  except  for  Liens  arising  under  applicable  securities  Laws.  As  of  and  immediately  following  the  Closing,  after  giving
effect to the Sale and the issuance of the Purchase Consideration, a wholly owned Subsidiary of Purchaser Parent will own legally
and  beneficially  680,000  A  Ordinary  Shares  and  300,000  Preference  Shares,  and  Seller  Parent  (or  its  applicable  designee(s))  will
own legally and beneficially 320,000 B Ordinary Shares, in each case on the terms and subject to the rights and restrictions set forth
in  the  Restated  Purchaser  Articles  of  Association  and  the  Purchaser  Shareholders  Agreement,  which  such  shares  shall  together
constitute the entire issued share capital of Purchaser, and there will be no other ordinary shares, preference shares or other equity
interests, or warrants, options, agreements, subscriptions, convertible or exchangeable securities or other commitments pursuant to
which  Purchaser  is  or  may  become  obliged  to  issue,  sell,  purchase,  return,  redeem  or  otherwise  acquire  any  shares,  or  any  other
equity interests, or any securities convertible into or exchangeable for shares, or any other equity interests, of Purchaser.

(b)      Each Subsidiary of Purchaser is, or will be as of the Closing, a corporation, partnership or other legal entity
duly  organized  and  validly  existing  under  the  laws  of  its  jurisdiction  of  organization,  with  all  requisite  corporate  or  other  similar
applicable power and authority to own,

78

lease and operate its properties and assets and to carry on its respective business, as currently conducted, except where the failure to
be so organized or existing or to have such power and authority would not, individually or in the aggregate, be materially adverse to
Purchaser or the Purchaser Business. Each Subsidiary of Purchaser is duly qualified to do business and, where applicable, in good
standing  in  each  jurisdiction  where  the  nature  of  its  business  or  properties  makes  such  qualification  necessary,  except  where  the
failure to be so qualified or in good standing would not, individually or in the aggregate, be materially adverse to Purchaser or the
Purchaser  Business.  Section  5.3(b)  of  the  Purchaser  Parent  Disclosure  Letter  sets  forth  (i)  the  name  and  the  jurisdiction  of
organization of each Subsidiary of Purchaser and (ii) the record owners of such outstanding equity interests. All of the issued and
outstanding  equity  interests  of  each  Subsidiary  of  Purchaser  are  validly  issued,  fully  paid  and,  in  the  case  of  any  Subsidiary  of
Purchaser which is a corporation, non-assessable, and are not subject to, and were not issued in violation of, any preemptive right. As
of the Closing, there will be no outstanding warrants, options, agreements, subscriptions, convertible or exchangeable securities or
other commitments pursuant to which any Subsidiary of Purchaser is or may become obliged to issue, sell, purchase, return, redeem
or otherwise acquire any equity interests of any Subsidiary of Purchaser, or any securities convertible into or exchangeable for any
equity interests of any Subsidiary of Purchaser. As of the Closing, there will be no rights of first refusal, rights of first offer, voting
trusts, stockholder agreements, proxies or other Contracts in effect with respect to the sale or voting of the equity interests of any
Subsidiary  of  Purchaser.  Purchaser  or  another  wholly  owned  Subsidiary  of  Purchaser  owns  legally  and  beneficially,  or  will  own
legally and beneficially as of the Closing, all of the issued and outstanding equity interests of each Subsidiary of Purchaser, free and
clear  of  all  Liens  except  for  Liens  arising  under  applicable  securities  Laws.  Except  for  the  equity  interests  of  the  Subsidiaries  of
Purchaser, Purchaser and its Subsidiaries do not own any other equity interests of any Person.

Section  5.4            No  Conflicts;  Consents  .  Subject  to  the  receipt  of  the  Purchaser  Parent  Shareholder  Approval,  the
execution,  delivery  and  performance  by  Purchaser  Parent  and  Purchaser  of  this  Agreement  and  each  Ancillary  Implementing
Agreement  by  Purchaser  Parent,  Purchaser  or  a  Purchaser  Designated  Affiliate  party  to  such  Ancillary  Implementing  Agreement,
and  the  consummation  of  the  transactions  contemplated  hereby  and  thereby  by  Purchaser  Parent,  Purchaser  and  such  Purchaser
Designated  Affiliate,  do  not  and  will  not  (a)  violate  any  provision  of  the  articles  of  association  or  equivalent  organizational
documents of Purchaser Parent, Purchaser or any of their Affiliates, (b) subject to obtaining the consents set forth in Section 5.4 of
the Purchaser  Parent  Disclosure  Letter,  result  in a violation  of, or require  the  consent  of any  Person  pursuant  to, or  conflict  with,
constitute a default under, or result in the breach or termination, cancellation or acceleration (whether with or without the giving of
notice or the lapse of time or both) of any right or obligation of (or to the loss of any benefit of) Purchaser Parent, Purchaser or any
of their Affiliates under any Purchaser Material Contract or Purchaser Real Property Lease, or result in the imposition of a Lien on
any assets, properties or rights, other than Purchaser Permitted Liens, relating to the Purchaser Business or owned, used or held by
Purchaser or any of its Subsidiaries, or (c) assuming compliance with the matters set forth in Sections 4.5 and 5.5 , violate or result in
a breach of or constitute a default under any Law, Governmental Authorization or other restriction of any Governmental Authority to
which  Purchaser  Parent,  Purchaser  or  any  of  their  Affiliates  is  subject,  except,  with  respect  to  clauses (b) and (c) ,  as  would  not,
individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business or prevent or reasonably be expected
to prevent Purchaser

79

Parent, Purchaser or any Purchaser Designated Affiliate from consummating the Closing prior to the Outside Date.

Section  5.5            Governmental  Authorization  .  The  execution,  delivery  and  performance  of  this  Agreement  by
Purchaser  Parent  and  Purchaser  and  each  Ancillary  Implementing  Agreement  by  any  of  Purchaser  Parent,  Purchaser  or  any
Purchaser Designated Affiliate party thereto does not require any Approval of, or Filing with, any Governmental Authority, except
for (a) the expiration or early termination of the applicable waiting period under the HSR Act, (b) the Approvals and Filings set forth
in  Section  5.5  of  the  Purchaser  Parent  Disclosure  Letter,  (c)  Approvals  and  Filings  which  if  not  obtained  or  made  would  not,
individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business or prevent or reasonably be expected
to prevent Purchaser Parent, Purchaser or any Purchaser Designated Affiliate from consummating the Closing prior to the Outside
Date, and (d) the Approvals and Filings required due to the regulatory obligations of Seller Parent or any of its Subsidiaries.

Section 5.6      Financial Information .

(a)      Section 5.6(a) of the Purchaser Parent Disclosure Letter contains copies of (i) the unaudited balance sheet of
Purchaser Business as of September 30, 2018, June 30, 2018 and March 31, 2018 (the “ Purchaser Working Capital Statements ”)
and (ii) the audited balance sheet of the Purchaser Business as of December 31, 2017, December 31, 2016, and December 31, 2015,
and the related audited income statement for the years ended December 31, 2017, December 31, 2016 and December 31, 2015 (the “
Audited Purchaser Financial Statements ”) (the foregoing clauses (i) and (ii) collectively, and together with any notes thereto, the “
Purchaser Financial Statements ”).

(b)            Except  as  set  forth  in  Section  5.6(b)  of  the  Purchaser  Parent  Disclosure  Letter  or  as  noted  in  the  Audited
Purchaser Financial Statements, the Audited Purchaser Financial Statements were prepared in accordance with IFRS, on a consistent
basis for each period presented and present a true and fair view of (x) the state of affairs of the Purchaser Business as of the dates
therein specified and (y) the results of operations of the Purchaser Business for the periods indicated. The Purchaser Working Capital
Statements were prepared using principles, procedures, policies and methods consistent in all material respects with those used in the
preparation of the balance sheet of the Purchaser Business as of the Balance Sheet Date included in the Audited Purchaser Financial
Statements.

(c)      Except as set forth in Section 5.6(c) of the Purchaser Parent Disclosure Letter, the Purchaser Business does not
have  any  Indebtedness  or  other  Liabilities  of  any  nature  or  kind  whatsoever  (whether  accrued,  known  or  unknown,  absolute,
contingent or otherwise) that would be required to be reflected on a balance sheet of the Purchaser Business prepared in accordance
with  IFRS,  except  for  (i)  Liabilities  accrued  for,  reflected  on,  disclosed  and/or  reserved  against  on  the  Purchaser  Financial
Statements,  (ii) Liabilities  incurred  subsequent  to the Balance  Sheet Date in the ordinary  course of business, (iii) Liabilities  taken
into account in the Final Closing Statement, Final Purchaser Working Capital or Final Purchaser Net Cash, (iv) Liabilities incurred
in  connection  with  or  arising  out  of  the  transactions  contemplated  hereby,  (v)  Liabilities  disclosed  or  set  forth  in  the  Purchaser
Disclosure  Letter  and  (vi)  Liabilities  which  would  not,  individually  or in  the aggregate,  be materially  adverse  to  Purchaser  or  the
Purchaser Business.

80

Section  5.7            Absence  of  Material  Changes  .  Except  as  otherwise  contemplated  by  this  Agreement  and  the
transactions  contemplated  hereby  (including  in  connection  with  the  review  of  strategic  alternatives  with  respect  to  the  Purchaser
Business),  since  December  31,  2017  (a)  there  has  not  been  any  Purchaser  Material  Adverse  Effect  and  (a)  until the  date of this
Agreement, the Purchaser Business has been operated, in all material respects, in the ordinary course of business.

Section 5.8      Securities Act . Purchaser is acquiring the Shares solely for the purpose of investment and not with a
view to, or for sale in connection with, any distribution thereof in violation of the Securities Act. Purchaser acknowledges that the
Shares are not registered under the Securities Act, any applicable state securities Laws or any applicable foreign securities Laws, and
that such Shares may not be transferred  or sold except pursuant to the registration  provisions of the Securities Act and applicable
state  and  foreign  securities  Laws  or  pursuant  to  an  applicable  exemption  therefrom.  Purchaser  has  sufficient  knowledge  and
experience in financial and business matters so as to be capable of evaluating the merits and risks of its investment in the Shares and
is capable of bearing the economic risks of such investment.

Section 5.9      No Litigation . Except as set forth in Section 5.9 of the Purchaser Parent Disclosure Letter, there is no
Action  pending  or,  to  the  Knowledge  of  Purchaser  Parent,  threatened  against  Purchaser  or  any  of  its  Subsidiaries,  or  against
Purchaser Parent or any of its Affiliates relating to the Purchaser Business or any assets, properties or rights relating to the Purchaser
Business or owned, used or held by Purchaser or any of its Subsidiaries, before any Governmental Authority or arbitration tribunal
other than Actions which would not, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.
Neither  Purchaser  nor  any  of  its  Affiliates  is  subject  to  any  outstanding  Governmental  Order  which  would,  individually  or  in  the
aggregate, be materially adverse to Purchaser or the Purchaser Business.

Section 5.10      Compliance with Laws . Except as set forth in Section 5.10 of the Purchaser Parent Disclosure Letter:

(a)      Purchaser Parent and its Subsidiaries (including Purchaser and its Subsidiaries) are, and for the last three (3)
years  have  been,  in  compliance  with  all  Laws  applicable  to  the  ownership,  lease  or  operation  of  the  assets,  properties  or  rights
relating  to  the  Purchaser  Business  or  owned,  used  or  held  by  Purchaser  or  any  of  its  Subsidiaries  and  the  Purchaser  Business,
including  (i)  the  Federal  Food,  Drug,  and  Cosmetic  Act,  21  U.S.C.  §301  et  seq.  and  applicable  binding  implementing  regulations
issued  by  the  U.S.  Food  and  Drug  Administration,  (ii)  the  applicable  Laws  of  the  European  Union  and  applicable  binding
implementing regulations issued by applicable Governmental Authorities in those jurisdictions in the European Union in which the
Purchaser  Business  markets,  commercializes,  distributes  and  sells  Purchaser  Products,  or  otherwise  operates,  or  has  marketed,
commercialized,  distributed  or  sold  Purchaser  Products,  or  otherwise  operated,  in  the  last  three  (3)  years  (including  European
Union’s Directive 95/46/EC, as amended, and Regulation EU 2016/679 (the General Data Protection Regulation), and any national
implementing  legislation of the foregoing) and (iii) the applicable Laws of any other jurisdiction  in which the Purchaser Business
markets,  commercializes,  distributes  and  sells  Purchaser  Products,  or  otherwise  operates,  or  has  marketed,  commercialized,
distributed or sold Purchaser Products, or otherwise operated, in the last three (3) years, except in the case of each of the foregoing
clauses

81

(i) , (ii) and (iii) to the extent that the failure to comply therewith would not, individually or in the aggregate, be materially adverse to
the Purchaser Business.

(b)      Purchaser and its Subsidiaries collectively possess all Governmental Authorizations necessary for the conduct
of  the  Purchaser  Business,  as  currently  conducted,  and  each  such  Governmental  Authorization  is  in  full  force  and  effect,  except
where the failure to possess any such Governmental Authorization or the failure of such Governmental Authorization to be in full
force and effect would not, individually or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business,
taken as a whole.

Section 5.11           Product Registrations; Manufacturing Registrations; Regulatory Compliance; Product Liability and

Recalls .

(a)      Except with respect to Purchaser Environmental Permits (which are the subject of Section 5.12 ):

(i)            Purchaser  and  its  Subsidiaries  own,  possess  or  validly  have  the  right  to  use  all  Governmental
Authorizations required to research, develop, manufacture, market, commercialize, distribute, test, use, store and sell
the Purchaser Products, except where the failure to so own, possess or validly have such right would not, individually
or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole;

(ii)      All Purchaser Products sold under the Purchaser Product Registrations are manufactured and marketed
in  accordance  with  the  specifications  and  standards  contained  in  such  Purchaser  Product  Registrations,  and  the
applicable  Purchaser  Manufacturing  Registrations,  except  where  the  failure  to  comply  therewith  would  not,
individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business; and

(iii)           Except  as  set  forth  in  Section 5.11(a)(iii) of  the  Purchaser  Parent  Disclosure  Letter,  Purchaser  or  a
Subsidiary  of  Purchaser  is,  or  will  be  as  of  the  Closing,  the  sole  and  exclusive  owner  of  each  Purchaser  Product
Registration and Purchaser Manufacturing Registration.

(b)      Except as set forth in Section 5.11(b) of the Purchaser Parent Disclosure Letter, there is no Action pending, or,
to the Knowledge of Purchaser Parent, threatened, against Purchaser or any of its Subsidiaries or relating to the Purchaser Business
or any assets, properties or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries (i)
arising from complaints, allegations or Actions relating to any injury to person or property or as a result of ownership, possession,
provision or use of any of the Purchaser Products that were manufactured, processed, distributed, shipped or sold prior to the date of
this Agreement or (ii) relating to any alleged hazard or alleged defect in design, manufacture, materials or workmanship, including
any failure to warn or alleged breach of express or implied warranty or representation, relating to the Purchaser Products, except in
the case of each of the foregoing clauses

82

(i)  and  (ii)  ,  for  Actions  which  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to  Purchaser  or  the  Purchaser
Business.

(c)      Except as set forth in Section 5.11(c) of the Purchaser Parent Disclosure Letter, since January 1, 2016, there
have  been  no  recalls  or  market  withdrawals  of  Purchaser  Products  and,  to  the  Knowledge  of  Purchaser  Parent,  no  facts  or
circumstances exist that would reasonably be expected to result in recalls or market withdrawals of Purchaser Products that would,
individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.

(d)           Notwithstanding  any  other  provision  of  this  Agreement,  this  Section 5.11 sets  forth  the  sole  and  exclusive
representations  and  warranties  of  Purchaser  Parent  with  respect  to  Purchaser  Product  Registrations  and  Purchaser  Manufacturing
Registrations, products liability and product recalls, and the other regulatory matters described in this Section 5.11 .

Section 5.12      Environmental Matters . Except as set forth in Section 5.12 of the Purchaser Parent Disclosure Letter:

(a)      (i) Purchaser Parent and its Subsidiaries (in each case, with respect to the Purchaser Business), Purchaser and its
Subsidiaries, the Purchaser Business (as currently or formerly conducted), the assets, properties or rights relating to the Purchaser
Business or owned, used or held by Purchaser or any of its Subsidiaries, and the Purchaser Real Property are and have been since
January  1,  2016  in  compliance  with  all  applicable  Environmental  Laws  and  Governmental  Authorizations  required  under
Environmental Law (including Purchaser Environmental Permits); (ii) neither Purchaser Parent n or its Subsidiaries (in each case,
with respect to the Purchaser Business or the assets, properties or rights relating to the Purchaser Business or owned, used or held by
Purchaser or any of its Subsidiaries ) are undertaking or required to undertake any Remedial Action at the Purchaser Facilities or any
property  formerly  owned,  leased  or  operated  by  Purchaser  or  its  Subsidiaries  (or  any  of  their  respective  predecessors)  or  by  the
Purchaser  Business  (as  currently  or  formerly  conducted)  ;  and  (iii)  since  January  1,  2016,  neither  Purchaser  Parent  n  or  its
Subsidiaries  has  received  written  notice  from  a  Governmental  Authority  or  other  Person  that  it  is  subject  to  any  unresolved
enforcement  action  or  Liability  with  respect  to  Purchaser  or  its  Subsidiaries,  the  Purchaser  Business  (as  currently  or  formerly
conducted),  the  assets,  properties  or  rights  relating  to  the  Purchaser  Business  or  owned,  used  or  held  by  Purchaser  or  any  of  its
Subsidiaries, or the Purchaser Facilities under any applicable Environmental Laws or Purchaser Environmental Permits, except for
such  noncompliance,  Remedial  Actions,  Liabilities  or  enforcement  actions  that  would  not,  individually  or  in  the  aggregate,  be
materially adverse to the Purchaser Business;

(b)      all Governmental Authorizations (including Purchaser Environmental Permits) required of Purchaser Parent and
its  Subsidiaries  (in  each  case,  with  respect  to  the  Purchaser  Business  or  the  assets,  properties  or  rights  relating  to  the  Purchaser
Business  or  owned,  used  or  held  by  Purchaser  or  any  of  its  Subsidiaries  )  under  all  applicable  Environmental  Laws  have  been
obtained and are held by Purchaser or a Subsidiary of Purchaser, except for such failures to obtain as would not, individually or in
the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole; and

83

(c)            no  Actions  or  written  claims  are  pending  or,  to  the  Knowledge  of  Purchaser  Parent,  threatened  against
Purchaser Parent or its Subsidiaries (in each case, with respect to the Purchaser Business or the assets, properties or rights relating to
the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries ) arising from or as a result of, and there have
been no (i) exposures to Hazardous Materials , including on, in, under, about or from the assets, properties or rights relating to the
Purchaser  Business  or  owned,  used  or  held  by  Purchaser  or  any  of  its  Subsidiaries  or at  the  Purchaser  Facilities,  (ii)  Releases  of
Hazardous Materials, including at , on, in, under, or from any assets, properties or rights relating to the Purchaser Business or owned,
used or held by Purchaser or any of its Subsidiaries or from any Purchaser Facilities, (iii) off-site treatment, storage or disposal of
Hazardous Materials generated by t he Purchaser Business (as currently or formerly conducted), Purchaser Parent or its Subsidiaries
(with respect to the Purchaser Business ) or Purchaser or its Subsidiaries or (iv) any violations of any Environmental Laws arising,
directly or indirectly, in connection with the Purchaser Business (as currently or formerly conducted) or any of the assets, properties
or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries or Purchaser Facilities, in
each case that has resulted or would result in Environmental Liability , except for such claims, Actions, Environmental Liabilities or
investigations that would not, individually or in the aggregate, be materially adverse to the Purchaser Business.

(d)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations  and  warranties  set  forth  in  this
Section  5.12  are  the  sole  and  exclusive  representations  and  warranties  of  Purchaser  Parent  with  respect  to  Environmental  Laws,
Purchaser Environmental Permits, Environmental Liabilities, Hazardous Materials and other environmental matters.

Section 5.13      Material Contracts .

(a)      Except (x) for Contracts entered into after the date of this Agreement, (y) for intercompany agreements solely
between or among Purchaser (or any of its Subsidiaries) and any of its Subsidiaries or that shall be terminated as of or prior to the
Closing Date in accordance with Section 6.7 or (z) as set forth in Section 5.13(a) of the Purchaser Parent Disclosure Letter, neither
Purchaser  Parent  nor  any of its Affiliates  is a party to or bound by any Contract  in effect  as of the date hereof  that  is material  to
Purchaser or the Purchaser Business, taken as a whole (a “ Purchaser Material Contract ”).

(b)            Except  as  set  forth  in  Section  5.13(b)  of  the  Purchaser  Parent  Disclosure  Letter,  (i)  except  as  would  not,
individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business, each Purchaser Material Contract is
legal, valid and binding on Purchaser or its Subsidiary that is a party thereto and, to the Knowledge of Purchaser Parent, each other
party  thereto,  and  is  in  full  force  and  effect,  except  as  enforcement  may  be  limited  by  bankruptcy,  insolvency,  reorganization,
fraudulent  conveyance,  moratorium  or  similar  Laws  affecting  creditors’  rights  generally  or  by  general  principles  of  equity
(regardless  of  whether  enforcement  is  sought  in  a  proceeding  in  equity  or  law),  and  (ii)  neither  Purchaser  Parent  nor  any  of  its
Affiliates or, to the Knowledge  of Purchaser  Parent, any other party thereto, is in breach of, or default under, any such Purchaser
Material  Contract,  except  for  such  breaches  or  defaults  as  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to
Purchaser or the Purchaser Business. Neither Purchaser nor

84

any  of  its  Subsidiaries  is  a  party  to  or  bound  by  any  Contract  that  contains  any  non-compete  or  similar  provision  that  would
materially  limit  or  impair  Seller  Parent  or  any  of  the  Retained  Subsidiaries’  ability  to  operate  the  Retained  Businesses  after  the
Closing.

(c)      Section 5.13(c) of the Purchaser Parent Disclosure Letter lists all material Purchaser Related Party Contracts.

Section 5.14      Intellectual Property .

(a)            To  the  Knowledge  of  Purchaser  Parent  (but  only  as  to  validity  and  enforceability),  as  of  the  date  of  this
Agreement, except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, all issued Patent
Rights,  pending  applications  for  Patent  Rights,  registered  Trademarks,  pending  Trademark  registration  applications  and  registered
Copyrights that are included in the Purchaser IP (collectively, the “ Registered Purchaser IP ”) are in effect and subsisting, and, if
registered, not invalid or unenforceable. The Purchaser Trademark Rights, together with Trademarks that are licensed to Purchaser or
its Subsidiaries by Purchaser Parent or its Subsidiaries or by a third party, include all of the Purchaser Key Brands.

(b)      All material Purchaser IP and Purchaser Licensed IP shall be, following the Closing, transferable and licensable
(or  sublicensable  as  the  case  may  be)  by  Purchaser  and  its  Subsidiaries,  without  payment  of  any  kind  to  Purchaser  Parent  or  any
Affiliate of Purchaser Parent, as may be needed in the ordinary course of the operation of the Purchaser Business, and shall be fully
transferable,  assignable  and  assumable,  as  the  case  may  be,  without  payment  of  any  kind  to  Purchaser  Parent  or  any  Affiliate  of
Purchaser Parent, in connection with a change of control (that constitutes an assignment) of Purchaser or any Listing Transaction (as
defined in the Purchaser Shareholders Agreement) or the sale of substantially all of the assets of a business unit of Purchaser to the
extent such Purchaser IP or Purchaser Licensed IP is related to such business unit.

(c)           Except  as  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to  the  Purchaser  Business,  and
taking into account Section 6.22 , the Purchaser IP and the Purchaser Licensed IP constitutes all of the Intellectual Property owned
by either Purchaser Parent or any of its Subsidiaries or Purchaser or any of its Subsidiaries that is used or held for use in, or that is
necessary for, the conduct of the Purchaser Business as conducted as of the date of this Agreement. The operation of the Purchaser
Business immediately following the Closing will not infringe any of Purchaser Parent’s or any of its Affiliates’ Intellectual Property.

(d)      Except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, (x) the
conduct of the Purchaser Business does not, to the Knowledge of Purchaser Parent, infringe, misappropriate or otherwise violate the
Intellectual  Property  of  any  Person  and  (y)  as  of  the  date  of  this  Agreement,  there  is  no  Action  pending  or,  to  the  Knowledge  of
Purchaser  Parent,  threatened  in  writing  against  Purchaser  Parent  or  any  of  its  Affiliates  (i)  alleging  any  such  infringement,
misappropriation, or other violation, or (ii) challenging the validity, enforceability, ownership, use, registrability, or patentability of
the Purchaser IP, other than ordinary course prosecution proceedings associated with the application for or registration of Registered
Purchaser IP.

85

(e)      Except as would not, individually or in the aggregate, be materially adverse to the Purchaser Business, as of the
date of this Agreement, to the Knowledge of Purchaser Parent, no Person is infringing, misappropriating or otherwise violating any
Purchaser IP and as of the date of this Agreement, no such Actions are pending or, to the Knowledge of Purchaser Parent, threatened
against any Person by Purchaser Parent or any of its Affiliates.

(f)           Purchaser  or  its  Subsidiaries,  as  applicable,  are  the  sole  legal  owners  of  all  Registered  Purchaser  IP  that  is
owned  or  purported  to  be  owned  by  Purchaser  or  its  Subsidiaries.  None  of  the  Registered  Purchaser  IP  or  any  other  material
Purchaser IP is subject to any Lien, other than Purchaser Permitted Liens.

(g)      Since January 1, 2016, to the Knowledge of Purchaser Parent, there (i) have been no failures of the Purchaser IT
Systems that have materially and adversely impacted the conduct of the Purchaser Business and (ii) has been no unauthorized access,
loss,  use  or  breach  of  security  with  respect  to  the  Purchaser  IT  Systems  or  any  material  sensitive,  confidential  or  proprietary
information  (including  personally  identifiable  information)  relating  to  the  Purchaser  Business  that  have  materially  and  adversely
impacted the Purchaser Business.

(h)      Except for the Trademarks licensed by Purchaser Parent or any of its Subsidiaries (other than Purchaser and its
Subsidiaries) to Purchaser or any of its Subsidiaries under a Purchaser Ancillary Agreement (the “ Purchaser Licensed Trademark
Rights ”), and taking into account Section 6.22 , as of the Closing Date, the Purchaser Trademark Rights will include all material
Trademarks under which the Purchaser Business operates that are owned by Purchaser Parent or any Subsidiary of Purchaser Parent.
The  Purchaser  Licensed  Trademark  Rights  are licensed  to Purchaser  or one or more  of its Subsidiaries  by Purchaser  Parent  or its
Subsidiaries (other than Purchaser and its Subsidiaries) on a perpetual, royalty free basis, and such license is (i) exclusive in the field
in  which  the  Purchaser  Business  operates  (subject  to  limited  exceptions  to  exclusivity  for  brands  managed  by  Purchaser  Parent’s
Affiliates’ pharmaceutical division, rights granted to third parties prior to the date licensed to Purchaser Parent, brands used for both
prescription  and  non-prescription  products,  and  products  switched  from  prescription  to  non-prescription  sales)  and  (ii)  non-
terminable solely due to a change of control of Purchaser or the occurrence of any Listing Transaction (as defined in the Purchaser
Shareholders  Agreement)  and  assignable,  without  restriction,  on  the  sale  of  substantially  all  of  the  assets  of  a  business  unit  of
Purchaser to the extent such Purchaser Licensed Trademarks is related to such business unit.

(i)            Notwithstanding  any  provision  of  this  Agreement  to  the  contrary,  except  with  respect  to  Section  5.7  ,
Section 5.13 , and this Section 5.14 sets forth the sole and exclusive representations and warranties of Purchaser Parent with respect
to Intellectual Property.

Section 5.15      Real Property .

(a)      Except as set forth in Section 5.15(a)(i) of the Purchaser Parent Disclosure Letter, Purchaser or a Subsidiary of
Purchaser has insurable title in fee simple to the Owned Purchaser Real Property, free and clear of any Liens, other than Purchaser
Permitted Liens. Except as set forth in Section 5.15(a)(ii) of the Purchaser Parent Disclosure Letter or as would not, individually or
in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken

86

as a whole, neither Purchaser Parent nor any of its Subsidiaries is leasing or otherwise granting to any third party the right to use or
occupy any Owned Purchaser Real Property or any portion thereof.

(b)      Except as set forth in Section 5.15(b)(i) of the Purchaser Parent Disclosure Letter, Purchaser or a Subsidiary of
Purchaser  has  a  valid  leasehold  interest  and  valid  and  continuing  right  to  use  and  occupy  each  Leased  Purchaser  Real  Property
pursuant to a Purchaser Real Property Lease. Except (x) as set forth in Section 5.15(b)(ii) of the Purchaser Parent Disclosure Letter
or (y) as would not, individually or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken
as a whole, (i) each Purchaser Real Property Lease is legal, valid and binding on Purchaser or its Subsidiary party thereto and, to the
Knowledge of Purchaser  Parent, each other party thereto and is in full force and effect, except as enforcement  may be limited by
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or
by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law), (ii) neither Purchaser
Parent nor any of its Subsidiaries or, to the Knowledge of Purchaser Parent, any other party thereto, is in breach of, or default under,
any such Purchaser Real Property Lease and (iii) neither Purchaser Parent nor any of its Subsidiaries is leasing or otherwise granting
to any third party the right to use or occupy any Purchaser Leased Real Property or any portion thereof.

(c)           Except  as  set  forth  in  Section 5.15(c) of  the  Purchaser  Parent  Disclosure  Letter,  (i)  no  certificate,  permit  or
license from any Governmental Authority having jurisdiction over any of the Purchaser Real Property, or any Contract, easement or
other  right  which  is  necessary  to  permit  the  lawful  occupancy  of  the  buildings  and  improvements  on  any  of  the  Purchaser  Real
Property or which is necessary to permit the lawful use of all driveways, roads and other means of egress and ingress to and from
any of the Purchaser Real Property, in each case, with respect to the Purchaser Business, has not been obtained or, to the Knowledge
of Purchaser Parent, is not in full force and effect, which would, individually or in the aggregate, materially impair the operations of
Purchaser or the Purchaser Business, taken as a whole, and (ii) neither Purchaser Parent or any of its Subsidiaries (in respect of the
Purchaser  Business)  or  Purchaser  or  its  Subsidiaries  has  received  any  written  notice  from  any  Governmental  Authority  that  the
Purchaser  Real  Property  is  currently  in  violation  of  any  applicable  Law  that  would,  individually  or  in  the  aggregate,  materially
impair the operations of Purchaser or the Purchaser Business, taken as a whole.

(d)           Section 5.15(d)(i) of the Purchaser Parent Disclosure Letter sets forth each manufacturing and research and
development facility at which Purchaser Products are manufactured or developed that is owned or operated by Purchaser Parent or
its  Subsidiaries  (the  “  Purchaser Facilities ”).  Except  as  set  forth  in  Section 5.15(d)(ii) of  the  Purchaser  Parent  Disclosure  Letter,
Purchaser or a Subsidiary of Purchaser has insurable title in fee simple to, or a valid leasehold interest and valid and continuing right
to use and occupy, each Purchaser Facility.

Section 5.16      Assets .

(a)      Except as otherwise provided in this Agreement or as would not, individually or in the aggregate, materially
impair the operations of Purchaser or the Purchaser Business, taken as a whole, Purchaser or its Subsidiaries have, or will have as of
the Closing, good and valid title to, or other legal rights to possess and use, all of the assets, properties and rights Relating to the

87

Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries, free and clear of any Liens other than Purchaser
Permitted Liens.

(b)      Except as set forth in Section 5.16(b) of the Purchaser Parent Disclosure Letter and as would not, individually
or in the aggregate, materially impair the operations of Purchaser or the Purchaser Business, taken as a whole (assuming all consents
and Approvals as may be required in connection with the consummation of the transactions contemplated by this Agreement and the
Ancillary Agreements have been obtained; provided , that no such assumption shall be made to the extent Purchaser Parent is not in
compliance  with  its  obligations  under  Section  2.2  or  Section  6.3  of  this  Agreement),  together  with  the  benefits,  services,  assets,
licenses, sublicenses and other rights and benefits to be provided to Purchaser and its Subsidiaries pursuant to this Agreement, the
Ancillary Agreements and the Purchaser Ancillary Agreements, the assets, properties and rights owned, or leased and licensed from
third parties, by Purchaser or its Subsidiaries do and will following the Closing, in the aggregate, constitute all of the assets either
used  in  or  necessary  for  Purchaser  and  its  Subsidiaries  to  conduct  the  Purchaser  Business  as  conducted  as  of  the  date  of  this
Agreement and as of the Closing.

(c)      Except as set forth in Section 5.16(c) of the Purchaser Parent Disclosure Letter, there are no material assets,
properties  or rights  that  are  used  or held  for use by Purchaser  or any Subsidiary  of Purchaser  or  necessary  for the  conduct  of the
Purchaser  Business  and  owned  or  controlled  by  Purchaser  Parent  or  any  Affiliate  of  Purchaser  Parent  (other  than  Purchaser  or  a
Subsidiary of Purchaser).

(d)      Purchaser and its Subsidiaries are not, or will not at Closing be, directly or indirectly, engaged in any Purchaser
Parent Retained Businesses, and do not, or will not at Closing, hold and are not, or will not at Closing be, subject to any Purchaser
Parent Retained Liability or assets, properties and rights not relating to the Purchaser Business (other than non-material or ministerial
liabilities, assets, rights or properties).

Section 5.17      Taxes .

(a)      All income and other material Tax Returns that are required to be filed by (i) Purchaser or any Subsidiary of
Purchaser  or  (ii)  in  respect  of  the  Purchaser  Business  have,  in  each  case,  been  timely  filed  (taking  into  account  any  applicable
extensions), and all such Tax Returns are true, correct and complete in all material respects.

(b)      All income and other material Taxes required to be paid by (i) Purchaser or any Subsidiary of Purchaser or (ii)

in respect of the Purchaser Business have, in each case, been timely paid (taking into account any applicable extensions).

(c)      Purchaser and its Subsidiaries, and Purchaser Parent and its Subsidiaries with respect to the Purchaser Business,
have deducted or withheld and paid over to the applicable Taxing Authority all material Taxes required to have been deducted or
withheld and paid over in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder
or other third party, and Purchaser and each of its Subsidiaries, and Purchaser Parent and each of its

88

Subsidiaries  with  respect  to  the  Purchaser  Business,  has  (if  required  by  any  applicable  Laws  to  do  so)  provided  appropriate
certificates of deduction.

(d)      There are no Liens for material Taxes upon any of the assets relating to the Purchaser Business or owned, used

or held by Purchaser or any of its Subsidiaries, except for Purchaser Permitted Liens.

(e)            Within  the  past  three  (3)  years,  neither  Purchaser  nor  any  of  its  Subsidiaries  has  been  a  “distributing

corporation” or a “controlled corporation” in a distribution intended to qualify under Section 355(a) of the Code.

(f)      There are no current or pending audits, examinations, contests or other Actions with respect to material Taxes of
Purchaser or any Subsidiary of Purchaser or of Purchaser Parent or any of its Subsidiaries with respect to the Purchaser Business,
and no such audits, examinations, contests or other Actions have been threatened in writing.

(g)      There are no outstanding powers of attorney granted by Purchaser or any Subsidiary of Purchaser with respect
to  material  Taxes  for  any  taxable  period  beginning  after  the  Closing  Date,  other  than  powers  of  attorney  granted  to  Purchaser  or
another Subsidiary of Purchaser.

(h)      Neither Purchaser nor any Subsidiary of Purchaser is party to any Tax sharing, allocation, indemnity or similar
agreement or arrangement (other than (x) any such agreement or arrangement solely between or among Purchaser and/or any of the
Subsidiaries of Purchaser and (y) provisions contained in commercial agreements or arrangements the primary purpose of which is
not Taxes (including employment agreements, credit agreements, leases and supply or manufacturing agreements)).

(i)      Neither Purchaser nor any Subsidiary of Purchaser is or has been party to any “listed transaction” as defined in
Section 6707A of the Code and Treasury Regulations Section 1.6011-4. Neither Purchaser nor any Subsidiary of Purchaser has at
any  time  entered  into  or  been  engaged  in  or  been  a  party  to  or  promoter  of  any  scheme,  transaction  or  arrangement  which  was
required  by  Law  to  be  specifically  disclosed  to  a  Taxing  Authority  or  a  main  or  dominant  purpose  or  object  of  which  was  the
avoidance or deferral of or the obtaining of a reduction in or other advantage in respect of any Taxes.

(j)      In the last three (3) years, no claim has been made in writing by any Taxing Authority in any jurisdiction in
which  Purchaser  or  any  Subsidiary  of  Purchaser,  or  Purchaser  Parent  or  any  of  its  Subsidiaries  with  respect  to  the  Purchaser
Business, does not file income or franchise Tax Returns to the effect that such entity is or may be subject to income or franchise
taxation by such jurisdiction.

(k)      Neither Purchaser nor any Subsidiary of Purchaser will be required to include any material item of income in,
or exclude any material item of deduction from, taxable income for any taxable period beginning after the Closing Date as a result
of: (i) change in method of accounting  for a taxable period ending on or prior to the Closing  Date made prior to the Closing,  (ii)
“closing agreement” executed prior to the Closing, (iii) intercompany transaction or excess loss account

89

described in Treasury Regulations under Section 1502 of the Code entered into or existing prior to the Closing, (iv) prepaid amount
received on or prior to the Closing, (v) election under Section 108(i) of the Code made prior to the Closing or (vi) installment sale or
open transaction disposition occurring on or before the Closing Date.

(l)      Neither entering into this Agreement nor consummating the transactions contemplated hereby, nor, so far as the
Purchaser  or Purchaser  Parent  is aware,  will give  rise to any other event,  transaction,  action,  or circumstance  Liability  for Tax  or
result in the withdrawal or clawback of any Tax Benefit for Purchaser or any Subsidiary of Purchaser as a result of Purchaser or any
Subsidiary of Purchaser ceasing to be a member of a group with any other Person for Tax purposes.

(m)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations and  warranties set  forth  in  this
Section 5.17 and Section 5.18 (to the extent relating to Taxes) are the sole and exclusive representations and warranties of Purchaser
Parent with respect to Taxes.

Section 5.18      Employee Benefits; Employees .

(a)      Set forth in Section 5.18(a) of the Purchaser Parent Disclosure Letter is a true and complete list of each material
Purchaser Group Plan and Foreign Purchaser Group Plan categorized by (i) whether the Purchaser Group Plan or Foreign Purchaser
Group Plan is a Purchaser Business Plan and (ii) the country or countries for which such Purchaser Group Plan or Foreign Purchaser
Group  Plan  provides  benefits.  No  Purchaser  Business  Plan  provides  benefits  to,  or  otherwise  covers,  any  individual  who  is  not  a
Purchaser Business Employee, Former Purchaser Business Employee, or the dependents or beneficiaries thereof.

(b)      With respect to each material Purchaser Business Plan (other than Foreign Purchaser Group Plans that are not
defined benefit pension plans), Purchaser Parent has made available to Seller Parent, prior to the date of this Agreement, true and
complete copies of (i) each such plan’s governing document and any amendments thereto (or a written summary of all material terms
if the plan has not been reduced to writing) and (ii) any applicable Plan Regulatory or Funding Documents. In addition, within thirty
(30)  days  following  the  date  hereof,  with  respect  to  each  (x)  material  Purchaser  Business  Plan  that  is  a  Foreign  Purchaser  Group
Plan,  Purchaser  Parent  shall  make  available  to  Seller  Parent  true  and  complete  copies  of  the  documents  contemplated  by  the
immediately  preceding  sentence,  and  (y)  each  other  material  Purchaser  Group  Plan  or  Foreign  Purchaser  Group  Plan  for  which
Purchaser  or  its  Subsidiaries  has  any  Liability,  Purchaser  Parent  shall  make  available  to  Seller  Parent  summaries  of  the  material
terms of such plans, the most recent summary plan description (if any) and excerpts or summaries of the actuarial reports for such
plans to the extent relevant to the Liabilities of Purchaser or its Subsidiaries. Purchaser Parent has made available to Seller Parent, on
or prior to the date of this Agreement, a summary that is accurate in all material respects of the value of the assets and Liabilities of
all Purchaser Business Plans that are defined benefit pension plans as of the end of the 2017 fiscal year of Purchaser Parent.

(c)      The IRS has issued a favorable determination letter, or for a prototype plan, opinion letter, with respect to each
Purchaser Business Plan intended to be qualified within the meaning of Section 401(a) of the Code or, if no such determination has
been made, either an

90

application for such determination is pending with the IRS or the time within which such determination may be sought from the IRS
has not yet expired, and, to the Knowledge of Purchaser Parent, nothing has occurred since the date of such determination or opinion
that would reasonably be expected to result in disqualification of such Purchaser Business Plan. Each Purchaser Business Plan that is
intended  to qualify for any particular  tax or regulatory  treatment  under the Laws of a country  other than the United States (i) has
received  documentation  of  such  qualification  from  a  Governmental  Authority  (if  available),  and,  to  the  Knowledge  of  Purchaser
Parent, nothing has occurred since the date of such documentation that would reasonably be expected to result in disqualification of
such Purchaser Business Plan or (ii) if such documentation is not available, to the Knowledge of Purchaser Parent, so qualifies.

(d)      No Purchaser Group Plan is a “multiemployer plan,” as such term is defined in Section 3(37) of ERISA, nor is
any  Purchaser  Business  Plan  subject  to  Section  302  or  Title  IV  of  ERISA  or  Section  412  of  the  Code.  Neither  Purchaser  nor  its
Subsidiaries (or any assets of Purchaser or its Subsidiaries) is subject to a lien under Section 430(k) of the Code or Section 4068 of
ERISA, and neither Purchaser Parent nor any of its ERISA Affiliates has incurred any liability under Title IV of ERISA (other than
premium payments to the Pension Benefit Guaranty Corporation in the ordinary course) or Section 4971 of the Code which has not
been and will not be fully paid as of the Closing. None of Purchaser, its Subsidiaries or the Purchaser Business has as of the date of
this Agreement, or will have as of the Closing, any Liability in respect of post-employment or post-retirement medical, health or life
insurance benefits for any current or former employees, except as required by applicable Law or to avoid excise tax under Section
4980B of the Code. Except as set forth on Section 5.18(d) of the Purchaser Parent Disclosure Letter, no Purchaser Group Plan or
Foreign Purchaser Group Plan is a defined benefit pension plan.

(e)      Each Purchaser Group Plan and Foreign Purchaser Group Plan (other than a Purchaser Business Plan) has been
maintained,  operated,  funded  and  administered  in  compliance  in  all  respects  with  its  terms  and  applicable  Law,  except  for  such
instances  of  noncompliance  that  would  not,  individually  or  in  the  aggregate,  be  materially  adverse  to  Purchaser  or  the  Purchaser
Business.  Each  Purchaser  Business  Plan  has  been  established,  maintained,  funded  and  administered  in  compliance  in  all  material
respects  its  terms  and  applicable  Law.  All  material  contributions  or  premiums  with  respect  to  each  Purchaser  Business  Plan  have
been paid or deducted in a timely fashion and there are no material outstanding defaults or violations thereunder that have not been
properly  recorded  in  the  Purchaser  Financial  Statements.  Other  than  routine  claims  for  benefits,  there  are  no  suits,  claims,
proceedings, actions, governmental audits or investigations that are pending or threatened against or involving any Purchaser Group
Plan or Foreign Purchaser Group Plan or asserting any rights to or claims for benefits under any Purchaser Group Plan or Foreign
Purchaser  Group  Plan,  except  for  such  actions  that  have  not  had  and  would  not,  individually  or  in  the  aggregate,  be  materially
adverse to Purchaser or the Purchaser Business.

(f)           Except  as set  forth  in  Section 5.18(f) of  the  Purchaser  Parent  Disclosure  Letter:  (i)  none  of  Purchaser  or  its
Subsidiaries (or employers of Purchaser Business Employees other than Purchaser or its Subsidiaries) recognize a labor union (in the
case of employers that are not Purchaser or its Subsidiaries, excluding any labor union that does not represent the Purchaser Business
Employees) and none of the Purchaser Business Employees are represented by any labor

91

organization, works council or consultation body (other than industry-wide or national labor organizations) or subject to, or covered
by, the terms of any material Collective Bargaining Agreement in connection with their services to the Purchaser Business, (ii) no
labor union, labor organization, works council or consultation body has made a demand for recognition or certification, and there are
no representation or certification proceedings, union elections or, to the Knowledge of Purchaser Parent, union organizing activities
pending or threatened in writing with respect to the Purchaser Business or Purchaser or its Affiliates with respect to the Purchaser
Business, (iii)  there are no pending or threatened in writing strikes, lockouts, work stoppages or slowdowns involving the Purchaser
Business  Employees  or  against  the  Purchaser  Business  or  Purchaser  or  its  Affiliates  with  respect  to  the  Purchaser  Business  and
(iv) there is no unfair labor practice charge, labor arbitration or labor grievance proceeding pending or threatened in writing against
the Purchaser Business or Purchaser or its Affiliates with respect to the Purchaser Business that would, in the case of the foregoing
clauses (iii)  and (iv) , individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business. As of the date
hereof,  Purchaser  Parent  has  provided  copies  to  Seller  Parent  of  all  material  Collective  Bargaining  Agreements  applicable  to
Purchaser  Business  Employees,  the  Purchaser  Business  or  Purchaser  or  its  Subsidiaries.  Purchaser  Parent,  Purchaser  and  their
respective Subsidiaries  have satisfied any material pre-signing  requirement  to provide notice to, or enter into any information  and
consultation  procedure  with,  any  labor  union,  labor  organization,  works  council  or  consultation  body  in  connection  with  the
execution of this Agreement or the transactions contemplated by this Agreement as required by any Contract or Laws.

(g)            As  of  the  Closing,  Purchaser  Parent  represents  that  each  Purchaser  Business  Employee  devotes,  and  has
devoted seventy percent (70%) or more of his or her working time in the last twelve (12) months (or such shorter period he or she
has been employed by Purchaser Parent and its Affiliates) to performing services on behalf of the Purchaser Business.

(h)      Except as required by plans, programs, or arrangements required to be maintained or contributed to by the Laws
of  a  non-U.S.  jurisdiction,  neither  the  execution  and  delivery  of  this  Agreement,  nor  the  consummation  of  the  transactions
contemplated hereby (either alone or in conjunction with any other event), will cause any (i) payments to become due or payable to
any Purchaser Business Employee, Former Purchaser Business Employee, current or former consultant or director, (ii) acceleration,
vesting  or  increase  in  any  compensation  or  benefits  to  any  Purchaser  Business  Employee,  Former  Purchaser  Business  Employee,
current or former consultant or director, or (iii) Purchaser or any of its Subsidiaries to transfer or set aside any assets to fund any
benefits under any Purchaser Business Plan, or limit or restrict in any material respect the right of Purchaser or any of its Affiliates to
amend, terminate or transfer the assets of any Purchaser Business Plan. Neither the execution and delivery of this Agreement, nor the
consummation  of  the  transactions  contemplated  herein,  will  constitute  a “change  in  ownership  or  control”  or “change  in  effective
control” of Purchaser Parent within the meaning of Section 280G of the Code. Neither Purchaser nor any of its Subsidiaries is party
to  any plan,  program,  policy  or arrangement  providing  for  the “gross-up”  or other  compensation  to  any  individual  because  of  the
imposition of any Tax on any payment to the individual related to Section 4999 or Section 409A of the Code.

Section 5.19      Global Trade Controls; Anti-Corruption Matters .

92

(a)            Purchaser  Parent  and  its  Subsidiaries  (with  respect  to  the  Purchaser  Business)  and  Purchaser  and  its
Subsidiaries, as well as their respective directors, officers, and employees, are in compliance with all Global Trade Control Laws,
including possession of and compliance with Governmental Authorizations required by Global Trade Control Laws, except for such
noncompliance as would not, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.

(b)            Purchaser  and  its  Subsidiaries  and,  with  respect  to  the  Purchaser  Business,  Purchaser  Parent  and  its  other
Subsidiaries, do not engage in any business with, or use, directly or indirectly, any corporate funds to contribute to or finance the
activities of, any Restricted Party or in any Restricted Market except as permitted by Governmental Authorization, except as would
not, individually or in the aggregate, be materially adverse to Purchaser or the Purchaser Business.

(c)      None of Purchaser or its Subsidiaries or, with respect to the Purchaser Business, Purchaser Parent or its other
Subsidiaries,  nor  any  of  their  respective  directors,  officers,  and  employees,  is  a  Restricted  Party  or  owned  or  controlled  by  a
Restricted Party.

(d)            To  Purchaser  Parent’s  Knowledge,  Purchaser  and  its  Subsidiaries,  and  Purchaser  Parent  and  its  other
Subsidiaries (with respect to the Purchaser Business), as well as their respective directors, officers, and employees are in compliance
with all Anti-Corruption Laws, except for such noncompliance as would not, individually or in the aggregate, be materially adverse
to  Purchaser  or  the  Purchaser  Business.  For  purposes  of  this  Section  5.19  only,  “Purchaser  Parent’s  Knowledge”  means  that  the
conduct  giving  rise  to  the  noncompliance  with  or  violation  of  Anti-Corruption  Law  was  reported  to  the  Compliance  Division  (or
similar responsible group or body) of Purchaser Parent and such conduct is or was the subject of an investigation by it on or prior to
the Closing Date.

(e)           Notwithstanding  any  other  provision  of  this  Agreement,  the  representations  and  warranties  set  forth  in  this
Section  5.19  are  the  sole  and  exclusive  representations  and  warranties  of  Purchaser  Parent  with  respect  to  Global  Trade  Control
Laws and Anti-Corruption Laws.

Section 5.20      Brokers . No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or
commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of
Purchaser  Parent  or  its  Affiliates  for  which  Purchaser  or  any  of  its  Subsidiaries  would  be  liable.  Purchaser  Parent  is  solely
responsible for the fees and expenses of Citigroup Global Markets Limited, J.P. Morgan Securities plc and Greenhill & Co., which
shall be a Purchaser Parent Transaction Expense hereunder.

Section 5.21      No Other Representations or Warranties .

(a)           Except  for  the  representations  and  warranties  contained  in  this  Article V or  in  any  Ancillary  Implementing
Agreement, neither Purchaser Parent nor Purchaser nor any of their respective Affiliates, Representatives or any other Person makes
any  express  or  implied  representation  or  warranty  with  respect  to  Purchaser  Parent  or  Purchaser  or  any  of  their  respective
Subsidiaries or Affiliates, the Purchaser Business or with respect to any other information provided,

93

or  made  available,  to  Seller  Parent  or  any  of  its  Affiliates  or  Representatives  in  connection  with  the  transactions  contemplated
hereby.  Except  as  expressly  set  forth  in  the  representations  and  warranties  contained  in  this  Article  V  or  in  any  Ancillary
Implementing Agreement, neither Purchaser Parent nor Purchaser nor any of their respective Affiliates, Representatives or any other
Person has made any representation or warranty, express or implied, as to the prospects of Purchaser or the Purchaser Business or
their  profitability,  or  with  respect  to  any  forecasts,  projections  or  business  plans  or  other  information  (including  any  Evaluation
Material  (as  defined  in  the  Confidentiality  Agreement))  delivered  to  Seller  Parent  or  any  of  its  Affiliates  or  Representatives  in
connection with Seller Parent’s review of Purchaser or the Purchaser Business and the negotiation and execution of this Agreement,
including  as  to  the  accuracy  or  completeness  thereof  or  the  reasonableness  of  any  assumptions  underlying  any  such  forecasts,
projections  or  business  plans  or  other  information.  Except  to  the  extent  expressly  provided  in  this  Agreement  with  respect  to  the
representations and warranties contained in this Article V or in any Ancillary Implementing Agreement, neither Purchaser Parent nor
Purchaser nor any of their respective Affiliates, Representatives or any other Person will have, or be subject to, any Liability or other
obligation to Seller Parent, its Affiliates or Representatives or any other Person resulting from Seller Parent’s use of, or the use by
any of its Affiliates or Representatives of, any information, including information, documents, projections, forecasts, business plans
or other material made available to Seller Parent, its Affiliates or Representatives by any means, including in any virtual data room,
confidential information memorandum, management presentations, offering materials, site tours or visits, diligence calls or meetings
or any documents prepared by, or on behalf of, Purchaser Parent, Purchaser or any of their respective Affiliates or Representatives.
Each  of  Purchaser  Parent,  Purchaser  and  their  respective  Affiliates  disclaims  any  and  all  representations  and  warranties,  whether
express  or  implied,  except  for  the  representations  and  warranties  contained  in  this  Article  V  or  in  any  Ancillary  Implementing
Agreement. Notwithstanding anything to the contrary contained in this Agreement, neither Purchaser Parent, Purchaser nor any of
their  respective  Affiliates  makes  any  express  or  implied  representation  or  warranty  with  respect  to  the  Purchaser  Parent  Retained
Businesses or Purchaser Parent Retained Liabilities.

(b)            Purchaser  Parent  and  Purchaser  acknowledge  and  agree  that,  except  for  the  representations  and  warranties
contained  in  Article  IV  or  in  any  Ancillary  Implementing  Agreement,  neither  Seller  Parent,  the  other  Sellers  nor  any  of  their
respective Affiliates, Representatives or any other Person makes any express or implied representation or warranty with respect to
Seller Parent, the other Sellers, the Conveyed Subsidiaries or any of their respective Subsidiaries or Affiliates, the Purchased Assets,
the  Business  or  with  respect  to  any  other  information  provided,  or  made  available,  to  Purchaser  Parent,  Purchaser  or  any  of  their
respective  Affiliates  or  Representatives  in  connection  with  the  transactions  contemplated  hereby.  Purchaser  Parent  and  Purchaser
acknowledge  and  agree  that,  except  to  the  extent  expressly  provided  in  this  Agreement  with  respect  to  the  representations  and
warranties contained in Article IV or in any Ancillary Implementing Agreement, neither Seller Parent, the other Sellers nor any of
their  respective  Affiliates,  Representatives  or  any  other  Person  will  have,  or  be  subject  to,  any  Liability  or  other  obligation  to
Purchaser  Parent,  Purchaser,  any  of  their  respective  Affiliates  or  Representatives  or  any  other  Person  resulting  from  the  sale  and
purchase  of  the  Purchased  Assets  or  the  Business  to  Purchaser  Parent,  Purchaser  or  their  Affiliates  or  Purchaser  Parent’s  or
Purchaser’s  use  of,  or  the  use  by  any  of  their  respective  Affiliates  or  Representatives  of  any  information,  including  information,
documents, projections,

94

forecasts, business plans or other material (including any Evaluation Material (as defined in the Confidentiality Agreement)) made
available to Purchaser Parent, Purchaser, any of their respective Affiliates or Representatives by any means, including in any virtual
data room, confidential information memorandum, management presentations, offering materials, site tours or visits, diligence calls
or meetings or any documents prepared by, or on behalf of, Seller Parent, the other Sellers or any of their respective Affiliates or
Representatives. Purchaser Parent and Purchaser acknowledge and agree that they are not relying on any representation or warranty
of Seller Parent, the other Sellers, or any of their Affiliates or Representatives or any other Person, other than those representations
and  warranties  specifically  set  forth  in  Article  IV  or  in  any  Ancillary  Implementing  Agreement.  Purchaser  Parent  and  Purchaser
acknowledge  and  agree  that  each  of  Seller  Parent  and  the  other  Sellers  and  their  respective  Affiliates  disclaims  any  and  all
representations and warranties, whether express or implied, except for the representations and warranties contained in Article IV or
in  any  Ancillary  Implementing  Agreement.  Purchaser  Parent  and  Purchaser  acknowledge  and  agree  that  neither  Seller  Parent,  the
other Sellers nor any of their respective Affiliates makes any express or implied representation or warranty with respect to Excluded
Assets, Retained Businesses or Retained Liabilities.

(c)            Purchaser  Parent  and  Purchaser  acknowledge  that  they  have  conducted  to  their  satisfaction  an  independent
investigation of the financial condition, results of operations and projected operations of the Business and the nature and condition of
its  properties,  assets,  liabilities  and  businesses  and,  in  making  the  determination  to  proceed  with  the  transactions  contemplated
hereby, have relied solely on the results of their own independent investigation and the representations and warranties set forth in
Article IV or any Ancillary  Implementing Agreement. In light of  these inspections and investigations and  the representations and
warranties  made  to  Purchaser  Parent  and  Purchaser  by  Seller  Parent  in  Article  IV  or  in  any  Ancillary  Implementing  Agreement,
Purchaser Parent and Purchaser are relinquishing any right to any claim based on any representations and warranties other than those
specifically  included  in Article IV or  in  any  Ancillary  Implementing  Agreement.  Any  claims  Purchaser  Parent  or  Purchaser  may
have for breach of representation or warranty shall be based solely on the representations and warranties of Seller Parent set forth in
Article IV or in any Ancillary Implementing Agreement.

(d)      Purchaser Parent and Purchaser acknowledge that, except as explicitly set forth herein, neither Seller Parent nor
any of its Affiliates has made any warranty, express or implied, as to the prospects of the Business or its profitability for Purchaser,
or with respect to any forecasts, projections or business plans or other information (including any Evaluation Material (as defined in
the Confidentiality Agreement)) delivered to Purchaser Parent or Purchaser or any of their respective Affiliates or Representatives in
connection  with  Purchaser  Parent’s  and  Purchaser’s  review  of  the  Business  and  the  negotiation  and  execution  of  this  Agreement,
including  as  to  the  accuracy  or  completeness  thereof  or  the  reasonableness  of  any  assumptions  underlying  any  such  forecasts,
projections or business plans or other information.

ARTICLE VI

COVENANTS

95

Section 6.1      Information and Documents .

(a)          From and after the date of this Agreement and to the earlier of the Closing Date and the date on which this
Agreement is terminated pursuant to Section 9.1 , to the extent permitted by applicable Law and upon reasonable advance notice,
and  solely  for  purposes  of  integration  planning  or  in  furtherance  of  the  transactions  contemplated  by  this  Agreement  and  the
Ancillary Agreements, (1) Seller Parent shall, and shall cause its Subsidiaries to, permit Purchaser Parent and its Representatives to
have  reasonable  access,  during  normal  business  hours,  to  the  books  and  records  that  constitute  Purchased  Assets,  and  to  such
personnel,  offices  and  other  facilities  and  properties  that  constitute  Purchased  Assets,  and  to  provide  such  other  information  in
respect of the Business as may be reasonably requested by Purchaser Parent for such purposes and (2) Purchaser Parent shall, and
shall cause its Subsidiaries to, permit Seller Parent and its Representatives to have reasonable access, during normal business hours,
to  the  books  and  records  of  Purchaser  and  its  Subsidiaries  or  that  are  related  to  the  Purchaser  Business  (  provided that Purchaser
Parent may redact any information in any such record not related to the Purchaser Business), and to such personnel, offices and other
facilities  and  properties  of  Purchaser  and  its  Subsidiaries  or  that  are  related  to  the  Purchaser  Business,  and  to  provide  such  other
information in respect of the Purchaser Business as may be reasonably requested by Seller Parent for such purposes; provided that all
requests for access pursuant to this Section 6.1 shall be directed to and coordinated with a person or persons designated by Seller
Parent  or  Purchaser  Parent,  as  applicable,  in  writing;  provided  ,  further  ,  that  each  Parent  and  its  Subsidiaries  may  restrict  the
foregoing  access or the provision  of such information  to the extent  that, in the reasonable  judgment  of such  Parent,  (i) applicable
Law  requires  such  Parent  or  any  of  its  Subsidiaries  to  restrict  or  prohibit  such  access  or  the  provision  of  such  information,  (ii)
providing such access would unreasonably interfere with the operation of such Parent’s and its Subsidiaries’ respective businesses,
including  the  Business  and  the  Purchaser  Business,  as  applicable,  (iii)  providing  such  access  or  information  would  breach  a
confidentiality obligation to a third party, (iv) providing such access or information would result in disclosure of any information that
is competitively or commercially sensitive, (v) in the case of access or information provided by Seller Parent, the information relates
to the Strategic Process, or in the case of access or information provided by Purchaser Parent, the information relates to review of
strategic  alternatives  with  respect  to  the  Purchaser  Business,  or  (vi)  providing  such  access  or  disclosure  of  any  such  information
would reasonably be expected to result in the loss or waiver of the attorney-client or other applicable privilege or protection. In the
event that a Parent or its Subsidiaries restricts access or withholds information on the basis of the foregoing clauses (i) through (vi) ,
such Parent shall, if permitted, inform the other Parent as to the general nature of what is being restricted or withheld and the reason
therefor,  and  such  Parent  shall,  and  shall  cause  its  Subsidiaries  to,  use  its  commercially  reasonable  efforts  to  make  appropriate
substitute  arrangements  to  permit  disclosure  of  the  relevant  information  in  a  manner  that  does  not  suffer  from  such  impediments.
Notwithstanding the foregoing, (A) prior to the Closing, neither Parent, nor any of its Affiliates and Representatives, shall conduct
any  phase  II  environmental  site  assessment  or  conduct  any  invasive  testing  or  any  sampling  of  soil,  sediment,  surface  water,
groundwater or building material at, on, under or within any property of the other Parent or its Subsidiaries and (B) prior to Closing,
none of Seller Parent or any of its Affiliates, including the Conveyed Subsidiaries (and their Subsidiaries), shall provide Business
Employee  personnel  files  to  Purchaser  Parent  or  its  Affiliates  or  Representatives  and  none  of  Purchaser  Parent  or  any  of  its
Affiliates, including Purchaser (and its Subsidiaries), shall provide

96

Purchaser  Business  Employee  personnel  files  to  Seller  Parent  or  its  Affiliates  or  Representatives.  Notwithstanding  the  foregoing,
following Closing (x) to the extent permitted by Law, Seller Parent shall, and shall cause its Affiliates to, provide Purchaser and its
Subsidiaries  access  to personnel  records  and other  personnel  information  related  to the  Business  Employees  and  Former  Business
Employees reasonably requested by Purchaser and its Subsidiaries and (y) Seller Parent shall, and shall cause its Affiliates to, retain
all material records related to the Business Employees and Former Business Employees in accordance with Seller Parent’s records
retention policies and, in no event, for less than such period of time required by applicable Law. It is further agreed that, prior to the
Closing,  each  Parent  and  its  Affiliates  and  Representatives  shall  not  contact  any  of  the  directors,  officers,  employees,  agents,
customers, suppliers, licensors, licensees, distributors or other business partners of the other Parent or any of its Affiliates (including,
with respect to Seller Parent, the Conveyed Subsidiaries (or their Subsidiaries) and, with respect to Purchaser Parent, Purchaser and
its  Subsidiaries)  in  connection  with  the  transactions  contemplated  by  this  Agreement,  whether  in  person  or  by  telephone,  mail  or
other  means  of  communication,  without  the  specific  prior  authorization  by  the  other  Parent  (not  to  be  unreasonably  withheld,
conditioned  or  delayed); provided that  the  foregoing  shall  not  prevent  any  Parent  or  its  Affiliates  from  operating  in  the  ordinary
course  of  business  and  communicating  with  such  parties  on  matters  unrelated  to  the  Business  or  the  Purchaser  Business,  as
applicable, and the transactions contemplated by this Agreement. Notwithstanding anything to the contrary contained herein, in no
event shall Seller Parent or any of its Affiliates, including the Conveyed Subsidiaries (and their Subsidiaries), be required to provide
any information  as and to the extent it relates to any Retained Businesses, any Excluded  Assets or any Retained  Liabilities,  or be
required  to  provide  a  copy  of,  or  otherwise  disclose  the  contents  of,  any  Seller  Combined  Tax  Return,  and  in  no  event  shall
Purchaser Parent or any of its Affiliates, including Purchaser and its Subsidiaries, be required to provide any information as and to
the extent it relates to any Purchaser Parent Retained Businesses or any Purchaser Parent Retained Liabilities. The Parties agree that,
with respect to any matters that are the subject of both this Section 6.1(a) and Section 6.5(i) , the provisions of Section 6.5(i) (and not
this Section 6.1(a) ) shall control.

(b)           Subject to Section 6.12 ,  all  information  received  or  otherwise  obtained  by  either  Parent  or  its  Affiliates  or
Representatives  from,  by  or  on  behalf  of  the  other  Parent  or  any  of  its  Affiliates  or  Representatives,  in  connection  with  the
negotiation, execution, performance or consummation of this Agreement and the transactions contemplated hereby, whether prior to,
on or following the date of this Agreement, will be held by such Parent and its Affiliates and Representatives pursuant to the terms of
the Confidentiality Agreement and Section 6.12 . Subject to Section 6.12(d) , the Confidentiality Agreement and the Clean Team
Agreement  shall  remain  in  full  force  and  effect  in  accordance  with  their  terms  (subject  to  Section  9.2(d)  )  notwithstanding  any
termination of this Agreement.

(c)           From  and  after  the  date  of  this  Agreement  until  the  earlier  of  the  Closing  Date  and  the  date  on  which  this
Agreement is terminated pursuant to Section 9.1 , Seller Parent and its Subsidiaries shall consult with and provide material updates
to Purchaser Parent regarding the matters disclosed on Section 6.1(c) of the Purchaser Disclosure Letter.

97

Section 6.2      Conduct of Business .

(a)           From  and  after  the  date  of  this  Agreement  until  the  earlier  of  the  Closing  Date  and  the  date  on  which  this
Agreement  is  terminated  pursuant  to  Section  9.1  ,  except  (i)  as  set  forth  in  Section  6.2(a)  of  the  Seller  Disclosure  Letter  or  as
otherwise  expressly  contemplated  by  this  Agreement  (including  Section 6.3 ),  (ii)  as  Purchaser  Parent  shall  otherwise  consent  in
writing,  which  consent  shall  not  be  unreasonably  withheld,  conditioned  or  delayed,  (iii)  in  connection  with  the  Seller  Internal
Restructurings, the settlement of any intercompany accounts or arrangements pursuant to Section 6.7 or the transfer of the Excluded
Assets pursuant to Section 2.3(b) , (iv) as required by Law or the terms of any Contract currently in effect and made available to
Purchaser Parent, Purchaser or any of their Representatives prior to the date hereof or (v) to the extent solely related to any Excluded
Assets,  Retained  Businesses  or  Retained  Liabilities,  Seller  Parent  covenants  and  agrees  that  (x)  it  shall,  and  shall  cause  its
Subsidiaries  to,  use  commercially  reasonable  efforts  to  conduct  the  Business  in  the  ordinary  course  of  business  in  all  material
respects and to maintain and preserve intact the Business in all material respects, and (y) it shall not, and shall cause its Subsidiaries
not to, in each case, to the extent with respect to the Purchased Assets and the Business:

(A)            change  or  amend  the  charter,  bylaws  or  similar  organizational  documents  of  any  of  the  Conveyed

Subsidiaries (or any of their Subsidiaries);

(B)      incur, create or assume any Lien, other than Permitted Liens, with respect to any Purchased Asset that is
material to the Business other than (1) those that will be discharged at or prior to the Closing or (2) in the ordinary
course of business;

(C)      acquire any assets outside of the ordinary course of business, except for transactions where the amount
of upfront consideration  paid or transferred  in connection  with such transactions  would not exceed the amounts set
forth on Section 6.2(a)(C) of the Seller Disclosure Letter;

(D)            (1)  amend  any  material  term  of,  or  waive  any  material  right  under,  or  terminate  (other  than  upon
expiration in accordance with its terms), any Material Contract or Real Property Lease, or (2) enter into any Contract
that, if in effect on the date hereof, would be a Material Contract or Real Property Lease, other than, in the case of
each  of  clauses  (1)  and  (2)  ,  in  the  ordinary  course  of  business  or  Contracts  entered  into  in  order  to  effect  an
acquisition, divestiture or other transaction or action expressly permitted under this clause (y) of this Section 6.2(a) ,
or (3) enter into any Contract that, if in effect on the date hereof, would be a Shared Contract;

(E)      issue, sell, pledge or transfer to any third party or propose to issue, sell, pledge or transfer to any third
party any shares or equity interests of any of the Conveyed Subsidiaries (or any of their Subsidiaries), or securities
convertible into, or exchangeable or exercisable for, or options with respect to, or warrants to purchase, or rights to
subscribe for, shares or equity interests of any of the Conveyed Subsidiaries (or any of their Subsidiaries);

98

(F)            change  in  any  material  respect  any  financial  accounting  method  used  with  respect  to  the  Business,

unless required by GAAP or Law or interpretation thereof;

(G)      (1) enter into, adopt, amend in any material respect or terminate any Conveyed Subsidiary Plan (or any
other  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  to  the  extent  applicable  to  any  Business  Employee,  Former
Business  Employee,  current  or  former  consultant  or  director),  (2)  grant  any  new,  or  increase  any  existing,  or
accelerate the vesting, funding or payment of any compensation or benefits of, or pay or otherwise grant any benefit
not  required  by  any  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  to,  any  Business  Employee,  Former  Business
Employee,  current  or former  consultant  or director,  except,  in the case of either  clause (1) or (2) , (I) to the extent
required by applicable Law or as required under any Seller Group Plan or Foreign Seller Group Plan as in effect on
the  date  of  this  Agreement  (or  as  amended  in  accordance  with  the  terms  of  this  Agreement),  (II)  other  than  with
respect  to  any  transaction  or  retention  bonus  or  similar  award  or  severance  or  termination  enhancements,  in  the
ordinary course of business consistent with past practice, (III) as would not reasonably be expected, individually or in
the aggregate, to result in any non- de
minimis
Liabilities to Purchaser or any of its Affiliates or (IV) for amendments
similarly affecting all participating employees in any Seller Group Plan or Foreign Seller Group Plan, (3) grant any
transaction  or  retention  bonus  or  similar  award  to  any  Business  Employee,  Former  Business  Employee,  current  or
former  consultant  or  director  or  (4)  transfer  any  Seller  Retained  Plan  to  a  Conveyed  Subsidiary  (or  Subsidiary
thereof);

(H)      solely with respect to the Conveyed Subsidiaries or their Subsidiaries or the other Purchased Assets,
and except with respect to any Seller Combined Tax Return, (1) make, change or revoke any material Tax election,
(2) adopt or change any material method of Tax accounting on which Tax reporting is based, (3) amend any material
Tax Return, (4) settle any Tax Proceeding, or (5) enter into any “closing agreement” within the meaning of 7121 of
the Code (or any similar provision of state, local or foreign Law) that would be binding on Purchaser or any of its
Affiliates  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries)  in  respect  of  a  Post-Closing  Tax  Period,  in
each case, if such action would reasonably  be expected  to materially  increase the Tax liability  of Purchaser  and its
Affiliates  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries  after  the  Closing)  for  any  Post-Closing  Tax
Period;

(I)      except in the ordinary course of business or as contemplated by Section 6.6 , (1) enter into, materially
amend,  extend  or  terminate  any  material  Collective  Bargaining  Agreement  covering  any  Business  Employee  or
otherwise binding upon the Business or the Conveyed Subsidiaries or their Subsidiaries, (2) hire any individual who
will be a Business Employee at Closing, (3) terminate the employment of (other than for cause) any individual who
would have been a Business Employee at Closing, but for such termination of employment, or (4) reassign the

99

duties of (x) any individual who would have been a Business Employee at Closing, but for such reassigned duties, or
(y) any employee of Seller Parent or its Affiliates who would not have been a Business Employee at Closing, but for
such reassigned duties;

(J)      incur, assume or guarantee any material Indebtedness, other than (1) as would not exceed the amounts
set forth on Section 6.2(a)(J) of the Seller Disclosure Letter or (2) intercompany Indebtedness that will be settled at or
prior to the Closing;

(K)            defer  payment  of  any  accounts  payable  or  accelerate  payment  of  any  accounts  receivable,  in  any

material respect, outside of the ordinary course of business;

(L)            make  capital  expenditures  in  connection  with  the  operation  of  the  Business  that  are  materially
inconsistent  with,  or fail to make capital  expenditures  materially  consistent  with, the capital  expenditure  budget  set
forth in Section 6.2(a)(L) of the Seller Disclosure Letter;

(M)            sell,  assign,  transfer,  license,  sublicense,  abandon  or  otherwise  dispose  of  any  material  Purchased
Assets, other than sales of Inventory and other assets, and non-exclusive licenses or sublicenses, in each case, in the
ordinary course of business;

(N)           (1)  settle  or  compromise  any  Action  made  or  pending  against  the  Business  or  any  of  the  Conveyed
Subsidiaries  (or  any  of  their  Subsidiaries)  to  the  extent  such  settlement  or  compromise  imposes  material  ongoing
obligations or restrictions on the operations of the Business, or (2) settle, compromise or file any Action that relates to
the Business IP that could materially impact such Business IP without consulting with and considering in good faith
the opinion of Purchaser;

(O)      materially accelerate or increase the quantity of the Products distributed to the relevant distributors or
wholesalers outside of the ordinary course of business, except with respect to a bona
fide
increase in demand for any
Product by the relevant distributor or wholesaler which has not been stimulated in any way following the date hereof
by discounts, rebates, claw-backs or the like outside the ordinary course of business or the grant of preferred terms
offered by Seller Parent or any of its Affiliates outside the ordinary course of business; or

(P)      agree to take any of the foregoing actions described in this clause (y) of this Section 6.2(a) .

(b)           From  and  after  the  date  of  this  Agreement  until  the  earlier  of  the  Closing  Date  and  the  date  on  which  this
Agreement is terminated pursuant to Section 9.1 , except (i) as set forth in Section 6.2(b) of the Purchaser Parent Disclosure Letter or
as  otherwise  expressly  contemplated  by  this  Agreement  (including  Section  6.3  ),  (ii)  as  Seller  Parent  shall  otherwise  consent  in
writing, which consent shall not be unreasonably withheld, conditioned or delayed, (iii) in

100

connection with the Purchaser Internal Restructurings or the settlement of any intercompany accounts or arrangements pursuant to
Section 6.7 , (iv) as required by Law or the terms of any Contract currently in effect and made available to Seller Parent or any of its
Representatives prior to the date hereof or (v) to the extent solely related to any Purchaser Parent Retained Businesses or Purchaser
Parent  Retained  Liabilities,  each  of  Purchaser  Parent  and  Purchaser  covenants  and  agrees  that  (x)  it  shall,  and  shall  cause  its
Subsidiaries  to,  use  commercially  reasonable  efforts  to  conduct  the  Purchaser  Business  in  the  ordinary  course  of  business  in  all
material respects and to maintain and preserve intact the Purchaser Business in all material respects, and (y) it shall not, and shall
cause  its  Subsidiaries  not  to,  in  each  case,  to  the  extent  with  respect  to  the  Purchaser  Business  or  the  assets,  properties  or  rights
comprising the Purchaser Business or owned, used or held by Purchaser or any of its Subsidiaries:

(A)          change or amend the charter, bylaws or similar organizational documents of Purchaser or any of its

Subsidiaries;

(B)            incur,  create  or  assume  any  Lien,  other  than  Purchaser  Permitted  Liens,  with  respect  to  any  asset,
property or right that is material to the Purchaser Business other than (1) those that will be discharged at or prior to
the Closing or (2) in the ordinary course of business;

(C)      acquire any assets outside of the ordinary course of business, except for transactions where the amount
of upfront consideration  paid or transferred  in connection  with such transactions  would not exceed the amounts set
forth on Section 6.2(b)(C) of the Purchaser Parent Disclosure Letter;

(D)            (1)  amend  any  material  term  of,  or  waive  any  material  right  under,  or  terminate  (other  than  upon
expiration in accordance with its terms), any Purchaser Material Contract or Purchaser Real Property Lease, (2) enter
into  any  Contract  that,  if  in  effect  on  the  date  hereof,  would  be  a  Purchaser  Material  Contract  or  Purchaser  Real
Property Lease, other than, in the case of each of clauses (1) and (2) , in the ordinary course of business or Contracts
entered into in order to effect an acquisition, divestiture or other transaction or action expressly permitted under this
clause  (y)  of  this  Section  6.2(b)  ,  or  (3)  enter  into  any  Contract  that,  if  in  effect  on  the  date  hereof,  would  be  a
Purchaser Shared Contract;

(E)      issue, sell, pledge or transfer to any third party or propose to issue, sell, pledge or transfer to any third
party  any  shares  or  equity  interests  of  Purchaser  or  any  of  its  Subsidiaries,  or  securities  convertible  into,  or
exchangeable or exercisable for, or options with respect to, or warrants to purchase, or rights to subscribe for, shares
or equity  interests  of Purchaser  or any of its Subsidiaries,  including  in each  case  any ordinary  shares  or preference
shares of Purchaser (other than the Preference Shares issued in accordance with this Agreement);

(F)            change  in  any  material  respect  any  financial  accounting  method  used  with  respect  to  Purchaser,  its

Subsidiaries or the Purchaser Business, unless required by IFRS or Law or interpretation thereof;

101

(G)      (1) enter into, adopt, amend in any material respect or terminate any Purchaser Business Plan (or any
other  Purchaser  Group  Plan  or  Foreign  Purchaser  Group  Plan  to  the  extent  applicable  to  any  Purchaser  Business
Employee,  Former  Purchaser  Business  Employee,  current  or  former  consultant  or  director),  (2)  grant  any  new,  or
increase  any  existing,  or  accelerate  the  vesting,  funding  or  payment  of  any  compensation  or  benefits  of,  or  pay  or
otherwise  grant  any  benefit  not  required  by  any  Purchaser  Group  Plan  or  Foreign  Purchaser  Group  Plan  to,  any
Purchaser Business Employee, Former Purchaser Business Employee, current or former consultant or director, except,
in the case of either clause (1) or (2) , (I) to the extent required by applicable Law or as required under any Purchaser
Group Plan or Foreign Purchaser Group Plan as in effect on the date of this Agreement (or as amended in accordance
with the terms of this Agreement), (II) other than with respect to any transaction or retention bonus or similar award
or  severance  or  termination  enhancements,  in  the  ordinary  course  of  business  consistent  with  past  practice,  (III)  as
would  not  reasonably  be  expected,  individually  or  in  the  aggregate,  to  result  in  any  non-  de
minimis
Liabilities to
Purchaser  or  any  of  its  Affiliates  or  (IV)  for  amendments  similarly  affecting  all  participating  employees  in  any
Purchaser Group Plan or Foreign Purchaser Group Plan, (3) grant any transaction or retention bonus or similar award
to any Purchaser Business E mployee, Former Purchaser Business Employee, current or former consultant or director
or (4) transfer any Purchaser Group Plan or Foreign Purchaser Group Plan that is not a Purchaser Business Plan to
Purchaser or any of its Subsidiaries;

(H)      solely with respect to Purchaser and its Subsidiaries, and except with respect to any Purchaser Parent
Combined Tax Return, (x) (1) make, change or revoke any material Tax election, (2) adopt or change any material
method of Tax accounting on which Tax reporting is based, (3) amend any material Tax Return, (4) settle any Tax
Proceeding,  or  (5)  enter  into  any  “closing  agreement”  within  the  meaning  of  7121  of  the  Code  (or  any  similar
provision  of state, local  or foreign  Law) that would be binding on Purchaser  or any of its Affiliates  in respect  of a
Post-Closing  Tax  Period,  in  each  case,  if  such  action  would  reasonably  be  expected  to  materially  increase  the  Tax
liability  of  Purchaser  and  its  Affiliates  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries  following  the
Closing)  for  any  Post-Closing  Tax  Period,  or  (y)  take  any  action  other  than  in  the  ordinary  course  of  business  that
would reasonably be expected to violate Clauses 11.4(a) and 11.4(b) of the Structuring Considerations Agreement if
such Clauses were in effect from and after the date of this Agreement until the earlier of the Closing Date and the date
on which this Agreement is terminated pursuant to Section 9.1 ;

(I)            except  in  the  ordinary  course  of  business,  (1)  enter  into,  materially  amend,  extend  or  terminate  any
material Collective Bargaining Agreement covering any Purchaser Business Employee or otherwise binding upon the
Purchaser  Business  or  Purchaser  or  its  Subsidiaries,  (2)  hire  any  individual  who  will  be  a  Purchaser  Business
Employee at Closing, (3) terminate the employment of (other than for cause) any individual who would have been a
Purchaser Business Employee at

102

Closing,  but  for  such  termination  of  employment,  or  (4)  reassign  the  duties  of  (x)  any  individual  who  would  have
been  a  Purchaser  Business  Employee  at  Closing,  but  for  such  reassigned  duties,  or  (y)  any  employee  of  Purchaser
Parent or its Affiliates who would not have been a Purchaser Business Employee at Closing, but for such reassigned
duties;

(J)      incur, assume or guarantee any material Indebtedness, other than (1) as would not exceed the amounts
set forth on Section 6.2(b)(J) of the Purchaser Parent Disclosure Letter or (2) intercompany Indebtedness that will be
settled at or prior to the Closing;

(K)            defer  payment  of  any  accounts  payable  or  accelerate  payment  of  any  accounts  receivable,  in  any

material respect, outside of the ordinary course of business;

(L)           make  capital  expenditures  in  connection  with  the  operation  of  the  Purchaser  Business  or  for  which
Purchaser or any Subsidiary of Purchaser is responsible that are materially inconsistent with, or fail to make capital
expenditures materially consistent with, the capital expenditure budget set forth in Section 6.2(b)(L) of the Purchaser
Parent Disclosure Letter;

(M)            sell,  assign,  transfer,  license,  sublicense,  abandon  or  otherwise  dispose  of  any  material  assets,
properties or rights (x) Related to the Purchaser Business and owned by Purchaser Parent or any of its Subsidiaries or
(y)  owned  or  held  by  Purchaser  or  any  of  its  Subsidiaries,  other  than  sales  of  inventory  and  other  assets,  and  non-
exclusive licenses or sublicenses, in each case, in the ordinary course of business;

(N)      (1) settle or compromise any Action made or pending against the Purchaser Business or Purchaser or
any  of  its  Subsidiaries  to  the  extent  such  settlement  or  compromise  imposes  material  ongoing  obligations  or
restrictions on the operations of Purchaser or the Purchaser Business, or (2) settle, compromise or file any Action that
relates to the Purchaser IP that could materially impact such Purchaser IP without consulting with and considering in
good faith the opinion of Seller Parent;

(O)      enter into or modify the terms of any material transaction, arrangement or Contract between Purchaser
or  its  Subsidiaries,  on  the  one  hand,  and  Purchaser  Parent  or  any  of  its  Affiliates  other  than  Purchaser  or  its
Subsidiaries, on the other hand;

(P)            materially  accelerate  or  increase  the  quantity  of  the  Purchaser  Products  distributed  to  the  relevant
distributors or wholesalers outside of the ordinary course of business, except with respect to a bona
fide
increase in
demand for any Purchaser Product by the relevant distributor or wholesaler which has not been stimulated in any way
following the date hereof by discounts, rebates, claw-backs

103

or the like outside the ordinary course of business or the grant of preferred terms offered by Purchaser Parent or any
of its Affiliates outside the ordinary course of business; or

(Q)      agree to take any of the foregoing actions described in this clause (y) of this Section 6.2(b) .

(c)      Notwithstanding any provision in this Agreement to the contrary, subject to Section 6.5(f) , prior to the Closing
and  without  the  consent  of  Purchaser  Parent  or  Purchaser,  each  of  Seller  Parent  and  its  Affiliates,  including  the  Conveyed
Subsidiaries and their Subsidiaries, will be permitted in their sole discretion in compliance with applicable Law to (i) declare and pay
dividends and distributions of, or otherwise transfer to Seller Parent or any Subsidiary thereof, (A) any Cash Equivalents or, subject
to  Section  2.3(b)  ,  Excluded  Assets,  and  (B)  any  of  the  books  and  records  of  Seller  Parent  or  any  of  its  Affiliates  that  are  not
Purchased  Assets,  (ii)  conduct  their  activities  regarding  cash  management  matters  (including,  to  the  extent  consistent  with
Section 6.2(a)(K) ,  the  collection  and  transfer  of  accounts  receivable  and  disbursement  of  funds,  or  in  connection  with  any  “cash
sweep”  practices),  including  to  settle  intercompany  payables  and  receivables  and  to  effect  intercompany  funding,  (iii)  make  any
payments  under,  or  repay  (in  part  or  in  full),  any  indebtedness  and  (iv)  execute,  deliver  and  perform  obligations  under  the  Local
Implementing Agreements.

(d)      Notwithstanding any provision in this Agreement to the contrary, subject to Section 6.5(f) , prior to the Closing
and without the consent of Seller Parent, each of Purchaser Parent and its Affiliates, including Purchaser and its Subsidiaries, will be
permitted  in  their  sole  discretion  in  compliance  with  applicable  Law  to  (i)  declare  and  pay  dividends  and  distributions  of,  or
otherwise  transfer  to  Purchaser  Parent  or  any  Subsidiary  thereof,  (A)  any  Cash  Equivalents  or  assets  that  are  not  Related  to  the
Purchaser  Business,  and  (B)  any  of  the  books  and  records  of  Purchaser  Parent  or  any  of  its  Affiliates  that  are  not  Related  to  the
Purchaser  Business,  (ii)  conduct  their  activities  regarding  cash  management  matters  (including,  to  the  extent  consistent  with
Section 6.2(b)(K) ,  the  collection  and  transfer  of  accounts  receivable  and  disbursement  of  funds,  or  in  connection  with  any  “cash
sweep”  practices),  including  to  settle  intercompany  payables  and  receivables  and  to  effect  intercompany  funding,  (iii)  make  any
payments  under,  or  repay  (in  part  or  in  full),  any  indebtedness  and  (iv)  execute,  deliver  and  perform  obligations  under  the  Local
Implementing  Agreements.  Until  the  earlier  of  the  Closing  Date  and  the  date  on  which  this  Agreement  is  terminated  pursuant  to
Section 9.1 , neither Purchaser nor any of its Subsidiaries shall, and Purchaser Parent shall cause Purchaser and its Subsidiaries not
to,  without  the  written  consent  of  Seller  Parent,  make  any  distributions  of,  or  otherwise  transfer,  any  assets,  properties  or  rights
(other than Cash Equivalents) Related to the Purchaser Business to Purchaser Parent or any of its Affiliates (other than to Purchaser
or a Subsidiary of Purchaser).

(e)      Nothing contained in this Agreement shall be construed to give to Purchaser Parent or Purchaser, directly or
indirectly,  rights to control  or direct the Business’s operations  prior to the Closing,  or give to Seller Parent,  directly  or indirectly,
rights  to  control  or  direct  the  Purchaser  Business’s  operations  prior  to  the  Closing.  Prior  to  the  Closing,  Seller  Parent  (and  its
Affiliates) shall exercise, consistent with the terms and conditions of this Agreement, complete control and

104

supervision of the operations of the Business and Purchaser Parent (and its Affiliates) shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision of the operations of the Purchaser Business.

(f)           Purchaser  agrees  that  it  shall,  and  shall  cause  its  applicable  Affiliates  to,  on  and  immediately  following  the
Closing,  use  the  Purchased  Assets  to  carry  on  the  same  kind  of  business  as  that  carried  on  by  the  Sellers  with  respect  to  the
Purchased Assets prior to the Closing.

Section 6.3      Regulatory Approvals .

(a)      Upon the terms and subject to the conditions herein provided, Purchaser Parent, Purchaser and Seller Parent
each agree to take, and to cause their Affiliates to take, all actions and to do, and cause their Affiliates to do, all things necessary
under  applicable  Antitrust  Laws  to  consummate  and  make  effective  the  transactions  contemplated  by  this  Agreement  or  any
Ancillary Agreement as promptly as reasonably practicable (and in any event as required to effect the Closing prior to the Outside
Date), including all actions and all things necessary (i) to obtain, as promptly as reasonably practicable (and in any event as required
to effect the Closing prior to the Outside Date), any consent, authorization, order or approval of, or any exemption by, or negative
clearance from, or the expiration or early termination of any waiting period imposed by, or any other Approval of, any Governmental
Antitrust Authority required to be obtained or made by Seller Parent, Purchaser Parent, Purchaser or their Affiliates in connection
with  the  acquisition  of  the  Purchased  Assets  or  the  consummation  of  the  transactions  contemplated  hereby  or  by  the  Ancillary
Agreements, (ii) to satisfy, as promptly as reasonably practicable and in any event prior to the date that is the third (3rd) Business
Day prior to the Outside Date, the conditions precedent set forth in Sections 8.1(a) and 8.1(b) to the extent relating to Antitrust Laws,
(iii) to defend any Actions, whether judicial or administrative, brought by any Governmental Antitrust Authority or brought under,
pursuant  to  or  relating  to  any  Antitrust  Law  challenging  this  Agreement,  the  Ancillary  Agreements  or  the  consummation  of  the
transactions contemplated hereby or thereby, and (iv) to comply as promptly as reasonably practicable with all legal requirements
under  Antitrust  Laws  which  may  be  imposed  with  respect  to  this  Agreement,  the  Ancillary  Agreements  or  the  transactions
contemplated hereby or thereby. Without limiting the foregoing, Purchaser Parent, Purchaser, Seller Parent and their Affiliates shall
be obligated to take such actions as are necessary to obtain, as promptly as reasonably practicable and in any event prior to the date
that is the third (3rd) Business Day prior to the Outside Date, the expiration or termination of any applicable waiting period under the
HSR Act and any consent, authorization, order or approval of, or any exemption by, or negative clearance from, or the expiration or
early termination  of any waiting  period imposed by, or any other Approval  under, Antitrust  Laws of the jurisdictions  set forth on
Annex C .

(b)            Subject  to  appropriate  confidentiality  protections,  each  of  the  Parties  will  furnish  to  the  other  Parties  such
necessary information and reasonable assistance as such other Parties may reasonably request in connection with the foregoing and
will provide the other Parties with any information supplied by such Party or its Affiliates to a Governmental Antitrust Authority in
connection with this Agreement and the transactions contemplated hereby.

105

(c)      Without limiting the generality of the undertakings pursuant to this Section 6.3 :

(i)            Purchaser  Parent,  Purchaser,  Seller  Parent,  and  their  respective  Affiliates  shall,  with  respect  to  the
execution of this Agreement and the Ancillary Agreements and the consummation of the transactions contemplated
hereby and thereby, (A) as promptly as reasonably practicable, and in any event no later than fifteen (15) Business
Days after the date hereof unless otherwise agreed to in writing by the Parties, file any notification and report form
and related material required under the HSR Act, and (A) as promptly as reasonably practicable submit all necessary
Filings with the Governmental Antitrust Authorities set forth in Section 6.3(c)(i) of the Seller Disclosure Letter;

(ii)      In addition to the foregoing, in the event that a Party reasonably determines following the date hereof
that Filings other than the Filings described in Section 6.3(c)(i) are required to be made by one or more of the Parties
with, or additional Approvals are required to be obtained by the Parties from, any Governmental Antitrust Authorities
under any applicable Antitrust Law in connection with the execution and delivery of this Agreement and the Ancillary
Agreements and the consummation of the transactions contemplated hereby and thereby, the applicable Parties shall
timely make all such Filings and timely seek all such Approvals in accordance with the terms of this Section 6.3 . If,
following  good  faith  discussion  and  consideration,  the  Parties  mutually  agree  that  any  such  additional  Approval
would be required under applicable Antitrust Law to effect the Closing, and that effecting the Closing without having
obtained such additional Approval would reasonably be expected to violate applicable Antitrust Law (and that such
violation  could  not  be  avoided  or  cured  if  the  Business  in  the  relevant  jurisdiction  were  a  Delayed  Business),  the
jurisdiction  to  which  such  additional  Approval  relates  shall  be  added  to  Annex  C,  Part  1  ,  subject  to  each  Party’s
consent (which shall not be unreasonably withheld, conditioned or delayed). If, following good faith discussion and
consideration,  the  Parties  mutually  agree  that  effecting  the  Closing  without  having  obtained  the  Approval  of  any
Governmental Antitrust Authority under applicable Antitrust Laws of any jurisdiction set forth on Annex C, Part 2 (as
it may be supplemented pursuant to the immediately preceding sentence) would not violate applicable Antitrust Law
(or that such violation could be avoided or cured if the Business in the relevant jurisdiction were a Delayed Business),
such jurisdiction shall be removed from Annex C , subject to each Party’s consent (which shall not be unreasonably
withheld, conditioned or delayed).

(iii)      Purchaser Parent, Purchaser, Seller Parent and their respective Affiliates shall each promptly respond to
any  formal  or  informal  requests  for  additional  information  or  documentary  material  that  may  be  made  by  a
Governmental  Antitrust  Authority  and,  in  the  case  of  a  formal  request  for  additional  information  and  documentary
material  under  the  HSR  Act  or  any  other  Antitrust  Law  (to  the  extent  applicable),  certify  substantial  compliance
therewith as promptly as

106

reasonably practicable, unless the Parties otherwise agree in order to allow the Closing to occur more promptly;

(iv)            In  addition  to  the  foregoing,  Purchaser  Parent,  Purchaser  and  their  Affiliates  shall,  as  promptly  as
reasonably practicable take, or cause to be taken, any and all actions and do, or cause to be done, any and all things
necessary, required or advisable to avoid, eliminate and resolve each and every impediment and obtain all Approvals
under  Antitrust  Laws  that  may  be  required  by  any  Governmental  Antitrust  Authority  with  respect  to  the
consummation of the transactions contemplated hereby or by the Ancillary Agreements, in order to allow the Closing
to occur as promptly as reasonably practicable after the date of this Agreement but in any event prior to the Outside
Date, including proposing, negotiating, offering to commit and effect (and if such offer is accepted, committing to and
effecting) through order, consent decree, settlement or otherwise, to (d) license, sell, divest, hold separate or otherwise
dispose  of,  directly  or  indirectly,  any  of  the  Purchased  Assets  (including  any  of  the  Shares),  or  any  operations,
divisions,  Subsidiaries,  specific  assets  or  categories  of  assets,  specific  products  (including  any  of  the  Products  or
Purchaser Products) or categories of products, product lines or businesses of Purchaser (or any of its Subsidiaries), the
Conveyed Subsidiaries (or any Subsidiary thereof), the Purchaser Business or the Business (whether now owned or
hereafter  acquired  by  Purchaser  Parent,  Purchaser  or  their  Affiliates),  (e)  terminate  any  existing  relationships  and
contractual  rights  and  obligations  of  Purchaser  and  its  Subsidiaries,  the  Conveyed  Subsidiaries  (and  their
Subsidiaries)  and  any  such  relationships,  rights  or  obligations  that  form  part  of  the  Purchased  Assets,  (f)  amend  or
terminate  any  licenses  or  other  Intellectual  Property  agreements  of  Purchaser  and  its  Subsidiaries,  the  Conveyed
Subsidiaries (and their Subsidiaries) and any such licenses or other Intellectual Property agreements that form a part
of the Purchased Assets and enter into such new licenses or other Intellectual Property agreements and (g) take any
actions or make any behavioral commitments that may limit or modify Purchaser’s (or any of its Subsidiaries’) or the
Conveyed Subsidiaries’ (or any of their Subsidiaries’) rights of ownership in, or ability to conduct the business of, one
or  more  of  its  operations,  divisions,  businesses,  product  lines,  specific  products  (including  any  of  the  Products  or
Purchaser  Products),  categories  of  products,  customers,  specific  assets  or  categories  of  assets,  including,  after  the
Closing,  those  of  the  Business  or  any  of  the  Purchased  Assets;  provided  that,  without  limiting  any  of  Purchaser
Parent’s and its Subsidiaries’ obligations hereunder, Seller Parent and its Affiliates shall not take or agree to take any
of the actions listed in this Section 6.3(c)(iv) without the prior written consent of Purchaser Parent and Purchaser (not
to be unreasonably withheld, delayed or conditioned); provided further that  neither  Parent  shall  be required  to take
any  action  listed  in  Section  6.3(c)(iv)(A)-(D)  (“  Regulatory  Action  ”)  with  respect  to  the  Retained  Businesses,
Excluded  Assets  or  Purchaser  Parent  Retained  Businesses,  as  applicable;  and  provided  further  that  the  proceeds,
payments or consideration received or receivable in respect of any action contemplated by clauses (A) through (D) of
this Section 6.3(c)(iv) shall  be  paid  directly  to  Purchaser  and  held  by  Purchaser  through  the  Closing  Date,  it  being
agreed that such proceeds, payments and

107

consideration shall not be included in the calculation of Purchaser Net Cash or Purchaser Working Capital.

(v)            In  furtherance  of  the  foregoing:  (x)  (I)  Purchaser  Parent  and  Purchaser  shall  keep  Seller  Parent
reasonably  informed  of  all  matters,  discussions  and  activities  relating  to  any  of  the  matters  described  in  or
contemplated  by  clauses  (A)  through  (D)  of  Section  6.3(c)(iv)  ,  including  satisfying  each  of  its  obligations  under
Section 6.3(d) with respect to any such matters, and (II) Purchaser Parent and Purchaser shall consider in good faith
any of Seller Parent’s reasonable suggestions with respect to potential purchasers, licensees or other counterparties in
respect of any of the agreements,  arrangements,  transactions or other relationships  described in or contemplated  by
clauses (A) through (D) of Section 6.3(c)(iv) ,  (y)  (I)  Purchaser  Parent  and  Purchaser  shall  permit  Seller  Parent  to
review  on  a  reasonably  current  basis,  and  shall  discuss  with  Seller  Parent,  drafts  of  any  agreements  that  Purchaser
Parent  or Purchaser  contemplates  entering  into, or contemplates  causing  any of their Affiliates  (including,  after the
Closing, the Conveyed Subsidiaries and their Subsidiaries) to enter into, with respect to any of the matters described
in  or  contemplated  by  clauses  (A)  through  (D)  of  Section  6.3(c)(iv)  ,  (II)  Purchaser  Parent  and  Purchaser  shall
consider in good faith Seller Parent’s views and comments with respect to such agreements, and (III) the Parties and
their  respective  Affiliates,  as  applicable,  shall  not  be  required  to  enter  into  any  such  agreements  unless  the
effectiveness of the transactions contemplated by such agreements is subject to the Closing and (IV) in the case of any
license, sale, divestiture, disposition or similar transaction, neither Purchaser Parent nor Seller Parent nor any of their
respective Affiliates (other than Purchaser and its Subsidiaries) shall be the licensing, selling, divesting or disposing
party  under  any  such  agreements  unless  and  except  to  the  extent  required  by  the  relevant  Governmental  Antitrust
Authority or applicable Law and, even if so required, shall have no direct or indirect obligation thereunder for which
they are not fully indemnified by Purchaser and (z) notwithstanding anything in any such agreement to the contrary,
Seller Parent, Purchaser Parent and Purchaser agree (I) that neither Purchaser Parent nor Seller Parent nor any of their
respective  Affiliates  (other  than  Purchaser  and  its  Subsidiaries)  shall  have  any  Liability,  including  with  respect  to
indemnification obligations, in respect of any agreements, arrangements, transactions or other relationships described
in  or  contemplated  by  clauses  (A)  through  (D)  of  Section  6.3(c)(iv)  ,  including  the  cooperation  contemplated  by
Section 6.3(d)(ii) , (II) that Purchaser shall indemnify Purchaser Parent, Seller Parent and their respective Affiliates
(other  than  Purchaser  and  its  Subsidiaries)  for  any  Liabilities  arising  from,  or  attributable  or  related  to,  any  such
agreements,  arrangements,  transactions  or  other  relationships,  including  with  respect  to  any  agreements  to  which
Purchaser  Parent,  Seller  Parent  or  any  of  their  respective  Affiliates  (other  than  Purchaser  and  its  Subsidiaries)  are
party  (except,  in  the  case  of  (I)  and  (II),  to  the  extent  Seller  Parent  or  Purchaser  Parent,  as  applicable,  is expressly
liable for such Liabilities or indemnification pursuant to this Agreement or any Ancillary Agreement) and (IV) that
neither  Purchaser  Parent  nor Seller  Parent  nor their  respective  Affiliates  (other  than Purchaser  and its Subsidiaries)
shall be

108

required  to take any of the  actions  contemplated  by clauses (A) through (D) of Section 6.3(c)(iv) , or otherwise in
connection  with  the  matters  contemplated  by  this  Section  6.3  ,  with  respect  to  any  of  the  Retained  Businesses,
Excluded Assets or Purchaser Parent Retained Businesses.

(vi)           In  the  event  that  any  Action  is  threatened  or  commenced  under  Antitrust  Laws,  or  a  permanent  or
preliminary injunction or other Governmental Order is threatened or entered under Antitrust Laws, that would make
consummation of the transactions contemplated hereby or by the Ancillary Agreements in accordance with the terms
of  this  Agreement  and  the  Ancillary  Agreements  unlawful  or  that  would  prevent  or  delay  consummation  of  the
transactions  contemplated  hereby  or  by  the  Ancillary  Agreements  (in  each  case,  under  Antitrust  Laws),  each  of
Purchaser Parent, Purchaser and Seller Parent shall reasonably promptly take any and all actions and steps (including
the  defense  against  or  appeal  thereof,  the  posting  of  a  bond  and  the  taking  of  the  steps  contemplated  by  this
Section 6.3(c) ) necessary to resist and contest such Action and to have vacated, modified, reversed or suspended such
injunction or Governmental Order so as to permit such consummation as promptly as reasonably practicable, but in
any event as required to allow the Closing to occur prior to the Outside Date.

(d)      Cooperation .

(i)      Each Parent shall, and shall cause its Affiliates to, to the extent permitted by applicable Antitrust Law,
(i) promptly notify the other Parent of, and, if in writing, provide to the other Parent copies of (or in the case of oral
communications, advise the other orally of) all material or substantive communications between it (or its Affiliates or
Representatives)  and  any  Governmental  Antitrust  Authority  relating  to  the  consummation  of  the  transactions
contemplated hereby and by the Ancillary Agreements or any of the matters described in this Section 6.3 , (ii) consult
with the other in good faith as regards strategy,  permit the other to review and discuss in advance,  and consider in
good  faith  the  views  of  the  other  in  connection  with,  any  Filings,  notifications  or  material  or  substantive
communications  (whether  written  or  oral)  with  any  Governmental  Antitrust  Authority,  including  any  presentations,
memoranda, briefs, arguments, opinions or proposals and (iii) not participate in any material or substantive telephone
calls  or  any  meetings  with  a  Governmental  Antitrust  Authority  regarding  the  consummation  of  the  transactions
contemplated  hereby  and  by  the  Ancillary  Agreements  or  any  of  the  matters  described  in  this  Section  6.3  without
consulting with the other Parent in advance and, to the extent permitted by such Governmental Antitrust Authority,
giving the other Parent a reasonable opportunity to attend and participate thereat.

(ii)      Subject to and without limiting Section 6.3(c)(iv) , Seller Parent shall, and shall cause its Affiliates to,
reasonably  cooperate,  at  Purchaser’s  sole  cost  and  expense  (it  being  agreed  that  any  expenses  incurred  by  Seller
Parent or any of its Affiliates shall be reasonable, documented and out-of-pocket), with Purchaser Parent

109

and  Purchaser  on  any  proposed  license,  sale,  divestiture,  hold  separate,  disposal  or  other  action  undertaken  by
Purchaser  Parent  or  Purchaser  which  Purchaser  Parent  or  Purchaser  reasonably  concludes,  in  good  faith,  may  be
necessary  to  comply  with  its  obligations  under  Section  6.3(c)(iv)(A)  (a  “  Proposed  Divestiture  ”),  including  using
reasonable best efforts in connection with:

(A)            providing,  or  causing  to  be  provided,  to  Purchaser  Parent  and  Purchaser,  as  well  as  any  potential
counterparty in any Proposed Divestiture (each, a “ Counterparty ”), any information, in an electronic data room or
other  customary  format,  solely  with  respect  to  the  business,  operations,  financial  condition  and  projections  of  the
assets  or  business  which  are  the  subject  of  the  Proposed  Divestiture  as  may  be  reasonably  requested  by  Purchaser
Parent,  Purchaser  or  the  Counterparty,  in  each  case,  solely  to  the  extent  such  information  is  in  Seller  Parent’s
possession at such time;

(B)      reasonably cooperating with Purchaser Parent and Purchaser in the preparation for Counterparties of a
customary  confidential  information  memorandum  and  other  customary  marketing  materials  related  to  the  Proposed
Divestiture  (and  Seller  Parent  and  its  Affiliates  hereby  consent  to  the  use  of  the  logos  of  Seller  Parent  and  its
Affiliates  that  solely  relate  to  the  Business  in  such  confidential  information  memorandum  and  marketing  materials
and solely in connection with the Proposed Divestiture during the period prior to the Closing (so long as such logos
are  used  solely  in  a  manner  that  is  not  intended  to  and  is  not  reasonably  likely  to  suggest  or  imply  any  affiliation,
association or similar relationship with Seller Parent or its Affiliates, cause confusion arising out of their use of such
logos simultaneously with the use of such logos by Seller Parent and its Affiliates, or harm or disparage Seller Parent
or  its  Affiliates  or  the  goodwill  of  Seller  Parent  or  its  Affiliates,  including  the  Business,  and  are  used  solely  in
connection  with  a  truthful,  non-misleading  description  of  the  Business  and  the  Products  subject  to  the  Proposed
Divestiture, and subject to Seller Parent’s review thereof);

(C)      causing the reasonable participation by relevant employees of the Business in marketing efforts related
to  the  Proposed  Divestiture  and  its  potential  transfer,  during  normal  business  hours,  including  participation  in  a
reasonable  number  of  customary  due  diligence  sessions,  management  presentations  and  other  meetings  with
Counterparties;

(D)          taking  such  actions  within  its reasonable  control  as are  reasonably  requested  by Purchaser  Parent  to
facilitate the timely satisfaction of all conditions to the completion of the Proposed Divestiture, subject in all respects
to Section 2.2 and the other applicable provisions of this Agreement;

(E)            seeking  any  consents  and  Approvals  required  to  consummate  the  Proposed  Divestiture  from  third
parties  (other  than  Governmental  Authorities)  reasonably  requested  by  Purchaser  Parent,  subject  in  all  respects  to
Section 2.2 ; and

110

(F)      requesting Seller Parent’s independent auditors to cooperate with Counterparties as may be reasonably

requested by Seller Parent;

provided , however , that notwithstanding the foregoing or anything to the contrary in this Agreement, nothing herein
shall (i) require Seller Parent and its Affiliates to provide any information to any Counterparties prior to receipt of
executed confidentiality and clean team agreements with respect to such information and on terms no less favorable
(to the extent relevant) to Seller Parent than the Confidentiality Agreement and Clean Team Agreement, (ii) require
the  Sellers  or  any  of  their  Affiliates  to  agree  to  pay  any  amounts  for  which  they  are  not  promptly  reimbursed  by
Purchaser, or deliver or execute any opinions, authorization letters, certificates or other instruments, (iii) require the
Sellers or any of their Affiliates to take any action that would reasonably be expected to conflict with, or result in any
violation  or  breach  of,  or  default  (with  or  without  notice  or  lapse  of  time  or  both)  under,  any  of  their  respective
organizational  documents,  any  applicable  Laws  or  Governmental  Authorization  or  any  material  Contract  or  other
material  obligation  to  a  third  party,  (iv)  cause  any  representation  or  warranty  in  this  Agreement  to  be  breached  by
Seller Parent (unless such breach is waived by Purchaser Parent and Purchaser), (v) cause any Representative of the
Sellers or any of their Affiliates to incur any personal liability, (vi) provide access to or disclose information that any
of the Sellers or any of their Affiliates reasonably determines would jeopardize any attorney-client or other privilege
or  protection  of  any  of  the  Sellers  or  any  of  their  Affiliates  or  (vii)  prevent,  impair  or  materially  delay  the
consummation of the transactions contemplated hereby or by the Ancillary Agreements; provided , further , that in the
case of the foregoing clause (iii) and (vi) Sellers shall, and shall cause their Affiliates to, inform Purchaser as to the
general  nature  of  what  is  being  restricted  or  withheld  and  the  reason  therefor,  and  shall  use  its  commercially
reasonable  efforts to make appropriate  substitute arrangements  to permit disclosure of the relevant information  in a
manner that does not suffer from such impediments.

(e)      Delayed Antitrust Approvals .

(i)      Subject to Section 6.3(c)(ii) , in the event an Approval of a Governmental Antitrust Authority (other than
a Governmental  Antitrust  Authority  of the United States or Approvals  under Antitrust  Laws of the jurisdictions  set
forth on Annex C ) having jurisdiction that is necessary to lawfully consummate the transactions contemplated hereby
is  not  obtained  on  or  prior  to  the  date  on  which  the  conditions  set  forth  in  Sections  8.1  and  8.2  (other  than  the
conditions that, by their nature, are to be satisfied on the Closing Date) shall have been satisfied or waived (each, a “
Delayed Antitrust Approval ” and, each such jurisdiction, an “Outstanding Antitrust Jurisdiction”), the Parties agree
(subject to the satisfaction of the conditions set forth in Article VIII ) that, provided that the Laws of such Outstanding
Antitrust  Jurisdiction  permit  consummation  of  the  transactions  contemplated  hereby  in  all  territories  other  than  the
Outstanding Antitrust Jurisdiction, they will effect the Closing (which the Parties shall determine in

111

accordance  with  Section  6.3(c)(ii))  (including  the  issuance,  allotment  and  delivery  of  the  full  Purchase
Consideration),  subject  to  the  terms  of  this  Agreement,  including  by  selling,  conveying,  assigning,  transferring  or
delivering  to Purchaser or the applicable  Purchaser Designated Affiliates all of Seller Parent’s and its Subsidiaries’
right, title and interest in the Purchased Assets pursuant to the terms and conditions hereof to the extent permissible
under any applicable Law and subject to Section 2.2 , it being agreed that the Closing shall refer to the consummation
of  such  sale,  conveyance,  assignment,  transfer  or  delivery  of  such  Purchased  Assets  at  such  time  and  shall  only
exclude,  subject  to  Section  2.2  ,  the  Purchased  Assets  in  that  Outstanding  Antitrust  Jurisdiction  to  which  such
Delayed  Antitrust  Approval  relates  (a  “  Delayed  Business  ”).  The  obligations  of  the  Parties  set  forth  in  this
Section 6.3 shall continue with respect to each such Delayed Antitrust Approval until the earliest to occur of (A) the
date  such  Delayed  Antitrust  Approval  is  obtained,  (B)  the  date  on  which  such  Delayed  Business  is  sold  to  a  third
party designated  by Purchaser  (a “ Delayed Business Purchaser ”)  (it  being  agreed  that  Purchaser  shall  consider  in
good faith Seller Parent’s reasonable suggestions with respect to potential purchasers), as set forth in a written notice
(a  “  Delayed  Business  Notice  ”)  delivered  by  Purchaser  to  Seller  Parent  in  accordance  with  Section  10.1  and
Section 6.3(e)(iii) and (C) the date that is thirty-six (36) months after the Closing Date (the “ Hold-Back Termination
Date ”), and until the earliest to occur of the foregoing (the date of such earliest occurrence, the “ Delayed Business
Cut-Off Date ”), Seller Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to operate
the Delayed Business in the ordinary course of business in all material respects.

(ii)      Upon obtaining a Delayed Antitrust Approval pursuant to Section 6.3(e)(i)(A) , the Parties shall effect
the  transfer  of  such  Delayed  Business  pursuant  to  a  Local  Implementing  Agreement  for  the  jurisdiction  relating
thereto, and, to the extent permissible  under applicable  Antitrust  Laws, such transfer shall be retroactive  to, and be
deemed to have occurred on, the Closing Date; provided that, in accordance with Section 2.2(a) , to the fullest extent
permitted by applicable Law, the Parties shall treat Purchaser or the applicable Purchaser Designated Affiliate, as the
case may be, as the owner of the Delayed Business as of the Closing Date.

(iii)            In  the  event  that  Purchaser  delivers  a  Delayed  Business  Notice  to  Seller  Parent  with  respect  to  a
Delayed  Business,  Seller  Parent  shall,  and  shall  cause  its  Affiliates  to,  use  commercially  reasonable  efforts  to
facilitate the sale of such Delayed Business to the Delayed Business Purchaser by Purchaser and on its behalf and at
its direction as promptly as reasonably practicable, including the efforts described in Section 6.3(d)(ii) ; provided that
(A)  Purchaser  acknowledges  and  agrees  nothing  in  this  Section 6.3(e) shall  require  Seller  Parent  to  transfer  to  the
Delayed  Business  Purchaser  such  Delayed  Business  if  Purchaser  Parent  or  Purchaser  is  in  material  breach  of  its
obligations under this Section 6.3 , (B) such Delayed Business Purchaser has obtained or will obtain prior to such sale
all necessary Approvals under applicable Antitrust Laws with respect to such Delayed Business

112

and  the  sale  of  such  Delayed  Business  would  reasonably  be  expected  to  be  consummated  within  ninety  (90)  days
following  the  delivery  of  such  Delayed  Business  Notice,  (C)  the  sale  of  such  Delayed  Business  to  such  Delayed
Business Purchaser is not prohibited by, illegal under, or in contravention of, any applicable Law or Governmental
Order and (D) neither Purchaser Parent nor Seller Parent nor any of their respective Affiliates (other than Purchaser
and its Subsidiaries) shall be the selling party under any agreements required to implement the transfer of the Delayed
Business unless and except to the extent required by the relevant Governmental Antitrust Authority or applicable Law
and, even if so required, shall have no direct or indirect obligation thereunder for which they are not fully indemnified
by  Purchaser.  The  Parties  agree  (I)  that  neither  Purchaser  Parent  nor  Seller  Parent  nor  any  of  their  respective
Affiliates  (other  than  Purchaser  and  its  Subsidiaries)  shall  have  any  Liability,  including  with  respect  to
indemnification  obligations,  in  respect  of  any  agreements,  arrangements  or  transactions  contemplated  by  this
Section  6.3(e)(iii)  and  (II)  that  Purchaser  shall  indemnify  Purchaser  Parent  and  Seller  Parent  and  their  respective
Affiliates (other than Purchaser and its Subsidiaries) for any Liabilities arising from, or attributable or related to, any
such  agreements,  arrangements  or  transactions,  including  with  respect  to  any  agreements  to  which  Seller  Parent  or
Purchaser Parent or any of their respective Affiliates are party (except in the case of (I) and (II) to the extent Seller
Parent or Purchaser Parent, as applicable, is expressly liable for such Liabilities or indemnification pursuant to this
Agreement or any Ancillary Agreement). Purchaser shall promptly reimburse Seller Parent and Purchaser Parent, as
applicable,  for  any  and  all  reasonable  and  documented  out-of-pocket  costs  and  expenses  (including  reasonable
attorneys’  and  other  Representatives’  fees)  incurred  in  connection  with  the  foregoing,  including  any  such  costs
(including  payments)  or  expenses  incurred  or  made  following  the  consummation  of  such  transaction.  Subject  to
applicable Law, the proceeds of any sale of a Delayed Business shall be paid directly to Purchaser (or a Subsidiary of
Purchaser)  by  the  Delayed  Business  Purchaser;  provided that  Seller  Parent  or  Purchaser  Parent,  as  applicable,  may
require payment of its reasonable and documented out-of-pocket fees and expenses (or an estimate thereof) and any
Taxes payable as a result of such transaction  from such proceeds as a direct wire transfer of immediately  available
funds at such applicable closing.

(iv)      In the event that a Delayed Antitrust Approval is not obtained with respect to a Delayed Business and
Purchaser  does  not  deliver  a  Delayed  Business  Notice  in  accordance  with  Section  6.3(e)(iii)  with  respect  to  such
Delayed  Business,  in  each  case,  prior  to  the  Hold-Back  Termination  Date,  the  Parties  shall  withdraw  any  pending
Filing  or  notification  for  Approval  for  the  transfer  of  such  Delayed  Business  under  applicable  Antitrust  Laws  and
Seller Parent may, as mutually agreed by the Parties, dispose of such Delayed Business, including by way of a sale to
a  third  party.  Purchaser  Parent  and  Purchaser  agree  (1)  that  Seller  Parent  and  its  Affiliates  shall  not  have  any
obligation  or  Liability,  including  with  respect  to  indemnification  obligations,  in  respect  of  any  agreements,
arrangements or transactions contemplated by this Section 6.3(e)(iv) for which it is not fully

113

indemnified  by  Purchaser  and  (2)  that  Purchaser  shall  indemnify  Seller  Parent  and  its  Affiliates  for  any  Liabilities
arising from, or attributable or related to, any such agreements, arrangements or transactions, including with respect to
any agreements to which Seller Parent or any of its Affiliates are party (except in the case of (1) and (2) to the extent
Seller Parent is expressly liable for such Liabilities or indemnification pursuant to this Agreement or any Ancillary
Agreement).  Purchaser  shall  promptly  reimburse  Seller  Parent  for  any  and  all  reasonable  and  documented  out-of-
pocket  costs  and  expenses  (including  reasonable  attorneys’  and  other  Representatives’  fees)  incurred  in  connection
with  the  foregoing,  including  any  such  costs  (including  payments)  or  expenses  incurred  or  made  following  the
consummation  of  such  transaction.  Subject  to  applicable  Law,  the  proceeds  of  any  sale  of  a  Delayed  Business  in
accordance  with  this  Section  6.3(e)(iv)  shall  be  paid  directly  to  Purchaser  (or  a  Subsidiary  of  Purchaser)  by  the
purchaser  of  such  Delayed  Business;  provided  that  Seller  Parent  may  require  payment  of  its  reasonable  and
documented  out-of-pocket  fees  and  expenses  (or  an  estimate  thereof)  and  any  Taxes  payable  as  a  result  of  such
transaction from such proceeds as a direct wire transfer of immediately available funds at such applicable closing.

(f)            None  of  Purchaser  Parent,  Purchaser  or  any  of  their  Affiliates  shall,  or  shall  agree  to,  acquire,  whether  by
merging with or into, consolidating with, purchasing all or a portion of the assets of or all or a portion of the equity in, or otherwise,
any  business  or  corporation,  partnership,  or  other  business  organization  or  division  thereof  or  other  Person,  or  dissolve,  merge  or
consolidate  with  any  other  Person,  or  engage  in  any  business  combination  transaction  or  sale,  whether  by  merging  with  or  into,
consolidating with, or selling all or a portion of its or its Affiliates’ assets or equity to, any other Person, or enter into, or agree to
enter into, any license, joint venture or other similar agreement or transaction, which would reasonably be expected to, in each case
or in the aggregate, (i) impose any material delay in the obtaining of, or increase in any material respect the risk of not obtaining, the
expiration, termination or waiver of any applicable waiting period or any consent, approval, permit, ruling, authorization, clearance
or other Approval pursuant to the Antitrust Laws necessary to consummate the transactions contemplated hereby or by the Ancillary
Agreements, (ii) increase in any material respect the risk of any Governmental  Antitrust Authority entering an injunction or other
Governmental  Order  prohibiting  the  consummation  of  the  transactions  contemplated  hereby  or  by  the  Ancillary  Agreements,
(iii) increase in any material respect the risk of not being able to remove any such injunction or other Governmental Order on appeal
or  otherwise,  (iv)  impair,  impede,  hinder,  or  prevent  or  materially  delay  or  adversely  affect  the  consummation  of  the  transactions
contemplated hereby or by the Ancillary Agreements or (v) cause any of the conditions set forth in Article VIII to fail to be satisfied
or  impair,  impede,  hinder,  or  prevent  or  materially  delay  or  adversely  affect  the  ability  of  Purchaser  Parent,  Purchaser  and  their
Affiliates to perform their obligations under this Agreement and the Ancillary Agreements (any foregoing action or transaction, a “
Purchaser Adverse Action ”).

(g)      Neither Seller Parent nor any of its Affiliates shall, or shall agree to, acquire, whether by merging with or into,
consolidating  with,  purchasing  all  or  a  portion  of  the  assets  of  or  all  or  a  portion  of  the  equity  in,  or  otherwise,  any  business  or
corporation, partnership, or other business organization or division thereof or other Person, or dissolve, merge or consolidate with

114

any other Person, or engage in any business combination transaction or sale, whether by merging with or into, consolidating with, or
selling all or a portion of its or its Affiliates’ assets or equity to, any other Person, or enter into, or agree to enter into, any license,
joint  venture  or  other  similar  agreement  or  transaction,  which  would  reasonably  be  expected  to,  in  each  case  or  in  the  aggregate,
(i)  impose  any  material  delay  in  the  obtaining  of,  or  increase  in  any  material  respect  the  risk  of  not  obtaining,  the  expiration,
termination  or  waiver  of  any  applicable  waiting  period  or  any  consent,  approval,  permit,  ruling,  authorization,  clearance  or  other
Approval  pursuant  to  the  Antitrust  Laws  necessary  to  consummate  the  transactions  contemplated  hereby  or  by  the  Ancillary
Agreements, (ii) increase in any material respect the risk of any Governmental  Antitrust Authority entering an injunction or other
Governmental  Order  prohibiting  the  consummation  of  the  transactions  contemplated  hereby  or  by  the  Ancillary  Agreements,
(iii) increase in any material respect the risk of not being able to remove any such injunction or other Governmental Order on appeal
or  otherwise,  (iv)  impair,  impede,  hinder,  or  prevent  or  materially  delay  or  adversely  affect  the  consummation  of  the  transactions
contemplated hereby or by the Ancillary Agreements or (v) cause any of the conditions set forth in Article VIII to fail to be satisfied
or impair, impede, hinder, or prevent or materially delay or adversely affect the ability of Seller Parent and its Affiliates to perform
their obligations under this Agreement and the Ancillary Agreements.

(h)            Each  Party  may,  as  each  deems  advisable  or  necessary,  reasonably  designate  any  competitively  sensitive
material  provided  to  the  other  under  this  Section 6.3 or  otherwise  as  “Antitrust  Counsel  Only  Material”  or  some  similar  notation
agreed by the Parties. Such materials and the information contained therein shall be given only to the internal and outside antitrust
counsel  of  the  recipient  and  will  not  be  disclosed  by  such  counsel  to  employees,  officers  or  directors  of  the  recipient  and  any
economic  consultants  retained  in  connection  with  the  Parties’  obligations  under  this  Section  6.3  unless  express  permission  is
obtained in advance from the source of the materials (Seller Parent, Purchaser Parent or Purchaser, as the case may be) or its legal
counsel. Notwithstanding anything to the contrary in this Section 6.3 , and without limiting the restrictions on access and disclosure
set forth in Section 6.1(a) , materials provided to the other Party or its counsel pursuant to this Agreement may be redacted (i) as
necessary  to  comply  with  contractual  requirements,  (ii)  as  necessary  to  address  attorney-client  or  other  privilege  or  protection  or
confidentiality  concerns  and  (iii)  to  remove  references  concerning  the  valuation  of  the  Purchased  Assets,  the  Business,  or  the
Purchaser Business (or the Retained Businesses or Purchaser Parent Retained Businesses).

(i)      Purchaser shall be responsible for the payment of all filing and other fees owed to any Governmental Authority

in connection with the Filings to be made, and Approvals to be obtained, pursuant to this Section 6.3 .

Section 6.4      Reasonable Best Efforts; Further Assurances .

(a)      Under the terms and subject to the conditions set forth herein, except as otherwise provided in this Agreement
or  any  Ancillary  Agreement  (and  subject  to  Section  6.3  ),  each  of  the  Parties  agrees  to  use  and  to  cause  its  Affiliates  to  use  its
reasonable best efforts before and, as may be applicable, after the Closing Date, until the earlier to occur of (i) thirty-six (36) months
following the Closing Date and (ii) the completion of a Listing Transaction (as defined in the

115

Purchaser Shareholders Agreement), to take or cause to be taken all action, to do or cause to be done, and to assist and cooperate
with the other Parties in doing, all things necessary, proper or advisable under applicable Laws (other than with respect to Antitrust
Laws, which are the subject of Section 6.3, and with respect to the Purchaser Parent Shareholder Approval, which is the subject of
Section 6.24 ) to consummate and make effective, as promptly as practicable, the transactions contemplated by this Agreement and
the Ancillary Agreements, including: (a) the satisfaction of the conditions precedent to the obligations of any of the Parties, (b) the
obtaining  of  all  necessary  actions,  consents,  approvals,  waivers  and  other  Approvals  of  all  Governmental  Authorities  under
applicable Law (other than with respect to Antitrust Laws, which are the subject of Section 6.3, and with respect to the Purchaser
Parent Shareholder Approval, which is the subject of Section 6.24 ), (c) without limiting the obligations of the Parties set forth in
Section 6.3 , the defending of any Action, whether judicial or administrative, challenging this Agreement or the performance of the
obligations  hereunder,  (d)  the  effecting  of  all  registrations,  filings  and  transfers  of  Governmental  Authorizations  (including
Environmental Permits) that constitute Purchased Assets, and the effecting of all registrations, filings and transfers of any licenses,
permits, certificates or other authorizations or approvals which constitute Excluded Assets to be transferred to Seller Parent or any
Retained Subsidiary and (e) the executing, acknowledging and delivering of such documents and instruments and the taking of such
other actions as may reasonably be requested by the other Party in furtherance of the matters described in the foregoing clauses (a)
through (d) ; provided that except as otherwise expressly provided by this Agreement or any Ancillary Implementing  Agreement,
including Section 6.3 , none of Seller Parent, Purchaser Parent or any of their respective Affiliates shall be required to expend any
money,  commence  any  litigation  or  offer  or  grant  any  accommodation  (financial  or  otherwise)  in  connection  with  the  foregoing
(other than filing and other fees owed to any Governmental Authority in connection with any Filings to be made with or Approvals
to be obtained  from  Governmental  Authorities,  for which  Purchaser  shall  be responsible  and shall  reimburse  Seller  Parent  and its
Affiliates).  Purchaser  agrees  to  provide  such  reasonable  security  and  assurances  as  to  financial  capability,  resources  and
creditworthiness as may be reasonably requested by any Governmental Authority whose Approval is sought in connection with the
transactions contemplated hereby.

(b)            Without  limiting  and  in  furtherance  of  the  provisions  of  Section  6.4(a)  ,  and  in  order  to  facilitate  the
consummation  of  the  transactions  contemplated  by  this  Agreement  and  the  Ancillary  Agreements  on  a  timely  basis,  promptly
following the date hereof Seller Parent and Purchaser Parent shall organize a transition team (the “ Transition Team ”), co-chaired by
a representative of Seller Parent and by a representative of Purchaser Parent and including equal representation of Seller Parent and
Purchaser  Parent,  which  Transition  Team  shall,  following  the  Closing,  have  responsibility  for  (A)  coordinating  and  directing  the
efforts of the Parties with respect to (1) the administration and coordination of the Ancillary Agreements following the Closing, (2)
subject to the terms of this Agreement,  including Section 2.2 , Section 6.3 and Section 6.4(a) , the process for seeking applicable
third  party  consents,  Approvals,  and  Governmental  Authorizations  and  making  required  filings  or  notices  in  connection  with  the
consummation of the transactions contemplated hereby, and (3) coordinating and directing the efforts of the Parties with respect to
Shared  Contracts  in  accordance  with  Section  2.2  as  well  as  the  efforts  of  the  Parties  with  respect  to  the  assets  and  liabilities
contemplated by Section 2.2 , (B) coordinating communications, public relations and investor relations strategy and approach of the
Parties regarding this Agreement and

116

the transactions contemplated hereby in accordance with this Agreement, and (C) overseeing other business and operational matters
relating  to  this  Agreement  and  the  transactions  contemplated  hereby  in  accordance  with  this  Agreement,  in  the  case  of  each  of
clauses (A) , (B) and (C) , subject to applicable Laws, including Laws regarding the exchange of information and Antitrust Laws,
and  the  other  provisions  of  this  Agreement,  including  those  regarding  access  and  cooperation  (it  being  understood  that  this
Section 6.4(b) is intended to facilitate the administration of the matters referred to herein and is not intended to expand the scope of
or alter the substantive rights and obligations of the Parties under any other provisions of this Agreement).

(c)            Purchaser  Parent  shall  develop,  in  consultation  with  Seller  Parent,  a  detailed  written  transition  plan  (the  “
Transition Plan ”) which shall set forth integration planning goals, activities and processes with respect to the period from the date
hereof through the Closing Date and the transition activities to be implemented after the Closing Date. The Transition Plan shall also
include reasonably detailed plans in respect of the matters set forth in Section 6.4(c) of the Purchaser Parent Disclosure Letter. The
Parties acknowledge and agree that the Transition Plan shall be prepared for convenience and informational purposes only, shall not
be binding on any Party or its respective Affiliates, and the taking of, or failure to take, any action set forth in the Transition Plan
shall in no event be a condition to the obligations of either Party to consummate the Sale and the other transactions contemplated by
this Agreement.

(d)      Purchaser Parent shall consult in good faith with Seller Parent prior to the Closing regarding (i) the identity of
the initial direct reports to the Chief Executive Officer and to the Chief Financial Officer of Purchaser and (ii) the initial Business
Plan (as defined in the Purchaser Shareholders Agreement), including any updates to any draft Business Plan previously provided, to
be adopted by Purchaser as of the Closing. If, as part of such consultation, Seller Parent wishes to escalate any matter regarding the
foregoing  matters,  it  shall  be  entitled  to  convene,  on  reasonable  notice,  a  meeting  between  the  Chief  Executive  Officers  of  Seller
Parent  and  Purchaser  Parent  to  discuss  such  matters.  In  the  event  any  disagreements  regarding  the  foregoing  matters  cannot  be
resolved by such Chief Executive Officers prior to the Closing, the Chief Executive Officer of Purchaser Parent shall make the final
determination with respect thereto.

Section 6.5      Tax Matters .

(a)      Preparation and Filing of Tax Returns .

(i)      Seller Parent shall prepare or cause to be prepared all (A) Tax Returns that include Seller Parent or any
of its Affiliates (other than any Conveyed Subsidiary or any Subsidiary thereof), on the one hand, and any Conveyed
Subsidiary or Subsidiary thereof, on the other hand (“ Seller Combined Tax Returns ”) and (B) Tax Returns of the
Conveyed Subsidiaries (and their Subsidiaries) for any Pre-Closing Tax Period other than any Straddle Period (“ Pre-
Closing  Separate  Tax  Returns  ”).  All  Pre-Closing  Separate  Tax  Returns  shall,  where  applicable,  be  prepared  in  a
manner consistent with the past practices of the applicable Conveyed Subsidiary (or Subsidiary thereof), other than as
required as a result of the Seller Internal Restructurings and except to the extent that there is not at least a “more likely
than not” basis for a position under applicable Law. In the case of any Pre-Closing

117

Separate  Tax  Return  that  is  required  to  be  filed  after  the  Closing  (taking  into  account  any  applicable  extensions),
Seller Parent shall deliver to Purchaser for its review and comment, at least thirty (30) days, in the case of Income Tax
Returns, and fifteen (15) days, in the case of non-Income Tax Returns, prior to the due date for the filing of such Pre-
Closing  Separate  Tax  Return  (taking  into  account  any  applicable  extensions),  a  draft  copy  of  such  Pre-Closing
Separate Tax Return, together with any additional information that Purchaser may reasonably request. Purchaser shall
have the right to review such Pre-Closing Separate Tax Return and any such additional information prior to the filing
of  such  Pre-Closing  Separate  Tax  Return,  and  Seller  Parent  shall  consider  in  good  faith  any  reasonable  comments
submitted by Purchaser at least fifteen (15) days, in the case of Income Tax Returns, and five (5) days, in the case of
non-Income  Tax  Returns,  prior  to  the  due  date  of  such  Pre-Closing  Separate  Tax  Return  (taking  into  account  any
applicable  extensions).  Purchaser  shall  timely  file  (taking  into  account  any  applicable  extensions),  or  cause  to  be
timely  filed,  such  Pre-Closing  Separate  Tax  Returns  as prepared  by  Seller  Parent  (and  as  may  be  revised  by  Seller
Parent to reflect any comments received from Purchaser pursuant to the immediately preceding sentence), provided
that such Tax Return was delivered to Purchaser at least five (5) days, in the case of Income Tax Returns, and three
(3) days, in the case of non-Income Tax Returns, prior to the due date for filing such Tax Return (taking into account
any  applicable  extensions).  Seller  Parent  shall  timely  file,  or  cause  to  be  timely  filed  (taking  into  account  any
applicable  extensions),  any  Seller  Combined  Tax  Returns  and  any  Pre-Closing  Separate  Tax  Returns  that  are  due
prior to the Closing (taking into account any applicable extensions) and pay any Taxes due on any such Tax Return
and, at least three (3) days before any Pre-Closing Separate Tax Return that is required to be filed after the Closing is
due (taking into account any applicable extensions), shall pay Purchaser (or a Subsidiary of Purchaser designated by
Purchaser) the amount of Taxes shown as due thereon to the extent any such Taxes are Seller Indemnified Taxes for
which Seller Parent is liable pursuant to this Agreement.

(ii)      Other than Tax Returns for which Seller Parent is responsible pursuant to Section 6.5(a)(i) and any Tax
Returns described in Section 6.5(g)(iii) , Purchaser shall prepare and timely file, or cause to be prepared and timely
filed,  all  Tax  Returns  of  the  Conveyed  Subsidiaries  and  their  Subsidiaries  (taking  into  account  any  applicable
extensions). Any such Tax Return required to be filed by Purchaser for a Tax period that includes (but does not end
on) the Closing Date (any such Tax period, a “ Straddle Period, ” and any such Tax Return, a “ Straddle Period Tax
Return  ,”)  and  any  Tax  Return  (or  relevant  portion  thereof)  of  Purchaser  or  any  of  its  Affiliates  (including  the
Conveyed Subsidiaries and their Subsidiaries after the Closing) that includes or reflects (or is required to include or
reflect) Seller Indemnified Taxes for which Seller Parent would reasonably be expected to be liable pursuant to this
Agreement  (any  such  Tax  Return,  or  relevant  portion  thereof,  or  any  Straddle  Period  Tax  Return,  a  “  Seller
Indemnifiable Tax Return ”) shall, where applicable, be prepared (1) in a manner consistent with the past practices of
the applicable Conveyed Subsidiary (or Subsidiary thereof), other than as required as a

118

result of the Seller Internal Restructurings and except to the extent that there is not at least a “more likely than not”
basis for a position under applicable Law or such position would reasonably be expected to result in Purchaser or its
Subsidiaries being liable for any material Taxes that are not Seller Indemnified Taxes for which Seller Parent is liable
pursuant  to  this  Agreement  and  (2)  in  accordance  with  the  terms  of  this  Agreement.  With  respect  to  any  Seller
Indemnifiable Tax Return, Purchaser shall deliver to Seller Parent for its review, comment and approval, at least thirty
(30) days, in the case of Income Tax Returns, and fifteen (15) days, in the case of non-Income Tax Returns, prior to
the due date for the filing of such Seller Indemnifiable Tax Return (taking into account any applicable extensions), a
statement setting forth the amount of Tax for which Seller Parent is responsible pursuant to Section 6.5(d)(i) and a
copy  of  such  Seller  Indemnifiable  Tax  Return,  together  with  any  additional  information  that  Seller  Parent  may
reasonably request. Seller Parent shall have the right to review such Seller Indemnifiable Tax Return, statement and
any additional information prior to the filing of such Seller Indemnifiable Tax Return, and Purchaser shall reflect on
such Seller Indemnifiable Tax Return, as filed, any reasonable comments submitted by Seller Parent at least fifteen
(15) days, in the case of Income Tax Returns, and five (5) days, in the case of non-Income Tax Returns, prior to the
due date of such Seller Indemnifiable Tax Return (taking into account any applicable extensions) to the extent any
such  comments  would  not  be  reasonably  expected  to  result  in  Purchaser  or  its  Subsidiaries  being  liable  for  any
material  Taxes  that  are  not  Seller  Indemnified  Taxes  for  which  Seller  Parent  is  liable  pursuant  to  this  Agreement.
Seller  Parent  shall,  at  least  three  (3)  days  before  any  Tax  Return  that  Purchaser  is  obligated  to  file  under
Section 6.5(a)(ii) is due, pay Purchaser (or a Subsidiary of Purchaser designated by Purchaser) the amount of Taxes
shown as due thereon to the extent any such Taxes are Seller Indemnified Taxes.

(iii)      Neither Purchaser nor any of its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries
after the Closing) shall amend or revoke any Pre-Closing Separate Tax Return or Straddle Period Tax Return, or agree
to any waiver or extension of the statute of limitations, relating to Taxes with respect to any Conveyed Subsidiary (or
any  Subsidiary  thereof)  for  a  Pre-Closing  Tax  Period,  without  the  prior  written  consent  of  Seller  Parent  (which
consent shall not be unreasonably withheld, conditioned or delayed). Upon Seller Parent’s reasonable request, at the
sole cost and expense of Seller Parent, Purchaser shall file, or cause to be filed, any amended Pre-Closing Separate
Tax Return in the form and substance reasonably requested by Seller Parent and in a manner consistent with the past
practices  of  the  applicable  Conveyed  Subsidiary  or  its  Subsidiary  (other  than  as  required  as  a  result  of  the  Seller
Internal  Restructurings),  except  to  the  extent  that  there  is  not  at  least  a  “more  likely  than  not”  basis  for  a  position
under applicable Law, provided that Purchaser shall not be required to file any such amended Tax Return to the extent
it would reasonably be expected to result in Purchaser or its Subsidiaries being liable for any material Taxes that are
not Seller Indemnified Taxes

119

for  which  Seller  Parent  is  liable  pursuant  to  this  Agreement  or  otherwise  result  in  commercial  consequences  that
materially and adversely affect Purchaser.

(iv)      Notwithstanding anything herein to the contrary, this Section 6.5(a) shall not apply to any Tax Returns

in respect of Transfer Taxes described in Section 6.5(j) or any VAT described in Section 6.5(k) .

(b)      Carryforwards and Carrybacks . Purchaser shall cause the Conveyed Subsidiaries and their Subsidiaries, to the
extent permitted by applicable Law, not to carry back into any Pre-Closing Tax Period, and to carry forward into any taxable period
beginning  after the Closing  Date any Tax Asset arising  after the Closing  Date (a “ Subsequent  Loss ”) that could, whether in the
absence of an election or otherwise, be carried back to a Pre-Closing Tax Period. Purchaser shall take, and shall cause its Affiliates
(including the Conveyed  Subsidiaries and their Subsidiaries)  to take, all steps reasonably  necessary to avoid such carry back (and
achieve such carryforward), including by making all necessary elections. If a Subsequent Loss is not permitted by applicable Law to
be carried forward into any taxable period beginning after the Closing Date and is required to be carried back into any Pre-Closing
Tax Period, then after providing notice to Seller Parent of such required carryback, Purchaser and its Subsidiaries shall be entitled to
any  refund  of  Taxes  resulting  from  any  carryback  of  such  Subsequent  Loss  into  any  such  Pre-Closing  Tax  Period;  provided that
Purchaser shall indemnify and hold Seller Parent and its Affiliates harmless from and against any Tax Liability resulting from the
carryback  of  a  Subsequent  Loss  and  any  other  costs  and  expenses  associated  with  or  incurred  in  connection  with  obtaining,
collecting or paying over a refund resulting from such carryback to the extent such carryback of a Subsequent Loss is reflected on a
Seller Combined Tax Return. To the extent any such Subsequent Loss or related refund is subsequently disallowed or required to be
returned by Seller Parent or its Affiliates to a Governmental Authority, Purchaser agrees to promptly repay any amounts previously
paid over by Seller Parent to Purchaser (or its Subsidiaries) in respect of such Subsequent Loss or related refund, together with any
interest, penalties or other additional amounts imposed by such Governmental Authority, to Seller Parent.

(c)      Refunds and Other Tax Benefits .

(i)      Any Loss or Tax that Seller Parent or any of its Affiliates (including the Conveyed Subsidiaries and their
Subsidiaries prior to the Closing), on the one hand, or Purchaser Parent or any of its Affiliates on the other hand, is
responsible  for  under  this  Agreement  (including  pursuant  to  this  Section  6.5  ,  Section  6.6  or  Article  VII  ,  and
including any amounts that are economically borne by Seller Parent or Purchaser Parent, as the case may be, through
an adjustment under Section 2.8 or Section 2.9 ), shall be determined net of any Tax Benefit arising from any Tax
Item in respect of any such Loss or Tax realized in the taxable year of such Loss or Tax or the subsequent two taxable
years. If any such Tax Benefit was not included in the initial computation of such Loss or Tax, the Purchaser shall pay
to Seller Parent or Purchaser Parent, as the case may be, the amount of the applicable Tax Benefit. The amount of any
payment for a Tax Benefit that is due under the prior sentence shall be paid within fifteen (15) days of the filing of the
Tax Return with respect to

120

which the Tax Benefit is actually realized (or, if the Tax Benefit is in the form of an increased cash Tax refund, within
fifteen (15) days of the receipt of such cash Tax refund from the applicable Governmental Authority). To the extent
permitted to be claimed or deducted on a “more likely than not” basis on an applicable relevant Tax Return, Purchaser
shall, and shall cause its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries after the Closing) to
claim any Tax Item in respect of any Loss or Tax described in the first sentence of this Section 6.5(c) resulting in a
Tax Benefit described in this Section 6.5(c) on such Tax Return.

(ii)           Without  duplication  of  amounts  covered  by  Section 6.5(c)(i) ,  Seller  Parent  shall  be  entitled  to  any
refund  or  credit  against  any  Seller  Indemnified  Taxes  for  which  Seller  Parent  is  liable  pursuant  to  this  Agreement
except to the extent any such refund or credit was (A) reflected as an asset on the Final Closing Statement and taken
into account in the calculation of the Final Business Working Capital or Final Business Net Cash (with respect to the
determination  of  Seller  Accrued  Income  Taxes  to  the  extent  offsetting  a  Tax  Liability  in  such  calculation),  (B)  is
described in Section 6.5(b) , or (C) is required to be paid to any other Person pursuant to any Contract entered into
prior to the Closing by a Conveyed Subsidiary or any Subsidiary thereof. Purchaser shall be entitled to any refunds or
credits of or against any Taxes of the Conveyed Subsidiaries (and their Subsidiaries) other than refunds or credits to
which  Seller  Parent  is  entitled  pursuant  to  the  foregoing  sentence.  If  Seller  Parent  determines  that  any  of  the
Conveyed Subsidiaries (or Subsidiaries thereof) is entitled to file or make a formal or informal claim for a refund of
Taxes (including by filing an amended Tax Return) to which Seller Parent would be entitled under this Section 6.5(c)
(ii) , Seller Parent shall be entitled to file or make, or to request that Purchaser or its relevant Affiliate (including the
applicable  Conveyed  Subsidiary  or Subsidiary  thereof)  file  or make,  such formal  or informal  claim  for refund,  and
Seller  Parent  shall  be  entitled  to  control  the  prosecution  of  such  claim  for  refund  as  if  such  claim  was  a  Tax
Proceeding described in Section 6.5(e)(iii) and Seller Parent were the Controlling Party provided , that Seller Parent
shall  not  be  entitled  to  file  or  make,  or  to  request  that  Purchaser  or  its  relevant  Affiliate  (including  the  applicable
Conveyed  Subsidiary  or  Subsidiary  thereof)  file  or  make,  such  formal  or  informal  claim  for  refund  to  the  extent  it
would reasonably be expected to result in Purchaser or its Subsidiaries being liable for any material Taxes that are not
Seller  Indemnified  Taxes  for  which  Seller  Parent  is  responsible  under  this  Agreement  or  otherwise  result  in
consequences  that  materially  and  adversely  affect  Purchaser.  Purchaser  shall  reasonably  cooperate,  and  cause  its
Affiliates (including the Conveyed Subsidiaries and their Subsidiaries after the Closing) to reasonably cooperate, with
respect to any such request by Seller Parent or in any such claim for refund, and shall pay or cause to be paid to Seller
Parent the amount (including interest) of any related refund or credit received by Purchaser or any Affiliate thereof
(including  any  Conveyed  Subsidiary  or  Subsidiary  thereof),  net  of  any  costs,  expenses  and  Taxes  occurred  in
obtaining,  collecting  or  paying  over  such  refund,  credit,  offset  or  other  similar  benefit  within  fifteen  (15)  days  of
receipt  (or  realization)  thereof.  Any  refund  of,  or  credit  against,  Taxes  that  is  received  or  realized  with  respect  to
Taxes attributable to any

121

Conveyed  Subsidiary  (or  Subsidiary  thereof),  the  Purchased  Assets  or  the  Business  for  a  Straddle  Period  shall  be
equitably  apportioned  between  Seller  Parent  and  Purchaser  in  a  manner  consistent  with  the  principles  set  forth  in
Section 6.5(d)(iii) and the first sentence of this Section 6.5(c)(ii) .

(iii)      Without duplication of amounts covered by Section 6.5(c)(i) , Purchaser Parent shall be entitled to any
refund or credit against any Purchaser Parent Indemnified Taxes for which Purchaser Parent is responsible under this
Agreement except to the extent any such refund or credit was (A) reflected as an asset on the Final Closing Statement
and taken into account in the calculation of the Final Purchaser Working Capital or Final Purchaser Net Cash (with
respect  to  the  determination  of  Purchaser  Accrued  Income  Taxes  to  the  extent  offsetting  a  Tax  Liability  in  such
calculation) or (B) required to be paid to any other Person pursuant to any Contract entered into prior to the Closing
by Purchaser or any Subsidiary thereof. Purchaser shall be entitled to any refunds or credits of or against any Taxes of
Purchaser or the Subsidiaries of Purchaser (other than the Conveyed Subsidiaries (and their Subsidiaries)) other than
refunds  or  credits  to  which  Purchaser  Parent  is  entitled  pursuant  to  the  foregoing  sentence.  If  Purchaser  Parent
determines  that  Purchaser  or  any  of  the  Subsidiaries  of  Purchaser  (other  than  the  Conveyed  Subsidiaries  (and  their
Subsidiaries))  is  entitled  to  file  or  make  a  formal  or  informal  claim  for  a  refund  of  Taxes  (including  by  filing  an
amended  Tax  Return)  to  which  Purchaser  Parent  would  be  entitled  under  this  Section 6.5(c)(iii) , Purchaser  Parent
shall  be  entitled  to  file  or  make,  or  to  request  that  Purchaser  or  its  relevant  Affiliate  (including  the  applicable
Subsidiary of Purchaser thereof) file or make, such formal or informal claim for refund, and Purchaser Parent shall be
entitled  to  control  the  prosecution  of  such  claim  for  refund  as  if  such  claim  was  a  Tax  Proceeding  described  in
Section  6.5(e)(iii)  and  Purchaser  Parent  were  the  Controlling  Party;  provided  that  Purchaser  Parent  shall  not  be
entitled  to  file  or  make,  or  to  request  that  Purchaser  or  its  relevant  Affiliate  file  or  make,  such  formal  or  informal
claim for refund to the extent it would reasonably be expected to result in Purchaser or its Subsidiaries being liable for
any material Taxes that are not Purchaser Parent Indemnified Taxes for which Purchaser Parent is responsible under
this  Agreement  or  otherwise  result  in  consequences  that  materially  and  adversely  affect  Purchaser.  Purchaser  shall
reasonably cooperate, and cause its Affiliates to reasonably cooperate, with respect to any such request by Purchaser
Parent or in any such claim for refund, and shall pay or cause to be paid to Purchaser Parent the amount (including
interest)  of  any  related  refund  or  credit  received  or  realized  by  Purchaser  or  any  Affiliate  thereof  (including  any
Conveyed Subsidiary or Subsidiary thereof), net of any costs, expenses and Taxes occurred in obtaining, collecting or
paying over such refund or credit within fifteen (15) days of receipt (or realization) thereof. Any refund of, or credit
against, Taxes that is received or realized with respect to Taxes attributable to Purchaser or its Subsidiaries (other than
the  Conveyed  Subsidiaries  (and  their  Subsidiaries))  for  a  Straddle  Period  shall  be  equitably  apportioned  between
Purchaser Parent and Purchaser in a manner consistent with the principles set forth in Section 6.5(d)(iii) and the first
sentence of this Section 6.5(c)(iii) .

122

(d)      Tax Indemnification .

(i)           Subject to Section 6.5(d)(v) , from  and  after  the Closing,  Seller  Parent  agrees  to  indemnify  and  hold
harmless Purchaser and its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries after the Closing
Date) (collectively, the “ Purchaser Tax Indemnified Parties ”) from and against all liability, without duplication, for
(1) Taxes of the Conveyed Subsidiaries and their Subsidiaries for any Pre-Closing Tax Period (including any Taxes
payable in respect of an election under Section 965(h) of the Code), (2) Taxes of any Seller (other than any Transfer
Taxes and VAT for which Purchaser is responsible hereunder) including, Taxes (other than Taxes of the Conveyed
Subsidiaries and their Subsidiaries) imposed with respect to, arising out of or relating to the Purchased Assets or the
Business  for  a  Pre-Closing  Tax  Period,  (3)  Taxes  of  any  Person  (other  than  the  Conveyed  Subsidiaries  and  their
Subsidiaries) for a Pre-Closing Tax Period for which any Conveyed Subsidiary (or any Subsidiary thereof) is liable
under Treasury Regulation Section 1.1502-6 (or a similar provision of state, local or foreign Law), or as a transferee
or successor or by Contract (other than Contracts that do not relate primarily to Taxes), (4) Taxes arising out of or
resulting  from  any  breach  of  any  covenant  or  agreement  of  Seller  Parent  or  any  of  its  Affiliates  contained  in  this
Agreement, (5) Taxes for a Pre-Closing Tax Period imposed on (x) any transaction effected pursuant to Section 2.3(b)
, (y) any settlement of any intercompany accounts of Seller Parent or its Subsidiaries pursuant to Section 6.7 , or (z)
any transaction or step forming part of the Seller Internal Restructurings, (6) Transfer Taxes for which Seller Parent is
responsible under Section 6.5(j) , (7) Taxes required to be deducted or withheld with respect to the payment of the
Purchase Consideration or any amounts payable to Seller Parent pursuant to Section 2.8 or Section 2.9 , including any
penalties  imposed  on  Purchaser  as  a  result  of  Purchaser’s  failure  to  deduct  or  withhold  any  such  amounts  that
Purchaser (or a Purchaser Designated Affiliate) was permitted to withhold under Section 2.10 (in each case, subject to
Purchaser’s compliance with the notice and cooperation requirements of Section 2.10 and except for any such Taxes
(and any related penalties) required to be deducted or withheld solely as a result of any assignment by Purchaser or its
Affiliates  for  which  Purchaser  is  responsible  pursuant  to  Section 10.3 ),  (8)  Taxes  arising  from  any  breach  of  any
representation or warranty contained in Section 4.16(k) , (9) Taxes arising as a result of any Conveyed Subsidiary or
any Subsidiary of any Conveyed Subsidiary at any time ceasing to be a member of a group for the purposes of any
Tax, of which group Seller Parent or any Subsidiary of Seller Parent is or was also a member and (10) any costs and
expenses,  including  reasonable  legal  and  accounting  fees  and  expenses,  attributable  to  any  item  described  in
clauses  (1)  through  (9)  (any  such  Taxes  for  which  Seller  Parent  is  responsible  pursuant  to  this  Section  6.5(d)(i)  ,
subject to the following proviso, “ Seller Indemnified Taxes ”); provided that Seller Parent shall not be required to
indemnify  or  hold  harmless  any  Purchaser  Tax  Indemnified  Party  from  and  against  any  liability  pursuant  to  this
Section 6.5(d)(i) for  (A)  Taxes  attributable  to  any  action  taken  after  the  Closing  by  Purchaser,  any  of  its  Affiliates
(including the Conveyed Subsidiaries and their Subsidiaries), or any transferee of Purchaser or any of its Affiliates

123

(including  the  Conveyed  Subsidiaries  and  their  Subsidiaries),  other  than  any  such  action  that  (1)  is  in  the  ordinary
course  of  business,  (2)  is  expressly  permitted  or  contemplated  by  this  Agreement,  or  (3)  is  required  to  be  taken  in
order to comply with applicable Law or as a result of a change in applicable Law (a “ Purchaser Tax Act ”), (B) Taxes
that were reflected, accrued or reserved for in the Final Closing Statement, Final Business Working Capital, or Final
Business Net Cash, (C) Income Taxes to the extent that a Conveyed Subsidiary or any Subsidiary thereof had any Tax
Assets as of the close of business on the Closing Date that were available, or would have been available but for their
prior utilization by Purchaser or any of its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries after
the Closing) to offset or otherwise reduce the applicable Tax Liability in respect of such Income Taxes (except any
Tax Asset reflected as an asset in the Final Closing Statement and taken into account in the calculation of the Final
Business Working Capital or the Final Business Net Cash), or (D) Taxes for which Purchaser Parent is responsible
under Section 6.5(d)(ii) .

(ii)          Subject to Section 6.5(d)(v) , from and after the Closing, Purchaser Parent shall indemnify and hold
harmless the Purchaser Tax Indemnified Parties from and against all liability, without duplication, for (1) all Taxes of
Purchaser Parent and its Affiliates (other than Purchaser and its Subsidiaries) for any Tax period (other than Transfer
Taxes and VAT for which Seller Parent is responsible hereunder), (2) Taxes of Purchaser and its Subsidiaries (other
than the Conveyed Subsidiaries and their Subsidiaries) for any Pre-Closing Tax Period, (3) Taxes of any Person for a
Pre-Closing  Tax  Period  for  which  Purchaser  (or  any  Subsidiary  thereof  other  than  any  Conveyed  Subsidiaries  and
their  Subsidiaries)  is  liable  under  Treasury  Regulation  Section  1.1502-6  (or  a  similar  provision  of  state,  local  or
foreign  Law),  or  as  a  transferee  or  successor  or  by  Contract  (other  than  Contracts  that  do  not  relate  primarily  to
Taxes),  (4)  Taxes  arising  out  of  or  resulting  from  any  breach  of  any  covenant  or  agreement  of  Purchaser  Parent,
Purchaser or their respective Affiliates contained in this Agreement, (5) Transfer Taxes for which Purchaser Parent is
responsible  under  Section  6.5(j)  ,  (6)  Taxes  arising  from  any  breach  of  any  representation  or  warranty  in
Section 5.17(k ), (7) Taxes for a Pre-Closing Tax Period imposed on (x) any settlement of any intercompany accounts
of Purchaser or any Subsidiary of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser
Parent (other than Purchaser and its Subsidiaries), on the other hand, pursuant to Section 6.7 or (y) any transaction or
step forming part of the Purchaser Internal Restructurings, (8) Taxes required to be deducted or withheld with respect
to any amounts payable to Purchaser Parent pursuant to Section 2.8 or Section 2.9 , including any penalties imposed
on Purchaser as a result of Purchaser’s failure to deduct or withhold any such amounts, (9) Taxes arising as a result of
Purchaser or any Subsidiary of Purchaser (other than any Conveyed Subsidiary or a Subsidiary thereof) at any time
ceasing to be a member of a group for the purposes of any Tax, of which group Purchaser Parent or any Subsidiary of
Purchaser Parent (other than Purchaser or any Subsidiary of Purchaser) is or was also a member and (10) any costs
and expenses, including reasonable legal and accounting fees and expenses,

124

attributable  to  any  item  described  in  clauses  (1)  through  (9  )  (any  such  Taxes  for  which  Purchaser  Parent  is
responsible pursuant to this Section 6.5(d)(ii) , subject to the following proviso, “ Purchaser Parent Indemnified Taxes
”); provided that Purchaser Parent shall not be required to indemnify or hold harmless any Purchaser Tax Indemnified
Party from and against any liability for (A) Taxes attributable to any action taken after the Closing by Seller Parent or
any of its Affiliates, other than any such action that (1) is in the ordinary course of business, (2) is expressly permitted
or  contemplated  by  this  Agreement,  or  (3)  is  required  to  be  taken  in  order  to  comply  with  applicable  Law  or  as  a
result of a change in applicable Law (a “ Seller Tax Act ”), (B) Taxes that were reflected, accrued or reserved for in
the Final Closing Statement, Final Purchaser Working Capital or the Final Purchaser Net Cash, (C) Income Taxes to
the extent that Purchaser or any Subsidiary thereof had any Tax Assets as of the close of business on the Closing Date
that were available, or would have been available but for their prior utilization by Purchaser or any of its Affiliates
(including  the  Conveyed  Subsidiaries  and  their  Subsidiaries  after  the  Closing),  to  offset  or  otherwise  reduce  the
applicable  Tax  Liability  in  respect  of  such  Income  Taxes  (except  any  Tax  Asset  reflected  as  an  asset  in  the  Final
Closing  Statement  and  taken  into  account  in  the  calculation  of  the  Final  Purchaser  Working  Capital  or  the  Final
Purchaser Net Cash), or (D) Taxes for which Seller Parent is responsible under Section 6.5(d)(i) .

(iii)            To  the  extent  permitted  or  required  by  applicable  Law,  the  taxable  year  of  each  of  the  Conveyed
Subsidiaries and their Subsidiaries and any Subsidiary of Purchaser that includes the Closing Date shall be treated as
closing on (and including) the Closing Date. Otherwise, for purposes of this Agreement, in the case of any Straddle
Period:

(A)      Property Taxes allocable to the Pre-Closing Tax Period shall be computed based upon the ratio of the

number of days in the Pre-Closing Tax Period to the number of days in the entire Straddle Period; and

(B)      Taxes (other than Property Taxes) allocable to the Pre-Closing Tax Period shall be computed as if such
Tax  period  ended  as  of  the  close  of  business  on  the  Closing  Date  and,  in  the  case  of  any  Taxes  of  Conveyed
Subsidiaries (and their Subsidiaries) and Seller Parent, or in the case of any Taxes of Purchaser Parent and Purchaser
(and their Subsidiaries prior to the Closing), in each case attributable to the ownership of any equity interest in any
partnership  or  other  “flow  through”  entity  for  tax  purposes  (including  of  any  “controlled  foreign  corporation,”  as
defined under the Code) as if the Tax period of such partnership or other “flow through” entity ended as of the close
of business on the Closing Date with the Taxes of such entity for the Pre-Closing Tax Period deemed to include any
Taxes on the allocable income of such entity in respect of such Tax period; provided that exemptions, allowances or
deductions  that  are  calculated  on  an  annual  basis  (including  depreciation  and  amortization  deductions)  shall  be
allocated between the period ending on the Closing

125

Date and the period beginning after the Closing Date in proportion to the number of days in each period.

(iv)      Any claim for indemnification under this Section 6.5(d) shall be made in writing upon the party from
whom  indemnification  is  sought,  and  shall  specify  in  reasonable  detail  the  basis  for  such  claim.  Any  indemnity
payment  required  to  be  made  pursuant  to  this  Section  6.5(d)  shall  be  made  within  thirty  (30)  days  after  the
indemnified party makes written demand upon the indemnifying party, but in no case earlier than five (5) Business
Days prior to the date on which the relevant Taxes are required to be paid to the applicable Taxing Authority.

(v)      With respect to any Taxes suffered or incurred by any Conveyed Subsidiary (or any Subsidiary thereof)
that  was  not  wholly  owned  by  Seller  Parent  (directly  or  indirectly)  as  of  immediately  prior  to  the  Closing,  the
indemnification obligations of Seller Parent pursuant to Section 6.5(d)(i) in respect of such Taxes (or related costs and
expenses) shall in no event exceed an amount equal to (A) the amount of such Taxes (or related costs and expenses)
for  which  the  Purchaser  Tax  Indemnified  Parties  would  otherwise  be  entitled  to  indemnification  pursuant  to
Section  6.5(d)  ,  as  if  such  Conveyed  Subsidiary  (or  any  Subsidiary  thereof)  were  wholly  owned  by  Seller  Parent,
multiplied
by
 (B)  the  direct  and  indirect  percentage  ownership  of  Seller  Parent  of  such  Conveyed  Subsidiary  (or
Subsidiary  thereof)  as  of  immediately  prior  to  the  Closing.  With  respect  to  any  Taxes  suffered  or  incurred  by  any
Subsidiary  of  Purchaser  Parent  (including  Purchaser  and  its  Subsidiaries)  that  was  not  wholly  owned  by  Purchaser
Parent  (directly  or  indirectly)  as  of  immediately  prior  to  the  Closing,  the  indemnification  obligations  of  Purchaser
Parent pursuant to Section 6.5(d)(ii) in respect of such Taxes (or related costs and expenses) shall in no event exceed
an  amount  equal  to  (A)  the  amount  of  such  Taxes  (or  related  costs  and  expenses)  for  which  the  Purchaser  Tax
Indemnified Parties would otherwise be entitled to indemnification pursuant to Section 6.5(d) , as if such Subsidiary
were wholly owned by Purchaser Parent, multiplied
by
(B) the direct and indirect percentage ownership of Purchaser
Parent of such Subsidiary as of immediately prior to the Closing.

(vi)      Without duplication to any other amounts paid pursuant to this Section 6.5:

(A)      Within thirty (30) days following the filing of any Income Tax Return for any Conveyed Subsidiary (or
any  Subsidiary  thereof),  on  the  one  hand,  or  Purchaser  (or  any  Subsidiary  thereof,  other  than  the  Conveyed
Subsidiaries  and  their  Subsidiaries),  on  the  other  hand,  for  any  Pre-Closing  Tax  Period  or  for  any  Straddle  Period,
Seller Parent or Purchaser Parent shall (or Purchaser Parent shall cause Purchaser to) prepare a statement showing (i)
the amount of Income Taxes shown as due on such filed Income Tax Return with respect to the relevant Pre-Closing
Tax Period or the portion of any Straddle Period ending on and including the Closing Date (the “ Final Pre-Closing
Income Tax Amount ”) and (ii) the amount of the Seller

126

Accrued Income Taxes or Purchaser Accrued Income Taxes, as applicable, attributable to such Income Tax Return as
reflected  on  the  Final  Closing  Statement  (the  “  Pre-Closing  Income  Tax  Amount  ”)  and  deliver  such  statement  to
Seller Parent and Purchaser Parent, as applicable. Purchaser Parent or Seller Parent, as applicable, shall have a period
of fifteen (15) Business Days to provide comments to a schedule prepared (or caused to be prepared) by Seller Parent
or Purchaser Parent, respectively. If Purchaser Parent or Seller Parent, as applicable, do not provide any comments to
Seller  Parent  or  Purchaser  Parent,  respectively,  during  such  period,  the  statement  as  so  prepared  shall  be  final  and
binding.

(B)      In the event the Final Pre-Closing Income Tax Amount with respect to any Income Tax Return is less
than the amount of the Pre-Closing Income Tax Amount attributable to such Income Tax Return that was included on
the Final Closing Statement, the Purchaser shall within five (5) Business Days following the finalization of the Final
Pre-Closing Income Tax Amount hereunder (i) pay to Seller Parent the amount of such difference with respect to a
Conveyed  Subsidiary  and  their  Subsidiaries  and  (ii)  pay  to  Purchaser  Parent  the  amount  of  such  difference  with
respect to Purchaser and its Subsidiaries.

(vii)      The Parties shall use reasonable best efforts to structure any indemnity payment, true-up payment, or
payment in respect of Tax Benefits made by any Party pursuant to this Agreement (including pursuant to this Section
6.5 , Section 6.6 and Article VII ) and any payment made by Purchaser Parent to Purchaser pursuant to Section 2.8 or
Section 2.9 in the manner set forth in Clause 10 of the Structuring Considerations Agreement. The Parties shall use
reasonable best efforts to structure as a special dividend any payment made by Purchaser to Purchaser Parent pursuant
to Section 2.8 , Section 2.9 or this Section 6.5 .

(e)      Tax Contests .

(i)            If  a  claim  shall  be  made  by  any  Taxing  Authority  (a  “  Tax  Claim  ”)  which,  if  successful,  would
reasonably  be  expected  to  result  in  an  indemnity  payment  pursuant  to  Section  6.5(d)  ,  the  indemnified  party  shall
promptly notify the indemnifying party in writing of such claim (and provide copies of any documents received from
the Taxing Authority in respect of such claim); provided that the failure to provide such notice shall not relieve the
indemnifying  party  of  its  indemnification  obligations  hereunder  except  to  the  extent  the  indemnifying  party  is
prejudiced thereby and expenses are incurred during the period in which notice was not provided. Such notice shall
specify  in  reasonable  detail  the  basis  for  such  Tax  Claim  and  shall  include  a  copy  of  the  relevant  portion  of  any
correspondence received from the Taxing Authority.

(ii)      With respect to any Tax Claim relating to a Conveyed Subsidiary (or any Subsidiary thereof) for any
Tax period ending on or before the Closing Date, to Seller Parent (or any Subsidiary thereof) for any taxable period,
or with respect to, a Seller Combined Tax Return, Seller Parent shall control all Tax Proceedings and

127

shall make all decisions taken in connection with such Tax Proceeding (including selection of counsel), and, without
limiting  the  foregoing,  may  pursue  or  forego  any  and  all  administrative  appeals,  proceedings,  hearings  and
conferences with any Taxing Authority with respect thereto, and may either pay the applicable Tax Liability and sue
for a refund or contest the Tax Claim; provided , that in the case of such Tax Proceeding with respect to a Tax Return
of a Conveyed Subsidiary (or any Subsidiary thereof) other than a Seller Combined Tax Return, Seller Parent shall
not settle such Tax Proceeding if doing so would reasonably be expected to materially increase the Tax Liability of
Purchaser  or  its  Subsidiaries  (including  the  Conveyed  Subsidiaries  and  any  Subsidiary  thereof  after  the  Closing),
taking into account any indemnification for Tax Liabilities under this Agreement, without the prior written consent of
Purchaser,  which  consent  shall  not  be  unreasonably  withheld,  delayed  or  conditioned.  In  the  case  of  any  such  Tax
Proceeding with respect to a Conveyed Subsidiary (or a Subsidiary thereof), Seller Parent shall (x) notify Purchaser of
any material development with respect to any such Tax Proceeding, (y) provide Purchaser with copies of any material
documents submitted in connection with such Tax Proceeding and (z) notify Purchaser regarding any material action
to be taken by Seller Parent with respect to such Tax Proceeding (and take Purchaser’s comments into consideration
in  good  faith),  in  each  case,  solely  to  the  extent  relating  to  matters  or  aspects  of  such  Tax  Proceeding  that  would
reasonably be expected to materially increase the Tax Liability of a Conveyed Subsidiary (or a Subsidiary thereof) in
a Post-Closing Tax Period.

(iii)            In  the  case  of  any  Tax  Proceeding  relating  to  Taxes  of  the  Conveyed  Subsidiaries  (and  their
Subsidiaries) for any Straddle Period, the Controlling Party shall have the right and obligation to conduct such Tax
Proceeding;  provided  that  the  Controlling  Party  shall  (u)  notify  the  Non-Controlling  Party  of  any  material
development with respect to such Tax Proceeding, (v) provide the Non-Controlling Party with copies of any material
documents  submitted  in  connection  with  such  Tax  Proceeding,  (w)  consult  with  the  Non-Controlling  Party  before
submitting  any  written  materials  or  taking  any  significant  action  in  connection  with  the  conduct  of  such  Tax
Proceeding, (x) provide, to the extent possible, for the Non-Controlling Party to participate in such Tax Proceeding at
its  own  expense,  (y)  defend  such  Tax  Proceeding  diligently  and  in  good  faith,  and  (z)  not  settle  any  such  Tax
Proceeding if doing so would reasonably be expected to materially increase the Tax Liability of the Non-Controlling
Party or its Affiliates (taking into account any indemnification for Tax Liabilities under this Agreement), without the
prior  written  consent  of  the  Non-Controlling  Party,  which  consent  shall  not  be  unreasonably  withheld,  delayed  or
conditioned. For purposes of this Agreement, “ Controlling Party ” shall mean Seller Parent if Seller Parent and its
Affiliates  are  reasonably  expected  to  bear  the  greater  Tax  Liability  in  connection  with  such  Tax  Proceeding,  or
Purchaser if Purchaser and its Affiliates are reasonably expected to bear the greater Tax Liability in connection with
such  Tax  Proceeding;  and  “  Non-Controlling  Party  ”  means  whichever  of  Seller  Parent  or  Purchaser  is  not  the
Controlling Party with respect to such Tax Proceeding.

128

(iv)      Except as otherwise provided herein, Purchaser shall control all Tax Proceedings with respect to the
Conveyed Subsidiaries (and their Subsidiaries) for any taxable period beginning after the Closing Date and any Tax
Proceeding with respect to Purchaser or any of its Affiliates relating to any Seller Indemnifiable Tax Return; provided
that Seller Parent shall be deemed to be a Non-Controlling Party (with the rights described in Section 6.5(e)(iii) ) with
respect  to  any  such  Tax  Proceeding  if  the  resolution  of  any  such  Tax  Proceeding  would  reasonably  be  expected  to
materially increase the Tax Liability of a Conveyed Subsidiary (or a Subsidiary thereof) in a Pre-Closing Tax Period
or the amount of indemnification for which Seller Parent is responsible pursuant to Section 6.5(d)(i) .

(v)      Purchaser, the Conveyed Subsidiaries and each of their respective Affiliates, on the one hand, and Seller
Parent  and  its  Affiliates,  on  the  other  hand,  shall  cooperate  in  contesting  any  Tax  Claim,  which  cooperation  shall
include  the  retention  and,  upon  request,  the  provision  to the  requesting  Party  of  records  and information  which  are
reasonably relevant to such Tax Claim, and making employees available on a mutually convenient basis to provide
additional  information  or  explanation  of  any  material  provided  hereunder  or  to  testify  at  related  Tax  Proceedings.
Purchaser Parent and Seller Parent and their applicable Affiliates shall execute and deliver such powers of attorney
and  other  documents  as  are  necessary  to  carry  out  the  intent  of  this  Section  6.5(e)(v)  .  Notwithstanding  anything
herein  to  the  contrary,  (A)  Seller  Parent  shall  not  be  required  to  provide  Purchaser  or  its  Affiliates  with  a  copy,  or
otherwise  disclose  the  contents,  of  any  Seller  Combined  Tax  Return  (except  to  the  extent  such  information  relates
solely to a Conveyed Subsidiary or its Subsidiaries), (B) Seller Parent shall have the exclusive right to control in all
respects,  and neither  Purchaser  nor  any  of its Affiliates  shall  be entitled  to participate  in, any Tax  Proceeding  with
respect  to  any  Tax  Return  of  Seller  Parent  or  any  of  its  Affiliates  or  any  Seller  Combined  Tax  Return,  and
(C)  Purchaser  Parent  shall  not  be  required  to  provide  Seller  Parent,  Purchaser  or  its  Affiliates  with  a  copy,  or
otherwise disclose the contents, of any Tax Return that includes Purchaser Parent or any of its Affiliates (other than
Purchaser  and  any  Subsidiary  thereof),  on  the  one  hand,  and  Purchaser  and  any  Subsidiary  thereof  (other  than  any
Conveyed  Subsidiary  or  Subsidiary  thereof),  on  the  other  hand  (“  Purchaser  Parent  Combined  Tax  Returns  ”) and
Purchaser  Parent  shall  have  the  exclusive  right  to  control  in  all  respects,  and  neither  Seller  Parent  nor  any  of  its
Affiliates shall be entitled to participate in, any Tax Proceeding with respect to any Purchaser Parent Combined Tax
Return.

(f)      Internal Restructurings .

(i)      Notwithstanding anything herein to the contrary, but subject to Section 2.2 , Section 6.3 and Section 6.4 ,
Seller Parent shall, at its sole cost and expense, effective from a date on or prior to the Closing Date, implement the
transactions necessary to deliver on the Closing Date the Business and the Purchased Assets in a manner consistent
with Section 6.5(f) of the Seller Disclosure  Letter (such transactions,  as finally described  in the Seller Parent Final
Plan (as defined below),

129

the “ Seller Internal Restructurings ”); provided that within seventy-five  (75) days of the date hereof, Seller Parent
shall deliver to Purchaser Parent for Purchaser Parent’s review and reasonable comment an initial draft of a step plan
(the “ Seller Parent Preliminary Plan ”) setting forth the steps Seller Parent shall undertake to effect the Seller Internal
Restructurings;  provided  ,  further  ,  that  Seller  Parent  shall  (x)  consider  in  good  faith  any  reasonable  amendments,
modifications or supplements to the Seller Parent Preliminary Plan proposed by Purchaser Parent and Purchaser and
(y)  shall,  to  the  extent  consistent  with  the  principles  set  forth  in  Section  6.5(f)  of  the  Seller  Disclosure  Letter,
incorporate the input of Purchaser Parent and Purchaser on the Seller Parent Preliminary Plan (including the timing,
structure and other details of such transactions). Subject to the finalization of the Seller Parent Final Plan pursuant to
Section  6.5(f)(iii),  at least  twenty  (20)  Business  Days  prior  to  the  Closing,  Seller  Parent  shall  provide  to  Purchaser
Parent  a  list  of  the  U.S.  federal  tax  classification  elections  for  each  of  the  Conveyed  Subsidiaries  and  Subsidiaries
thereof as of the Closing, which list shall be true, correct and complete in all material respects and consistent with the
Seller Parent Final Plan.

(ii)      Notwithstanding anything herein to the contrary, but subject to Section 2.2 , Section 6.3 and Section 6.4,
Purchaser Parent shall, at its sole cost and expense, effective from a date on or prior to the Closing Date and Section
6.3(e) ),  implement  the  transactions  necessary  to  deliver  on  the  Closing  Date  any  assets  of  Purchaser  Parent  or  its
Affiliates (other than Purchaser and its Subsidiaries  and except for any assets and/or employees based in France  or
employed by any French Affiliate of Purchaser Parent ) transferred to Purchaser or its Subsidiaries in connection with
the transactions described herein in a manner consistent with Section 6.5(f) of the Purchaser Parent Disclosure Letter
(such transactions, as finally described in the Purchaser Parent Final Plan (as defined below), the “ Purchaser Internal
Restructurings ”); provided that  within  seventy-five  (75)  days  of  the  date  hereof,  Purchaser  Parent  shall  deliver  to
Seller  Parent  an initial  draft  of a step plan (the  “ Purchaser  Parent Preliminary  Plan ”, and together with the Seller
Parent Preliminary Plan, the “ Preliminary Plans ”) setting forth steps Purchaser Parent shall undertake to effect the
Purchaser  Internal  Restructurings  for  Seller  Parent’s  review  and  reasonable  comment;  provided  ,  further  ,  that
Purchaser  Parent  shall  (x)  consider  in  good  faith  any  reasonable  amendments,  modifications  or  supplements  to  the
Purchaser Parent Preliminary Plan proposed by Seller Parent and (y) Purchaser Parent shall, to the extent consistent
with the principles set forth in Section 6.5(f) of the Purchaser Parent Disclosure Letter, incorporate the input of Seller
Parent  on  the  Purchaser  Parent  Preliminary  Plan  (including  the  timing,  structure  and  other  details  of  such
transactions).  Subject  to  the  finalization  of  the  Purchaser  Parent  Final  Plan  pursuant  to  Section  6.5(f)(iv),  at  least
twenty  (20)  Business  Days  prior  to  the  Closing,  Purchaser  Parent  shall  provide  to  Seller  Parent  a  list  of  the  U.S.
federal tax classification elections for each of Purchaser and its Subsidiaries as of the Closing, which list shall be true,
correct and complete in all material respects and consistent with the Purchaser Parent Final Plan.

130

(iii)            Following  the  delivery  of  the  Seller  Parent  Preliminary  Plan,  any  amendments,  modifications  or
supplements to the Seller Parent Preliminary Plan reasonably proposed by Seller Parent shall be considered in good
faith  by  Purchaser  Parent,  and  the  Parties  shall  negotiate  in  good  faith  regarding  any  such  proposed  amendments,
modifications or supplements to which Purchaser Parent objects. Purchaser Parent’s approval shall be required before
the  Seller  Parent  Preliminary  Plan  becomes  final  (such  approval  not  to  be  unreasonably,  withheld,  conditioned  or
delayed) (such plan, once finalized pursuant to this Section 6.5(f) , the “ Seller Parent Final Plan ”). For the avoidance
of doubt, if no amendments, modifications or supplements are reasonably proposed by Purchaser Parent following the
delivery of the Seller Parent Preliminary Plan, the Seller Parent Preliminary Plan shall be the Seller Parent Final Plan.

(iv)          Following the delivery of the Purchaser Parent Preliminary Plan, any amendments, modifications or
supplements to the Purchaser Parent Preliminary Plan reasonably proposed by Purchaser Parent shall be considered in
good faith by Seller Parent, and the Parties shall negotiate in good faith regarding any such proposed amendments,
modifications  or  supplements  to  which  Seller  Parent  objects.  Seller  Parent’s  approval  shall  be  required  before  the
Purchaser  Parent  Preliminary  Plan  becomes  final  (such  approval  not  to  be  unreasonably,  withheld,  conditioned  or
delayed)  (such  plan,  once  finalized  pursuant  to  this  Section  6.5(f)  ,  the  “  Purchaser  Parent  Final  Plan  ”).  For  the
avoidance  of  doubt,  if  no  amendments,  modifications  or  supplements  are  reasonably  proposed  by  Seller  Parent
following the delivery of the Purchaser Parent Preliminary Plan, the Purchaser Parent Preliminary Plan shall be the
Purchaser Parent Final Plan.

(v)            Seller  Parent  and  Purchaser  Parent  each  shall,  when  proposing  amendments,  modifications  and
supplements to the Preliminary Plans and when reviewing and considering such proposed amendments, modifications
and supplements for their respective approval, act reasonably and in good faith consistent with the principles set forth
in Section 6.5(f) of the Seller Disclosure Letter.

(g)      Certain Tax Elections and Post-Closing Actions .

(i)            Purchaser  shall  not,  and  shall  cause  its  Affiliates  (including  the  Conveyed  Subsidiaries  and  their
Subsidiaries)  not  to,  take  any  action  on  the  Closing  Date  (after  the  Closing)  other  than  in  the  ordinary  course  of
business with respect to the Purchased Assets, the Assumed Liabilities, the Business or any Conveyed Subsidiaries or
Subsidiaries thereof, except as expressly contemplated herein.

(ii)      With respect to any Conveyed Subsidiary (or Subsidiary thereof), Purchaser shall not (A) make or cause
or permit to be made an election under Section 338(g) of the Code (or any similar election permitted under state, local
or foreign Law), (B) make or cause or permit to be made any election (including any election pursuant to Treasury
Regulation Section 301.7701-3) that would be effective

131

on or prior to the Closing Date or otherwise have retroactive effect with respect to a Pre-Closing Tax Period.

(iii)

(A)            Prior  to  the  Closing,  an  Affiliate(s)  of  Seller  Parent  shall  transfer  the  equity  interests  in  Wyeth
Pharmaceutical  Co.  Ltd  and  Treerly  Health  Co.  Ltd  (the  “ China Entities ”) to  an Affiliate  (or Affiliates)  of Seller
Parent  in  a  direct  equity  transfer  (the  “  Direct  Transfers  ”)  that  is  intended  to  be  fully  taxable  for  Chinese  Tax
purposes. Seller Parent or an applicable Affiliate shall timely pay any Chinese Taxes attributable to any such Direct
Transfer, based on a third-party valuation by an independent PRC licensed appraiser of Seller Parent's choosing, to
the  appropriate  PRC  Taxing  Authority  and  file  any  applicable  Tax  Returns  with  the  appropriate  PRC  Taxing
Authority.  The applicable  Seller(s)  shall, within five (5) business days in China after (i) the filing of any such Tax
Returns, deliver to Purchaser  complete copies of such Tax Returns and (ii) the tax receipts(s) are issued by the tax
bureau(s),  provide  Purchaser  with  complete  copies  of  such  tax  receipt(s).  Any  such  Taxes  shall  be  the  sole
responsibility of Seller Parent or the applicable Affiliate and subject to Section 6.5(d)(i) .

(B)      Following the Direct Transfers, Seller Parent shall effect, through Local Implementing Agreements, the
indirect transfer of the China Entities to the Purchaser (the “ Indirect Transfers ”). Within thirty (30) days following
the Indirect Transfers, Seller Parent or the applicable Affiliate shall voluntarily file (whether in one or more filings),
on  behalf  of  the  applicable  Seller(s)  and  Purchaser  (or  the  applicable  Purchaser  Designated  Affiliate),  the
documentation required by Circular – SAT Notice [2015] 7 (“ Notice 7 ”) as a result of the Indirect Transfers, and any
related transfers, with the applicable PRC Taxing Authority. Seller Parent or the applicable Affiliate shall, within five
(5)  Business  Days  after  the  submission  of  such  Notice  7  filing(s),  deliver  to  Purchaser  complete  copies  of  any
applicable Notice 7 filing(s) and, if provided, an acknowledgement of receipt of such Notice 7 filing(s) issued by the
applicable  PRC  Taxing  Authority.  Seller  Parent  or  the  applicable  Affiliate  shall,  in  its  sole  discretion,  control  all
communications relating to the Indirect Transfers and such Notice 7 filing(s) with the relevant PRC Taxing Authority
and  shall  keep  Purchaser  reasonably  informed  of  the  progress  of  such  communications  (including  by  providing  to
Purchaser copies of all material reporting and filings relating to the Indirect Transfers and the Notice 7 filing(s)). If
Seller  Parent  or  the  applicable  Affiliate  has  fully  complied  with  its  obligations  pursuant  to  this Section 6.5(g)(iii) ,
then  Purchaser  (and  its  Affiliates)  shall  not  communicate  with  or  make  any  reporting  to  a  PRC  Taxing  Authority
regarding  the  Indirect  Transfers  or  the  Notice  7  filing(s),  except  in  agreement  with  Seller  Parent  or  the  applicable
Affiliate.  Purchaser  shall  notify  the  applicable  Seller(s)  promptly,  but  in  any  event  not  later  than  five  (5)  Business
Days  after  receipt,  of  any  queries  or  requests  by  any  PRC  Taxing  Authority  related  to  the  transfer  of  the  China
Entities to the Purchaser.

132

(C)            If  the  Indirect  Transfers  are  determined  to  be  taxable  transactions  in  China,  Seller  Parent  or  the
applicable  Affiliate  shall  timely  pay  any  additional  China  Taxes  attributable  to  the  Indirect  Transfers  to  the
appropriate PRC Taxing Authority and file any applicable Tax Returns with the appropriate PRC Taxing Authority.
Any  such  Taxes  shall  be  the  sole  responsibility  of  Seller  Parent  or  the  applicable  Affiliate  and  subject  to  Section
6.5(d)(i) .

(D)      Absent a change in Law after the date hereof and subject to compliance with Clauses (A) through (C) of
this  Section  6.5(g)(iii)  ,  Purchaser  Parent  acknowledges  and  agrees  that,  notwithstanding  anything  herein  to  the
contrary,  it shall not, and it shall cause its Affiliates  not to, withhold  any amount with respect to Chinese Taxes in
respect of the payment of the Purchase Consideration or any amounts payable to Seller Parent pursuant to Section 2.8
or  Section  2.9  herein  (nor  reflect  any  such  amount  in  the  Final  Closing  Statement  or  take  any  such  amount  into
account in the calculation of the Final Business Working Capital or the Final Business Net Cash).

(h)      Tax Sharing Agreements . All Tax sharing agreements and arrangements between (i) any Conveyed Subsidiary
or Subsidiary thereof, on the one hand, and Seller Parent or any of its Affiliates (other than any Conveyed Subsidiary or Subsidiary
thereof),  on  the  other  hand,  and  (ii)  Purchaser  or  any  Subsidiary  of  Purchaser,  on  the  one  hand,  and  Purchaser  Parent  or  any
Subsidiary  of  Purchaser  Parent  (other  than  Purchaser  and  its  Subsidiaries),  on  the  other  hand,  shall  be  terminated  effective  at  or
before the Closing and shall have no further effect for any Tax period (whether past, present or future) and, after the Closing Date,
neither Seller Parent nor any of its Affiliates, nor Purchaser nor any of its Affiliates, shall have any rights or obligations thereunder,
and  no  additional  payments  shall  be  made  thereunder  with  respect  to  any  Tax  period,  whether  in  respect  of  a  redetermination  of
Liabilities for Taxes or otherwise.

(i)      Cooperation . Each of Purchaser and Seller Parent shall (and shall cause their respective Affiliates to) provide
the other with such cooperation, information and records, and make such of its officers, directors, employees and agents available, as
may reasonably be requested by the other Party in connection with the preparation or filing of any Tax Return, determining a liability
for Taxes or payment under this Section 6.5 , conducting any Tax Proceeding and the matters described in Section 6.5(f) of the Seller
Disclosure Letter and Section 6.5(f) of the Purchaser Parent Disclosure Letter. Each of Purchaser and Seller Parent shall, within the
earlier  to  occur  of  one  hundred  twenty  (120)  days  after  the  Closing  Date  and  forty-five  (45)  days  prior  to  the  due  date  for  a  Tax
Return requiring such information (or as promptly as practicable to the extent any Tax Return is due within forty-five (45) days after
the  Closing  Date),  provide  the  other  with  Tax  information  materials,  including  schedules  and  work  papers  (including  any
information reasonably necessary to compile applicable transfer pricing documentation), prepared in a manner consistent with the
Conveyed  Subsidiaries’  (and  their  Subsidiaries’)  past  practices,  as  requested  by  one  another  to  enable  one  another  to  prepare,  or
cause to be prepared, all Tax Returns that each Party is obligated to prepare, or cause to be prepared, pursuant to Section 6.5(a)(i) or
Section 6.5(a)(ii) , as applicable. Notwithstanding anything in this Agreement to the contrary, (i) Seller Parent shall not be required
to provide Purchaser Parent or Purchaser, or any of their respective Affiliates, with a copy of, or

133

otherwise disclose the contents of, any Seller Combined Tax Return ( provided that Seller Parent shall extract information therein
and provide such information to Purchaser hereunder to the extent such information relates solely to a Conveyed Subsidiary or its
Subsidiaries),  and  (ii)  Purchaser  Parent  shall  not  be  required  to  provide  Seller  Parent  or  any  of  its  Affiliates  with  a  copy  of,  or
otherwise disclose the contents of, any Purchaser Parent Combined Tax Return. Each Party shall retain (and cause to be retained) all
Tax  Returns,  schedules  and  work  papers,  and  all  material  records  and  other  documents  relating  to  Tax  matters,  of  the  Conveyed
Subsidiaries and their Subsidiaries for the Pre-Closing Tax Period until the expiration of the statute of limitations for the Tax periods
to which the Tax Returns and other documents relate.

(j)      Transfer Taxes . Notwithstanding anything to the contrary in this Agreement, Seller Parent shall be responsible
for half of, and Purchaser Parent shall be responsible for half of, any Transfer Taxes imposed on the transfer of the Purchased Assets
and  Assumed  Liabilities  to  Purchaser  (or  a  Purchaser  Designated  Affiliate)  and  the  costs  of  preparing  and  filing  Tax  Returns  in
respect  of  any  such  Transfer  Taxes.  The  Party  responsible  under  applicable  Law  for  filing  Tax  Returns  with  respect  to  Transfer
Taxes  shall  prepare  and  timely  file  such  Tax  Returns.  Seller  Parent  and  Purchaser  Parent  shall,  and  shall  cause  their  respective
Affiliates to, reasonably cooperate to timely prepare and file any Tax Returns or other filings relating to such Transfer Taxes and to
minimize any such Transfer Taxes. For clarity, this Section 6.5(j) does not apply to any Transfer Taxes imposed on any transaction
or  step  forming  part  of  the  Seller  Internal  Restructurings  or  the  Purchaser  Internal  Restructurings.  Seller  Parent  shall  be  solely
responsible for any Transfer Taxes imposed on any transaction or step forming part of the Seller Internal Restructurings and the costs
of preparing and filing any Tax Returns in respect of any such Transfer Taxes and Purchaser Parent shall be solely responsible for
any  Transfer  Taxes  imposed  on  any  transaction  or  step  forming  part  of  the  Purchaser  Internal  Restructurings  and  the  costs  of
preparing and filing any Tax Returns in respect of any such Transfer Taxes.

(k)      VAT .

(i)      Subject to Section 6.5(k)(ii) , all payments made pursuant to this Agreement are exclusive of VAT. Any
VAT imposed on the transfers of the Purchased Assets and Assumed Liabilities to Purchaser (or any of the Purchaser
Designated Affiliates) shall be charged to Purchaser (or the relevant Purchaser Designated Affiliate) in addition to the
Purchase  Consideration.  Purchaser  (or  the  relevant  Purchaser  Designated  Affiliate)  shall  pay  any  such  VAT  upon
receipt of the relevant VAT invoices, if such invoice is required under applicable Law. Purchaser and Seller Parent
shall, and shall cause their respective Affiliates to, exercise commercially reasonable efforts to satisfy all compliance
obligations  necessary  in  order  to  treat  any  such  transfer  as  a  transfer  of  a  going  concern  for  VAT  purposes  where
permissible under applicable Law. Where Seller Parent has treated, or caused its Affiliates to treat, a transaction under
this Agreement as a transfer of a going concern or otherwise exempt from or outside the scope of VAT and it receives
notice  that  a  Taxing  Authority  disagrees  with  that  treatment,  it  shall  promptly  notify  Purchaser  and  reasonably
cooperate  with  Purchaser  to  contest  such  disagreement  upon  Purchaser’s  request,  provided  that  Purchaser  shall
indemnify Seller Parent in respect of any costs,

134

expenses, fees or Taxes incurred in connection with such contest. Seller Parent shall issue (or shall cause to be issued)
any  invoice  necessary  and  reasonably  cooperate  with  Purchaser  and  its  Affiliates  to  provide  information  and
documentation necessary for Purchaser and its Affiliates to comply with its VAT obligations under applicable Law.
For clarity, this Section 6.5(k)(i) does not apply to any VAT imposed on any transaction or step forming part of the
Seller  Internal  Restructurings  or  the  Purchaser  Internal  Restructurings.  Seller  Parent  shall  be  solely  responsible  for
any  VAT  imposed  on  any  transaction  or  step  forming  part  of  the  Seller  Internal  Restructurings  and  the  costs  of
preparing and filing any Tax Returns in respect of any such VAT and Purchaser Parent shall be solely responsible for
any VAT imposed on any transaction or step forming part of the Purchaser Internal Restructurings and the costs of
preparing and filing any Tax Returns in respect of any such VAT.

(ii)            The  Purchaser  Parent  Termination  Fee  is  inclusive  of  any  amounts  in  respect  of  VAT  thereon  but
subject  to  the  calculations  set  out  in  this  Section 6.5(k)(ii) .  The  Parties  intend,  and  shall  use  reasonable  efforts  to
secure,  that  the  Purchaser  Parent  Termination  Fee,  being  compensatory  in  nature,  is  not  and  will  not  be  treated  for
VAT  purposes  as  consideration  for  a  taxable  supply.  If  a  Taxing  Authority  determines  that  the  Purchaser  Parent
Termination Fee is, in whole or in part, consideration for a Tax supply for VAT purposes, then:

(A)      if Purchaser Parent (or any other member of the VAT group to which it belongs) is liable to account for
any  VAT  on  the  Purchaser  Parent  Termination  Fee  under  a  VAT  reverse  charge  mechanism,  the  amount  of  the
Purchaser Parent Termination Fee shall be reduced so that the sum of (x) the Purchaser Parent Termination Fee (as so
reduced), and (y) any VAT reverse charge thereon which Purchaser Parent (or any other member of the VAT group to
which  it  belongs)  is not  entitled  to recover  (by  way of credit  or  repayment)  as input  tax,  is equal  to  the unreduced
amount  of  the  Purchaser  Parent  Termination  Fee.  In  that  scenario,  Purchaser  Parent  shall  be  responsible  for
complying with all obligations relating to that reverse charge imposed by the Laws of the jurisdiction  in which the
VAT is accountable under the reverse charge mechanism; and

(B)      if Seller Parent is liable to account for any VAT on the Purchaser Parent Termination Fee, then to the
extent that such VAT is recoverable (by way of credit or repayment) as input tax by Purchaser Parent (or any other
member  of  the  VAT  group  to  which  it  belongs),  the  amount  of  the  Purchaser  Parent  Termination  Fee  shall  be
increased such that, less any such recoverable VAT in respect thereof, it equals the amount of the Purchaser Parent
Termination Fee before taking into account any adjustment under this Section 6.5(k)(ii)(B) .

(l)      Coordination . Notwithstanding anything herein to the contrary, (i) the indemnification obligations set forth in
Section 6.5(d) shall survive until thirty (30) days following the expiration of the applicable statutes of limitations in respect of the
relevant Taxes, (ii) the representations and warranties contained in Section 4.16(k) and Section 5.17(k) shall survive until

135

thirty (30) days following the expiration of the applicable statute of limitations in respect of the relevant Taxes, and (iii) any and all
indemnification in respect of Tax matters and the procedures relating thereto shall be governed exclusively by this Section 6.5 and,
to the extent specified therein, Section 7.4 , Section 7.6 , Section 7.7 , Section 7.8 , Section 7.9 , Section 7.10 and Section 7.11 , and
shall not be governed by the provisions of Article VII (other than, to the extent specified in Section 7.4 , Section 7.6 , Section 7.7 ,
Section 7.8 , Section 7.9 , Section 7.10 and Section 7.11 ).

Section 6.6      Employees and Employee Benefits .

(a)      Division of Liabilities Generally .

(i)      Purchaser Assumed Employee Liabilities . Purchaser and its Subsidiaries (including, after the Closing,
the  Conveyed  Subsidiaries  and  the  Subsidiaries  thereof)  shall,  effective  as  of  the  Closing,  assume  or  retain  all
Liabilities in respect of (A) the Conveyed Subsidiary Plans (including Liabilities thereunder that relate to an employee
or  former  employee  who  is  not  a  Business  Employee  or  Former  Business  Employee),  (A)  except  as  otherwise
expressly provided in this Section 6.6 , the service of the Business Employees and Former Business Employees to the
Business or Purchaser Business prior to, on or following the Closing Date, including all Liabilities for compensation
(including  commissions,  bonuses,  incentive  pay,  overtime,  premium  pay,  shift  differentials  and  severance  or
termination  pay)  that  become  payable  on  or  after  the  Closing,  (A)  except  as  otherwise  expressly  provided  in  this
Section  6.6  ,  compensation  and  benefits  required  to  be  provided  by,  or  transferring  to  Purchaser  pursuant  to,
applicable Law with respect to a Business Employee or Former Business Employee, (A) the other Liabilities specified
in  this  Section  6.6  as  being  assumed,  retained  or  reimbursable  by  Purchaser  or  its  Subsidiaries,  (A)  except  as
otherwise expressly provided in this Section 6.6 , all costs and expenses arising from the obligations of Purchaser or
its Subsidiaries under this Section 6.6 , and the implementation by Purchaser of the compensation and benefit plans as
contemplated hereunder, and (A) any Liabilities arising out of the failure of Purchaser or its Subsidiaries to comply
with  its  obligations  under  this  Section  6.6  ,  including  the  failure  to  extend  offers  pursuant  to  Section  6.6(b)(i)  or
engage in any consultations required or contemplated by Section 6.6(b)(i) or Section 6.6(j) (the Liabilities assumed by
Purchaser  and  its  Subsidiaries  pursuant  to  this  Section  6.6  ,  collectively,  the  “  Purchaser  Assumed  Employee
Liabilities ”). For the avoidance of doubt, except as contemplated by clause (A)  of this  Section 6.6(a)(i) , the term
Purchaser Assumed Employee Liabilities shall not include Liabilities with respect to current or former employees of
Seller Parent or its Affiliates who are not Business Employees or Former Business Employees. For purposes of this
Section 6.6 ,  Liabilities  in  respect  of  all  compensation  and  benefits  items  shall  include  the  employer  side  Taxes  or
other payments related thereto.

(ii)            Seller  Parent  Retained  Employee  Liabilities  .  Seller  Parent,  or  its  applicable  Affiliate  (other  than  a
Conveyed  Subsidiary  or  Subsidiary  thereof),  shall,  effective  as  of  the  Closing,  retain  or  assume  (A)  all  assets  and
Liabilities under or

136

relating to each Seller Group Plan and each Foreign Seller Group Plan, and each other benefit or compensation plan,
program,  policy,  agreement  or  arrangement  at  any  time  sponsored  or  maintained  by  Seller  or  any  of  its  ERISA
Affiliates  (including  non-U.S.  Affiliates)  that  is not  a  Conveyed  Subsidiary  Plan,  other  than  those  Liabilities  under
any  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  expressly  assumed  by  Purchaser  and  its  Affiliates  under  this
Section 6.6 ; (B) all Liabilities with respect to current or former employees of Seller Parent or its Affiliates who are
not  Business  Employees  or  Former  Business  Employees;  (C)  all  Liabilities  with  respect  to  the  service  prior  to  the
Closing Date of the Business Employees and Former Business Employees to Seller Parent or its Affiliates (other than
the  Conveyed  Subsidiaries  and  their  Subsidiaries)  to  the  extent  such  service  was  not  related  to  the  Business,  and
(D) all other Liabilities  specified in this Section 6.6 as being retained or assumed by Seller Parent or its applicable
Affiliates pursuant to this Section 6.6 , which Liabilities shall be Retained Liabilities. Notwithstanding clause (A) of
the  immediately  preceding  sentence,  this  Section  6.6(a)(ii)  shall  not  prevent  Seller  Parent  or  its  Affiliates  from
allocating chargebacks to Purchaser or its Subsidiaries with respect to compensation and benefits costs that constitute
current  Liabilities  for  purposes  of  GAAP  or  IFRS  (and  excluding  all  other  costs  or  Liabilities,  such  as  pension
underfunding or prior years’ accruals under qualified or non-qualified retirement or deferred compensation plans) in
the ordinary course of business consistent with past practice related to Business Employees’ service for periods prior
to the Closing; provided , however , that any such chargebacks shall be reflected as a Liability in Business Working
Capital.  Subject  to  the  immediately  preceding  sentence,  no  Retained  Liability  shall  be  reflected  as  a  Liability  in
Business Working Capital. Other than as expressly contemplated by this Section 6.6 , in no event may Seller Parent or
its  Affiliates  transfer  a  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  (or  any  related  Liabilities)  that  is  not
maintained  by  a  Conveyed  Subsidiary  or  a  Subsidiary  thereof  as  of  the  date  of  this  Agreement  to  a  Conveyed
Subsidiary or a Subsidiary thereof.

(iii)            Purchaser  Parent  Retained  Employee  Liabilities  .  Purchaser  Parent  and  its  Affiliates  (other  than
Purchaser and its Subsidiaries), shall, effective as of the Closing, retain or assume (A) all assets and Liabilities under
or  relating  to  each  Purchaser  Group  Plan  and  each  Foreign  Purchaser  Group  Plan,  and  each  other  benefit  or
compensation  plan,  program,  policy,  agreement  or  arrangement  at  any  time  sponsored  or  maintained  by  Purchaser
Parent  or  any  of  its  ERISA  Affiliates  (including  non-U.S.  Affiliates)  that  is  not  a  Purchaser  Business  Plan;  (B)  all
Liabilities  with  respect  to  current  or  former  employees  of  Purchaser  Parent  or  its  Affiliates  who  are  not  Purchaser
Business Employees or Former Purchaser Business Employees; (C) all Liabilities with respect to the service prior to
the  Closing  Date  of  the  Purchaser  Business  Employees  and  Former  Purchaser  Business  Employees  to  Purchaser
Parent  or  its  Affiliates  (other  than  Purchaser  and  its  Subsidiaries)  to  the  extent  such  service  was  not  related  to  the
Purchaser  Business;  and  (D)  all  other  Liabilities  specified  in  this  Section  6.6  as  being  retained  or  assumed  by
Purchaser Parent or its applicable Affiliates pursuant to this Section 6.6 , which Liabilities shall

137

be  Purchaser  Parent  Retained  Liabilities.  Notwithstanding  clause  (A)  of  the  immediately  preceding  sentence,  this
Section 6.6(a)(iii) shall not prevent Purchaser Parent or its Affiliates from allocating chargebacks to Purchaser or its
Subsidiaries with respect to compensation and benefits costs that constitute current Liabilities for purposes of GAAP
or  IFRS  (and  excluding  all  other  costs  or  Liabilities,  such  as  pension  underfunding  or  prior  years’  accruals  under
qualified  or  non-qualified  retirement  or  deferred  compensation  plans)  in  the  ordinary  course  of  business  consistent
with  past  practice  related  to  Purchaser  Business  Employees  and,  with  respect  to  periods  following  the  Closing,
Transferred  Employees;  provided , however ,  that  any  chargebacks  in  respect  of  the  service  of  Purchaser  Business
Employees for periods prior to the Closing shall be reflected as a Liability in Purchaser Working Capital. Subject to
the  immediately  preceding  sentence,  no  Purchaser  Parent  Retained  Liability  shall  be  reflected  as  a  Liability  in
Purchaser  Working  Capital.  In  no  event  may  Purchaser  Parent  or  its  Affiliates  transfer  a  Purchaser  Group  Plan  or
Foreign Purchaser Group Plan (or any related Liabilities) that is not maintained by Purchaser or a Subsidiary thereof
as of the date of this Agreement to Purchaser or a Subsidiary thereof.

(b)      Transfer of Employees .

(i)      Business Employees Generally . At least ninety (90) days prior to the Closing Date, Seller Parent shall
provide Purchaser with a list of all Business Employees  as of such time, including each such Business Employee’s
name, job title, date of hire, annual salary or hourly rate (as applicable) and incentive opportunity to which each such
Business Employee is entitled, provided that such information may be redacted to the extent Seller Parent is required
to  comply  with  data  privacy  and  other  applicable  Laws  (the  “  Transferring  Employee  List  ”).  At  least  fifteen  (15)
Business Days prior to the Closing Date (or earlier, if required by applicable Law), Purchaser agrees to offer or cause
to be offered continued employment as of the Closing Date to each Business Employee detailed on the Transferring
Employee List who is not employed at a Conveyed Subsidiary or a Subsidiary thereof or who is not a TUL Employee,
in  the  same  or  a  Comparable  Position  (as  defined  herein)  and  with  compensation  and  benefits  on  terms  that  are
consistent with this Section 6.6 and Seller Parent and its Affiliates  will facilitate  in finalizing  and distributing  such
offers.  In  addition,  effective  as  of  the  Closing,  Purchaser  agrees  to  cause  the  Conveyed  Subsidiaries  and  their
Subsidiaries  to  continue  the  employment  of  each  Business  Employee  employed  by  such  entities  as  of  the  Closing
Date in the same or a Comparable Position and with compensation and benefits on terms that are consistent with this
Section 6.6 . A “ Comparable Position ” is a position with Purchaser or its Subsidiaries (including, after the Closing, a
Conveyed  Subsidiary  or  Subsidiary  thereof)  in  which  (A)  the  Business  Employee’s  level  of  responsibilities  is  not
significantly reduced, and (B) the Business Employee is not required to relocate more than fifty (50) miles from the
Business Employee’s principal business location immediately prior to the Closing.

138

(ii)      TUL Employees . Except as agreed between the Parties, with respect to each Business Employee who is
not employed by a Conveyed Subsidiary or Subsidiary thereof and is employed in a jurisdiction in which the Transfer
of  Undertakings  Laws  have  been  implemented  or  apply  (a  “  TUL  Employee  ”),  Seller  Parent  and  Purchaser
acknowledge  that  the  transactions  contemplated  by  this  Agreement  are  likely  to  give  rise  to  a  relevant  transfer  (or
otherwise  sustain  the  automatic  transfer  of  employees)  for  purposes  of  the  Transfer  of  Undertakings  Laws  and  to
apply the Transfer of Undertakings Laws insofar as they apply by Law, and accept and agree that in such event the
terms and conditions of employment of each such TUL Employee shall transfer effective as of the Closing and in a
manner  contemplated  by  the  Transfer  of  Undertakings  Laws  or  other  applicable  Law.  Seller  Parent  and  Purchaser
shall inform and consult with the TUL Employees or any appropriate representatives of the TUL Employees to the
extent  required  by  the  Transfer  of  Undertakings  Laws  or  other  applicable  Law.  In  the  event  that  a  TUL  Employee
objects  to  the  transfer  of  employment  and  cannot  be  transferred  to  Purchaser  or  its  Subsidiaries,  all  Liabilities
associated  with  the  continued  employment  of  such  TUL  Employee  by  Seller  Parent  or  its  Affiliates  for  up  to  a
maximum of two (2) calendar months (or any longer period required by applicable Law or the notice period under any
Foreign Seller Group Plan) following Closing, and the termination of employment of such TUL Employee by Seller
Parent or its Affiliates shall be considered Purchaser Assumed Employee Liabilities.  For the avoidance of doubt, if
the  Transfer  of  Undertakings  Laws  are  determined  not  to  apply  to  a  TUL  Employee,  Purchaser  agrees  to  offer  or
cause to be offered continued employment as of the Closing Date to such TUL Employee in accordance with Section
6.6(b)(i) .

(iii)      Delayed Transfer Employees . Notwithstanding the foregoing, in the case of any Business Employee
whose employment does not and cannot commence or be transferred at the Closing by applicable Laws or Purchaser
and Seller Parent mutually determine cannot commence or be transferred at the Closing or whose commencement or
transfer  of  employment  is  otherwise  delayed  (a  “  Delayed Transfer  Employee ”),  Seller  Parent  and  Purchaser  shall
cooperate in good faith to cause the employment of such Delayed Transfer Employee to remain with Seller Parent or
a Retained Subsidiary to allow such Delayed Transfer Employee to continue to participate on the compensation and
benefit  platforms,  plans  and  programs  of  Seller  Parent  or  such  Retained  Subsidiary.  The  Parties  agree  that  each
Delayed  Transfer  Employee  shall  commence  employment  with  Purchaser,  a  Conveyed  Subsidiary  or  another
Subsidiary  of  Purchaser,  as  appropriate,  as  soon  as  reasonably  practicable  following  the  Closing  as  permitted  by
applicable  Laws  in  such a  manner  that  to the  maximum  extent  possible  does  not trigger  the  right  of such  Business
Employee  to  separation  pay  and  is  otherwise  consistent  with  the  terms  and  conditions  of  this  Section  6.6  and
applicable Law. Notwithstanding the foregoing, Seller Parent shall have no obligation to transfer the employment of a
Delayed Transfer Employee out of a Conveyed Subsidiary if the delayed transfer of employment is due to a delay in
the transfer of the Conveyed Subsidiary to Purchaser. In respect of the Delayed

139

Transfer Employees, each reference in Section 6.6(a)(iii) (other than in this Section 6.6(b)(iii) and Section 6.6(b)(iv) )
through Section 6.6(j) to “Closing” and “Closing Date” shall be treated as a reference to the first date on which the
applicable Delayed Transfer Employee’s employment commences with or transfers to Purchaser. Notwithstanding the
delayed transfer of such Delayed Transfer Employees, from and for a period of two (2) years after the Closing or, if
earlier, the date of the applicable Delayed Transfer Employee’s termination of employment (“ Delayed Employment
Period ”),  the  (A)  compensation  paid  to  such  Delayed  Transfer  Employees  in  respect  of  the  Delayed  Employment
Period and (B) the fringe benefit rate for such Delayed Transferred Employees’ benefits under a Seller Group Plan or
Foreign Seller Group Plan that Seller Parent charges in the ordinary course of business consistent with past practice in
respect  of  the  Delayed  Employment  Period  shall,  in  the  case  of  (A)  and  (B),  be  considered  Purchaser  Assumed
Employee Liabilities; provided that, during such period, Purchaser and its Subsidiaries receive the economic benefit
of such Delayed Transferred Employee’s services.

(iv)      Disability Employees . Without limiting the generality of Section 6.6(b)(iii) , and except as prohibited
by applicable Law or provided in the immediately following sentence, each Business Employee who is on a leave of
absence as of the Closing due to short- or long-term disability (a “ Disability Employee ”) and is eligible for, or in an
elimination  period  to  be  eligible  for,  long-term  disability  insurance  coverage  under  a  Seller  Group  Plan  or  Foreign
Seller  Group  Plan  (a  “  Seller  LTD  Plan  ”)  that  is  not  a  Conveyed  Subsidiary  Plan  shall  be  a  Delayed  Transfer
Employee  until  he  or  she  returns  to  active  employment;  provided  ,  that  such  return  to  active  employment  occurs
within six (6) months following the Closing (or such longer period as may be required by applicable Law or the notice
period under any Seller Group Plan or Foreign Seller Group Plan). If it is administratively impractical to delay the
transfer of a Disability Employee because Seller Parent and its Affiliates (other than the Conveyed Subsidiaries and
their  Subsidiaries)  do  not  have  an  employing  entity  in  the  applicable  jurisdiction  following  the  Closing  or  because
such Disability Employee is, prior to the Closing and prior his or her disability, already an employee of a Conveyed
Subsidiary, such Disability Employee shall be treated in the same manner as all other Business Employees, except he
or  she  shall  remain  eligible  for  coverage  under  the  Seller  LTD  Plan  until  the  elimination  period  in  effect  as  of  the
Closing  elapses,  and  neither  Purchaser  nor  its  Affiliates  shall  have  any  Liability  to  provide  long-term  disability
benefits  or  otherwise  with  respect  to  the  Seller  LTD  Plan.  If  such  Disability  Employee  who  is  not  a  Delayed
Transferred Employee in accordance with the first sentence hereof satisfies the requirements for coverage under the
Seller LTD Plan at the end of such elimination period, the employment of such Disability Employee with Purchaser
and  its  Affiliates  shall  terminate,  and  such  Disability  Employee  shall  be  entitled  to  benefits  under  the  Seller  LTD
Plan,  and  neither  Purchaser  nor  its  Affiliates  shall  have  any  Liability  to  provide  long-term  disability  benefits  or
otherwise with respect to the Seller LTD Plan. Any Disability Employee who is a Delayed Transferred Employee in
accordance with the first sentence hereof and who does not return to active employment within six

140

(6) months following the Closing (or such longer period as may be required by applicable Law or the notice period
under any Seller Group Plan or Foreign Seller Group Plan) shall not be a Transferred Employee under this Agreement
and, upon the conclusion of such six (6)-month period (or such longer period as may be required by applicable Law or
the notice period under any Seller Group Plan or Foreign Seller Group Plan), shall no longer be considered a Business
Employee under this Agreement.

(v)      Definitions . For purposes of this Agreement, (A) any Business Employee (U.S.) whose employment
transfers  pursuant  to  this  Section 6.6(a)(iii) shall  be  referred  to  as  a  “  Transferred  Employee  (U.S.)  ”  and  (B)  any
Business Employee (non-U.S.) whose employment transfers pursuant to this Section 6.6(a)(iii) shall be referred to as
a “ Transferred Employee (non-U.S.) ” (collectively, the “ Transferred Employees ”).

(c)      Compensation and Employee Benefits .

(i)      Continued Employee Benefits . For a period from the Closing Date until December 31, 2020 (or such
longer  period  as  required  by  applicable  Law)  (the  “  Continuation  Period  ”),  Purchaser  shall,  or  shall  cause  its
Affiliates to, provide to each Transferred Employee whose terms and conditions of employment are not subject to an
applicable Collective Bargaining Agreement (A) a Comparable Position, (B) base salary or wage rates that, in each
case, are no less favorable than those in effect for each such Transferred Employee immediately prior to the Closing,
(C) cash-based incentive opportunities (which shall include, collectively, commission, cash bonus and cash incentive
pay opportunities), equity incentive opportunities and nonqualified deferred compensation benefits that, in each case,
are no less favorable than those provided to similarly situated Purchaser Business Employees, (D) employee benefits
(excluding  equity  incentive  opportunities  and  non-qualified  deferred  compensation)  that,  in  the  aggregate,  are
substantially comparable to those in effect for each such Transferred Employee immediately prior to the Closing and
(E)  severance  benefits  that  are  no  less  favorable  than  the  severance  benefits  that  would  have  been  payable  to  each
such Transferred Employee under the Seller Group Plans or Foreign Seller Group Plans set forth in Section 6.6(c) of
the Seller Disclosure Letter in which such Transferred Employee participated or was eligible for benefits immediately
prior to the Closing, taking into account such Transferred Employee’s additional period of service and increases (but
not decreases) in  compensation following the Closing. In  addition, notwithstanding anything to the  contrary in this
Agreement, Purchaser or its Subsidiaries shall, and shall cause the Conveyed Subsidiaries and their Subsidiaries to,
maintain  terms  and  conditions  of  employment  for  Transferred  Employees  to  the  extent  necessary  to  (x)  effect  the
automatic  transfer  of  such  employees  under  applicable  Laws  (including  the  Transfer  of  Undertakings  Laws),
Collective  Bargaining  Agreements  or  employment  agreements,  (y)  comply  with  applicable  Laws  and  (z)  prevent
severance from

141

becoming  payable  to  any  such  employee  under  applicable  Law  as  a  result  of  the  transactions  contemplated  by  this
Agreement.

(ii)      Severance or Other Termination Liabilities . Purchaser and its Subsidiaries shall be solely responsible
for any severance, redundancy, long service, notice or garden leave pay, or similar payments, contributions or benefits
(collectively,  “  Termination  Expenses  ”)  that  may  become  payable  to  any  Business  Employee  arising  out  of  or  in
connection with the transactions contemplated by this Agreement (whether or not such Business Employee becomes a
Transferred Employee), including any Termination Expenses that are required to be paid by applicable Law, that may
become  payable  to  any  Business  Employee  who  does  not  become  an  employee  of  Purchaser  or  its  Subsidiaries
because Purchaser or its Subsidiaries fail to take all actions required by applicable Law to effectuate such Business
Employee’s transfer, because such Business Employee rejects an offer of employment made in compliance with this
Section  6.6  ,  refuses  to  transfer  employment,  or  otherwise  challenges  such  transfer  of  employment;  provided  ,
however  ,  that  Seller  Parent  and  its  Affiliates  shall  retain  any  Termination  Expenses  that  may  become  payable  in
connection with the Seller Internal Restructurings (collectively, the “ Seller Retained Severance Liabilities ”), which
shall be Retained Liabilities for all purposes hereunder. If Purchaser or any of its Subsidiaries becomes liable for, or is
legally  required  to  make,  severance,  redundancy,  long  service,  notice  or  garden  leave  pay,  or  similar  payments,
contributions or benefits to or on behalf of any Business Employee as a result of the transactions contemplated by this
Agreement (whether or not such Business Employee becomes a Transferred Employee), all such payments and any
related costs and expenses paid or incurred by Purchaser or its applicable Subsidiary, other than any Seller Retained
Severance Liabilities, shall be Purchaser Assumed Employee Liabilities. Seller Parent and its Affiliates shall consult
with  Purchaser  prior  to  paying  or  committing  to  pay  severance  to  a  Business  Employee  who  rejects  an  offer  of
employment made in compliance with this Section 6.6 , refuses to transfer employment, or otherwise challenges such
transfer of employment.

(iii)      Service Credit . For purposes of vesting, eligibility to participate and level of benefits (and for all other
purposes to the extent required by applicable Law) under the employee benefit plans of Purchaser and its Affiliates
providing benefits to any Transferred Employees after the Closing, each Transferred Employee shall be credited with
his  or  her  years  of  service  with  Seller  Parent  and  its  Affiliates  (including  the  Conveyed  Subsidiaries  and  their
Subsidiaries)  and  their  respective  predecessors  to  the  same  extent  and  for  the  same  purpose  as  such  Transferred
Employee  was  credited,  before  the  Closing,  under  any  similar  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  in
which  such  Transferred  Employee  participated  or  was  eligible  to  participate  immediately  prior  to  the  Closing,
provided  that  the  foregoing  shall  not  apply  (A)  to  the  extent  that  its  application  would  result  in  a  duplication  of
benefits (including accrual of severance or termination related entitlements where these have been paid out as a result
of the transactions contemplated by this

142

Agreement)  or  (B)  for  purposes  of  level  of  benefits  under  any  defined  benefit  pension  plan  (other  than  under
Purchaser  Pension  Plans  with  respect  to  the  transfer  of  Liabilities  from  Seller  Pension  Plans  as  described  in
Section 6.6(e) , or as required by applicable Law).

(iv)      Welfare Benefit Plan Obligations . Commencing as of 12:01 a.m. (local time wherever applicable) on
the Closing Date, Purchaser shall, or shall cause its applicable Affiliates to, provide the Transferred Employees with
welfare benefits under plans and arrangements maintained or sponsored by Purchaser and its Affiliates that satisfy the
standards set forth in Section 6.6(c)(i) . Purchaser shall, or shall cause its applicable Affiliates to, waive any waiting
periods  under  their  welfare  benefit  plans  (including  medical,  dental,  life  insurance  and  short-term  and  long-term
disability  plans) and, with respect to any group health plans, shall waive any limitations  for preexisting  conditions,
and, if applicable, shall ensure that such employees are given credit for any amounts paid toward deductibles, out-of-
pocket  limits  or  other  fees  on  or  prior  to  the  Closing  Date.  Other  than  with  respect  to  claims  incurred  under  a
Conveyed Subsidiary Plan, claims by a Transferred Employee for welfare benefit plan benefits or services rendered
(A) as of or following 12:01 a.m. (local time wherever applicable) on the Closing Date shall be the responsibility of
Purchaser  and its Subsidiaries,  and (B) prior to the Closing Date shall be the responsibility  of Seller  Parent  and its
Affiliates (other than a Conveyed Subsidiary or any Subsidiary thereof). Seller Parent and its Affiliates (other than a
Conveyed  Subsidiary  or  any  Subsidiary  thereof)  will  retain  any  obligations  under  Section  4980B  of  the  Code  or
similar  state  Law  (“  COBRA  ”)  with  respect  to  Business  Employees,  Former  Business  Employees  and  any  other
qualified  beneficiaries  who  are  enrolled  in  COBRA  continuation  coverage  under  a  Seller  Group  Plan  that  is  not  a
Conveyed Subsidiary Plan as of the Closing or with respect to whom a COBRA qualifying event occurred prior to the
Closing.  This  Section  6.6(c)(ii)  does  not  apply  to  any  Liabilities  under  a  Conveyed  Subsidiary  Plan,  regardless  of
whether  the  event  giving  rise  to  the  cost  occurred  before,  on  or  after  the  Closing  Date,  which  Liabilities  shall  be
retained or assumed by Purchaser in accordance with Section 6.6(a)(i)(A) .

(v)           Cash  Incentive  Compensation  .  Following  the  Closing,  Purchaser  shall,  or  shall  cause  its  applicable
Subsidiaries to pay awards under Seller Parent cash-based annual incentive plan (the “ Seller Cash Incentive Plan ”)
in which Transferred Employees participate for the performance period in which the Closing occurs, prorated for the
period elapsed as of immediately prior to the Closing Date, or with respect to any Delayed Transfer Employee, the
date  on  which  such  Delayed  Transferred  Employee  transfers  employment  (based  upon  actual  performance  as
determined  in  good  faith  in  the  ordinary  course  of  business  consistent  with  past  practice  by  Seller  Parent  or  its
applicable Affiliate), to each Transferred Employee who is eligible to receive such an award pursuant to the terms of
the  Seller  Cash  Incentive  Plan,  which  awards  shall  be  paid  at  such  time  and  to  the  extent  that  the  Transferred
Employees  would  have  otherwise  become  entitled  to  such  bonuses  under  the  Seller  Cash  Incentive  Plan  (such
prorated bonus, the “ Seller Closing Bonus ”);

143

provided , however , if Purchaser’s or its applicable Subsidiary’s payment of the Seller Closing Bonus is prohibited
under applicable Law, Purchaser and Seller Parent will agree to an alternative arrangement with respect to any such
Seller  Closing  Bonus  acting  in  good  faith  (which  alternative  arrangement  shall  preserve  the  division  of  Liabilities
between Seller Parent and its Affiliates, on the one hand, and Purchaser and its Affiliates, on the other hand, generally
contemplated  by  this  Section  6.6(c)(v)  ).  The  aggregate  amount  of  the  Seller  Closing  Bonuses  and  any  related
employer-side Taxes (but less the amount of the Tax deduction that Seller Parent or its Affiliates would have realized
had  they  paid  the  Seller  Closing  Bonuses)  shall  be  reflected  as  a  Liability  in  Business  Working  Capital.  Without
limiting  the  generality  of  Section  6.6(c)(i)  ,  effective  as  of  the  Closing,  Purchaser  shall  cause  the  Transferred
Employees  to  participate  in  the  cash-based  incentive  plans  of  Purchaser  and  its  Affiliates  for  the  remainder  of  the
performance period in which the Closing occurs, which plans shall provide (A) incentive compensation opportunities
that  are  no  less  favorable  than  those  provided  to  such  Transferred  Employees  immediately  prior  to  the  Closing  (
provided that such opportunities may be prorated for the period from and including the Closing Date until the end of
the applicable performance period and may be based on reasonable performance criteria established by Purchaser in
the  ordinary  course  of  business)  and  (B)  for  payment  of  awards  for  the  performance  period  in  which  the  Closing
occurs at the time prescribed by the Seller Cash Incentive Plan as in effect immediately prior to the Closing and in
accordance with the historical past practices of Seller and its Affiliates, it being understood that this clause (B) shall
not require Purchaser to pay such awards automatically upon the Closing.

(vi)          Equity Incentive Compensation . Upon the Closing, each incentive award in respect of the common
stock  of  Seller  Parent  (a  “  Seller  Parent  Equity  Award ”)  held  by  a  Transferred  Employee  shall  become  vested  or
eligible  to  vest  (subject  to  the  satisfaction  of  any  applicable  performance  goals)  in  a  prorated  amount,  determined
based  on  the  number  of  days  in  the  applicable  vesting  period  elapsed  as  of  the  Closing  Date.  Effective  as  of  the
Closing, Purchaser or its Affiliates shall grant to each Transferred Employee an equity- or cash-based incentive award
(a “ Make-Whole Award ”) with a grant date fair value that is no less favorable than the value of the portion of the
Seller Parent Equity Awards forfeited by the Transferred Employee in connection with the Closing (which forfeited
amount shall be disclosed to Purchaser Parent no later than five (5) Business Days prior to the Closing), which Make-
Whole  Award  shall  have  terms  and  conditions  that  are  no  less  favorable  than  the  terms  and  conditions  (including
vesting schedule and accelerated vesting terms) that were applicable to the corresponding Seller Parent Equity Award.
In  the  event  that  the  post-Closing  transfer  of  a  Delayed  Transfer  Employee  results  in  a  larger  portion  of  the  Seller
Parent  Equity  Awards  held  by  such  Delayed  Transfer  Employee  becoming  vested  upon  such  Delayed  Transfer
Employee’s transfer of employment than if the employment of such Delayed Transfer Employee had transferred upon
the Closing, then the incremental cost of such additional vesting (which cost shall be measured based on the taxable
income  the  Delayed  Transfer  Employee  either  realized  or  would  have  realized  had  such  awards  been  settled  or
exercised upon such

144

Delayed Transfer Employee’s transfer of employment to Purchaser or its Subsidiaries) shall be considered Purchaser
Assumed Employee Liabilities.

(vii)      Accrued Time Off Entitlements . Subject to applicable Law and any required consents, from and after
the  Closing,  with  respect  to  each  Business  Employee,  either  (A)  Purchaser  shall,  or  shall  cause  its  Affiliates  to,
assume  and  honor  all  accrued  but  unused  vacation  and  other  paid  time  off  of  Business  Employees  or  (B)  if  Seller
Parent or any of its Affiliates is required under applicable Law to make a payment in settlement of accrued vacation
or  paid  time  off  of  any  Business  Employee,  such  payments  shall  be  considered  Purchaser  Assumed  Employee
Liabilities and such accruals under (A) shall not be assumed and/or honored by Purchaser or its Affiliates.  Under no
circumstance shall Purchaser or its Affiliates be responsible for satisfying both (A) and (B) with respect to the same
Business Employee.

(d)            Seller  Benefit  Plans  .  Except  as  otherwise  provided  in  this  Section  6.6  ,  from  and  after  the  Closing,  the
Transferred Employees shall cease to be active participants in the Seller Group Plans and Foreign Seller Group Plans that are not
Conveyed Subsidiary Plans.

(e)      Foreign Defined Benefit Pension or Termination Benefit Plans .

(i)      Effective as of the Closing, Purchaser shall establish or designate non-U.S. defined benefit pension or
pension-like termination benefit plans or arrangements, as applicable (collectively, the “ Purchaser Pension Plans ”),
for the benefit of the Transferred Employees (non-U.S.) who participate in the Foreign Seller Group Plans and other
non-U.S. arrangements that provide for similar benefits, whether under a plan or pursuant to applicable Law or local
practice set forth on Section 6.6(e) of the Seller Disclosure Letter (collectively, the “ Seller Pension Plans ,” and the
Transferred  Employees  (non-U.S.)  who  participate  in  or  accrue  benefits  pursuant  to  the  Seller  Pension  Plans,  the  “
Transferred  Pension  Plan  Employees  ”).  Each  Purchaser  Pension  Plan  shall  provide,  upon  the  transfer  of  assets
referred to below (or, if there is no transfer of assets with respect to a particular plan because the plan is not funded, as
of the Closing), that the accrued benefits for the Transferred Pension Plan Employees under such Purchaser Pension
Plan  shall  in  no  event  be  less  than  their  accrued  benefits  under  the  corresponding  Seller  Pension  Plan  as  of  the
Closing. With respect to any Seller Pension Plan that is funded, Seller Parent shall cause to be transferred from the
trusts  or  other  funding  vehicles  under  such  Seller  Pension  Plan  to  the  trusts  or  other  funding  vehicles  under  the
corresponding Purchaser Pension Plan assets in the form of cash, cash equivalents, marketable securities or insurance
contracts (to the extent allowable under the terms of such contracts and exclusively intended to cover plan benefits),
the value of which shall be equal to: (x) the actuarial present value of accumulated benefits (that is, the “accumulated
benefit obligation” as defined in Topic 715 in the FASB’s Accounting Standards Codification, the “ ABO ”) under
such Seller Pension Plan as of the Closing that are attributable to the Transferred Pension Plan Employees, divided by
the ABO

145

of all participants in such Seller Pension Plan as of the Closing, multiplied
by
the market value of the assets of such
Seller  Pension  Plan  at  the  Closing,  provided that  such  transferred  amount  shall  not,  in  any  event,  exceed  the  ABO
under such Seller Pension Plan of all Transferred Pension Plan Employees as of the Closing Date or (y) such greater
amount as is required by applicable Law.

(ii)            The  amounts  determined  in  accordance  with  Section  6.6(e)(i)  are  collectively  referred  to  as  the  “
Pension Transfer Amounts .” The transfer of the Pension Transfer Amounts, and the assumption by Purchaser and its
Subsidiaries of Liabilities with respect to or relating to the Transferred Pension Plan Employees under the applicable
Seller  Pension  Plans,  shall  be  subject  to  such  consents,  Approvals  and  other  requirements  as  may  apply  under
applicable  Law.  Purchaser  shall  use  commercially  reasonable  efforts  to  cause  the  corresponding  Purchaser  Pension
Plans  to  accept  the  Pension  Transfer  Amounts.  Actuarial  determinations  shall  be  made  in  accordance  with
Section 6.6(e)(vi) . If a Seller Pension Plan is not required to be funded by applicable Law, and is not funded, there
shall be no transfer of assets by the Seller Pension Plan or by Seller Parent or its Affiliates.

(iii)            As  of  the  Closing,  Seller  Parent  shall  cause  the  Transferred  Employees  to  cease  further  accrual  of

benefits under the Seller Pension Plans.

(iv)      The Pension Transfer Amount, if any, from each Seller Pension Plan shall be equitably adjusted to take
into account benefit payments made from the Seller Pension Plan to the Transferred Pension Plan Employees after the
Closing  but  prior  to  the  date  of  transfer  and  for  any  earnings  and  losses  on  such  amount  during  such  period.  The
Pension Transfer Amount, if any, shall be determined pursuant to Section 6.6(e)(vi) .

(v)      At the times of the transfers of the Pension Transfer Amounts (or if there is no transfer of assets with
respect to a particular plan because the plan is not required to be funded under applicable Law and is not funded, from
and after the Closing), Purchaser and the Purchaser Pension Plans shall assume all Liabilities for all accrued benefits,
including  all  disability,  part-time,  early  retirement  and  other  ancillary  benefits,  under  the  corresponding  Seller
Pension  Plans  in  respect  of  the  Transferred  Pension  Plan  Employees  whose  benefits  are  so  transferred,  and  Seller
Parent  and  its  Affiliates  and  the  corresponding  Seller  Pension  Plans  shall  be  relieved  of  all  Liabilities  to  provide
benefits under the Seller Pension Plans to the Transferred Pension Plan Employees whose benefits are so transferred.
From and after the date of such applicable transfer of the Pension Transfer Amounts (or if there is no transfer of assets
with respect to a particular plan because the plan is not required to be funded under applicable Law and is not funded,
from and after the Closing), Purchaser agrees to indemnify and hold harmless Seller Parent and its Affiliates and its
officers,  directors,  employees,  and  agents  from  and  against  any  and  all  costs,  damages,  losses,  expenses,  or  other
Liabilities arising out of or related to the Transferred Pension Plan

146

Employees’  benefits  under  the  Seller  Pension  Plans  that  are  transferred  to  Purchaser  or  Purchaser  Pension  Plans
pursuant to this Section 6.6(e) .

(vi)            For  purposes  of  this  Section  6.6(e)  ,  actuarial  determinations  shall  be  based  upon  the  actuarial
assumptions and methodologies used in preparing the most recent audited financial statements of Seller Parent as of
the date of the determination. The applicable plan sponsor of the Seller Pension Plans shall cause the plan actuary or
administrator to provide a report of its determination of such amount within ninety (90) days following the Closing
Date and any back-up information reasonably required by Purchaser to confirm the accuracy of such determination. If
Purchaser disputes the accuracy of the calculation, Purchaser and Seller Parent shall cooperate to identify the basis for
such  disagreement  and  act  in  good  faith  to  resolve  such  dispute.  To  the  extent  that  a  dispute  is  unresolved  after  a
forty-five (45)-day period following identification of such dispute, the calculations shall be verified by an independent
third-party benefits consulting firm selected by the mutual agreement of Seller Parent and Purchaser. The decision of
such  consulting  firm  shall  be  final,  binding  and  conclusive  on  Seller  Parent  and  Purchaser.  Notwithstanding
Section 6.6(a)(i)(E) , Seller Parent and Purchaser Parent shall share equally the costs of such consulting firm.

(vii)            This  Section  6.6(e)  does  not  apply  to  any  Liabilities  under  a  Conveyed  Subsidiary  Plan,  which
Liabilities  shall  be  retained  or  assumed  by  Purchaser  in  accordance  with  Section  6.6(a)(i)(A)  .  For  clarity,  Seller
Parent  and  its  Affiliates  shall  retain  all  assets  and  Liabilities,  including  those  related  to  Business  Employees  and
Former Business Employees (and their service prior to Closing), in respect of Seller Group Plans and Foreign Seller
Group Plans that are defined benefit pension plans or pension-like termination benefit plans or arrangements but not
Conveyed Subsidiary Plans, or with respect to Transferred Employees (non-U.S.), Seller Pension Plans.

(f)      Defined Contribution Plans (U.S.) .

(i)            Effective  as  of  the  Closing,  Purchaser  shall  create  or  designate  defined  contribution  pension  plans
(collectively, the “ Purchaser DC Plans (U.S.) ”) for the benefit of the Transferred Employees (U.S.) who participate
in  one or  more  of  the  defined  contribution  pension  plans  maintained  by Seller  Parent  or  its Affiliates  (other  than  a
Conveyed Subsidiary Plan) that are intended to be qualified under Section 401(a) of the Code immediately prior to the
Closing or the corresponding provisions of the Puerto Rico Internal Revenue Code (collectively, the “Seller DC Plans
(U.S.),” and the Transferred Employees who participate in the Seller DC Plans (U.S.) , the “ DC Employees (U.S. )”).
The applicable Purchaser DC Plans (U.S.) shall be tax-qualified in the same manner as the corresponding Seller DC
Plans  (U.S.),  and,  prior  to  the  Closing,  Purchaser  shall  provide  Seller  Parent  any  determination  letters  or  similar
documentation evidencing such qualification.

147

(ii)          Each Purchaser DC Plan (U.S.) shall allow for the receipt in cash from the DC Employees (U.S.) of
“eligible rollover distributions” (as such term is defined under Section 402 of the Code or any equivalent term under
the Puerto Rico Internal Revenue Code), but also including notes corresponding to loans. Purchaser and Seller Parent
shall work together in order to facilitate any such distribution or rollover and to effect an eligible rollover distribution
for those DC Employees (U.S.) who elect to rollover their account balances, including notes, directly into a Purchaser
DC Plan (U.S.).

(iii)      Any DC Employee (U.S.) who has an unvested account balance under a Seller DC Plan (U.S.) as of the
Closing Date shall become vested on the Closing Date in a prorated portion thereof, determined based on the number
of  days  in  the  applicable  vesting  period  elapsed  as  of  the  Closing  Date.  Any  DC  Employee  (U.S.)  who  would  be
eligible for an employer contribution  had he or she remained an active participant in the applicable  Seller DC Plan
(U.S.)  until  the  next  date  on  which  such  employer  contribution  would  be  made,  shall  receive  a  prorated  employer
contribution under the applicable Seller DC Plan (U.S.) on or as soon as reasonably practicable following the Closing
Date, determined based on the number of days in the applicable service period elapsed as of the Closing Date. The
contributions and vesting of benefits described in this Section 6.6(f)(iii) shall be Retained Liabilities.

(g)      Defined Contribution Plans (non-U.S.) .

(i)            Effective  as  of  the  Closing,  Purchaser  shall  establish  or  designate  defined  contribution  plans  or
arrangements (collectively, the “ Purchaser DC Plans (non-U.S.) ”) for the benefit of the Transferred Employees (non-
U.S.)  who  participate  in one  or more of the defined  contribution  plans maintained  by Seller  Parent  or its Affiliates
(other  than  a  Conveyed  Subsidiary  Plan)  or  any  other  arrangement  that  provides  for  similar  benefits  pursuant  to
applicable Law or local practice (collectively, the “ Seller DC Plans (non-U.S.), ” and the Transferred Employees who
participate in the Seller DC Plans (non-U.S.), the “ DC Employees (non-U.S.) ”). The applicable Purchaser DC Plans
(non-U.S.) shall be tax-qualified in the same manner as the corresponding Seller DC Plans (non-U.S.), and, prior to
the Closing, Purchaser shall provide Seller Parent any determination letters or similar documentation evidencing such
qualification.  To  the  extent  permitted  by  applicable  Law,  each  Purchaser  DC  Plan  (non-U.S.)  shall  allow  for  the
receipt in cash from the DC Employees (non-U.S.) of rollover distributions, but also including notes corresponding to
loans.  Purchaser  and Seller  Parent  shall  work together  in order  to facilitate  any  such  distribution  or rollover  and to
effect  a  rollover  distribution  for  those  DC  Employees  (non-U.S.)  who  elect  to  rollover  their  account  balances,
including notes, directly into a Purchaser DC Plan (non-U.S.).

(ii)      Notwithstanding Section 6.6(g)(i) , if applicable Law requires Purchaser to assume the Liabilities of the
DC Employees (non-U.S.) under a Seller DC Plan (non-U.S.), Seller Parent shall cause the transfer under each such
Seller

148

DC  Plan  (non-U.S.)  to  the  corresponding  Purchaser  DC  Plan  (non-U.S.)  of  (A)  the  account  balances  of  such  DC
Employees  (non-U.S.)  as  of  the  Closing  or  cash,  cash  equivalents  or  other  property  equal  to  the  actual  account
balances  of  the  DC  Employees  (non-U.S.)  under  each  such  Seller  DC  Plan  (non-U.S.)  as  of  the  Closing  or  such
greater amount as is required by any applicable Governmental Authority having jurisdiction over the Seller DC Plan
(non-U.S.)  in  order  to  obtain  approval  of  such  transfer,  and  (B)  any  notes  corresponding  to  loans  of  the  DC
Employees (non-U.S.) (collectively, the “ DC Transfer Amounts ”). The transfer of the DC Transfer Amounts shall be
subject to such consents, Approvals and other legal requirements as may apply under applicable Law. Purchaser shall
use  commercially  reasonable  efforts  to  cause  the  DC  Transfer  Amounts  to  be  accepted  by  such  plans.  The  DC
Transfer Amounts to be transferred, if any, from the respective Seller DC Plans (non-U.S.) shall be equitably adjusted
to  take  into  account  benefit  payments  made  from  the  respective  Seller  DC  Plans  (non-U.S.)  to  the  DC  Employees
(non-U.S.) after the Closing but prior to the date of transfer and for any earnings and losses on such amount during
such period. The transfer of the DC Transfer Amounts, if any, shall take place within one hundred eighty (180) days
after the Closing Date. At the times of the transfers of the DC Transfer Amounts, Purchaser  and the Purchaser DC
Plans  (non-U.S.)  shall  assume  all  Liabilities  with  respect  to  the  DC  Transfer  Amounts  relating  to  Transferred
Employees (non-U.S.) that were transferred from the applicable Seller DC Plan (non-U.S.), and Seller Parent and its
Affiliates and the Seller DC Plans (non-U.S.) shall be relieved of all such Liabilities under such Seller DC Plan (non-
U.S.)  with  respect  to  such  Transferred  Employees  (non-U.S.).  From  and  after  the  date  of  the  transfer  of  the  DC
Transfer  Amounts,  Purchaser  agrees  to  indemnify  and  hold  harmless  Seller  Parent  and  its  Affiliates  and  their
respective officers, directors, employees and agents from and against any and all costs, damages, losses, expenses, or
other Liabilities arising out of or related to the DC Transfer Amounts for Transferred Employees (non-U.S.) under the
applicable Seller DC Plans (non-U.S.).

(iii)      Any DC Employee (non-U.S.) who has an unvested account balance under a Seller DC Plan (non-U.S.)
as of the Closing Date shall become vested on the Closing Date in a prorated portion thereof, determined based on the
number of days in the applicable vesting period elapsed as of the Closing Date. Any DC Employee (non-U.S.) who
would be eligible for an employer contribution had he or she remained an active participant in the applicable Seller
DC Plan (non-U.S.) until the next date on which such employer contribution would be made, shall receive a prorated
employer  contribution  under  the  applicable  Seller  DC  Plan  (non-U.S.)  on  or  as  soon  as  reasonably  practicable
following the Closing Date, determined based on the number of days in the applicable service period elapsed as of the
Closing  Date.  The  contributions  and  vesting  of  benefits  described  in  this  Section  6.6(g)(iii)  shall  be  Retained
Liabilities.

149

(iv)      This Section 6.6 does not apply to any Liabilities under a Conveyed Subsidiary Plan, which Liabilities

shall be retained or assumed by Purchaser in accordance with Section 6.6(a)(i)(A) .

(h)      Retiree Medical Plans . Effective as of the Closing, each Transferred Employee who is eligible to become a
participant upon termination of service in the Seller Retained Plans that provide retiree medical benefits set forth on Section 6.6(h) of
the  Seller  Disclosure  Letter  (the  “  Seller  Retiree  Medical  Plans  ”)  as  of  the  Closing  (i)  shall  cease  being  eligible  to  become  a
participant, or accrue service towards eligibility, in the Seller Retiree Medical Plans, and Seller Parent and its Affiliates shall have no
Liabilities  in  respect  of  the  provision  of  post-retirement  medical  benefits  to  such  Transferred  Employee,  and  (ii)  shall  commence
accruing service towards eligibility and level of benefits (taking into account the recognition of all prior service credit in accordance
with  Section  6.6(c)(iii)  )  in  a  retiree  medical  plan  maintained  by  Purchaser  or  its  Affiliates  that  provides  benefits  that  are  either
(A) no less favorable than those provided under the applicable Seller Retiree Medical Plans, including with respect to an employer
subsidy, or (B) the same as those provided to similarly situated Purchaser Business Employees (“ Purchaser Retiree Medical Plan ”),
which  Purchaser  Retiree  Medical  Plan  shall  not  be  modified  in  a  manner  adverse  to  the  Transferred  Employees  relative  to  other
participants; provided , however , such plans shall have requirements for retirement-eligibility that are the same as those provided to
other Purchaser Retiree Medical Plan participants or, if more favorable, during the Continuation Period, the same as the applicable
Seller  Retiree  Medical  Plan  with  respect  to  the  Transferred  Employees.  Subject  to  continued  employment,  the  Transferred
Employees shall continue accruing service towards eligibility and levels of benefits thereunder, for at least the Continuation Period
(or such longer period as required by applicable Law). This Section 6.6(h) shall not limit Purchaser’s obligations with respect to a
Conveyed Subsidiary Plan or any other arrangement that provides for similar benefits as required by applicable Law, which shall be
considered Purchaser Assumed Employee Liabilities, in accordance with Section 6.6(a)(i) .

(i)      Flexible Spending Accounts . Seller Parent and Purchaser shall take all actions necessary or appropriate so that,
effective as of the Closing Date (i) the account balances (whether positive or negative) (the “ Transferred FSA Balances ”) under the
applicable  flexible  spending  plan  of  Seller  Parent  or  its  Affiliates  (collectively,  the  “  Seller  FSA  Plan  ”)  of  the  Transferred
Employees  who  are  participants  in  the  Seller  FSA  Plan  shall  be  transferred  to  one  or  more  comparable  plans  of  Purchaser  or  its
Affiliates (collectively, the “ Purchaser FSA Plan ”); (ii) the elections, contribution levels and coverage levels of such Transferred
Employees shall apply under the Purchaser FSA Plan in the same manner as under the Seller FSA Plan; and (iii) such Transferred
Employees shall be reimbursed from the Purchaser FSA Plan for claims incurred at any time during the plan year of the Seller FSA
Plan in which the Closing Date occurs that are submitted to the Purchaser FSA Plan from and after the Closing Date on substantially
the same basis and substantially the same terms and conditions as under the Seller FSA Plan. As soon as practicable after the Closing
Date,  and  in  any  event  within  thirty  (30)  Business  Days  after  the  amount  of  the  Transferred  FSA  Balances  is  determined,  Seller
Parent  or  its  Affiliates  shall  pay  to  Purchaser  or  its  Affiliates  the  net  aggregate  amount  of  the  Transferred  FSA  Balances,  if  such
amount  is  positive,  and  Purchaser  or  its  Subsidiaries  shall  pay  to  Seller  Parent  or  its  Affiliates  the  net  aggregate  amount  of  the
Transferred FSA Balances, if such amount is negative.

150

(j)      Employment Agreements . Except for any Liabilities related to transaction bonuses or retention awards granted
prior  to  Closing  to  any  Transferred  Employee  that  are  or  were  adopted  without  Purchaser  Parent’s  prior  written  approval
(collectively, the “ Seller Retention Awards ”), any employment, severance, retention or other individual agreement between Seller
Parent  or  its  Affiliates  and  a  Transferred  Employee  and  the  related  Liabilities  shall,  effective  as  of  the  Closing,  be  assumed  by
Purchaser or its Subsidiaries, and shall be considered Purchaser Assumed Employee Liabilities in accordance with Section 6.6(a)(i) .
Seller Parent shall reimburse Purchaser or its applicable Affiliate, as soon as practicable but in any event within thirty (30) days of
receipt  of  appropriate  verification,  for  all  costs  and  expenses  paid  or  incurred  by  Purchaser  or  its  applicable  Affiliate  after  the
Closing Date with respect to the Seller Retention Awards, including the employer side Taxes or other payments related thereto.

(k)      Deferred Compensation . Seller Parent and its Affiliates shall retain all assets and Liabilities in respect of the
Seller Group Plans and Foreign Seller Group Plans set forth on Section 6.6(k) of the Seller Disclosure Letter, which are nonqualified
or non-approved retirement plans that are not Conveyed Subsidiary Plans. For purposes of any Seller Group Plan or Foreign Seller
Group Plan that provides for “nonqualified deferred compensation” within the meaning of Section 409A of the Code, in accordance
with  Treasury  Regulation  §  1.409A-1(h)(4),  Seller  Parent  and  Purchaser  agree  that  the  transfer  of  a  Transferred  Employee’s
employment in accordance with this Agreement shall not constitute a “separation from service” within the meaning of Section 409A
of  the  Code,  and,  further,  for  any  such  Seller  Group  Plan  or  Foreign  Seller  Group  Plan  in  respect  of  which  Seller  Parent  or  its
Affiliates  are  retaining  Liabilities  related  to  a  Transferred  Employee,  that  Purchaser  shall  notify  Seller  Parent  in  writing  of  a
Transferred Employee’s separation from service with Purchaser or its Affiliates within thirty (30) days thereafter.

(l)            Labor  and  Employment  Law  Matters  .  Purchaser  and  Seller  Parent  shall,  and  shall  cause  their  respective
Affiliates  to,  cooperate  to  take  all  steps,  on  a  timely  basis,  as  are  required  under  applicable  Law  (including  the  Transfer  of
Undertakings Laws) or any Collective Bargaining Agreement to notify, consult with, or negotiate the effect, impact, terms or timing
of  the  transactions  contemplated  by  this  Agreement  with  each  works  council,  union,  labor  board,  employee  group  (or  employees
directly) or Governmental Authority related to the foregoing. Seller Parent shall regularly review with Purchaser the progress of the
notifications,  consultations  and  negotiations  with  each  such  works  council,  union,  labor  board,  employee  group  (or  employees
directly)  and  Governmental  Authority  regarding  the  effect,  impact  or  timing  of  the  transactions  contemplated  by  this  Agreement.
Purchaser  and  Seller  Parent  shall,  and  shall  cause  their  respective  Affiliates  to,  comply  with  all  applicable  Laws,  directives  and
regulations relating to the Business Employees in connection with this Section 6.6(l) . To the extent required by Law or Collective
Bargaining Agreement (and within the time periods required by Law or Collective Bargaining Agreement), Purchaser shall or shall
cause its applicable Affiliate to (i) become a party to any Collective Bargaining Agreement with respect to applicable Transferred
Employees  and  shall  be  responsible  for  all  Liabilities  under  any  Collective  Bargaining  Agreement  with  respect  to  any  Business
Employee  or  Former  Business  Employee,  regardless  of  whether  arising  prior  to,  on  or  after  the  Closing  Date,  and  (ii)  join  any
industrial, employer or similar association or federation. Purchaser shall indemnify Seller Parent and its Affiliates for any Liabilities
incurred by Seller Parent and its Affiliates with respect to Purchaser or its Affiliates’ failure to comply with the obligations under
this Section 6.6(l) , which

151

shall  be  considered  Purchaser  Assumed  Employee  Liabilities  in  accordance  with  Section 6.6(a)(i) .  Seller  Parent  shall  indemnify
Purchaser and its Affiliates for any Liabilities incurred by Purchaser and its Affiliates with respect to Seller Parent’s or its Affiliates’
failure to comply with the obligations under this Section 6.6(l) .

(m)      Immigration . Purchaser and Seller Parent shall, or shall cause their respective Affiliates to, use commercially
reasonable efforts to ensure that any foreign national, who requires a visa in order to work for Seller Parent or its Affiliate in his or
her current position, may continue to work in such position as a Transferred Employee following the Closing Date, or, as applicable,
such later date that such Business Employee’s employment transfers to Purchaser or its applicable Affiliate.

(n)      Access to Independent Contractors and Service Providers . During the period prior to the Closing Date, Seller
Parent shall use commercially reasonable efforts to make individual natural person independent contractors related to the Business
and directly engaged by Seller Parent or its Affiliates available to Purchaser for the purpose of allowing Purchaser to interview each
such contractor  and determine  the nature and extent of each such person’s continuation  with Purchaser,  if any. Seller Parent shall
provide  to  Purchaser  contact  information  for  third-party  service  providers  providing  contingent  personnel  to  the  Business  and
reasonably cooperate in identifying and facilitating Purchaser’s engagement of such contingent work force to the extent requested by
Purchaser.

(o)      Communications . Prior to the Closing, any employee notices or communication materials (including website
postings)  from  Purchaser  or  its  Affiliates  to  the  Business  Employees  (including  their  representatives),  including  notices  or
communication  materials  with  respect  to  employment,  compensation  or  benefits  matters  addressed  in  this  Agreement  or  related,
directly  or  indirectly,  to  the  transactions  contemplated  by  this  Agreement  or  employment  thereafter,  shall  be  subject  to  the  prior
review, comment and approval of Seller Parent (such approval not to be unreasonably withheld, conditioned or delayed). Prior to the
Closing, any employee notices or communication materials (including website postings) from Seller Parent or its Affiliates to the
Business  Employees  (or  their  representatives)  with  respect  to  employment  with,  or  compensation  or  benefits  to  be  provided  by,
Purchaser  or  its  Affiliates  following  the  Closing,  shall  be  subject  to  the  prior  review,  comment  and  approval  of  Purchaser  (such
approval not to be unreasonably withheld, conditioned or delayed). Further, prior to the Closing, Purchaser and its Affiliates shall not
make broad-based unwritten communications to the Business Employees without Seller Parent’s prior approval (such approval not to
be unreasonably withheld, conditioned or delayed). Seller Parent and Purchaser shall coordinate to establish a protocol for reviewing
and approving forms of employee notices and communication materials, and employee notices and communication materials that are
consistent with the agreed form shall not be subject to further review and approval.

(p)          Taxes and Filings . With respect to each Transferred Employee (U.S.), the Parties shall, or shall cause their
respective  Affiliates  to, (i) treat  Purchaser  or its applicable  Affiliate  as a “successor  employer”  and Seller Parent  or its applicable
Affiliate as a “predecessor,” within the meaning of Sections 3121(a)(1) and 3306(b)(1) of the Code, for purposes of Taxes imposed
under the U.S. Federal Insurance Contributions Act, as amended (“ FICA ”), or the U.S. Federal

152

Unemployment Tax Act, as amended (“ FUTA ”), (ii) cooperate with each other to avoid the restart of FICA and FUTA upon or
following  the  Closing  with  respect  to  each  such  Transferred  Employee  for  the  year  during  which  the  Closing  occurs,  and
(iii) implement the alternate procedure described in Section 5 of Revenue Procedure 2004-53, including with respect to the filing of
all  applicable  forms  (including  Form  941).  In  addition,  with  respect  to  each  Transferred  Employee  (U.S.),  Purchaser  shall  be
responsible  for  the  filing  of  Form  1095-C  in  respect  of  the  year  in  which  the  Closing  occurs.  In  accordance  with  Section 6.5(c) ,
Seller  Parent  and  its  Affiliates  shall  be  entitled  to  any  Tax  deduction  available  in  respect  of  all  compensation  and  benefit-related
Liabilities that it retains pursuant to this Section 6.6 .

(q)      Cooperation . Subject to applicable Law and Section 2.2 and Section 6.4 , from the date of this Agreement until
the Closing, Seller Parent, Purchaser, and their respective Affiliates will reasonably cooperate in all matters reasonably necessary to
effect  the  transactions  contemplated  by  this  Section 6.6 ,  including  (i)  exchanging  information  and  data  reasonably  necessary  for
Seller  Parent  and  Purchaser  to  comply  with  their  respective  obligations  under  this  Section  6.6  ,  (ii)  making  any  and  all  required
filings  and  notices,  (iii)  making  any  and  all  required  communications  with  Business  Employees,  and  (iv)  obtaining  any  required
approvals of a Governmental Authority.

(r)      No Third Party Beneficiaries . This Section 6.6 is included for the sole benefit of the Parties and their respective
permitted transferees and permitted assigns and does not and shall not create any right in any Person, including any current or former
employee of Seller Parent or any of its Affiliates, any Business Employee, any Transferred Employee or beneficiary or dependent of
the foregoing, who is not a Party. Nothing contained in this Agreement (express or implied) is intended to (a) create or amend any
employee benefit plan or arrangement or (b) confer upon any individual any right to employment for any period of time, or any right
to a particular term or condition of employment. No current or former employee of Seller Parent or any of its Affiliates, any Business
Employee, Former Business Employee or any Transferred Employee, including any beneficiary or dependent thereof, or any other
Person not a Party or permitted transferee or permitted assign thereof, shall be entitled to assert any claim against Purchaser, Seller
Parent or any of their respective Affiliates under this Section 6.6 .

Section 6.7      Intercompany Accounts and Arrangements .

(a)      Seller Parent may take (or cause one or more of its Affiliates to take) such action as is necessary or advisable to
settle, effective as of, or prior to, the Closing Date, all intercompany accounts that are in the nature of Funded Indebtedness between
a  Conveyed  Subsidiary  or  any  Subsidiary  thereof,  on  the  one  hand,  and  Seller  Parent  or  any  of  the  Retained  Subsidiaries,  on  the
other hand, in such a manner as Seller Parent shall determine in its sole discretion without any further Liability or obligation therefor
of  any  Person.  Any  intercompany  accounts  that  are  in  the  nature  of  Funded  Indebtedness  between  a  Conveyed  Subsidiary  or  any
Subsidiary thereof, on the one hand, and Seller Parent or any of the Retained Subsidiaries, on the other hand, that are settled after
12:01 a.m. (New York time) on the Closing Date but in connection with the Closing shall be deemed for purposes of this Agreement
to have been settled as of 12:01 a.m. (New York time) on the Closing Date, and any intercompany accounts that are in the nature of
Funded

153

Indebtedness between a Conveyed Subsidiary (or any of its Subsidiaries), on the one hand, and Seller Parent or any of the Retained
Subsidiaries, on the other hand, that remain outstanding following the Closing shall not be deemed Purchased Assets or Assumed
Liabilities  for  purposes  of  this  Agreement.  Except  for  the  Ancillary  Agreements  or  the  agreements  set  forth  in  Section 6.7 of the
Seller Disclosure Letter or as otherwise expressly contemplated by this Agreement, all intercompany arrangements and agreements,
that are in the nature of Funded Indebtedness whether written or oral, between Seller Parent or any of the Retained Subsidiaries, on
the one hand, and any of the Conveyed Subsidiaries or their Subsidiaries, on the other hand, shall be terminated as of or prior to the
Closing Date without any further Liability or obligation thereunder of any Person and shall be of no further force and effect after the
Closing.

(b)            Purchaser  Parent  may  take  (or  cause  one  or  more  of  its  Affiliates  to  take)  such  action  as  is  necessary  or
advisable  to  settle,  effective  as  of,  or  prior  to,  the  Closing  Date,  all  intercompany  accounts  that  are  in  the  nature  of  Funded
Indebtedness  (other  than  intercompany  accounts  arising  pursuant  to  a  Purchaser  Ancillary  Agreement)  between  Purchaser  or  any
Subsidiary of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser Parent (other than Purchaser and its
Subsidiaries),  on  the  other  hand,  in  such  a  manner  as  Purchaser  Parent  shall  determine  in  its  sole  discretion  without  any  further
Liability  or  obligation  therefor  of  any  Person.  Any  such  intercompany  accounts  that  are  in  the  nature  of  Funded  Indebtedness
between  Purchaser  or  any  Subsidiary  of  Purchaser,  on  the  one  hand,  and  Purchaser  Parent  or  any  Subsidiary  of  Purchaser  Parent
(other than Purchaser and its Subsidiaries), on the other hand, that are settled after 12:01 a.m. (New York time) on the Closing Date
but in connection with the Closing shall be deemed for purposes of this Agreement to have been settled as of 12:01 a.m. (New York
time) on the Closing Date, and any intercompany accounts that are in the nature of Funded Indebtedness between Purchaser or any
Subsidiary of Purchaser, on the one hand, and Purchaser Parent or any Subsidiary of Purchaser Parent (other than Purchaser and its
Subsidiaries),  on  the  other  hand  (other  than  intercompany  accounts  arising  pursuant  to  a  Purchaser  Ancillary  Agreement),  that
remain  outstanding  following  the  Closing  shall  not  be  deemed  an  asset  of  Purchaser  or  a  Purchaser  Liability  for  purposes  of  this
Agreement  (including  for  purposes  of calculating  the Purchaser  Working  Capital),  and  Purchaser  Parent  shall  cancel  or otherwise
transfer such intercompany account from Purchaser and its Subsidiaries for no consideration. All Liabilities related to or arising out
of  the  intercompany  loan  between  Setfirst  Limited  and  Purchaser  in  respect  of  the  acquisition  by  Purchaser  or  its  applicable
Affiliates  of  Novartis  AG’s  interest  in  Purchaser  and  its  applicable  Affiliates  shall  be  fully  extinguished  and  cancelled,  effective
prior  to  the  Closing  Date,  or  shall  otherwise  be  transferred  to  Purchaser  Parent  or  its  Affiliates  (other  than  Purchaser  and  its
Subsidiaries) prior to the Closing Date and shall constitute a Purchaser Parent Retained Liability for all purposes hereunder, in any
case without any further Liability or obligation therefor for Purchaser or any of its Subsidiaries. Except for the Ancillary Agreements
or the Purchaser Related Party Contracts set forth in Section 6.7 of the Purchaser  Parent Disclosure  Letter (the Purchaser  Related
Party  Contracts  set  forth  thereon,  the  “  Purchaser  Ancillary  Agreements  ”)  or  as  otherwise  expressly  contemplated  by  this
Agreement, all Purchaser Related Party Contracts shall be terminated as of or prior to the Closing Date without any further Liability
or obligation thereunder of any Person and shall be of no further force and effect after the Closing.

154

(c)      Except to the extent provided to the contrary in this Section 6.7 and for any rights or obligations pursuant to this
Agreement or any Ancillary Agreement or any commercial or other matter unrelated to this Agreement, effective as of the Closing,
each  of  Purchaser  Parent  and  Purchaser,  on  behalf  of  itself  and  its  respective  Affiliates,  including  the  Conveyed  Subsidiaries  and
their Subsidiaries, hereby releases Seller Parent and each of its Subsidiaries and Affiliates (and their respective officers, directors and
employees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any and all past actions
or failures to take action prior to the Closing directly or indirectly relating to or arising out of the Business, the Retained Businesses,
the Purchaser Business or the operations of the Conveyed Subsidiaries (or their Subsidiaries) prior to the Closing, or relating to or
arising out of Seller Parent’s or its Affiliate’s ownership of the Purchased Assets.

(d)      Except to the extent provided to the contrary in this Section 6.7 and for any rights or obligations pursuant to this
Agreement or any Ancillary Agreement, effective as of the Closing, Purchaser Parent, on behalf of itself and its respective Affiliates
(other  than  Purchaser  and  its  Subsidiaries)  hereby  releases  Purchaser  and  each  of  its  Subsidiaries  (and  their  respective  officers,
directors and employees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any and
all past actions or failures to take action prior to the Closing directly or indirectly relating to or arising out of the Purchaser Business,
the Purchaser Parent Retained Businesses or the operations of Purchaser and its Subsidiaries prior to the Closing, or relating to or
arising  out of the assets, properties  or rights relating  to the Purchaser  Business  or owned, used or held by Purchaser  or any of its
Subsidiaries.

(e)      Except to the extent provided to the contrary in this Section 6.7 and for any rights or obligations pursuant to this
Agreement  or  any  Ancillary  Agreement  or,  in  the  case  of  Purchaser  Parent,  Purchaser  and  each  of  its  Subsidiaries  and  Affiliates
(other than the Conveyed Subsidiaries and their Subsidiaries), any commercial or other matter unrelated to this Agreement, effective
as of the Closing, Seller Parent, on behalf of itself and its Affiliates, hereby releases each of Purchaser Parent, Purchaser and each of
its Subsidiaries and Affiliates (including the Conveyed Subsidiaries and their Subsidiaries) (and their respective officers, directors
and employees, acting in their capacity as such) from any Liability, obligation or responsibility to any of them for any and all past
actions  or  failures  to  take  action  prior  to  the  Closing  directly  or  indirectly  relating  to  or  arising  out  of  the  Business,  Purchaser
Business, the Retained Businesses or the operations of the Conveyed Subsidiaries (or their Subsidiaries) prior to the Closing.

Section 6.8      Access to Records and Information .

(a)      Each of Seller Parent and its Affiliates and each of Purchaser Parent, Purchaser and their Affiliates shall retain
the books, records, documents, instruments, accounts, correspondence, writings, evidences of title and other papers relating to the
Business or the Purchaser Business in its possession for at least seven (7) years following the Closing Date or for such longer period
as  may  be  required  by  Law  or  any  applicable  Governmental  Order.  Each  Party  shall  give  reasonable  written  notice  to  the  other
Parties before ceasing to maintain any such materials, and shall deliver to the other Parties at the other Parties’ expense upon request
any such materials that it has proposed no longer to maintain.

155

(b)      Following the Closing and subject to applicable Law, each Party shall, and shall cause its Affiliates (including,
in the case of Purchaser Parent and Purchaser, the Conveyed Subsidiaries and their Subsidiaries) to, permit the other Parties and their
Affiliates  and  Representatives  reasonable  access  during  normal  business  hours  to  such  books,  records,  documents,  instruments,
accounts, correspondence, writings, evidences of title and other papers and to personnel having knowledge of the whereabouts and/or
contents of such books, records, documents, instruments, accounts, correspondence, writings, evidences of title and other papers, for
legitimate business reasons, including in connection with financial statements, reporting obligations and compliance with applicable
Laws, and to provide such other information relating to the Business or the Purchaser Business as may be reasonably requested by
any  such  other  Party  for  such  purposes;  provided  that  each  Party  may  restrict  the  foregoing  access  or  the  provision  of  such
information  to  the  extent  that,  in  the  reasonable  judgment  of  such  Party,  (i)  applicable  Law  requires  it  or  any  of  its  Affiliates  to
restrict or prohibit such access or the provision of such information, (ii) providing such access would unreasonably interfere with the
operation of its and its Subsidiaries’ respective businesses, (iii) providing such access or information would breach a confidentiality
obligation  to  a  third  party,  (iv)  providing  such  access  or  information  would  result  in  disclosure  of  any  information  that  is
competitively or commercially sensitive, (v) in the case of Seller Parent, the information relates to the Strategic Process, or in the
case of Purchaser Parent, the information relates to the review of strategic alternatives with respect to the Purchaser Business, and for
clarity  in  each  case  (with  respect  to  both  Seller  Parent  and  Purchaser  Parent)  pertaining  to  such  review  prior  to  the  Closing,  or
(vi) providing such access or disclosure of any such information would reasonably be expected to result in the loss or waiver of the
attorney-client or other applicable privilege or protection. In the event that a Party restricts access or withholds information on the
basis of the foregoing clauses (i) through (vi), such Party shall, if permitted, inform the Party requesting such access or information
as  to  the  general  nature  of  what  is  being  restricted  or  withheld  and  the  reason  therefor,  and  such  Parties  shall  each  use  their
commercially  reasonable  efforts  to  make  appropriate  substitute  arrangements  to  permit  disclosure  of  the  relevant  information  in  a
manner that does not suffer from such impediments. Each Party will hold in confidence all Confidential Information obtained from
the other Parties or any of their Affiliates in accordance with Section 6.12 . The Parties agree that, with respect to any matters that
are the subject of this Section 6.8(b) and Section 6.5(i) , the provisions of Section 6.5(i) (and not this Section 6.8(b) ) shall control.

(c)      Without limiting the foregoing in this Section 6.8 , Purchaser Parent and Purchaser acknowledge and agree that
Seller  Parent  and  its  Affiliates  shall  retain,  after  the  Closing,  access  and  use  rights  with  respect  to,  and  may  retain  copies  of,  the
Registration Information (including in relation to pending applications for Product Registrations and Manufacturing Registrations)
for Seller Parent’s and its Affiliates’ use for legal and regulatory compliance purposes.

Section 6.9      Mail and Other Communications . After the Closing Date, each Party and their respective Affiliates
may receive mail and other communications properly belonging to the other Parties (or the other Parties’ Affiliates). Accordingly, at
all times after the Closing Date, each Party authorizes each of the other Parties and their respective Affiliates to receive and open all
mail and other communications received by it and not unambiguously intended for any other Party (or its Affiliates) or any other
Party’s (or its Affiliates’) officers or directors, and to retain the same to the extent that they relate to the business of the receiving
Party or, to the extent that they

156

do not relate to the business of the receiving Party, the receiving Party shall promptly deliver such mail or other communications (or,
in case the same relate to both businesses, copies thereof) to the Party for which such mail and communications are intended. The
provisions of this Section 6.9 are not intended to, and shall not be deemed to, constitute an authorization by any Party to permit the
other to accept service of process on its behalf and no Party is or shall be deemed to be the agent of any other for service of process
purposes.

Section  6.10            Transfer  of  Business  IP  and  Registrations  .  Notwithstanding  anything  to  the  contrary  in  this
Agreement or any Ancillary Agreement, Purchaser Parent shall be responsible for preparing and filing all instruments and documents
necessary to effect the assignment of the Business IP that is owned by Seller Parent or its Subsidiaries, Product Registrations and
Manufacturing  Registrations  to  Purchaser  and  its  Affiliates,  including  all  costs  and  expenses  of  preparing  and  recording  country-
specific assignments and legalization of signatures (where required). Subject to Section 2.2 and Section 6.4 , Seller Parent shall, and
shall  cause  its  Affiliates  to,  cooperate  with  the  foregoing  as  set  forth  herein  and  in  Section  6.4  ;  provided  that,  notwithstanding
anything  to  the  contrary  herein,  such  obligation  of  Seller  Parent  to  cooperate  shall  expire  twenty-four  (24)  months  following  the
Closing  Date  (except  with  respect  to  Registered  Business  IP  that  is  owned  or  purported  to  be  owned  by  Seller  Parent  or  its
Subsidiaries or their predecessors with respect to which there are gaps in the chain of title and the record or beneficial title is, as of
the Closing Date, not in the name of a Seller, which obligation  shall continue until forty-eight (48) months following the Closing
Date.

Section 6.11      No Solicitation . For a period of two (2) years after the Closing Date, (a) Seller Parent shall not, and
shall cause its Affiliates not to, directly or indirectly, solicit for employment or hire any employee of Purchaser or its Subsidiaries
with  the  title  of  vice-president  or  senior  director  or  more  senior  and  (b)  Purchaser  Parent  shall  not,  and  shall  cause  its  Affiliates
(other than Purchaser and its Subsidiaries) not to, solicit for employment or hire any employee of Purchaser or its Subsidiaries with
the title of vice-president or senior director or more senior; provided , however , that the foregoing will not restrict Seller Parent’s,
Purchaser Parent’s or their respective Affiliates’ ability to conduct generalized searches for officers or employees, including through
search firms, bona fide public advertisements on websites or in periodicals of general circulation, so long as such searches are not
targeted at any such employees (or hire any person as a result of such searches), or to solicit (or hire) any person whose employment
has been terminated by Purchaser or any of its Affiliates at least six (6) months prior to any such solicitation.

Section 6.12      Confidentiality .

(a)          For a period of five (5) years after the Closing Date (and for trade secrets, for so long as they remain trade
secrets), each Party shall hold, and shall cause their respective Affiliates to hold, and shall cause their respective Representatives to
hold, in confidence and not to disclose or release or use in any manner without the prior written consent of the other Parties any and
all of the other Parties’ Confidential Information; provided that the Parties may disclose, or may permit disclosure of, Confidential
Information (i) to their respective Affiliates or Representatives who have a need to know such information and are informed of their
obligation to treat such information in the same manner as is applicable to the Parties and in respect of whose

157

failure to comply with such obligations Seller Parent, Purchaser Parent or Purchaser, as the case may be, will be responsible, (ii) if
the  Parties  or  their  respective  Affiliates  or  Representatives  are  compelled  to  disclose,  on  the  advice  of  legal  counsel,  any  such
Confidential Information by judicial or administrative process or by other requirements of Law or any securities exchange, market or
automated  quotation  system  to  which  such  Person  is  subject  or  (iii)  in  connection  with  any  Action  to  enforce  such  Party’s  rights
under  this  Agreement  or  any  Ancillary  Agreement,  or  otherwise  in  the  performance  by  such  Party  of  this  Agreement  or  any
Ancillary  Agreement  in  accordance  with  its  terms.  Notwithstanding  the  foregoing,  in  the  event  that  any  demand  or  request  for
disclosure  of  Confidential  Information  is  made  by  a  Party  pursuant  to  clause (ii) above,  such  Party  shall  (x)  to  the  extent  legally
permissible, promptly notify the other Parties of the existence of such request or demand and the disclosure that is expected to be
made in respect thereto, in each case with sufficient specificity so that the other Parties may, at their expense, seek a protective order
or other appropriate remedy or waive compliance with the provisions of this Section 6.12 and (y) if requested by another Party, assist
such other Party, at such other Party’s expense, in seeking a protective order or other appropriate remedy in respect of such request
or demand; provided that a Party and its Affiliates and Representatives shall be permitted to disclose such Confidential Information
without  notice  in  response  to  a  demand  or  request  for  disclosure  of  Confidential  Information  in  connection  with  a  routine
examination  or  audit  by  a  Governmental  Authority  that  is  not  specifically  directed  at  the  transactions  contemplated  by  this
Agreement or such Confidential Information, provided that such disclosing Party and, if applicable, such Affiliate or Representative,
exercise its and their reasonable best efforts to preserve the confidentiality of such Confidential Information, including by obtaining
reasonable assurances that confidential treatment shall be accorded any Confidential Information so disclosed. If such a protective
order or other remedy or the receipt of a waiver by another Party is not obtained and such disclosing Party or any of its Affiliates or
Representatives  is,  nonetheless,  following  consultation  with  its  legal  counsel,  required  by  such  judicial  or  administrative  process,
Law or securities exchange, market or automated quotation system to disclose any Confidential Information, such disclosing Party
(or  such  Affiliate  or  Representative)  may,  after  compliance  with  the  immediately  preceding  sentence  of  this  Section  6.12(a)  ,
disclose only that portion of the Confidential Information which it has been advised by its legal counsel is required to be disclosed,
provided that such disclosing Party and, if applicable, such Affiliate or Representative, exercise its and their reasonable best efforts
to  preserve  the  confidentiality  of  such  Confidential  Information,  including  by  obtaining  reasonable  assurances  that  confidential
treatment shall be accorded any Confidential Information so disclosed.

(b)      As used in this Agreement, “ Confidential Information ” means all non-public proprietary, technical, economic,
environmental, operational, financial or other business information or material, data, reports, interpretations, forecasts and business
plans,  in  written,  oral  (including  by  recording),  electronic  or  visual  form,  in  the  possession  of,  or  which  has  been  disclosed  to,
whether  prior  to  or  following  the  Closing  Date,  a  Party  or  its  Affiliates  or  Representatives  by  any  other  Party  or  its  Affiliates  or
Representatives,  including  pursuant  to  the  access  provisions  of  this  Agreement  or  any  Ancillary  Agreement,  (i)  related  to  the
transactions  contemplated  by  this  Agreement  or  the  Strategic  Process,  (ii)  in  the  case  of  Seller  Parent  and  its  Affiliates  and
Representatives, to the extent relating to the Purchaser Parent Retained Businesses or the Purchaser Parent Retained Liabilities, and
(iii)  in  the  case  of  Purchaser  Parent,  Purchaser  and  their  respective  Affiliates  and  Representatives,  to  the  extent  relating  to  the
Excluded Assets, the Retained Businesses

158

or  the  Retained  Liabilities  (except,  in  each  case,  to  the  extent  that  such  information  can  be  shown  to  have  been  (A)  in  the  public
domain (other than as a result of a disclosure by such Party or its Affiliates or Representatives), (B) available after the date hereof to
such  Party  or  its  Affiliates  or  Representatives  on  a  non-confidential  basis  from  a  source  other  than  the  other  Parties  or  their
respective Affiliates or Representatives without, to such Party’s knowledge after reasonable inquiry, being subject to any contractual
or  other  obligation  of  confidentiality  to  the  other  Parties  or  their  respective  Affiliates  or  Representatives  or  (C)  independently
developed  by  or  on  behalf  of  such  Party  or  its  Affiliates  or  Representatives  without  use  of,  reference  to  or  reliance  upon  any
Confidential Information of the other Parties (as can be demonstrated by such Party by appropriate documentary evidence) and not,
to  such  Party’s  knowledge  after  reasonable  inquiry,  subject  to  any  contractual  or  other  obligation  of  confidentiality  to  the  other
Parties or their respective Affiliates or Representatives).

(c)      Notwithstanding anything to the contrary set forth herein, (i) Seller Parent and its Affiliates, on the one hand,
and Purchaser Parent, Purchaser and their respective Affiliates, on the other hand, shall be deemed to have satisfied their obligations
hereunder with respect to Confidential Information if they exercise the same degree of care (but no less than a reasonable degree of
care) as they take to preserve confidentiality for their own similar information, materials or other documents and (ii) confidentiality
obligations contained in any agreement between Seller Parent or any of its Affiliates, or Purchaser Parent, Purchaser or any of their
respective Affiliates, on the one hand, and any employee of Seller Parent or any of its Affiliates, or Purchaser Parent, Purchaser or
any of their respective Affiliates, on the other hand, shall remain in full force and effect.

(d)            Notwithstanding  the  foregoing  in  this  Section  6.12  ,  to  the  extent  that  an  Ancillary  Agreement  or  another
Contract pursuant to which a Party or any of its Affiliates is bound provides that certain Confidential Information shall be maintained
confidential on a basis that is more protective of such Confidential Information or for a longer period of time than provided for in
this Section 6.12 , then the applicable provisions contained in such Ancillary Agreement or other Contract shall control with respect
thereto. After the Closing Date, the Confidentiality Agreement shall be deemed to have been terminated by the parties thereto and
shall  no  longer  be  in  effect.  Seller  Parent  shall  enforce,  or  otherwise  assign  to  Purchaser,  its  rights  under  any  confidentiality
agreements  entered  into  by  Seller  Parent  with  other  potential  purchasers  of  the  Business  in  connection  with  the  Strategic  Process
with respect to the confidentiality, non-disclosure or use of Evaluation Material (as defined in such confidentiality agreements) to the
extent  related  to  the  Business.  Seller  Parent  shall,  promptly  after  the  date  hereof,  request  the  return  or  destruction  of  any  such
Evaluation Material provided to such other potential purchasers to the extent required to be returned or destroyed in accordance with
and subject to the terms of such confidentiality agreements.

Section 6.13      Guarantees; Letters of Credit .

(a)      Without limiting Section 6.13(b) in any respect, Purchaser shall use its reasonable best efforts to cause itself,
one of its Affiliates or the Conveyed Subsidiaries to be substituted in all respects for the Sellers and any of their respective Affiliates
and for the Sellers

159

and their respective Affiliates to be released, effective as of the Closing, in respect of all Liabilities and obligations of the Sellers and
any of their respective Affiliates under or related to each of the Seller Parent Guarantees and Seller Parent LCs (other than to the
extent  related  to  the  Retained  Business,  Excluded  Assets  or  Retained  Liabilities),  and  Purchaser  Parent  and  the  Sellers  shall
reasonably cooperate in Purchaser’s efforts. Subject to the parenthetical in the preceding sentence, for any Seller Parent Guarantee or
Seller Parent LC for which Purchaser or any Conveyed Subsidiary, as applicable, is not substituted in all respects for the Sellers and
their  respective  Affiliates  (or  for  which  the  Sellers  and  their  respective  Affiliates  (other  than  the  Conveyed  Subsidiaries)  are  not
released),  effective  as  of  the  Closing,  Purchaser  shall  continue  to  use  its  reasonable  best  efforts,  and  shall  cause  the  Conveyed
Subsidiaries to use their reasonable best efforts, to effect such substitution and release after the Closing, and Purchaser Parent and the
Sellers shall continue to reasonably cooperate in Purchaser’s efforts; provided that none of the Sellers, Purchaser Parent or any of
their respective Affiliates (other than Purchaser and its Subsidiaries) shall have any obligation to make payments or incur any costs
or  expenses,  grant  any  concession  or  incur  any  other  Liability  in  connection  with  such  cooperation  pursuant  to  this  Section 6.13
except to the extent Purchaser agrees to promptly reimburse Sellers, Purchaser Parent and their Affiliates (other than Purchaser and
its Subsidiaries), as applicable, or agrees to fully indemnify the Sellers, Purchaser Parent and their Affiliates (other than Purchaser
and  its  Subsidiaries),  as  applicable,  for  any  such  Liabilities  to  Seller  Parent’s  or  Purchaser  Parent’s  reasonable  satisfaction,  as
applicable.  Without  limiting  the  foregoing,  neither  Purchaser  nor  any  of  its  Affiliates  shall  extend,  renew,  increase  its  obligations
under or transfer to a third party any Contract containing or underlying a Seller Parent Guarantee or Seller Parent LC or any Contract
to which any Seller Parent Guarantee or Seller Parent LC relates or pursuant to which any Seller Parent Guarantee or Seller Parent
LC was issued or required to be issued unless, prior to or concurrently with such extension, renewal, increase or transfer, Purchaser
or a Subsidiary of Purchaser is substituted in all respects for the Sellers and each of their respective Affiliates, and the Sellers and
their respective Affiliates are released, in respect of all Liabilities and obligations of the Sellers and each of their respective Affiliates
under or in respect of such Seller Parent Guarantee or Seller Parent LC. In no event shall Seller Parent or any of its Affiliates be
obligated to pay any money to any Person to effect the substitutions described in this Section 6.13(a) . The Parties agree that neither
Seller Parent nor any of the Retained Subsidiaries will have any obligation to renew any Seller Parent LCs after the expiration of any
such letter of credit. Neither the Seller Parent Guarantees nor the Seller Parent LCs shall be deemed Purchased Assets hereunder.

(b)           Without limiting Section 6.13(a) in  any  respect,  from  and  after  the  Closing,  Purchaser  and  its  Subsidiaries,
including  the  Conveyed  Subsidiaries  (and  their  Subsidiaries),  jointly  and  severally,  shall  indemnify  and  hold  harmless  the  Seller
Parent Indemnified Parties against any Liabilities that the Sellers or any of their respective Affiliates suffer, incur or are liable for
following the Closing by reason of or arising out of or in consequence of (i) the Sellers or any of their respective Affiliates issuing,
making payment under, being required to pay or reimburse the issuer of or any other Person in connection with, or being a party to,
any Seller Parent Guarantee or Seller Parent LC, (ii) any claim or demand for payment made on the Sellers or any of their respective
Affiliates with respect to any Seller Parent Guarantee or Seller Parent LC or (iii) any Action by any Person who is or claims to be
entitled to the benefit of or claims to be entitled to payment, reimbursement or indemnity with respect to any Seller Parent Guarantee
or Seller Parent LC.

160

Section 6.14      Certain Ancillary Agreements .

(a)            Prior  to  the  date  hereof,  Purchaser  Parent  has  delivered  to  Seller  Parent  true  and  complete  copies  of  all
Purchaser  Ancillary  Agreements  currently  in effect  (and within  forty-five  (45) days following  the date hereof  shall provide  Seller
Parent with true and complete copies of any other material Purchaser Related Party Contracts to the extent not previously provided).
Following  the  date  hereof,  the  Parties  will  discuss,  cooperate  and  negotiate  reasonably  and  in  good  faith  to  cause  to  be  prepared
reasonably in advance of the Closing, and in any event to be finalized within one hundred and twenty (120) days following the date
hereof,  forms  of  each  of  the  following:  (i)  a  transition  services  agreement  with  respect  to  the  provision  of  certain  services  on  a
transitional  basis  following  the  Closing  by  Seller  Parent,  or  certain  of  its  Affiliates,  to  Purchaser  and  its  Subsidiaries  (and,  to  the
extent  reasonably  requested  by  Seller  Parent,  a  reciprocal  reverse  transition  services  agreement  with  respect  to  the  provision  of
services by Purchaser and its Subsidiaries to Seller Parent and its Affiliates relating to any Excluded Assets that are not transferred
out of the Conveyed  Subsidiaries  or their Subsidiaries  prior to the Closing,  if any) (the “  Transition  Services Agreement ”), (ii) a
cross-license agreement with respect to the license of certain Intellectual Property related to and used in the Business to Purchaser
and its Subsidiaries and certain Business IP related to and used in the Retained Businesses to Seller Parent and its Affiliates (the “
Intellectual  Property  License  Agreement  ”),  (iii)  a  manufacturing  and  supply  agreement  with  respect  to  the  supply  of  certain
Products manufactured at Retained Facilities by Seller Parent, or certain of its Affiliates, to Purchaser, or certain of its Subsidiaries
(the “ Manufacturing and Supply Agreement (Seller Parent as Supplier) ”), (iv) a manufacturing and supply agreement with respect
to the supply of certain products commercialized by the Retained Businesses that are manufactured at the Facilities by Purchaser, or
certain  of  its  Subsidiaries,  to  Seller  Parent,  or  certain  of  its  Affiliates  (the  “  Manufacturing  and  Supply  Agreement  (Purchaser  as
Supplier) ”), (v) Intellectual Property assignment agreements with respect to the assignment of Seller Parent’s and its Subsidiaries’
right, title and interest in the Business IP in accordance with this Agreement to Purchaser and its Subsidiaries (the “ IP Assignment
Agreements ”),  (vi)  a  transitional  trademark  license  agreement  with  respect  to  the  license  of  certain  Trademarks  on  a  transitional
basis  following  the  Closing  by  Seller  Parent,  or  certain  of  its  Affiliates,  to  Purchaser  and  its  Subsidiaries  (the  “  Transitional
Trademark  License  Agreement  ”),  (vii)  a  safety  data  exchange  agreement  to  govern  the  provision  and  safeguarding  of  certain
information  provided  pursuant  to  this  Agreement  in  a  manner  compliant  with  applicable  Law  (the  “  Safety  Data  Exchange
Agreement ”), and (viii) the Local Implementing Agreements (the forms of each of the agreements described in the foregoing clauses
(i) through (viii), collectively the “ Form Ancillary Agreements ”). The Parties agree that the Form Ancillary Agreements shall be
prepared substantially based on the Form Ancillary Agreements previously provided by Seller Parent to Purchaser Parent appended
hereto as Exhibit F and the Parties shall negotiate in good faith those terms that were not agreed to as reflected in Purchaser Parent’s
responses to such, which are appended hereto as Exhibit G . The Manufacturing and Supply Agreement (Purchaser as Supplier) and
the Manufacturing and Supply Agreement (Seller Parent as Supplier) shall be negotiated in accordance with the specific terms and
principles set forth on Section 6.14 of the Seller Disclosure Letter. The terms of such Form Ancillary Agreements shall in each case
be consistent with the terms of this Agreement.

161

(b)            At  the  Closing,  Purchaser  Parent,  Purchaser  and  Seller  Parent,  as  applicable,  shall  enter  into,  execute  and
deliver,  or  cause  their  applicable  Affiliates  to  enter  into,  execute  and  deliver,  each  Form  Ancillary  Agreement,  a  shareholders
agreement  substantially  in  the  form  set  forth  in  Exhibit  C  (the  “  Purchaser  Shareholders  Agreement  ”),  and  a  Structuring
Considerations Agreement substantially in the form set forth in Exhibit D (the “ Structuring Considerations Agreement ”).

(c)           Promptly  after  the  date  hereof,  Seller  Parent  and  Purchaser  Parent  shall  reasonably  cooperate  to  discuss  the
service charges in the Support Services Agreement, dated as of March 2, 2015, by and between GlaxoSmithKline Services Unlimited
and Purchaser, as amended, and to provide details on such charges to ensure a reasonable methodology is being applied.

(d)            Promptly  after  the  date  here,  the  Seller  Parent  and  Purchaser  Parent  shall  negotiate  a  lease  agreement  and
related  documentation  in  accordance  with  the  terms  set  forth  on  Section  6.14(d)  of  the  Seller  Disclosure  Letter  (the  “  Lease
Agreement ”).

Section 6.15      Retained and Transferred Names .

(a)      Retained Names . (i) As soon as reasonably practicable, but in no event later than forty-five (45) days after the
Closing, unless a longer period of time is necessary to comply with applicable Law (including to the extent a longer period of time is
necessary to assign or update any Product Registrations, Manufacturing Registrations, or Governmental Authorizations or for legal
or  regulatory  compliance  purposes)  (“  Compliance  Requirements  ”),  and,  in  such  event,  as  reasonably  promptly  as  possible  as
allowed under applicable Law, Purchaser shall cause each Conveyed Subsidiary (and each Subsidiary thereof) to file to change its
name and cause its certificate of incorporation (or equivalent organizational document), as applicable, to be amended to remove any
and  all  references  to  (A)  “Pfizer”,  “Wyeth”  or  “Pfizer  Consumer  Health”,  and  (B)  all  other  Retained  Names  set  forth  in  Section
1.1(E) of the Seller Disclosure Letter or otherwise designated by Seller Parent in writing prior to the Closing (clauses (A) and (B),
collectively, the “ Retained Brands ”); and (ii) notwithstanding anything to the contrary in this Agreement, in the event any name
change of any Conveyed Subsidiary (or Subsidiary thereof) in accordance with this Section 6.15(a) would take effect during the term
of  the  Transition  Services  Agreement,  including  any  extensions  thereof,  Purchaser  shall  (a)  at  least  thirty  (30)  days  prior  to  such
name  change,  consult  with  Seller  Parent  regarding  the  contemplated  change  and  (b)  upon  Seller  Parent’s  request,  refrain  from
making  any  such  change  if  Seller  Parent  determines  in  good  faith  that  such  change  would  reasonably  be  expected  to  result  in
additional cost or operation burden to Seller Parent or any of its Affiliates in connection with one or more Services (as defined in the
Transition  Services  Agreement)  provided  by  Seller  Parent  or  any  of  its  Affiliates  under  the  Transition  Services  Agreement,  until
such  time  as  is  as  soon  as  reasonably  practicable  after  the  term  of  the  applicable  Service  (or  Services)  is  terminated  or  expires
pursuant to the terms of the Transition Services Agreement (the date that Purchaser is required to cause each Conveyed Subsidiary to
make such name change filing in accordance with clauses (i) and (ii), the “ Name Change Date ”). Except as authorized pursuant to
an Ancillary Agreement, as soon as reasonably practicable after the later of (a) the Closing, but in no event later than forty-five (45)
days after the Closing (or, if later, by the later of the Name Change Date or such other date as agreed between Purchaser and Seller
Parent) and (b) any longer period of time necessary

162

with  respect  to  any  Compliance  Requirement,  Purchaser  shall,  and  shall  cause  its  Affiliates  to,  remove,  strike  over  or  otherwise
obliterate  all Retained  Brands  from all assets and other materials  owned by the Conveyed  Subsidiaries  (and Subsidiaries  thereof),
including  any  sales  and  product  literature,  vehicles,  business  cards,  schedules,  stationery,  packaging  materials,  displays,  signage,
advertising, marketing, promotional and related materials, training materials, audio and visual materials, manuals, forms, websites,
social media pages and accounts, e-mail and e-mail addresses, computer software and other materials and systems, and shall cease
and  discontinue  any  other  use  of  the  Retained  Brands  as  of  the  Closing  in  the  operation  of  their  businesses.  Notwithstanding  the
foregoing, nothing in this Agreement is intended to prohibit any use (or require any removal, striking over, or other obliteration) by
Purchaser or any of its Affiliates of any Retained Brand (x) for historical references, including in regulatory filings and to describe
the past ownership and affiliation of the Business, and (y) in any manner as is or would have been permitted by applicable Law with
respect to Trademarks, including fair use, or nominal use, and other uses not prohibited by Law.

(b)      Purchaser Names . As soon as reasonably practicable after the Closing, but in no event later than forty-five (45)
days  unless  a  longer  period  of  time  is  necessary  to  comply  with  applicable  Law,  and,  in  such  event,  as  reasonably  promptly  as
possible  as  allowed  under  applicable  Law,  Seller  Parent  shall,  and  shall  cause  its  Affiliates  to,  remove,  strike  over  or  otherwise
obliterate all Business Trademark Rights, as applicable, from all assets and other materials owned by Seller Parent and its Affiliates
and,  to  the  extent  applicable  file  to  change  its  name  and  cause  its  certificate  of  incorporation  (or  equivalent  organizational
document),  as  applicable,  to  be  amended  to  remove  any  and  all  references  to  any  Business  Trademark  Rights,  as  applicable,
including  any  sales  and  product  literature,  vehicles,  business  cards,  schedules,  stationery,  packaging  materials,  displays,  signage,
advertising, marketing, promotional and related materials, training materials, audio and visual materials, manuals, forms, websites,
social media pages and accounts, e-mail and e-mail addresses, computer software and other materials and systems, and shall cease
and discontinue any other use of such Business Trademark Rights in the operation of their business.

Section 6.16      Compliance with WARN . Purchaser agrees to provide or cause to be provided any required notice
under WARN, and otherwise to comply with WARN with respect to any “plant closing” or “mass layoff” or similar event affecting
Transferred Employees and occurring on or after the Closing Date. Purchaser agrees to, and shall cause its Affiliates to, indemnify
and  hold  harmless  Seller  Parent  and  the  Retained  Subsidiaries  from  and  against  any  and  all  Losses  which  Seller  Parent  and  the
Retained Subsidiaries  may incur in connection with any Action or claim of violation brought against Seller Parent and any of the
Retained Subsidiaries under WARN (including with respect to any “plant closing” or “mass layoff”), which relate, in whole or in
part,  to  actions  taken  by  Purchaser  or  any  of  its  Affiliates  following  the  Closing  with  regard  to  any  site  of  employment  of  the
Conveyed Subsidiaries (or their Subsidiaries) or the Purchased Assets or any of their respective operating units within any site where
a Transferred Employee is located. On or as soon as reasonably practicable following the Closing Date, Seller Parent shall provide,
by termination date and work location, the name or employee identification number of each employee or former employee of Seller
Parent  or  its  Affiliates  and  the  Conveyed  Subsidiaries  who  has  suffered  an  “employment  loss”  under  WARN  at  any  site  of
employment where a Business Employee is located within the ninety (90) days immediately preceding the Closing Date.

163

Section 6.17      Litigation Support; Non-Indemnified Claims .

(a)          Following the Closing, each Party and its respective Affiliates, shall cooperate with each other Party and its
respective  Affiliates  in  the  mitigation,  defense  or  settlement  of  any  Liabilities  or  Actions  involving  the  Business  or  Retained
Businesses or the Purchaser Business or Purchaser Parent Retained Businesses for which such other Party has responsibility under
this  Agreement,  including  with  respect  to  any  Retained  Liabilities,  Purchaser  Parent  Retained  Liabilities,  Assumed  Liabilities  or
Purchaser Liabilities, by providing such other Party and such other Party’s legal counsel, upon reasonable advance notice in writing
and  during  normal  business  hours,  access  to  current  and  former  employees,  contractors,  records,  documents,  data,  equipment,
facilities, products, parts, prototypes and other information as such other Party may reasonably request, to the extent maintained or
under  the  possession  or  control  of  such  Party  and  its  Affiliates;  provided  that  any  Party  may  restrict  the  foregoing  access  or  the
provision of such information to the extent that, in the reasonable judgment of such Party, (i) applicable Law requires such Party or
any of its Affiliates, as applicable, to restrict or prohibit such access or the provision of such information, (ii) providing such access
would  unreasonably  interfere  with  the  operation  of  its  and  its  Subsidiaries’  respective  businesses,  (iii)  providing  such  access  or
information  would  breach  a  confidentiality  obligation  to  a  third  party,  (iv)  providing  such  access  or  information  would  result  in
disclosure of any information that is competitively or commercially sensitive, (v) in the case of Seller Parent, the information relates
to the Strategic Process or, in the case of Purchaser Parent, the information relates to review of strategic alternatives with respect to
the  Purchaser  Business,  and  for  clarity  in  each  case  (with  respect  to  both  Seller  Parent  and  Purchaser  Parent)  pertaining  to  such
review  prior to the Closing,  or (vi) providing  such access  or disclosure  of any such  information  would  reasonably  be expected  to
result in the loss or waiver of the attorney-client or other applicable privilege or protection. In the event that a Party restricts access
or withholds information on the basis of the foregoing clauses (i) through (vi) , such Party shall, if permitted, inform the requesting
Party as to the general nature of what is being restricted or withheld and the reason therefor, and such Parties shall each use their
commercially  reasonable  efforts  to  make  appropriate  substitute  arrangements  to  permit  disclosure  of  the  relevant  information  in  a
manner that does not suffer from such impediments. The requesting Party shall reimburse the other Party for its reasonable out-of-
pocket expenses paid to third parties in performing its obligations under this Section 6.17 . The Parties agree that, with respect to any
matters that are the subject of this Section 6.17 and Section 6.5(i) , the provisions of Section 6.5(i) (and not this Section 6.17 ) shall
control.

(b)            From  and  after  the  Closing,  (i)  Purchaser  shall  promptly  notify  Seller  Parent  of  any  Action  brought  by  or
against a third party with respect to the Business that would reasonably be expected to affect any Retained Business, Excluded Asset
or Retained Liability, (ii) Purchaser shall promptly notify Purchaser Parent of any Action brought by or against a third party with
respect to the Purchaser Business that would reasonably be expected to affect any Purchaser Parent Retained Business or Purchaser
Parent  Retained  Liability,  (iii)  Seller  Parent  shall  promptly  notify  Purchaser  and  Purchaser  Parent  of  any  Action  brought  by  or
against  a  third  party  with  respect  to  the  Retained  Businesses  that  would  reasonably  be  expected  to  affect  the  Business  or  any
Purchased  Asset  or  Assumed  Liability  and  (iv)  Purchaser  Parent  shall  promptly  notify  Purchaser  and  Seller  Parent  of  any  Action
brought by or against a third party with respect to the Purchaser Parent Retained Businesses that would reasonably be expected to
affect the Purchaser Business or any Purchaser

164

Liability  or  any  assets,  properties  or  rights  relating  to  the  Purchaser  Business  or  owned,  used  or  held  by  Purchaser  or  any  of  its
Subsidiaries.  The  provisions  of  Article VII shall  apply  to  any  Third  Party  Claim  with  respect  to  which  any  Indemnified  Party  is
entitled to indemnification under Article VII . With respect to any other third party Action (“ Non-Indemnified Claims ”), if such
Non-Indemnified  Claim  could  reasonably  be  expected  to  (i)  affect  any  Purchaser  Parent  Retained  Businesses  or  Purchaser  Parent
Retained Liability, Purchaser Parent shall have the right but not the obligation, at its option and its own expense, to participate in the
defense or settlement of such Non-Indemnified Claim and to employ counsel of its own choosing for such purpose, (ii) affect any
Retained Business, Excluded Asset or Retained Liability, Seller Parent shall have the right but not the obligation, at its option and its
own expense, to participate in the defense or settlement of such Non-Indemnified Claim and to employ counsel of its own choosing
for  such  purpose  or  (iii)  affect  the  Business,  the  Purchaser  Business  or  any  Purchased  Asset  or  Assumed  Liability  or  Purchaser
Liability, or any other assets, properties or rights relating to the Purchaser Business or owned, used or held by Purchaser or any of its
Subsidiaries, Purchaser shall have the right but not the obligation, at its option and its own expense, to participate in the defense or
settlement of such Non-Indemnified Claim; provided , in each case, that such participation would not materially adversely affect the
defense of such Non-Indemnified Claim and there is no material conflict of interest between the applicable Parties with respect to
such Action.

(c)      In furtherance of the foregoing, from and after the Closing Date, each Party shall, and shall cause its respective
Affiliates to, (i) cooperate with each other Party and its respective Affiliates in the mitigation, defense or settlement of any Liabilities
or  Actions  described  in  Section  6.17(b)  and  (ii)  provide  to  each  other,  upon  written  request,  reasonable  access  during  normal
business  hours  to  their  current  and  former  officers,  directors,  employees,  contractors,  personnel  and  agents  for  fact  finding,
consultation and interviews and as witnesses in connection with any Action in which the requesting Party may from time to time be
involved relating to the matters described in Section 6.17(b) , in each case subject to Section 6.17(a) . The requesting party agrees to
reimburse the other for reasonable out-of-pocket expenses (other than officers’ or employees’ salaries) incurred in connection with
providing individuals and witnesses pursuant to this Section 6.17(c) .

Section 6.18      Insurance .

(a)      From and after the Closing Date, the Conveyed Subsidiaries and their Subsidiaries shall cease to be insured by
Seller Parent’s or its Affiliates’ insurance policies or by any of their self-insured programs. Seller Parent or any of its Affiliates may
amend,  effective  at  or  prior  to  the  Closing,  any  insurance  policies  in  the  manner  it  deems  appropriate  to  give  effect  to  this
Section 6.18 . From and after the Closing, Purchaser shall be responsible for securing all insurance it considers appropriate for its
operation  of  the  Conveyed  Subsidiaries  and  their  Subsidiaries  and  the  Business.  Seller  Parent  shall  use  reasonable  best  efforts  to
keep or cause its Affiliates to keep all insurance policies currently maintained with respect to the Business, or suitable replacements
or renewals, in full force and effect through 12:01 a.m. (New York time) on the Closing Date.

(b)           With  respect  to  any  Assumed  Liability  arising  out  of  events  or  circumstances  pertaining  to  the  Business  or
Purchased Assets that occurred or existed prior to the Closing and are covered under any occurrence-based unaffiliated third party
automobile or general liability

165

insurance  policy  of  Seller  Parent  or  its  Subsidiaries  (an  “  Insurance  Policy  ”)  in  effect  as  of  the  Closing  (such  events  or
circumstances, an “ Insurance Matter ”), Purchaser may tender such Insurance Matter for submission by Seller Parent or one of its
Subsidiaries to the applicable insurer under such Insurance Policy under which the Sellers or the Conveyed Subsidiaries (or any of
their  Subsidiaries)  were  insured  as  of  the  date  of  the  applicable  events  or  circumstances,  in  which  case  Seller  Parent  will  use
commercially  reasonable  efforts  to  submit  a  claim  with  respect  to  such  Insurance  Matter  to  the  applicable  insurer;  provided  that
Purchaser and the Conveyed Subsidiaries (and their Subsidiaries) shall indemnify Seller Parent and its Affiliates for any reasonable
direct  costs  and  expenses  (including  reasonable  costs  of  investigation  of  the  underlying  claim  and  of  collection  and  any  Taxes
imposed in respect of such insurance proceeds) in connection with the foregoing and shall be solely responsible for (i) any per claim
deductible or per claim self-insured retentions with respect to such Insurance Matter, (ii) any claims, costs and expenses (including
attorneys’  fees)  with  respect  to  such  Insurance  Matter  that  are  not  covered  under  the  relevant  Insurance  Policy,  and  (iii)  any
collateral  requirements  with  respect  to  such  Insurance  Matter;  provided  ,  further  that  (A)  Purchaser  shall  not,  and  shall  cause  its
Affiliates  not  to,  in  connection  with  any  Insurance  Matter  under  any  Insurance  Policy,  take  any  action  that  would  be  reasonably
likely to result in the applicable insurer terminating or materially reducing coverage under such Insurance Policy, (B) if an Insurance
Policy  aggregate  is  exhausted,  or  believed  likely  to  be  exhausted,  due  to  noticed  claims,  Purchaser,  on  the  one  hand,  and  Seller
Parent, on the other hand, shall be responsible for their pro rata portion of the reinstatement premium, if any, based upon the amount
of the claims submitted by each of them (or their respective Affiliates) thereunder and (C) Purchaser shall not be entitled to make
any  claims  or  receive  any  proceeds  to  the  extent  the  related  Liabilities  are  included  in  the  calculation  of  Final  Business  Working
Capital or Final Business Net Cash or such proceeds were otherwise credited to Purchaser at or prior to the Closing. Except as set
forth in Section 2.1(o) and the immediately preceding sentence, from and after the Closing, none of Purchaser Parent, Purchaser or
any of their respective Affiliates (including the Conveyed Subsidiaries and their Subsidiaries)  shall have any access, right, title or
interest  to  or  in  any  of  Seller  Parent’s  or  its  Affiliates’  past  or  current  insurance  policies  or  any  of  their  self-insured  programs
(including to all claims and rights to make claims and all rights to proceeds) to cover any assets of the Conveyed Subsidiaries or their
Subsidiaries or any Assumed Liability or any other Liability arising from the operation of the Business or the ownership or use of
any Purchased Asset before, on or after the Closing, and Purchaser shall not and shall cause its Affiliates (including the Conveyed
Subsidiaries and their Subsidiaries)  not to seek to assert or to exercise any rights or claims of any Conveyed Subsidiaries or their
Subsidiaries or the Business under or in respect of any such past or current insurance policy, including under which any Conveyed
Subsidiary  or  Affiliate  thereof  or  the  Business  is  a  named  insured,  and  without  limiting  the  foregoing  shall  not  seek  to  assert  or
exercise (w) any rights with respect to any self-insurance programs of Seller Parent or any of its Affiliates, (x) any rights under any
fronting  insurance  programs  or  arrangements  of  Seller  Parent  or  its  Affiliates,  (y)  any  rights  under  any  claims-made  insurance
programs of Seller Parent or its Affiliates or (z) any rights to cause Seller Parent or any of its Affiliates to pay any deductible or self-
insured retention amount with respect to any claim. Purchaser shall notify Seller Parent promptly of any such Insurance Matter for
which it seeks coverage and Purchaser and Seller Parent shall keep each reasonably informed regarding the status of the Insurance
Matter.

166

Section 6.19      Trade Notification . Seller Parent and Purchaser Parent shall agree on the method and content of the
notifications  to  partners,  customers,  suppliers,  wholesalers  and  distributors  of  the  Business  and  the  Purchaser  Business  of  the
transactions  contemplated  by this  Agreement  prior  to the Closing.  Seller  Parent  and Purchaser  agree  that  such notifications  are to
provide sufficient advance notice of the transactions contemplated hereby and the plans associated therewith, with the objective of
minimizing any disruption of the Business and the Purchaser Business.

Section 6.20      Accounts; Products Received .

(a)            All  payments  and  reimbursements  received  by  Seller  Parent,  Purchaser  Parent  or  their  Affiliates  after  the
Closing that, consistent with the terms and conditions of this Agreement or any Ancillary Agreement, are the property of Purchaser
or its Subsidiaries (including the Conveyed Subsidiaries and their Subsidiaries) shall be held by such Person in trust for the benefit of
Purchaser  and,  promptly  following  receipt  by  such  Person  of  any  such  payment  or  reimbursement,  such  Person  shall  pay  over  to
Purchaser the amount of such payment or reimbursement without right of set-off. All payments and reimbursements received after
the  Closing  by  Purchaser  Parent,  Purchaser  or  their  Affiliates  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries)  that,
consistent with the terms and conditions of this Agreement or any Ancillary Agreement, are the property of Seller Parent or any of
its Affiliates, shall be held by such Person in trust for the benefit of Seller Parent and, promptly following receipt by such Person of
any  such  payment  or  reimbursement,  such  Person  shall  pay  over  to  Seller  Parent  the  amount  of  such  payment  or  reimbursement
without  right  of  set-off.  All  payments  and  reimbursements  received  after  the  Closing  by  (x)  Seller  Parent  or  its  Affiliates  or  (y)
Purchaser or its Subsidiaries that, consistent with the terms and conditions of this Agreement or any Ancillary Agreement, are the
property of Purchaser Parent or any of its Affiliates (other than Purchaser and its Subsidiaries), shall be held by such Person in trust
for  the  benefit  of  Purchaser  Parent  and,  promptly  following  receipt  by  such  Person  of  any  such  payment  or  reimbursement,  such
Person shall pay over to Purchaser Parent the amount of such payment or reimbursement without right of set-off.

(b)            If  Products  or  Purchaser  Products  are  received  by  Seller  Parent  or  its  Affiliates  or  Purchaser  Parent  or  its
Affiliates (other than Purchaser and its Subsidiaries) after the Closing, Seller Parent or Purchaser Parent, as applicable, shall or shall
cause such Affiliate to ship those Products or Purchaser Products to Purchaser, or Purchaser’s stated representative, at Purchaser’s
sole  cost  and  expense.  Purchaser  shall  have  sole  responsibility  for  accepting  and  processing  all  returns  following  the  Closing  of
Products  and  disbursing  refunds  and  credits  in  respect  thereof  (whether  such  Products  were  sold  prior  to,  on  or  after  the  Closing
Date).

Section 6.21      Directors’ and Officers’ Indemnification .

(a)      If the Closing occurs, Purchaser shall, and shall cause the Conveyed Subsidiaries and their Subsidiaries to, take
any necessary actions to provide that all rights to indemnification and all limitations on liability existing in favor of any current or
former  officers,  directors,  partners,  members,  or  managers  of  the  Conveyed  Subsidiaries  or  their  Subsidiaries  (or  their  respective
predecessors) (collectively, the “ D&O Indemnitees ”), as provided in (i) the organizational documents of the Conveyed Subsidiaries
and their Subsidiaries or (ii) any agreement

167

providing for indemnification by the Conveyed Subsidiaries or their Subsidiaries of any of the D&O Indemnitees, which agreements
are set forth in Section 6.21 of the Seller Disclosure Letter, shall survive the consummation of the transactions contemplated hereby
and continue in full force and effect and be honored by the Conveyed Subsidiaries or their Subsidiaries after the Closing.

(b)      In the event that any of the Conveyed Subsidiaries or their Subsidiaries or Purchaser or any of their respective
successors  or  assigns  (i)  consolidates  with  or  merges  into  any  other  Person  and  is  not  the  continuing  or  surviving  corporation  or
entity of such consolidation or merger or (ii) transfers or conveys all or a majority of its properties and assets to any Person, then,
and  in  each  such  case,  proper  provision  shall  be  made  so  that  the  successors  and  assigns  of  the  Conveyed  Subsidiaries  or  their
Subsidiaries or Purchaser, as the case may be, shall succeed to the obligations set forth in this Section 6.21 .

(c)      The obligations of Purchaser under this Section 6.21 shall not be terminated or modified in such a manner as to
adversely  affect  any  D&O  Indemnitee  without  the  express  written  consent  of  such  affected  D&O  Indemnitee  (it  being  expressly
agreed that the D&O Indemnitees shall be third party beneficiaries of this Section 6.21 ).

Section 6.22      Return of Assets; Transfer of Purchased Assets .

(a)      If, at any time after the Closing, any asset held by Purchaser or any of its Subsidiaries (including the Conveyed
Subsidiaries and their Subsidiaries) is ultimately determined to be an Excluded Asset or an asset of the Purchaser Parent Retained
Business, or Purchaser or any of its Subsidiaries is found subject to a Retained Liability, or Purchaser or any of its Subsidiaries is
found  subject  to  a  Purchaser  Parent  Retained  Liability,  within  thirty  (30)  days  of  such  determination  (i)  Purchaser  shall  return  or
transfer and convey (without further consideration) to Seller Parent or the appropriate Affiliate of Seller Parent such Excluded Asset
or  Retained  Liability,  or  to  Purchaser  Parent  or  the  appropriate  Affiliate  of  Purchaser  Parent  (other  than  Purchaser  and  its
Subsidiaries)  such  asset  of  the  Purchaser  Parent  Retained  Business  or  such  Purchaser  Parent  Retained  Liability,  as  applicable;
(ii) Seller Parent shall, or shall cause its appropriate Affiliate to, assume (without further consideration) such Retained Liability, or
Purchaser  Parent  shall  assume  (without  further  consideration)  such  Purchaser  Parent  Retained  Liability;  and  (iii)  Seller  Parent  or
Purchaser  Parent,  as  applicable,  and  Purchaser  shall,  and  shall  cause  their  appropriate  Affiliates  to,  execute  such  documents  or
instruments of conveyance or assumption and take such further acts, in each case consistent with the terms of this Agreement and the
Ancillary Agreements, as are reasonably necessary or desirable to effect the transfer of such Excluded Asset or Retained Liability
back  to  Seller  Parent  or  its  appropriate  Affiliate  or  such  asset  of  the  Purchaser  Parent  Retained  Business  or  Purchaser  Parent
Retained Liability back to Purchaser Parent, as applicable, in each case such that each Party is put into the same economic position
as if such action had been taken on or prior to the Closing Date. In furtherance of the foregoing, Purchaser and its Affiliates shall,
and shall cause the Conveyed Subsidiaries and their Subsidiaries to, promptly pay or deliver (1) to Seller Parent (or its designee) any
monies  or  checks  which  have  been  sent  to  Purchaser  or  any  of  its  Affiliates  (including  the  Conveyed  Subsidiaries  and  their
Subsidiaries) to the extent they are not due to the Business and which should have been sent to Seller Parent or one of its Affiliates
(including promptly forwarding invoices or similar documentation to Seller Parent) or (2) to Purchaser Parent

168

(or  its  designee  other  than  Purchaser  and  its  Subsidiaries)  any  monies  or  checks  which  have  been  sent  to  Purchaser  or  any  of  its
Subsidiaries to the extent they are not due to the Purchaser Business and which should have been sent to Purchaser Parent or one of
its  Affiliates  (other  than  Purchaser  and  its  Subsidiaries)  (including  promptly  forwarding  invoices  or  similar  documentation  to
Purchaser Parent).

(b)      Subject to Sections 2.1 and 2.2 , if, at any time after the Closing, any asset held by Seller Parent or its Affiliates
is  ultimately  determined  to  be  a  Purchased  Asset  or  Seller  Parent  or  any  of  its  Affiliates  is  found  to  be  subject  to  an  Assumed
Liability,  within  thirty  (30)  days  of  such  determination,  (i)  Seller  Parent  shall  return  or  transfer  and  convey  (without  further
consideration) to Purchaser such Purchased Asset or Assumed Liability; (ii) Purchaser shall, or shall cause its appropriate Affiliate
to, assume (without further consideration) such Assumed Liability; and (iii) Seller Parent and Purchaser shall, and shall cause their
appropriate  Affiliates  to, execute  such documents  or instruments  of conveyance  or assumption  and  take  such  further  acts,  in each
case consistent with the terms of this Agreement and the Ancillary Agreements, as are reasonably necessary or desirable to effect the
transfer  of  such  Purchased  Asset  or  Assumed  Liability  back  to  Purchaser,  in  each  case  such  that  each  Party  is  put  into  the  same
economic  position as if such action had been taken on or prior to the Closing Date. In furtherance  of the foregoing,  Seller Parent
shall promptly pay or deliver to Purchaser (or its designee) any monies or checks which have been sent to Seller Parent or any of its
Affiliates to the extent they are due to the Business and which should have been sent to Purchaser or one of its Affiliates (including
promptly forwarding invoices or similar documentation to Purchaser).

(c)           If  any  asset,  property  or  right  held  by  Purchaser  Parent  or  any  of  its  Affiliates  (other  than  Purchaser  or  its
Subsidiaries) is determined to be an asset of the Purchaser Business or Purchaser Parent or any of its Affiliates (other than Purchaser
and its Subsidiaries) is found subject to a Purchaser Liability, within thirty (30) days of such determination (i) Purchaser Parent shall
(or  shall  cause  its  Affiliate  to)  transfer  and  convey  (without  consideration)  to  Purchaser  or  its  appropriate  Subsidiary  such  asset,
property  or  right  or  Purchaser  Liability;  (ii)  Purchaser  shall,  or  shall  cause  its  appropriate  Subsidiary  to,  assume  (without
consideration) such Purchaser Liability; and (iii) Purchaser Parent and Purchaser shall, and shall cause their appropriate Subsidiaries
to, in each case consistent with the terms of this Agreement and the Ancillary Agreements, execute such documents or instruments of
conveyance or assumption and take such further acts as are reasonably necessary or desirable to effect such transfer of such asset,
property or right or Purchaser Liability back to Purchaser or its appropriate Subsidiary, in each case such that each Party is put into
the  same  economic  position  as  if  such  action  had  been  taken  on  or  prior  to  the  Closing  Date.  In  furtherance  of  the  foregoing,
Purchaser  Parent  and  its  Affiliates  (other  than  Purchaser  or  its  Subsidiaries)  shall  promptly  pay  or  deliver  to  Purchaser  (or  its
designee) any monies or checks which have been sent to Purchaser Parent or any of its Affiliates to the extent they are due to the
Business  or  the  Purchaser  Business  and  which  should  have  been  sent  to  Purchaser  or  one  of  its  Subsidiaries  (including  promptly
forwarding invoices or similar documentation to Purchaser).

Section 6.23      Bulk Transfer Laws . Purchaser Parent and Purchaser acknowledge that Seller Parent has not taken,
and  does  not  intend  to  take,  any  action  required  to  comply  with  any  applicable  so-called  “bulk  sale”  or  “bulk  transfer”  Laws  or
similar Laws, and Purchaser Parent

169

and Purchaser hereby waive, to the fullest extent permitted by applicable Law, compliance by Seller Parent and its Affiliates with the
provisions of any such Laws of any jurisdiction in connection with the sale of the Purchased Assets.

Section 6.24      Purchaser Parent Shareholder Meeting; Purchaser Parent Board Recommendation .

(a)      Subject to Section 6.24(f) and Section 6.24(g) , Purchaser Parent shall, and shall cause its Representatives to,
(i) as soon as reasonably practicable, prepare and file with the UKLA the Purchaser Parent Shareholder Circular, which shall comply
with the content requirements of the Listing Rules, including Chapter 11 thereof, and applicable Law, and include a notice of general
meeting for the purpose of placing the Purchaser Parent Shareholder Approval Resolution before Purchaser Parent’s shareholders,
and (ii) use reasonable best efforts to finalize the Purchaser Parent Shareholder Circular and have it approved by the UKLA as soon
as  reasonably  practicable  after  such  filing,  including  by  taking  all  such  actions  (including  supplying  undertakings,  executing
documents and paying fees and expenses) as may be required by the UKLA. As promptly as practicable (and in any event within
three  (3)  Business  Days)  after  UKLA  approval  of  the  Purchaser  Parent  Shareholder  Circular,  Purchaser  Parent  shall  publish  the
Purchaser Parent Shareholder Circular and send it to its shareholders and shall, subject to Section 6.24(f) and Section 6.24(g) , cause
a general meeting of the shareholders of Purchaser Parent for the purpose of obtaining the Purchaser Parent Shareholder Approval
(together with any adjournment or postponement thereof, the “ Purchaser Parent Shareholder Meeting ”) to be convened and held on
twenty-one (21) clear days’ notice (subject to the notice being deemed served in accordance with the Deposit Agreement to enable
ADR  voting),  in  each  case  in  compliance  with  the  Listing  Rules  and  applicable  Law  and  Purchaser  Parent’s  constitutional
documents, and, subject to Section 6.24(f) and Section 6.24(g) , shall propose the Purchaser Parent Shareholder Approval Resolution
(without amendment) at the Purchaser Parent Shareholder Meeting.

(b)      Seller Parent and its Representatives shall cooperate reasonably and in good faith with Purchaser Parent, and
provide,  at  Purchaser’s  sole  cost  and  expense,  all  such  information  and  documentation  requested  by  Purchaser  Parent  or  its
Representatives, in each case to the extent reasonably necessary for the purposes of Purchaser Parent’s preparation of the Purchaser
Parent  Shareholder  Circular  and  any  supplementary  circular  thereto,  including  for  the  purposes  of  the  preparation  of  pro  forma
financial  information  (and  related  reporting  requirements),  if  applicable.  Seller  Parent  and  its  Representatives  shall  be  given  a
reasonable  opportunity  to  review  and  comment  upon  the  Purchaser  Parent  Shareholder  Circular  (and  any  supplementary  circular
thereto)  before  each  such  document  is  filed  with  the  UKLA  and  is  published,  and  Purchaser  Parent  shall  give  reasonable
consideration to any additions, deletions or changes reasonably and timely suggested thereto by Seller Parent and its Representatives.
In  addition,  Purchaser  Parent  shall  provide  Seller  Parent  and  its  Representatives  with  copies  of  any  written  comments,  and  shall
inform them of any material or substantive oral comments, Purchaser Parent or its Representatives may receive from time to time
from  the  UKLA  or  its  staff  with  respect  to  the  Purchaser  Parent  Shareholder  Circular  (and  any  supplementary  circular  thereto)
promptly after receipt of such comments, and any written or oral responses thereto. Seller Parent and its Representatives shall be
given a reasonable opportunity to review and comment upon any such written responses and Purchaser Parent shall

170

give  reasonable  consideration  to  any  additions,  deletions  or  changes  reasonably  suggested  thereto  by  Seller  Parent  and  its
Representatives. In the event that Purchaser Parent or its Representatives receives any comments from the UKLA or their staff with
respect  to  the  Purchaser  Parent  Shareholder  Circular  (or  any  amendment  or  supplement  thereto),  Purchaser  Parent  and  its
Representatives shall use reasonable best efforts to respond as promptly as practicable to such comments and shall take such other
actions  as  may  be  reasonably  necessary  to  resolve  the  issues  raised  therein  as  promptly  as  practicable,  and  Seller  Parent  and  its
Representatives shall cooperate reasonably and in good faith with Purchaser Parent and its Representatives to the extent reasonably
necessary for the purposes of resolving such comments.

(c)      Subject to Section 6.24(f) and Section 6.24(g) , Purchaser Parent and the Board of Directors of Purchaser Parent
shall (i) include the Purchaser Parent Board Recommendation in the Purchaser Parent Shareholder Circular, (ii) use its reasonable
best efforts to obtain the Purchaser Parent Shareholder Approval as promptly as practicable, and to the extent any further Purchaser
Parent’s shareholders’ resolution is required to approve the transactions contemplated hereby or by any of the Ancillary Agreements
prior to Closing, use its reasonable best efforts to procure that such further shareholder resolution is passed by the requisite vote of
Purchaser  Parent’s  shareholders,  and  (iii)  ensure  that  the  Purchaser  Parent  Shareholder  Circular  includes  a  statement  that  each
Director of Purchaser Parent who holds shares in Purchaser Parent intends to vote his or her shares in favor of the Purchaser Parent
Shareholder  Approval  Resolution.  Subject  to  Section  6.24(f)  and  Section  6.24(g)  ,  Purchaser  Parent  shall  not,  without  the  prior
written  consent  of  Seller  Parent,  adjourn,  postpone  or  otherwise  delay  the  Purchaser  Parent  Shareholder  Meeting;  provided  that
Purchaser Parent may adjourn, postpone or otherwise delay the Purchaser Parent Shareholder Meeting (including an adjournment to
allow  reasonable  additional  time  for  the  preparation  and  publication  of  any  supplement  or  amendment  to  the  Purchaser  Parent
Shareholder Circular) if required to comply with Purchaser Parent’s obligations under the Listing Rules or otherwise by applicable
Law,  and/or  where,  and  to  the  extent  that,  the  Board  of  Directors  of  Purchaser  Parent  shall  have  determined  in  good  faith  (after
consultation with its legal counsel) that the failure to so adjourn, delay or postpone the Purchaser Parent Shareholder Meeting would
be inconsistent with its fiduciary duties under applicable Law. After Purchaser Parent has established a record date for the Purchaser
Parent Shareholder Meeting, Purchaser Parent shall not change such record date or establish a different record date for the Purchaser
Parent  Shareholder  Meeting  without  the  prior  written  consent  of  Seller  Parent,  unless  (x)  required  to  do  so  by  applicable  Law  or
Purchaser Parent’s constitutional documents or (y) as required in connection with any adjournment, postponement or delay of the
Purchaser Parent Shareholder Meeting permitted by the immediately preceding sentence (it being understood that Purchaser Parent
shall consult with and consider in good faith the reasonable views of Seller Parent in connection with setting such new record date).
Without the prior written consent of Seller Parent, the Purchaser Parent Shareholder Approval Resolution shall be the only resolution
(other than matters of procedure and matters required by applicable Law or Purchaser Parent’s constitutional documents to be voted
on by Purchaser  Parent’s  shareholders  in connection  with  the approval  of the Sale  and  the  transactions  contemplated  hereby)  that
Purchaser Parent shall propose to be acted on by Purchaser Parent’s shareholders at the Purchaser Parent Shareholder Meeting.

171

(d)            Purchaser  Parent  shall  notify  Seller  Parent:  (i)  on  a  regular  basis  after  publication  of  the  Purchaser  Parent
Shareholder Circular and prior to the Purchaser Parent Shareholder Meeting of the proxy votes received in respect of the Purchaser
Parent Shareholder Meeting; and (ii) promptly following the Purchaser Parent Shareholder Meeting, of the result of the vote on the
resolutions proposed to the Purchaser Parent’s shareholders at the Purchaser Parent Shareholder Meeting.

(e)      Except as expressly permitted by Section 6.24(f) , Purchaser Parent and the Board of Directors of Purchaser
Parent (and any committee or other subdivision thereof) shall not, and shall not permit its Representatives to, directly or indirectly,
(i) fail to make, withdraw, withhold, change, amend, qualify or modify in a manner adverse to Seller Parent, or publicly propose to
fail  to  make  in  the  Purchaser  Parent  Shareholder  Circular,  withdraw,  withhold,  change,  amend,  qualify  or  modify  in  a  manner
adverse to Seller Parent, the Purchaser Parent Board Recommendation, (ii) make any public announcement or statement inconsistent
with the Purchaser Parent Board Recommendation, (iii) fail to include the Purchaser Parent Board Recommendation in the Purchaser
Parent Shareholder Circular (or any supplement or amendment thereto), (iv) recommend in favor of, or fail to recommend against,
any  matter  that  could  reasonably  be  expected  to  result  in  a  Purchaser  Adverse  Action  or  a  Purchaser  Material  Adverse  Effect  or
(v)  publicly  propose  to  do  any  of  the  foregoing  (any  of  the  foregoing  in  this  sentence,  a  “  Purchaser  Parent  Adverse
Recommendation Change ”).

(f)      Notwithstanding any other provision of this Section 6.24 , at any time prior to obtaining the Purchaser Parent
Shareholder Approval, the Board of Directors of Purchaser Parent may effect a Purchaser Parent Adverse Recommendation Change
if the Board of Directors of Purchaser Parent shall have determined in good faith (after consultation with its legal counsel) that the
failure  to  effect  a  Purchaser  Parent  Adverse  Recommendation  Change  would  be  inconsistent  with  its  fiduciary  duties  under
applicable  Law.  Subject  always  to  applicable  Law  and  the  fiduciary  duties  of  the  Board  of  Directors  of  Purchaser  Parent  under
applicable Law, Purchaser Parent shall promptly notify Seller Parent in the event that it intends to effect a Purchaser Parent Adverse
Recommendation  Change,  describing  in  reasonable  detail  the  underlying  facts  giving  rise  to,  and  the  reasons  for  making,  such
Purchaser Parent Adverse Recommendation Change and shall provide Seller Parent with a reasonable opportunity to consult with
Purchaser Parent in respect of the same.

(g)            Notwithstanding  anything  to  the  contrary  contained  in  this  Agreement,  a  Purchaser  Parent  Adverse
Recommendation  Change  pursuant  to  Section  6.24(f)  shall  relieve  Purchaser  Parent  of  its  obligations  to  convene  the  Purchaser
Parent  Shareholder  Meeting,  to  prepare  and  file  the  Purchaser  Parent  Shareholder  Circular  and  have  the  Purchaser  Parent
Shareholder Circular approved by the UKLA and publish the Purchaser Parent Shareholder Circular and send it to its shareholders,
and to submit the Purchaser Parent Shareholder Approval Resolution to a vote of the holders of ordinary shares of Purchaser Parent
at the Purchaser Parent Shareholder Meeting and seek to obtain the Purchaser Parent Shareholder Approval for all purposes of this
Agreement.

(h)      As required by Listing Rule 11.1.7R(4), Seller Parent shall not, and shall use reasonable efforts to ensure that its
associates (as defined in the Listing Rules) do not, vote on any resolution(s) proposed at the Purchaser Parent Shareholder Meeting
relating to the Sale and/or other

172

transactions  contemplated  by  this  Agreement,  in  each  case  to  the  extent  that  Seller  Parent  or  any  such  associate  either  holds  or
acquires any shares or other securities in Purchaser Parent.

Section 6.25      Resignations . Seller Parent shall use reasonable best efforts to deliver to Purchaser Parent, at or prior
to  the  Closing,  the  resignations,  effective  as  of  the  Closing,  of  all  officers  and  directors  of  each  Conveyed  Subsidiary  (and  each
Subsidiary thereof) who will be officers, directors or employees of Seller Parent or any of its Affiliates after the Closing Date from
their positions with such Conveyed Subsidiary (or such Subsidiary thereof).

Section 6.26      Remedial Action Access . In respect of its indemnity obligations under Article VII of this Agreement,
each  Parent  shall  have  the  right,  but  not  the  obligation,  to  conduct  and  control  any  relevant  Remedial  Action.  If  a  Parent  opts  to
conduct a Remedial Action at any Real Property or Purchaser Real Property, the applicable Parent shall use reasonable best efforts to
not unreasonably interfere with Purchaser’s operations, and the Purchaser Indemnified Parties shall, and shall cause their respective
Representatives  to,  reasonably  cooperate  with  the  applicable  Parent,  including  by  timely  filing  any  required  documents  with  the
appropriate Governmental Authorities, providing reasonable access to and reasonable use of the subject site, employees, documents
and on-site structures, infrastructure and utility services (including electricity, underground piping or wastewater or sewer systems)
and/or utilities as necessary to perform any required Remedial Action, including reasonable access to install, maintain, replace and
operate wells and remove impacted soil and/or groundwater. To the extent required under any Environmental Law, the applicable
Purchaser Indemnified Parties shall execute, record, obtain and maintain in good standing any authorization, permit or “generator
number” as may be necessary for the proper storage, transportation and/or off-site disposal of any Hazardous Material generated in
the course of the Remedial Action. The applicable Purchaser Indemnified Parties shall sign (with respect to the Owned Real Property
or the Owned Purchaser Real Property) or use commercially reasonable efforts to cause to be signed (with respect to the Leased Real
Property or the Leased Purchaser Real Property) and record (with respect to the Owned Real Property or the Owned Purchaser Real
Property)  or use commercially  reasonable  efforts to cause to be recorded  (with respect to the Leased Real Property  or the Leased
Purchaser Real Property) any deed or other recordable real property instrument reasonably requested by the Parent conducting the
Remedial  Action  which  is  necessary  to  permit  the  use  of  site  specific  corrective  action  remedies  or  remedies  based  on  exposure
controls as part of such Remedial Action; provided , however , that the instrument does not unreasonably interfere with the operation
of the Facilities or the Purchaser Facilities or materially impact the value of the Real Property or Purchaser Real Property that are the
subject  of  such  Remedial  Action.  The  applicable  Purchaser  Indemnified  Parties  agree  not  to  use  groundwater  under  any  Real
Property  or  Purchaser  Real  Property,  as  applicable,  to  the  extent  such  restriction  is  necessary  to  permit  the  use  of  site  specific
corrective action remedies or remedies based on exposure controls as part of such Remedial Action. All reasonable and documented
out-of-pocket costs incurred by the applicable Purchaser Indemnified Parties or their respective Representatives cooperating with or
otherwise  assisting  the  Parent  conducting  the  Remedial  Action  pursuant  to  this Section 6.26 shall  be  promptly  reimbursed  by  the
Parent conducting the Remedial Action.

Section 6.27      Acknowledgements . The Parties acknowledge and agree that certain of the Sellers and the Conveyed

Subsidiaries (the “ New Subsidiaries ”) will be established, formed

173

or incorporated, as applicable, following the date of this Agreement and prior to the Closing in connection with the Seller Internal
Restructurings, and such New Subsidiaries are therefore not in existence as of the date of this Agreement. Accordingly, the Parties
acknowledge and agree that, notwithstanding anything in this Agreement to the contrary, Seller Parent makes no representations and
warranties with respect to the organization, good standing, authority, capital structure, operations and Liabilities of any such New
Subsidiary  as of  or prior  to the  date of  each  respective New  Subsidiary’s establishment, formation or  incorporation. Seller  Parent
may  at  any  time  prior  to  the  Closing  supplement  or  amend  the  lists  set  forth  in  Section  4.3(b)  or  Section  4.3(c)  of  the  Seller
Disclosure Letter, solely to reflect any changes pursuant to the Seller Internal Restructurings (including any steps Seller Parent shall
undertake to effect the Seller Internal Restructurings) made in accordance with (f)(i) .

ARTICLE VII

INDEMNIFICATION

Section 7.1      Indemnification by Seller Parent and Purchaser Parent .

(a)      Subject to the provisions of this Article VII , from and after the Closing, Seller Parent agrees to indemnify and
hold  harmless  (x)  Purchaser  and  its  Subsidiaries  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries)  (collectively,  the  “
Purchaser  Indemnified  Parties  ”)  and  (y)  Purchaser  Parent  and  its  Subsidiaries  (other  than  Purchaser  and  its  Subsidiaries)  (the  “
Purchaser Parent Indemnified Parties ”) from and against any and all Losses (other than Taxes arising out of a Tax Claim, which are
the subject of Section 6.5(d) ) that any such Purchaser Indemnified Party or Purchaser Parent Indemnified Party suffers or incurs to
the extent resulting from (b) any Retained Liability, (c) any breach by any Seller of any of its covenants or agreements contained in
this Agreement or in any Ancillary Implementing Agreement or (d) any breach of any representation or warranty of Seller Parent
contained in Article IV (other than Section 4.16 ) or in any Ancillary Implementing Agreement, in each case as of the Closing Date
as though made on the Closing Date (or, in the case of representations and warranties that address matters only as of a particular
date, as of such date).

(e)      Subject to the provisions of this Article VII , from and after the Closing, Purchaser Parent agrees to indemnify
and hold harmless (x) the Purchaser Indemnified Parties and (y) Seller Parent and its Subsidiaries (collectively, the “ Seller Parent
Indemnified Parties ”) from and against any and all Losses (other than Taxes arising out of a Tax Claim, which are the subject of
Section 6.5(d) ) that any such Purchaser Indemnified Party or Seller Parent Indemnified Party suffers or incurs to the extent resulting
from (f) any Purchaser Parent Retained Liability, (g) any breach by Purchaser Parent or any of its Affiliates (which shall not include
Purchaser  or  its  Subsidiaries  with  respect  to  post-Closing  covenants  or  agreements)  of  any  of  their  respective  covenants  or
agreements  contained  in  this  Agreement  or  in  any  Ancillary  Implementing  Agreement  or  (h) any breach of  any representation or
warranty of Purchaser Parent contained in Article V (other than Section 5.17 ) or in any Ancillary Implementing Agreement, in each
case  as  of  the  Closing  Date  as  though  made  on  the  Closing  Date  (or,  in  the  case  of  representations  and  warranties  that  address
matters only as of a particular date, as of such date).

174

(i)      The Parties acknowledge and agree that indemnification shall not be available with respect to any Loss resulting
from a breach of any representation or warranty contained in this Agreement or in any Ancillary Implementing Agreement to the
extent (and only to the extent) the Loss (or related Liability) was accrued or reserved for in the Financial Statements or the Purchaser
Financial  Statements,  as  applicable,  or  actually  taken  into  account  in  the  Final  Closing  Statement  or  the  calculation  of  the  Final
Business Working Capital, the Final Business Net Cash, the Final Purchaser Working Capital or the Final Purchaser Net Cash, as
applicable.

Section 7.2      Indemnification by Purchaser . Subject to the provisions of this Article VII , from and after the Closing,
Purchaser agrees to indemnify and hold harmless the Seller Parent Indemnified Parties and the Purchaser Parent Indemnified Parties
(collectively,  the  “  Parent  Indemnified  Parties  ”)  (a)  from  and  against  any  and  all  Losses  (other  than  Taxes  arising  out  of  a  Tax
Claim, which are the subject of Section 6.5(d) ) that any such Parent Indemnified Party suffers or incurs to the extent resulting from
(i) any Assumed Liability or (ii) any Purchaser Liability and (b) from and against any and all Losses (other than Taxes arising out of
a Tax Claim, which are the subject of Section 6.5(d) ) any such Parent Indemnified  Party suffers or incurs to the extent resulting
from any breach following the Closing by Purchaser of any covenant or agreement expressly made by Purchaser in this Agreement
or in any Ancillary Implementing Agreement, in its capacity as a Party hereto (and not in its capacity as an Affiliate or Subsidiary of
Purchaser Parent), which covenant or agreement by its terms contemplates actions or imposes obligations following the Closing.

Section 7.3      Indemnification Procedures .

(a)      Any Person entitled to be indemnified under this Article VII (the “ Indemnified Party ”) shall promptly give
written notice to the Party from whom indemnification may be sought (the “ Indemnifying Party ”) and each other Party hereto of
any pending or threatened Action against the Indemnified Party that has given or would reasonably be expected to give rise to such
right of indemnification with respect to such Action (a “ Third Party Claim ”), indicating, with reasonable specificity, and based on
the facts then known to the Indemnified Party, the nature of such Third Party Claim, the basis therefor, a copy of any documentation
received from the third party, the amount and calculation of the Losses for which the Indemnified Party is entitled to indemnification
under this Article VII (and a good faith estimate of any such future Losses relating thereto), and the provisions of this Agreement or
any  Ancillary  Implementing  Agreement  in  respect  of  which  such  Losses  shall  have  occurred,  and  the  Indemnified  Party  shall
promptly deliver to the Indemnifying Party any information or documentation related to the foregoing reasonably requested by the
Indemnifying Party. A failure by the Indemnified Party to give notice in a timely manner pursuant to this Section 7.3(a) shall not
limit the obligations of the Indemnifying Party under this Article VII , except (i) to the extent such Indemnifying Party is actually
prejudiced thereby and (ii) as provided by Section 7.4 (unless, with respect to indemnification pursuant to Section 7.1(b) or Section
7.2  ,  in  the  case  of  the  foregoing  clauses  (i)  and  (ii),  Purchaser  Parent  has  Intentionally  Breached  (or  caused  Purchaser  to
Intentionally Breach) its obligations pursuant to the immediately foregoing sentence).

(b)      With respect to any Third Party Claim, the Indemnifying Party under this Article VII shall have the right, but

not the obligation, to assume the defense, at its own expense

175

and by counsel of its own choosing, of such Third Party Claim and any Third Party Claims related to the same or a substantially
similar set of facts; provided that the Indemnifying Party shall not be entitled to assume the defense of such Third Party Claim, and
shall  pay  the  reasonable  fees  and  expenses  of  counsel  retained  by  the  Indemnified  Party,  if  such  Third  Party  Claim  seeks  an
injunction or equitable relief against the Indemnified Party or is a criminal Action. If the Indemnifying Party so undertakes to defend
any such Third Party Claim, it shall notify the Indemnified Party of its intention to do so, and the Indemnified Party shall cooperate
fully with the Indemnifying Party and its counsel in the defense against, and settlement of, any such Third Party Claim; provided ,
however ,  that  the  Indemnifying  Party  shall  not  settle  any  such Third  Party  Claim  without  the  written  consent  of the  Indemnified
Party (not to be unreasonably withheld, conditioned or delayed) unless such settlement does not involve any injunctive relief against
or any finding or admission of any violation of Law or wrongdoing by the Indemnified Party, and any money damages are borne
solely  by  the  Indemnifying  Party  (other  than  solely  with  respect  to  the  Deductible,  to  the  extent  such  damages  would  constitute
Losses to which such Deductible  would be applicable);  provided , further , that if the Indemnifying  Party is Purchaser,  Purchaser
shall not settle any such Third Party Claim without the written consent of both Parents (not to be unreasonably withheld, conditioned
or delayed). Subject to the foregoing, the Indemnified Party shall have the right to employ separate legal counsel and to participate in
but not control the defense of such Action at its own cost and expense; provided that, subject to the provisions of this Article VII ,
the Indemnifying Party shall bear the reasonable fees of one firm of legal counsel (and one additional firm of legal counsel in each
jurisdiction implicated in such Action) representing all Indemnified Parties in such Action and all related Actions, if, but only if, the
defendants  in  such  Action  include  both  an  Indemnified  Party  and  the  Indemnifying  Party,  and  such  Indemnified  Party  shall  have
reasonably concluded, based on the advice of legal counsel, that there is a conflict of interest between the Indemnifying Party and the
Indemnified Party with respect to such Action. In any event, the Indemnified Party shall cause its legal counsel to cooperate with the
Indemnifying Party and its legal counsel. No Indemnified Party may settle any Third Party Claim without the written consent of the
Indemnifying Party (not to be unreasonably withheld, conditioned or delayed) and, if the Indemnified Party is Purchaser, the written
consent of both Parents (not to be unreasonably withheld, conditioned or delayed). If the Indemnifying Party does not assume the
defense  of  a  Third  Party  Claim,  it  shall  nevertheless  be  entitled  to  participate  in  the  defense  of  such  Action  at  its  own  cost  and
expense, and the Indemnified Party shall cooperate with the Indemnifying Party and its counsel in the defense against, and settlement
of, any such Third Party Claim.

(c)      In the event that any Indemnified Party has or may have an indemnification claim against any Indemnifying
Party  under  this  Article  VII  that  does  not  involve  a  Third  Party  Claim,  the  Indemnified  Party  shall  promptly  give  written  notice
thereof to the Indemnifying Party indicating, with reasonable specificity, and based on the facts then known to the Indemnified Party,
the nature of such claim, the basis therefor, the amount and calculation of the Losses for which the Indemnified Party is entitled to
indemnification under this Article VII (and a good-faith estimate of any such future Losses relating thereto), and the provisions of
this Agreement or any Ancillary Implementing Agreement in respect of which such Losses shall have occurred, and the Indemnified
Party  shall  promptly  deliver  to  the  Indemnifying  Party  any  information  or  documentation  related  to  the  foregoing  reasonably
requested  by  the  Indemnifying  Party.  A  failure  by  the  Indemnified  Party  to  give  notice  in  a  timely  manner  pursuant  to  this
Section 7.3(c) shall not limit the obligations of

176

the Indemnifying Party under this Article VII , except (i) to the extent such Indemnifying Party is actually prejudiced thereby and (ii)
as  provided  by  Section 7.4 (unless,  with  respect  to  indemnification  pursuant  to  Section 7.1(b) or Section 7.2 ,  in  the  case  of  the
foregoing  clauses  (i)  and  (ii),  Purchaser  Parent  has  Intentionally  Breached  (or  caused  Purchaser  to  Intentionally  Breach)  its
obligations  pursuant  to  the  immediately  foregoing  sentence).  If  the  Indemnifying  Party  disputes  its  liability  with  respect  to  such
claim, the Indemnifying Party and the Indemnified Party shall proceed in good faith to negotiate a resolution of such dispute and, if
not  resolved  through  negotiations  within  thirty  (30)  days  of  the  receipt  of  the  notice  of  such  indemnification  claim  by  the
Indemnifying  Party,  such  dispute  shall  be  resolved  by  litigation  in  the  appropriate  court  of  competent  jurisdiction  set  forth  in
Section  10.10  ;  provided  that  if  the  Indemnifying  Party  or  the  Indemnified  Party  is  Purchaser,  the  Indemnifying  Parties  and  the
Indemnified Party shall not agree to settle or resolve any such claim with the written consent of both Parents (not to be unreasonably
withheld, conditioned or delayed).

Section 7.4      Expiration . If the Closing has occurred, all covenants and agreements made herein or in any Ancillary
Implementing Agreement which, in each case, by their terms contemplate actions or impose obligations following the Closing shall
survive  the  Closing  and  remain  in  full  force  and  effect  in  accordance  with  their  terms;  provided  that,  other  than  indemnification
obligations  in  respect  of  Taxes  (the  survival  of  which  shall  be  governed  exclusively  by  Section  6.5(l)  ),  (a)  the  obligations  of
Purchaser to assume, and to indemnify and hold harmless the Seller Parent Indemnified Parties and the Purchaser Parent Indemnified
Parties for, the Assumed Liabilities and the Purchaser Liabilities, (b) the obligations of Seller Parent to retain, and indemnify and
hold harmless the Purchaser Indemnified Parties and the Purchaser Parent Indemnified Parties for, the Retained Liabilities and (c)
the  obligations  of  Purchaser  Parent  to  retain,  and  indemnify  and  hold  harmless  the  Purchaser  Indemnified  Parties  and  the  Seller
Parent Indemnified Parties for, the Purchaser Parent Retained Liabilities, shall in each case survive the Closing indefinitely. All other
covenants  and  agreements  contained  herein  or  in  any  Ancillary  Implementing  Agreement  shall  survive  the  Closing  and  shall
terminate and expire on the twelve (12) month anniversary of the Closing Date (other than the covenants and agreements set forth
therein which by their terms contemplate actions or impose obligations following the Closing, which shall survive the Closing and
remain in full force and effect in accordance with their terms). All representations and warranties made herein or in any Ancillary
Implementing  Agreement,  and  all  indemnification  obligations  under  Section  7.1  with  respect  to  any  such  representations  or
warranties,  shall  terminate  and  expire  on  the  fifteen  (15)  month  anniversary  of  the  Closing  Date;  provided  ,  however  ,  that  the
Fundamental Seller Parent Representations and the Fundamental Purchaser Parent Representations shall terminate and expire on the
three  (3)  year  anniversary  of  the  Closing  Date.  No  Person  shall  be  entitled  to  indemnification,  and  no  Action  seeking  to  recover
Taxes,  Losses  or  other  relief  shall  be  commenced  or  maintained,  with  respect  to  any  breach  of  any  covenants,  agreements,
representations or warranties contained in this Agreement or any Ancillary Implementing Agreement after the date on which such
covenant, agreement, representation or warranty shall terminate pursuant to this Section 7.4 or Section 6.5(l) , unless prior to such
termination date a claim for indemnification with respect thereto has been made by written notice in accordance with Section 7.3 (in
the case of Losses or other relief) or Section 6.5(d) (in the case of Taxes), in which case such claim for indemnification shall survive
until finally resolved in accordance with this Agreement.

177

Section 7.5      Certain Limitations .

(a)            Notwithstanding  the  other  provisions  of  this  Agreement,  neither  Seller  Parent  nor  Purchaser  Parent,  as
applicable, shall have any indemnification obligations (i) under Section 7.1(a)(iii) or Section 7.1(b)(iii) , as applicable, for any Loss
(together  with  any  and  all  other  Losses  resulting  from  the  same  facts  or  circumstances)  that  is  less  than  $20,000,000  (the  “  De
Minimis  Claim  Threshold  ”),  or  (ii)  under  Section  7.1(a)(iii)  or  Section  7.1(b)(iii)  (except  with  respect  to  any  breach  of  any
Fundamental Seller Parent Representation or Fundamental Purchaser Parent Representation) for any Loss that is equal to or greater
than the De Minimis Claim Threshold, unless the aggregate amount of all Losses for which indemnification is available under the
applicable provision exceeds $200,000,000 (the “ Deductible ”), in which event the Indemnifying Party shall be required to pay only
the  amount  of  such  Losses  that  exceeds  the  Deductible  but  only  up  to  a  maximum  amount  in  respect  of  all  such  Losses  (without
giving effect to the Deductible) in the aggregate of $2,000,000,000.

Section 7.6      Losses Net of Insurance, Etc. The amount of any Tax or Loss for which indemnification is provided
under  Section  6.5(d),  Section  7.1  or  Section  7.2  shall  be  net  of  (i)  any  amounts  recovered  by  the  applicable  Indemnified  Party
pursuant to any indemnification by or indemnification agreement with any third party, and (ii) any insurance proceeds or other cash
receipts  or  sources  of  reimbursement  received  with  respect  to  such  Tax  or  Loss,  and  (iii)  in  the  case  of  Purchaser  Parent  as  the
Indemnifying Party, any amounts recovered by the Purchaser pursuant to the Contribution Agreement, dated as of April 22, 2014, by
and among Purchaser Parent, Purchaser and Novartis AG, as amended (the source of any such amounts referred to in clause (i) or (ii)
, a “ Collateral Source ”), in each case net of any Taxes imposed or reasonable out-of-pocket costs incurred in connection with the
collection  of  such  insurance  proceeds,  cash  receipts  or  sources  of  reimbursement.  The  applicable  Indemnified  Party  shall  use  its
commercially reasonable efforts to seek recovery for such Taxes or Losses from all Collateral Sources. The Indemnifying Party may
require  an  Indemnified  Party  to  assign  to  the  Indemnifying  Party  the  rights  to  seek  recovery  from  any  Collateral  Sources  (to  the
extent such rights are capable of assignment); provided that the Indemnifying Party will then be responsible for pursuing such claim
at its own expense; provided , further ,  that  the  Indemnified  Party  shall  cooperate  (at  the  Indemnifying  Party’s  expense)  with  the
Indemnifying Party to seek such recovery. If the amount to be netted hereunder from any payment required under Section 6.5(d) or
this  Article  VII  is  determined  after  payment  by  the  Indemnifying  Party  of  any  amount  otherwise  required  to  be  paid  to  an
Indemnified  Party  pursuant  to  Section  6.5(d)  or  this  Article  VII  ,  the  Indemnified  Party  shall  repay  to  the  Indemnifying  Party,
promptly after such determination, any amount that the Indemnifying Party would not have had to pay pursuant to Section 6.5(d) or
this Article VII had such determination been made at the time of such payment.

Section 7.7      No Right of Set-Off . No Party shall have any right to set off any Taxes or Losses under Section 6.5(d)
and this Article VII against any payments to be made by such Party pursuant to this Agreement or any other agreement among the
Parties, including any Ancillary Agreement.

Section 7.8      Materiality . For purposes of Tax Claims subject to Section 6.5 and of this Article VII , no effect shall

be given to any qualification in the relevant representations and

178

warranties  as  to  “material,”  “materiality,”  “Material  Adverse  Effect”  or  “Purchaser  Material  Adverse  Effect”  for  purposes  of
determining the amount of any Loss suffered or incurred by an Indemnified Party, but all such qualifications shall be given effect for
purposes of determining whether there has been a breach or inaccuracy of any representation or warranty.

Section 7.9      Mitigation; Other Limitations .

(a)            Each  of  Seller  Parent,  Purchaser  Parent,  Purchaser  and  each  Indemnified  Party  shall  take,  and  cause  its
Affiliates to take, all commercially reasonable steps to mitigate any Tax or Loss upon becoming aware of any event which would
reasonably be expected to, or does, give rise thereto.

(b)      Notwithstanding anything to the contrary contained in this Agreement, the obligations to indemnify under this
Agreement, and the amount of any Loss for which indemnification is provided under Section 7.1 , shall be subject to the following
limitations:

(i)      With respect to any Remedial Action, the applicable Indemnifying Party shall only be liable to the extent
such  Remedial  Action  is  conducted  in  the  Most  Cost-Effective  Manner.  Regardless  of  whether  any  Indemnifying
Party or any Indemnified Party conducts any such Remedial Action, the applicable Indemnifying Party shall not be
responsible  for  any  operation  and  maintenance  with  respect  to  any  such  institutional  or  engineering  controls
subsequent to completion of their initial installation at the applicable Real Property or Purchaser Real Property subject
to  such  Remedial  Action,  and  such  post-installation  costs  shall  not  be  subject  to  claims  for  indemnification  or
reimbursement under this Article VII .

(ii)            With  respect  to  any  particular  Environmental  Liability,  an  Indemnifying  Party’s  obligations  for
indemnification  or  reimbursement  in  respect  of  such  Environmental  Liability,  shall  be  deemed  satisfied,  completed
and fully discharged upon the relevant Remediation Completion Date, and the Indemnifying Party shall no longer be
responsible for ongoing obligations and Liabilities with respect to such Environmental Liabilities to the extent related
to the Real Property (or Facilities thereon) or Purchaser Real Property (or Purchaser Facilities thereon), including the
operation and maintenance of any institutional and engineering controls.

(iii)            An  Indemnifying  Party  shall  not  have  any  indemnification  obligations  for  Losses  relating  to  any
Environmental Liabilities to the extent such Losses relate to, result from, or arise out of any (1) exacerbation of an
existing  condition  due  to  a  negligent  or  intentional  act  or  omission  by  or  on  behalf  of  the  Indemnified  Party  or  its
Affiliates,  (2)  environmental  investigation,  drilling,  sampling,  testing  or  monitoring  of  any  soil,  surface  water  or
groundwater, by or on behalf of the applicable Indemnified Party or its Affiliates, after the Closing Date (except to the
extent  required  by  Environmental  Laws  or  Environmental  Permits  or  a  Governmental  Authority;  conducted  in
response  to  facts  or  conditions  potentially  indicating  a  material  risk  to  health  or  the  environment;  conducted  in
connection with defending

179

against  or  otherwise  responding  to  a  Third  Party  Claim;  conducted  to  comply  with  the  requirements  of  any  Real
Property Lease or Purchaser Real Property Lease; reasonably and independently requested in writing by a third party
in  connection  with  a  sale,  lease,  sublease,  financing,  mortgage  or  other  transaction  involving  any  Real  Property,
Purchaser  Real  Property,  Facility  or  Purchaser  Facility  as  part  of  the  third  party’s  normal  business  practices;  or
conducted consistent with industry practice in connection  with the ordinary course of business and the Indemnified
Party’s  bona  fide  construction,  renovation,  demolition,  removal,  repair  or  expansion  of  improvements  at  any  Real
Property,  Purchaser  Real  Property,  Facility  or  Purchaser  Facility);  or  (3)  decommissioning,  closure  or  voluntary
shutdown  of  any  Real  Property,  Purchaser  Real  Property,  Facility  or  Purchaser  Facility  by  or  on  behalf  of  the
Indemnified Party or its Affiliates.

(c)      Notwithstanding anything to the contrary contained in this Agreement, in no event shall any Party be entitled to
duplicative  recovery  directly  or  indirectly  for  the  same  Loss,  including,  in  the  case  of  either  Parent  (or  any  of  their  respective
Subsidiaries), in their respective capacities as direct or indirect equity holders of Purchaser post-Closing; it being understood that to
the extent a Loss is suffered in the applicable  Parent’s (or any of its respective  Subsidiaries’)  capacity as direct or indirect equity
holders of Purchaser post-Closing, the Purchaser Parent Indemnified Parties and the Seller Parent Indemnified Parties, as applicable,
shall only be entitled to directly seek indemnification or recover for such Loss under Section 7.1(a)(ii) or Section 7.1(a)(iii) (in the
case of the Purchaser Parent Indemnified Parties) or under Section 7.1(b)(ii) or Section 7.1(b)(iii) (in the case of the Seller Parent
Indemnified Parties) to the extent such Loss cannot be remedied by means of an indemnification claim or recovery by Purchaser and
its Subsidiaries under Section 7.1(a) or Section 7.1(b) , respectively.

Section 7.10      Sole Remedy/Waiver . Except with respect to claims seeking specific performance or other equitable
relief with respect to covenants or agreements to be performed after the Closing pursuant to this Agreement, and except in the case
of  fraud  with  respect  to  the  representations,  warranties,  covenants  and  agreements  contained  in  this  Agreement,  the  Parties
acknowledge and agree that the remedies provided for in Section 2.9 , Section 6.5 and this Article VII shall be the Parties’ sole and
exclusive  remedy,  from  and  after  the  Closing,  with  respect  to  the  subject  matter  of  this  Agreement  or  any  of  the  Ancillary
Implementing Agreements (but not with respect to any claims under the other Ancillary Agreements, which shall be governed by the
terms  thereof).  In  furtherance  of  the  foregoing,  and  except  as  set  forth  in  the  exceptions  set  forth  in  the  preceding  sentence  and
except as provided in Section 2.9 , Section 6.5 and this Article VII , from and after the Closing, the Parties hereby waive, on behalf
of themselves and their Affiliates, to the fullest extent permitted by applicable Law, any and all other rights, claims and causes of
action (including rights of contribution, if any) known or unknown, foreseen or unforeseen, which exist or may arise in the future,
that they may have against the Sellers or any of their Affiliates, or Purchaser Parent or any of its Affiliates (including Purchaser and
its Subsidiaries),  as the case  may be, in connection  with  the transactions  contemplated  by this  Agreement  or any of the  Ancillary
Implementing  Agreements  (but  not  with  respect  to  any  rights,  claims  or  causes  of  action  under  the  other  Ancillary  Agreements
which,  in each case, shall be governed  by the terms thereof),  whether  arising  under or based upon breach  of warranty  or contract
(including for breach of any representation, warranty, covenant or

180

agreement), tortious conduct (including negligence), any Law (including any such Law relating to environmental matters (including
Environmental Laws) or arising under or based upon any securities Law, common law or otherwise) or otherwise. Each Party shall
cause its respective Affiliates party to an Ancillary Implementing Agreement not to assert any claims or causes of action under such
Ancillary Implementing Agreement, and all such claims shall be asserted only under this Agreement. Without limiting the generality
of the foregoing, in no event shall any Party, its Affiliates, successors or permitted assigns be entitled to claim or seek rescission of
the transactions contemplated by this Agreement and the Ancillary Agreements.

Section 7.11      Indemnification Payments . A Party shall not be deemed to have suffered a Loss or Tax with respect
to an item to the extent such Party was actually compensated therefor by reason of an increase in the amount otherwise paid to it or a
reduction in the amount otherwise paid by it pursuant to Section 2.9 .

ARTICLE VIII

CONDITIONS TO CLOSING

Section  8.1            Conditions  to  the  Obligations  of  the  Parties  .  The  respective  obligations  of  each  of  the  Parties  to
consummate the Closing shall be subject to the satisfaction or written waiver (to the extent permitted by Law) by Purchaser Parent
and Seller Parent, at or prior to the Closing, of each of the following conditions precedent:

(a)            There  shall  not  be  any  Governmental  Order  in  effect  issued  by  a  Governmental  Authority  of  competent

jurisdiction that enjoins or otherwise prohibits the Closing.

(b)      (i) The waiting period required under the HSR Act shall have expired or been terminated and any agreement
between  Purchaser  Parent  or  Purchaser  and  a  competent  Governmental  Antitrust  Authority  in  a  jurisdiction  set  forth  on  Annex C
entered  into in accordance  with  this  Agreement  to delay consummation  of the Closing  has expired  or been terminated;  and (i) all
other Approvals under Antitrust Laws of the jurisdictions set forth on Annex C required to be obtained for the consummation of the
Closing shall have been obtained.

(c)      The Purchaser Parent Shareholder Approval shall have been obtained.

Section 8.2      Conditions to the Obligations of Purchaser and Purchaser Parent . The obligation of Purchaser Parent
and Purchaser to consummate the Closing shall be subject to the satisfaction, or the written waiver (to the extent permitted by Law)
by Purchaser Parent, at or prior to the Closing, of each of the following further conditions precedent:

(a)            The  representations  and  warranties  of  Seller  Parent  contained  in  Article  IV  (other  than  as  set  forth  in  the
following  two  sentences)  shall  be  true  and  correct  (without  giving  effect  to  any  “material”,  “materiality”  or  “Material  Adverse
Effect” qualifications set forth therein) as of the Closing Date as though made on the Closing Date (or, in the case of representations
and  warranties  that  address  matters  only  as  of  a  particular  date,  as  of  such  date),  except  to  the  extent  that  failures  to  be  true  and
correct would not, individually or in the aggregate, have a Material

181

Adverse Effect. The Fundamental Seller Parent Representations shall be true and correct in all material respects as of the Closing
Date  as  though  made  on  the  Closing  Date  (or,  in  the  case  of  representations  and  warranties  that  address  matters  only  as  of  a
particular date, as of such date). The representation and warranty of Seller Parent set forth in Section 4.7(a) shall be true and correct
in all respects as of the Closing Date as though made on the Closing Date.

(b)          Seller Parent shall have performed  and complied in all material respects with the agreements and covenants

required by this Agreement to be performed or complied with by Seller Parent on or prior to the Closing Date.

(c)      Seller Parent shall have delivered to Purchaser Parent a certificate signed by a duly authorized officer of Seller

Parent to the effect that the conditions set forth in Sections 8.2(a) and 8.2(b) have been satisfied.

Section 8.3            Conditions  to  the  Obligations  of  Seller  Parent  .  The  obligation  of  Seller  Parent  to  consummate  the
Closing shall be subject to the satisfaction, or the written waiver (to the extent permitted by Law) by Seller Parent, at or prior to the
Closing, of each of the following further conditions precedent:

(a)          The representations and warranties of Purchaser Parent contained in Article V (other than as set forth in the
following  two  sentences)  shall  be  true  and  correct  (without  giving  effect  to  any  “material”,  “materiality”  or  “Purchaser  Material
Adverse  Effect”  qualifications  set  forth  therein)  as  of  the  Closing  Date  as  though  made  on  the  Closing  Date  (or,  in  the  case  of
representations and warranties that address matters only as of a particular date, as of such date), except to the extent that failures to
be  true  and  correct  would  not,  individually  or  in  the  aggregate,  have  a  Purchaser  Material  Adverse  Effect.  The  Fundamental
Purchaser  Parent  Representations  shall  be  true  and  correct  in  all  material  respects  as  of  the  Closing  Date  as  though  made  on  the
Closing Date (or, in the case of representations and warranties that address matters only as of a particular date, as of such date), other
than  the  representations  and  warranties  of  Purchaser  Parent  contained  in  Section  5.3(a)  ,  which  shall  be  true  and  correct  in  all
respects, other than de
minimis
inaccuracies (that do not impact the issued share capital of Purchaser following the Closing), as of the
Closing Date as though made on the Closing Date (or, in the case of representations and warranties that address matters only as of a
particular date, as of such date). The representation and warranty of Purchaser Parent set forth in  Section 5.7(a) shall be true and
correct in all respects as of the Closing Date as though made on the Closing Date.

(b)      Purchaser Parent and Purchaser shall have performed and complied in all material respects with the agreements
and  covenants  required  by  this  Agreement  to  be  performed  or  complied  with  by  Purchaser  Parent  or  Purchaser  on  or  prior  to  the
Closing Date.

(c)            Purchaser  Parent  shall  have  delivered  to  Seller  Parent  a  certificate  signed  by  a  duly  authorized  officer  of

Purchaser Parent to the effect that the conditions set forth in Sections 8.3(a) and 8.3(b) have been satisfied.

Section 8.4          Frustration of Closing Conditions . Without limiting Purchaser Parent’s rights under Section 6.24(f)

and Section 6.24(g) , no Party may rely as a basis for terminating

182

this Agreement on the failure of any condition set forth in this Article VIII to be satisfied if such failure was caused by such Party’s
or  its  Affiliates’  failure  to  act  in  good  faith  or  to  use  the  efforts  required  under  this  Agreement  to  cause  the  Closing  to  occur,
including as required in Section 6.3 .

ARTICLE IX

TERMINATION

Section 9.1      Termination . This Agreement may be terminated at any time prior to the Closing:

(a)      by written agreement of Purchaser Parent and Seller Parent;

(b)      by either Purchaser Parent or Seller Parent, by giving written notice of such termination to the other Party, if the
Closing shall not have occurred on or prior to the close of business (New York time) on September 30, 2019 (as it may be extended
below, the “ Outside Date ”); provided that  if  the conditions  set forth  in Sections  8.1(a)  (where the relevant Governmental Order
arises  from  or  relates  to  Antitrust  Laws)  or  8.1(b)  shall  not  have  been  satisfied  or  waived  by  September  30,  2019,  then  either
Purchaser Parent or Seller Parent may extend the Outside Date to the close of business (New York time) on December 31, 2019 by
providing written notice thereof to the other Party prior to the initial Outside Date; provided , further , that following such extension
if  the  conditions  set  forth  in  Sections  8.1(a)  (where  the  relevant  Governmental  Order  arises  from  or  relates  to  Antitrust  Laws)  or
8.1(b) shall not have been satisfied or waived by December 31, 2019, then either Purchaser Parent or Seller Parent may extend the
Outside Date to the close of business (New York time) on March 31, 2020 by providing written notice thereof to the other Party prior
to the Outside Date as extended pursuant to the immediately preceding proviso; provided , however , that (without limiting Purchaser
Parent’s rights under Section 6.24(f) and Section 6.24(g) ) the right to terminate this Agreement pursuant to this Section 9.1(b) shall
not be available to (i) any Party whose action or failure to fulfill any obligation under this Agreement, or, in the case of Purchaser
Parent, if the action of Purchaser  or failure by Purchaser  to fulfill any obligation  under this Agreement,  has been the cause of, or
resulted in, the failure of the Closing to occur on or before such date or (ii) any Party during the pendency of any Action by any other
Party for specific performance of this Agreement;

(c)      by Purchaser Parent upon written notice to Seller Parent, if there shall have been a material breach of any of the
representations, warranties, agreements or covenants set forth in this Agreement on the part of Seller Parent which has rendered the
satisfaction of the conditions set forth in Section 8.2(a) or Section 8.2(b) incapable  of fulfillment  and such breach is incapable  of
being cured prior to the Outside Date; provided that Purchaser Parent has given written notice to Seller Parent of such breach stating
Purchaser Parent’s intention to terminate this Agreement pursuant to this Section 9.1(c) and the basis for such termination at least
forty-five (45) days prior to such termination ; provided , further , that the right to terminate this Agreement under this Section 9.1(c)
shall not be available to Purchaser Parent if it or Purchaser has materially breached any representation, warranty, covenant or other
agreement  contained  herein  in  a  manner  that  has  rendered  the  satisfaction  of  the  conditions  set  forth  in  Section  8.3(a)  or
Section 8.3(b) incapable of fulfillment;

183

(d)      by Seller Parent upon written notice to Purchaser Parent, if there shall have been a material breach of any of the
representations, warranties, agreements or covenants set forth in this Agreement on the part of Purchaser Parent or Purchaser which
has rendered the satisfaction of the conditions set forth in Section 8.3(a) or Section 8.3(b) incapable of fulfillment and such breach is
incapable of being cured prior to the Outside Date; provided that Seller Parent has given written notice to Purchaser Parent of such
breach stating Seller Parent’s intention to terminate this Agreement pursuant to this Section 9.1(d) and the basis for such termination
at  least  forty-five  (45)  days  prior  to  such  termination  ;  provided  ,  further  ,  that  the  right  to  terminate  this  Agreement  under  this
Section 9.1(d) shall  not  be  available  to  Seller  Parent  if  it  has  materially  breached  any  representation,  warranty,  covenant  or  other
agreement  contained  herein  in  a  manner  that  has  rendered  the  satisfaction  of  the  conditions  set  forth  in  Section  8.2(a)  or
Section 8.2(b) incapable of fulfillment;

(e)      by either Seller Parent or Purchaser Parent, by giving written notice of such termination to the other Party, if
any Governmental Authority of competent jurisdiction shall have issued a Governmental Order permanently enjoining or otherwise
prohibiting  the  Closing  and  such  Governmental  Order  shall  have  become  final  and  nonappealable;  provided  that  the  right  to
terminate  this  Agreement  pursuant  to  this  Section 9.1(e) shall  not  be  available  to  any  Party  whose  action  or  failure  to  fulfill  any
obligation under this Agreement, or, in the case of Purchaser Parent, if the action of Purchaser or failure by Purchaser to fulfill any
obligation under this Agreement, has been the cause of, or resulted in, the issuance of such Governmental Order;

(f)      by either Seller Parent or Purchaser Parent, by giving written notice of such termination to the other Party, if the
Purchaser Parent Shareholder Approval shall not have been obtained at the Purchaser Parent Shareholder Meeting at which a vote on
the Sale and the transactions contemplated by this Agreement is taken; or

(g)      by Seller Parent upon written notice to Purchaser Parent if there shall have been a Purchaser Parent Adverse

Recommendation Change.

Section 9.2      Effect of Termination .

(a)      In the event of termination of this Agreement pursuant to Section 9.1 , written notice thereof shall forthwith be
given to the other Parties, and, except as set forth in this Section 9.2 , this Agreement shall terminate and be void and have no effect
and  the  transactions  contemplated  hereby  shall  be  abandoned,  without  any  liability  or  obligation  on  the  part  of  any  Party  or  its
respective Affiliates, directors, officers or employees; provided that if such termination shall result from (i) the Intentional Breach by
a Party of any representation, warranty, covenant, or agreement in this Agreement, or (ii) fraud with respect to the representations,
warranties, covenants and agreements contained in this Agreement, such Party shall be fully liable to the other Parties for any and all
damages,  expenses  (including  reasonable  attorneys’  fees  and  expenses),  losses  or  liabilities  of  any  nature  and  kind  incurred  or
suffered by the other Parties or their Affiliates as a result of such Intentional Breach or fraud. Notwithstanding the foregoing, nothing
shall relieve any Party from reimbursement of the costs and expenses (and, as applicable, indemnification obligations) of any other
Party  and  its  Affiliates  pursuant  to  any  provision  of  this  Agreement  that,  by  its  express  terms,  requires  reimbursement,
indemnification or similar obligations by such Party. In the event of termination of this Agreement prior to the Closing pursuant to
Section 9.1 , the Parties shall, and

184

shall  cause  their  applicable  Affiliates  to,  take  all  action  necessary  to  terminate  any  Ancillary  Agreements,  including  any  Local
Implementing Agreements, entered into as of or prior to such time.

(b)      Without limiting Section 9.2(a) , in the event of a termination of this Agreement pursuant to (i)  Section 9.1(b)
(if and only if terminated at a time when the Purchaser Parent Shareholder Approval has not been obtained), (ii) Section 9.1(f) or (iii)
Section  9.1(g)  ,  Purchaser  Parent  shall  pay  to  Seller  Parent,  by  way  of  compensation,  $900,000,000  (the  “  Purchaser  Parent
Termination Fee ”) within one (1) Business Day after the date of the termination of this Agreement by Seller Parent and, in the event
of a termination by Purchaser Parent, concurrently with, and as a condition precedent to, the termination of this Agreement, by wire
transfer of immediately available funds to an account designated in writing by Seller Parent; provided that Purchaser Parent shall not
be  required  to  pay  the  Purchaser  Parent  Termination  Fee  on  more  than  one  occasion.  Purchaser  Parent  acknowledges  that  the
agreements contained in this Section 9.2(b) are an integral part of the transactions contemplated by this Agreement and that, without
these  agreements,  Seller  Parent  would  not  enter  into  this  Agreement.  Accordingly,  if  Purchaser  Parent  fails  promptly  to  pay  any
amount due pursuant to this Section 9.2(b) , Purchaser Parent shall also pay any reasonable and documented costs, fees and expenses
incurred  by  Seller  Parent  (including  reasonable  attorneys’  fees)  in  connection  with  a  legal  action  to  enforce  this  Agreement  that
results in a judgment for such amount or any portion thereof against Purchaser Parent or its Affiliates. Any amount not paid when
due pursuant to this Section 9.2(b) shall bear interest from the date such amount is due until the date paid at a rate equal to the prime
rate as published in The
Wall
Street
Journal
, Eastern
Edition
, in effect on the date such amount is due, plus three percent (3%).
Notwithstanding anything to the contrary in this Agreement, except in the event of (i) an Intentional Breach by Purchaser Parent or
Purchaser of any representation, warranty, covenant, or agreement in this Agreement or (ii) Purchaser Parent’s or Purchaser’s fraud
with  respect  to  the  representations,  warranties,  covenants  and  agreements  contained  in  this  Agreement,  if  this  Agreement  is
terminated in circumstances requiring the payment of the Purchaser Parent Termination Fee to Seller Parent, the payment in full of
the  Purchaser  Parent  Termination  Fee  by  Purchaser  Parent  to  Seller  Parent,  together  with  any  interest,  costs,  fees  or  expenses
payable, in each case in accordance with this ‎ Section 9.2(b) , shall be the sole and exclusive remedy of Seller Parent and all of its
Affiliates against Purchaser Parent and its Affiliates, and upon such payment, except in the event of such an Intentional Breach or
fraud,  none  of  Purchaser  Parent  or  any  of  its  Affiliates  shall  have  any  further  liability  or  obligation  (whether  at  law  or  equity,  in
contract, in tort or otherwise) to Seller Parent or any of its Affiliates, and their respective directors, officers and employees or other
Representatives,  relating  to  or  arising  out  of  this  Agreement,  any  Ancillary  Agreement  or  any  of  the  transactions  contemplated
hereby or thereby.

(c)      Notwithstanding the termination of this Agreement, the following Sections of this Agreement shall remain in
full force and effect: Section 6.1(b) (Information and Documents), Section 9.1 (Termination), Section 9.2 (Effect of Termination)
and Article X (Miscellaneous).

(d)      If this Agreement is terminated in accordance with Section 9.1 , the Confidentiality Agreement and Clean Team
Agreement shall each remain in full force and effect for the term provided for therein; except that Seller Parent and Purchaser Parent
agree that the term

185

of the Confidentiality Agreement (including the employee non-solicitation prohibition therein) shall be extended (if a shorter term
would otherwise  remain)  to a period of two (2) years from the date of such termination  and this Agreement  shall be the requisite
mutual written consent amending such Confidentiality Agreement.

ARTICLE X

MISCELLANEOUS

Section 10.1      Notices . All notices or other communications hereunder shall be deemed to have been duly given and
made  if  in  writing  and  (a)  when  served  by  personal  delivery  upon  the  Party  for  whom  it  is  intended,  (b)  one  (1)  Business  Day
following  the  day  sent  by  overnight  courier,  return  receipt  requested,  (c)  when  sent  by  facsimile,  provided  that  the  facsimile  is
promptly confirmed, or (d) when sent by e-mail, provided that a copy of the same notice or other communication sent by e-mail is
also sent by overnight courier, return receipt requested, personal delivery, or facsimile as provided herein, on the same day as such e-
mail  is sent,  in each  case  to the  Person  at the address,  facsimile  number  or e-mail  address  set  forth  below,  or such  other  address,
facsimile number or e-mail address as may be designated in writing hereafter, in the same manner, by such Person:

To any Seller:

Pfizer Inc.
235 East 42nd Street
New York, NY 10017
Attn: General Counsel

with a copy (which shall not constitute notice) to:

Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
Attn: Edward D. Herlihy
   David K. Lam
   Jacob A. Kling
E-mail: EDHerlihy@wlrk.com
   DKLam@wlrk.com
   JAKling@wlrk.com
Fax: (212) 403-2000

186

To Purchaser Parent or Purchaser:

GlaxoSmithKline Plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Attn: General Counsel Consumer Healthcare

with a copy (which shall not constitute notice) to:

Kirkland & Ellis LLP
601 Lexington Avenue
New York, NY 10022
Attn: Daniel E. Wolf
   Eric L. Schiele, P.C.
   Claire E. James
   Patrick Jacobs
E-mail: daniel.wolf@kirkland.com
   eric.schiele@kirkland.com
   claire.james@kirkland.com
   patrick.jacobs@kirkland.com
Fax: (212) 446-4900

Section 10.2      Amendment; Waiver . Any provision of this Agreement may be amended or waived if, and only if,
such amendment or waiver is in writing and signed, in the case of an amendment, by the Parties hereto, or in the case of a waiver, by
the Party against whom the waiver is to be effective.  No failure or delay by any Party in exercising  any right, power or privilege
hereunder  shall  operate  as  a  waiver  thereof  nor  shall  any  single  or  partial  exercise  thereof  preclude  any  other  or  further  exercise
thereof or the exercise of any other right, power or privilege.

Section 10.3      Assignment . (a) No Party may assign any of its rights or obligations under this Agreement, including
by sale of stock, operation of Law in connection with a merger or sale of all or substantially all of the assets of such Party, without
the prior written consent of the other Parties.

(a)          Notwithstanding the foregoing and subject to Section 6.5(f) , Purchaser  shall be entitled  to designate  one or
more of its Affiliates that are directly or indirectly wholly owned by Purchaser (each, a “ Purchaser Designated Affiliate ”) to be the
purchaser  or  transferee  of  some  or  all  of  the  Shares  or  the  other  Purchased  Assets  and  be  the  entity  assuming  some  or  all  of  the
Assumed  Liabilities  (and  to  be  a  counterparty  to  one  or  more  of  the  Ancillary  Agreements),  provided  that  no  such  designation
(i)  shall  release  Purchaser  from  its  obligations  under  this  Agreement  or  (ii)  would  reasonably  be  expected  to  restrict  or  delay
consummation of the transactions contemplated hereby or by the Ancillary Agreements in any material respect. Purchaser shall be
responsible for and shall pay or reimburse the Sellers for any Taxes and other reasonable out-of-pocket costs and expenses to the
extent arising out of or resulting from the substitution of a Purchaser Designated Affiliate

187

(other  than  a  Purchaser  Designated  Affiliate  organized  under  the  Laws  of  or  Tax  resident  in  the  United  States  or  the  United
Kingdom) for Purchaser as the purchaser or transferee of any of the Shares or the other Purchased Assets, or as the entity assuming
some or all of the Assumed  Liabilities,  or as a counterparty  to one or more  of the  Ancillary  Agreements,  in accordance  with this
Section  10.3(b)  ,  in  each  case  other  than  (1)  any  such  Taxes,  costs  or  expenses  arising  out  of  or  resulting  from  a  substitution
requested by a Seller or required by applicable Law or (2) to the extent the applicable Seller is entitled to a refund, credit or offset in
respect of such Taxes from any Taxing Authority.

Section  10.4            Entire  Agreement  .  This  Agreement  (including  the  Seller  Disclosure  Letter,  the  Purchaser  Parent
Disclosure Letter and all Annexes and Exhibits) contains the entire agreement between the Parties with respect to the subject matter
hereof  and  supersedes  all  prior  agreements  and  understandings,  oral  or  written,  with  respect  to  such  matters,  except  for  (i)  the
Confidentiality Agreement and the Clean Team Agreement which shall each remain in full force and effect and (ii) the Ancillary
Agreements and any other written agreement of the Parties that expressly provides that it is not superseded by this Agreement. In the
event of a conflict between the terms of this Agreement and the terms of any Ancillary Agreement, the terms of this Agreement shall
control except to the extent expressly provided otherwise in any Ancillary Agreement.

Section 10.5      Parties in Interest . Except with respect to (i) the Purchaser Indemnified Parties, the Purchaser Parent
Indemnified  Parties  and  the  Seller  Parent  Indemnified  Parties  solely  with  respect  to  Article  VII  and  (ii)  the  Persons  entitled  to
indemnification under Section 6.5(d) solely with respect to Section 6.5(d) or, in each case, as expressly set forth herein (including
Section 6.21 ), nothing in this Agreement, express or implied, is intended to confer upon any Person other than Purchaser Parent,
Purchaser, the Sellers, or their permitted assigns, any rights or remedies under or by reason of this Agreement.

Section 10.6      Public Disclosure . Notwithstanding anything herein to the contrary, each Party agrees that, except (x)
subject to Section 6.24(f) and Section 6.24(g) , in making a Purchaser Parent Adverse Recommendation Change or (y) as may be
required to comply with the requirements of any applicable Laws, and the rules and regulations of each stock exchange upon which
the  securities  of  either  of  the  Parties  are  listed  (in  which  case  the  disclosing  Party  will  use  its  commercially  reasonable  efforts  to
(a) advise the other Party before making such disclosure  and (b) provide such other Party a reasonable  opportunity  to review and
comment  on  such  release  or  announcement  and  consider  in  good  faith  any  comments  with  respect  thereto),  no  press  release  or
similar public announcement or communication shall, if prior to the Closing, be made or caused to be made by the Parties or their
Affiliates concerning the execution or performance of this Agreement unless the Parties shall have consulted in advance with respect
thereto.

Section 10.7      Expenses . Except as otherwise expressly provided in this Agreement, whether or not the transactions
contemplated  by  this  Agreement  are  consummated,  all  costs  and  expenses  incurred  in  connection  with  this  Agreement  and  the
transactions contemplated hereby shall be borne by the Party incurring such costs and expenses.

Section 10.8      Disclosure Letters; Disclosures Modifying Other Sections of Agreement . The Seller Disclosure Letter

and the Purchaser Parent Disclosure Letter, and all

188

schedules attached thereto, and all Annexes and Exhibits attached to this Agreement, shall be construed with and as an integral part
of this Agreement to the same extent as if the same had been set forth verbatim herein. Any capitalized terms used in any Annex,
Exhibit or Schedule or in the Seller Disclosure Letter or Purchaser Parent Disclosure Letter but not otherwise defined therein shall be
defined as set forth in this Agreement.  Any information,  item or other disclosure set forth in any Section of the Seller Disclosure
Letter  or  the  Purchaser  Parent  Disclosure  Letter,  as  the  case  may  be,  shall  be  deemed  to  be  disclosed  with  respect  to  any  other
Section  of  this  Agreement  (or  to  have  been  set  forth  in  any  other  Section  of  the  Seller  Disclosure  Letter  or  the  Purchaser  Parent
Disclosure Letter, as the case may be), if the relevance of such disclosure to such other Section is reasonably apparent on the face of
such  disclosure  notwithstanding  the  omission  of  a  reference  or  a  cross-reference  with  respect  thereto  and  notwithstanding  any
reference  to  a  Section  of  the  Seller  Disclosure  Letter  or  Purchaser  Parent  Disclosure  Letter,  as  applicable,  in  such  Section  of  this
Agreement.  The  disclosure  of  any  matter  in  any  Section  of  the  Seller  Disclosure  Letter  or  the  Purchaser  Parent  Disclosure  Letter
shall expressly not be deemed to constitute an admission by any Party, or to otherwise imply, that any such matter is material for
purposes of this Agreement.

Section 10.9      No Admission . Nothing in this Agreement, any Ancillary Agreement or in any Section of the Seller
Disclosure  Letter  or  the  Purchaser  Parent  Disclosure  Letter  shall  be  deemed  an  admission  by  any  Party  or  any  of  their  respective
Affiliates  (including  the  Conveyed  Subsidiaries  and  their  Subsidiaries),  in  any  Action  by  or  on  behalf  of  or  with  a  Governmental
Authority or other third party, that any such Party or any of their respective Affiliates, or that such third party or any of its respective
Affiliates,  is  or  is  not  violating  or  in  contravention  or  breach  of  or  default  under,  as  applicable,  any  Law,  Governmental
Authorization, Contract or Intellectual Property of any other Person.

Section 10.10      Governing Law; Jurisdiction .

(a)      This Agreement (and any claim or controversy arising out of or relating to this Agreement) shall be exclusively
governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law rules of such
state.

(b)      Any Action relating to this Agreement, or the transactions contemplated hereby, shall be brought exclusively in
the U.S. District Court for the Southern District of New York or, if for any reason the U.S. District Court for the Southern District of
New  York  lacks  subject  matter  jurisdiction,  any  New  York  State  court  sitting  in  New  York  City,  and  each  Party  irrevocably
(i) agrees and consents to be subject to the jurisdiction of the U.S. District Court for the Southern District of New York or, if for any
reason  the  U.S.  District  Court  for  the  Southern  District  of  New  York  lacks  subject  matter  jurisdiction,  any  New  York  State  court
sitting in New York City and (ii) waives any objection which it may have at any time to the laying of venue of such Action brought
in  any  such  court,  waives  any  claim  that  such  Action  has  been  brought  in  an  inconvenient  forum  and  further  waives  the  right  to
object,  with  respect  to  such  Action,  that  such  court  does  not  have  any  jurisdiction  over  such  Party.  Each  of  Purchaser  Parent  and
Purchaser hereby irrevocably designates, appoints and empowers GSK plc, with offices located at 980 Great West Road, Brentford
Middlesex TW8 9GS, England, as its designee, appointee and agent to receive, accept and acknowledge for and on its behalf service
of any legal process, summons notices and documents

189

which  may  be  served  in  any  such  Action.  If  for  any  reason  GSK  plc  is  unable  or  unwilling  to  continue  to  act  as  such  designee,
appointee  and  agent,  each  of  Purchaser  Parent  and  Purchaser  agrees  to  immediately  appoint  a  successor  designee,  appointee  and
agent  in  New  York  City  acceptable  to  Seller  Parent.  THE  PARTIES  HEREBY  AGREE  THAT  MAILING  OF  PROCESS  OR
OTHER PAPERS IN CONNECTION WITH ANY SUCH ACTION IN THE MANNER PROVIDED IN SECTION 10.1 , OR IN
SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE THEREOF
AND HEREBY WAIVE ANY OBJECTIONS TO SERVICE ACCOMPLISHED IN THE MANNER HEREIN PROVIDED.

(c)            THE  PARTIES  AGREE  THAT  THEY  HEREBY  IRREVOCABLY  WAIVE  AND  AGREE  TO  CAUSE
THEIR  RESPECTIVE  AFFILIATES  TO  WAIVE,  THE  RIGHT  TO  TRIAL  BY  JURY  IN  ANY  ACTION  TO  ENFORCE  OR
INTERPRET THE PROVISIONS OF THIS AGREEMENT.

Section 10.11      Counterparts . This Agreement may be executed in counterparts (including by facsimile or electronic
.pdf submission), each of which shall be deemed an original, and all of which shall constitute one and the same agreement and shall
become effective when one or more counterparts have been signed by each of the Parties and delivered (by telecopy or otherwise) to
the other Parties, it being understood that all Parties need not sign the same counterpart.

Section  10.12            Headings  .  The  heading  references  herein  and  the  table  of  contents  hereto  are  for  convenience

purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

Section  10.13            Severability  .  The  provisions  of  this  Agreement  shall  be  deemed  severable  and  the  invalidity,
illegality or unenforceability of any provision shall not affect the validity, legality or enforceability of the other provisions hereof. If
any  term  or  other  provision  of  this  Agreement,  or  the  application  thereof  to  any  Person  or  any  circumstance,  is  invalid,  illegal  or
unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid, legal
and enforceable, the intent and purpose of such invalid, illegal or unenforceable provision and (b) the remainder of this Agreement
and  the  application  of  such  provision  to  other  Persons  or  circumstances  shall  not  be  affected  by  such  invalidity,  illegality  or
unenforceability,  nor  shall  such  invalidity,  illegality  or  unenforceability  affect  the  validity,  legality  or  enforceability  of  such
provision, or the application thereof, in any other jurisdiction.

Section 10.14            Rules  of  Construction  .  The  Parties  agree  that  they  have  been  represented  by  counsel  during  the
negotiation  and  execution  of  this  Agreement  and  have  participated  jointly  in  the  negotiation  and  drafting  of  this  Agreement  and,
therefore, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted
by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any
provision of this Agreement.

Section 10.15      Specific Performance . The Parties acknowledge and agree that irreparable harm would occur and
that  the  Parties  would  not  have  any  adequate  remedy  at  Law  (i)  for  any  actual  or  threatened  breach  of  the  provisions  of  this
Agreement  or  (ii)  in  the  event  that  any  of  the  provisions  of  this  Agreement  were  not  performed  in  accordance  with  their  specific
terms.

190

It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches or threatened breaches of
this  Agreement  and  to  specifically  enforce  the  terms  and  provisions  of  this  Agreement  (including  Section  6.3  )  and  any  other
agreement or instrument executed in connection herewith, without proof of actual damages, and each Party further agrees to waive
any requirement for the securing or posting of any bond in connection with such remedy. Each of the Parties agrees that it will not
oppose the granting of an injunction, specific performance and other equitable relief on the basis that any other Party has an adequate
remedy  at  Law  or  that  any  award  of  specific  performance  is  not  an  appropriate  remedy  for  any  reason  at  Law  or  in  equity.  The
Parties further agree that (x) by seeking the remedies provided for in this Section 10.15 , a Party shall not in any respect waive its
right to seek any other form of relief that may be available  to a Party under this Agreement,  including  monetary  damages (or the
right  to reimbursement  of its  costs and  expenses  relating  to any  enforcement  actions  hereunder)  and  (y) nothing  contained  in  this
Section  10.15  shall  require  any  Party  to  institute  any  proceeding  for  (or  limit  any  Party’s  right  to  institute  any  proceeding  for)
specific performance under this Section 10.15 before exercising any termination right under Section 9.1 (and pursuing damages after
such  termination)  nor  shall  the  commencement  of  any  action  pursuant  to  this  Section  10.15  or  anything  contained  in  this
Section 10.15 restrict or limit any Party’s right to terminate this Agreement in accordance with the terms of Section 9.1 or pursue any
other  remedies  under  this  Agreement  that  may  be  available  then  or  thereafter.  Notwithstanding  the  foregoing,  under  no
circumstances  shall  any  Seller  be  permitted  to  receive  both  (1)  a  grant  of  specific  performance  to  require  Purchaser  or  Purchaser
Parent to consummate, and that results in the consummation of, the Closing and (2) payment of the Purchaser Parent Termination
Fee.

Section 10.16      Affiliate Status . To the extent that a Party is required hereunder to take certain action with respect to
entities designated in this Agreement as such Party’s Affiliates, such obligation shall apply to such entities only during such period
of  time  that  such  entities  are  Affiliates  of  such  Party.  To  the  extent  that  this  Agreement  or  any  Ancillary  Agreement  requires  an
Affiliate of any Party to take or omit to take any action, such agreement and obligation includes the obligation of such Party to cause
such Affiliate to take or omit to take such action.

Section 10.17      Waiver of Conflicts Regarding Representation; Nonassertion of Attorney-Client Privilege .

(a)      Each of Purchaser Parent and Purchaser waives and will not assert, and agrees to cause its Affiliates, including,
following the Closing, the Conveyed Subsidiaries and their Subsidiaries, to waive and not assert, any conflict of interest arising out
of  or  relating  to  the  representation,  after  the  Closing  (the  “  Seller  Post-Closing  Representation  ”),  of  Seller  Parent  or  any  of  its
Affiliates,  or  any  shareholder,  officer,  employee  or  director  of  Seller  Parent  or  any  of  its  Affiliates  (any  such  Person,  a  “  Seller
Designated  Person ”)  in  any  matter  involving  this  Agreement,  the  Ancillary  Agreements  or  any  other  agreements  or  transactions
contemplated  hereby or thereby, by any legal counsel currently  representing  any Seller Designated Person in connection  with this
Agreement, the Ancillary Agreements or any other agreements or transactions contemplated hereby or thereby, including Wachtell,
Lipton, Rosen & Katz (any such representation, the “ Seller Current Representation ”).

191

(b)      Seller Parent waives and will not assert, and agrees to cause its Affiliates to waive and not assert, any conflict of
interest  arising  out  of  or  relating  to  the  representation,  after  the  Closing  (the  “  Purchaser  Post-Closing  Representation  ”),  of
Purchaser  Parent  or  Purchaser  or  any  of  their  Affiliates  or  any  shareholder,  officer,  employee  or  director  of  Purchaser  Parent,
Purchaser or any of their Affiliates (any such Person, a “ Purchaser Designated Person ”) in any matter involving this Agreement, the
Ancillary  Agreements  or  any  other  agreements  or  transactions  contemplated  hereby  or  thereby,  by  any  legal  counsel  currently
representing any Purchaser Designated Person in connection with this Agreement, the Ancillary Agreements or any other agreements
or transactions contemplated hereby or thereby, including Kirkland & Ellis LLP and Slaughter and May (any such representation, the
“ Purchaser Current Representation ”).

(c)      Each of Purchaser Parent and Purchaser waives and will not assert, and agrees to cause its Affiliates, including,
following  the  Closing,  the  Conveyed  Subsidiaries  and  their  Subsidiaries,  to  waive  and  not  assert,  any  attorney-client  or  other
applicable  legal  privilege  or  protection  with  respect  to  any  communication  between  any  legal  counsel  and  any  Seller  Designated
Person  occurring  during  the  Seller  Current  Representation  (the  “  Seller Privileged Communications ”)  or  in  connection  with  any
Seller  Post-Closing  Representation,  including  in  connection  with  a  dispute  with  Purchaser  Parent  or  Purchaser  or  its  Affiliates
(including,  following  the  Closing,  any  Conveyed  Subsidiary  or  any  of  their  Subsidiaries),  including  in  respect  of  any  claim  for
indemnification hereunder by a Purchaser Indemnified Party or a Purchaser Parent Indemnified Party, it being the intention of the
Parties that all such rights to such attorney-client and other applicable legal privilege or protection and to control such attorney-client
and  other  applicable  legal  privilege  or  protection  shall  be  retained  by  the  Sellers  and  their  Affiliates  and  that  the  Sellers,  and  not
Purchaser Parent, Purchaser or their Affiliates or the Conveyed Subsidiaries and their Subsidiaries, shall have the sole right to decide
whether or not to waive any attorney-client or other applicable legal privilege or protection. Accordingly, from and after Closing,
none of Purchaser Parent, Purchaser or their Affiliates, including the Conveyed Subsidiaries and their Subsidiaries, shall have any
access to any such communications or to the files of the Seller Current Representation, all of which shall be and remain the property
of the Sellers and not of Purchaser Parent, Purchaser or their Affiliates, including the Conveyed Subsidiaries and their Subsidiaries,
or to internal counsel relating to such engagement, and none of Purchaser Parent, Purchaser or their Affiliates, including, following
the Closing, the Conveyed Subsidiaries and their Subsidiaries, or any Person acting or purporting to act on their behalf shall seek to
obtain the same by any process on the grounds that the privilege and protection attaching to such communications and files belongs
to Purchaser Parent, Purchaser or their Affiliates, including, following the Closing, the Conveyed Subsidiaries and their Subsidiaries,
or  does  not  belong  to  the  Sellers.  Notwithstanding  the  foregoing,  in  the  event  that  a  dispute  arises  between  Purchaser  Parent,
Purchaser or their Affiliates,  including,  following the Closing, the Conveyed Subsidiaries  and their Subsidiaries,  on the one hand,
and  a  third  party  other  than  the  Sellers  or  their  Affiliates,  on  the  other  hand,  Sellers  shall  not  disclose  any  such  Seller  Privileged
Communications to such third party without the prior written consent of Purchaser unless required to do so by applicable Law or
Governmental Order.

(d)      Seller Parent waives and will not assert, and agrees to cause its Affiliates, to waive and not assert, any attorney-
client  or  other  applicable  legal  privilege  or  protection  with  respect  to  any  communication  between  any  legal  counsel  and  any
Purchaser Designated Person occurring

192

during  the  Purchaser  Current  Representation  (the  “  Purchaser  Privileged  Communications  ”)  or  in  connection  with  any  Purchaser
Post-Closing Representation, including in connection with a dispute with Seller Parent or its Affiliates, including in respect of any
claim for indemnification hereunder by a Seller Parent Indemnified Party, it being the intention of the Parties that all such rights to
such attorney-client and other applicable legal privilege or protection and to control such attorney-client and other applicable legal
privilege or protection shall be retained by Purchaser Parent and its Affiliates (other than Purchaser) and that Purchaser Parent, and
not Seller Parent or Purchaser, shall have the sole right to decide whether or not to waive any attorney-client or other applicable legal
privilege or protection. Accordingly, from and after Closing, none of Seller Parent or Purchaser shall have any access to any such
communications or to the files of the Purchaser Current Representation, all of which shall be and remain the property of Purchaser
Parent and not of Seller Parent or its Affiliates or Purchaser or its Subsidiaries or to internal counsel relating to such engagement,
and none of Seller Parent or its Affiliates or Purchaser or its Subsidiaries or any Person acting or purporting to act on their behalf
shall seek to obtain the same by any process on the grounds that the privilege and protection attaching to such communications and
files  belongs  to  Seller  Parent  or  its  Affiliates  or  Purchaser  or  its  Subsidiaries  or  does  not  belong  to  the  Purchaser  Parent.
Notwithstanding the foregoing, in the event that a dispute arises between Seller Parent or its Affiliates, on the one hand, and a third
party  other  than  Purchaser  Parent,  Purchaser  or  their  Affiliates,  on  the  other  hand,  Purchaser  Parent  shall  not  disclose  any  such
Purchaser Privileged Communications to such third party without the prior written consent of Seller Parent unless required to do so
by applicable Law or Governmental Order.

Section 10.18      Translation of Currencies . Unless otherwise agreed in writing by Seller Parent and Purchaser Parent,
all  payments  to  be  made  under  or  pursuant  to  this  Agreement  shall  be  made  in  Pound  sterling.  Except  with  respect  to  the
determinations  set  forth  in  the  following  sentence,  and  except  to  the  extent  otherwise  provided  in  the  Accounting  Principles  or
Purchaser  Accounting  Principles  with  respect  to  the  determinations  of  amounts  included  in  the  calculations  of  Business  Working
Capital, Business Net Cash, Purchaser Working Capital or Purchaser Net Cash, as applicable, in the event that the Parties need to
convert currencies under this Agreement, the relevant exchange rate shall be determined based on the Bloomberg BFIX rate in effect
as  of  5:00  p.m.  (New  York  time)  two  (2)  Business  Days  preceding  the  applicable  determination  date  as  published  on
Bloomberg.com. In the event that any Person needs to convert currencies for purposes of calculating the amount of any claim under
Section 6.5(d) or Article VII , the relevant exchange rate shall be determined based on the Bloomberg BFIX rate in effect as of 5:00
pm (New York time) two (2) Business Days preceding the date of the written notice given for such claim under Section 6.5(d) or
under Section 7.3 , as applicable, as published on Bloomberg.com.

[ Signature
page
follows
]

193

IN  WITNESS  WHEREOF,  the  Parties  have  executed  or  caused  this  Agreement  to  be  executed  as  of  the  date  first

written above.

PFIZER INC.

By:

/s/ Albert Bourla
Name: Albert Bourla
Title: Chief Operating Officer

GLAXOSMITHKLINE PLC

By:

/s/ Simon Dingemans
Name: Simon Dingemans
Title: Chief Finance Officer

GLAXOSMITHKLINE CONSUMER HEALTHCARE
HOLDINGS LIMITED

By:

/s/ Simon Dingemans
Name: Simon Dingemans
Title: Director

[ Signature
Page
to
Stock
and
Asset
Purchase
Agreement
]

Amendment No. 1
Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees
(Amended and Restated December 31, 2016)

* * *

EXHIBIT 10.7

A new Appendix I is added to the end of “Part B: Provisions Applicable To The Pfizer Sub-Plan” of the Pfizer Consolidated Supplemental Pension Plan

for United States and Puerto Rico Employees to read as follows:

1

APPENDIX I

SUPPLEMENTAL PRAP VOLUNTARY EARLY RETIREMENT PLAN

ARTICLE I

Purpose

SECTION 1.1

This Appendix I contains the Supplemental PRAP Voluntary Early Retirement Plan (the "VERP/SSP SERP"), a Subplan to the Plan, which is being
adopted in order to provide a pension enhancement to certain members of the Retirement Plan who are U.S. employees of Pfizer Inc., and who elect to be
included in the Voluntary Early Retirement Program (the “VERP”), or who are involuntarily terminated in connection with the new Organizing for Growth (“OFG”)
operating model and receive the Special Separation Program (“SSP”) enhanced benefits under either the Pfizer Separation Plan, the Senior Leadership Council
Separation Plan or the Executive Severance Plan (the “OFG U.S. Program”).

ARTICLE II

Definitions

SECTION 2.1.

Whenever used herein, unless the context otherwise indicates, the following terms shall have the respective meanings as set forth below or as defined

in Part A of the Plan:

Administrative Committee: the Administrative Committee of the Company.

Calculation Date: the first day of the month coincident with or next following the later of (1) the date the Participant attains age 55 (or

the date the Participant would have attained Rule of 90 if he or she had remained employed, if earlier) or (2) the date of the Participant’s Separation
from Service.

under the VERP and the OFG U.S. Program.

Coordinating Office or Separation Coordinating Office: the staff designated by the Plan Administrator to handle claims for benefits

Election Period: the period of time in which an eligible Employee may elect to participate in the VERP.

Employee: any person who is a regular full-time or part-time employee of Pfizer Inc. or one of its affiliates in one of the 50 states or

the District of Columbia, or an employee paid from the United States under the Pfizer International Assignment Policy, and in each case such employee
is on U.S. payroll and participating in U.S. benefits. Employees working for a Pfizer legal entity based in Puerto Rico are excluded from participating in
the VERP/SSP SERP.

OFG U.S. Program: the enhanced involuntary severance program established in connection the new OFG operating model which

consists of enhanced benefits under this VERP/SSP SERP, the Retirement Plan, the Pfizer Inc. Retiree Medical Plan, the Pfizer Inc. Health and
Insurance Plan, the Pfizer Savings Plan, the Pfizer Supplemental Savings Plan, and with respect to a Participant’s annual equity awards, and
severance benefits under either the Pfizer Separation Plan, the Senior Leadership Council Separation Plan or the Executive Severance Plan.

2

Participant: a person who is eligible for participation in the VERP/SSP SERP under the provisions of Appendix I; Article III.

Payment Date: the date described in Appendix I; Section 4.2 below.

PRAP: the Pfizer Retirement Annuity Plan which is contained in Part B of the Retirement Plan.

Separation Date or Separation from Service or Separate(s) from Service: a Participant’s date of termination which shall constitute a

"separation from service" within the meaning of Code section 409A. With respect to an OFG Participant separated under the VERP, the Separation
Date shall be the OFG Participant’s date of termination, which shall be December 31, 2018 unless otherwise deferred by the Company. With respect to
an OFG Participant separated under the SSP, the Separation Date shall be the OFG Participant’s date of termination.

as described in Appendix I; Article IV.

Supplemental VERP/SSP Plan Benefit: the amount of the benefit that a Participant is eligible to receive under this VERP/SSP SERP

VERP: the Voluntary Early Retirement Program established in connection the new OFG operating model which consists of enhanced benefits

offered under this VERP/SSP SERP, the Retirement Plan, the Pfizer Inc. Retiree Medical Plan, the Pfizer Inc. Health and Insurance Plan, the Pfizer
Savings Plan, the Pfizer Supplemental Savings Plan, and with respect to a Participant’s annual equity awards.

benefits offered under the VERP and OFG U.S. Program.

VERP/SSP SERP: this Subplan contained in this Appendix I to the Plan established in order to implement the enhanced pension

VERP/SSP SERP Benefit Commencement Date or VERP BCD: the first day of the month coincident with or next following the date as

of which the Participant would first be eligible to retire after reaching either (a) attainment of age 55 and completion of 10 years of retirement eligibility
service or (b) Rule of 90, as described in Part B of the Retirement Plan. If the addition of 5 points enables the Participant to reach both (a) age 55 with
10 years of service and (b) Rule of 90, the Participant’s VERP/SSP SERP Benefit Commencement Date shall be the date that corresponds to the more
valuable benefit.

ARTICLE III

Eligibility for Plan Benefit

SECTION 3.1.    An Employee shall be a Participant and eligible to receive a Supplemental VERP/SSP Plan Benefit under this VERP/SSP SERP in an

amount determined in accordance with Appendix I; Article IV if he or she meets the following requirements:

(a) he is an active Employee (including an Employee on short-term disability or a paid or unpaid leave of absence) who is a regular full-time or part-time

employee of Pfizer Inc. or one of its affiliates in one of the 50 states or the District of Columbia, or an employee paid from the United States under the Pfizer
International Assignment Policy, and in each case such employee is on U.S. payroll and participating in U.S. benefits;

(b) he elects to be voluntarily terminated under the VERP during the Election Period, and he is eligible for, signs a release and does not revoke it, and

receives benefits under the VERP or his employment is involuntarily terminated under the OFG U.S. Program and he signs a release and does not revoke it, and
receives benefits under the OFG U.S. Program;

    (c) he has a Retirement Benefit under Part B of the Retirement Plan and the addition of five (5) points as of December 31, 2018 for a VERP
Participant (including a VERP Participant who is re-classified as SSP subsequent to his termination of employment), or as of his Separation Date in the case of a
Participant who is terminated under the SSP, to his age, service, or any combination thereof would enable him to qualify for subsidized early retirement because
he would reach either (i) age 55 and completion of 10 years of retirement eligibility service or (ii) Rule of 90, as described in Part B of the Retirement Plan.
Employees who have already

3

reached either: (i) age 55 and completion of 10 years of retirement eligibility service; or (ii) Rule of 90, as described in Part B of the Retirement Plan as of their
Separation Date, cannot benefit from the five (5) points ;

under Part B of the Plan; and

(d) he has more than or equal to $235,000 in pensionable earnings under Part B of the Retirement Plan in 2017 or has an accrued benefit

(e) he is not an Excluded Employee. For this purpose, an Employee is an Excluded Employee if any of the following applies:

•

•

•

•

•

•

•

The Employee’s terms and conditions of employment are subject to collective bargaining.

The Employee is or has been a Named Executive Officer in the Company’s Annual Proxy Statement.

The Employee is currently working for a Pfizer legal entity based in Puerto Rico.

The Employee is receiving benefits from a Company-sponsored long-term disability plan.

The Employee is on secondment in the United States.

The Employee is not paid through the U.S. payroll and/or is not eligible for U.S. benefits.

The Employee has been deemed ineligible through the Claims and Appeals Procedure.

SECTION 3.2.    For the purposes of Appendix I; Section 3.1, with respect to a Participant who dies while in active service on or after his election to
participate in VERP but before executing the release agreement, t he spouse or the estate may sign the release agreement on his or her behalf, if applicable.

ARTICLE IV

Supplemental VERP/SSP Plan Benefits

SECTION 4.1    If a Participant is eligible as determined in Appendix I; Article III, the Company shall make a lump sum cash payment to the Participant

in an amount equal to the difference between (i) and (ii) below, discounted or increased if applicable from the Participant’s VERP/SSP SERP Benefit
Commencement Date (“VERP BCD”) to the Participant’s Payment Date, using a discount rate equal to the first segment rate in Code Section 417(e)(3)(C),
published in the third month prior to the Calculation Date, where:

(i) is the present value of the Participant’s accrued benefit under the PRAP portion of the Retirement Plan and the Plan, determined as of the VERP

BCD, reflecting (a) the early retirement reduction factor that would apply if five (5) points were added to the Participant’s age, service, or a combination thereof
as of December 31, 2018 (or as of his Separation Date in the case of a Participant whose employment is terminated under the OFG U.S. Program), and (b)
without reference to the limitations of Code Sections 415 and 401(a)(17);

(ii) is the present value of the Participant’s accrued benefit under the PRAP portion of the Retirement Plan and the Plan, determined as of the VERP

BCD, without reflecting the 5-point enhancement described in (i) and without reference to the limitations in Code Sections 415 and 401(a)(17);

For purposes of (ii) above, in the event the Participant’s VERP BCD is prior to his attainment of age 55, the early retirement reduction applied to years

below age 55 shall be the actuarial equivalent of the benefit at age 55, where actuarial equivalence is determined using an interest discount rate of 5% and
mortality in accordance with Code Section 417(e).

4

The present values shall be calculated using the PRAP portion of the Retirement Plan’s actuarial assumptions for payment of lump sums as published
in the third month prior to the Calculation Date. The five (5) point enhancement applies solely for the purpose of determining the reduction for early retirement, if
any, with respect to the PRAP portion of the benefit; it does not count for any purpose with respect to benefit formulas, the computation of the Normal Retirement
Benefit, or the computation of the lump sum factors.

In the event the Participant has chosen a single life annuity as his payment election, the amount determined in Section 4.1 shall be converted to a life

annuity using an immediate annuity factor determined as of the Participant’s Payment Date, determined using the Code Section 417(e)(3)(C) interest rate
published in the third month prior to the Calculation Date and mortality table under Code Section 417(e) in effect as of the Participant’s Payment Date.

SECTION 4.2.    Such lump sum payment shall be made as soon as practicable in the January coincident with or following the later of (1) such

Participant’s Separation from Service, or (2) the Participant’s attainment of age 55 (or the date the Participant would have attained Rule of 90 if he or she had
remained employed, if earlier), unless the Participant has an Accrued Benefit under Part B of the Plan in which case the Supplemental VERP/SSP Plan Benefit
will be paid in accordance with the payment elections under Part B of the Plan. Notwithstanding the foregoing, payments may not be made to a Key Employee
upon Separation from Service before the date which is six (6) months after the date of the Key Employee’s Separation from Service (within the meaning of Code
section 409A). In the event that payment is delayed pursuant to the preceding sentence, payment shall be made (i) on the first day of the seventh month
following the Key Employee’s Separation from Service (within the meaning of Code section 409A), or, (ii) if earlier, the first day of the month after such
Participant’s death during this period of delay. The above shall define the Participant’s Payment Date regardless of whether due to administrative delays, the
actual payment is made after the Payment Date.

SECTION 4.3    If a Participant dies after becoming eligible to receive a Supplemental VERP/SSP Plan Benefit and prior to the Participant’s Payment

Date, the following benefits are payable from the Plan in the form of a rollover to the Pfizer Supplemental Savings Plan in accordance with the provisions in Part
B, Section 5.4 of the Plan, as if the Participant had died during active employment:

benefit determined in accordance with Appendix I; Section 4.1 of the VERP/SSP SERP shall be transferred to the PSSP account.

(i) If the Participant is married at the time of death, and the Participant’s spouse waives the QPSA, the lump sum death benefit equal to the

SERP. However, pre-retirement death benefits may be payable from the Retirement Plan and the Plan.

(II) If the Participant is married at the time of death and the spouse does not waive the QPSA, no benefit is payable from the VERP/SSP

Appendix I; Section 4.1 of the VERP/SSP SERP shall be transferred to the Participant’s Pfizer Supplemental Savings Plan account.

(iii) If the Participant is not married at the time of death, the lump sum death benefit equal to the benefit determined in accordance with

(iv) The lump sum death benefit shall be payable as of the January 1 coincident with or next following the Participant’s death.

SECTION 4.4    If a Participant is rehired prior to the Participant’s Payment Date, the Participant shall be entitled to the VERP/SSP SERP Plan Benefit

determined in accordance with Appendix I; Section 4.1, payable as of the Participant’s Payment Date, as if the Participant had not been rehired. The five (5)
point enhancement may not be used towards any other milestone.

SECTION 4.5    The benefits payable under the VERP/SSP SERP are determined solely with respect to the PRAP formula and early retirement

provisions in Part B of the Retirement Plan and the corresponding section in the Plan. Nothing in the VERP/SSP SERP shall be construed as changing
retirement benefits corresponding to any legacy retirement plan benefit, other than PRAP benefits.

5

ARTICLE V

Administration and Claims and Appeals Procedure

SECTION 5.1.    The Committee has delegated the ministerial authority to administer claims for benefits under the Plan to the Company’s Separation

Coordinating Office or its successor. The Separation Coordinating Office is responsible for determining who is eligible to become a Participant and for
determining initial claims for benefits under the VERP/SSP SERP.

SECTION 5.2.    The Committee has delegated authority to administer the appeal of denied claims under the VERP/SSP SERP to the Administrative

Committee.

SECTION 5.3.    Any request by a Participant or any other person for any benefit alleged to be due under the Plan shall be known as a “Claim” and the

Participant or other person making a Claim, or the authorized representative of either, shall be known as a “Claimant.” To make a Claim, the Claimant must
submit the Claim in writing to the Separation Coordinating Office. The Claim must include a description of the benefit that the Claimant believes is due, the
reason(s) the Claimant believes such benefit is due and any information and documentation that the Claimant believes supports his Claim and that he wishes to
have the Separation Coordinating Office consider.

SECTION 5.4.    The Coordinating Office will process the Claim within 90 days of receipt of the Claim unless special circumstances require an
extension of time for determining the Claim. In such event, written notice of an extension of time to consider the Claim and the reasons for it, will be sent to the
Claimant before the end of the initial 90-day period. The extension will not exceed a period of 90 days from the end of the initial 90-day period. If the
Coordinating Office has not determined the Claimant’s eligibility for a Plan benefit within this 90-day period (180-day period if circumstances require an extension
of time) the Claimant may deem the Claim denied.

SECTION 5.5.    In the event a Claim is denied, in whole or in part, the notice of denial will set forth: (i) the specific reason(s) for the denial; (ii) specific
reference to the pertinent Plan provisions on which the denial is based; (iii) a description of any additional material or information necessary for the Claimant to
perfect the Claim and an explanation of why such material or information is necessary; and (iv) an explanation that, if an adverse determination is made on
review, the Claimant has a right to bring a civil action under Section 502(a) of ERISA.

SECTION 5.6.    Within 60 days of receipt of notice of a Claim that has been denied in whole or in part, or from the date that a Claim is deemed denied,
the Claimant may (i) submit an appeal, which is a written request for review by the Administrative Committee that includes all information and documents that the
Claimant wishes to have the Administrative Committee consider; and (ii) review documents pertinent to the Claim. The Claimant shall be provided upon request
and free of charge, reasonable access to all documents and records and other information relevant to the Claim. If the Claimant does not request an appeal of
the denied claim within the 60-day period, the Claimant shall be barred and estopped from challenging the denial.

SECTION 5.7.    The Administrative Committee will review a denied Claim for which an appeal has been submitted and render a decision no later than
60 days after receipt of the appeal, provided, however, that if special circumstances require an extension of time for determining the appeal, a decision shall be
rendered no later than 120 days after receipt of the appeal. Written notice of any such extension and the reasons for it, shall be furnished to the Claimant before
the end of the initial 60-day period. The extension will not exceed a period of 60 days from the end of the initial 60-day period. If the Administrative Committee
has not rendered a decision within this 60-day period (120-day period if circumstances require an extension of time) the Claimant may deem the appeal denied.

SECTION 5.8.    In the event an appeal is denied, in whole or in part, the Administrative Committee’s decision will set forth: (i) the specific reason(s) for
the denial; (ii) specific reference to the pertinent VERP/SSP SERP provisions on which the denial is based; and (iii) an explanation that the Claimant has a right
to bring a civil action under Section 502(a) of ERISA.

SECTION 5.9.    No legal action may be brought for benefits under this VERP/SSP SERP until the Claimant has exhausted the administrative

procedure described in this Article V. No legal action may be commenced at all unless commenced no later than one year following the issuance of a final
decision on the Claim, or the expiration of the appeal decision period if no decision is issued. This one-year statute of limitations

6

on suits for all benefits shall apply in any forum where the Claimant may initiate such a suit.

SECTION 5.10.    No member of the Board of Directors or of the Committee, the Administrative Committee, the Separation Coordinating Office, or its
delegates shall be liable for any act or action, whether of commission or omission, taken by any other member, or by any officer, agent or employee or by any
investment advisor or financial institution appointed by any such person; nor, except in circumstances involving his bad faith, for anything done or omitted to be
done by himself. Each member of the Committee, Administrative Committee, and Separation Coordinating Office shall be fully indemnified and entitled to receive
an advance of any related attorney fees in connection with legal proceedings related to the Plan.

ARTICLE VI

Miscellaneous

SECTION 6.1.    Each Participant shall, after his Separation Date, make himself available for such consultative and advisory services as the Company

may reasonably request, taking fairly into consideration the age, health, residence, and individual circumstances of the Participant, and provided such amount of
services to be provided shall not prevent the Participant’s termination from constituting a Separation from Service. If such Participant shall unreasonably refuse
to render such services, the Company may require such Participant to reimburse any payments made hereunder.

SECTION 6.2.    Any benefit hereunder which is unclaimed, including outstanding checks, may, as determined by the Retirement Committee, be

forfeited.

SECTION 6.3.    The adoption of this Appendix allows for the early vesting of certain benefits under the Plan and shall not be considered a modification

to the Plan.

SECTION 6.4.    The Company reserves the right to delay the Separation Date of any Participant who elected to be included in the VERP for a period of

up to six months (or until June 30, 2019) without the consent of the Participant. Further, provided the Participant consents, the Company may delay the
Separation Date up to June 30, 2020.

7

EXHIBIT 10.12

Amendment No. 4

Pfizer Supplemental Savings Plan (the “PSSP”)

* * *

(New material underlined; deletions crossed out)

1. Section 2.31 shall be clarified to read as follows:

2.31 Regular Earnings.

However, for Pension Transfers, solely for purposes of the Retirement Savings Contribution, Regular Earnings shall not include any bonuses (including
but not limited to, sales and GPP bonuses) earned paid or deferred in 2018 which reflects payment for services performed in 2017.

2. Section 3.5(c) is clarified to read as follows:

3.5(c) For any Pension Transfer, the definition of “Regular Earnings” in connection solely with the calculation of the 2018 Retirement Savings
Contributions under the Plan for such Pension Transfer shall not include any bonuses (including but not limited to, sales and GPP bonuses) earned in
paid to or deferred by such Pension Transfer during 2018 which reflects performance during 2017.

EXHIBIT 10.13

Amendment No. 5 to the

Pfizer Supplemental Savings Plan (“PSSP”)

* * *

(New material underlined)

1. Section 2.32 of the PSSP is amended to read as follows:

2.32         Retirement . The term “Retirement” means a termination of employment with an Employer after the Eligible Employee has attained either (i) age
65, or (ii) age 55 with at least 10 Years of Service (as determined in accordance with the Qualified Plan) , or an Eligible Employee who was eligible under
the Pfizer Voluntary Early Retirement Program or involuntarily terminated under the Special Separation Program under a Company-sponsored severance
plan, and who would attain either (i) age 65, or (ii) age 55 with at least 10 Years of Service, if credited with:

(a)    An additional five years of age;

(b)    An additional five Years of Service; or

(c)    A combination (in months) of years of age and Years of Service, which combination does not exceed 60 months .

EXHIBIT 10.26

Amendment No. 1 to the

Pfizer Inc. Executive Severance Plan

* * *

(New material underlined)

1. The Plan is clarified to provide that the Plan Administrator is the Executive Vice President, Worldwide Human Resources.

2. A new Appendix A is added to the end of the Pfizer Inc. Executive Severance Plan to read as follows:

APPENDIX A

Special Separation Program

INTRODUCTION

The Company is adopting this Special Separation Program (“SSP”) in connection with the new Organizing for Growth operating model to provide enhanced

severance benefits to impacted eligible employees under the Plan who meet the additional eligibility requirements set forth in this Appendix.

This Appendix A sets forth certain special provisions applicable to eligible employees who may become eligible under the SSP. To the extent not superseded or

specifically addressed by the provisions of this Appendix A, the provisions of the Plan shall govern.

ARTICLE I

DEFINITIONS

Unless specifically defined below, all other definitions are set forth in the Plan:

1.1 “Active Health & Insurance Continuation” means the period of time, beginning on an SSP Participant’s Termination Date, for which an SSP Participant is

offered Continuing Group Health and Life Insurance Coverage in accordance with Appendix A; Section 3.

1

1.2 “Five Points Brochure” means the brochure prepared and describing certain enhancements available under the pension plans, savings plans, retiree

medical plan and equity awards for certain eligible employees.

1.3 “SSP” means the Special Separation Program set forth in this Appendix A.

1.4 “SSP Participant” means an eligible employee under the Plan who is eligible to participate in the SSP pursuant to Appendix A: Section 2.1 and becomes a

Participant pursuant to Appendix A; Section 2.2.

ARTICLE 2

PARTICIPATION

2.1    Eligibility to Participate.

2.1.1

An eligible employee under the Plan shall become an SSP Participant if, on his Termination Date:

(a)

He is an eligible employee under the Plan and is not, and has not been, a “named executive officer” in the Company’s Annual Proxy

Statement;

(b)

He is involuntarily terminated due to business restructuring or job elimination (which will be determined by the Plan Administrator, or

its designee, in its sole and absolute discretion), or due to exhaustion of short-term disability benefits; and

(c)

His Official Notification Date is on or after December 21, 2018 and on or before August 2, 2019.

2.1.2

An eligible employee shall also be eligible to participate in the SSP under the Plan if he elected to terminate employment under the terms of

the Pfizer Voluntary Early Retirement Program and his position is eliminated by June 26, 2019. The Plan Administrator, or its designee, in its

sole and absolute discretion, will determine whether the position was eliminated by June 26, 2019. In the event that this determination is made

after the eligible employee’s Termination Date, such SSP Participant shall be eligible for the cash severance determined under Plan only, and

not the additional benefits (including Active Health & Insurance Continuation) described in Appendix A; Section 3.

2.2

Participation. An eligible employee who is determined to be eligible to participate in the SSP under the provisions of this Appendix A; Article 2 becomes

an SSP Participant after the Plan Administrator receives and accepts the eligible employee’s duly executed Release Agreement within the time period

specified by such agreement. The earliest date the Release Agreement may be signed is the eligible employee’s Termination Date. Participation will

begin on the eighth day after the eligible employee signs the Release Agreement, provided the eligible employee has not revoked the Release

Agreement during that time period. If an eligible employee dies while in active service on or after his or her Official Notification Date

2

but before executing the Release Agreement, the estate may sign the Release Agreement on his or her behalf and receive the applicable cash

severance under the Plan and the Active Health & Insurance Continuation.

ARTICLE 3

BENEFITS

3.1    Severance Pay.

3.1.1

If an eligible employee satisfies the eligibility requirements of Appendix A; Article 2. and becomes an SSP Participant, he will be entitled to

cash severance in the amount determined under the Plan.

3.1.2 Continuing Group Health and Life Insurance Coverage.

(a)    Health Benefits.

(i)    An SSP Participant may continue coverage (“Active Health & Insurance Continuation”) at the active employee rates in effect with respect

to his elections during the 2019 Annual Enrollment period, or on his Termination Date if his Termination Date is later than December 31, 2018, and as

adjusted thereafter for active Employees, in accordance with the same terms as applicable to active employees. Such Active Health & Insurance

Continuation will last for up to a maximum of three (3) years from the Termination Date. If an SSP Participant covers an eligible dependent who is not

their tax dependent, the value of any subsidized company provided healthcare coverage results in imputed income to the SSP Participant. Any Active

Health & Insurance Coverage will end on the date as of which the SSP Participant becomes eligible for coverage under another employer’s group

health plans (regardless of whether he actually enrolls in such other plan). In addition, Active Health & Insurance Coverage will end if required

contributions for such coverage are not received on a timely basis. Continuation under the Pfizer Flexible Spending Account Plan Health Care Account

may only be continued to the end of the calendar year in which the Termination Date occurs.

(ii)     After Active Health & Insurance Coverage ends and provided the SSP Participant was covered under the Company-sponsored medical

plan for the entire period and is not eligible for medical coverage under another employer’s plan, such SSP Participant may continue medical coverage

for an additional 18 months (except for the Health Care Account Plan that is beyond the calendar year following the year containing the Date of

Termination), at 102% of the full cost of coverage pursuant to his rights under the Consolidated Omnibus Budget Reconciliation Act (COBRA).

(iii)    An SSP Participant who elects the continuing medical coverage provided under the SSP is also electing to continue any Company-

sponsored dental, vision and basic life insurance coverage in effect on his Termination Date provided he is participating in such coverage on his

3

Termination Date. In all cases except for any COBRA elections, if an SSP Participant chooses to continue medical, dental, vision or basic life insurance

coverage pursuant to this package, he must choose to continue each of the medical, dental, vision and basic life insurance coverages (as capped in the

case of life insurance) in which he is participating on his Termination Date, or none of these coverages. There are no separate elections for these

coverages. Dental and vision coverages continue in the same manner as provided with respect to medical coverage described in (a)(i) and (a)(ii) set

forth above.

(iv)    If an SSP Participant who is eligible for Company-sponsored retiree medical coverage on his Termination Date, elects Active Health &

Insurance Coverage and/or an additional 18 months of COBRA coverage, he is also electing to defer enrollment in the Company-sponsored retiree

medical plan (if available).

(v)    If an SSP Participant does not elect Active Health & Insurance Coverage, the SSP Participant will be offered COBRA continuation

coverage, as applicable. The SSP Participant will be offered to continue basic life insurance in accordance with the terms of the Pfizer Life Insurance

Plan, as applicable.

(b)        Retiree Medical.

(i)    An SSP Participant who is eligible for Company-sponsored retiree medical coverage on his Termination Date may elect such coverage

pursuant to the terms of such plan. An SSP Participant may not be enrolled for Company-sponsored retiree medical coverage while in Active Health &

Insurance Continuation.

(ii)    An SSP Participant who is eligible for Company-sponsored retiree medical coverage may elect to terminate the Active Health & Insurance

Coverage or COBRA continuation before the end of the continuation period, as applicable, and begin retiree medical coverage in accordance with

qualified status changes and the provisions of the medical plan and retiree medical plan. To elect any applicable Company-sponsored retiree medical

coverage, the SSP Participant will be required to certify that he has been continuously enrolled in medical coverage from his date continuing medical

coverage ends to the date he enrolls for the Company-sponsored retiree medical coverage. For this purpose only, COBRA continuation coverage would

qualify as continuous medical coverage for the period such coverage is in effect. If an SSP Participant covers an eligible dependent who is not their tax

dependent, the value of any subsidized company provided retiree medical coverage results in imputed income to the SSP Participant.

(c)

Life Management Resources.

An SSP Participant who elects the Active Health & Insurance Coverage provided under the SSP is also electing to continue any coverage

under Life Management Resources, at no cost, for the Active Health & Insurance Continuation period. After the end of the Active Health & Insurance

Continuation period, coverage can still be continued under COBRA at a cost of 102% of the full cost of coverage.

4

(d)

Life Insurance.

(i)    An SSP Participant who is enrolled in a Company-sponsored life insurance plan on his Termination Date may continue his basic life

insurance coverage at active employee rates and in accordance with the same terms as applicable to active Employees, until the end of the three year

continuation period or the date as of which he becomes eligible for coverage under another employer’s group health plans (regardless of whether he

actually enrolls in such other plan). After such Active Health & Insurance Coverage ends, the SSP Participant will be eligible for the conversion and

portability rights offered under the plan, as applicable. There is no additional 18 months of active life insurance coverage.

(ii)    Company-sponsored basic life insurance coverage is limited to the lowest of: (A) the SSP Participant’s coverage in effect on the day

before his Termination Date; (B) one times the SSP Participant’s annual pay (as defined in the applicable life insurance plan); or (C) $2,000,000. The

cost of insurance in excess of $50,000 results in imputed income to the SSP Participant. Any employee supplemental and dependent life insurance

coverage ends as of the SSP Participant’s Termination Date, and the SSP Participant will be eligible for the conversion and portability rights offered

under the plan, as applicable.

(e)    Educational Assistance Program/Education/Retraining Benefit.

(i)    An SSP Participant who has begun attending an approved course(s) under the Pfizer Educational Assistance Program before his

Termination Date, remains eligible for reimbursement for that pre-approved and already started course(s), as long as the SSP Participant satisfies all of

the other requirements for reimbursement under the Educational Assistance Program. No additional courses will be approved.

(ii)    An SSP Participant shall be eligible for a $5,000 education/retraining allowance for approved courses and programs provided the courses

begin (and are not just enrolled in) within 12 months of the Termination Date and the required documentation for reimbursement is submitted within 18

months of the Termination Date.

(iii)    The Plan Administrator has final and absolute discretion to determine what constitutes “educational” or “retraining.”

(f)    Miscellaneous Provisions.

(i)    Except as otherwise provided in this Appendix A: Section 3, all of the terms of the employee benefit plans described herein and as

amended from time to time, shall apply. If there is a discrepancy, the terms of the official plan document for the applicable plan shall control.

(ii)    Active Health & Insurance Coverage described in this Appendix A; Section 3, is subject to the terms and conditions of the particular plan,

as in effect from time to time. All of the benefit plans

5

described herein, including this Plan, may be amended or terminated at any time and for any reason, with or without notice.

(iii)    SSP Participants may be eligible to participate in reasonable outplacement services as offered by the Company in its sole and absolute

discretion. In no case will the Company provide a payment to the Participant in lieu of these services.

3.1.4    Except as otherwise provided above or in the Five Points Brochure, no other severance benefits are payable to the SSP Participant under the

Plan and the SSP, and the following will apply:

(a)

(b)

(c)

Active employee benefits end as of the Termination Date;

Eligibility for any applicable retiree medical, dental and/or life insurance benefits, if any, is determined as of the SSP Participant’s
Termination Date and pursuant to the terms of the applicable plans;

The controlling conditions of any stock grants may be affected for an SSP Participant and are contained in the terms of the stock
grant letters, grant agreements, points of interest for each such grant, applicable stock plan, and Five Points Brochure.

6

TIME SHARING AGREEMENT

EXHIBIT 10.33

This Time Sharing Agreement (this "Agreement") is dated this 17th day of December 2018, by and between Pfizer Inc., a Delaware corporation (the

"Company") and Ian C. Read, an individual ("Lessee”).

RECITALS

WHEREAS, Company rightfully possesses and operates the aircraft identified on Schedule I hereto (the "Aircraft") under Part 91 of the Federal Aviation

Regulations (“FARs”) incidental to its primary business; and

WHEREAS, Company desires to make the Aircraft available to Lessee, and Lessee desires to utilize the Aircraft, from time to time on a non-exclusive

time-sharing basis as authorized under Sections 91.501(b)(6), 91.501(c)(1) and 91.501(d) of the FARs; and

WHEREAS, this Agreement is a time sharing agreement as defined in Section 91.501(c)(1) of the FAR, and use of the Aircraft pursuant to this

Agreement will comply with the requirements of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d).

NOW, THEREFORE, in consideration of the foregoing, and the other agreements contained herein, and for other good and valuable consideration, the

receipt and sufficiency of which is hereby conclusively acknowledged, the parties, intending to be legally bound hereby, agree as follows:

1.     Provision of Aircraft; Term. Company agrees to provide the Aircraft to and operate the Aircraft for Lessee on a non-exclusive basis from time to

time as mutually agreed between the parties pursuant to the provisions of FAR 91.501(b)(6), 91.501(c)(1) and 91.501(d) and to provide a fully qualified flight

crew for all operations conducted under this Agreement. This Agreement shall be effective on the date set forth above and shall remain in effect until terminated

by either party upon ten (10) business days’ prior written notice to the other.

2.     Lease Fee. Lessee shall pay to Company for each flight conducted under this Agreement a lease fee ("Lease Fee") not to exceed the actual

expenses of each specific flight as authorized by FAR Part 91.501(d) (including related deadhead flights, if applicable). Such actual expenses shall include and

are limited to:

(a)    Fuel, oil, lubricants, and other additives;

(b)    Travel expenses of the crew, including food, lodging and ground transportation;

(c)    Hangar and tie-down costs away from the Aircraft's base of operations;

(d)    Insurance obtained for the specific flight;

(e)

Landing fees, airport taxes and similar assessments;

(f)    Customs, foreign permit, and similar fees directly related to the flight;

(g)    In flight food and beverages;

(h)    Passenger ground transportation;

(i)    Flight planning and weather contract services; and

(j)

An additional charge equal to 100 percent of the expenses listed in subparagraph 2(a) above.

In no event shall the Lease Fee include any costs not listed above.

3.     Taxes . The parties acknowledge that, with the exception of Sections 2(g) and (h) hereof, the payments specified in Section 2 from Lessee to

Company are subject to federal excise tax imposed under Article 4261 of the Internal Revenue Code of 1986, as amended (the “Federal Excise Tax”). If

applicable, Lessee shall pay to Company (for remittance to the appropriate governmental agency) all Federal Excise Tax applicable to flights of the Aircraft

conducted hereunder.

4.     Prepayment. From time to time, Lessee may deliver to Company a mutually agreed sum to fund an account for anticipated Lease Fees (the

“Prepayment Fund”). No interest shall be paid on the Prepayment Fund. Immediately upon presentment of invoices for time sharing flights, Company shall apply

funds from the Prepayment Fund to pay for Lease Fees for such flights. Monthly reconciliations shall be provided to Lessee which shall set forth the expenses

comprising the Lease Fees of each specific flight through the last day of the month in which any flight or flights for the account of Lessee occur. In the event

Lease Fees exceed the Prepayment Fund in any given month, Lessee shall pay such Lease Fees upon receipt of the invoice for the amounts exceeding the

Prepayment Fund, which invoice shall be presented within fifteen (15) days of the time such Lease Fees are incurred. Upon termination of this Agreement, any

funds remaining in the Prepayment Fund shall be returned to Lessee within thirty (30) days. As a matter of clarification, the Prepayment Fund is in the nature of

a deposit and not payment for transportation unless and until such time as an invoice for Lease Fees is presented and funds are withdrawn to pay such invoice.

5.     Operating Expenses. Company shall pay all expenses related to the operation of the Aircraft for time-sharing flights when such expenses are

incurred.

6.     Flight Information. Lessee will provide Company with requests for flight time and proposed flight schedules as far in advance of any given flight

as possible. Requests for flight time shall be in a form, whether written or oral, mutually convenient to, and agreed upon by the parties. In addition to the

proposed schedules and flight times, Lessee shall provide at least the following information for each proposed flight prior to scheduled departure as required by

the Company or Company's flight crew:

(a)    proposed departure point;

(b)    destination;

(c)    date and time of flight;

(d)

the number, name, and relationship to the Lessee of anticipated passengers;

(e)    the nature and extent of luggage and/or cargo to be carried;

(f)    the date and time of return flight, if any; and

(g)    any other information concerning the proposed flight that may be pertinent or required by Company or Company's flight crew.

7.     Authority to Schedule. Company shall have final authority over the scheduling of the Aircraft. It is understood that Company shall not be

obligated to retain or contract for additional flight crew or maintenance personnel or equipment in order to accommodate Lessee's schedule requests.

2

8.     Operational Control. The Company shall be responsible for all aspects of the physical and technical operation of the Aircraft and the safe

performance of all flights, and shall retain and exercise exclusive operational control of the Aircraft during all phases of flight, including pre-flight and post-flight

duties, and including, without limitation, all flights during which Lessee and/or Lessee’s guests are on-board the Aircraft. Consistent with the Company’s

operational control responsibilities, Company shall be solely responsible to secure maintenance, preventive maintenance and required or otherwise necessary

inspections on the Aircraft, and shall take such requirements into account in scheduling the Aircraft. All costs and expenses related to the maintenance of the

Aircraft shall be the responsibility of the Company. No period of maintenance, preventative maintenance or inspection shall be delayed or postponed for the

purpose of scheduling the Aircraft, unless said maintenance or inspection can be safely conducted at a later time in compliance with all applicable laws and

regulations, and within the sound discretion of the pilot in command. All flight operations under this Agreement shall be conducted under Part 91 of the FAR.

9.     Authority of Pilot in Command and Flight Crew. For each flight conducted under this Agreement, the Aircraft will be operated only by a qualified

flight crew. The pilot in command shall have final and complete authority to cancel any flight for any reason or condition that in his or her judgment would

compromise the safety of the flight. Lessee specifically agrees that the flight crew, in its sole discretion, may terminate any flight, refuse to commence any flight,

or take other action which in the considered judgment of the pilot in command is necessitated by considerations of safety. No such action of the pilot in

command shall create or support any liability for loss, injury, damage or delay to Lessee or any other person. The parties further agree that Company shall not

be liable for delay or failure to furnish the Aircraft and crew pursuant to this Agreement for any reason whatsoever.

10.     Lessee’s Covenants, Representations and Warranties. Lessee covenants, represents and warrants to the Company that during the term of

this Agreement:

(a)    Lessee shall use the Aircraft for and on account of Lessee’s own business or personal use only, and will not use the Aircraft for the

purpose of providing transportation of passengers or cargo for compensation or hire or in violation of applicable FARs or any agreements

entered into by the Company relating to the Aircraft;

(b)    Lessee shall refrain from incurring any mechanics or other lien in connection with inspection, preventative maintenance, maintenance or

storage of the Aircraft, whether permissible or impermissible under this Agreement, and Lessee shall not attempt to convey, mortgage, assign,

lease or any way alienate the Aircraft or create any kind of lien or security interest involving the Aircraft or do anything or take any action that

might mature into such a lien; and

(c)    Lessee shall, and shall cause any passengers in Lessee’s party to, abide by and conform to all such laws, governmental and airport

orders, rules and regulations, as shall from time to time be in effect relating in any way to the use of the Aircraft by a timesharing lessee.

11.     Risk of Loss. The Company assumes and shall bear the entire risk of loss, theft, confiscation, damage to, or destruction of the Aircraft from any

cause whatsoever, except to the extent attributable to the gross negligence or willful misconduct of Lessee or Lessee’s guests on the Aircraft.

12.     Insurance. During the term of this Agreement, the Company shall maintain and have in force (i) all-risk hull insurance covering the fair market

value of the Aircraft which policy shall be deemed primary in the event of

3

any incident or accident and (ii) aviation liability insurance of at least Three Hundred Million Dollars ($300,000,000) combined single limit. Company shall cause

Lessee to be added as an additional insured to its aviation liability insurance.

13.     Home Base. For purposes of this Agreement, the permanent base of operation of the Aircraft shall be as set forth on Schedule A hereto, or such

other location as shall be determined by the Company from time to time.

14.     Successors and Assigns. Neither this Agreement, nor any party's interest herein shall be assignable to any other party whatsoever. This

Agreement shall inure to the benefit of and be binding upon the parties hereto, and their respective heirs, representatives, successors and permitted assigns.

15.     Governing Law. This Agreement constitutes the entire agreement of the parties with respect to the time share of the Aircraft as set forth herein.

This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

16.     Subordination. All rights and interests of Lessee hereunder and in and to the Aircraft are, and at all times shall be and remain, subject and

subordinate to the rights and interests of the owner of each Aircraft under the aircraft lease agreements between such owner and the Company. Notwithstanding

anything to the contrary contained herein, this Agreement shall terminate, or be canceled, immediately at the option of the Aircraft owner upon the occurrence of

an event of default thereunder.

17.     Counterparts . This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which

together shall constitute one and the same Agreement, binding on all the parties notwithstanding that all the parties are not signatories to the same counterpart.

The parties may effectively deliver an executed counterpart of a signature page of this Agreement by facsimile or in electronic (“pdf” or “tif”) format.

18.     Further Acts . Lessor and Lessee shall from time to time perform such other and further acts and execute such other and further instruments as

may be required by law or may be reasonably necessary to: (i) carry out the intent and purpose of this Agreement; and (ii) establish, maintain and protect the

respective rights and remedies of the other party.

19.     Entire Agreement . This Agreement constitutes the entire understanding among the Parties with respect to its subject matter, and there are no

representations, warranties, rights, obligations, liabilities, conditions, covenants, or agreements other than as expressly set forth herein.

20.     Severability . In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal, or

unenforceable, those provisions shall be replaced by provisions acceptable to both Parties to this Agreement.

21.     Disclaimer; Consequential Damages . EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER COMPANY NOR

AIRCRAFT OWNER HAVE MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE AIRCRAFT,

INCLUDING WITH RESPECT TO ITS DESIGN, CONDITION, QUALITY OF MATERIALS AND WORKMANSHIP, MERCHANTABILITY, FITNESS FOR ANY

PARTICULAR PURPOSE, AIRWORTHINESS OR SAFETY. IN NO EVENT SHALL COMPANY OR OWNER BE LIABLE TO THE LESSEE, ITS MEMBERS,

MANAGERS, OFFICERS, DIRECTORS, EMPLOYEES, AFFILIATES, GUESTS OR AGENTS (FOR THE PURPOSE OF THIS SECTION 21 HEREOF,

COLLECTIVELY, “LESSEE”), FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES, HOWEVER ARISING,

4

WHETHER COMPANY KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGE, LOSS OR EXPENSE INCLUDING, WITHOUT

LIMITATION, IN RESPECT OF ANY DELAY IN ARRIVAL OR DEPARTURE.

22.     Notices. All communications, declarations, demands, consents, directions, approvals, instructions, requests and notices required or permitted by

this Agreement shall be in writing and shall be deemed to have been duly given or made when delivered personally or transmitted electronically by e-mail or

facsimile, receipt acknowledged, or in the case of documented overnight delivery service or registered or certified mail, return receipt requested, delivery charge

or postage prepaid, on the date shown on the receipt therefor, in each case at the address set forth on Schedule A hereto:

23.    TRUTH IN LEASING STATEMENT PURSUANT TO 14 CFR PART 91.23

THE AIRCRAFT HAVE BEEN MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) DURING THE 12 MONTH PERIOD PRECEDING THE

DATE OF THIS AGREEMENT.

THE COMPANY, A DELAWARE CORPORATION, CERTIFIES THAT THE AIRCRAFT ARE IN COMPLIANCE WITH ALL APPLICABLE
MAINTENANCE AND INSPECTION REQUIREMENTS FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT. THE AIRCRAFT WILL BE
MAINTAINED AND INSPECTED UNDER FAR PART 91.409(f)(3) FOR OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT.

THE COMPANY CERTIFIES AND ACKNOWLEDGES THAT WHENEVER THE AIRCRAFT ARE OPERATED UNDER THIS AGREEMENT, THE

COMPANY SHALL BE KNOWN AS, CONSIDERED AND SHALL IN FACT BE RESPONSIBLE FOR OPERATIONAL CONTROL OF THE AIRCRAFT
IDENTIFIED AND TO BE OPERATED UNDER THIS AGREEMENT. EACH PARTY CERTIFIES THAT IT UNDERSTANDS ITS RESPECTIVE
RESPONSIBILITIES, IF ANY, FOR COMPLIANCE WITH APPLICABLE FEDERAL AVIATION REGULATIONS. I, THE UNDERSIGNED, JOHN D. WITZIG, AS
VICE PRESIDENT OF THE COMPANY, CERTIFY THAT THE COMPANY IS RESPONSIBLE FOR OPERATIONAL CONTROL OF THE AIRCRAFT FOR
OPERATIONS TO BE CONDUCTED UNDER THIS AGREEMENT AND THAT THE COMPANY UNDERSTANDS ITS RESPONSIBILITIES FOR COMPLIANCE
WITH APPLICABLE FEDERAL AVIATION REGULATIONS.

EACH PARTY UNDERSTANDS THAT AN EXPLANATION OF FACTORS BEARING ON OPERATIONAL CONTROL AND PERTINENT FEDERAL

AVIATION REGULATIONS CAN BE OBTAINED FROM THE NEAREST FAA FLIGHT STANDARDS DISTRICT OFFICE.

THE ADDRESS OF THE COMPANY IS 235 EAST 42 ND STREET, NEW YORK, NEW YORK 10017.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

PFIZER INC.

By:/s/ JOHN D. WITZIG

Name: John D. Witzig

Title: Vice President

/s/ IAN C. READ

IAN C. READ

5

Pfizer Inc. 2018 Financial Report

EXHIBIT 13

Financial Review
Pfizer Inc. and Subsidiary Companies

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2018 Financial Report (defined below) refer to Pfizer Inc. and its
subsidiaries. We also have used several other terms in this 2018 Financial Report, most of which are explained or defined below:

2018 Financial Report

2018 Form 10-K

ABO

This Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal
year ended December 31, 2018

Annual Report on Form 10-K for the fiscal year ended December 31, 2018

Accumulated postretirement benefit obligation

ACA (Also referred to as U.S. Healthcare

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

Legislation)

ACIP

ALK

Allergan

Advisory Committee on Immunization Practices

anaplastic lymphoma kinase

Allergan plc

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Allogene

AMPA

Anacor

AOCI

Astellas

ASU

ATM-AVI

Avillion

Bain Capital

Bamboo

Biogen

Biopharma

BMS

BRCA

CAR T

CDC

Cellectis

Cerevel

CIAS

Citibank

CML

Allogene Therapeutics, Inc.

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Anacor Pharmaceuticals, Inc.

Accumulated Other Comprehensive Income

Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

Accounting Standards Update

aztreonam-avibactam

Avillion LLP

Bain Capital Private Equity and Bain Capital Life Sciences

Bamboo Therapeutics, Inc.

Biogen Inc.

Pfizer Biopharmaceuticals Group

Bristol-Myers Squibb Company

BReast CAncer susceptibility gene

chimeric antigen receptor T cell

U.S. Centers for Disease Control and Prevention

Cellectis S.A.

Cerevel Therapeutics, LLC

cognitive impairment associated with schizophrenia

Citibank, N.A.

chronic myelogenous leukemia

Developed Markets

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New Zealand

EEA

EGFR

EH

EMA

Emerging Markets

EPS

EU

European Economic Area

epidermal growth factor receptor

Essential Health

European Medicines Agency

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle
East, Central Europe and Turkey

earnings per share

European Union

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

FDA

GAAP

GIST

GPD

GSK

GS&Co.

HER

HER2-

hGH-CTP

HIS

Hisun

Hisun Pfizer

Hospira

HR+

ICU Medical

IH

InnoPharma

IPR&D

Financial Accounting Standards Board

U.S. Food and Drug Administration

Generally Accepted Accounting Principles

gastrointestinal stromal tumors

Global Product Development organization

GlaxoSmithKline plc

Goldman, Sachs & Co. LLC

human epidermal growth factor receptor

human epidermal growth factor receptor 2-negative

human growth hormone

Hospira Infusion Systems

Zhejiang Hisun Pharmaceuticals Co., Ltd.

Hisun Pfizer Pharmaceuticals Company Limited

Hospira, Inc.

hormone receptor-positive

ICU Medical, Inc.

Innovative Health

InnoPharma, Inc.

in-process research and development

2018 Financial Report

i

Financial Review
Pfizer Inc. and Subsidiary Companies

IRC

IRS

IV

Janssen

J&J

King

LDL

LEP

LIBOR

Lilly

LOE

MCC

MCO

Medivation

Merck

Meridian

Moody’s

NAV

NDA

NovaQuest

NSCLC

NYSE

OPKO

OTC

PARP

PBM

PBO

Pharmacia

PPS

PP&E

PSAs

PsA

PTSRUs

PTUs

RA

RCC

R&D

RPI

RSUs

Sandoz

Sangamo

SEC

Servier

SFJ

Shire

SI&A

S&P

SIP

StratCO

Internal Revenue Code

U.S. Internal Revenue Service

intravenous

Janssen Biotech, Inc.

Johnson & Johnson

King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

low density lipoprotein

Legacy Established Products

London Interbank Offered Rate

Eli Lilly and Company

loss of exclusivity

Merkel Cell Carcinoma

Managed Care Organization

Medivation, Inc.

Merck & Co., Inc.

Meridian Medical Technologies, Inc.

Moody’s Investors Service

Net asset value

new drug application

NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable

non-small cell lung cancer

New York Stock Exchange

OPKO Health, Inc.

over-the-counter

poly ADP ribose polymerase

Pharmacy Benefit Manager

Projected benefit obligation

Pharmacia Corporation

Portfolio Performance Shares

Property, plant & equipment

Performance Share Awards

psoriatic arthritis

Performance Total Shareholder Return Units

Profit Units

rheumatoid arthritis

renal cell carcinoma

research and development

RPI Finance Trust

Restricted Stock Units

Sandoz, Inc., a division of Novartis AG

Sangamo Therapeutics, Inc.

U.S. Securities and Exchange Commission

Les Laboratoires Servier SAS

SFJ Pharmaceuticals

Shire International GmbH

Selling, informational and administrative

Standard and Poor’s

Sterile Injectable Pharmaceuticals

Strategy and Commercial Operations

Tax Cuts and Jobs Act or TCJA

Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

Teuto

Teva

TSR

TSRUs

U.K.

U.S.

ViiV

WRD

Laboratório Teuto Brasileiro S.A.

Teva Pharmaceuticals USA, Inc.

Total Shareholder Return

Total Shareholder Return Units

United Kingdom

United States

ViiV Healthcare Limited

Worldwide Research and Development

ii

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

INTRODUCTION

See the Glossary of Defined Terms at the beginning of this 2018 Financial Report for terms used throughout this Financial Review . Our Financial Review is provided to assist
readers in understanding the results of operations, financial condition and cash flows of Pfizer Inc. and its subsidiaries (the Company). It should be read in conjunction with the
consolidated financial statements and Notes to Consolidated Financial Statements. The discussion in this Financial Review contains forward-looking statements that involve
substantial risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, such as
those discussed in Part 1, Item 1A, “Risk Factors” of our 2018 Form 10-K and in the “Forward-Looking Information and Factors That May Affect Future Results”, “Our Operating
Environment” and “Our Strategy” sections of this Financial Review.

The Financial Review is organized as follows:

●

●

●

●

●

●

●

●

●

●

  Overview of Our Performance, Operating Environment, Strategy and Outlook

Beginning on page 2

This section provides information about the following: Financial Highlights; Our Business; Our 2018 Performance; Our Operating Environment;

The Global Economic Environment, Our Strategy; Our Business Development Initiatives, such as acquisitions, dispositions, licensing and
collaborations; and Our Financial Guidance for 2019.

  Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions

Beginning on page 16

This section discusses those accounting policies and estimates that we consider important in understanding our consolidated financial
statements. For additional discussion of our accounting policies, see Notes to Consolidated Financial Statements— Note 1. Basis of
Presentation and Significant Accounting Policies .
  Analysis of the Consolidated Statements of Income
  This section includes the following sub-sections:
○   Revenues—Overview

This sub-section provides a high-level summary of our revenues, including revenue deductions.

○   Revenues by Segment and Geography

This sub-section provides an overview of revenues by segment and geography.

○   Revenues––Selected Product Discussion

This sub-section provides an overview of several of our biopharmaceutical products.

○   Product Developments––Biopharmaceutical

This sub-section provides an overview of important biopharmaceutical product developments.

○   Costs and Expenses

This sub-section provides a discussion about our costs and expenses.

○   Provision/(Benefit) for Taxes on Income

This sub-section provides a discussion of items impacting our tax provisions.

○   Non-GAAP Financial Measure (Adjusted Income)

This sub-section provides a discussion of an alternative view of performance used by management.

  Analysis of Operating Segment Information
  This section provides a discussion of  the performance of each of our operating segments.
  Analysis of the Consolidated Statements of Comprehensive Income
  This section provides a discussion of changes in certain components of other comprehensive income.
  Analysis of the Consolidated Balance Sheets
  This section provides a discussion of changes in certain balance sheet accounts, including Accumulated other comprehensive loss .
  Analysis of the Consolidated Statements of Cash Flows
  This section provides an analysis of our consolidated cash flows for the three years ended December 31, 2018.
  Analysis of Financial Condition, Liquidity and Capital Resources

This section provides an analysis of selected measures of our liquidity and of our capital resources as of December 31, 2018 and

December 31, 2017, as well as a discussion of our outstanding debt and other commitments that existed as of December 31, 2018 and
December 31, 2017. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund
Pfizer’s future activities.
  New Accounting Standards

This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet

adopted.

  Forward-Looking Information and Factors That May Effect Future Results

Beginning on page 20

Beginning on page 20

Beginning on page 22

Beginning on page 24

Beginning on page 29

Beginning on page 33

Beginning on page 36

Beginning on page 37

Beginning on page 42

Beginning on page 51

Beginning on page 52

Beginning on page 53

Beginning on page 55

Beginning on page 59

Beginning on page 61

This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in

forward-looking statements presented in this Financial Review. Also included in this section are discussions of Financial Risk Management
and Contingencies, including legal and tax matters.

Certain amounts in our Financial Review may not add due to rounding. All percentages have been calculated using unrounded amounts.

2018 Financial Report

1

Financial Review
Pfizer Inc. and Subsidiary Companies

OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK

Financial Highlights

The following charts provide a summary of certain financial performance (in billions, except per share data):

2018 Total Revenues––$53.6 billion
An increase of 2% compared to 2017

2018 Net Cash Flow from Operations––$15.8 billion
A decrease of 6% compared to 2017

2018 Reported Diluted EPS––$1.87
A decrease of 47% compared to 2017

2018 Adjusted Diluted EPS (Non- GAAP )––$3.00*
An increase of 13% compared to 201 7

* For an understanding of Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP reported to non-GAAP adjusted information, see the “Non-GAAP Financial

Measure (Adjusted Income)” section of this Financial Review.

Our Business

We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of
healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across
developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare
providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our
products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us (Alliance revenues).

From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through two distinct business segments: Pfizer Innovative
Health (IH) and Pfizer Essential Health (EH). For additional information about this operating structure, see Notes to Consolidated Financial Statements–– Note 18A. Segment,
Geographic and Other Revenue Information: Segment Information. At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new
global commercial structure consisting of three businesses. See the “Our Strategy––Organizing for Growth” and “––Commercial Operations” sections of this Financial Review
below for additional information.

On January 1, 2019, Dr. Albert Bourla succeeded Ian Read as Chief Executive Officer of the company and Ian Read transitioned from his role as Chairman and Chief
Executive Officer to Executive Chairman of Pfizer’s Board of Directors.

The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The biopharmaceutical industry is highly competitive and highly regulated.
As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration
of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation,
pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For
additional information about these factors and challenges, see the “Our Operating Environment” and “The Global Economic Environment” sections of this Financial Review and
Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

2

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

The financial information included in our consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30 for each
year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented.

References to developed and emerging markets in this Financial Review include:

Developed markets

Emerging markets (include, but are not limited to)

U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian
countries, Finland and New Zealand

Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the
Middle East, Central Europe and Turkey

References to operational variances in this Financial Review pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances
are determined by multiplying or dividing, as appropriate, our current year U.S. dollar results by the current year average foreign exchange rates and then multiplying or
dividing, as appropriate, those amounts by the prior-year average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our
control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful
information to evaluate the results of our business.

On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changes
the U.S. corporate income tax system by, among other things, reducing the U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from a
worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. For information
on the TCJA, see Notes to Consolidated Financial Statements–– Note 5A . Tax Matters: Taxes on Income from Continuing Operations.

Our significant recent business development activities include:

• On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer
healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name. The joint venture is expected to
be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health and will be the largest global OTC
consumer healthcare business. In exchange for contributing our Consumer Healthcare business, we will receive a 32% equity stake in the company and GSK will own the
remaining 68%. The transaction is expected to close in the second half of 2019, subject to customary closing conditions including GSK shareholder approval and required
regulatory approvals. For additional information, see Notes to Consolidated Financial Statements–– Note 2C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale,
Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Assets and Liabilities
Held for Sale and the “Our Strategy” section of this Financial Review below.

• On February 3, 2017, we completed the sale of Pfizer’s global infusion systems net assets, HIS, to ICU Medical for up to approximately $900 million , composed of cash and

contingent cash consideration, ICU Medical common stock and seller financing . At closing, we received 3.2 million newly issued shares of ICU Medical common stock,
which we initially valued at approximately $428 million (all of which we sold during 2018), a promissory note in the amount of $75 million and net cash of approximately $200
million before customary adjustments for net working capital. In addition, we are entitled to receive a contingent amount of up to an additional $225 million in cash based on
ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The operating results of HIS are included in
our consolidated statement of income and EH’s operating results through February 2, 2017 and, therefore, our financial results, and EH’s operating results, for the year
ended December 31, 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial
results, and EH’s operating results, for the year ended December 31, 2016 reflect 12 months of HIS global operations. Our financial results, and EH’s operating results, for
2018 do not reflect any contribution from HIS global operations.

• On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to

AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. for $1,040 million , composed of cash and contingent consideration. Commencing from the
acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting
period, our financial results, EH’s operating results, and cash flows for the year ended December 31, 2017 reflect approximately 11 months of the small molecule anti-
infectives business acquired from AstraZeneca.

• On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash
( $13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities .
The remaining consideration was paid as of December 31, 2017 . Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating
results and cash flows of Medivation. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended
December 31, 2016 reflect approximately three months of Medivation operations.

• On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion ,
net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and
cash flows of Anacor. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016
reflect approximately six months of Anacor operations.

• On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the

companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an
“Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal
quarter of 2016), Pfizer paid Allergan

2018 Financial Report

3

Financial Review
Pfizer Inc. and Subsidiary Companies

$150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see the Notes to Consolidated Financial Statements–– Note 4 .
Other (Income)/Deductions –– Net ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement.

For additional information, see Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements,
Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment and the “Our Strategy” and “Our Business
Development Initiatives” sections of this Financial Review below.

Impact of Hurricanes in Puerto Rico

We have manufacturing and commercial operations in Puerto Rico, which were impacted by the hurricanes toward the end of the third quarter in 2017. While our three
manufacturing sites in Puerto Rico sustained some damage and became inoperable due to issues impacting Puerto Rico overall, all three sites have resumed operations and
remediation activities were completed in 2018. Our commercial sales offices in Puerto Rico have been operational since October 2017.

Product Manufacturing

We periodically encounter difficulties or delays in manufacturing, including due to suspension of manufacturing or voluntary recall of a product, or legal or regulatory actions
such as warning letters. For example, Hospira’s manufacturing facility in McPherson, Kansas is currently under the FDA inspection status of Official Action Indicated (OAI). As
a result of this status, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured
at our McPherson site until the site status is upgraded, which will require a successful re-inspection by the FDA. Future FDA inspections and regulatory activities will further
assess the adequacy and sustainability of corrections implemented at the site. Communication with the FDA on the status of the McPherson site is ongoing. For additional
information regarding the FDA inspection of the McPherson site, see Part I, Item 1A, “Risk Factors––Product Manufacturing, Sales and Marketing Risks” of our 2018 Form 10-
K.

The product shortages we have been experiencing within our portfolio are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints,
technical issues and supplier quality concerns. We continue to remediate issues at legacy Hospira facilities manufacturing sterile injectables. Any continuing product shortage
interruption at these manufacturing facilities could negatively impact our financial results, specifically in our SIP portfolio. We continue to make progress on our comprehensive
remediation plan to upgrade and modernize these facilities, and we expect our supply issues to be substantially improved by the end of 2019.

Our 2018 Performance

Revenues–– 2018

Revenues in 2018 increase d by $1.1 billion , or 2% , compared to 2017 , which reflects operational growth of $791 million , or 2% , and the favorable impact of foreign
exchange of $310 million , or less than 1%.

The following graph illustrates the components of the increase in revenues in 2018 :

* LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.

4

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

The following provides an analysis of the changes in revenues in 2018 :

(MILLIONS OF DOLLARS)

2017 Revenues

Operational growth/(decline):

Continued growth from key brands (a)  and from recently launched products (b) , as well as growth from Biosimilars (c)  and our Consumer

Healthcare business, and the impact from CentreOne

Declines from total Viagra (d)  (primarily in the U.S.), the Peri-LOE Products portfolio (excluding Viagra EH (d) , which was impacted by the shift
in the reporting of U.S. and Canada Viagra revenues to EH), the SIP portfolio (primarily in developed markets), the LEP portfolio (primarily in
developed markets), Enbrel (driven by declines in most developed Europe markets) and the hemophilia portfolio (primarily in developed
Europe)

Disposition-related impact of the February 2017 sale of HIS (e)

Other operational factors, net

Operational growth, net

Operational revenues

Favorable impact of foreign exchange

  $

52,546

3,377

(2,520)

(97)

31

791

53,337

310

53,647

  $

2018 Revenues
(a)   K ey brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi, Lyrica-IH and Chantix/Champix.
(b)   Growth from recently launched products include Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed Europe.
(c)  Growth in Biosimilars, primarily from Inflectra in certain channels in the U.S., as well as in developed Europe.
(d)

Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenues
excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra revenues were reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and
Viagra EH.
Impact on financial results for the sale of HIS in February 2017. The 2018 financial results do not reflect any contribution from HIS global operations, compared to approximately one month of HIS domestic
operations and approximately two months of HIS international operations in 2017.

(e)

See the “Analysis of the Consolidated Statements of Income –– Revenues –– Overview” section below for more information, including a discussion of key drivers of our
revenue performance.

Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income–– 2018

The following provides an analysis of the decrease in Income from continuing operations before provision/benefit) for taxes on income for 2018 :

(MILLIONS OF DOLLARS)

Income from continuing operations before provision/(benefit) for taxes on income for the year ended December 31, 2017

  $

Favorable change in revenues

Favorable/(Unfavorable) changes:

Higher certain asset impairments (a)

Higher Restructuring charges and certain acquisition-related costs (b)

Higher Research and development expenses (c)

Impact of net realized (gains)/losses on sales of investments in debt securities (a)

Lower net losses on early retirement of debt (a)

Impact of net periodic benefit costs/(credits) other than service costs (a)

Higher net gains recognized during the period on investments in equity securities (a)

Lower Selling, information and administrative expenses (d)

Higher income from collaborations, out-licensing arrangements and sales of compound/product rights (a)

All other items, net

12,305

1,101

(2,720)

(693)

(322)

(186)

996

389

362

350

271

33

Income from continuing operations before provision/(benefit) for taxes on income for the year ended December 31, 2018
(a)   See the Notes to Consolidated Financial Statements–– Note 4. Other (Income)/Deductions—Net .
(b)

See the “Costs and Expenses–– Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives ” and Notes to Consolidated Financial Statements–– Note 3 .
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
(c)  See the “Costs and Expenses––Research and Development (R&D) Expenses” section of this Financial Review.
(d)   See the “Costs and Expenses––Selling, Informational and Administrative (SI&A) Expenses” section of this Financial Review.
For information on our tax provision and effective tax rate see the “Provision/(Benefit) for Taxes on Income” section of this Financial Review and Notes to Consolidated
Financial Statements–– Note 5A . Tax Matters: Taxes on Income from Continuing Operations.

  $

11,885

2018 Financial Report

5

Financial Review
Pfizer Inc. and Subsidiary Companies

Our Operating Environment

Industry-Specific Challenges

Intellectual Property Rights and Collaboration/Licensing Rights

The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with generic manufacturers and the expiration of co-promotion and licensing rights
can have a significant adverse effect on our revenues. Many of our branded products have multiple patents that expire at varying dates, thereby strengthening our overall
patent protection. However, once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we lose exclusivity on these
products, and generic pharmaceutical manufacturers generally produce similar products and sell them for a lower price. The date at which generic competition commences
may be different from the date that the patent or regulatory exclusivity expires. However, when generic competition does commence, the resulting price competition can
substantially decrease our revenues for the impacted products, often in a very short period of time. Also, if one of our patents is found to be invalid by judicial, court or
administrative proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the
European Patent Office, or other foreign counterparts, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing
products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In
June 2018, the Patent Trial and Appeal Board ruled on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has
appealed the decision. Challenges to other patents remain pending before the U.S. Patent and Trademark Office. The invalidation of these patents could potentially allow a
competitor pneumococcal vaccine into the marketplace.

A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For example, as a result
of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S. in December 2017. In addition, the basic product patent for Lyrica in the U.S. will expire
in June 2019, which includes the FDA’s grant of pediatric exclusivity that extended the period of market exclusivity in the U.S. for Lyrica for an additional six months from
December 2018.

For additional information, see the “Recent Losses and Expected Losses of Product Exclusivity” section below.

Our biologic products, including BeneFIX, ReFacto, Xyntha, Bavencio, Prevnar 13/Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada), may face in the
future, or already face, competition from biosimilars (also referred to as follow-on biologics). If competitors are able to obtain marketing approval for biosimilars referencing our
biologic products, our biologic products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. For
example, Enbrel faces ongoing biosimilar competition in most developed Europe markets. The expiration or successful challenge of applicable patent rights could trigger this
competition, assuming any relevant regulatory exclusivity period has expired.

We have lost exclusivity for a number of our products in certain markets and we have lost collaboration rights with respect to a number of our alliance products in certain
markets, and we expect certain products to face significantly increased generic competition over the next few years.

Specifically:

Recent Losses and Expected Losses of Product Exclusivity

The following table provides information about certain of our products recently experiencing, or expected to experience in 2019 , patent expirations or loss of regulatory
exclusivity in the U.S., Europe or Japan, showing, by product, the key dates or expected key dates, the markets impacted and the revenues associated with those products in
those markets:

(MILLIONS OF DOLLARS)

Products

Key Dates (a)

Markets Impacted

Year Ended December 31,

Product Revenues in Markets Impacted

Viagra (b)

Lyrica (c)

Zyvox (d)

Relpax

Vfend

Tygacil

Pristiq (e)

June 2013
May 2014
December 2017
July 2014
June 2019
August 2014
First half of 2015
January 2016
December 2015
December 2016
July 2016
January 2016

  April 2016
  March 2017

Major European markets
Japan
U.S.
Major European markets
U.S.
Japan
U.S.
Major European markets
Major European markets
U.S.
Major European markets
Japan

  U.S.
  U.S.

2018
274

$

2017
850

$

2016

1,217

$

3,852

3,901

3,831

62

90

106

25
71

103

176

150

45
133

235

263

299

80

578

(a)   Unless stated otherwise, “Key Dates” indicate patent-based expiration dates.
(b)   As a result of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S. in December 2017.
(c)

In November 2018, the FDA granted pediatric exclusivity for Lyrica in the U.S. for an additional six months to June 2019; pediatric exclusivity applies to both the basic product patent for Lyrica and a method of
treatment patent, both of which expired in the U.S. in December 2018.
Pursuant to terms of a settlement agreement, certain formulations of Zyvox became subject to generic competition in the U.S. in January 2015. Other formulations of Zyvox became subject to generic competition
in the U.S. in the first half of 2015.

(d)

(e)   As a result of a patent litigation settlement with several generic manufacturers, generic versions of Pristiq launched in the U.S. in March 2017.

6

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product
patent expires, see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

Our financial results in 2018 reflect the impact of the loss of exclusivity of various products discussed above.

We will continue to aggressively defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see
Notes to Consolidated Financial Statements–– Note 17A1. Contingencies and Certain Commitments : Legal Proceedings –– Patent Litigation .

Regulatory Environment/Pricing and Access––U.S. Healthcare Legislation

In March 2010, the ACA was enacted in the U.S. For additional information, see the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business”, of our
2018 Form 10-K.

We recorded the following amounts as a result of the U.S. Healthcare Legislation:

(MILLIONS OF DOLLARS)

Reduction to Revenues , related to the Medicare “coverage gap” discount provision

Selling, informational and administrative expenses , related to the fee payable to the federal government (which is not
deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of
branded prescription drug sales to specified government programs. 2018 also reflected a favorable true-up associated
with the updated 2017 invoice received from the federal government, which reflected a lower expense than what was
previously estimated for invoiced periods.

Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures

Year Ended December 31,

2018

2017

$

674

$

450

$

2016

410

184

307

312

The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be
important to payers, governments, patients, and other stakeholders. We believe that medicines are amongst the most powerful tool for patients in curing, treating and
preventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when
determining a medicine’s price, including, for example, its impact on patients and their disease, other available treatments, the medicine’s potential to reduce other healthcare
costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with patients, doctors and healthcare plans regarding their views. We also
negotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the initial price. The price that patients pay in the U.S. for the medicines
their physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers cover a much lower share of prescription drug costs than
medical services, which results in a greater proportion of out-of-pocket costs being passed on to patients for medicines, thereby making them less accessible and affordable.
We will continue to work with insurance providers, governments and others to improve access to today’s innovative treatments.

Governments, MCOs and other payer groups continue to seek increasing discounts on our products through a variety of means, such as leveraging their purchasing power,
implementing price controls, and demanding price cuts (directly or by rebate actions). In Europe, Japan, China, Canada, South Korea and some other international markets,
governments provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices
or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global economic pressures. In the U.S.,
government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or services provided using our
products. Any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented
could have an adverse impact on our results of operations. Significant Medicare reductions could also result if, for example, Congress proceeds with certain proposals to
convert the Medicare fee-for-service program into a premium support program, or Congress chooses to implement the recommendations made annually by the Medicare
Payment Advisory Commission, which are primarily intended to extend the fiscal solvency of the Medicare program.

Consolidation among MCOs has increased the negotiating power of MCOs and other third-party payers. Private third-party payers, as well as governments, increasingly
employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain
or maintain timely or adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely
impact revenue.

Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could
adversely affect our business if implemented. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the
perceived high cost of pharmaceuticals. At the federal level, for example, in May 2018, President Trump released his Blueprint to Lower Drug Prices and Reduce Out-of-Pocket
Costs (Blueprint). Pfizer communicated a formal response to the request for information that accompanied the Blueprint, and is participating in the subsequent rule-making
process to advance the proposals that are most likely to bring meaningful out-of-pocket cost relief to patients. Certain proposals in the Blueprint, and related drug pricing
measures proposed since the Blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry. As another example, in October 2018,
the Centers for Medicare and Medicaid Services solicited public comments on potential changes to payment for certain Medicare Part B drugs, including reducing the Medicare
payment amount for selected Medicare Part B drugs to more closely align with international drug prices. In addition, in January 2019, the White House Office of Management
and Budget released the long awaited proposed rule submitted by the Office of Inspector General of the Department of Health and Human Services to remove safe harbor
protections for drug rebates paid to insurance plans and PBMs for Medicare Part D and Managed Medicaid

2018 Financial Report

7

Financial Review
Pfizer Inc. and Subsidiary Companies

and to create new safe harbors. Among other changes, the proposed rule would explicitly exclude the reductions in price offered by drug manufacturers to PBMs in Medicare
Part D and Managed Medicaid plans from protection under the “discount” safe harbor. It would also create a new safe harbor designed specifically for price reductions in
pharmaceutical products, but only those that are fully reflected in the price to the patient at the pharmacy counter. Additionally, a new safe harbor was proposed to protect
administrative fees paid to PBMs, which must be at fair market value, a fixed fee and not based upon a percentage of volume or list price. Manufacturers could continue to
negotiate price reductions with PBMs and Medicare Part D and Managed Medicaid plans if their reductions meet that criterion. The proposed rule represents a large step
toward significantly altering the current rebate model in place with MCOs. We are in the process of evaluating the implications of the proposed rule on our operations and
processes, as well as the infrastructure that will be required in order to implement the rule once it is finalized. There have also been state legislative efforts to address drug
costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. Certain state legislation has been subject to legal challenges.
Adoption of new legislation regulating drug pricing at the federal or state level could further affect demand for, or pricing of, our products.

We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We will continue to work
with lawmakers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and ensure access to medicines within an
efficient and affordable healthcare system.

There have been significant efforts at the federal and state levels to reform the healthcare system by enhancing access to healthcare, improving the delivery of healthcare and
further rationalizing payment for healthcare. For example, we face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate
some or all of the provisions of the ACA. For example, tax reform legislation enacted at the end of 2017 eliminates the tax penalty for individuals who do not maintain sufficient
health insurance coverage beginning in 2019 (the so-called “individual mandate”). We anticipate continued Congressional interest in modifying provisions of the ACA,
particularly given the recent ruling in Texas v. Azar to invalidate the law as unconstitutional. At this time, the law remains in effect pending appeals of the decision. Given the
outcomes of the 2018 U.S. midterm elections with Democrats taking over the U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we
believe it is unlikely Congress will find bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer
by the health insurance exchanges and Medicaid expansion under the ACA are not material, so the impact of the change in law and similar recent administration actions is
expected to be limited. Any future replacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislation reduces
incentives for employer-sponsored insurance coverage. As another example, the Bipartisan Budget Act of 2018, which increased the discount we pay in the Medicare Part D
“coverage gap” from 50% to 70%, will modestly increase our future Medicare Part D rebates. Any future healthcare reform efforts may adversely affect our business and
financial results.

Pfizer continues to monitor the ongoing dialogue around drug pricing and will take necessary action accordingly. After deferring previously announced price increases in July
2018, Pfizer increased the list price of certain products (comprising about 10% of its entire drug portfolio) effective January 15, 2019.

The potential for additional pricing and access pressures in the commercial sector continues to be significant. Some employers, seeking to avoid the tax on high-cost health
insurance in the ACA to be imposed in 2022, are already scaling back healthcare benefits and an increasing number are implementing high deductible benefit designs. This is
a trend that is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower
reimbursement rates and a reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare
provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review
processes.

Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health
outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward
providers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At
the same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as a means of forestalling more
costly medical interventions.

Outside the U.S., governments, including the different EU Member States, Japan, China, Canada and South Korea, may use a variety of cost-containment measures for our
pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access and international
reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries). This international patchwork of price regulation and differing
economic conditions and incomplete value assessments across countries has led to varying health outcomes and some third-party trade in our products between countries.

In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price variations,
exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting from this dynamic can be
expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some European countries.

In addition, several important multilateral organizations, such as the United Nations (UN), including the World Health Organization (WHO), and the Organization for Economic
Cooperation and Development (OECD), are increasing scrutiny of international pharmaceutical pricing through issuing reports and policy recommendations (e.g., 2016 UN
High Level Panel Report on Access to Medicines ). Late in 2018, two new reports critical of the pharmaceutical industry’s pricing practices were published: OECD’s
Pharmaceutical Innovation and Access to Medicines and WHO’s Pricing of Cancer Medicines and its Impacts . These reports and upcoming public forums focused on their
recommendations will continue to exert additional pricing pressures.

8

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

In response to the evolving U.S. and global healthcare spending landscape, we are continuing to work with health authorities, health technology assessment and quality
measurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products. Further,
we are seeking to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by
recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs.

Regulatory Environment––Pipeline Productivity

The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of
our businesses. We have encountered increasing regulatory scrutiny of drug safety and efficacy, even as we continue to gather safety and other data on our products, before
and after the products have been launched. Our product lines must be replenished over time in order to offset revenue losses when products lose their market exclusivity, as
well as to provide for earnings growth. We devote considerable resources to R&D activities. These activities involve a high degree of risk and cost and may take many years,
and with respect to any specific R&D project, there can be no assurance that the development of any particular product candidate or new indication for an in-line product will
achieve the desired clinical endpoints and safety profile, will be approved by regulators or will be successful commercially.

During the development of a product, we conduct clinical trials to provide data on the drug’s safety and efficacy to support the evaluation of its overall benefit-risk profile for a
particular patient population. In addition, after a product has been approved and launched, we continue to monitor its safety as long as it is available to patients, and
postmarketing trials may be conducted, including trials requested by regulators and trials that we do voluntarily to gain additional medical knowledge. For the entire life of the
product, we collect safety data and report safety information to the FDA and other regulatory authorities. The FDA and regulatory authorities in other jurisdictions may evaluate
potential safety concerns related to a product or a class of products and take regulatory actions in response, such as updating a product’s labeling, restricting the use of a
product, communicating new safety information to the public, or, in rare cases, removing a product from the market.

Competition

Many of our prescription pharmaceutical products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. For
additional information, see the “Competition” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

The Global Economic Environment

In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed to the economic cycle, which impacts our biopharmaceutical
operations globally.

• Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access
to medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. Government financing
pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private
health technology assessments), or other means of cost control. Examples include the different EU Member States, Japan, China, Canada, South Korea and a number of
other international markets. The U.S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growing
government influence as government programs continue to grow as a source of coverage.

• Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. We seek to
manage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency
assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments
and foreign currency debt. As we operate in multiple foreign currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound, the Canadian dollar
and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken
against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses
would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained
constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore,
significant changes in foreign exchange rates can impact our results and our financial guidance.

The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and Argentina, can
impact our results and financial guidance . For further information about our exposure to foreign currency risk, see the “Analysis of Financial Condition, Liquidity and Capital
Resources” and the “Our Financial Guidance for 2019 ” sections of this Financial Review.

•

In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as “Brexit”. In March 2017, the U.K. government formally notified
the European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of the
exit and outlining the future relationship between the U.K. and the EU. Formal negotiations officially started in June 2017. This process continues to be highly complex and
the end result of these negotiations may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the
approval and supply of our products. The EMA will be relocating from London, U.K. to Amsterdam, Netherlands by the scheduled date of Brexit at the end of March 2019.
At present, it is still unclear whether and to what extent the U.K. will remain within or aligned to the EU system of medicines regulation, and/or what separate requirements
will be imposed in the U.K. after it leaves the EU. However, both the U.K. and the EU have issued detailed guidance for the industry on how medicines, medical devices
and clinical trials will be separately regulated in their respective territories in the event of a ‘hard Brexit’, meaning an outcome where no negotiated settlement is reached.

2018 Financial Report

9

Financial Review
Pfizer Inc. and Subsidiary Companies

We generated approximately 2% of our worldwide revenues from the U.K. in 2018 including the foreign currency exchange impact from the weakening U.K. pound relative
to the U.S. dollar to date. We recognize that there are still significant uncertainties surrounding the ultimate resolution of Brexit negotiations, and we will continue to monitor
any changes that may arise and assess their potential impact on our business.

Pfizer’s preparations are well advanced to make the changes necessary to meet EU legal requirements after the U.K. is no longer a member state, especially in the
regulatory, research, manufacturing and supply chain areas. The aim is to ensure the continuity of supply to patients in Europe (EU and the U.K.) and other global markets
impacted by these changes. The one-time costs of making these adaptations are currently estimated at approximately $100 million and are expected to be incurred
between 2018 and 2021.

• On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly

changes the U.S. corporate income tax system by, among other things, reducing the U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international
taxation from a worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign
subsidiaries. For additional information, see the “Provision/(Benefit) for Taxes on Income” and “Analysis of Financial Condition, Liquidity and Capital Resources” sections of
this Financial Review and Notes to Consolidated Financial Statements–– Note 5A . Tax Matters: Taxes on Income from Continuing Operations.

Pfizer maintains a strong financial position while operating in a complex global environment. Due to our significant operating cash flows, financial assets, access to capital
markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the
foreseeable future. Our long-term debt is rated high quality by both S&P and Moody’s. As market conditions change, we continue to monitor our liquidity position. We have
taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid,
well-diversified, available-for-sale debt securities. For further discussion of our financial condition and credit ratings, see the “Analysis of Financial Condition, Liquidity and
Capital Resources” section of this Financial Review.

These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors
That May Affect Future Results” section of this Financial Review and in Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

Our Strategy

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction
in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in
dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue
to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access
and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company’s purpose: Breakthroughs that change patients’ lives . By doing so, we
expect to create value for the patients we serve and for our shareholders.

Organizing for Growth

Today Pfizer has what we believe is the best pipeline in our history and several new industry-leading medicines that position us well for future growth. Following the impact of
the expected patent expiration of Lyrica in the U.S. in mid-2019, we expect to enter a period of significantly reduced revenue impact from patent expiries. This confluence of
events has given us an opportunity to look at and refine how we organize our business to best achieve sustainable growth and to deliver our medicines and vaccines to the
maximum number of people who need them.

At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each of which is led by
a single manager—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and Pfizer’s Consumer Healthcare business. We designed this new global structure to take
advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets.

Some additional information about each business follows:

• Biopharma—a science-based innovative medicines business that includes our Innovative Health business units (except our Consumer Healthcare business), as well as a
new Hospital business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We also incorporated our biosimilar portfolio into our
Oncology and Inflammation & Immunology therapeutic areas.

• Upjohn—an off-patent branded and generic established medicines business, headquartered in China that includes 20 of our off-patent solid oral dose legacy brands

including Lyrica, Lipitor, Norvasc, Viagra and Celebrex, as well as certain generic medicines.

• Pfizer’s Consumer Healthcare business—an over-the-counter medicines business, which we announced on December 19, 2018 will be contributed to, and combined with,

GSK’s consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32%. See Notes to Consolidated Financial Statements–– Note
2C. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method
Investments and Privately Held Investment : Assets and Liabilities Held for Sale.

We also reorganized our R&D operations as part of our Organizing for Growth reorganization:

• WRD is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical & Safety organization in WRD that incorporates

the former Chief Medical Office as well as the Worldwide Safety function;

• The R&D organization within the EH business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars into WRDM and GPD and

realigning them with the relevant therapeutic areas (e.g., Oncology and Inflammation & Immunology);

• The Regulatory function has been moved from the WRDM organization into the GPD organization; and

• Late-stage portfolio spend has been moved from IH to GPD and from EH to GPD and Upjohn.

10

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

We re-aligned our commercial operations in 2019 for a number of reasons, including:

• Bringing biosimilars into their therapeutic categories gives us the potential to leverage our R&D, regulatory and commercial infrastructure within the Biopharma business to

more efficiently bring those assets to market;

• Making a business unit that is solely focused on medicines that are used in hospitals can potentially bring greater focus and attention to serving those customers and

developing those relationships;

• Giving the Upjohn business more autonomy and a focus on maximizing the value of its products, particularly in emerging markets, gives it the opportunity to operate as a

standalone business within Pfizer with the potential for sustainable modest growth; and

• We believe this new structure better positions each business to achieve its growth potential as we transition to a period post-2020 where we expect higher and more

sustained revenue growth due to declining LOEs and the potential of our late-stage pipeline.

Biopharma seeks to leverage a strong pipeline, organize around operational growth drivers, and capitalize on trends creating long-term growth opportunities, including:

• An aging global population that is generating increased demand for innovative medicines that address patients’ unmet needs;

• Advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines; and

• The increasingly significant role of hospitals in healthcare systems.

Urbanization and the rise of the middle class in emerging markets, particularly in Asia, provide growth opportunities for the Upjohn business. Our ability to work collaboratively
within local markets and to be fast, focused and flexible is intended to position this business to seize these opportunities. Upjohn will have distinct and dedicated
manufacturing, marketing, regulatory and, subject to limited exceptions, enabling functions that report directly into the business providing autonomy and positioning Upjohn to
operate as a true stand-alone division. We created this new structure to, among other things, position Upjohn to optimize its distinct growth potential and provide us with the
flexibility to access further opportunities to enhance value, which we continue to consider.

Results for 2018 and prior periods in our 2018 Form 10-K and in this 2018 Financial Report are reported on the basis under which we managed our business in 2018 and do
not reflect the 2019 reorganization. Beginning with our first-quarter 2019 financial results, our financial reporting will reflect the new organizational structure. We are evaluating
the impact to our operating segments and other costs and activities based on how the businesses are managed in 2019.

As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, process and governance within each business
and the functions that support them. As our innovative pipeline matures with the anticipated progression of current trials and the initiation of new pivotal trials, we will need to
increase our R&D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-
creation activities. We are also initiating an enterprise-wide digital effort to help speed up drug development, enhance patient and physician experiences and access and
leverage technology and robotics to simplify and automate our processes.

In the fourth quarter of 2018, we took steps to simplify the organization, increase spans of control and reduce organizational layers, which impacted some managerial roles and
responsibilities. The impacts of these voluntary and involuntary plans were recorded as a special termination benefit, as well as severance in the fourth quarter of 2018, and
were reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. We also offered enhancements to certain employee benefits for a
short period of time. The expenses related to these enhancements for certain employee benefits did not have a material impact on our 2018 results of operations and any
expected future impact of these enhancements are reflected in the totality of our annual guidance for 2019. To partially offset the incremental cost increases of increased R&D
investments and marketing activities in future periods, we expect to generate cost reduction opportunities, particularly in indirect SI&A.

Commercial Operations

From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through two distinct business segments: Pfizer Innovative
Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments were each led by a single manager. Each operating segment had responsibility for its
commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-
concept. Each business had a geographic footprint across developed and emerging markets.

2018 Financial Report

11

Financial Review
Pfizer Inc. and Subsidiary Companies

Some additional information about our business segments as of December 31, 2018 (prior to our new 2019 commercial organizational re-alignment) follows:

IH focused on developing and commercializing novel, value-creating medicines and
vaccines that significantly improve patients’ lives, as well as products for consumer
healthcare.

Key therapeutic areas included internal medicine, vaccines, oncology, inflammation &
immunology, rare disease and consumer healthcare.

EH included legacy brands that have lost or will soon lose market exclusivity in both
developed and emerging markets, branded generics, generic sterile injectable
products, biosimilars and select branded products including anti-infectives. EH also
included an R&D organization, as well as our contract manufacturing business.
Through February 2, 2017, EH also included HIS.

Leading brands included:
- Prevnar 13/Prevenar 13
- Xeljanz
- Eliquis
- Lyrica  (U.S., Japan and certain other markets)
- Enbrel (outside the U.S. and Canada)
- Ibrance
- Xtandi
- Chantix/Champix
- Several OTC consumer healthcare products*

Leading brands included:
- Lipitor
- Norvasc
- Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries)
- Celebrex
- Viagra**
- Inflectra/Remsima
- Sulperazon
- Several other sterile injectable products

* According to Nicholas Hall’s retail sales data (based on moving annual total data through the third quarter of 2018), in 2018, our Consumer Healthcare business was the

fifth-largest branded multi-national, OTC consumer healthcare business in the world and produced two of the ten largest selling consumer healthcare brands ( Centrum and
Advil ) in the world.

** Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH

(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.

For additional information about the 2018 performance of each of our operating segments, see the “Analysis of Operating Segment Information” section of this Financial
Review.

Description of Research and Development Operations

The following description of R&D operations reflects operations as of December 31, 2018 .

Innovation is critical to the success of our company, and drug discovery and development is time-consuming, expensive and unpredictable. Our goal is to discover, develop
and bring to market innovative products that address major unmet medical needs. Our R&D priorities include:

• delivering a pipeline of differentiated therapies and vaccines with the greatest medical and commercial potential;

• advancing our capabilities that can position Pfizer for long-term leadership; and

• creating new models for biomedical collaboration that will expedite the pace of innovation and productivity.

To that end, our R&D primarily focuses on:

•

•

Inflammation and Immunology ;

Internal Medicine ;

• Oncology ;

• Rare Diseases ;

• Vaccines ; and

• Biosimilars.

In January 2018, we announced our decision to end internal neuroscience discovery and early development efforts and re-allocate funding to other areas where we have
stronger scientific leadership. The development of tanezumab and potential treatments for rare neuromuscular disorders is not impacted by this decision. In June 2018, we
announced our plan to invest up to $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, our venture investment vehicle. In September
2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical
stage neuroscience assets primarily targeting disorders of the central nervous system, including Parkinson’s disease, epilepsy, Alzheimer’s disease, schizophrenia and
addiction. For additional information on the transaction with Bain Capital, see the Notes to Consolidated Financial Statements–– Note 2B. Acquisitions, Divestitures, Assets and
Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Divestitures .

In 2018, we continued to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable
pipeline that is positioned to deliver value in the near term and over time. Our R&D spending was conducted through a number of matrix organizations:

• Research Units within our WRD organization were generally responsible for research and early-stage development assets for our IH business (assets that have not yet

achieved proof-of-concept). Our Research Units were organized by therapeutic area to enhance flexibility, cohesiveness and focus. Because of our structure, we were able
to rapidly redeploy resources within a Research Unit between various projects as necessary because in many instances the workforce shares similar skills, expertise and/or
focus.

12

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

• Our R&D organization within the EH business supported the large base of EH products and helped develop potential new sterile injectable drugs and therapeutic solutions,

as well as biosimilars.

• Our GPD organization, a unified center for late-stage development for our innovative products that was generally responsible for the operational execution of clinical trials for

both early-stage assets in the WRD portfolio as well as late-stage assets in the Innovative portfolio. For WRD assets, GPD worked in close collaboration with the Early
Clinical Development group, which has expertise in various disciplines such as Biostatistics, Clinical Pharmacology and Digital Medicine. GPD helped enable more efficient
and effective development and enhance our ability to accelerate and progress assets through our pipeline.

• Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurred, provided technical expertise and other services to

the various R&D projects, and were organized into science-based functions (which were part of our WRD organization), such as Pharmaceutical Sciences, Medicine Design,
Regulatory and Drug Safety, and non-science-based functions, such as Facilities, Business Technology and Finance. As a result, within each of these functions, we were
able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react quickly in response to
evolving needs.

We manage R&D operations on a total-company basis through our matrix organizations described above. Specifically, a single committee with representation from the R&D
groups and the IH commercial organization was accountable for aligning resources among all of our WRD, GPD and IH R&D projects and for seeking to ensure optimal capital
allocation across the Innovative R&D portfolio. We believe that this approach also served to maximize accountability and flexibility. Our EH R&D organization managed its
resources separately from the WRD and GPD organizations.

Generally, we do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we do not manage a significant portion of our
R&D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, as conditions change, we believe
that any prior-period information about R&D expense by development phase or by therapeutic area would not necessarily be representative of future spending.

While a significant portion of R&D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies developed by third
parties to incorporate into our discovery and development processes or projects, as well as our product lines, by entering into collaboration, alliance and license agreements
with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising
compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees to fund a portion of the development costs of one or more of our
pipeline products in exchange for rights to receive potential milestone payments, revenue sharing payments, profit sharing payments and/or royalties. Collaboration, alliance,
license and funding agreements and equity- or debt-based investments allow us to share risk and cost and to access external scientific and technological expertise, and
provide us the opportunity to advance our own products as well as the in-licensed or acquired products.

For additional information about R&D by operating segment, see the “Analysis of Operating Segment Information” section of this Financial Review. For additional information
about our pending new drug applications and supplemental filings, see the “Analysis of the Consolidated Statements of Income––Product Developments––Biopharmaceutical”
section of this Financial Review. For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline, see
the “Our Business Development Initiatives” section of this Financial Review.

Intellectual Property Rights

We continue to aggressively defend our patent rights whenever appropriate against increasingly aggressive infringement, and we will continue to support efforts that strengthen
worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches
designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and we will continue to
participate in the generics market for our products, whenever appropriate, once they lose exclusivity. Also, the pursuit of valid business opportunities may require us to
challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not
always be successful. For additional information about our current efforts to enforce our intellectual property rights and certain other patent proceedings, see Notes to
Consolidated Financial Statements–– Note 17A1. Contingencies and Certain Commitments : Legal Proceedings –– Patent Litigation. For information on risks related to patent
protection and intellectual property claims by third parties, see Part I, Item 1A, “Risk Factors––Risks Related to Intellectual Property” in our 2018 Form 10-K.

Capital Allocation and Expense Management

We seek to maintain a strong balance sheet and robust liquidity so that we continue to have the financial resources necessary to take advantage of prudent commercial,
research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our
financial condition, liquidity, capital resources, share repurchases (including accelerated share repurchases) and dividends, see the “Analysis of Financial Condition, Liquidity
and Capital Resources” section of this Financial Review. For additional information about our recent business development activities, see the “Our Business Development
Initiatives” section of this Financial Review.

In December  2018 , our Board of Directors declared a first-quarter 2019 dividend of $0.36 per share, an increase from the $0.34 per-share quarterly dividend paid during 2018
. For additional information, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this Financial Review and Notes to Consolidated Financial
Statements–– Note 12. Equity.

We remain focused on achieving an appropriate cost structure for our company. For additional information about our cost-reduction and productivity initiatives, see the “Costs
and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-

2018 Financial Report

13

Financial Review
Pfizer Inc. and Subsidiary Companies

Reduction/Productivity Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements–– Note 3 . Restructuring Charges and Other Costs
Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Increasing Investment in the U.S. ––After evaluating the expected positive net impact the TCJA will have on us, in early 2018, we decided to take several actions:

• Over the five-year period from 2018 through 2022, we plan to invest approximately $5.0 billion in capital projects in the U.S., including the strengthening of our manufacturing
presence in the U.S. As part of this plan, in July 2018, we announced that we will increase our commitment to U.S. manufacturing with a $465 million investment to build one
of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen our capability to
produce and supply critical, life-saving injectable medicines for patients around the world. Known as Modular Aseptic Processing, the new, multi-story, 400,000-square-foot
production facility will also support the area economy by creating an estimated 450 new jobs over the next several years.

• We made a $500 million voluntary contribution to the U.S. Pfizer Consolidated Pension Plan in February 2018.

•

•

In the fourth quarter of 2017, we made a $200 million charitable contribution to the Pfizer Foundation, an organization that provides grant and investment funding to support
organizations and social entrepreneurs in an effort to improve healthcare delivery.

In the first quarter of 2018, we paid a special, one-time bonus to virtually all Pfizer colleagues, excluding executives, of $119 million in the aggregate.

Our Business Development Initiatives

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of
business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view
our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic
and financial approach to evaluating business development opportunities. We continue to evaluate business development transactions that have the potential to strengthen our
businesses and their capabilities, such as our acquisitions of Hospira, Medivation, Anacor and AstraZeneca’s small molecule anti-infectives business, as well as collaborations,
and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio
review process and also continue to consider business development activities that will advance our businesses.

For additional information on our business development activities, see Notes to Consolidated Financial Statements ––Note 2. Acquisitions, Divestitures, Assets and Liabilities
Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment .

The more significant recent transactions and events are described below:

• Agreement to Form a New Consumer Healthcare Joint Venture (IH) ––On December 19, 2018, we announced that we entered into a definitive agreement with GSK under

which we and GSK agreed to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK
Consumer Healthcare name. The joint venture is expected to be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health
and therapeutic oral health and will be the largest global OTC consumer healthcare business.

• Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) ––On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU
Medical. In connection with this transaction, we recognized pre-tax income of $1 million in 2018 and pre-tax losses of $55 million in 2017 in Other (income)/deductions––net,
representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell.

• Acquisition of AstraZeneca’s Small Molecule Anti-Infectives Business (EH) ––On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international

operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. The total fair
value of the consideration transferred for this business was approximately $1,040 million , inclusive of cash paid and the fair value of contingent consideration.

• Acquisition of Medivation, Inc. (IH) ––On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation
was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that
blocks multiple steps in the androgen receptor signaling pathway within tumor cells, and talazoparib, which was approved by the FDA in October 2018, under the trade name
Talzenna, for the treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other
types of cancer. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the
U.S.

• Acquisition of Bamboo Therapeutics, Inc. (IH) –– On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on
developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous
system, for $150 million plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval
and commercialization.

• Acquisition of Anacor Pharmaceuticals, Inc. (IH) –– On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor
was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired) plus $698 million debt assumed. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with
anti-inflammatory properties, was approved by the FDA in December 2016 under the trade name, Eucrisa , for the treatment of mild-to-moderate atopic dermatitis in patients
two years of age and older, commonly referred to as a type of eczema. Anacor also holds the rights to Kerydin, a topical treatment for onychomycosis (toenail fungus) that is
distributed and commercialized by Sandoz in the U.S.

14

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

• Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. –– On November 1, 2016, we announced the discontinuation of the global clinical

development program for bococizumab. During December 2016, $31.3 million was refunded to NovaQuest representing amounts NovaQuest prepaid for development costs
(under the May 2016 agreement described below) that were not used for program expenses due to the discontinuation of the development program. No additional payments
have been or are expected to be received from or paid to NovaQuest with respect to this agreement, which was terminated effective as of November 18, 2016.

In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to fund up to $250 million in development costs related to certain Phase 3
clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound.
NovaQuest’s development funding was expected to cover up to 40% of the development costs and was to be received over five quarters during 2016 and 2017. As there
was a substantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses during 2016 was recognized as an obligation to
perform contractual services and therefore has been recognized as a reduction of Research and development expenses as incurred. The reduction to Research and
development expenses for 2016 totaled $180.3 million .

• Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. –– In April 2016, Pfizer entered into an agreement with NovaQuest under which
NovaQuest would fund up to $200 million in development costs related to certain Phase 3 clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially
reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding is expected to cover up to 100% of the development
costs and will be received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer will be responsible for the remaining development
costs. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding is recognized by us as an obligation to perform contractual services and
therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses totaled $57.6 million for 2018, $72.1
million for 2017 and $46.6 million for 2016. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to
approximately $267 million in total, based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over
approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated
commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when incurred.

• Research and Development Arrangement with RPI Finance Trust –– In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under

which RPI would fund up to $300 million in development costs related to certain Phase 3 clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment
of hormone receptor positive early breast cancer (the Indication). RPI’s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical
trials until the second quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a substantive and genuine transfer of risk to RPI,
the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as
incurred. The reduction to Research and development expenses totaled $99.3 million in 2018, $75.6 million for 2017 and $44.9 million for 2016. If successful and upon
approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of
approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven
years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial
life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred.

Our Financial Guidance for 2019

The following table provides our financial guidance for full-year 2019 (a), (b) :

Revenues
Adjusted cost of sales as a percentage of revenues
Adjusted selling, informational and administrative expenses
Adjusted research and development expenses
Adjusted other (income)/deductions
Effective tax rate on adjusted income
Adjusted diluted EPS
(a)  The 2019 financial guidance reflects the following:

$52.0 to $54.0 billion
20.8% to 21.8%
$13.5 to $14.5 billion
$7.8 to $8.3 billion
Approximately $100 million of income
Approximately 16.0%
$2.82 to $2.92

• A full year of revenue and expense contributions from Pfizer’s Consumer Healthcare business.
• Does not assume the completion of any business development transactions not completed as of December 31, 2018 , including any one-time upfront payments associated with such transactions.
• Financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS now excludes the impact of gains and losses on investments in equity securities. In 2018, Pfizer’s 2018 financial results

included net gains on investments in equity securities, which favorably impacted Adjusted other (income)/deductions by $586 million and Adjusted diluted EPS (2) by approximately $0.08 in 2018. Beginning In
2019, we will exclude the gains and losses from equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control and cannot predict with any level of certainty
and because we do not believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. For example, we contributed assets
related to our allogeneic CAR T therapy to Allogene and received equity securities. We will restate our Adjusted income and Adjusted diluted EPS for prior periods for consistency with our 2019 presentation.
• Reflects an anticipated negative revenue impact of $2.6 billion due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent

protection.

• Exchange rates assumed are as of mid-January 2019. Reflects the anticipated unfavorable impact of approximately $0.9 billion on revenues and approximately $0.06 on adjusted diluted EPS as a result of

changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2018.

• Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.7 billion shares, which reflects share repurchases totaling $12.2 billion in 2018 and the weighted-

average impact of an anticipated approximately $9 billion of share repurchases in 2019 , which

2018 Financial Report

15

Financial Review
Pfizer Inc. and Subsidiary Companies

have been completed through February 28, 2019. Dilution related to share-based employee compensation programs is currently expected to offset the reduction in shares associated with these share

repurchases by approximately half.

(b)

For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Non-GAAP Financial Measure (Adjusted Income)” section of this
Financial Review.
Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported
financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, net gains
or losses on equity securities and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported
results for the guidance period.

For information about our actual costs and anticipated costs and cost savings associated with our three-year cost-reduction initiative entered into in the fourth quarter of 2016,
the Hospira acquisition, our recent business development activities, and global commercial structure, see the “Costs and Expenses––Restructuring Charges and Other Costs
Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements–– Note 3 .
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Our 2019 financial guidance is subject to a number of factors and uncertainties as described in the “Our Operating Environment”, “The Global Economic Environment”, “Our
Strategy” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this Financial Review; and Part I, Item 1A, “Risk Factors” of our 2018
Form 10-K.

SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND
ASSUMPTIONS

For a description of our significant accounting policies, see Notes to Consolidated Financial Statements–– Note 1. Basis of Presentation and Significant Accounting Policies .
Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and
the most complex judgments: (i) Acquisitions (Note 1D); (ii) Fair Value (Note 1E); (iii) Revenues (Notes 1B and 1G); (iv) Asset Impairments (Note 1L); (v) Tax Assets and
Liabilities and Income Tax Contingencies (Note 1P); (vi) Pension and Postretirement Benefit Plans (Note 1Q); and (vii) Legal and Environmental Contingencies (Note 1R).

Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. See also Notes to Consolidated Financial
Statements–– Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions for a discussion about the risks associated with estimates and
assumptions.

Acquisitions and Fair Value

For a discussion about the application of fair value to our recent acquisitions, see Notes to Consolidated Financial Statements— Note 2A. Acquisitions, Divestitures, Assets
and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Acquisitions .

For a discussion about the application of fair value to our investments, see Notes to Consolidated Financial Statements— Note 7A. Financial Instruments : Fair Value
Measurements .

For a discussion about the application of fair value to our benefit plan assets, see Notes to Consolidated Financial Statements–– Note 11D. Pension and Postretirement Benefit
Plans and Defined Contribution Plans: Plan Assets .

For a discussion about the application of fair value to our asset impairment reviews, see “Asset Impairment Reviews” below.

Revenues

Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such
variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such,
knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.

Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our
adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues.
Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. If any of our ratios, factors, assessments, experiences or
judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type
of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material
adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because
of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.

Asset Impairment Reviews

We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least
annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the
amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in the Notes to Consolidated Financial
Statements–– Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

16

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Examples of events or circumstances that may be indicative of impairment include:

• A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights

would likely result in generic competition earlier than expected.

• A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affect

our ability to manufacture or sell a product.

• A projection or forecast that indicates losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement

program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that results in
a significant loss of market share or the inability to achieve the previously projected revenue growth, as well as the lack of acceptance of a product by patients, physicians
and payers. For IPR&D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or
additional expenditures to commercialize the product.

Identifiable Intangible Assets

As a result of our identifiable intangible asset impairment review work, we recognized a number of impairments of identifiable intangible assets for the years ended
December 31, 2018 , 2017 and 2016 . See Notes to Consolidated Financial Statements–– Note 4. Other (Income)/Deductions — Net.

When we are required to determine the fair value of intangible assets other than goodwill, we use an income approach, specifically the discounted cash flow method. We start
with a forecast of all the expected net cash flows associated with the asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply an
asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and
timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological risk
associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash
flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, in general, intangible assets other than goodwill that are most at
risk of impairment include IPR&D assets (approximately $2.2 billion as of December 31, 2018 ) and newly acquired or recently impaired indefinite-lived brand assets. IPR&D
assets are high-risk assets, as R&D is an inherently risky activity. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets
are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after
acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment
charge.

Goodwill

As a result of our goodwill impairment review work, we concluded that none of our goodwill was impaired as of December 31, 2018 , and we do not believe the risk of
impairment is significant at this time.

We first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we
consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more
likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.

When we are required to determine the fair value of a reporting unit, as appropriate for the individual reporting unit, we mainly use the income approach but we may also use
the market approach, or a weighted-average combination of both approaches.

• The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, the method that we use is
the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal
value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in
this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or
regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected
cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

• The market approach is a historical approach to estimating fair value and relies primarily on external information. Within the market approach are two methods that we may

use:

◦ Guideline public company method—this method employs market multiples derived from market prices of stocks of companies that are engaged in the same or similar lines

of business and that are actively traded on a free and open market and the application of the identified multiples to the corresponding measure of our reporting unit’s
financial performance.

◦ Guideline transaction method—this method relies on pricing multiples derived from transactions of significant interests in companies engaged in the same or similar lines

of business and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.

The market approach is only appropriate when the available external information is robust and deemed to be a reliable proxy for the specific reporting unit being valued;
however, these assessments may prove to be incomplete or inaccurate. Some of the more significant estimates and assumptions inherent in this approach include: the
selection of appropriate guideline companies and transactions and the determination of applicable premiums and discounts based on any differences in ownership
percentages, ownership rights, business ownership forms or marketability between the reporting unit and the guideline companies and transactions.

2018 Financial Report

17

Financial Review
Pfizer Inc. and Subsidiary Companies

For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of
subsequent goodwill impairment testing. For a list of these factors, see the “Forward-Looking Information and Factors That May Affect Future Results” section of this Financial
Review and Part I, Item 1A, “Risk Factors” in our 2018 Form 10-K.

Benefit Plans

The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and
supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for
retirees and their eligible dependents.

The accounting for benefit plans is highly dependent on actuarial estimates, assumptions and calculations, which can result from a complex series of judgments about future
events and uncertainties. The assumptions and actuarial estimates required to estimate the net employee benefit obligations for the defined benefit and postretirement plans
include the discount rate; expected salary increases; certain employee-related factors, such as turnover, retirement age and mortality (life expectancy); expected return on plan
assets; and healthcare cost trend rates.

Effective January 1, 2018, accruals for future benefits under the Pfizer Consolidated Pension Plan (our largest U.S. defined benefit plan) and the defined benefit section of the
Pfizer Group Pension Scheme (our largest pension plan in the U.K.) were frozen and resulted in elimination of future service costs for the plans. The Pfizer defined contribution
savings plan provides additional annual contributions to those previously accruing benefits under the Pfizer Consolidated Pension Plan and active members of the Pfizer Group
Pension Scheme started accruing benefits under the defined contribution section of that plan.

As of December 31, 2018 , the noncurrent portion of our pension benefit obligations, net, and our postretirement benefit obligations, net decreased, in the aggregate, by
approximately $747 million compared to December 31, 2017 . The decrease reflects, among other things, the $500 million voluntary contribution we made to the U.S. Pfizer
Consolidated Pension Plan in February 2018 and an increase in the discount rate used in the measurement of plan obligations, partially offset by the decrease in the actual
returns on plan assets.

Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made
in determining the costs of our benefit plans can materially impact our results of operations.

The following table provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan
assets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. qualified pension plans
and our international pension plans (a) :

U.S. Qualified Pension Plans

Expected annual rate of return on plan assets

Actual annual rate of return on plan assets

Discount rate used to measure the plan obligations

International Pension Plans

Expected annual rate of return on plan assets

Actual annual rate of return on plan assets

Discount rate used to measure the plan obligations

2018

2017

2016

7.2 %

7.5%

(5.3)

4.4

3.9

(0.9)

2.5

16.2

3.8

4.4

10.3

2.3

8.0%

8.1

4.3

4.7

9.3

2.4

(a)

For detailed assumptions associated with our benefit plans, see Notes to Consolidated Financial Statements— Note 11B. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Actuarial
Assumptions.

Expected Annual Rate of Return on Plan Assets

The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking
return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our
respective plans.

The expected annual rate of return on plan assets for our U.S. plans and the majority of our international plans is applied to the fair value of plan assets at each year-end and
the resulting amount is reflected in our net periodic benefit costs in the following year.

The following table illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets,
holding all other assumptions constant (in millions, pre-tax):

Change

Increase in 2019 Net Periodic
Benefit Costs

Assumption

Expected annual rate of return on plan assets

50 basis point decline

$104

The actual return on plan assets resulted in a net loss on our plan assets of approximately $895 million during 2018 .

18

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Discount Rate Used to Measure Plan Obligations

The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as
required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits
could be effectively settled. The discount rate used to measure the plan obligations for our international plans is determined at least annually by reference to investment grade
corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local
requirements.

The measurement of the plan obligations at the end of the year will affect the amount of service cost, interest cost and amortization expense reflected in our net periodic benefit
costs in the following year.

The following table illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all
other assumptions constant (in millions, pre-tax):

Assumption

Discount rate

Change

Increase in 2019 Net
Periodic Benefit Costs
Increase
$13

2018 Benefit
Obligations

Increase

$417

10 basis point decline

The change in the discount rates used in measuring our plan obligations as of December 31, 2018 resulted in a decrease in the measurement of our aggregate plan obligations
by approximately $1.5 billion .

Income Tax Assets and Liabilities

In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the
U.S. Federal corporate tax rate from 35% to 21% , (ii) the impact on valuation allowances and other state income tax considerations, (iii) a repatriation tax liability on
accumulated post-1986 foreign earnings for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through
2026 that is reported in Other taxes payable in our consolidated balance sheet as of December 31, 2017, and (iv) deferred taxes on basis differences expected to give rise to
future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a
result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax
system.

The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5,
Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis
differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We
elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. We were able to make a reasonable
estimate of the deferred taxes on the temporary differences expected to reverse in the future and provided a provisional deferred tax liability as of December 31, 2017.

In 2018, we finalized our provisional accounting for the tax effects of the TCJA based on our best estimates of available information and data, and have reported and disclosed
the impacts within the applicable measurement period, in accordance with guidance issued by the SEC. The amounts recorded may change in the future due to uncertain tax
positions. With respect to the aforementioned repatriation tax liability, the first installment, due in April 2019, is reported in Income taxes payable, and the remaining liability is
reported in Other taxes payable in our consolidated balance sheet as of December 31, 2018. We believe that there may be additional interpretations, clarifications and
guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in
the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other
credit carryforwards.

Income tax assets and liabilities also include income tax valuation allowances and accruals for uncertain tax positions. For additional information, see Notes to Consolidated
Financial Statements— Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions ; Note 1P. Basis of Presentation and Significant
Accounting Policies: Tax Assets and Liabilities and Income Tax Contingencies and Note 5A. Tax Matters: Taxes on Income from Continuing Operations, as well as the
“Analysis of Financial Condition, Liquidity and Capital Resources––Selected Measures of Liquidity and Capital Resources—Contractual Obligations” section of this Financial
Review .

Contingencies

For a discussion about income tax contingencies, see Notes to Consolidated Financial Statements— Note 5D. Tax Matters: Tax Contingencies.

For a discussion about legal and environmental contingencies, guarantees and indemnifications, see Notes to Consolidated Financial Statements— Note 17. Contingencies
and Certain Commitments .

2018 Financial Report

19

Financial Review
Pfizer Inc. and Subsidiary Companies

ANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

% of revenues

Year Ended December 31,

% Change

2018

2017

2016

18/17

17/16

  $

  $

53,647

11,248

  $

52,546

11,228

52,824

12,322

2
—

21.0%

21.4 %

23.3%

Selling, informational and administrative expenses

14,455

14,804

14,844

(2)

% of revenues

Research and development expenses

% of revenues

Amortization of intangible assets

% of revenues

Restructuring charges and certain acquisition-related costs

% of revenues

Other (income)/deductions—net
Income from continuing operations before provision/(benefit) for

taxes on income

% of revenues

Provision/(benefit) for taxes on income

Effective tax rate

Income from continuing operations

% of revenues

Discontinued operations—net of tax

Net income before allocation to noncontrolling interests

% of revenues

Less: Net income attributable to noncontrolling interests

26.9%

8,006
14.9%

4,893

9.1%

1,044

1.9%

2,116

11,885

22.2%

706
5.9%

11,179

20.8%

10

11,188

20.9%

36

28.2 %

7,683
14.6 %

4,758

9.1 %

351
0.7 %

1,416

12,305

23.4 %

(9,049)
(73.5)%

21,353

40.6 %

2

21,355

40.6 %

47

Net income attributable to Pfizer Inc.

% of revenues

  $

11,153

  $

21,308

  $

20.8%

40.6 %

Certain amounts and percentages may reflect rounding adjustments.
* Indicates calculation not meaningful or result is equal to or greater than 100%.

Revenues — Overview

28.1%

7,892
14.9%

4,056

7.7%

1,565

3.0%

3,794

8,351
15.8%

1,123
13.4%

7,229
13.7%

17

7,246
13.7%

31

7,215
13.7%

4

3

*

49

(3)

*

(48)

*

(48)

(24)

(48)

(1)

(9)

—

(3)

17

(78)

(63)

47

*

*

(87)

*

54

*

Total revenues in 2018 compared to 2017 reflects operational growth of $791 million , or 2% , and the favorable impact of foreign exchange of $310 million , or less than 1% ,
in 2018 , compared to 2017 .

Compared to 2016, total revenues for 2017 were unfavorably impacted by approximately $200 million as a result of 2017 having one less selling day in both U.S. and
international markets.

Total revenues in 2017 compared to 2016 reflect a slight operational decrease of $20 million, or less than 1%, and an unfavorable impact of foreign exchange of $259 million,
or less than 1%, in 2017 compared to 2016 .

See the “Revenues by Segment and Geography” and “Revenues—Selected Product Discussion” sections of this Financial Review for additional analyses.

See the “Our Operating Environment—Industry-Specific Challenges—Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Review for
information about recent losses and expected losses of product exclusivity impacting product revenues.

A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For additional information,
see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

We have significant operations outside the U.S., with revenues exceeding $500 million in the following number of countries:

20

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

By total revenues, the U.S., China and Japan are our three largest national markets:

Inventory Stocking

Our policy relating to the supply of pharmaceutical inventory at domestic wholesalers, and in major international markets, is to generally maintain stocking levels under one
month on average and to keep monthly levels consistent from year to year based on patterns of utilization. We historically have been able to closely monitor these customer
stocking levels by purchasing information from our customers directly or by obtaining other third-party information. We believe our data sources to be directionally reliable but
cannot verify their accuracy. Further, as we do not control this third-party data, we cannot be assured of continuing access. Unusual buying patterns and utilization are promptly
investigated.

Revenue Deductions

Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such
variable consideration represents chargebacks, rebates, sales allowances and sales returns.These deductions represent estimates of related obligations and, as such,
knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, our adjustments of estimates,
to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results
generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a
significant impact on year-over-year individual product growth trends.

The following table provides information about revenue deductions:

(MILLIONS OF DOLLARS)

Medicare rebates (a)

Medicaid and related state program rebates (a)

Performance-based contract rebates (a), (b)

Chargebacks (c)

Sales allowances (d)

Sales returns and cash discounts

Year Ended December 31,
2017
1,316   $
1,860
3,245
6,047
5,165
1,493
19,126   $

2018
1,706   $
1,969
3,377
6,461
5,592
1,522
20,627   $

2016

1,063

1,473

2,560

5,736

4,623

1,441

16,895

  $

  $

Total (e)
(a)  Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.
(b)

Performance-based contract rebates include contract rebates with managed care customers within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement
of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted
performance for specific products or sales milestones.

(c)  Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.
(d)  Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.
(e)

For 2018 , associated with the following segments: IH ( $8.9 billion ); and EH ( $11.7 billion ). For 2017 , associated with the following segments: IH ( $9.0 billion ); and EH ( $10.1 billion ). For 2016 , associated
with the following segments: IH ( $7.1 billion ); and EH ( $9.8 billion ).

Total revenue deductions for 2018 increase d 8% compared to 2017 , primarily as a result of:

• an increase in sales allowances as a result of sales growth, primarily in international markets;

• higher chargebacks to U.S. wholesalers of certain IH and EH products, partially offset by decreases in chargebacks as a result of decreases in sales of sterile injectable

products;

• an increase in Medicare rebates driven by increased sales of IH products through this channel; and

• an increase in Medicaid and related state program rebates, primarily as a result of increased sales of IH products through these programs.

For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and
sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Consolidated Financial Statements–– Note 1G. Basis of
Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable .

2018 Financial Report

21

Financial Review
Pfizer Inc. and Subsidiary Companies

Revenues by Segment and Geography

The following graphs show revenues by geography (dollars in billions):

The following table provides worldwide revenues by operating segment and geography:

(MILLIONS OF DOLLARS)

2018

2017

2016

2018

Operating Segments (a) :

Worldwide

U.S.

2017

International

Worldwide

2016

2018

2017

2016

  18/17

  17/16

  18/17

U.S.
  17/16

International
18/17   17/16

Year Ended December 31,

% Change

IH

  $ 33,426

  $ 31,422

  $ 29,197

  $ 18,959

  $ 18,460

  $ 16,773

  $ 14,467

  $ 12,962

  $ 12,424

6

8

3

10

EH

Total revenues

9,596
  $ 26,369
IH = the Innovative Health segment; and EH = the Essential Health segment. For additional information about each operating segment, see the “Our Strategy––Commercial Operations” section of this Financial
Review and Notes to Consolidated Financial Statements–– Note 18A. Segment, Geographic and Other Revenue Information: Segment Information.

13,851
  $ 28,318

7,567
  $ 26,026

6,370
  $ 25,329

21,124
  $ 52,546

20,221
  $ 53,647

23,627
  $ 52,824

13,557
  $ 26,519

14,031
  $ 26,455

(11)

(16)

(21)

(1)

(3)

(1)

(4)

2

(a)

12
2
7

4

(3)

—

We recorded direct product and/or alliance revenues of more than $1 billion for each of 10 products in 2018 and for nine products in 2017 and 2016 .

Direct Product And/Or Alliance Revenues of More Than $1 Billion

2018

2017

2016

Prevnar 13/Prevenar 13

Prevnar 13/Prevenar 13

Prevnar 13/Prevenar 13

Lyrica

Ibrance

Eliquis*

Enbrel

Lipitor

Xeljanz

Chantix/Champix

Sutent

Norvasc

Lyrica

Ibrance

Eliquis*

Enbrel

Lipitor

Xeljanz

Viagra

Sutent

Lyrica

Enbrel

Ibrance

Lipitor

Eliquis*

Viagra

Sutent

Premarin family of products

* Eliquis  includes alliance revenues and direct sales in 2018, 2017 and 2016.
These direct product sales and/or alliance product revenues represent 51% of our revenues in 2018 , 46% of our revenues in 2017 and 43% of our revenues in 2016 . See the
“Analysis of the Consolidated Statements of Income—Revenues—Selected Product Discussion” section of this Financial Review for additional information.

22

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

2018 v. 2017

The following provides an analysis of the change in revenues by geographic areas in 2018 :

(MILLIONS OF DOLLARS)

Operational growth/(decline):

Continued growth from certain key brands (a)
Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe

markets

Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio,

primarily in the U.S. and developed Europe

Growth in our Consumer Healthcare business across all markets

Impact from CentreOne primarily in emerging markets
Lower revenues for total Viagra (b) , primarily in the U.S. due to generic competition that began in December

2017

Decline from the Peri-LOE Products portfolio, driven by lower revenues in developed markets (excluding

Viagra EH), primarily due to expected declines in Lyrica in developed Europe and Celebrex and Pristiq in
the U.S. due to generic competition

Impact from the SIP portfolio, driven by lower revenues in developed markets, primarily due to increased

competition across the portfolio and continued legacy Hospira product shortages in the U.S.

Impact from the LEP portfolio, driven by lower revenues in developed markets, primarily as a result of

industry-wide pricing challenges in the U.S. and generic competition

Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar

competition

Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed

Europe

Impact on financial results from the sale of HIS in February 2017. 2018 does not reflect any contribution from

HIS global operations, compared to approximately one month of HIS domestic operations and
approximately two months of HIS international operations in the same period in 2017

Other operational factors, net

Operational growth/(decline), net

Favorable impact of foreign exchange

Worldwide

U.S.

International

  $

2,815   $

1,150   $

1,664

217

195
107
45

(572)

(558)

(504)

(436)

(350)

(100)

(97)
31
791

147

158
26
(127)

(572)

(188)

(589)

(592)

—

(13)

(64)
(34)
(698)

  $

310
1,101   $

—
(698)   $

69

37

81

172

—

(371)

86

156

(350)

(88)

(33)

65

1,489

310

1,799

Revenues increase/(decrease)
(a)

(b)

Certain key brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi, Lyrica––IH and Chantix/Champix. See the “Analysis of the Consolidated Statements of Income––Revenues––Selected
Product Discussion" section of this Financial Review for product analysis information.
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenues
excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra revenues were reported in EH. Total Viagra revenues in 2017 represent the aggregate of worldwide revenues from Viagra IH and
Viagra EH.

Emerging markets revenues increase d $1.3 billion , or 11% , in 2018 to $12.7 billion , from $11.4 billion , reflecting an operational increase of $1.5 billion , or 13% . Foreign
exchange had an unfavorable impact of approximately 2% on emerging markets revenues. The operational increase in emerging markets was driven by our EH segment,
primarily by the Legacy Established Products portfolio and the Sterile Injectable Pharmaceuticals portfolio, as well as Prevenar 13, Ibrance and Eliquis in our IH segment.

2018 Financial Report

23

Financial Review
Pfizer Inc. and Subsidiary Companies

2017 v. 2016

The following provides an analysis of the change in revenues by geographic areas in 2017 :

(MILLIONS OF DOLLARS)

Disposition-related operational impact:

Worldwide

U.S.

International

Approximately one month of HIS domestic operations and approximately two months of HIS international
operations in 2017, compared to twelve months of HIS global operations in 2016 (February 2017 sale)

  $

(1,062)   $

(841)   $

(221)

Other operational growth/(decline):

Continued growth from certain key brands (a)
Ibrance global growth: U.S. revenues increased primarily due to continued strong uptake in the metastatic
breast cancer setting. International revenues increased operationally, but were negatively impacted by a
one-time price adjustment to 2017 revenues related to finalizing reimbursement agreements in certain
developed Europe markets.

Increase in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation)

Growth from Biosimilars, primarily from Inflectra in the U.S. and developed Europe markets
Decline from Peri-LOE Products, primarily due to expected declines in Pristiq in the U.S. as well as Lyrica

(EH) and Vfend (both primarily in developed Europe markets)

Lower revenues for Enbrel primarily in developed Europe markets due to continued biosimilar competition

Lower revenues for Viagra (IH) in the U.S. due to generic competition that began in December 2017
Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product

shortages in the U.S.

Decline in the Legacy Established Products portfolio primarily due to generic competition in developed

markets

Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the expected decline

in revenues for the adult indication in the U.S. due to a high initial capture rate of the eligible population
following its successful fourth-quarter 2014 launch, which resulted in a smaller remaining “catch up”
opportunity compared to 2016, partially offset by growth from the pediatric indication. International revenues
increased primarily due to the favorable overall impact of timing and increased volume associated with
government purchases in certain emerging markets for the pediatric indication compared with prior year, as
well as from the inclusion of Prevenar 13 in additional national immunization programs in certain emerging
markets for the adult and pediatric indications in the fourth of quarter 2017.

Other operational factors, net

Operational growth (decline), net

Unfavorable impact of foreign exchange

Revenues increase/(decrease)
(a)  Certain k ey brands represent Eliquis (globally), as well as Xeljanz and Lyrica - IH (both primarily in the U.S.).

  $

1,608

1,104

993
450
209

(957)
(448)
(359)

(315)

(188)

757
450
115

(448)
—
(359)

(460)

(419)

(108)
157
(20)

(259)
(278)   $

(311)
68
(343)

—
(343)   $

503

236

—

94

(509)

(448)

—

145

231

203

89

323

(259)

64

Emerging markets revenues increased $979 million , or 9% , in 2017 to $11.4 billion , reflecting an operational increase of $1.1 billion , or 11% . Foreign exchange had an
unfavorable impact of approximately 2% on emerging markets revenues. The operational increase in emerging markets was primarily driven by our IH segment as well as our
Legacy Established Products and Sterile Injectable Pharmaceuticals portfolios.

For additional information about operating segment revenues, see the “Analysis of Operating Segment Information” section of this Financial Review.

Revenues—Selected Product Discussion
The tables below provide worldwide revenues, by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign
exchange. The difference between the total change and operational change represents the impact of foreign exchange. Amounts may not add due to rounding. All percentages
have been calculated using unrounded amounts. An asterisk (*) indicates the calculation is not meaningful or results are equal to or greater than 100%.

• Prevnar 13/Prevenar 13 (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
3,360   $

2,443
5,802   $

2017
3,334

2,268
5,601

% Change
Total

1

8
4

Oper.

8

4

The worldwide growth in 2018 was primarily driven by international operational growth due to higher volumes for the pediatric indication resulting from the second-quarter
2017 launch in China and increased orders associated with Gavi, the Vaccine Alliance, partially offset by

24

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

lower birth cohort and volumes in certain developed markets. The growth in 2018 in the U.S. was primarily due to the pediatric indication partially offset by the continued
decline in revenues for the adult indication due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a
smaller remaining “catch up” opportunity (i.e., the opportunity to reach adults aged 65 years and older who have not been previously vaccinated with Prevnar 13),
compared to the prior-year period.

In 2014, the ACIP voted to recommend Prevnar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which for adults includes
pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the CDC
and U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. As with other
vaccines, the CDC regularly monitors the impact of vaccination and reviews the recommendations. During the October 2018 ACIP meeting, the CDC presented initial data
and indicated formal evaluation of evidence (grading) and a potential vote on the maintenance of the 65 years and older recommendation would likely happen in 2019. A
potential adverse change in the ACIP recommendation would negatively impact future Prevnar 13 revenues. We continue to generate and publish data and communicate
with the ACIP on the burden of pneumococcal disease and Prevnar 13 vaccine effectiveness and safety.

•

Lyrica (EH (revenues from all of Europe, Russia, Turkey, Israel and Central Asia)/IH (revenues from all other geographies)):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
3,594   $

1,375
4,970   $

2017
3,463

1,601
5,065

% Change

Total

Oper.

4

(14)
(2)

(15)

(2)

The operational decline in worldwide Lyrica revenues in 2018 was primarily driven by losses of exclusivity in developed Europe markets and Australia, partially offset by
growth in the U.S. and growth in the orally dissolving tablet formulation in Japan.

The following table provides worldwide revenues for Lyrica in our IH segment, by geography:

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
3,594   $

1,028
4,622   $

2017
3,463

1,048
4,511

% Change

Total

Oper.

4

(2)
2

(3)

2

The operational growth in worldwide Lyrica revenues in our IH segment in 2018 was primarily due to growth in the U.S. and growth in the orally dissolving tablet formulation
in Japan, partially offset by losses of exclusivity primarily in Australia.

The following table provides worldwide revenues for Lyrica in our EH segment, by geography:

Year Ended December 31,

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

  $

  $

2018

—   $

347
347   $

2017
—

553
553

The worldwide operational decline in our EH segment in 2018 was primarily due to losses of exclusivity in developed Europe markets.

•

Ibrance (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
2,922   $

1,196
4,118   $

2017
2,825

300
3,126

% Change

Total

Oper.

—

(37)
(37)

% Change
Total

3

*
32

(39)

(39)

Oper.

*

32

The worldwide operational growth in 2018 reflects continued uptake in international markets, mostly driven by developed Europe, Japan and select emerging markets as
we launched and secured access and reimbursement through 2017 and 2018, as well as the non-recurrence of a one-time price adjustment in 2017 related to finalizing
reimbursement agreements in certain developed Europe markets. The growth in 2018 in the U.S. was primarily due to continued demand growth partially offset by uptake
of competitors and increased rebates. Ibrance maintains class leadership among cyclin-dependent kinase inhibitors in major markets, supported by our scientific/clinical
data and continued positive patient experience.

2018 Financial Report

25

Financial Review
Pfizer Inc. and Subsidiary Companies

• Eliquis alliance revenues and direct sales (IH): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all
development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and
pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus
a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant (NOAC) market; the agents in this class were developed as
alternative treatment options to warfarin in appropriate patients.

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
1,849   $

1,585
3,434   $

2017
1,418

1,105
2,523

% Change
Total

30

43
36

Oper.

40

35

The worldwide operational growth in 2018 was primarily driven by continued increased adoption in non-valvular atrial fibrillation, as well as oral anti-coagulant market share
gain.

• Enbrel (IH, outside the U.S. and Canada):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018

—   $

2,112
2,112   $

2017
—

2,452
2,452

—

(14)
(14)

% Change

Total

Oper.

The worldwide operational decline in 2018 was primarily due to ongoing biosimilar competition in most developed Europe markets, which is expected to continue.

•

Lipitor (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
110   $

1,952
2,062   $

2017
161

1,754
1,915

% Change

Total

(31)

11
8

(14)

(14)

Oper.

9

5

The worldwide operational growth in 2018 was primarily driven by increased demand in China, partially offset by pricing pressures in China, the non-recurrence of favorable
U.S. rebates that occurred in the third quarter of 2017 and generic competition in Japan.

• Xeljanz (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
1,394   $

380
1,774   $

2017
1,133

212
1,345

% Change
Total

23

79
32

Oper.

84

33

The growth in the U.S. in 2018 was primarily driven by increased adoption among rheumatologists, growing awareness among patients and improvements in payer access,
and to a lesser extent, launches of the PsA indication in the first quarter of 2018 and ulcerative colitis indication in the third quarter of 2018.

The operational growth internationally in 2018 was primarily driven by the 2017 approval of the RA indication in certain European markets, as well as continued uptake in
Japan, Canada and emerging markets.

• Chantix/Champix (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
838   $

247
1,085   $

2017
742

255
997

% Change

Total

Oper.

13

(3)
9

(5)

8

The growth in the U.S. in 2018 was primarily due to increased volume, improved patient access and positive price impact. The operational decline in 2018 internationally
was primarily driven by lower demand in South Korea.

26

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

• Sutent (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
357   $

692
1,049   $

2017
374

707
1,081

% Change

Total

Oper.

(4)

(2)
(3)

(3)

(4)

The worldwide operational decline in 2018 was primarily due to lower volumes driven by competitive pressure in the U.S. and key European markets.

• Norvasc (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018

36   $

988
1,024   $

2017
38

888
926

% Change

Total

Oper.

(5)

11
11

9

9

The worldwide operational growth in 2018 was primarily driven by increased demand in China, partially offset by generic competition in Japan and pricing pressures in
China.

•

The Premarin family of products (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
783   $

49
832   $

2017
921

56
977

% Change

Total

Oper.

(15)

(12)
(15)

(12)

(15)

The worldwide operational decline in 2018 was primarily driven by generic competition in the U.S.

• Xtandi alliance revenues (IH): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits
(losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S.
market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi
net sales (recorded in Other (income)/deductions—net ).

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
699   $

—
699   $

2017
590

—
590

% Change
Total

18

—
18

Oper.

—

18

The growth in the U.S. in 2018 was driven by continued growth of Xtandi in castration-resistant prostate cancer as well as reduction in patient assistance program (PAP)
utilization in 2018 compared to 2017.

• Celebrex (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

% Change

2018

2017

Total

Oper.

  $

  $

65   $

621
686   $

164

611
775

(60)

2
(11)

—

(13)

The worldwide operational decline in 2018 was primarily driven by the non-recurrence of the favorable U.S. rebates that occurred in 2017, lower volumes in the U.S., as
well as pricing pressure in Mexico and China, partially offset by increased demand in China.

2018 Financial Report

27

Financial Review
Pfizer Inc. and Subsidiary Companies

•

Inflectra/Remsima (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

2018

2017

  $

  $

259   $

383
642   $

118

301
419

% Change
Total

*

27
53

Oper.

23

50

The worldwide operational growth in 2018 was primarily due to continued uptake in certain channels in the U.S., as well as in developed markets in Europe, partially offset
by pricing pressures in these markets.

Inflectra uptake in the U.S. is being driven by a number of factors, including purchases by closed systems, which value long-term savings over short-term rebating, and
consistent reimbursement in Medicare. To date, reimbursement coverage has been mixed. While we achieved 100% Medicare coverage, in the face of exclusionary
conduct by J&J, we have experienced access challenges among commercial payers where our lower priced product has not received access at parity to the innovator
product. We will continue to work with commercial payers to enable greater access for Inflectra. Additionally, in September 2017, Pfizer filed suit in the U.S. District Court
for the Eastern District of Pennsylvania against J&J alleging that J&J’s exclusionary contracts and other anticompetitive practices concerning Remicade® (infliximab) violate
federal antitrust laws.

• Viagra (EH): Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, are
reported in EH (which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra revenues are reported in EH.

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018
217   $

419
636   $

2017
789

416
1,204

% Change

Total

Oper.

(73)

1
(47)

—

(47)

The decline in the U.S. in 2018 was primarily due to the loss of exclusivity in December 2017.

The relatively flat operational performance in 2018 internationally was primarily driven by increased demand in China offset by lower volumes in Russia and developed
Europe.

• Sulperazon (EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

  $

  $

2018

—   $

613
613   $

2017
—

471
471

% Change
Total

—

30
30

The international operational growth in 2018 was primarily due to increased demand in China.

• Xalkori (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

2018

2017

158   $
366
524   $

223
371
594

  $

  $

% Change

Total

Oper.

(29)
(1)
(12)

Oper.

27

27

(4)

(14)

The worldwide operational decline in 2018 was primarily due to volume declines in the ALK indication across certain developed markets, primarily in the U.S. and certain
markets in developed Europe, due to competitive pressure. The decline was partially offset by a continued increase in diagnostic rates for the ALK gene mutation across
key markets and share in first-line ALK treatment outside the U.S., primarily in certain emerging markets, as well as uptake in treatment of patients with metastatic NSCLC
whose tumors are ROS1-positive.

•

Inlyta (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

% Change

2018

2017

Total

Oper.

  $

  $

119   $

178
298   $

126

213
339

(5)

(16)
(12)

(16)

(12)

The worldwide operational decline in 2018 was primarily due to increased competition across developed markets.

28

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

• Eucrisa (IH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

2018

2017

  $

  $

147   $

—
147   $

67

—
67

% Change
Total

*

—
*

The growth in the U.S. in 2018 was driven by increasing prescriber trial and adoption, enhanced patient awareness and availability of patient access programs.

• Alliance revenues (IH/EH):

(MILLIONS OF DOLLARS)

U.S.

International

Worldwide revenues

Year Ended December 31,

2018

2017

2,576   $

1,263
3,838   $

2,037

890
2,927

  $

  $

% Change
Total

26

42
31

Oper.

—

*

Oper.

37

30

The worldwide operational growth in 2018 was mainly due to increases in Eliquis and Xtandi alliance revenues discussed above.

◦ Bavencio (IH) is being developed and commercialized in collaboration with Merck KGaA. Both companies jointly fund the majority of development and commercialization
costs, and split equally any profits generated from selling any products containing avelumab from this collaboration. Bavencio is currently approved in metastatic MCC in
the U.S., Europe and Japan and selected other markets, as well as in second line treatment of locally advanced or metastatic urothelial carcinoma in the U.S.

See Notes to Consolidated Financial Statements–– Note 18C. Segment, Geographic and Other Revenue Information : Other Revenue Information for additional information
regarding the primary indications or class of the selected products discussed above.

See the “Our Operating Environment—Industry-Specific Challenges—Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Review for
information regarding the expiration of various patent rights.

See Notes to Consolidated Financial Statements— Note 17. Contingencies and Certain Commitments for a discussion of recent developments concerning patent and product
litigation relating to certain of the products discussed above.

PRODUCT DEVELOPMENTS—BIOPHARMACEUTICAL

We continue to invest in R&D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and
alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or
any of our other products in development.

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline
that will deliver value in the near term and over time.

For additional information about our R&D organization, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Strategy—Organizing for
Growth” and “—Description of Research and Development Operations” sections of this Financial Review.

A comprehensive update of Pfizer’s development pipeline was published as of January 29, 2019 and is available at www.pfizer.com/science/drug-product-pipeline. It includes
an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in
Phase 1 and all candidates from Phase 2 through registration.

The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as
well as additional indications and new drug candidates in late-stage development.

PRODUCT

Daurismo (glasdegib)

Lorbrena (lorlatinib)

Talzenna (talazoparib)

Vizimpro (dacomitinib)

Nivestym (filgrastim-aafi) (a)

Xtandi (enzalutamide)

Xeljanz (tofacitinib)

Retacrit (epoetin alfa-epbx) (b)

INDICATION

RECENT FDA APPROVALS

Treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who have
comorbidities that preclude use of intensive induction chemotherapy

Treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one
other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK
inhibitor therapy for metastatic disease

Treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer

First-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19
deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test, which is being developed in
collaboration with SFJ

A biosimilar to Neupogen ®  (filgrastim) for all eligible indications of the reference product

Treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a
collaboration with Astellas

Treatment of adult patients with moderately to severely active ulcerative colitis

A biosimilar to Epogen® and Procrit® (epoetin alfa) for all indications of the reference product

DATE APPROVED

November 2018

November 2018

October 2018

September 2018

July 2018

July 2018

May 2018

May 2018

(a)  Neupogen ® is a registered trademark of Amgen Inc.
(b)   Epogen® is a registered U.S. trademark of Amgen Inc.; Procrit® is a registered U.S. trademark of J&J.

2018 Financial Report

29

Financial Review
Pfizer Inc. and Subsidiary Companies

PRODUCT

Bavencio (avelumab)

PF-06410293 (a)

tafamidis meglumine

tafamidis free acid

PF-05280586 (b)

PF-06439535 (c)

PF-05280014 (d)

PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS

PROPOSED INDICATION

A monoclonal antibody that inhibits PD-L1, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line
treatment of advanced renal cell carcinoma, which is being developed in collaboration with Merck KGaA, Germany

A potential biosimilar to Humira® (adalimumab)

Treatment of transthyretin amyloid cardiomyopathy

Treatment of transthyretin amyloid cardiomyopathy

A potential biosimilar to Rituxan ®  (rituximab)

A potential biosimilar to Avastin ®  (bevacizumab)

A potential biosimilar to Herceptin ®  (trastuzumab)

tafamidis meglumine (e)

Treatment of transthyretin familial amyloid polyneuropathy

DATE FILED*

February 2019

January 2019

January 2019

January 2019

September 2018

August 2018

August 2017

February 2012

* The dates set forth in this column are the dates on which the FDA accepted our submissions.
(a)   Humira ® is a registered trademark of AbbVie Biotechnology Ltd.
(b)   Rituxan ® is a registered trademark of Biogen MA Inc.
(c)  Avastin ® is a registered trademark of Genentech, Inc.
(d)

(e)

Herceptin ® is a registered trademark of Genentech, Inc. In April 2018, we received a “complete response” letter from the FDA with respect to our biologics license application (BLA) for PF-05280014, our proposed
biosimilar to trastuzumab, which was submitted for all indications of the reference product. The FDA highlighted the need for additional technical information, which does not relate to safety or clinical data
submitted in the application. In October 2018, the FDA acknowledged for review our BLA resubmission.
In May 2012, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is
reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a “complete response” letter with respect to this tafamidis NDA. The FDA has requested the completion of a second efficacy study, and
also has asked for additional information on the data within the current tafamidis NDA. Pfizer has completed study B3461028, a global Phase 3 study to support a potential new indication in transthyretin
cardiomyopathy, which includes patients with wild type and variant transthyretin. This study has achieved its primary endpoint, and we are working with the FDA to identify next steps.

PRODUCT

Zirabev (a)

REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN

DESCRIPTION OF EVENT

Application approved in the EU for a biosimilar to Avastin ®  (bevacizumab) for the treatment of metastatic
carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent
NSCLC, advanced and/or metastatic renal cell cancer and persistent, recurrent, or metastatic carcinoma of
the cervix

Vyndaqel (tafamidis free acid)

Application filed in the EU for the treatment of adult symptomatic transthyretin cardiomyopathy

Application filed in Japan for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line
treatment of advanced renal cell carcinoma, which is being developed in collaboration with Merck KGaA,
Germany

DATE APPROVED

DATE FILED*

February 2019

—

—

—

January 2019

January 2019

Bavencio (avelumab)

Vizimpro (dacomitinib)

PF-06410293 (b)

tafamidis meglumine

Xtandi (enzalutamide)

Trastuzumab BS for IV Infusion
60mg/150mg “Pfizer” (c)

Lorbrena (lorlatinib)

PF-05280586 (d)

Xeljanz (tofacitinib)

Trazimera (c)

Infliximab BS for IV Infusion 100mg “Pfizer”
(e)

Xeljanz (tofacitinib)

talazoparib

Xeljanz (tofacitinib)

crisaborole

30

2018 Financial Report

Application approved in Japan for the treatment of patients with locally advanced or metastatic non-small
cell lung cancer with EGFR mutations, which is being developed in collaboration with SFJ

January 2019

—

Application filed in the EU for a potential biosimilar to Humira ®  (adalimumab)

Application filed in Japan for treatment of transthyretin amyloid cardiomyopathy

—

—

November 2018

November 2018

Application approved in the EU for treatment of adult men with high-risk non-metastatic castration-resistant
prostate cancer, which is being developed through a collaboration with Astellas

October 2018

Application approved in Japan for a biosimilar to Herceptin ®  (trastuzumab)

September 2018

Application approved in Japan for the treatment of patients with ALK-positive metastatic non-small cell lung
cancer, previously treated with one or more ALK inhibitor

September 2018

Application filed in the EU for a potential biosimilar to Rituxan ®  (rituximab)

—

August 2018

Application approved in the EU for the treatment of adult patients with moderately to severely active
ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either
conventional therapy or a biologic agent

July 2018

Application approved in the EU for a biosimilar to Herceptin ®  (trastuzumab) for the treatment of human
epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric
or gastroesophageal junction adenocarcinoma

July 2018

Application approved in Japan for a biosimilar to Remicade ®  (infliximab)

Application approved in the EU for Xeljanz in combination with methotrexate for the treatment of active PsA
in adult patients who have had an inadequate response or who have been intolerant to a prior disease-
modifying antirheumatic drug therapy

Application filed in the EU for the treatment of patients with germline BRCA-mutated advanced breast
cancer

July 2018

June 2018

Application approved in Japan for the treatment of ulcerative colitis

May 2018

Application filed in the EU for the treatment of mild-to-moderate atopic dermatitis

—

—

June 2018

May 2018

—

—

—

—

—

—

—

—

Financial Review
Pfizer Inc. and Subsidiary Companies

PRODUCT

DESCRIPTION OF EVENT

DATE APPROVED

DATE FILED*

REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN (cont’d.)

Mylotarg (gemtuzumab ozogamicin)

Application approved in the EU for treatment of patients age 15 years and above with previously untreated,
de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia

April 2018

Bosulif (bosutinib)

dacomitinib (f)

Steglatro (ertugliflozin)

Segluromet (ertugliflozin and metformin)

Steglujan (ertugliflozin and sitagliptin)

Application approved in the EU for the treatment of adults with newly diagnosed chronic phase Philadelphia
chromosome-positive chronic myelogenous leukemia (Ph+ CML), which is being developed in collaboration
with Avillion

April 2018

Application filed in the EU for the first-line treatment of patients with locally advanced or metastatic non-
small cell lung cancer with EGFR activating mutations, which is being developed in collaboration with SFJ

—

March 2018

as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance

Approval in the EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2
diabetes mellitus:
•
or contraindications; and
•
collaboration with Merck

in addition to other medicinal products for the treatment of diabetes, which is being developed in

in patients not adequately controlled on their maximally tolerated dose of metformin alone;
in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the

Approval in the EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2
diabetes mellitus:
•
•
treatment of diabetes; and
•
which is being developed in collaboration with Merck

in patients already being treated with the combination of ertugliflozin and metformin as separate tablets,

when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not

Approval in the EU as an adjunct to diet and exercise to improve glycemic control in adults with type 2
diabetes mellitus:
•
provide adequate glycaemic control; and
•
which is being developed in collaboration with Merck

in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets,

March 2018

March 2018

March 2018

—

—

—

—

—

Xeljanz (tofacitinib)

lorlatinib (PF-06463922)

Application filed in the EU for modified release 11mg tablet for RA

Application filed in the EU for the treatment of patients with ALK-positive metastatic non-small cell lung
cancer, previously treated with one or more ALK inhibitors

—

—

March 2018

February 2018

* For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.
(a)   Avastin ® is a registered trademark of Genentech, Inc.
(b)   Humira ® is a registered trademark of AbbVie Biotechnology Ltd.
(c)  Herceptin ® is a registered trademark of Genentech, Inc.
(d)   Rituxan ® is a registered trademark of Biogen MA Inc.
(e)

Remicade ® is a registered Japan trademark of Janssen. In February 2016, we divested the rights for development and commercialization of PF-06438179, a potential biosimilar to Remicade ® (infliximab) in the 28
countries that form the EEA to Sandoz, which was a condition to the European Commission’s approval of the Hospira transaction. We retain commercialization rights to PF-06438179 in all countries outside of the
EEA.

(f)   In February 2019, the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for dacomitinib, as monotherapy, for the first-line treatment of

adult patients with locally advanced or metastatic NSCLC with EGFR-activating mutations.

2018 Financial Report

31

Financial Review
Pfizer Inc. and Subsidiary Companies

PRODUCT

Bavencio (avelumab)

Bavencio (avelumab)

Bavencio (avelumab)

Bavencio (avelumab)

Bavencio (avelumab)

Bavencio (avelumab)

Daurismo (glasdegib)

Ibrance (palbociclib)

Ibrance (palbociclib)

Ibrance (palbociclib)

Lorbrena (lorlatinib)

Xeljanz (tofacitinib)

Xtandi (enzalutamide)

Xtandi (enzalutamide)

Talzenna (talazoparib)

LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS
FOR IN-LINE AND IN-REGISTRATION PRODUCTS

PROPOSED INDICATION

A monoclonal antibody that inhibits PD-L1, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma,
which is being developed in collaboration with Merck KGaA, Germany (ex-U.S./Japan)

A monoclonal antibody that inhibits PD-L1, in combination with Talzenna (talazoparib), in patients with previously untreated advanced ovarian cancer, which is being
developed in collaboration with Merck KGaA, Germany

A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung
cancer, which is being developed in collaboration with Merck KGaA, Germany

A monoclonal antibody that inhibits PD-L1 for maintenance treatment, in the first-line setting, for patients
with urothelial cancer, which is being developed in collaboration with Merck KGaA, Germany

A monoclonal antibody that inhibits PD-L1 for maintenance treatment of advanced or metastatic gastric/
gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany

A monoclonal antibody that inhibits PD-L1 for treatment of locally advanced squamous cell carcinoma of the
head and neck, which is being developed in collaboration with Merck KGaA, Germany

A smoothened inhibitor, in combination with azacitidine,   for the treatment of acute myeloid leukemia

Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC

Treatment of high-risk early breast cancer, in collaboration with the German Breast Group

Treatment of HR+ early breast cancer, in collaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study Group

A next generation ALK/ROS1 tyrosine kinase inhibitor for the first-line treatment of patients with ALK-positive advanced non-small cell lung cancer

Treatment of ankylosing spondylitis

Treatment of non-metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas

Treatment of metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas

An oral PARP inhibitor, in combination with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer

In February 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that the Bavencio Phase 3 trial in patients with previously treated NSCLC did not meet its
pre-specified primary endpoint. The alliance made the decision to discontinue further development in this indication.

In November 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that the Bavencio Phase 3 trial in platinum-resistant/refractory ovarian cancer did not
meet the pre-specified primary endpoints . We continue to evaluate the detailed results of the trial.

In December 2018, we and our partner Merck KGaA, Darmstadt, Germany, announced that data from a planned interim analysis of the Bavencio Phase 3 trial in previously

untreated advanced ovarian cancer did not support the study’s initial hypothesis, and therefore the alliance made the decision to terminate the trial in alignment with the

independent Data Monitoring Committee.

In February 2019, we announced that the company has taken steps to transition rheumatoid arthritis study patients who were on tofacitinib 10 mg twice daily to tofacitinib 5 mg
twice daily in the FDA post-marketing requirement study A3921133, a study performed in patients considered to be at high risk for certain side effects. This action is being
taken as the result of notification from the tofacitinib Rheumatology Data Safety Monitoring Board of a safety signal regarding the tofacitinib 10 mg twice daily treatment arm in
study A3921133. The 5 mg twice daily dose is the FDA approved dose in the U.S. for adult patients with moderate to severe rheumatoid arthritis. We continue to evaluate the
information.

CANDIDATE

aztreonam-avibactam
(PF-06947387)

NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT

PROPOSED INDICATION

A beta lactam/beta lactamase inhibitor for the treatment of complicated intra-abdominal infections, hospital acquired pneumonia/ventilator associated pneumonia

fidanacogene elaparvovec (PF-06838435)

An investigational gene therapy for the treatment of hemophilia B

PF-06482077

PF-06651600

PF-04965842

PF-06425090

rivipansel (GMI-1070)

somatrogon (PF-06836922)

somatrogon (PF-06836922)

tanezumab

A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae  serotypes
covered by the vaccine in adults 18 years of age and older

A Janus kinase 3 (JAK3) inhibitor for the treatment of patients with moderate to severe alopecia areata

A Janus kinase 1 (JAK1) inhibitor for the treatment of moderate-to-severe atopic dermatitis

A prophylactic vaccine for active immunization to prevent clostridium difficile disease

A pan-selectin inhibitor for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease, which was licensed from GlycoMimetics Inc.

A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO

A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO

An anti-nerve growth factor monoclonal antibody for the treatment of pain, which is being developed in collaboration with Lilly

Additional product-related programs are in various stages of discovery and development.

32

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

COSTS AND EXPENSES

The changes in expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in our operating
results through February 2, 2017 and, therefore, operating results for 2017 include approximately one month of HIS domestic operations and approximately two months of HIS
international operations, while operating results for 2016 reflect 12 months of HIS global operations. Our operating results for 2018 do not reflect any HIS global operations.

Cost of Sales

(MILLIONS OF DOLLARS)

Cost of sales

As a percentage of Revenues

2018 v. 2017

Year Ended December 31,

2018

2017

  $

11,248

  $

11,228

  $

2016

12,322

21.0%

21.4%

23.3%

% Change

18/17
—

17/16

(9)

Cost of sales increased $21 million , or were relatively flat in 2018 , compared to 2017 , primarily due to:

•

increased sales volumes primary related to key products within our product portfolio;

• higher costs across the SIP portfolio, as a result of the complexity of high quality product manufacture across the legacy Hospira plants, which was partially offset by

decreases in other costs across various markets;

• an increase in royalty expenses based on the mix of products sold; and

•

the unfavorable impact of hedging activity on intercompany inventory of $65 million ,

partially offset by:

•

•

•

•

•

lower volumes from the SIP portfolio, in developed markets, primarily due to increased competition across the SIP portfolio and continued legacy Hospira product shortages
in the U.S.;

the non-recurrence of $195 million in inventory losses, overhead costs, and incremental costs related to the period in 2017 during which our Puerto Rico plants were not
operational due to hurricanes;

the favorable impact of foreign exchange of $153 million ;

the non-recurrence of charges related to a product recall that occurred in 2017; and

the favorable impact of the sale of HIS of $35 million.

The decrease in Cost of sales as a percentage of revenues in 2018 , compared to 2017 , was primarily due to all of the factors discussed above, as well as an increase in
alliance revenues, which have no associated cost of sales.

2017 v. 2016

Cost of sales decreased $1.1 billion , or 9% , in 2017 , compared to 2016 , primarily due to:

•

•

•

•

the favorable impact of the sale of HIS global operations (which carried a higher cost of sales than other products) of $561 million;

recognition of synergies related to our cost-reduction/productivity initiatives;

the nonrecurring unfavorable impact of $248 million of acquired Hospira inventory, which is measured at fair value on the acquisition date and was amortized over the turn of
the related inventory;

the favorable impact of foreign exchange of $140 million and the favorable offset of hedging gains of $52 million ; and

• a favorable change in product mix, including an operational decline in the SIP portfolio and the favorability attributed to products that have lost exclusivity,

partially offset by:

• $195 million in inventory losses, overhead costs related to the period in 2017 during which our Puerto Rico plants were not operational, and incremental costs, all of which

resulted from the hurricanes in Puerto Rico.

The decrease in Cost of sales as a percentage of revenues in 2017 , compared to 2016 , was primarily due to all of the factors discussed above, as well as an increase in
alliance revenues, which have no associated cost of sales.

Selling, Informational and Administrative (SI&A) Expenses

(MILLIONS OF DOLLARS)

Year Ended December 31,

2018

2017

Selling, informational and administrative expenses

  $

14,455

  $

14,804

  $

2016

14,844

% Change

18/17
(2)

17/16

—

As a percentage of Revenues

2018 v. 2017

26.9%

28.2%

28.1%

SI&A expenses decreased $350 million , or 2% , in 2018 , compared to 2017 , primarily due to:

•

•

lower advertising, promotional and field force expenses, as well as general and administrative expenses, reflecting the benefits of cost-reduction and productivity initiatives;

the non-recurrence of a $200 million charitable contribution to the Pfizer Foundation;

• decreased investment across several of our key products, primarily Viagra and Enbrel; and

2018 Financial Report

33

Financial Review
Pfizer Inc. and Subsidiary Companies

•

lower healthcare reform expenses as a result of a true up of the prior year amount,

partially offset by:

• additional investment across several of our key products, primarily, Xeljanz, Ibrance, Eucrisa and Prevnar 13/Prevenar 13.

• additional investments in China; and

• a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, of $119 million , in the aggregate, in the first quarter of 2018.

2017 v. 2016

SI&A expenses decreased $40 million , or were relatively flat in 2017 , compared to 2016 , primarily due to:

•

•

•

•

•

the non-recurrence of an allowance for doubtful trade accounts receivable of approximately $265 million, resulting from unfavorable developments with a distributor that was
recorded in the first quarter of 2016 ;

lower advertising, promotional and field force expenses, reflecting the benefits of cost-reduction and productivity initiatives;

lower spending for certain products, primarily Prevnar 13/Prevenar 13;

the favorable impact of the sale of HIS global operations of $135 million; and

lower spending for Viagra due to the loss of exclusivity in December 2017,

offset by:

• additional investment across several of our key products, primarily Eucrisa, Ibrance and Xeljanz, as well as biosimilars, primarily related to the U.S. launch of Inflectra; and

• an increase in charitable contributions, including a $200 million charitable contribution to the Pfizer Foundation, an organization that provides grant and investment funding to

support organizations and social entrepreneurs in an effort to improve healthcare delivery.

Research and Development (R&D) Expenses

(MILLIONS OF DOLLARS)

Research and development expenses

As a percentage of Revenues

2018 v. 2017

Year Ended December 31,

  $

2018

  $

8,006
14.9%

2017

  $

7,683
14.6%

2016

7,892
14.9%

% Change

18/17
4

17/16

(3)

R&D expenses increased $322 million , or 4% , in 2018 , compared to 2017 , primarily due to:

•

•

increased costs associated with our Phase 3 clinical trials related to our JAK1 inhibitor (which was initiated in December 2017) and the C. difficile vaccine program (which
was initiated in March 2017) as well as increased spending for our 20 valent pneumococcal conjugate vaccine candidate;

increased costs associated with the Bavencio program; and

• an increase in the value of the portfolio performance share grants reflecting changes in the price of Pfizer’s common stock, as well as management’s assessment of the

probability that the specified performance criteria will be achieved,

partially offset by:

• decreased spending for biosimilars as several programs have reached completion; and

•

the impact of our decision to end internal neuroscience discovery and early development efforts.

2017 v. 2016

R&D expenses decreased $208 million , or 3% , in 2017 , compared to 2016 , primarily due to:

•

lower expenses of approximately $743 million due to the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016 and the
non-recurrence of its associated close-out costs;

partially offset by:

•

•

•

increased costs associated with our oncology programs, primarily clinical trial spend on Medivation assets;

lower development funding credits of approximately $124 million primarily related to the discontinuation of the global clinical development program for bococizumab in the
fourth quarter of 2016;

increased costs associated with our C. difficile vaccine program, which initiated a Phase 3 clinical study in March 2017;

• an expense of $75 million resulting from our May 2017 agreement with Sangamo to develop and commercialize gene therapy programs for Hemophilia A; and

•

increased costs associated with late stage development programs, including Xtandi, talazoparib and tanezumab.

For additional information on Cost of sales, SI&A and R&D expenses by operating segment, see the “Analysis of Operating Segment Information” section of this Financial
Review.

34

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Amortization of Intangible Assets

(MILLIONS OF DOLLARS)

Amortization of intangible assets

As a percentage of Revenues

  $

Year Ended December 31,

2018

4,893

  $

9.1%

2017

4,758

  $

9.1%

2016

4,056

7.7%

% Change

18/17
3

17/16

17

Amortization of intangible assets increased $135 million , or 3% in 2018 , compared to 2017 , primarily due to amortization expense of approximately $151 million (pre-tax) in
2018 associated with the approval of Xtandi in the U.S. for the treatment of non-metastatic castration-resistant prostate cancer. The U.S. approval resulted in the transfer of
$2.7 billion from an indefinite-lived IPR&D intangible asset to a finite-lived Developed technology rights intangible asset.

Amortization of intangible assets increased $703 million , or 17% , in 2017 , compared to 2016 , primarily due to amortization expense of approximately $797 million (pre-tax) in
2017 associated with the identifiable intangible assets acquired from Medivation and Anacor, partially offset by assets that became fully amortized at the end of their estimated
useful lives and the favorable impact of the February 2017 sale of HIS.

See also Notes to Consolidated Financial Statements— Note 10A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

(MILLIONS OF DOLLARS)

Restructuring charges––acquisition-related costs (a)

  $

Restructuring charges/(credits)––cost reduction initiatives (b)

Restructuring charges

Transaction costs (c)

Integration costs (c)
Restructuring charges and certain acquisition-related costs

Net periodic benefit costs (d)

Total additional depreciation––asset restructuring

Total implementation costs

Year Ended December 31,
2017
105   $

2018

37   $
745
782
1
260
1,044
146
50
194

(75)
30
4
317
351
136
91
227

2016
207
849
1,055
127
383
1,565
159
207
340

2,271

% Change

18/17

(64)

*

*

(62)

(18)

*
8

(45)

(15)

78

17/16

(49)

*

(97)

(97)

(17)

(78)

(15)

(56)

(33)

(65)

Costs associated with acquisitions and cost-reduction/productivity

initiatives (e)

  $

1,434   $

805   $

(a)

(b)

Restructuring charges––acquisition-related costs include employee termination costs, asset impairments and other exit costs associated with business combinations. Charges for 2018 were primarily due to asset
write downs, partially offset by the reversal of previously recorded accruals for employee termination costs related to our acquisition of Hospira. Restructuring charges for 2017 were primarily due to asset write-
downs, partially offset by the reversal of previously recorded accruals for employee termination costs. For 2017 and 2016, restructuring charges––acquisition-related costs were mainly related to our acquisitions of
Hospira and Medivation.
Restructuring (credits)/charges––cost reduction initiatives relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions. For 2018, the charges were primarily related
to employee termination costs and asset write downs. The employee termination costs are associated with our improvements to operational effectiveness as part of the realignment of our organizational structure
effective at the beginning of 2019. For 2017, the credits are mostly related to the reversal of previously recorded accruals for employee termination costs, partially offset by asset write downs.

(c)  For additional information, see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
(d)

For additional information, see Notes to Consolidated Financial Statements— Note 1B . Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 and Note 3.
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
Comprises Restructuring charges and certain acquisition-related costs as well as costs associated with our cost-reduction/productivity initiatives included in Cost of sales , Research and development expenses,
Selling, informational and administrative expenses and/or Other (income)/deductions––net as appropriate. For additional information, see Notes to Consolidated Financial Statements— Note 3. Restructuring
Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
Indicates calculation not meaningful or result is equal to or greater than 100%.

(e)

*

In connection with our acquisition of Hospira in September 2015, we focused our efforts on achieving an appropriate cost structure for the combined company. We achieved
our expected $1 billion of annual cost savings in connection with the Hospira acquisition, 25% more than our initial cost savings target of $800 million . The one-time costs to
generate the savings were approximately $1 billion (not including costs of $215 million for full-year 2015 associated with the return of acquired IPR&D rights), and the majority
of these costs were incurred within the three-year period post-acquisition.

In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our 2014 global commercial structure reorganization,
manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise. Through December 31, 2016,
we incurred $3.1 billion (pre-tax) in total costs for the 2014-2016 program. The cumulative ongoing annual cost savings associated with the 2014-2016 program (but not
including expected cost savings associated with the

2018 Financial Report

35

Financial Review
Pfizer Inc. and Subsidiary Companies

Hospira acquisition), are approximately $3.1 billion. These savings were recognized, for the most part, through the end of 2016. However, savings from costs incurred in the
last half of 2016 largely occurred in 2017.

2017-2019 Initiatives and Organizing for Growth

During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start of our
2019 fiscal year, we would begin operating under our new commercial structure, which reorganizes our operations into three businesses –– Biopharma, a science-based
Innovative medicines business; Upjohn, a global off-patent branded and generic established medicines business; and a Consumer Healthcare business. To operate effectively
in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the functions
that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new
structure and have combined the 2017 to 2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. For the combined programs, to achieve
targeted savings of approximately $1.9 billion , we expect to incur approximately $2.2 billion in costs over the three-year period 2017-2019. Of this amount, we expect
approximately 40% to be related to manufacturing operations, and we expect approximately 20% of the charges to be non-cash. Anticipated savings through 2020 associated
with the Organizing for Growth initiatives of approximately $500 million will be reinvested in our R&D pipeline and in selling and marketing to support our current and recently
launched products and indications. For additional information about these programs and expected and actual total costs, see Notes to Consolidated Financial Statements—
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .

In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity
and the expiration of collaborative arrangements for various products.

Other (Income)/Deductions––Net

(MILLIONS OF DOLLARS)

Other (income)/deductions—net

Year Ended December 31,
2017
1,416   $

2018
2,116   $

  $

2016
3,794

% Change

18/17
49

17/16

(63)

For information about the components of Other (income)/deductions—net , see Notes to Consolidated Financial Statements— Note 4. Other (Income)/Deductions—Net.

See also the “Analysis of Operating Segment Information” section of this Financial Review.

PROVISION/(BENEFIT) FOR TAXES ON INCOME

(MILLIONS OF DOLLARS)

Provision/(benefit) for taxes on income

Effective tax rate on continuing operations

*

Indicates calculation not meaningful or result is equal to or greater than 100%.

2018 v. 2017

  $

Year Ended December 31,

2018

  $

706
5.9%

2017

  $

(9,049)
(73.5)%

2016

1,123
13.4%

% Change

18/17
*

17/16

*

The higher effective tax rate in 2018 compared to 2017 was primarily the result of:

•

the non-recurrence of a $10.7 billion tax benefit recorded in 2017 to reflect the enactment of the TCJA,

partially offset by:

•

•

tax benefits related to the TCJA, including certain current year tax initiatives as well as favorable adjustments to the provisional estimate of the impact of the legislation,
reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC;

the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as

• an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of

certain statutes of limitations.

2017 v. 2016

The lower effective tax rate in 2017 compared to 2016 was primarily the result of:

•

the tax benefits associated with the remeasurement of deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of
foreign subsidiaries associated with the enactment of the TCJA; and

• a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business,

partially offset by:

•

the decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities and the expiration of
certain statutes of limitations; and

36

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

•

the non-recurrence of tax benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims
related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax
position.

For details about discrete elements that impacted our tax provisions, see Notes to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from
Continuing Operations .

Changes in Tax Laws

On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changes
the U.S. corporate income tax system by, among other things, reducing the U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from a
worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries. In accordance
with guidance issued by the SEC we recorded provisional estimates of the legislation in the fourth-quarter 2017. In 2018, we finalized our provisional accounting for the tax
effects of the TCJA based on our best estimates of available information and data, and have reported and disclosed the impacts within the applicable measurement period, in
accordance with guidance issued by the SEC. For additional information, see Notes to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from
Continuing Operations and the “Analysis of Financial Condition, Liquidity and Capital Resources––Selected Measures of Liquidity and Capital Resources—Contractual
Obligations” section of this Financial Review.

On January 23, 2017, the Governor of Puerto Rico signed into law Act No. 3-2017, amending Section 2101 of the Puerto Rico Internal Revenue Code of 1994, which imposes
an excise tax that was effective beginning in 2011 (Act 154). The excise tax is imposed on the purchase of products by multinational corporations and their affiliates from their
Puerto Rico affiliates. As originally adopted, the excise tax was to be in effect from 2011 through 2016 and the tax rate was to decline over time from 4% in 2011 to 1% in 2016.
Act No. 2-2013 extended the excise tax through 2017 and, effective July 1, 2013, increased the tax rate to 4% for all years through 2017. Act No. 3-2017 further extended the
excise tax for all years through 2027 at a rate of 4%. The excise tax has been recorded in Cost of sales and Provision/(benefit) for taxes on income, as appropriate. All
expected impacts in 2019 have been reflected in our financial guidance for 2019.

NON-GAAP FINANCIAL MEASURE (ADJUSTED INCOME)

General Description of Non-GAAP Financial Measure (Adjusted Income)

Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other
performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors’ understanding of our performance is enhanced by
disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the
results of our major operations––the discovery, development, manufacture, marketing and sale of prescription medicines, vaccines and consumer healthcare (OTC) products––
prior to considering certain income statement elements. We have defined Adjusted income as Net income attributable to Pfizer Inc. before the impact of purchase accounting
for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Similarly, we have defined the Adjusted income
components as Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets and Other
(income)/deductions––net each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted
diluted earnings per share as Earnings per common share attributable to Pfizer Inc.––diluted before the impact of purchase accounting for acquisitions, acquisition-related
costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per
share measure are not, and should not be viewed as,substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share.
The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:

• senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;

• our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and

• senior management’s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures. The bonus plans for virtually all
bonus-eligible, non-sales-force employees worldwide, including the Executive Leadership Team members and other members of senior management, are funded from a
pool based on the performance measured by three financial metrics, including Adjusted diluted earnings per share, which is derived from Adjusted income. This metric
accounts for 40% of the bonus pool funding. In addition, Adjusted operating income, which is derived from Adjusted income, is one of the measures utilized to determine
payout for performance share awards.

Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP
and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income
and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of
other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how
management assesses performance.

We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations,
and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without
including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to
other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D
organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis

2018 Financial Report

37

Financial Review
Pfizer Inc. and Subsidiary Companies

and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer’s long-term incentive compensation plans.

See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for 2018 , 2017 and 2016 below.

Purchase Accounting Adjustments

Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These
impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in June 2016) and Medivation (acquired in September 2016), can
include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the
acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily
manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the
Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.

Certain of the purchase accounting adjustments can occur through 20 or more years, but this presentation provides an alternative view of our performance that is used by
management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and
investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which R&D costs previously have been
expensed.

However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This
component of Adjusted income is derived solely from the impacts of the items listed in the first paragraph of this section. We have not factored in the impacts of any other
differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be
representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our
speed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may
have been received differently by our customers. As such, in total, there can be no assurance that our Adjusted income amounts would have been the same as presented had
we discovered and developed the acquired intangible assets.

Acquisition-Related Costs

Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because
these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For
additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset
acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in connection
with a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring a fully integrated set of activities.
For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a
business combination) can be viewed differently from those costs incurred in other, more normal, business contexts.

The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts typically ending within three
years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities
can be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the closure of excess facilities can take several years, as all manufacturing
changes are subject to extensive validation and testing and must be approved by the FDA and/or other global regulatory authorities.

Discontinued Operations

Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such
operations. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines for strategic fit with our operations, we do
not build or run our businesses with the intent to sell them. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure
for the compensation in respect of the restated periods, but are presented for consistency across all periods.

Certain Significant Items

Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an
individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to
predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs
stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost
productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances
specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition.
Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our
normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be
included as certain

38

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

significant items would be a major non-acquisition-related restructuring charge and associated implementation costs; amounts related to certain disposals of businesses,
products or facilities that do not qualify as discontinued operations under U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax
positions; the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes to Consolidated Financial Statements— Note 5A. Tax
Matters: Taxes on Income from Continuing Operations or charges related to certain legal matters, such as certain of those discussed in Notes to Consolidated Financial
Statements— Note 17A. Contingencies and Certain Commitments : Legal Proceedings and in Part II, Item 1, “Legal Proceedings” in our Quarterly Reports on Form 10-Q.
Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain
significant items.

Beginning In 2019, we will exclude the gains and losses from equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control
and cannot predict with any level of certainty and because we do not believe that including these gains and losses assists investors in understanding our business or is
reflective of our core operations and business. For example, we contributed assets related to our allogeneic CAR T therapy to Allogene and received equity securities. We will
restate our Adjusted income and Adjusted diluted EPS for prior periods for consistency with our 2019 presentation.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items

IN MILLIONS, EXCEPT PER COMMON SHARE DATA

Revenues

Cost of sales

Selling, informational and administrative

expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-

related costs

Other (income)/deductions––net

Income from continuing operations before
provision/(benefit) for taxes on income

Provision/(benefit) for taxes on income (b)

Income from continuing operations

Discontinued operations––net of tax

Net income attributable to noncontrolling

interests

Net income attributable to Pfizer Inc.

Earnings per common share attributable to

Pfizer Inc.––diluted

GAAP
Reported

  $

53,647   $
11,248

14,455
8,006
4,893

1,044
2,116

11,885
706
11,179
10

36
11,153

1.87

Purchase
Accounting
Adjustments (a)

Acquisition-
Related Costs (a)

Discontinued
Operations (a)

Certain
Significant
Items (a)

Non-GAAP
Adjusted

2018

—   $
3

—   $
(10)

—   $
—

2
3
(4,612)

—
(182)

4,786
915
3,871
—

—
3,871

0.65

(2)
—
—

(299)
(7)

318
54
264
—

—
264

0.04

—
—
—

—
—

—
—
—
(10)

—
(10)

—

—   $

(110)

(222)
(47)
—

(745)
(3,181)

4,305
1,625
2,680
—

—
2,680

0.45

53,647

11,130

14,232

7,962

281

—

(1,253)

21,294

3,301

17,994

—

36

17,958

3.00

2018 Financial Report

39

Financial Review
Pfizer Inc. and Subsidiary Companies

IN MILLIONS, EXCEPT PER COMMON SHARE DATA

Revenues

Cost of sales

Selling, informational and administrative

expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-

related costs

Other (income)/deductions––net

Income from continuing operations before
provision/(benefit) for taxes on income

Provision/(benefit) for taxes on income (b)

Income from continuing operations

Discontinued operations––net of tax

Net income attributable to noncontrolling

interests

Net income attributable to Pfizer Inc.

Earnings per common share attributable to

Pfizer Inc.––diluted

GAAP
Reported

  $

52,546   $
11,228

14,804
7,683
4,758

351
1,416

12,305
(9,049)
21,353
2

47
21,308

3.52

Purchase
Accounting
Adjustments (a)

Acquisition-
Related Costs (a)

Discontinued
Operations (a)

Certain
Significant
Items (a)

Non-GAAP
Adjusted

2017

—   $
(47)

—   $
(39)

—   $
—

(16)
8
(4,565)

—
(138)

4,758
1,331
3,426
—

—
3,426

0.57

—
—
—

(426)
9

456
173
283
—

—
283

0.05

2016

—
—
—

—
—

—
—
—
(2)

—
(2)

—

—   $

(363)

(299)
(38)
—

75
(2,020)

2,647
11,577
(8,930)
—

—
(8,930)

(1.47)

52,546

10,778

14,489

7,653

193

—

(733)

20,166

4,033

16,132

—

47

16,085

2.65

Acquisition-
Related Costs (a)

Discontinued
Operations (a)

Certain
Significant
Items (a)

Non-GAAP
Adjusted

IN MILLIONS, EXCEPT PER COMMON SHARE DATA

Revenues

Cost of sales

Selling, informational and administrative

expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-

related costs

Other (income)/deductions––net

Income from continuing operations before
provision/(benefit) for taxes on income

Provision/(benefit) for taxes on income (b)

Income from continuing operations

Discontinued operations––net of tax

Net income attributable to noncontrolling

interests

Net income attributable to Pfizer Inc.

GAAP
Reported

  $

52,824   $
12,322

Purchase
Accounting
Adjustments (a)

—   $

(295)

14,844
7,892
4,056

1,565
3,794

8,351
1,123
7,229
17

31
7,215

(3)
3
(3,928)

—
39

4,185
1,248
2,937
—

—
2,937

—   $
(7)

—
—
—

(716)
(62)

785
104
682
—

—
682

—   $
—

—   $

(397)

—
—
—

—
—

—
—
—
(17)

—
(17)

—

(89)
(34)
—

(849)
(4,519)

5,888
1,943
3,944
—

—
3,944

0.64

52,824

11,622

14,751

7,861

128

—

(748)

19,210

4,418

14,792

—

31

14,761

2.40

Earnings per common share attributable to

Pfizer Inc.––diluted

1.17
(a)  For details of adjustments, see “Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income” below.
(b)

0.48

0.11

The effective tax rate on Non-GAAP Adjusted income was 15.5% in 2018 , 20.0% in 2017 and 23.0% in 2016 . The decrease in the effective tax rate on Non-GAAP Adjusted income for 2018 compared with 2017
was primarily due to tax benefits associated with the December 2017 enactment of the TCJA, a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of
business, as well as an increase in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of
limitations. The decline in the effective tax rate on Non-GAAP Adjusted income in 2017 compared to 2016 was primarily due to tax benefits associated with the enactment of the TCJA, primarily reflecting the
remeasurement of U.S. deferred tax liabilities on deemed repatriated post-1986 earnings of foreign subsidiaries that were accrued during 2017, as well as a favorable change in the jurisdictional mix of earnings as
a result of operating fluctuations in the normal course of business, partially offset by a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various
foreign tax authorities, and the expiration of certain statutes of limitations.

40

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income

Adjusted income, as shown above, excludes the following items:

(MILLIONS OF DOLLARS)

Purchase accounting adjustments

Amortization, depreciation and other (a)

Cost of sales

Total purchase accounting adjustments—pre-tax

Income taxes (b)

Total purchase accounting adjustments—net of tax

Acquisition-related costs

Restructuring charges (c)

Transaction costs (c)

Integration costs (c)

Net periodic benefit costs/(credits) other than service costs (d)

Additional depreciation—asset restructuring (e)

Total acquisition-related costs—pre-tax

Income taxes (f)

Total acquisition-related costs—net of tax

Discontinued operations

Total discontinued operations—net of tax, attributable to Pfizer Inc. (g)

Certain significant items

Restructuring charges/(credits) –– cost reduction initiatives (h)

Implementation costs and additional depreciation—asset restructuring (i)

Certain legal matters, net (j)

Loss on sale and impairment on remeasurement of HIS net assets (j)

Certain asset impairments (j)

Business and legal entity alignment costs (j)

Net losses on early retirement of debt (i)

Other (k)

Total certain significant items—pre-tax

Income taxes (l)

Total certain significant items—net of tax

  $

Year Ended December 31,
2017

2018

4,789   $
(3)
4,786
(915)
3,871

4,711   $
47
4,758
(1,331)
3,426

37
1
260
7
12
318
(54)
264

(10)

745
232
157
(1)
3,101
4
3
65
4,305
(1,625)
2,680

105

4
317
(9)
39
456
(173)
283

(2)

(75)
279
237
55
379
71
999
700
2,647
(11,577)
(8,930)

Total purchase accounting adjustments, acquisition-related costs, discontinued operations and

certain significant items—net of tax, attributable to Pfizer Inc.

  $

6,805   $

(5,223)   $

2016

3,890

295

4,185

(1,248)

2,937

207

127

383

62

7

785

(104)

682

(17)

849

540

494

1,712

1,426

261

312

294

5,888

(1,943)

3,944

7,546

(a)  Included primarily in Amortization of intangible assets .
(b)

(c)

(d)

Included in Provision/(benefit) for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying
that jurisdiction’s applicable tax rate. Income taxes recorded in 2017 do not reflect any changes associated with the enactment of the TCJA. These changes resulting from the TCJA have been reflected in the line
item, Certain significant items “Income taxes”.
Included in Restructuring charges and certain acquisition-related costs . Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations.
Restructuring charges in 2018 were primarily due to asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs related to our acquisition of Hospira.
Restructuring charges for 2017 were primarily due to asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs. For 2017 and 2016, restructuring charges––
acquisition-related costs were mainly related to our acquisitions of Hospira and Medivation. Transaction costs represent external costs for banking, legal, accounting and other similar services. Integration costs
represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. For additional information,
see Notes to Consolidated Financial Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
Amounts for the 2017 and 2016 represent the net periodic benefit costs/(credits), excluding service costs, reclassified to Other (income)/deductions––net as a result of the retrospective adoption of a new
accounting standard in the first quarter of 2018. For additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of New
Accounting Standards in 2018 . The credits for full-year 2017 included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the
remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan.

(e)  Primarily included in C ost of sales. Represents the impact of changes in estimated useful lives of assets involved in restructuring actions related to acquisitions .
(f)  Included in Provision/(benefit) for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying

that jurisdiction’s applicable tax rate. Income taxes recorded in 2017 do not reflect any changes

2018 Financial Report

41

Financial Review
Pfizer Inc. and Subsidiary Companies

associated with the December 2017 enactment of the TCJA. These changes resulting from the TCJA have been reflected in Certain significant items “Income taxes”. 2016 also includes an unfavorable impact of

the remeasurement of certain deferred tax liabilities resulting from our plant network restructuring activities.
(g)  Included in Discontinued operations––net of tax. For all years presented, represents post-close adjustments.
(h)

Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in Restructuring charges and certain acquisition-related costs (see Notes
to Consolidated Financial Statements— Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives ). For 2018, the charges were primarily related to
employee termination costs and asset write downs. The employee termination costs are associated with our improvements to operational effectiveness as part of the realignment of our organizational structure
effective at the beginning of 2019. For 2017, the credits were mostly related to the reversal of previously recorded accruals for employee termination costs, partially offset by asset write downs.

(i)  Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Other Costs Associated with

Acquisitions and Cost-Reduction/Productivity Initiatives ). For 2018 , included in Cost of sales ( $121 million ), Selling, informational and administrative expenses ( $72 million ) and Research and development
expenses ( $39 million ). For 2017 , included in Cost of sales ( $170 million ), Selling, informational and administrative expenses ( $71 million ) and Research and development expenses ( $38 million ). For 2016 ,
primarily included in Cost of sales ( $423 million ), Selling, informational and administrative expenses ( $81 million ) and Research and development expenses ( $32 million ).

(j)  Included in Other (income)/deductions—net (see the Notes to Consolidated Financial Statements— Note 4. Other (Income)/Deductions—Net ).
(k)

For 2018 , included in Cost of sales ( $10 million income), Selling, informational and administrative expenses ( $151 million ), Research and development expenses ( $8 million ) and Other (income)/deductions––
net ( $83 million income). For 2017 , included in Cost of sales ( $193 million ), Selling, informational and administrative expenses ( $229 million ) and Other (income)/deductions––net ( $278 million ). For 2016 ,
primarily included in Cost of sales ( $27 million income), Selling, informational and administrative expenses ( $8 million ) and Other (income)/deductions––net ( $311 million ). For 2018 , includes, among other
things, (i) a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development
of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, (ii) a $119 million charge, in the aggregate, in Selling, informational and administrative
expenses for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December
2017 enactment of the legislation commonly referred to as the TCJA, (iii) $59 million of incremental costs associated with the design, planning and implementation of the new organizational structure, effective in
the beginning of 2019, and primarily include consulting, legal, tax, and advisory services and (iv) a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a result of the contribution of our
allogeneic chimeric antigen receptor T cell therapy development program assets in connection with our contribution agreement entered into with Allogene (see Notes to Consolidated Financial Statements— Note
2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held
Investment : Divestitures ). For 2017 includes, among other things, (i) a charitable contribution to the Pfizer Foundation of $200 million , which is included in Selling, i nformational and administrative expenses ; (ii)
$195 million in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and
are included in Cost of sales ; (iii) an $81 million loss related to the sale of our 49% equity share in Hisun Pfizer, which is included in Other (income)/deductions––net; and (iv) a net loss of $30 million related to the
sale of our then 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest, which is included in Other (income)/deductions––net . For 2016,
includes, among other things, $150 million paid to Allergan for reimbursement of Allergan's expenses associated with the terminated transaction, which is included in Other (income)/deductions—net .

(l)  Included in Provision/(benefit) for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying
that jurisdiction’s applicable tax rate. The amount in 2018 was favorably impacted primarily by tax benefits related to the TCJA, including certain current year tax initiatives as well as adjustments to the provisional
estimate of the legislation, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC. The amount in 2017 was favorably impacted by tax benefits primarily
associated with the remeasurement of deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries associated with the TCJA. The
amount in 2016 was favorably impacted by benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix,
which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position. See Notes to Consolidated Financial Statements—
Note 5A. Tax Matters : Taxes on Income from Continuing Operations .

ANALYSIS OF OPERATING SEGMENT INFORMATION

The following tables and associated notes provide additional information about the performance of our two operating segments for the periods presented—the IH segment and
the EH segment. For additional information about each operating segment, see the “Our Strategy –– Commercial Operations” section of this Financial Review and Notes to
Consolidated Financial Statements— Note 18. Segment, Geographic and Other Revenue Information .

As described in Notes to Consolidated Financial Statements— Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation , acquisitions and
divestitures have impacted our results of operations in 2017 and 2016 .

42

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our consolidated statements of income:

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

% of revenue

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets
Restructuring charges and certain acquisition-

related costs

Other (income)/deductions––net
Income/(loss) from continuing operations before

provision/(benefit) for taxes on income

Innovative Health
(IH) (a)

Essential Health
(EH) (a)

  $

33,426

  $

20,221

  $

4,140
12.4%

6,961

2,866

219

—

(1,017)

6,056
29.9%

2,612

937

62

—

(158)

2018

Other (b)

—   $

934

*
4,659
4,160
—

—
(78)

Non-GAAP
Adjusted (c)

Reconciling
Items (d)

GAAP
Reported

  $

53,647

11,130

20.7%

14,232

7,962

281

—

(1,253)

—   $

118

*
223
43
4,612

1,044
3,369

53,647

11,248

21.0%

14,455

8,006

4,893

1,044

2,116

  $

20,258

  $

10,712

  $

(9,676)   $

21,294

  $

(9,409)   $

11,885

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

% of revenue

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets
Restructuring charges and certain acquisition-related

costs

Other (income)/deductions––net
Income/(loss) from continuing operations before

provision/(benefit) for taxes on income

Innovative
Health (IH) (a)

Essential Health
(EH) (a)

  $

31,422

  $

21,124

  $

4,091
13.0%

6,727

2,544

129

—

(878)

5,937
28.1%

2,898

1,052

65

—

(287)

2017

Other (b)

—   $

750

*
4,864
4,057
—

—
432

Non-GAAP
Adjusted (c)

Reconciling
Items (d)

GAAP
Reported

  $

52,546

10,778

20.5%

14,489

7,653

193

—

(733)

—   $

449

*
316
31
4,565

351
2,150

52,546

11,228

21.4%

14,804

7,683

4,758

351

1,416

  $

18,809

  $

11,460

  $

(10,104)   $

20,166

  $

(7,861)   $

12,305

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

% of revenue

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets
Restructuring charges and certain acquisition-related

costs

Other (income)/deductions––net
Income/(loss) from continuing operations before

provision/(benefit) for taxes on income

Innovative
Health (IH) (a)

Essential Health
(EH) (a)

Other (b)

Non-GAAP
Adjusted (c)

Reconciling
Items (d)

GAAP
Reported

2016

  $

29,197

  $

23,627

  $

—   $

4,049
13.9%

6,957

2,921

102

—

(998)

6,272
26.5%

3,296

1,237

26

—

(269)

1,301

*
4,499
3,703
—

—
519

  $

52,824

11,622

22.0%

14,751

7,861

128

—

(748)

—   $

699

*
92
31
3,928

1,565
4,543

  $

16,166

  $

13,065

  $

(10,021)   $

19,210

  $

(10,858)   $

52,824

12,322

23.3%

14,844

7,892

4,056

1,565

3,794

8,351

Indicates calculation not meaningful or result is equal to or greater than 100%.

*
(a)  Amounts represent the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment.

The following organizational change impacted our operating segments in 2018:
Effective in the first quarter of 2018, certain costs for Pfizer’s StratCO group, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated.
StratCO costs primarily include headcount costs, vendor costs and data costs largely in support of Pfizer’s commercial operations. The majority of the StratCO costs reflect additional amounts that our operating
segments would have incurred had each segment operated as a standalone company during the periods presented. The reporting change was made to streamline accountability and speed decision making. In
2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs to conform to the
current period presentation, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other
unallocated costs to conform to the current period presentation.

2018 Financial Report

43

Financial Review
Pfizer Inc. and Subsidiary Companies

(b)  Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below) that are managed outside of our two operating segments and includes the following:

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net
Loss from continuing operations before provision/(benefit) for taxes on

income

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net
Loss from continuing operations before provision/(benefit) for taxes on

income

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net
Loss from continuing operations before provision/(benefit) for taxes on

income

  Other Business Activities

2018

WRD (i)

GPD (ii)

Corporate (iii)

Other
Unallocated (iv)

Total

  $

—   $
—
—
2,341
—
—
(148)

—   $
—
—
788
—
—
(5)

—   $

—   $

168
3,958
957
—
—
13

767
701
73
—
—
62

—

934

4,659

4,160

—

—

(78)

  $

(2,193)   $

(784)   $

(5,096)   $

(1,603)

  $

(9,676)

2017

Other Business Activities

WRD (i)

GPD (ii)

Corporate (iii)

Other
Unallocated (iv)

Total

  $

—   $
—
—
2,402
—
—
(42)

—   $
—
(1)
783
—
—
(5)

—   $
32
4,159
823
—
—
439

—   $

718
706
50
—
—
40

—

750

4,864

4,057

—

—

432

  $

(2,361)   $

(777)   $

(5,452)   $

(1,514)

  $

(10,104)

Other Business Activities

2016

WRD (i)

GPD (ii)

Corporate (iii)

Other
Unallocated (iv)

Total

  $

—   $
—
—
2,359
—
—
(28)

—   $
—
—
690
—
—
(2)

—   $

—   $

198
3,957
612
—
—
681

1,103
542
41
—
—

(131)

—

1,301

4,499

3,703

—

—

519

  $

(2,332)   $

(688)   $

(5,448)   $

(1,554)

  $

(10,021)

(ii)

(i)  WRD—the R&D expenses managed by our WRD organization, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects
to the IH segment via the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization
also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is
also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.
GPD––the costs associated with our GPD organization, which is generally responsible for the operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in
the Innovative portfolio. GPD also provides technical support and other services to Pfizer R&D projects.
Corporate—the costs associated with Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs,
compliance, and worldwide procurement), the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for
healthcare quality improvement and medical education, and partnerships with global public health and medical associations, as well as certain compensation and other corporate costs, such as interest income
and expense, and gains and losses on investments. Effective in the first quarter of 2018, certain costs for StratCO, which were previously reported in the operating results of our operating segments and
Corporate, are reported in Other Unallocated. For additional information, see note (iv) below.
We recognized a net $13 million loss in 2018 in Cost of sales primarily related to euro-denominated losses, partially offset by Japanese yen denominated gains on forward-exchange contracts designated as
cash flow hedges of a portion of our foreign exchange-denominated intercompany forecasted inventory sales. We recognized a $52 million gain in 2017 as an offset to Cost of sales related to foreign currency
forward-exchange contracts designated as cash flow

(iii)

44

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

(iv)

hedges of a portion of our foreign exchange-denominated intercompany forecasted inventory sales. For additional information, see Notes to Consolidated Financial Statements–– Note 7F. Financial
Instruments : Derivative Financial Instruments and Hedging Activities .
Other Unallocated—other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business
unit (segment) management does not manage these costs (which include manufacturing variances associated with production). In connection with the StratCO reporting change, in 2017 we reclassified
approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs to conform to the current period
presentation, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated
costs to conform to the current period presentation.

For information purposes only, the following tables present reconciliations of our segment operating results to segment operating results including estimated Other costs
generally associated with each segment for 2018. While we do not manage our segments or have performance goals under such an allocated manner, we believe that some
investors may find this information useful in their analyses.

The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have
incurred had each segment operated as a standalone company during the period presented.

For information purposes only, for 2018 , we estimate that Other costs, as described above, for combined WRD and GPD costs of $3.0 billion , and combined Corporate and
Other Unallocated costs of $5.8 billion after excluding (i) net interest-related expense not attributable to an operating segment included in Corporate (approximately $1.0 billion
in Other (income)/deductions––net ); and (ii) net income from investments and other assets not attributable to an operating segment included in Corporate (approximately $72
million in Other (income)/deductions––net ), are generally associated with our operating segments, as follows:

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

  $

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net

Income/(loss) from continuing operations before

provision/(benefit) for taxes on income

(MILLIONS OF DOLLARS)

Revenues

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net

Income/(loss) from continuing operations before provision/(benefit)

for taxes on income

  Estimated Other Costs Associated with IH (ii)

2018

Innovative Health
Non-GAAP
Adjusted (i), (iii)

Estimated WRD/GPD (ii)

Estimated
Corporate/Other
Unallocated (ii)

Innovative Health with
Estimated Other Costs
Associated with
Innovative Health
Non-GAAP Adjusted (ii),   (iii)

33,426
4,140
6,961
2,866
219
—

(1,017)

20,258

—
—
3,097

(152)

(2,945)

  $

142
2,708
938

(4)

(672)

(3,112)

33,426

4,282

9,669

6,901

215

—

(1,841)

14,201

Estimated Other Costs Associated with EH (ii)

2018

Essential Health
Non-GAAP
Adjusted (i), (iii)

Estimated WRD/GPD (ii)

Estimated
Corporate/Other
Unallocated (ii)

Essential Health with Estimated
Other Costs Associated with
Essential Health
Non-GAAP Adjusted (ii), (iii)

  $

20,221
6,056
2,612
937
62
—

(158)

10,712

—
—
32

—

(32)

  $

792
1,952
92
4

(192)

(2,648)

20,221

6,849

4,563

1,061

66

—

(351)

8,032

(i)   Amount represents the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment. See note (a) above for

(ii)

more information.
Represents costs not assessed to an operating segment, as business unit (segment) management does not manage these costs. For a description of these other costs and business activities, see note (b)
above.
• WRD/GPD –– The information provided for WRD and GPD was substantially all derived from our estimates of the costs incurred in connection with the R&D projects associated with each operating segment.
• Corporate/Other Unallocated –– The information provided for Corporate and Other Unallocated was derived mainly using proportional allocation methods based on global, regional or country revenues or

global, regional or country headcount, as well as certain cost metrics, as appropriate, such as those derived from R&D and manufacturing costs, and, to a lesser extent, specific identification and estimates.
Management believes that the allocations of Corporate and Other Unallocated costs are reasonable.
The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment
operated as a standalone company during the period presented.

(iii)  See note (c) below for an explanation of our Non-GAAP Adjusted financial measure.

(c)  See the “Non-GAAP Financial Measure (Adjusted Income)” section of this Financial Review for a definition of these “Adjusted Income” components.

2018 Financial Report

45

Financial Review
Pfizer Inc. and Subsidiary Companies

(d)

Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such
as restructuring or legal charges), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see
the “Non-GAAP Financial Measure (Adjusted Income)” section of this Financial Review.

Innovative Health Operating Segment

2018 vs. 2017

IH Revenues increase d $2.0 billion , or 6% , to $33.4 billion , reflecting an operational increase of $1.9 billion , or 6% , and a de minimis impact of foreign exchange of $130
million .

The following graph illustrates the components of the increase in IH Revenues :

* LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.

The following provides an analysis of the increase in worldwide IH Revenues :

(MILLIONS OF DOLLARS)

IH Revenues , 2017

Operational growth/(decline):

Continued growth from certain key brands (a)
Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed

Europe

Growth in our Consumer Healthcare business across all markets
Negative impact of the loss of exclusivity of Viagra in the U.S. in December 2017 and the resulting shift in the reporting of U.S. and Canada Viagra

revenues from IH to EH in 2018

Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition

Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed Europe

Other operational factors, net

Operational growth, net

Favorable impact of foreign exchange
IH Revenues  increase

IH Revenues , 2018

  $

31,422

2,815

195

107

(823)

(350)

(100)

31

1,873

130

2,004

33,426

  $

(a)

Certain key brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi, Lyrica––IH and Chantix/Champix. See the “Analysis of the Consolidated Statements of Income––Revenues––Selected
Product Discussion" section of this Financial Review for product analysis information.

Total IH revenues from emerging markets increased $507 million , or 12% , to $4.9 billion in 2018 from $4.4 billion in 2017, reflecting a 16% operational increase . Foreign
exchange had an unfavorable impact of 5% on total IH revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13,
Ibrance and Eliquis.

Costs and Expenses

• Cost of sales as a percentage of Revenues decrease d 0.6 percentage points, primarily driven by the favorable impact of foreign exchange.

• The increase in Cost of sales of 1% was primarily driven by an increase in royalty expenses based on the mix of products sold and an increase in sales volumes for various

key products within our product portfolio, partially offset by the favorable impact of foreign exchange.

• The increase in Selling, informational and administrative expenses of 3% was primarily driven by additional investment across several of our key products, primarily Xeljanz,
Ibrance, Eucrisa and Prevnar 13/Prevenar 13 (pediatric indication), partially offset by a reduction related to Viagra as a result of the reclassification of Viagra IH to EH and
lower healthcare reform expenses.

• The increase in Research and development expenses of 13% primarily reflects:

◦

increased costs associated with the Bavencio program; and

46

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

◦

increased costs associated with our Phase 3 clinical trials related to our JAK1 inhibitor (which was initiated in December 2017) and the C. difficile vaccine program (which
was initiated in March 2017) as well as increased spending for our 20 valent pneumococcal conjugate vaccine candidate.

• The favorable change in Other (income)/deductions––net primarily reflects a $116 million increase in income from collaborations, out-licensing arrangements and sales of

compound/product rights, partially offset by a $13 million decrease in dividend income from our investment in ViiV.

2017 vs. 2016

IH Revenues increase d $2.2 billion , or 8% , to $31.4 billion , reflecting an operational increase of $2.3 billion , or 8% , partially offset by a de minimis impact of foreign
exchange of $80 million .

The following graph illustrates the components of the increase in IH Revenues :

* LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.

The following provides an analysis of the increase in IH Revenues :

(MILLIONS OF DOLLARS)

IH Revenues,  2016

Operational growth/(decline):

  $

29,197

Continued growth from key brands (a)
Ibrance global growth: U.S. revenues increased primarily due to continued strong uptake in the metastatic breast cancer setting. International

revenues increased operationally, but were negatively impacted by a one-time price adjustment to 2017 revenues related to finalizing
reimbursement agreements in certain developed Europe markets.

Increase in Xtandi alliance revenues in the U.S. (September 2016 acquisition of Medivation)

Lower revenues for Enbrel primarily in developed Europe markets due to continued biosimilar competition

Lower revenues for Viagra in the U.S. due to generic competition that began in December 2017
Decline in Prevnar 13/Prevenar 13 revenues. U.S. revenues decreased primarily due to the expected decline in revenues for the adult indication in
the U.S. due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a smaller
remaining “catch up” opportunity compared to 2016, partially offset by growth from the pediatric indication. International revenues increased
primarily due to the favorable overall impact of timing and increased volume associated with government purchases in certain emerging markets
for the pediatric indication compared with prior year, as well as from the inclusion of Prevenar 13 in additional national immunization programs in
certain emerging markets for the adult and pediatric indications in the fourth of quarter 2017.

Other operational factors, net

Operational growth, net

Unfavorable impact of foreign exchange

IH Revenues  increase

IH Revenues, 2017
(a)  Key brands represent Eliquis (globally), as well as Xeljanz and Lyrica –– IH (both primarily in the U.S.).

  $

1,608

993

450

(448)

(359)

(108)

169

2,305

(80)

2,225

31,422

Total IH revenues from emerging markets increased $656 million, or 18%, to $4.4 billion in 2017 from $3.7 billion in 2016, reflecting an 18% operational increase. Foreign
exchange had a de minimis impact on total IH revenues from emerging markets.

2018 Financial Report

47

Financial Review
Pfizer Inc. and Subsidiary Companies

Costs and Expenses

• Cost of sales as a percentage of Revenues decrease d 0.9 percentage points primarily driven by a favorable change in product mix, including an increase in alliance

revenues, which have no associated cost of sales, partially offset by an increase in royalty expense, mostly related to Ibrance.

• The increase in Cost of sales of 1% was primarily driven by an increase in royalty expense, mostly related to Ibrance, partially offset by a favorable change in product mix.

• The decrease in Selling, informational and administrative expenses of 3% was primarily driven by the non-recurrence of an allowance for doubtful trade accounts receivable,
resulting from unfavorable developments with a distributor that was recorded in the first quarter 2016, lower spending for certain products, primarily Prevnar 13/Prevenar 13
and Viagra (which lost exclusivity in the U.S. in December 2017), partially offset by additional investment across several of our key products, primarily Eucrisa, Ibrance and
Xeljanz.

• The decrease in Research and development expenses of 13% primarily reflects:

◦

the discontinuation of the global clinical development program for bococizumab in the fourth quarter of 2016 and the non-recurrence of its associated close-out costs,

partially offset by increased costs associated with:

◦ our oncology programs, including clinical trial spend on Medivation assets;

◦ our C. difficile vaccine program, which initiated a Phase 3 clinical study in March 2017;

◦ our tanezumab development program; and

◦ an expense of $28 million, representing IH’s portion of the $75 million expense resulting from our May 2017 agreement with Sangamo to develop and commercialize gene

therapy programs for Hemophilia A.

• The unfavorable change in Other (income)/deductions––net primarily reflects:

◦

lower royalty income for Enbrel of $470 million, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for
Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013); and

◦ a $51 million decrease in Prezista royalties,

partially offset by:

◦ a $256 million increase in dividend income from our investment in ViiV; and

◦ a $176 million increase in Xtandi royalty income.

Essential Health Operating Segment

2018 vs. 2017

EH Revenues decrease d $903 million, or 4% to $20.2 billion , reflecting an operational decrease of $1.1 billion, or 5% , partially offset by the favorable impact of foreign
exchange of $180 million, or 1%.

The following graph illustrates the components of the decrease in EH Revenues :

* LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.

48

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

The following provides an analysis of the decrease in worldwide EH Revenues :

(MILLIONS OF DOLLARS)

EH Revenues , 2017

Operational growth/(decline):

Decline from the Peri-LOE Products portfolio, driven by lower revenues in developed markets (excluding Viagra EH), primarily due to expected

declines in Lyrica in developed Europe and Celebrex and Pristiq in the U.S. due to generic competition

Impact from the SIP portfolio, driven by lower revenues in developed markets, primarily due to increased competition across the portfolio and

continued legacy Hospira product shortages in the U.S.

Impact from the LEP portfolio, driven by lower revenues in developed markets, primarily as a result of industry-wide pricing challenges in the U.S.

and generic competition

Impact on financial results for the sale of HIS in February 2017. 2018 does not reflect any contribution from HIS global operations, compared to

approximately one month of HIS domestic operations and approximately two months of HIS international operations in 2017

Positive impact of Viagra, mostly driven by the shift in the reporting of U.S. and Canada Viagra revenues from IH to EH in 2018 (due to the loss of
exclusivity of Viagra in the U.S. in December 2017), partially offset by lower revenues in developed Europe markets (previously reported in EH)

Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe markets

Impact from CentreOne primarily in emerging markets

Operational decline, net

Favorable impact of foreign exchange
EH Revenues decrease

EH Revenues , 2018

  $

21,124

(558)

(504)

(436)

(97)

251

217

45

(1,082)

180

(903)

20,221

  $

Total EH revenues from emerging markets increased $745 million, or 11% , to $7.8 billion in 2018 from $7.0 billion in 2017, primarily driven by 11% operational growth from the
LEP portfolio and 13% operational growth from the SIP portfolio, partially offset by a 2% operational decline from the Peri-LOE Products portfolio. Foreign exchange had a de
minimis impact on total EH revenues from emerging markets.

Costs and Expenses

The changes in EH expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in EH’s
operating results through February 2, 2017 and, therefore, operating results for EH for 2017 include approximately one month of HIS domestic operations and approximately
two months of HIS international operations. Operating results for EH for 2018 do not reflect any contribution from HIS global operations.

• Cost of sales as a percentage of Revenues increase d 1.8 percentage points, primarily due to:

◦ higher sales volume of Inflectra in the U.S. and developed Europe, and higher Pfizer CentreOne sales volumes, both of which carry higher product costs; and

◦

lower sales volumes and margins as a result of product losses of exclusivity and generic competition in developed markets,

partially offset by:

◦

lower sales volumes in the SIP portfolio, which carries a higher cost to produce, in developed markets, primarily due to increased competition across the SIP portfolio and
continued legacy Hospira product shortages in the U.S.;

◦ the favorable impact of foreign exchange; and
◦

the non-recurrence of charges related to a product recall that occurred in 2017.

• The increase in Cost of sales of 2% was primarily due to:

◦ higher sales volumes of Inflectra in the U.S. and developed Europe, and higher Pfizer CentreOne sales volumes, both of which carry higher product costs; and

◦

lower sales volumes in the SIP portfolio, which carries a higher cost to produce, in developed markets, primarily due to increased competition across the SIP portfolio and
continued legacy Hospira product shortages in the U.S.,

partially offset by:

◦

◦

lower sales volumes as a result of product losses of exclusivity and generic competition in developed markets; and

the non-recurrence of charges related to a product recall that occurred in 2017.

• Selling, informational and administrative expenses decrease d 10% mainly due to lower advertising, promotional and field force expenses, reflecting the benefits of cost-

reduction and productivity initiatives, and lower general and administrative expenses , partially offset by additional investments in China .

• Research and development expenses decrease d 11% , primarily due to decreased spending for biosimilars as several programs have reached completion.

• The unfavorable change in Other (income)/deductions––net primarily reflects the non-recurrence of income from resolution of a contract disagreement, the non-recurrence of

a gain on the redemption of an acquired bond in 2017 and the unfavorable impact of foreign exchange, partially offset by an increase in income from collaborations, out-
licensing arrangements and sales of compound/product rights.

2018 Financial Report

49

Financial Review
Pfizer Inc. and Subsidiary Companies

2017 vs. 2016

EH Revenues decrease d $2.5 billion , or 11% , to $21.1 billion , reflecting an operational decrease of $2.3 billion , or 10%, and a 1% unfavorable impact from foreign
exchange.

The following graph illustrates the components of the decrease in EH Revenues :

* LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.

The following provides an analysis of the decrease in EH Revenues :

(MILLIONS OF DOLLARS)

EH Revenues , 2016

Disposition:

Approximately one month of HIS domestic operations and approximately two months of HIS international operations in 2017, compared to twelve

months of HIS global operations in 2016 (February 2017 sale)

Other Operational growth/(decline):

Decline from Peri-LOE Products, primarily due to expected declines in Pristiq in the U.S. as well as Lyrica and Vfend (both primarily in developed

Europe markets)

Decline from the Sterile Injectable Pharmaceuticals portfolio, primarily due to legacy Hospira product shortages in the U.S.

Decline in the Legacy Established Products portfolio primarily due to generic competition in developed markets

Growth from Biosimilars, primarily from Inflectra in the U.S. and developed Europe markets

Other operational factors, net

Operational decline, net

Unfavorable impact of foreign exchange

EH Revenues  decrease

EH Revenues,  2017

  $

23,627

(1,062)

(957)

(315)

(188)

209

(13)

(2,325)

(178)

(2,503)

21,124

  $

Total EH revenues from emerging markets increased $323 million, or 5%, to $7.0 billion in 2017 from $6.7 billion in 2016, reflecting 7% operational growth, primarily driven by
6% operational growth from the Legacy Established Products portfolio and 17% operational growth from the Sterile Injectable Pharmaceuticals portfolio. Foreign exchange had
an unfavorable impact of 2%. Excluding HIS in both periods, EH revenues in emerging markets grew 8% operationally.

Costs and Expenses

The changes in EH expenses below reflect, among other things, the favorable impact of the February 2017 sale of HIS. The operating results of HIS are included in EH’s
operating results through February 2, 2017 and, therefore, operating results for EH for 2017 include approximately one month of HIS domestic operations and approximately
two months of HIS international operations, while operating results for EH for 2016 reflect 12 months of HIS global operations.

• Cost of sales as a percentage of Revenues increase d 1.6 percentage points primarily due to cost increases reflecting the shift to EH of certain legacy Hospira costs that

were previously unallocated to EH as a result of harmonizing the Hospira cost policy, and the impact of product losses of exclusivity, partially offset by the favorable impact
of the sale of HIS, which had a higher cost of sales than the other EH products, and the favorable impact of foreign exchange.

• The decrease in Cost of sales of 5% primarily reflects:

◦

◦

the favorable impact of the sale of HIS, which had a higher cost of sales than the other EH products;

the favorable impact of foreign exchange;

◦  a net decrease in royalty expense and, to a lesser extent,

◦

lower volumes driven by, among other things, the SIP portfolio, primarily due to legacy Hospira product shortages in the U.S.,

50

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

partially offset by:

◦ cost increases reflecting the shift to EH of certain legacy Hospira costs that were previously unallocated to EH as a result of harmonizing the Hospira cost policy.

• Selling, informational and administrative expenses decrease d 12% , primarily due to the favorable impact of the sale of HIS, lower advertising, promotional, and field force
expenses, reflecting the benefits of cost-reduction and productivity initiatives, as well as lower expenses associated with products that recently lost marketing exclusivity,
partially offset by increased spending for biosimilars, primarily related to the U.S. launch of Inflectra.

• Research and development expenses decrease d 15% primarily due to decreased spending for biosimilars, the close-out of certain postmarketing clinical trials and the

favorable impact of the sale of HIS.

• The favorable change in Other (income)/deductions––net primarily reflects the favorable impact of foreign exchange, a gain on the redemption of an acquired bond and an

increase in Inflectra royalty income, partially offset by the non-recurrence of a resolution of a contract disagreement in the first quarter of 2016.

ANALYSIS OF THE CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Changes in the components of Accumulated other comprehensive loss reflect the following:

2018

• For Foreign currency translation adjustments, net, primarily reflects the strengthening of the U.S. dollar against the euro, U.K. pound and Chinese renminbi.

• For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflects the impact of
fair value re-measurements and the reclassification of amounts into income. For additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of
Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 and Notes to Consolidated Financial Statements— Note 7. Financial
Instruments.

• For Benefit plans: actuarial losses, net, primarily reflects (i) an increase due to the cumulative effect adjustment as of January 1, 2018 resulting from the adoption of a new
accounting standard related to certain tax effects from AOCI; (ii) a decrease in actual returns on plan assets; (iii) an increase in our discount rate assumptions; (iv) the
amortization of changes in the pension benefit obligation previously recognized in Other comprehensive income ; and (v) the favorable impact of foreign exchange. For
additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting
Standards in 2018 and Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans .

• For Tax provision/(benefit) on other comprehensive income/(loss), reflect the reclassification of the stranded tax amounts related to the TCJA from AOCI to Retained

earnings, which was recorded in the first quarter of 2018. For additional information, see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and
Significant Accounting Policies––Adoption of New Accounting Standards and Notes to Consolidated Financial Statements— Note 5E. Tax Matters : Tax Provision/(Benefit)
on Other Comprehensive Income/(Loss).

2017

• For Foreign currency translation adjustments, net, primarily reflects the weakening of the U.S. dollar against the euro, U.K. pound and the Canadian dollar, as well as the

reclassification of amounts related to (i) the agreement to sell our 40% ownership investment in Teuto and (ii) the sale of our 49% equity share in Hisun Pfizer. For additional
information, see Notes to Consolidated Financial Statements— Note 2F. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research
and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Equity-Method Investments .

• For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflect the impact of

fair value re-measurements and the reclassification of amounts into net income. For additional information, see Notes to Consolidated Financial Statements— Note 7.
Financial Instruments

• For Benefit plans: actuarial losses, net, primarily reflects (i) an increase in the actuarial losses due to a decrease in our discount rate assumptions; (ii) an increase in actual
returns on plan assets; (iii) the amortization of changes in the pension benefit obligation previously recognized in Other comprehensive income ; and (iv) the unfavorable
impact of foreign exchange. For additional information, see Notes to Consolidated Financial Statements— Note 11. Pension and Postretirement Benefit Plans and Defined
Contribution Plans.

2016

• Foreign currency translation adjustments, net, primarily reflects the strengthening of the U.S. dollar against the U.K. pound, Chinese renminbi, Mexican peso, and Argentine

peso, partially offset by the weakening of the U.S. dollar against the Australian dollar and Japanese yen.

• For Unrealized holding gains/(losses) on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflects the impact of

fair value re-measurements and the reclassification of amounts into net income. For additional information, see Notes to Consolidated Financial Statements— Note 7.
Financial Instruments .

• For Benefit plans: actuarial losses, net, reflects the actuarial losses related primarily to a decrease in the discount rate, partially offset by (i) the amortization of changes in
the pension benefit obligation previously recognized in Other comprehensive income , and (ii) higher actual return on plan assets as compared to the expected return on
plan assets. For additional information, see Notes to Consolidated Financial Statements— Note 11. Pension and Postretirement Benefit Plans and Defined Contribution
Plans and the “Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions––Benefit Plans” section of this Financial Review.

2018 Financial Report

51

Financial Review
Pfizer Inc. and Subsidiary Companies

ANALYSIS OF THE CONSOLIDATED BALANCE SHEETS

For information about certain of our financial assets and liabilities, including Cash and cash equivalents, Short-term investments, Long-term investments, Short-term
borrowings, including current portion of long-term debt , and Long-term debt , see the “Analysis of the Consolidated Statements of Cash Flows” and the “Analysis of Financial
Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources” sections of this Financial Review and Notes to Consolidated Financial
Statements— Note 7. Financial Instruments .

For information about events and circumstances impacting our tax-related accounts, see Notes to Consolidated Financial Statements— Note 5. Tax Matters .

For a description of changes in Total Equity , see the consolidated statements of equity.

For information related to changes in Accumulated other comprehensive loss , see the “Analysis of the Consolidated Statements of Comprehensive Income” section of this
Financial Review and Notes to Consolidated Financial Statements— Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests .

The changes in our asset and liability accounts as of December 31, 2018 , compared to December 31, 2017 , generally reflect, among other things, fluctuations in foreign
currency exchange rates, the impact of the adoption of new accounting standards in the first quarter of 2018 and the reclassification to assets and liabilities held for sale in
connection with our pending consumer business joint venture with GSK . The following explanations exclude the impacts of foreign exchange, the adoption of new accounting
standards in the first quarter of 2018 and the pending consumer healthcare business joint venture with GSK (see Notes to Consolidated Financial Statements— Note 1B. Basis
of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 and Note 2C. Acquisitions, Divestitures, Assets and Liabilities Held for
Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Asset and Liabilities
Held for Sale for additional information).

• For Trade accounts receivable, less allowance for doubtful accounts, the change reflects the timing of sales and collections in the normal course of business.

• For Inventories, the change reflects increases for certain products to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery,

new product launches and the movement of products within our manufacturing network.

• For Other current assets, the change reflects an increase in receivables associated with derivative financial instruments, partially offset by the receipt of a milestone payment
related to the first marketing authorization for ertugliflozin (see Notes to Consolidated Financial Statements— Note 2E. Acquisitions, Divestitures, Assets and Liabilities Held
for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Research and
Development and Collaborative Arrangements ).

• For PP&E, the change primarily reflects capital additions in the normal course of business, partially offset by depreciation during the period and reductions due to asset
impairments largely associated with cost reduction initiatives not associated with acquisitions (see Notes to Consolidated Financial Statements— Note 3 . Restructuring
Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives ).

• For Identifiable intangible assets, less accumulated amortization , the change primarily reflects amortization for the period and intangible asset impairment charges (see

Notes to Consolidated Financial Statements— Note 4. Other (Income)/Deductions-Net ), partially offset by an intangible asset recorded in connection with the EU approval of
Mylotarg (see Notes to Consolidated Financial Statements— Note 10A. Identifiable Intangible Assets and Goodwill : Identifiable Intangible Assets ).

• For Trade accounts payable, the change reflects the timing of purchases and payments in the normal course of business.

• For Other current liabilities , the change reflects an increase in liabilities associated with:

◦ payments and accruals in the normal course of business;

◦

reclassifications from noncurrent liabilities; and

◦ accruals for restructuring activities associated with our Organizing for Growth initiative (see Notes to Consolidated Financial Statements— Note 3. Restructuring Charges

and Other Costs Associated with Acquisitions and Cost Reduction/Productivity Initiatives) ;

partially offset by decreases related to:

◦ payments for contingent consideration obligations;

◦ payments to settle certain legal and product liability obligations;

◦ payables related to derivative financial instruments; and

◦ payments for the current portion of obligations recorded in connection with the U.S. approval of Bosulif, and the EU and U.S. approvals of Besponsa (see Notes to

Consolidated Financial Statements— Note 7E. Financial Instruments : Other Noncurrent Liabilities ) .

• For Pension benefit obligations, net , the decrease primarily reflects the $500 million voluntary pension contribution we made to the U.S. Pfizer Consolidated Pension Plan in
February 2018 and the impact of an increase in the discount rate used in the measurement of plan obligations, partially offset by a decrease in actual returns on plan assets.

• For Other noncurrent liabilities , the change reflects an increase in liabilities associated with:

◦ an increase in payables, associated with derivative financial instruments;

◦ an increase in liabilities associated with the sale-leaseback of our New York headquarters (see the “Analysis of Financial Condition, Liquidity and Capital Resources—

Selected Measures of Liquidity and Capital Resources —Contractual Obligations” section of this Financial Review for additional information); and

◦ a change in the fair value of contingent consideration (see Notes to Consolidated Financial Statements— Note 4 . Other (Income)/Deductions—Net ),

52

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

partially offset by:

◦

reclassifications to current liabilities.

• For Treasury stock, the change reflects open market share repurchases of $8.2 billion in 2018, as well as $4.0 billion paid to Citibank in March 2018 pursuant to the terms of

an accelerated share repurchase agreement. See Notes to Consolidated Financial Statements— Note 12A. Equity: Common Stock for additional information.

ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS

(MILLIONS OF DOLLARS)

Cash provided by/(used in):

Operating activities

Investing activities

Financing activities

Effect of exchange-rate changes on cash and cash equivalents and restricted

cash and cash equivalents

Net decrease in Cash and cash equivalents and restricted cash and cash
equivalents

* Indicates calculation not meaningful or result is equal to or greater than 100%.

Year Ended December 31,

% Change

2018

2017

2016

18/17

17/16

  $

15,827   $
4,525

(20,441)

(116)

16,802   $

(4,740)

(13,350)

53

16,192
(7,791)
(9,228)

(215)

(6)

*
53

*

  $

(205)

  $

(1,235)

  $

(1,041)

(83)

4

(39)

45

*

19

In the consolidated statements of cash flows, the line item, Other changes in assets and liabilities, net of acquisitions and divestitures , is presented excluding the effects of
changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements.
Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our consolidated balance sheets.

Operating Activities

2018 v. 2017

Our net cash provided by operating activities was $15.8 billion in 2018 , compared to $16.8 billion in 2017 . The decrease in net cash provided by operating activities reflects a
decrease in net cash generated from net income. The net cash generated reflects the timing of receipts from customers and payments to vendors in the ordinary course of
business.

In 2018 , the change in the line item Other adjustments, net primarily reflects, among other items:

• non-recurrence of a non-cash net loss on early retirement of debt under an exchange offer in 2017;

• unrealized net gains on equity securities resulting from the adoption of a new accounting standard on January 1, 2018 related to financial assets and liabilities (see Notes to

Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 );

• a decrease in debt extinguishment costs in 2018 related to early retirement of debt under an exchange offer in 2017, which have been reclassified from operating to
financing activities in 2018 and 2017 in accordance with our implementation of a new accounting standard on January 1, 2018 related to the classification of debt
prepayment and extinguishment costs (see Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of
New Accounting Standards in 2018 );

• a non-cash gain associated with our transaction with Bain Capital to create a new biopharmaceutical company to continue development of a portfolio of clinical and

preclinical stage neuroscience assets (see Notes to Consolidated Financial Statements–– Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing
Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Divestitures ); and

• a non-cash gain on the contribution of Pfizer’s allogeneic CAR T developmental program assets, in connection with our contribution agreement with Allogene (see Notes to
Consolidated Financial Statements— Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and
Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Divestitures ),

partially offset by:

• decreases in net realized gains on sales of investments in debt and equity securities;

• net losses on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales (that fixes the cost of inventory later sold to customers); and

• a decrease in gains on the sale of property, plant and equipment.

In 2018 and 2017 , the line item Other changes in assets and liabilities, net of acquisitions and divestitures, primarily reflects changes, in the normal course of business, in
trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation and other current and noncurrent
liabilities.

For additional information about changes in other assets and liabilities account balances, see the “Analysis of the Consolidated Balance Sheets” in this Financial Review.

2018 Financial Report

53

Financial Review
Pfizer Inc. and Subsidiary Companies

2017 v. 2016

Our net cash provided by operating activities was $16.8 billion in 2017 , compared to $16.2 billion in 2016 . The increase in net cash provided by operating activities reflects the
timing of receipts from customers and payments to vendors in the ordinary course of business, partially offset by an increase in benefit plan contributions. In 2017 , the change
in the line item Other adjustments, net primarily reflects, among other items:
• a decrease in the provision for bad debt expense;

• an increase in dividends from our investment in ViiV reclassified from operating to investing activities;

• an increase in gains from sales of available-for-sale securities; and

• an increase in gains on the sale of property, plant and equipment,

partially offset by:

• a non-cash net loss on early retirement of debt under an exchange offer.

In 2017 and 2016 , the line item Other changes in assets and liabilities, net of acquisitions and divestitures, primarily reflects changes, in the normal course of business, in
trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation and other current and noncurrent
liabilities. For 2016 , this line item also includes the adjustments necessary to reflect the payments of certain legal claims accrued in prior periods, including for Protonix-related
matters.

For additional information about changes in other assets and liabilities account balances, see the “Analysis of the Consolidated Balance Sheets” in this Financial Review.

Investing Activities

2018 v. 2017

Our net cash provided by investing activities was $4.5 billion in 2018 , compared to net cash used in investing activities of $4.7 billion in 2017 . The change in net cash used in
investing activities was primarily attributable to:

• an increase in net proceeds generated from the sale of investments of $8.6 billion in 2018 for cash needs; and

• a decrease in cash used for acquisitions, net of cash acquired of $1.0 billion due to the acquisition of the development and commercialization rights to AstraZeneca’s small

molecule anti-infectives business and substantially all of the remaining consideration for the Medivation acquisition in 2017 (see Notes to Consolidated Financial Statements
— Note 2A. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-
Method Investments and Privately Held Investment: Acquisitions ).

2017 v. 2016

Our net cash used in investing activities was $4.7 billion in 2017 , compared to net cash used in investing activities of $7.8 billion in 2016 . The change in net cash used in
investing activities was primarily attributable to:

• a decrease in cash used for acquisitions — cash paid of $1.0 billion, net of cash acquired, primarily for the acquisition of AstraZeneca’s small molecule anti-infectives

business in 2017 and substantially all of the remaining consideration for the Medivation acquisition, compared to cash paid of $18.4 billion , net of cash acquired, primarily for
the acquisitions of Medivation, Bamboo and Anacor in 2016 (see Notes to Consolidated Financial Statements— Note 2A. Acquisitions, Divestitures, Assets and Liabilities
Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment:
Acquisitions ); and

• an increase in Other investing activities, net, including dividends received from our investment in ViiV,

partially offset by:

•

lower net proceeds generated from the sale of investments of $14.7 billion in 2017 for cash needs.

Financing Activities

2018 v. 2017

Our net cash used in financing activities was $20.4 billion in 2018 , compared to $13.3 billion in 2017 . The increase in net cash used in financing activities was primarily
attributable to:

• $2.3 billion less proceeds raised from short-term borrowings in 2018 , compared to 2017 ; and

• higher purchases of common stock of $7.2 billion ,

partially offset by:

•

lower repayments on long-term debt of $2.6 billion .

2017 v. 2016

Our net cash used in financing activities was $13.3 billion in 2017 , compared to $9.2 billion in 2016 . The increase in net cash used in financing activities was primarily
attributable to:

•

the issuance of long-term debt of $5.3 billion in 2017 , compared to $11.0 billion in 2016 (see Notes to Consolidated Financial Statements–– Note 7D. Financial Instruments:
Long-Term Debt ); and

• $7.7 billion cash dividends paid in 2017 , compared to $7.3 billion in the same period in 2016 ,

54

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

partially offset by:

•

•

lower repayments on long-term debt of $1.5 billion , compared to 2016 ; and

lower net repayments on short-term borrowings in 2017 of $619 million , compared to 2016 .

ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We
continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable,
and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital
markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable
future, which include:

•

•

the working capital requirements of our operations, including our R&D activities;

investments in our business;

• dividend payments and potential increases in the dividend rate;

• share repurchases;

•

the cash requirements associated with our cost-reduction/productivity initiatives;

• paying down outstanding debt;

• contributions to our pension and postretirement plans; and

• business-development activities.

Our long-term debt is rated high-quality by both S&P and Moody’s. See the “Credit Ratings” section below. As market conditions change, we continue to monitor our liquidity
position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-
quality, highly liquid, well-diversified available-for-sale debt securities.

Selected Measures of Liquidity and Capital Resources

The following table provides certain relevant measures of our liquidity and capital resources:

(MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA)

Selected financial assets (a) :

Cash and cash equivalents

Short-term investments

Long-term investments

Debt:

Short-term borrowings, including current portion of long-term debt

Long-term debt

Selected net financial liabilities (b)

Working capital (c)

Ratio of current assets to current liabilities

  $

  $

  $

As of December 31,

2018

1,139   $
17,694
2,767
21,600

8,831
32,909
41,740
(20,140)   $

18,068   $
1.57:1
11.09   $

2017

1,342

18,650

7,015

27,007

9,953

33,538

43,491

(16,484)

10,714

1.35:1

11.93

Total Pfizer Inc. shareholders’ equity per common share (d)
(a)  See Notes to Consolidated Financial Statements–– Note 7. Financial Instruments for a description of certain assets held and for a description of credit risk related to our financial instruments held.
(b)

The increase in selected net financial liabilities was primarily driven by the decrease in long-term investments used for cash needs, partially offset by the repayment of debt. We retain a strong financial liquidity
position as a result of our net cash provided by operating activities, our high-quality financial asset portfolio and access to capital markets. For additional information, see the “Credit Ratings” section of this
Financial Review.

  $

(c)  The increase in working capital was primarily due to:

• the reclassification to assets and liabilities held for sale in connection with our pending consumer business joint venture with GSK (see Notes to Consolidated Financial Statements–– Note 2 C. Acquisitions,

Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment : Assets and
Liabilities Held for Sale ) ;

• a decrease in short-term borrowings as a result of repayments of commercial paper;
• an increase in inventory related to increases for certain products to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery, new product launches and the

movement of products within our manufacturing network; and

• the timing of accruals, cash receipts and payments in the ordinary course of business,
partially offset by:
• a decrease in S hort-term investments mainly driven by the financing requirements for share repurchase activities, dividend payments, capital expenditures and debt repayment, partially offset by operating cash

flow generation, cash from employee stock option exercises and reclassification of long-term to short-term investments;

• an increase in income taxes payable primarily related to the reclassification of the first federal installment of the repatriation tax previously recorded in noncurrent liabilities and the timing of accruals in certain

major markets in the ordinary course of business; and

• the net impact of foreign currency exchange.

(d)  Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury stock).

2018 Financial Report

55

Financial Review
Pfizer Inc. and Subsidiary Companies

In September 2018, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes (see Notes to Consolidated Financial Statements––
Note 7D. Financial Instruments : Long-Term Debt ) .

In December 2017, we exchanged approximately £833 million principal amount of senior unsecured notes due 2038 with an interest rate of 6.50% for £ 1.376 billion principal
amount of senior unsecured notes due 2043 with an interest rate of 2.735% (see Notes to Consolidated Financial Statements–– Note 7D. Financial Instruments: Long-Term
Debt ).

In March 2017, we completed a public offering of $1.065 billion principal amount of senior unsecured notes due 2047 with an interest rate of 4.20% , and on March 6, 2017, we
completed a public offering of € 4.0 billion principal amount of senior unsecured notes with a weighted-average effective interest rate of 0.23% (see Notes to Consolidated
Financial Statements–– Note 7D. Financial Instruments: Long-Term Debt ).

In November 2016, we completed a public offering of $6.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 3.10%
.

In June 2016, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% .

For additional information about the sources and uses of our funds, see the “Analysis of the Consolidated Balance Sheets ” and “ Analysis of the Consolidated Statements of
Cash Flows ” sections of this Financial Review.

Domestic and International Selected Financial Assets

Many of our operations are conducted outside the U.S., and significant portions of our selected financial assets are held internationally. The amount of funds held in U.S. tax
jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As
part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the
TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, will also allow us to more easily access our selected
financial assets globally. As a result of the enactment of the TCJA, in 2018 we repatriated the majority of our cash we held internationally as of year-end 2017.

Credit Ratings

Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or
hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt:

NAME OF RATING AGENCY

Moody’s

S&P

Debt Capacity––Lines of Credit

Pfizer
Commercial Paper

Pfizer
Long-Term Debt

Rating
P-1
A-1+

Rating
A1
AA

Outlook
Stable
Stable

Date of Last Rating Change

October 2009

October 2009

We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent
balances and short-term investments in excess of our commercial paper and other short-term borrowings. As of December 31, 2018, we had access to a $7.0 billion U.S.
revolving credit facility expiring in 2023, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have
provided us an additional $553 million lines of credit, of which $502 million expire within one year. Of these total lines of credit, $7.5 billion were unused as of December 31,
2018.

LIBOR

From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. Banks currently reporting
information used to set LIBOR will stop doing so after 2021. Various parties, including government agencies, are seeking to identify an alternative rate to replace LIBOR. We
are monitoring their efforts, and we will likely amend contracts to accommodate any replacement rate where it is not already provided.

Global Economic Conditions––General

The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash
flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability
to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. For additional information see
the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” section in this Financial
Review.

56

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Global Economic Conditions––Venezuela Operations

Our Venezuela operations continue to operate with the U.S. dollar as the functional currency due to the hyperinflationary status of the Venezuelan economy.

We used the Venezuelan bolivar soberano rate of 85.87 as our best estimate to revalue our Venezuelan bolivar denominated net monetary assets. The current DICOM rate is
about 3,298.64. Future actions by the Venezuelan government in response to economic uncertainties could impact the recoverability of our investment in Venezuela, which
could result in an impairment charge and, under extreme circumstances, could impact our ability to continue to operate in the country in the same manner as we have
historically. We have in Venezuela a few net monetary assets and $39 million of non-monetary assets, and $11 million of deferred foreign exchange losses reported in the
balance sheet in Accumulated other comprehensive loss––Foreign currency translation adjustments at November 30, 2018 , our international quarter-end.

Global Economic Conditions––Argentina Operations

Our Argentina operations function in a hyperinflationary economy. The impact to Pfizer is not considered material.

Contractual Obligations

Payments due under contractual obligations as of December 31, 2018 , mature as follows:

(MILLIONS OF DOLLARS)

Long-term debt, including current portion (a)

Interest payments on long-term debt obligations (b)

Other long-term liabilities (c)

Operating leases (d)

Purchase obligations and other (e)
Other taxes payable — deemed repatriated accumulated post-1986 earnings
of foreign subsidiaries (f)

Uncertain tax positions (g)
(a)

  $

Total

37,684   $
20,680
2,798
3,317
3,722

11,000
19

2019
4,776   $
1,443
414
300
1,322

800
19

Years

2020-2021

2022-2023

Thereafter

5,935   $
2,518
611
462
1,294

1,775
—

4,067   $
2,330
549
515
337

1,775
—

22,907

14,389

1,224

2,040

769

6,650

—

(b)

(c)

(d)

(e)

Long-term debt consists of senior unsecured notes (including fixed and floating rate, foreign currency denominated, and other notes), carried at historical proceeds, as adjusted, and capital lease obligations (see
Notes to Consolidated Financial Statements— Note 7. Financial Instruments ). Commitments under capital leases are not significant.
Our calculations of expected interest payments incorporate only current period assumptions for interest rates, foreign currency translation rates and hedging strategies (see Notes to Consolidated Financial
Statements— Note 7. Financial Instruments ), and assume that interest is accrued through the maturity date or expiration of the related instrument.
Includes expected payments relating to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans. Excludes amounts relating to our U.S. qualified
pension plans and international pension plans, all of which have a substantial amount of plan assets, because the required funding obligations are not expected to be material and/or because such liabilities do not
necessarily reflect future cash payments, as the impact of changes in economic conditions on the fair value of the pension plan assets and/or liabilities can be significant. Also, excludes $4.6 billion of liabilities
related to the fair value of derivative financial instruments, legal matters and employee terminations, among other liabilities, most of which do not represent contractual obligations. See also our liquidity discussion
above in this “Analysis of Financial Condition, Liquidity and Capital Resources” section, as well as the Notes to Consolidated Financial Statements— Note 3. Restructuring Charges and Other Costs Associated
with Acquisitions and Cost-Reduction/Productivity Initiatives, Note 7A. Financial Instruments: Fair Value Measurements, Note 11E. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Cash
Flows, and Note 17. Contingencies and Certain Commitments .
Includes future minimum rental commitments under non-cancelable operating leases. These amounts include an agreement we entered in April 2018 to lease space in an office building in New York City. We will
relocate our global headquarters to this property with occupancy expected beginning in 2022. Our future minimum rental commitment under this 20-year lease is approximately $1.7 billion . In July 2018, we
completed the sale of our current headquarters buildings. We also agreed to lease these properties from the buyer while we complete our relocation.
Includes agreements to purchase goods and services that are enforceable and legally binding and includes amounts relating to advertising, information technology services, employee benefit administration
services, and potential milestone payments deemed reasonably likely to occur. Also includes obligations to make guaranteed fixed annual payments over the next 8 years in connection with the U.S. and EU
approvals for Besponsa ( $422 million ) and an obligation to make guaranteed fixed annual payments over the next 9 years for Bosulif ( $240 million ), both associated with R&D arrangements. For additional
information, see Notes to Consolidated Financial Statements— Note 7E. Financial Instruments: Other Noncurrent Liabilities. Also includes consideration of $175 million paid in January 2019 related to our
purchase of AstraZeneca’s small molecule anti-infective business. For additional information, see Notes to Consolidated Financial Statements— Note 2A. Acquisitions, Divestitures, Assets and Liabilities Held for
Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Acquisitions .

(f)  Represents estimated cash payments related to the TCJA repatriation tax for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through
2026 (with the first installment due in April 2019). Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.
For additional information, see Notes to Consolidated Financial Statements— Note 5A. Tax Matters: Taxes on Income from Continuing Operations and Note 5C. Tax Matters: Deferred Taxes.
Includes only income tax amounts currently payable. We are unable to predict the timing of tax settlements related to our noncurrent obligations for uncertain tax positions as tax audits can involve complex issues
and the resolution of those issues may span multiple years, particularly if subject to negotiation or litigation.

(g)

The above table includes amounts for potential milestone payments under collaboration, licensing or other arrangements, if the payments are deemed reasonably likely to
occur. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization
milestones, which may span several years and which may never occur.

In 2019 , we expect to spend approximately $2.3 billion on property, plant and equipment. We rely largely on operating cash flows to fund our capital investment needs. Due to
our significant operating cash flows, we believe we have the ability to meet our capital investment needs and anticipate no delays to planned capital expenditures.

2018 Financial Report

57

Financial Review
Pfizer Inc. and Subsidiary Companies

Off-Balance Sheet Arrangements

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain
liabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a
successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various
restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2018 , the estimated fair value of our
indemnification obligations was not significant.

Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-
promotion or other rights in specified countries with respect to certain of our products.

Share-Purchase Plans and Accelerated Share Repurchase Agreements

Our December 2015 $11 billion share repurchase program was exhausted in the third quarter of 2018.

In December 2017, the Board of Directors authorized an additional $10 billion share repurchase program, and share repurchases commenced thereunder in the third quarter of
2018 (the 2017 program).

On March 12, 2018 , we entered into an accelerated share repurchase agreement with Citibank to repurchase $4.0 billion of our common stock.

In December 2018, the Board of Directors authorized a new $10.0 billion share repurchase program to be utilized over time. This new program is in addition to the $4.2 billion
remaining under the company’s 2017 program authorization as of December, 31 2018. For additional information, see Notes to Consolidated Financial Statements–– Note 12.
Equity.

The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including
our accelerated share repurchase agreements:

(SHARES IN MILLIONS, DOLLARS IN BILLIONS)

Shares of common stock purchased

Cost of purchase

2018 (a)

307
12.2   $

2017 (b)

150
5.0   $

2016 (c)

154

5.0

  $

(a)

(b)

(c)

Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank entered into on March 12, 2018, as well as other share repurchases. For additional information, see Notes to
Consolidated Financial Statements–– Note 12 . Equity.
Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank entered into on February 2, 2017. For additional information, see Notes to Consolidated Financial
Statements–– Note 12. Equity.
Represents shares purchased pursuant to an accelerated share repurchase agreement entered into on March 8, 2016. For additional information, see Notes to Consolidated Financial Statements–– Note 12.
Equity.

At December 31, 2018 , our remaining share-purchase authorization was approximately $14.2 billion .

In 2019, Pfizer anticipates approximately $9 billion of share repurchases, which have been completed through February 28, 2019.

On February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. This
agreement was entered into pursuant to our previously announced share repurchase authorization. For additional information, see Notes to Consolidated Financial Statements
— Note 19. Subsequent Event .

Dividends on Common Stock

We paid dividends on our common stock of $8.0 billion in 2018 , $7.7 billion in 2017 and $7.3 billion in 2016 . In December 2018 , our Board of Directors declared a first-quarter
2019 dividend of $0.36 per share, payable on March 1, 2019 , to shareholders of record at the close of business on February 1, 2019 . The first-quarter 2019 cash dividend will
be our 321 st consecutive quarterly dividend.

Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses and to seek to increase
shareholder value. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer’s Board of Directors and will continue to be
evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events.

58

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

NEW ACCOUNTING STANDARDS

Recently Adopted Accounting Standards

See Notes to Consolidated Financial Statements— Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018.

Recently Issued Accounting Standards, Not Adopted as of December 31, 2018

Standard/Description

Effective Date

  Effect on the Financial Statements or Other Significant Matters

In February 2016, the FASB issued new guidance on accounting
for leases . The new ASU provides guidance for both lessee and
lessor accounting models. Among other things, the new guidance
requires that a right of use asset and a lease liability be
recognized for leases with a duration of greater than one year.
Since its issuance, the FASB has issued several ASUs, including
amending the guidance to offer an additional transition method.

January 1, 2019.

We have substantially completed our review of the impact of this new
guidance. We will adopt this standard in the first quarter of fiscal 2019
utilizing the modified retrospective method, and therefore no
adjustments will be made to amounts in our prior period financial
statements. We expect to recognize approximately $1.5 billion of
additional assets and corresponding liabilities on our balance sheet as
of the beginning of fiscal 2019 and will record any cumulative effect of
adopting the new standard as an adjustment to the opening balance of
Retained Earnings. We do not expect that this adjustment to Retained
Earnings  at adoption will have a material impact on our consolidated
financial statements. We have also assessed the potential impact of
embedded leases on our consolidated financial statements, given our
manufacturing outsourcing, service arrangements and other
agreements. In connection with this guidance we have designed new
global processes, technological solutions and related controls to
provide the appropriate financial accounting and disclosure data. We
continue to monitor changes, modifications, clarifications or
interpretations undertaken by the FASB, which may impact our
conclusions.

We do not have any investments with features subject to this standard
and do not expect this new guidance to have a material impact on our
consolidated financial statements.

We do not have any financial instruments with features subject to this
standard and do not expect this new guidance to have a material
impact on our consolidated financial statements.

January 1, 2019.

January 1, 2019.

In March 2017, the FASB issued new guidance that shortens the
amortization period for certain callable debt securities held
at a premium . The new guidance requires the premium to be
amortized to the earliest call date.

In July 2017, the FASB issued new guidance on accounting for
certain financial instruments with characteristics of liabilities
and equity,  and accounting for certain financial instruments with
down round features (a feature in a financial instrument that
reduces the strike price of an issued financial instrument if the
issuer sells shares of its stock for an amount less than the
currently stated strike price of the issued financial instrument or
issues an equity-linked financial instrument with a strike price
below the currently stated strike price of the issued financial
instrument).

In June 2018, the FASB issued new guidance to simplify the
accounting for share-based payments to nonemployees  by
aligning it with the accounting for share-based payments to
employees, with certain exceptions. Under the guidance, the
measurement of equity-classified nonemployee awards will be
fixed at the grant date.

In June 2016, the FASB issued new guidance on accounting for
credit losses of financial instruments . The new guidance
replaces the probable initial recognition threshold for incurred loss
estimates in current GAAP with a methodology that reflects
expected credit loss estimates.

January 1, 2019.

We do not have any share-based awards issued to nonemployees and
do not expect this new guidance to have a material impact on our
consolidated financial statements.

January 1, 2020. Earlier
application is permitted as of
fiscal years beginning after
December 15, 2018, including
interim periods within that fiscal
year.

We are assessing the impact of the provisions of this new guidance on
our consolidated financial statements. This standard includes our
financial instruments, such as accounts receivable, and investments
that are generally of high credit quality.
Previously, when credit losses were measured under GAAP, an entity
generally only considered past events and current conditions in
measuring the incurred loss.
The new guidance requires us to identify, analyze, document and
support new methodologies for quantifying expected credit loss
estimates for our financial instruments, using information such as
historical experience and current economic conditions, plus the use of
reasonable supportable forecast information.

2018 Financial Report

59

Financial Review
Pfizer Inc. and Subsidiary Companies

Standard/Description

Effective Date

  Effect on the Financial Statements or Other Significant Matters

In January 2017, the FASB issued new guidance for goodwill
impairment testing . The new guidance eliminates the
requirement to perform a hypothetical purchase price allocation to
measure goodwill impairment. Under the new guidance the
goodwill impairment test is performed by comparing the fair value
of a reporting unit with its carrying amount, and recognizing an
impairment charge for the amount by which the carrying amount
of the reporting unit exceeds its fair value, although it cannot
exceed the total amount of goodwill allocated to that reporting
unit.

In August 2018, the FASB issued new guidance related to
customers’ accounting for implementation costs incurred in
a cloud computing arrangement that is considered a service
contract . The new guidance aligns the requirements for
capitalizing implementation costs in such arrangements with the
requirements for capitalizing implementation costs incurred to
develop or obtain internal-use software. The new guidance can
be adopted either prospectively or retrospectively.

In November 2018, the FASB issued new guidance clarifying the
interaction between the accounting guidance for collaboration
agreements and revenue from contracts with customers .

60

2018 Financial Report

January 1, 2020. Earlier
application is permitted.

We do not expect this new guidance to have a material impact on our
consolidated financial statements.

January 1, 2020. Earlier
application is permitted.

We are assessing the impact of the provisions of this new guidance on
our consolidated financial statements. We do not expect this new
guidance to have a material impact on our consolidated financial
statements.

January 1, 2020. Earlier
application is permitted

We have assessed the impact of the provisions of this new guidance
and do not expect it will have a material impact on our consolidated
financial statements.

Financial Review
Pfizer Inc. and Subsidiary Companies

FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks
and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,”
“expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning or by
using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, in-line
products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, performance, timing of exclusivity and potential benefits
of Pfizer’s products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial
operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, our ability to successfully
capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include
statements relating to future actions, business plans and prospects, our acquisitions and other business development activities, our proposed transaction with GSK to combine
our respective consumer healthcare businesses into a new consumer healthcare joint venture, prospective products or product approvals, our product pipeline, future
performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal
proceedings, plans relating to share repurchases and dividends, government regulation and financial results, including, in particular, the anticipated progress in remediation
efforts at certain of our Hospira manufacturing facilities and the expectations related to our supply issues set forth in the “Overview of Our Performance, Operating
Environment, Strategy and Outlook––Our Business––Product Manufacturing” section of this Financial Review, the benefits expected from the reorganization of our commercial
operations into three businesses effective at the beginning of our 2019 fiscal year and our expectations regarding growth set forth in the “Overview of Our Performance,
Operating Environment, Strategy and Outlook––Our Strategy––Organizing for Growth” section of this Financial Review, the expected timing of completion and benefits of our
proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture set forth in the “Overview of Our
Performance, Operating Environment, Strategy and Outlook––Our Business,” “––Our Strategy” and “––Our Business Development Initiatives” sections of this Financial
Review, the anticipated costs related to our preparations for Brexit set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our
Operating Environment––The Global Economic Environment” section of this Financial Review, our anticipated liquidity position set forth in the “Overview of Our Performance,
Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” and the “Analysis of Financial Condition, Liquidity and
Capital Resources” sections of this Financial Review, our plans for increasing investment in the U.S. set forth in the “Overview of Our Performance, Operating Environment,
Strategy and Outlook––Our Strategy––Capital Allocation and Expense Management––Increasing Investment in the U.S.” section of this Financial Review, the financial
guidance set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Financial Guidance for 2019 ” section of this Financial Review,
the anticipated costs and savings, including from our cost-reduction/productivity initiatives, as well as from our Organizing for Growth initiative, set forth in the “Costs and
Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review and in Notes to
Consolidated Financial Statements–– Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives , the benefits
expected from our business development transactions, the planned capital spending set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources––
Selected Measures of Liquidity and Capital Resources––Contractual Obligations” section of this Financial Review and the contributions that we expect to make from our
general assets to the Company’s pension, postretirement and deferred compensation plans during 2019 set forth in the “Analysis of Financial Condition, Liquidity and Capital
Resources––Selected Measures of Liquidity and Capital Resources––Contractual Obligations” section of this Financial Review and in Notes to Consolidated Financial
Statements–– Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans . Among the factors that could cause actual results to differ materially from
past results and future plans and projected future results are the following:

•

•

•

•

•

the outcome of R&D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our
pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial
results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;

the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators,
which will depend on myriad factors, including such regulator making a determination as to whether a product’s benefits outweigh its known risks and a determination of the
product’s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory
committees, such as the Advisory Committee on Immunization Practices, that may impact the use of our vaccines;

the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;

the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the
side effects or efficacy of, a product that could affect its availability or commercial potential;

the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy the
conditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the anticipated benefits of any such transactions, and the potential
need to obtain additional equity or debt financing to pursue these opportunities which could result in increased leverage and impact our credit ratings;

• competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products,

biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;

•

the implementation by the FDA and regulatory authorities in many other countries of an abbreviated legal pathway to approve biosimilar products, which could subject our
biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;

2018 Financial Report

61

Financial Review
Pfizer Inc. and Subsidiary Companies

•

•

•

risks related to our ability to develop and launch biosimilars, including risks associated with “at risk” launches, defined as the marketing of a product by Pfizer before the final
resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party,
and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the
innovator product;

the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;

the ability to successfully market both new and existing products domestically and internationally;

• difficulties or delays in manufacturing, including delays caused by natural events, such as hurricanes; supply shortages at our facilities; and legal or regulatory actions, such

as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, voluntary recall of a product or failure to secure product approvals;

•

•

•

•

•

trade buying patterns;

the impact of existing and future legislation and regulatory provisions on product exclusivity;

trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our
products;

the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax
treatment of employer-sponsored health insurance that may be implemented;

the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;

• U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, reimbursement or access, including
under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases
that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the
U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under government programs; restrictions on
U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be
implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to
innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;

•

•

legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-
mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;

the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions,
changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;

• contingencies related to actual or alleged environmental contamination;

• claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;

• any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;

•

•

•

legal defense costs, insurance expenses and settlement costs;

the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalid
and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged
infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion,
securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means
for resolving asbestos litigation, as well as tax issues;

the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seek
may not be granted on a timely basis, if at all;

• our ability to protect our patents and other intellectual property, both domestically and internationally;

•

interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;

• governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the
U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of the TCJA;

• any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;

•

•

the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our
medicines;

the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.’s exit from the EU, which could have implications on our
research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;

• any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and

compliance with applicable legal or regulatory requirements and industry standards;

62

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

• any significant issues that may arise related to our joint ventures and other third-party business arrangements;

• changes in U.S. generally accepted accounting principles;

•

further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries;

• uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on

us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and
possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate; and the risks related to volatility of our
income due to changes in the market value of equity investments;

• any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military

action overseas;

• growth in costs and expenses;

• changes in our product, segment and geographic mix;

•

•

•

•

•

•

•

the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;

the impact of acquisitions, divestitures, restructurings, internal reorganizations, including the reorganization of our commercial operations into three businesses effective at
the beginning of the company’s 2019 fiscal year, any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs
but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;

the impact of product recalls, withdrawals and other unusual items;

the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;

risks related to internal control over financial reporting;

risks and uncertainties related to acquisitions, including, among other things, the ability to realize the anticipated benefits of those acquisitions, including the possibility that
the expected cost savings and/or accretion from certain of those acquisitions will not be realized or will not be realized within the expected time frame; the risk that the
businesses will not be integrated successfully; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our
ability to grow revenues for certain acquired products; significant transaction costs; and unknown liabilities; and

risks and uncertainties related to our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint
venture, including, among other things, risks related to the satisfaction of the conditions to closing the transaction (including the failure to obtain necessary regulatory and
GSK shareholder approvals) in the anticipated timeframe or at all and the possibility that the transaction does not close, risks related to the ability to realize the anticipated
benefits of the transaction, including the possibility that the expected benefits and cost synergies from the proposed transaction will not be realized or will not be realized
within the expected time period, the risk that the businesses will not be integrated successfully, the possibility that a future separation of the joint venture may not occur,
disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the announcement or the consummation of the
proposed transaction on the market price of Pfizer’s common stock and on Pfizer’s operating results, significant transaction costs, unknown liabilities, the risk of litigation
and/or regulatory actions related to the proposed transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions,
future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals and competitive developments.

We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate
assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past
results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue
reliance on forward-looking statements.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by
the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.

Certain risks, uncertainties and assumptions are discussed here and under the heading entitled “Risk Factors” in Part I, Item 1A. of our Form 10-K for the year ended
December 31, 2018 . We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to
predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes
on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.

This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of
clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial
data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for
an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

2018 Financial Report

63

Financial Review
Pfizer Inc. and Subsidiary Companies

Financial Risk Management

The objective of our financial risk management program is to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We
manage these financial exposures through operational means and through the use of third-party instruments. These practices may change as economic conditions change.

Foreign Exchange Risk

We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations, as well as in our financial assets (investments) and liabilities
(borrowings). Our net investments in foreign subsidiaries are also subject to currency risk.

On the commercial side, a significant portion of our revenues and earnings is exposed to changes in foreign exchange rates. See the “ Our Operating Environment — The
Global Economic Environment ” section of this Financial Review for the key currencies in which we operate. We seek to manage our foreign exchange risk, in part, through
operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Where
foreign exchange risk cannot be mitigated via operational means, we may use foreign currency forward-exchange contracts and/or foreign currency swaps to manage that risk.

With respect to our financial assets and liabilities, our primary foreign exchange exposure arises predominantly from short-term and long-term intercompany receivables and
payables, and, to a lesser extent, from short-term and long-term investments and debt, where the assets and/or liabilities are denominated in currencies other than the
functional currency of the business entity.

We also hedge some forecasted intercompany sales denominated in euro, Japanese yen, Chinese renminbi, U.K. pound, Canadian dollar, and Australian dollar to protect
against longer-term movements.

In addition, under certain market conditions, we may seek to protect against possible declines in the reported net investments of our foreign business entities. In these cases,
we may use foreign currency swaps, foreign currency forward-exchange contracts and/or foreign currency debt.

For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements— Note 7A. Financial
Instruments : Fair Value Measurements .

The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this sensitivity analysis, holding
all other assumptions constant and assuming that a change in one currency’s rate relative to the U.S. dollar would not have any effect on another currency’s rates relative to
the U.S. dollar, if the dollar were to appreciate against all other currencies by 10%, as of December 31, 2018 , the expected adverse impact on our net income would not be
significant.

Interest Rate Risk

We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on Pfizer’s immediate and
intermediate liquidity needs.

With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. Our
floating-rate assets are subject to the risk that short-term interest rates may fall and, as a result, the investments would generate less interest income. Fixed-rate investments
provide a known amount of interest income regardless of a change in interest rates. We sometimes use interest rate swaps in our financial investment portfolio.

We borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into
derivative financial instruments like interest rate swaps.

For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements— Note 7A. Financial
Instruments : Fair Value Measurements .

The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this sensitivity analysis, holding all other
assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point decrease in
interest rates as of December 31, 2018 , the expected adverse impact on our net income would not be significant.

Equity Price Risk

We hold equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such
securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. From
time to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk.

Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the
expected adverse impact on our net income would not be significant.

64

2018 Financial Report

Financial Review
Pfizer Inc. and Subsidiary Companies

Contingencies

Legal Matters

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other
product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications (see Notes to
Consolidated Financial Statements— Note 17. Contingencies and Certain Commitments ) .

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.

We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We
do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our
expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the
amounts are accrued and/or our cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore,
determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in
excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process
relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to
change those estimates and assumptions.

Tax Matters

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business for tax matters (see Notes to Consolidated Financial
Statements— Note 5D. Tax Matters : Tax Contingencies ).

We account for income tax contingencies using a benefit recognition model. If our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our
position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of
prevailing on the technical merits of the position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable
settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income
tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to
the “more-likely-than-not” standard.

Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential
tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when
the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal
administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such
changes could be significant.

2018 Financial Report

65

Management’s Report on Internal Control Over Financial Reporting

Management’s Report

We prepared and are responsible for the financial statements that appear in our 2018 Financial Report. These financial statements are in conformity with accounting principles
generally accepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the
preparation of other financial information that is included in this document.

Report on Internal Control Over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f)
under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of
America. The Company’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are
being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to
future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures
may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018 . In making this assessment,
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013) . Based
on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2018 .

The Company’s independent auditors have issued their auditors’ report on the Company’s internal control over financial reporting. That report appears in our 2018 Financial
Report under the heading, Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting .

Albert Bourla

Chief Executive Officer

Frank D’Amelio
Principal Financial Officer

February 28, 2019

66

2018 Financial Report

Loretta Cangialosi
Principal Accounting Officer

Audit Committee Report

The Audit Committee reviews Pfizer’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements
and the reporting process, including the system of internal controls.

The Committee met and held discussions with management and the independent registered public accounting firm regarding the fair and complete presentation of Pfizer’s
results and the assessment of Pfizer’s internal control over financial reporting. We discussed significant accounting policies applied in Pfizer’s financial statements, as well as,
when applicable, alternative accounting treatments. Management represented to the Committee that the consolidated financial statements were prepared in accordance with
accounting principles generally accepted in the United States of America, and the Committee reviewed and discussed the consolidated financial statements with management
and the independent registered public accounting firm. The Committee discussed with the independent registered public accounting firm matters required to be discussed
under applicable Public Company Accounting Oversight Board (PCAOB) standards.

In addition, the Committee reviewed and discussed with the independent registered public accounting firm the auditor’s independence from Pfizer and its management. As part
of that review, we received the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent registered public accounting
firm’s communications with the Audit Committee concerning independence, and the Committee discussed the independent registered public accounting firm’s independence
from Pfizer.

We also considered whether the independent registered public accounting firm’s provision of non-audit services to Pfizer is compatible with the auditor’s independence. The
Committee concluded that the independent registered public accounting firm is independent from Pfizer and its management.

As part of our responsibilities for oversight of Pfizer’s Enterprise Risk Management process, we reviewed and discussed company policies with respect to risk assessment and
risk management, including discussions of individual risk areas, as well as an annual summary of the overall process.

The Committee discussed with Pfizer’s Internal Audit Department and independent registered public accounting firm the overall scope of and plans for their respective audits.
The Committee meets with the Chief Internal Auditor, Chief Compliance, Quality and Risk Officer and representatives of the independent registered public accounting firm, in
regular and executive sessions, to discuss the results of their examinations, the evaluations of Pfizer’s internal controls, and the overall quality of Pfizer’s financial reporting and
compliance programs.

In reliance on the reviews and discussions referred to above, the Committee has recommended to the Board of Directors, and the Board has approved, that the audited
financial statements be included in Pfizer’s Annual Report on Form 10-K for the year ended December 31, 2018 , for filing with the U.S. Securities and Exchange Commission.
The Committee has selected, and the Board of Directors has ratified, the selection of Pfizer’s independent registered public accounting firm for 2019 .

The Audit Committee

Suzanne Nora Johnson, Chair
Dennis A. Ausiello
Joseph J. Echevarria
James C. Smith

February 28, 2019

The Audit Committee Report does not constitute soliciting material, and shall not be deemed to be filed or incorporated by reference into any Company filing under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates the Audit Committee
Report by reference therein.

2018 Financial Report

67

Report of Independent Registered Public Accounting Firm on the
Consolidated Financial Statements

The Board of Directors and Shareholders of Pfizer Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2018 and 2017 , and the related
consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2018 , and the related
notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of Pfizer Inc. and Subsidiary Companies as of December 31, 2018 and 2017 , and the results of their operations and their cash flows for each of the years in
the three-year period ended December 31, 2018 , in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over
financial reporting as of December 31, 2018 , based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO), and our report dated February 28, 2019 expressed an unqualified opinion on the effectiveness of the Company’s internal
control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial
statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of
material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.

KPMG LLP

We have not been able to determine the specific year that KPMG and our predecessor firms began serving as the Company’s auditor, however, we are aware that KPMG and
our predecessor firms have served as the Company’s auditor since at least 1942.

New York, New York

February 28, 2019

68

2018 Financial Report

Report of Independent Registered Public Accounting Firm on
Internal Control Over Financial Reporting

The Board of Directors and Shareholders of Pfizer Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Pfizer Inc. and Subsidiary Companies’ (the Company) internal control over financial reporting as of December 31, 2018 , based on criteria established in
Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company
maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018 , based on criteria established in Internal Control-Integrated
Framework (2013) issued by COSO.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of
Pfizer Inc. and Subsidiary Companies as of December 31, 2018 and 2017 , and the related consolidated statements of income, comprehensive income, equity, and cash flows
for each of the years in the three-year period ended December 31, 2018 , and the related notes (collectively, the consolidated financial statements), and our report dated
February 28, 2019 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting . Our responsibility is to express an opinion on the
Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.
Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those
policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of
the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could
have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to
future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures
may deteriorate.

KPMG LLP
New York, New York

February 28, 2019

2018 Financial Report

69

Consolidated Statements of Income
Pfizer Inc. and Subsidiary Companies

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

Revenues

Costs and expenses:

Cost of sales (a)

Selling, informational and administrative expenses (a)

Research and development expenses (a)

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net

Income from continuing operations before provision/(benefit) for taxes on income

Provision/(benefit) for taxes on income

Income from continuing operations

Discontinued operations:

Income from discontinued operations––net of tax

Gain on disposal of discontinued operations––net of tax

Discontinued operations––net of tax

Net income before allocation to noncontrolling interests

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

Earnings per common share––basic :

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations––net of tax

Net income attributable to Pfizer Inc. common shareholders

Earnings per common share––diluted :

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations––net of tax

Net income attributable to Pfizer Inc. common shareholders

Weighted-average shares––basic

Weighted-average shares––diluted
(a)

Year Ended December 31,

2018
53,647   $

2017
52,546   $

  $

11,248
14,455
8,006
4,893
1,044
2,116
11,885
706
11,179

10
—
10
11,188
36
11,153   $

1.90   $
—
1.90   $

1.86   $
—
1.87   $

11,228
14,804
7,683
4,758
351
1,416
12,305
(9,049)
21,353

(1)
3
2
21,355
47
21,308   $

3.57   $
—
3.57   $

3.52   $
—
3.52   $

5,872
5,977

5,970
6,058

  $

  $

  $

  $

  $

2016

52,824

12,322

14,844

7,892

4,056

1,565

3,794

8,351

1,123

7,229

16

—

17

7,246

31

7,215

1.18

—

1.18

1.17

—

1.17

6,089

6,159

Exclusive of amortization of intangible assets, except as disclosed in Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived
Assets.

Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.

70

2018 Financial Report

Consolidated Statements of Comprehensive Income
Pfizer Inc. and Subsidiary Companies

(MILLIONS)

Net income before allocation to noncontrolling interests

Foreign currency translation adjustments, net

Reclassification adjustments (a)

Unrealized holding gains/(losses) on derivative financial instruments, net

Reclassification adjustments for (gains)/losses included in net income (b)

Unrealized holding gains/(losses) on available-for-sale securities, net

Reclassification adjustments for (gains)/losses included in net income (b)

Reclassification adjustments for unrealized gains included in Retained earnings (c)

Benefit plans: actuarial losses, net

Reclassification adjustments related to amortization
Reclassification adjustments related to settlements, net

Other

Benefit plans: prior service (costs)/credits and other, net

Reclassification adjustments related to amortization

Reclassification adjustments related to curtailments, net

Other

Other comprehensive income/(loss), before tax

Tax provision/(benefit) on other comprehensive income/(loss) (d)

Other comprehensive income/(loss) before allocation to noncontrolling interests

Comprehensive income before allocation to noncontrolling interests

Less: Comprehensive income attributable to noncontrolling interests

Comprehensive income attributable to Pfizer Inc.

Year Ended December 31,

2018
11,188   $

2017
21,355   $

2016

7,246

(799)   $
(22)
(821)
220
27
247
(185)
124
(462)
(522)
(649)
242
142
112
(153)
(9)
(181)
(19)
2
(207)
(1,457)
518
(1,975)   $

1,116   $
162
1,278
(10)
(520)
(530)
818
(244)
—
574
(212)
588
117
(145)
348
(2)
(184)
(18)
—
(203)
1,468
(262)
1,730   $

9,214   $
16
9,198   $

23,085   $
62
23,023   $

(815)

—

(815)

(442)

452

10

248

(118)

—

130

(1,888)

558

127

195

(1,009)

184

(173)

(26)

6

(8)

(1,692)

(174)

(1,518)

5,728

28

5,701

  $

  $

  $

  $

  $

(a)

(b)

For the year ended December 31, 2017, the foreign currency translation adjustments reclassified into Other (income)/deductions—net in the consolidated statement of income primarily result from the sale of our
40% ownership investment in Teuto and the sale of our 49% equity share in Hisun Pfizer. See Note 2F. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and
Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Equity-Method Investments .
Reclassified into Other (income)/deductions—net and Cost of sales in the consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial
Instruments: Derivative Financial Instruments and Hedging Activities.

(c)  For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards in 2018 .
(d)  See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).
Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.

2018 Financial Report

71

Consolidated Balance Sheets
Pfizer Inc. and Subsidiary Companies

(MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA)

Assets

Cash and cash equivalents

Short-term investments

Trade accounts receivable, less allowance for doubtful accounts: 2018—$541; 2017—$584

Inventories

Current tax assets

Other current assets

Assets held for sale

Total current assets

Long-term investments

Property, plant and equipment, less accumulated depreciation

Identifiable intangible assets, less accumulated amortization

Goodwill

Noncurrent deferred tax assets and other noncurrent tax assets

Other noncurrent assets

Total assets

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2018—$4,776; 2017—$3,546

Trade accounts payable

Dividends payable

Income taxes payable

Accrued compensation and related items

Other current liabilities

Liabilities held for sale

Total current liabilities

Long-term debt

Pension benefit obligations, net

Postretirement benefit obligations, net

Noncurrent deferred tax liabilities

Other taxes payable

Other noncurrent liabilities

Total liabilities

Commitments and Contingencies

Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2018—-478; 2017—-524

Common stock, $0.05 par value; 12,000 shares authorized; issued: 2018—-9,332; 2017—-9,275

Additional paid-in capital

Treasury stock, shares at cost: 2018—3,615; 2017—-3,296

Retained earnings

Accumulated other comprehensive loss

Total Pfizer Inc. shareholders’ equity

Equity attributable to noncontrolling interests

Total equity

Total liabilities and equity

Amounts may not add due to rounding.

As of December 31,

2018

2017

  $

  $

  $

  $

1,139   $
17,694
8,025
7,508
3,374
2,461
9,725
49,926
2,767
13,385
35,211
53,411
1,924
2,799
159,422   $

8,831   $
4,674
2,047
1,265
2,397
10,753
1,890
31,858

32,909
5,272
1,338
3,700
14,737
5,850
95,664

19
467
86,253
(101,610)
89,554
(11,275)
63,407
351
63,758
159,422   $

1,342

18,650

8,221

7,578

3,050

2,289

12

41,141

7,015

13,865

48,741

55,952

1,855

3,227

171,797

9,953

4,656

2,029

477

2,196

11,115

—

30,427

33,538

5,926

1,504

3,900

18,697

6,149

100,141

21

464

84,278

(89,425)

85,291

(9,321)

71,308

348

71,656

171,797

See Notes to Consolidated Financial Statements, which are an integral part of these statements.

72

2018 Financial Report

Consolidated Statements of Equity
Pfizer Inc. and Subsidiary Companies

(MILLIONS, EXCEPT PREFERRED SHARES)

Shares

Stated
Value

Shares

Par
Value

Add’l
Paid-In
Capital

  Shares

Cost

Retained
Earnings

Accum.
Other
Comp.
Loss

Share -
holders’
Equity

Non-
controlling
Interests

Total
Equity

Preferred Stock

Common Stock

Treasury Stock

PFIZER INC. SHAREHOLDERS

649

  $

26

9,178

  $ 459

  $ 81,016

(3,003)

  $ (79,252)

  $

71,993

  $

(9,522)

  $ 64,720

  $

278

  $ 64,998

7,215

7,215

(1,514)

(1,514)

31

(3)

7,246

(1,518)

Balance, January 1, 2016

Net income

Other comprehensive income/(loss), net of tax

Cash dividends declared:

Common stock

Preferred stock

Noncontrolling interests

Share-based payment transactions

Purchases of common stock

Net income

Other comprehensive income/(loss), net of tax

Cash dividends declared:

Common stock

Preferred stock

Noncontrolling interests

Preferred stock conversions and redemptions

(52)

Other (a)

(7,446)

(2)

52

3

1,672

(3)

(111)

(2)
—

—

—

(154)

(5,000)

(2)
—

—
—

—
—

13

—

(7,446)

(2)
—

1,563

(5,000)

(5)

13

(7,446)

(2)

(10)

1,563

(5,000)

(5)

13

(10)

—

Balance, December 31, 2016

597

24

9,230

461

82,685

(3,160)

(84,364)

71,774

(11,036)

59,544

296

59,840

21,308

21,308

1,715

1,715

47

14

21,355

1,730

(7,789)

(1)

(8,060)

(1)

(7,789)

(7,789)

(1)
—

1,536

(5,000)

(5)
—

(1)

(9)

1,536

(5,000)

(5)

—

(9)

—

348

36

71,656

11,188

(1,955)

(1,955)

(20)

(1,975)

(8,060)

(1)
—

1,993

(12,198)

(4)

1,172

(12)

(8,060)

(1)

(12)

1,993

(12,198)

(4)

—

1,172

Share-based payment transactions (b)

45

2

1,597

15

(63)

Purchases of common stock

Preferred stock conversions and redemptions

(73)

(3)

Other

(150)

(5,000)

(3)
—

—
—

1

—

Balance, December 31, 2017

524

21

9,275

464

84,278

(3,296)

(89,425)

85,291

(9,321)

71,308

11,153

11,153

Net income

Other comprehensive income/(loss), net of tax

Cash dividends declared:

Common stock

Preferred stock

Noncontrolling interests

Share-based payment transactions

57

3

1,977

(12)

13

Purchases of common stock

Preferred stock conversions and redemptions

(46)

(2)

Other (c)

Balance, December 31, 2018

(307)

(12,198)

(3)
—

—
—

—

1,172

478

  $

19

9,332

  $ 467

  $ 86,253

(3,615)

  $ (101,610)

  $

89,554

  $ (11,275)

  $ 63,407

  $

351

  $ 63,758

(a)

Represents the $13 million cumulative effect of the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, for certain elements of the accounting for share-based payments. For
additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial
Report .

(b )

2017 treasury shares include the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. These common share equivalents were
paid in the first quarter of 2018.

(c
)

Primarily represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of
certain tax effects from Accumulated other comprehensive income . For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting
Policies: Adoption of New Accounting Standards in Pfizer’s 2018 Financial Report.

Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.

2018 Financial Report

73

Consolidated Statements of Cash Flows
Pfizer Inc. and Subsidiary Companies

(MILLIONS)

Operating Activities

Year Ended December 31,

2018

2017

2016

Net income before allocation to noncontrolling interests

  $

11,188   $

21,355   $

7,246

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

Asset write-offs and impairments

Loss on sale of HIS net assets

TCJA impact (a)

Deferred taxes from continuing operations

Share-based compensation expense

Benefit plan contributions in excess of expense

Other adjustments, net

Other changes in assets and liabilities, net of acquisitions and divestitures:

Trade accounts receivable

Inventories

Other assets

Trade accounts payable

Other liabilities

Other tax accounts, net

Net cash provided by operating activities

Investing Activities

Purchases of property, plant and equipment

Purchases of short-term investments

Proceeds from redemptions/sales of short-term investments

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less

Purchases of long-term investments

Proceeds from redemptions/sales of long-term investments

Acquisitions of businesses, net of cash acquired

Acquisitions of intangible assets

Other investing activities, net (b)

Net cash provided by/(used in) investing activities

Financing Activities

Proceeds from short-term borrowings

Principal payments on short-term borrowings

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

Proceeds from issuance of long-term debt

Principal payments on long-term debt

Purchases of common stock

Cash dividends paid

Proceeds from exercise of stock options

Other financing activities, net

Net cash used in financing activities

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

Net decrease in cash and cash equivalents and restricted cash and cash equivalents

Cash and cash equivalents and restricted cash and cash equivalents, beginning

Cash and cash equivalents and restricted cash and cash equivalents, end

- Continued -

6,384
3,398

(1)

(596)

(2,205)

949

(1,095)

(1,268)

(644)

(717)

(16)
431
98

(78)
15,827

6,269
634
55

(10,660)

(2,410)

840

(961)
344

259

(357)

7
46

(67)
1,446
16,802

(2,042)

(1,956)

(11,677)
17,581

(3,917)

(1,797)
6,244
—

(154)
288
4,525

3,711

(4,437)

(1,617)
4,974

(3,566)

(12,198)

(7,978)
1,259

(588)

(14,596)
10,302
2,058

(3,537)
3,579

8,464

(9,947)
1,422
5,274

(6,154)

(5,000)

(7,659)

862

(611)

(20,441)

(13,350)

(116)

(205)
1,431
1,225   $

53

(1,235)
2,666
1,431   $

  $

5,757

1,613

1,712

—

(700)

691

(712)

487

(134)

365

(47)

871

(223)

(734)

16,192

(1,823)

(15,957)

29,414

(4,218)

(8,011)

11,268

7,472

(5,093)

(3,060)

10,976

(7,689)

(5,000)

(7,317)

1,019

(536)

(9,228)

(215)

(1,041)

3,707

2,666

(1,000)

(18,368)

(261)
671

(176)

80

(4,740)

(7,791)

74

2018 Financial Report

Consolidated Statements of Cash Flows
Pfizer Inc. and Subsidiary Companies

Supplemental Cash Flow Information

Non-cash transactions:

Exchange of $1.1 billion net book value 6.50% U.K. pound-denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K.

pound-denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million (c)

  $

Receipt of ICU Medical common stock (b)

Promissory note from ICU Medical (b)

Equity investment in Cerevel Therapeutics, Inc. in exchange for Pfizer’s portfolio of clinical and preclinical neuroscience assets (b)

Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets (b)

Year Ended December 31,

2018

2017

2016

—   $
—
—
343
92

1,848   $
428
75
—
—

—

—

—

—

—

Cash paid (received) during the period for:

Income taxes

Interest

Interest rate hedges

  $

3,655   $
1,311

2,489   $
1,518

(38)

(199)

2,521

1,451

(338)

(a)

(b)

(c)

As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income (i) for the year ended December 31, 2017 was favorably impacted by approximately $10.7 billion ,
primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and (ii) for the year ended
December 31, 2018 was favorably impacted by approximately $600 million , primarily related to certain tax initiatives associated with the TCJA, as well as favorable adjustments to the provisional estimates of the
legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information.
For additional information, see Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method
Investments and Privately Held Investment: Divestitures .
The $747 million is included in the net loss of $846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional
information.

Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.

2018 Financial Report

75

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 1 . Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this 2018 Financial Report for terms used throughout the consolidated financial statements and related notes in this
2018 Financial Report.

The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the
United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic
or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is
included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each
year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses
have been eliminated. Beginning on January 1, 2018, only taxes paid on intercompany inventory sales transactions are deferred until recognized upon the sale of the inventory
to a third party, reflecting the adoption of a new accounting standard in the first quarter of 2018. Prior to the adoption of this new accounting standard in the first quarter of
2018, taxes paid on intercompany sales transactions were deferred until recognized upon sale of the asset to a third party. See Note 1B for further information.

From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through two distinct business segments: Pfizer Innovative
Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 18 .

Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

In the first quarter of 2018, as of January 1, 2018, we adopted eleven new accounting standards. See Note 1B for further information.

Our recent significant business development activities include:

• On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer

healthcare businesses into a new consumer healthcare joint venture, which will operate globally under the GSK Consumer Healthcare name. Assets and liabilities
associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. We expect to complete
the transaction during the second half of 2019, subject to customary closing conditions, including GSK shareholder approval and required regulatory approvals.

• On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical, a global device manufacturer, for up to approximately $900

million , composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing. HIS includes IV pumps,
solutions and devices. The operating results of HIS are included in the consolidated statement of income and EH’s operating results through February 2, 2017 and,
therefore, our financial results, and EH’s operating results, for the year ended December 31, 2017 reflect approximately one month of HIS domestic operations and
approximately two months of HIS international operations, while our financial results, and EH’s operating results, for the year ended December 31, 2016 reflect 12 months of
HIS global operations. Our financial results, and EH’s operating results, for 2018 do not reflect any contribution from HIS global operations.

• On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to

AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. for $1,040 million , composed of cash and contingent consideration. Commencing from the
acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting
period, our financial results, EH’s operating results, and cash flows for the year ended December 31, 2017 reflect approximately 11 months of the small molecule anti-
infectives business acquired from AstraZeneca.

• On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash

( $13.9 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of
Medivation. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016 reflect
approximately three months of Medivation operations.

• On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion ,
net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and
cash flows of Anacor. In accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2016
reflect approximately six months of Anacor operations.

• On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the

companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an
“Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal
quarter of 2016), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 4 ). Pfizer and
Allergan also released each other from any and all claims in connection with the merger agreement.

For additional information, see Note 2 .

76

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

B. Adoption of New Accounting Standards in 2018

On January 1, 2018, we adopted eleven new accounting standards. The quantitative impacts on our prior period consolidated financial statements of adopting the following
new standards are summarized in the tables within the section titled Impacts to our Consolidated Financial Statements , further below.

Revenues ––We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue
recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or
determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to
receive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior
period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $584 million
on a pre-tax basis ( $450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions –– net primarily for
upfront and milestone payments on our collaboration arrangements ( $394 million , pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84
million (pre-tax) related to the timing of recognizing Revenues and Cost of sales on certain product shipments. The impact of adoption did not have a material impact to our
consolidated statement of income for the year ended December 31, 2018 nor on our consolidated balance sheet as of December 31, 2018 . For additional information, see
Note 1G and Note 1H .

Financial Assets and Liabilities ––The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to
prior guidance and requires:

• certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readily

determinable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the
identical or similar investment of the same issuer;

• a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and

• separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to

the financial statements.

We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial
statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax
basis ( $419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity
securities. In 2018, we recorded net unrealized gains on equity securities of $477 million , in Other (income)/deductions––net . For additional information, see Note 4 and Note
7 .

Presentation of Net Periodic Pension and Postretirement Benefit Cost ––We adopted a new accounting standard that requires the net periodic pension and postretirement
benefit costs other than the service costs be presented in Other (income)/deductions––net, and that the presentation be applied retrospectively. We adopted the presentation
of the net periodic benefit costs other than service costs by reclassifying these costs from Cost of sales , Selling, informational and administrative expenses , Research and
development expenses and Restructuring charges and certain acquisition-related costs to Other (income)/deductions––net . We elected to apply the practical expedient as it is
impracticable to determine the disaggregation of the cost components for amounts capitalized within Inventories and property, plant and equipment and amortized in each of
those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in Note 11 to apply the retrospective presentation for comparative
periods.

As of January 1, 2018, only service costs will be included in amounts capitalized in Inventories or property, plant and equipment, while the other components of net periodic
benefit costs will be included in Other (income)/deductions –– net . For additional information, see Note 4 and Note 11 .

Income Tax Accounting ––The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has
been sold to a third party, unless the asset transferred is inventory. We adopted the standard utilizing the modified retrospective method, and, therefore, no adjustments were
made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to decrease the opening balance of
Retained earnings by $189 million .

Accounting for Hedging Activities ––The standard includes the following changes:

• Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk;

• Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest rate

risk;

• No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedging

instrument with the earnings effect of the hedged item;

• Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedge

effectiveness; and

• Simplifies hedge effectiveness testing.

We early adopted the new accounting standard on January 1, 2018 on a prospective basis. In 2018, we recorded income of $107 million in Other (income)/deductions –– net ,
whereas this item would have been classified in interest income in prior periods. For additional information, see Note 7F .

2018 Financial Report

77

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Reclassification of Certain Tax Effects from AOCI ––We early adopted a new accounting standard that provides guidance on the reclassification of certain tax effects from
AOCI. Under the new guidance, we elected to reclassify the stranded tax amounts related to the TCJA from AOCI to Retained earnings . We adopted the new accounting
standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained
earnings by $495 million , primarily due to the effect of the change in the U.S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application of
the TCJA was not material to our consolidated financial statements.

Classification of Certain Transactions in the Statement of Cash Flows ––We retrospectively adopted an accounting standard that changed the presentation of certain
information in the consolidated statements of cash flows, including the classification of:

• debt prepayment and extinguishment costs, resulting in an increase in Operating activities –– Other adjustments, net and a decrease in Financing activities –– Other

financing activities, net of $7 million for the year ended December 31, 2018 ; and

• accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities –– Other adjustments, net , and an increase in

Financing activities –– Other financing activities, net of $83 million for the year ended December 31, 2018 .

The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon
after a business acquisition date will be classified as Investing activities , while payments made thereafter will be classified as Financing activities . Payments made in excess
of the amount of the original contingent consideration liability will be classified as Operating activities . The adoption of this guidance did not have a material impact to our
consolidated financial statements.

Presentation of Restricted Cash in the Statement of Cash Flows ––We adopted, on a retrospective basis, the new accounting standard, which requires that restricted cash and
restricted cash equivalents be included with Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the consolidated
statements of cash flows. As a result, for the year ended December 31, 2018 , $2 million is presented as a decrease in Cash, cash equivalents, restricted cash and restricted
cash equivalents.

Definition of a Business ––We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or
disposals) of assets or businesses. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify
for treatment as a business. To be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together
significantly contribute to the ability to create outputs, without regard as to whether a purchaser could replace missing elements. In addition, the definition of the term “output”
has been narrowed to make it consistent with the updated revenue recognition guidance. In 2018, there was no impact to our consolidated financial statements from the
adoption of this new standard.

Derecognition of Nonfinancial Assets ––We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible
assets, real estate and inventory. The standard provides that the gain or loss is determined by the difference between the consideration received and the carrying value of the
asset. In 2018, there was no impact to our consolidated financial statements from the adoption of this new standard.

Accounting for Modifications of Share-Based Payment Awards ––We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a
share-based payment award be accounted for as a modification. There was no impact to our consolidated financial statements from the adoption of this new standard.

Impacts to our Consolidated Financial Statements ––The impacts on our prior period consolidated financial statements of adopting the new standards described above are
summarized in the following tables:

Adoption of the standard related to pension and postretirement benefit costs impacted our prior period consolidated statements of income as follows:

(MILLIONS OF DOLLARS)

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net

Income from continuing operations before provision for   taxes on income

(MILLIONS OF DOLLARS)

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Restructuring charges and certain acquisition-related costs

Other (income)/deductions––net

Income from continuing operations before provision for taxes on income

78

2018 Financial Report

As Previously

Reported

2017

Effect of Change
Higher/(Lower)

  $

11,240   $
14,784
7,657
487
1,315
12,305

(12)   $
20
27
(136)
101
—

As Previously

Reported

2016

Effect of Change
Higher/(Lower)

$

12,329

$

(7)

$

14,837

7,872

1,724

3,655

8,351

7

20

(159)

139

—

As Restated

11,228

14,804

7,683

351

1,416

12,305

As Restated

12,322

14,844

7,892

1,565

3,794

8,351

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Adoption of the standards impacted our consolidated balance sheet as follows:

(MILLIONS OF DOLLARS)

Trade accounts receivable

  $

Inventories

Current tax assets
Noncurrent deferred tax assets and

other noncurrent tax assets

Other noncurrent assets

Other current liabilities

Noncurrent deferred tax liabilities

Other noncurrent liabilities

Retained earnings
Accumulated other comprehensive loss

As Previously
Reported Balance at
December 31, 2017

Revenues

Financial Assets

and Liabilities

Income Tax
Accounting

Reclassification of
Certain Tax Effects
from AOCI

Balance at
January 1,
2018

Effect of New Accounting Standards Higher/(Lower)

8,221   $
7,578
3,050

1,855
3,227
11,115
3,900
6,149
85,291
(9,321)

13   $
(11)
(11)

(17)
—
(123)
106
(459)
450
—

—   $
—
—

—
—
—
—
—
419
(419)

—   $
—
(3)

—
(204)
—
(18)
—
(189)
—

—   $
—
—

—
—
—
—
—
495
(495)

8,234

7,567

3,036

1,838

3,023

10,992

3,988

5,690

86,466

(10,235)

2018 Financial Report

79

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Adoption of the standards related to the classification of certain transactions in the statements of cash flows and the presentation of restricted cash in the statement of cash
flows impacted our consolidated statement of cash flows as follows:

(MILLIONS OF DOLLARS)

Operating Activities

Other adjustments, net
Other changes in assets and liabilities, net of acquisitions and

  $

divestitures––Other assets

Investing Activities

Proceeds from redemptions/sales of short-term investments

Proceeds from redemptions/sales of long-term investments

Other investing activities, net

Financing Activities

Principal payments on short-term borrowings
Net proceeds from short-term borrowings with original maturities

of three months or less

Other financing activities, net
Net decrease in cash and cash equivalents and restricted cash

and cash equivalents

Cash and cash equivalents and restricted cash and cash

equivalents, beginning

Cash and cash equivalents and restricted cash and cash

equivalents, ending

(MILLIONS OF DOLLARS)

Operating Activities

Other adjustments, net
Other changes in assets and liabilities, net of acquisitions and

  $

divestitures––Other assets

Investing Activities

Proceeds from redemptions/sales of short-term investments

Proceeds from redemptions/sales of long-term investments

Other investing activities, net

Financing Activities

Principal payments on short-term borrowings
Net (payments on)/proceeds from short-term borrowings with

original maturities of three months or less

Other financing activities, net
Net decrease in cash and cash equivalents and restricted cash

and cash equivalents

Cash and cash equivalents and restricted cash and cash

equivalents, beginning

Cash and cash equivalents and restricted cash and cash

equivalents, ending

80

2018 Financial Report

Effect of New Accounting Standards Inflow/(Outflow)

As Previously

Reported

Cash Flow Classification

Restricted Cash

As Restated

2017

50   $

(31)

10,307
3,594
650

(9,990)

1,401
(233)

(1,254)

2,595

1,342

294   $

—

—
—
21

43

20
(378)

—

—

—

2016

—   $

38

(5)
(14)
—

—

—
—

19

70

89

344

7

10,302

3,579

671

(9,947)

1,422

(611)

(1,235)

2,666

1,431

Effect of New Accounting Standards Inflow/(Outflow)

As Previously

Reported

Cash Flow Classification

Restricted Cash

As Restated

208   $

(60)

29,436
11,254
51

(5,102)

(3,084)
(196)

(1,046)

3,641

2,595

278   $

—

—
—
28

9

24
(340)

—

—

—

—   $

13

(22)
14
—

—

—
—

5

65

70

487

(47)

29,414

11,268

80

(5,093)

(3,060)

(536)

(1,041)

3,707

2,666

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet that sum to the total of the same
amounts shown in the consolidated statements of cash flows:

(MILLIONS OF DOLLARS)

Cash and cash equivalents

Restricted cash and cash equivalents in Short-term investments

Restricted cash and cash equivalents in Long-term investments

Restricted cash and cash equivalents in Other current assets

Restricted cash and cash equivalents in Other noncurrent assets

Total cash and cash equivalents and restricted cash and cash equivalents shown in the consolidated balance sheets

December 31,

2018
1,139   $
32
55
—
—
1,225   $

December 31,
2017

1,342

—

—

14

75

1,431

  $

  $

Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of Pfizer
medicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines.

C. Estimates and Assumptions

In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and
disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated
statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the
cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as
determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as
accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&D assets), and estimates are used in
determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales
returns, and restructuring reserves, all of which also impact the consolidated statements of income.

Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our
estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.

As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and
circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ
from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and
assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for
change.

For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements–– Note 5A . Tax Matters: Taxes on Income from
Continuing Operations.

D. Acquisitions

Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the
acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the
acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration
transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S.
GAAP, no goodwill is recognized and acquired IPR&D is expensed.

Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally
estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date
until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions––net .

Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

E. Fair Value

We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair
value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting
of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to
sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the

2018 Financial Report

81

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.

When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:

•

Income approach, which is based on the present value of a future stream of net cash flows.

• Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

• Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.

Our fair value methodologies depend on the following types of inputs:

• Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

• Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than
quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means
(Level 2 inputs).

• Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For
information about the risks associated with estimates and assumptions, see Note 1C.

F. Foreign Currency Translation

For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their
U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar
equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss) .
The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions––net . For operations in
highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions––
net , and we translate non-monetary items at historical rates.

G . Revenues and Trade Accounts Receivable

On January 1, 2018, we adopted a new accounting standard for revenue recognition. For further information, see Note 1B .

We recorded direct product sales and/or alliance revenues of more than $1 billion for each of ten products in 2018 and for each of nine products in 2017 and 2016 . In the
aggregate, these direct products sales and/or alliance product revenues represent 51% of our revenues in 2018 , 46% of our revenues in 2017 and 43% of our revenues in
2016 . See Note 18C for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with
customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets
begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business includes OTC brands with a focus on dietary supplements, pain
management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent,
consumer healthcare products worldwide to developed and emerging market countries.

Revenue Recognition ––We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control
based on when the product is shipped or delivered and title passes to the customer.

• Customers ––Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and

pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and
integrated delivery networks. Our consumer healthcare customers include retailers and, to a lesser extent, wholesalers and distributors.

Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs,
including those managed through pharmacy benefit managers, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales
allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented).

• Our Sales Contracts ––Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter
cycles in the U.S. Sales are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity,
product recalls or a changing competitive environment.

• Deductions from Revenues –– Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the
revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the
related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.

Specifically:

•

In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers
and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We
record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions
written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is

82

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D
participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the
utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are
as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.

• Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within
each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted
pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of
reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.

• Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts

incurred, as we settle these deductions generally within two to five weeks of incurring the liability.

• Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices;
historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between
shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive
environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.

• We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the

cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.

Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and
cash discounts totaled $5.4 billion as of December 31, 2018 and $4.9 billion as of December 31, 2017 .

The following table provides information about the balance sheet classification of these accruals:

(MILLIONS OF DOLLARS)

Reserve against Trade accounts receivable, less allowance for doubtful accounts

Other current liabilities :

Accrued rebates

Other accruals

Other noncurrent liabilities

Total accrued rebates and other accruals

As of December 31,

2018
1,288   $

3,208
531

399
5,426   $

2017

1,352

2,674

512

385

4,923

  $

  $

The accrued rebates increased from the prior year-end due to an increase in Medicare rebates driven by increased sales of IH products through this channel.

Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues .

Trade Accounts Receivable —Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best
estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other
current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been
exhausted.

H. Collaborative Arrangements

Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual
terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as
alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance
revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable
period. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where
we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration
arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty
payments to collaboration partners as Cost of sales . Royalty payments received from collaboration partners are included in Other (income)/deductions—net.

Reimbursements to or from our collaboration partners for development costs are recorded net in Research and development expenses . Upfront payments and pre-approval
milestone payments due from us to our collaboration partners in development stage collaborations are recorded as Research and development expenses . Milestone payments
due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in Identifiable intangible assets—Developed technology rights
. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in Other (income)/deductions—net over the development period
for the collaboration products, when our performance obligations include providing R&D services to our collaboration partners. Upfront, pre-approval and post-approval
milestone payments earned by us may be recognized in Other (income)/deductions—net immediately when

2018 Financial Report

83

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a
medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may
recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be
probable of a significant reversal.

On January 1, 2018, we adopted a new accounting standard on revenue recognition (see Note 1B ). As a result of the adoption, we recognized the following cumulative effect
adjustments related to collaboration arrangements to Retained earnings :

• $394 million (pre-tax) for collaborative arrangements where upfront, pre-approval and regulatory approval milestone payments received from our collaboration partners are
recognized in Other (income)/deductions—net over a reduced period. Under the new standard, the income from upfront and pre-approval milestone payments due to us is
typically recognized over the development period for the collaboration when our performance obligation, in addition to granting a license, is to provide R&D services to our
collaboration partners, and major regulatory approval milestones are typically recognized immediately when earned as the related development period has ended. The
income from upfront and milestone payments is typically recognized immediately as earned if our performance obligation, in addition to granting a license, is only for
commercialization activities. Under the old standard, this income was recognized over the combined development and estimated commercialization (including co-promotion)
period for the collaboration products.

• $82 million (pre-tax) for collaborative arrangements where we manufacture products for our collaboration partners and recognize Revenues and Cost of sales for product
shipments at an earlier point in time. Under the new standard, revenue is recognized when we transfer control of the products to our collaboration partners. Under the old
standard, revenue was recognized when our collaboration partners sell the products and transfer title to their third party customers.

I. Cost of Sales and Inventories

We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We
regularly review our inventories for impairment and reserves are established when necessary.

J. Selling, Informational and Administrative Expenses

Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising,
shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $3.1 billion in 2018 , $3.1 billion in 2017 and $3.2 billion in 2016 .
Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs.

K. Research and Development Expenses

R&D costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing
arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as
expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives
regulatory approval, we record any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an
indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

R&D expenses related to upfront and milestone payments for intellectual property rights totaled $197 million in 2018 , $169 million in 2017 and $82 million in 2016 . For
additional information, see Note 2E .

L. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets

Long-lived assets include:

• Property, plant and equipment, less accumulated depreciation —These assets are recorded at cost and are increased by the cost of any significant improvements after

purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the
individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.

•

Identifiable intangible assets, less accumulated amortization —These acquired assets are recorded at fair value. Intangible assets with finite lives are amortized on a
straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can
be determined.

• Goodwill —Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds
and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to
intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and
administrative expenses and/or Research and development expenses, as appropriate.

We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least
annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the
amount by which the fair value is less than the carrying value of these assets.

84

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Specifically:

• For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment

indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the
carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an
impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.

• For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for
the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the
asset as indefinite-lived is appropriate.

• For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we
then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and
record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.

Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about
the risks associated with estimates and assumptions, see Note 1C.

M. Restructuring Charges and Certain Acquisition-Related Costs

We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our
cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs
associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is
classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Termination costs are generally
recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business
acquisition are expensed as incurred .

Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely
heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

N. Cash Equivalents and Statement of Cash Flows

On January 1, 2018, we adopted standards related to the classification of certain transactions in the statements of cash flows and the presentation of restricted cash in the
statement of cash flow. For further information, see Note 1B .

Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If
items meeting this definition are part of a larger investment pool, we classify them as Short-term investments .

Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the
classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the
hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting
nature.

O. Investments and Derivative Financial Instruments

On January 1, 2018, we adopted new accounting standards for financial assets and liabilities as well as accounting for hedging activities. For further information, see Note 1B .

Our investments are comprised of the following: trading funds and securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and
ability to hold the investment to maturity) and private equity securities. The classification of an investment can depend on the nature of the investment, our intent and ability to
hold the investment, and the degree to which we may exercise influence.

• Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.

• Available-for-sale debt securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.

• Held-to-maturity debt securities are carried at amortized cost.

• Private equity securities are carried at equity-method or at cost. For additional information, see Note 1B. For equity investments where we have significant influence over the

financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee’s income and
expenses in Other (income)/deductions—net . The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to
the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not
include amounts of contingent consideration.

Realized gains or losses on sales of investments are determined by using the specific identification cost method.

We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-
than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.

2018 Financial Report

85

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A ), with changes in fair value reported in Net income or, for derivative
financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7F ).

A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

P. Tax Assets and Liabilities and Income Tax Contingencies

On January 1, 2018, we adopted new accounting standards for income tax accounting as well as reclassification of certain tax effects from AOCI. For further information, see
Note 1B .

Current tax assets primarily includes income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax
obligations.

Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities
using enacted tax rates and laws, including the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not
recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if
necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of
our consolidated balance sheet.

Other taxes payable in our consolidated balance sheet as of December 31, 2018 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax
liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we plan to elect, with the filing of our 2018 U.S.
Federal Consolidated Income Tax Return, payment over eight years through 2026. See Note 5A for additional information.

We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on
the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon
settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.

Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the
tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the
position to “more likely than not”; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the
appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations
expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-
than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and
penalties, if any, are recorded in Provision/(benefit) for taxes on income and are classified on our consolidated balance sheet with the related tax liability.

Amounts recorded for valuation allowances and income tax contingencies can result from a complex series of judgments about future events and uncertainties and can rely
heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

Q. Pension and Postretirement Benefit Plans

On January 1, 2018, we adopted a new accounting standard for the presentation of net periodic pension and postretirement benefit cost. For further information, see Note 1B .

The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and
supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for
retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated
balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable
benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension
plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to
the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs).
Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in Other (income)/deductions—net .

Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on
estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

86

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

R. Legal and Environmental Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other
product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for
these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate
than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount,
we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
For information about the risks associated with estimates and assumptions, see Note 1C.

S. Share-Based Payments

Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values
are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, informational and administrative expenses and/or Research and development
expenses , as appropriate.

Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and
assumptions. For information about the risks associated with estimates and assumptions, see Note 1C .

Note 2 . Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and
Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment

A. Acquisitions

AstraZeneca’s Small Molecule Anti-Infectives Business (EH)

On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s
small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the marketed products Zavicefta™ (ceftazidime-
avibactam), Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). In 2017,
under the terms of the agreement, we made payments of approximately $605 million to AstraZeneca related to the transaction. We made an additional milestone payment of
$125 million in our first fiscal quarter of 2018 and we made a deferred payment of $175 million to AstraZeneca in January 2019. In addition, we may be required to pay an
additional milestone payment of $75 million if the related milestone is achieved prior to December 31, 2021, and up to $600 million if sales of Zavicefta™ exceed certain
thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta™ and ATM-AVI in certain markets for a period ending on the later of 10 years from first
commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted
payments are expected to be in the range of approximately $327 million to $553 million . The total fair value of consideration transferred for AstraZeneca’s small molecule anti-
infectives business was approximately $1,040 million inclusive of cash paid of $555 million and the fair value of contingent consideration of $485 million (which is composed of
the deferred payment, the $50 million milestone payment made in the second quarter of 2017, the $125 million milestone payment made in our first fiscal quarter of 2018 and
the future expected milestone and royalty payments). In connection with this acquisition, we recorded $894 million in Identifiable intangible assets , consisting of $728 million in
Developed technology rights and $166 million in IPR&D . We also recorded $92 million in Other current assets related to the economic value of inventory which was retained
by AstraZeneca for sale on our behalf, $73 million in Goodwill and $19 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets
acquired and the liabilities assumed has been completed.

Medivation, Inc. (IH)

On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash (
$13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities. The
remaining consideration was paid as of December 31, 2017 . Medivation is a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on
developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps
in the androgen receptor signaling pathway within tumor cells. Xtandi is approved for the treatment of castration-resistant prostate cancer. In the third quarter of 2018, upon the
approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, we transferred the remaining IPR&D value of Xtandi to
Developed technology rights (see Note 10A ). Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization
rights for Xtandi outside the U.S. The Medivation portfolio also includes talazoparib, which was approved by the FDA in October 2018, under the trade name Talzenna, for the
treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other types of cancer. In
connection with this acquisition, we recorded $12.2 billion in Identifiable intangible assets , primarily consisting of $8.1 billion of Developed technology rights with an average
useful life of approximately 12 years and $4.1 billion of IPR&D, and recorded $6.1 billion of Goodwill, $4.0 billion of net income tax liabilities, and $259 million of assumed
contingent consideration of which $35 million has been paid through December 31, 2018. In 2017 and 2016, we recorded measurement period adjustments to the estimated
fair values initially recorded in 2016, which resulted in a reduction in Identifiable intangible assets of approximately $1.0 billion with a corresponding change to Goodwill and net
income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the
acquisition date. The 2017 results included a decrease of approximately $38 million to Amortization of intangible assets which reflected the cumulative pre-tax impact of the
measurement period adjustments to Identifiable intangible assets that were amortized to the income statement since the acquisition date. The measurement period
adjustments did not result

2018 Financial Report

87

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been
completed.

Bamboo Therapeutics, Inc. (IH)

On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment
of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for $150 million , plus potential milestone payments
of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration
transferred for Bamboo was approximately $343 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $167 million ,
consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of $45 million . We previously purchased a minority stake in Bamboo
in the first quarter of 2016 for a payment of approximately $43 million . Upon acquiring the remaining interest in Bamboo in the third quarter of 2016, we recognized a gain of $2
million on our existing investment in Other (income)/deductions––net over the one-year allocation period . This acquisition provides us with several clinical and pre-clinical
assets that complement our rare disease portfolio, an advanced recombinant Adeno-associated virus vector design and production technology, and a fully functional Phase I/II
gene therapy manufacturing facility. Bamboo is a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded $330 million of Identifiable intangible
assets, consisting entirely of IPR&D. We also recorded $142 million of Goodwill and $94 million of net deferred tax liabilities. The final allocation of the consideration transferred
to the assets acquired and the liabilities assumed has been completed.

Anacor Pharmaceuticals, Inc. (IH)

On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net
of cash acquired), plus $698 million debt assumed. Anacor is a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule
therapeutics derived from its boron chemistry platform. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA
in December 2016 under the trade name, Eucrisa . In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and recorded $4.9
billion in Identifiable intangible assets , primarily consisting of $4.8 billion of IPR&D , and recorded $646 million of Goodwill and $346 million of net income tax liabilities. The
final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

B. Divestitures

Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH)

On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical agreed to acquire all of our global infusion systems net assets, HIS,
for approximately $1 billion in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU
Medical’s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately $900
million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing.

The revised transaction closed on February 3, 2017. At closing, we received 3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we
initially valued at approximately $428 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which
were reported as equity securities at fair value in Long-term investments on the consolidated balance sheet as of December 31, 2017. Upon the sale of these shares in 2018,
we realized a full gain of $302 million on these securities, although our income statement only reflects a gain of $47 million as the balance of the previously unrealized gain was
recorded as a cumulative effect adjustment upon the adoption of a new accounting standard (see Note 1B ). We also received a promissory note in the amount of $75 million ,
which was repaid in full as of December 31, 2017, and net cash of approximately $200 million before customary adjustments for net working capital, which is reported in Other
investing activities, net on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up to
an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. We
recognized a pre-tax gain of approximately $1 million in 2018 and pre-tax losses of $55 million in 2017 in Other (income)/deductions––net, representing adjustments to
amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. For additional information, see Note 4 .

The sale of the HIS net assets was fully completed in all jurisdictions as of year-end 2018.

In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These
agreements primarily related to administrative services, and were provided for a period of 24 months after the closing date. We will also manufacture and supply certain HIS
products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These
agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.

At December 31, 2016 , we determined that the carrying value of the HIS net assets held for sale exceeded their fair value less estimated costs to sell, resulting in a pre-tax
impairment charge of $1.7 billion , which is included in Other (income)/deductions––net for the year ended December 31, 2016 (see Note 4 ). The decline in value resulted from
lower expectations as to future cash flows to be generated by HIS, primarily as a result of an increase in competition for customer contracts and pricing factors that were not
initially anticipated.

Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc. (WRD)

In April 2018, Pfizer and Allogene announced that the two companies entered into a contribution agreement for Pfizer’s portfolio of assets related to allogeneic CAR T therapy,
an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene received from Pfizer rights to pre-clinical and clinical CAR T assets, all of
which were previously licensed to Pfizer from French cell therapy company, Cellectis, beginning in 2014 and French pharmaceutical company, Servier, beginning in 2015.
Allogene assumed responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer will continue to participate financially in the development of the CAR T
portfolio through an ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate 7% ownership stake in Cellectis that

88

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T
therapies in exchange for an upfront payment of $80 million , as well as potential future development, regulatory and commercial milestone payments and royalties. In
connection with the Allogene transaction, Pfizer recognized a non-cash $50 million pre-tax gain in Other (income)/deductions––net in the second quarter of 2018 , representing
the difference between the $127 million fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see Note 4 ).

In October 2018, Allogene consummated an initial public offering of new shares of its common stock, which resulted in Pfizer’s preferred stock converting into common stock
and a decrease in our ownership percentage from approximately 25% to approximately 18% as of December 31, 2018. The closing price on the day of the initial public offering
was $25 per share. Beginning as of the date of the initial public offering, our investment in Allogene is being measured at fair value with changes in fair value recognized in net
income (see Note 4 ).

Sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen Inc. (WRD)

In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIAS to Biogen. We received $75 million upfront and have the opportunity to receive up to $515
million in future development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized the $75 million upfront payment
in Other (income)/deductions––net in the second quarter of 2018 (see Note 4 ). In the fourth quarter of 2018, we recognized an additional $10 million milestone in Other
(income)/deductions––net (see Note 4). We will record the other milestones and royalties to Other (income)/deductions––net when due, or earlier if we have sufficient
experience to determine such amounts are not probable of significant reversal.

Divestiture of Neuroscience Assets (WRD)

In September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and
preclinical stage neuroscience assets primarily targeting disorders of the central nervous system including Parkinson’s disease, epilepsy, Alzheimer’s disease, schizophrenia
and addiction. These assets were part of the neuroscience discovery and early development efforts, which we announced we were ending in January 2018. In connection with
this transaction, we out-licensed the portfolio to Cerevel in exchange for a 25% ownership stake in Cerevel’s parent company, Cerevel Therapeutics, Inc., and potential future
regulatory and commercial milestone payments and royalties. Bain Capital has committed to invest $350 million to develop the portfolio, with the potential for additional funding
as the assets advance. In connection with the transaction, we recognized a non-cash $343 million pre-tax gain in Other (income)/deductions––net in the third quarter of 2018,
representing the fair value of the equity investment received as the assets transferred had a book value of $0 (see Note 4 ). Our investment in Cerevel Therapeutics, Inc. is
reported in Long-term investments on the consolidated balance sheet as of December 31, 2018.

C. Assets and Liabilities Held for Sale

On December 19, 2018, we announced that we entered into a definitive agreement with GSK under which we and GSK have agreed to combine our respective consumer
healthcare businesses into a new consumer healthcare joint venture that will operate globally under the GSK Consumer Healthcare name. In exchange for contributing our
Consumer Healthcare business, we will receive a 32% equity stake in the company and GSK will own the remaining 68% . The transaction is expected to close in the second
half of 2019, subject to customary closing conditions including GSK shareholder approval and required regulatory approvals. Upon the closing of the transaction, we will
deconsolidate our Consumer Healthcare business and recognize a gain for the difference in the fair value of our 32% equity stake in the company and the carrying value of our
Consumer Healthcare business. We will account for our 32% equity stake in the company after closing of the transaction as an equity-method investment. Assets and liabilities
associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. The Consumer Healthcare
business assets held for sale are reported in Assets held for sale and Consumer Healthcare business liabilities held for sale are reported in Liabilities held for sale . This
includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries. The amounts associated with the Consumer
Healthcare business, as well as other assets classified as held for sale consisted of the following:

2018 Financial Report

89

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

(MILLIONS OF DOLLARS)

Assets Held for Sale

Cash and cash equivalents

Trade accounts receivable, less allowance for doubtful accounts

Inventories

Other current assets

PP&E

Identifiable intangible assets, less accumulated amortization

Goodwill

Noncurrent deferred tax assets and other noncurrent tax assets

Other noncurrent assets

Total Consumer assets held for sale

Other assets held for sale (a)

Assets held for sale

Liabilities Held for Sale

Trade accounts payable

Income taxes payable

Accrued compensation and related items

Other current liabilities

Pension benefit obligations, net

Postretirement benefit obligations, net

Noncurrent deferred tax liabilities

Other noncurrent liabilities

Total Consumer liabilities held for sale
(a)   Other assets held for sale consist of PP&E.

As of December 31,

2018

2017

  $

  $

  $

  $

32   $
532
538
56
675
5,763
1,972
54
57
9,678
46
9,725   $

406   $
39
93
353
39
33
870
56
1,890   $

—

—

—

—

—

—

—

—

—

—

12

12

—

—

—

—

—

—

—

—

—

As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $977 million in 2018, $863 million in 2017 and $780
million in 2016.

D. Licensing Arrangements

Shire International GmbH (IH)

In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative
colitis and Crohn’s disease, to Shire for an upfront payment of $90 million , up to $460 million in development and sales-based milestone payments and potential future royalty
payments on commercialized products. The $90 million upfront payment was initially deferred and recognized in Other (income)/deductions––net ratably through December
2017. In the first quarter of 2018, we recognized $75 million in Other (income)/deductions––net for a milestone payment received from Shire related to their first dosing of a
patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis, and in the third quarter of 2018, we recognized $35 million in Other
(income)/deductions––net for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of
Crohn’s disease (see Note 4 ).

BionTech AG (WRD)

In August 2018, a multi-year R&D arrangement went into effect between BionTech AG (BionTech), a privately held company, and Pfizer to develop mRNA-based vaccines for
prevention of influenza (flu). In September 2018, we made an upfront payment of $50 million to BionTech, which was recorded in Research and development expenses, and
BionTech is eligible to receive up to an additional $325 million in future development and sales based milestones and future royalty payments associated with worldwide sales.
As part of the transaction, we also purchased 169,670 newly-issued ordinary shares of BionTech for $50 million in the third quarter of 2018, which are reported in Long-term
investments in the consolidated balance sheet as of December 31, 2018.

E. Research and Development and Collaborative Arrangements

We adopted a new accounting standard for revenue recognition and changed our accounting policies with respect to collaborative arrangements accordingly. For additional
information, see Note 1B .

Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P.

On November 1, 2016, we announced the discontinuation of the global clinical development program for bococizumab. During December 2016, $31.3 million was refunded to
NovaQuest representing amounts NovaQuest prepaid for development costs (under the May 2016 agreement described below) that were not used for program expenses due
to the discontinuation of the development program. No additional payments have been or are expected to be received from or paid to NovaQuest with respect to this
agreement, which was terminated effective as of November 18, 2016.

90

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to fund up to $250 million in development costs related to certain Phase 3
clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound.
NovaQuest’s development funding was expected to cover up to 40% of the development costs and was to be received over five quarters during 2016 and 2017. As there was a
substantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses during 2016 was recognized as an obligation to perform
contractual services and therefore has been recognized as a reduction of Research and development expenses as incurred. The reduction to Research and development
expenses for 2016 totaled $180.3 million .

Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.

In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to $200 million in development costs related to certain Phase 3 clinical
trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s
development funding is expected to cover up to 100% of the development costs and will be received over approximately 13 quarters from 2016 through the second quarter of
2019 after which Pfizer will be responsible for the remaining development costs. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding
is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to
Research and development expenses totaled $57.6 million for 2018, $72.1 million for 2017 and $46.6 million for 2016. Following potential regulatory approval, NovaQuest will
be eligible to receive a combination of fixed milestone payments of up to approximately $267 million in total, based on achievement of first commercial sale and certain levels of
cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. Fixed sales-based milestone payments will be recorded as intangible assets
and amortized to Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when
incurred.

Research and Development Arrangement with RPI Finance Trust

In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI would fund up to $300 million in development costs related to
certain Phase 3 clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI’s
development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials until the second quarter of 2020 after which Pfizer will be responsible
for the remaining cost of the trials. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform
contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses totaled $99.3
million for 2018, $75.6 million for 2017 and $44.9 million for 2016. If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication
based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of
the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and
amortized to Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when
incurred.

Collaborative Arrangements

In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of
research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or
commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and
obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and
we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.

The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:

Year Ended December 31,

(MILLIONS OF DOLLARS)

Revenues —Revenues (a)

Revenue s—Alliance revenues (b)

Total revenues from collaborative arrangements

Cost of sales (c)

Selling, informational and administrative expenses (d)

Research and development expenses (e)

  $

2018
571   $

3,838
4,409

(296)

(90)
162
281

2017
606   $

2,927
3,533
(329)
(54)
222
249

2016

659

1,746

2,405

(315)

(5)

64

542

Other income/(deductions)—net (f)
(a)  Represents sales to our partners of products manufactured by us.
(b)  Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.
(c)

Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with
inventory purchased from our partners.

(d)  Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(e)

Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $50 million in 2018 , $15
million in 2017 and $15 million in 2016 . Our collaboration with Lilly (see below) also includes reimbursements of $98 million in 2018, $147 million in 2017 and $120 million in 2016.

(f)  Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our  36 month royalty arrangement on sales of Enbrel in the U.S. and Canada,

partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.

2018 Financial Report

91

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under
the collaborative arrangements.

In addition, in connection with our collaborative arrangements, we paid post-approval milestones of $140 million in 2017 related to our collaboration with Merck KGaA (see
below). These payments were recorded in Identifiable intangible assets –– Developed technology rights. We did not pay post-approval milestones to collaboration partners in
2018 or 2016. We also recorded milestones earned related to our collaboration with Merck (see below) of $40 million in 2018 to Other (income)/deductions––net and $150
million in 2017, substantially all of which was included in the adjustment to increase the opening balance of Retained earnings upon the adoption of a new accounting standard
for revenue recognition, effective January 1, 2018 (see Note 1B ).

Collaboration with Merck & Co., Inc. (IH)

Under a worldwide collaboration agreement, except for Japan, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose
combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the European Commission in March 2018 as Steglatro,
Segluromet and Steglujan. Merck exclusively promotes Steglatro and the two fixed-dose combination products and we share revenues and certain costs with Merck on a 60% /
40% basis, with Pfizer having the 40% share.

In the first quarter of 2017 , we received a $90 million milestone payment from Merck upon the FDA’s acceptance for review of the NDAs for ertugliflozin and two fixed-dose
combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in Other noncurrent
liabilities, and through December 31, 2017, was being recognized in Other (income)/deductions––net over a multi-year period. As of December 31, 2017, we were due a $60
million milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As of December 31, 2017, the
$60 million due from Merck was deferred and primarily reported in Other noncurrent liabilities . In the first quarter of 2018, in connection with the approval of ertugliflozin in the
EU, we recognized a $40 million milestone payment from Merck in Other (income)/deductions––net (see Note 4 ). We are eligible for additional payments associated with the
achievement of future commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard, as of January 1, 2018, the $60 million
of deferred income and approximately $85 million of the $90 million of deferred income associated with the above-mentioned milestone payments were recorded to and
included in the $584 million cumulative effect adjustment to Retained earnings . See Note 1B for additional information.

Collaboration with Eli Lilly & Company (IH)

In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will equally
share product-development expenses as well as potential revenues and certain product-related costs. We received a $200 million upfront payment from Lilly in accordance
with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in Other noncurrent liabilities, and through December 31, 2017, was
being recognized in Other (income)/deductions––net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain
program for tanezumab in July 2015. The FDA granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis A and chronic low
back pain in June 2017. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory
and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard, as of January 1, 2018, approximately $107 million of
deferred income associated with the above-mentioned upfront payment was recorded to and included in the $584 million cumulative effect adjustment to Retained earnings .
See Note 1B for additional information. Approximately $37 million of the upfront payment continues to be deferred, of which approximately $30 million is reported in Other
current liabilities and approximately $8 million is reported in Other noncurrent liabilities as of December 31, 2018. This amount is expected to be recognized in Other
(income)/deductions––net over the remaining development period for the product between 2019 and 2020.

Collaboration with Merck KGaA (IH)

In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, currently approved as Bavencio for
metastatic MCC and for patients with locally advanced or metastatic UC in certain countries and in development as a potential treatment for multiple other types of cancer. We
and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA’s
broad portfolio of approved and investigational oncology therapies. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and
several other key markets. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of $850 million to Merck KGaA and Merck KGaA is
eligible to receive regulatory and commercial milestone payments of up to approximately $2.0 billion . During 2017, we made $140 million in milestone payments to Merck
KGaA, which were recorded in Identifiable intangible assets –– Developed technology rights, for approvals of avelumab received in 2017 for the MCC indication in the U.S., the
EU and Japan, and for the metastatic UC indication in the U.S. Both companies jointly fund the majority of development and commercialization costs, and split equally any
profits generated from selling any products containing avelumab from this collaboration. In September 2018, the companies announced positive top-line results from the pivotal
Phase 3 JAVELIN Renal 101 study evaluating Bavencio (avelumab) in combination with Inlyta (axitinib), compared with Sutent (sunitinib) as initial therapy for patients with
advanced RCC. In December 2018, both companies amended the collaborative agreement such that Pfizer will be solely responsible for the development and
commercialization of its anti PD-1 antibody. Under the terms of the amended agreement, Pfizer paid Merck KGaA an up-front payment and we will make a potential milestone
and tiered royalty payments should the Pfizer anti PD-1 antibody achieve regulatory and commercial success.

92

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

F. Equity-Method Investments

Investment in Hisun Pfizer Pharmaceuticals Company Limited (EH)

In September 2012, we and Hisun, a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell
pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of $250 million , of which our portion
was $122.5 million . As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious
disease, oncology, mental health and other therapeutic areas.

We accounted for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we had over the operations of Hisun Pfizer through our board
representation, minority veto rights and 49% voting interest. Our investment in Hisun Pfizer was reported in Long-term investments , and our share of Hisun Pfizer’s net income
was recorded in Other (income)/deductions––net.

On November 10, 2017, we sold our 49% equity share in Hisun Pfizer to Sapphire I (HK) Holdings Limited, an investment fund managed by Hillhouse Capital, for a total of
$286 million in cash which included our carrying value of $270 million in cash plus $16 million to cover certain taxes incurred on the transaction. As a result of the sale
transaction, we recognized a loss of $81 million in the fourth quarter of 2017 for the recognition in earnings of the currency translation adjustment associated with our
investment. After the sale transaction, Hisun Pfizer changed its name but retained its current rights to manufacture, sell and distribute all of Hisun Pfizer’s currently marketed
and pipeline products in China. We are providing technical, manufacturing and regulatory services in connection with a technology transfer process being run by Hisun Pfizer to
support Hisun Pfizer’s objective that the products that we had previously licensed to Hisun Pfizer, will in the future, be manufactured locally in China. We continue to supply
certain products to Hisun Pfizer for a period of time, after the sale transaction, to facilitate a smooth transition.

In 2016, we determined that we had other-than-temporary declines in the value of Hisun Pfizer, and, therefore, we recognized a loss of $452 million in Other
(income)/deductions––net (see Note 4 ), consisting of losses recognized in the first, second and fourth quarters of 2016. In the first and second quarters of 2016, we
determined that we had other-than-temporary declines in the value of Hisun Pfizer and, therefore, we recognized a loss of $81 million and $130 million , respectively. The
declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued
slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. In the fourth quarter of 2016, we recognized
a loss of $241 million to reduce the carrying value of our investment in Hisun Pfizer to approximately $270 million at December 31, 2016.

In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a
nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net
cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the
sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

Investment in Laboratório Teuto Brasileiro S.A. (EH)

We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a 40% -owned generics company in Brazil, and sell our 40% interest in Teuto to the majority
shareholders. As part of the agreement, we waived our option to acquire the remaining 60% of Teuto, and Teuto’s other shareholders have waived their option to sell their 60%
stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately $30 million in Other (income)/deductions––net (see Note 4 ),
which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders’ option to sell their 60%
stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16,
2017.

In 2016, we determined that we had an other-than-temporary decline in the value of Teuto, and, therefore, in 2016, we recognized a loss of $50 million in Other
(income)/deductions––net (see Note 4 ) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be
generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the
Brazilian Real.

In valuing our investment in Teuto, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a
nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net
cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the
sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

G. Privately Held Investment

AM-Pharma B.V. (WRD)

In April 2015, we acquired a minority equity interest in AM-Pharma, a privately-held Dutch biopharmaceutical company focused on the development of human recombinant
Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option became exercisable
after completion of a Phase 2 trial of recAP for the treatment of Acute Kidney Injury related to sepsis in the first quarter of 2018. We declined to exercise the option and the
option expired unexercised during the second quarter of 2018. Under the terms of the agreement, we originally paid $87.5 million for both the exclusive option and the minority
equity interest, which was recorded as a cost-method investment in Long-term investments . During the fourth quarter of 2017, we recognized a loss of $43 million in Other
(income)/deductions––net (see Note 4 ) for an impairment of our long-term investment.

2018 Financial Report

93

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity
Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For
example:

•

•

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include
expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees,
assets and activities that will not continue in the combined company); and

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions,
workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information
technology, shared services and corporate operations.

In connection with our acquisition of Hospira in September 2015, we focused our efforts on achieving an appropriate cost structure for the combined company. We incurred
costs of approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired IPR&D rights as described in the Current-Period Key
Activities section below) associated with the integration of Hospira. The majority of these costs were incurred within the three -year period post-acquisition.

In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our 2014 global commercial structure reorganization,
manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise.

2017-2019 Initiatives and Organizing for Growth

During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start of our
2019 fiscal year, we would begin operating under our new commercial structure, which reorganizes our operations into three businesses –– Biopharma, a science-based
Innovative medicines business; Upjohn, a global off-patent branded and generic established medicines business; and a Consumer Healthcare business. To operate effectively
in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the functions
that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new
structure and have combined the 2017 to 2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program
include activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and
optimization of our operating business structure and functions that support them. Through December 31, 2018, we incurred approximately $713 million associated with
manufacturing optimization, and approximately $752 million associated with other activities.

In 2019, we expect restructuring, implementation and additional depreciation charges of about $800 million and, of that amount, we expect approximately 20% of the total
charges will be non-cash.

Current-Period Key Activities

In 2018 , we incurred costs of $1.4 billion composed of $1.1 billion associated with the 2017-2019 and Organizing for Growth initiatives, $274 million associated with the
integration of Hospira and $45 million associated with all other acquisition-related initiatives.

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

(MILLIONS OF DOLLARS)

Restructuring charges/(credits):

Employee terminations

Asset impairments (a)

Exit costs

Total restructuring charges (b)

Transaction costs (c)

Integration costs (d)

  $

Restructuring charges and certain acquisition-related costs

Net periodic benefit costs recorded in Other (income)/deductions––net (e)

Additional depreciation––asset restructuring, virtually all of which is recorded in Cost of sales (f)

Implementation costs recorded in our consolidated statements of income as follows (g) :

Cost of sales

Selling, informational and administrative expenses

Research and development expenses

Other (income)/deductions––net

Total implementation costs

Total costs associated with acquisitions and cost-reduction/productivity initiatives

  $

94

2018 Financial Report

Year Ended December 31,

2018

2017

459   $
290
33
782
1
260
1,044
146
50

83
72
39
—
194
1,434   $

(181)   $
190
21
30
4
317
351
136
91

118
71
38
—
227
805   $

2016

839

142

74

1,055

127

383

1,565

159

207

230

81

25

3

340

2,271

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

(a)

(b)

The asset impairment charges for 2018 are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for 2017 are largely associated with our acquisitions of
Hospira and Medivation. The asset impairment charges included in restructuring charges for 2017 and 2016 are primarily associated with abandoned assets. See (b) below for additional information.
In 2018 , restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs are associated with our improvements to operational effectiveness as
part of the realignment of our organizational structure effective at the beginning of 2019 . In 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, partially offset by
credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from
revisions of our severance benefit estimates. In 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of
Hospira and Medivation. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of
which may be paid out during periods after termination.

The restructuring activities in 2018 are associated with the following:
•

IH ( $176 million charge ); EH ( $31 million charge ); WRD/GPD ( $135 million charge ); manufacturing operations ( $403 million charge ); and Corporate ( $38 million charge ).

The restructuring activities in 2017 are associated with the following:
•

IH ( $83 million credit ); EH ( $6 million credit ); WRD/GPD ( $19 million charge ); manufacturing operations ( $89 million charge ); and Corporate ( $12 million charge ),

(c)

(d)

(e)

IH ( $255 million charge ); EH ( $155 million charge ); WRD/GPD ( $145 million charge ); manufacturing operations ( $328 million charge ); and Corporate ( $172 million charge ).

The restructuring activities in 2016 are associated with the following:
•
Transaction costs represent external costs for banking, legal, accounting and other similar services, which in 2017 were directly related to our acquisitions of Hospira, Anacor and Medivation.Transaction costs in
2016 were mostly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan.
Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2018 ,
integration costs were primarily related to our acquisition of Hospira. In 2017 , integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of $12 million related to the
settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 11 ). In 2016, integration costs primarily related to our acquisition of Hospira and the terminated transaction with Allergan.
In 2018 , primarily represents the net pension curtailments and settlements included in Other (income)/deductions––net upon the adoption of a new accounting standard in the first quarter of 2018. In 2017,
primarily represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to
Other (income)/deductions––net as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated
amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. In 2016, primarily represents the net
pension curtailments and settlements as well as the accelerated amortization of unrecognized loss and prior service costs related to our acquisition of Hospira, which were reclassified to Other
(income)/deductions––net as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. For additional information, see Note 1B and Note 11 .

(f)   Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(g)   Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following table provides the components of and changes in our restructuring accruals:

(MILLIONS OF DOLLARS)

Balance, January 1, 2017

Provision/(Credit)

Utilization and other (a)

Balance, December 31, 2017 (b)

Provision

Utilization and other (a)

Balance, December 31, 2018 (c)
(a)  Includes adjustments for foreign currency translation.
(b)  Included in Other current liabilities ( $643 million ) and Other noncurrent liabilities ( $462 million ).
(c)  Included in Other current liabilities ( $823 million ) and Other noncurrent liabilities ( $428 million ).

Employee
Termination

Costs
1,547   $
(181)
(326)
1,039
459
(295)
1,203   $

  $

  $

Asset
Impairment

Charges

Exit Costs

—   $

190
(190)
—
290
(290)

—   $

36   $
21
9
66
33
(51)
49   $

Accrual

1,583

30

(508)

1,105

782

(636)

1,252

2018 Financial Report

95

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 4. Other (Income)/Deductions—Net

The following table provides components of Other (income)/deductions––net :

(MILLIONS OF DOLLARS)

Interest income (a)

Interest expense (a)

Net interest expense

Royalty-related income (b)

Net (gains)/losses on asset disposals (c)

Net gains recognized during the period on investments in equity securities (d)

Net realized (gains)/losses on sales of investments in debt securities (e)

Income from collaborations, out-licensing arrangements and sales of compound/product rights (f)

Net periodic benefit costs/(credits) other than service costs (g)

Certain legal matters, net (h)

Certain asset impairments (i)

Loss on sale and impairment on remeasurement of HIS net assets (j)

Business and legal entity alignment costs (k)

Net losses on early retirement of debt (l)

Other, net (m)

Year Ended December 31,

2018
(333)   $
1,316
983
(495)
(71)
(586)
141
(488)
(288)
157
3,115
(1)
4
3
(357)
2,116   $

2017
(391)   $
1,270
879
(499)
45
(224)
(45)
(217)
101
240
395
55
71
999
(383)
1,416   $

2016

(470)

1,186

716

(905)

(51)

(18)

(35)

(108)

139

510

1,447

1,712

261

312

(186)

3,794

  $

  $

Other (income)/deductions––net
(a)

(b)

(c)

(d)

(e)

2018 v. 2017 ––Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity
that occurred in the fourth quarter of 2017. 2017 v. 2016 ––Interest income decreased primarily driven by a lower investment balance. Interest expense increased, primarily as a result of higher short-term interest
rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt. Capitalized interest expense totaled $73 million in 2018 , $ 72 million in 2017 and $ 61 million in 2016 .
Royalty-related income decreased in 2017 , primarily due to lower royalty income for Enbrel of $470 million in 2017 , compared to 2016, resulting from the expiration on October 31, 2016 of the 36 -month royalty
period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by increases in Xtandi royalty-related
income of $176 million in 2017 , compared to 2016 .
In 2018, primarily includes a realized gain on sale of property of $60 million . In 2017 , primarily includes an $81 million realized loss related to the sale of our then 49% -owned equity-method investment in Hisun
Pfizer and a realized net loss of $30 million related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the then remaining 60% ownership interest, partially offset
by a realized gain on sale of property of $52 million . In 2016, primarily includes realized gains on sales of property and other assets.
The net gains on investments in equity securities in 2018 , include unrealized net gains on equity securities of $477 million , reflecting the adoption of a new accounting standard in the first quarter of 2018. Net
gains in 2018 were primarily driven by unrealized gains of $466 million related to our investment in Allogene. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains and
losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income . For additional information, see Note 1B, Note 2B and Note 7B .
In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of $402 million and a net loss of $18 million from derivative financial instruments used to hedge the foreign exchange
component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of $280 million . Proceeds from the sale of available-for-sale debt
securities were $5.7 billion in 2018.
In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of $451 million , partially offset by gross realized losses on sales of available-for-sale debt securities of $281 million and
a net loss of $120 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt
securities were $5.1 billion in 2017.
In 2016, primarily includes gross realized gains on sales of available-for-sale debt securities of $666 million , partially offset by gross realized losses on sales of available-for-sale debt securities of $548 million and
a net loss of $64 million from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt
securities were $10.2 billion in 2016.

(f)   Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In 2018 , primarily includes, among other
things, (i) approximately $118 million in milestone income from multiple licensees, (ii) $110 million in milestone payments received from Shire, of which $75 million was received in the first quarter of 2018 related
to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and $35 million was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3
clinical trial for the treatment of Crohn’s disease, (iii) an upfront payment to us and a recognized milestone totaling $85 million for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) $62 million in
gains related to sales of compound/product rights and (v) a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C,
Note 2D and Note 2E . In 2017, primarily includes, among other things, $101 million in milestone payments received from multiple licensees and an $85 million gain related to sales of compound/product rights. In
2016, primarily includes, among other things, a $50 million gain related to sales of compound/product rights and $33 million in milestone payments received from multiple licensees.
Represents the net periodic benefit costs/(credits), excluding service costs, as a result of the adoption of a new accounting standard in the first quarter of 2018. Effective January 1, 2018, the U.S. Pfizer
Consolidated Pension Plan was frozen to future benefit accruals and for 2018 , resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses.
There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see Note 1B and Note 11 .
In 2018 , primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a $94 million
charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a $79 million charge to reflect damages awarded by a jury in a patent
matter. In 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , partially offset by the
reversal of a legal accrual where a loss was no longer deemed probable. In addition, 2016 includes a settlement related to a patent matter.

(h)

(g)

(i)   In 2018 , primarily includes intangible asset impairment charges of $3.1 billion , mainly composed of (i) $2.6 billion related to EH developed technology rights, $242 million related to EH licensing agreements and
$80 million related to EH IPR&D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) $117 million related to a multi-antigen vaccine IPR&D
program for adults undergoing elective spinal fusion surgery; (iii) $31 million related to an IH developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus
market marketed in the U.S. market only; and (iv) $17 million of other IPR&D assets acquired in connection with our acquisition of Innopharma. In 2018,

96

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well

as higher manufacturing costs, largely stemming from ongoing manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&D program was the result of the Phase

2b trial reaching futility at a pre-planned interim analysis. The intangible asset impairment charge related to the IH developed technology right reflects , among other things, updated commercial forecasts. In

addition, 2018 includes other asset impairments of  $13 million .

In 2017, primarily includes intangible asset impairment charges of $337 million , reflecting (i) $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a
generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) $124 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a
sterile injectable pain reliever; (iii) $39 million related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) $26
million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) $20 million related to
other developed technology rights. The intangible asset impairment charges for 2017 are associated with EH and reflect, among other things, updated commercial forecasts and an increased competitive
environment. In addition, 2017 includes a loss of $43 million for an impairment of our AM-Pharma B.V. long-term investment (see Note 2G ).
In 2016, primarily includes intangible asset impairment charges of $869 million , reflecting (i) $366 million related to developed technology rights for a generic injectable antibiotic product for the treatment of
bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $128 million of sterile injectable IPR&D
compounds acquired in connection with our acquisition of InnoPharma; and (iv) $110 million of other IPR&D assets, $81 million of which were acquired in connection with our acquisition of Hospira and $29 million
of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for 2016 are associated with the following: EH ( $840 million ) and IH ( $29 million ). In addition,
2016 includes an impairment loss of $452 million related to Pfizer’s then 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -
owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2F .
The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory
delays, including delays resulting from a then recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016
for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles
of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things,
the impact of regulatory delays, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for
2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.

(j)   In 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February

(k)

3, 2017. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
Represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities,
as well as to streamline our intercompany supply operations to better support each business.

(l)   In 2017 and 2016, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps in 2017 and inclusive of the related termination of interest rate swaps in

(m)

2016.
In 2018 , includes (i) a non-cash $343 million pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical
and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see Note 2B ), (ii) dividend income of $253 million from our investment in ViiV, (iii) a non-cash $50 million pre-
tax gain on the contribution of Pfizer’s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which
Pfizer obtained a 25% ownership stake in Allogene (see Note 2B ), and (iv) a non-cash $17 million pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg
(see Note 7E ), partially offset by charges of $207 million , reflecting the change in the fair value of contingent consideration and $59 million of incremental costs associated with the design, planning and
implementation of the new organizational structure, effective in the beginning of 2019, and primarily include consulting, legal, tax, and advisory services. In 2017, includes, among other things, dividend income of
$266 million from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In 2016, includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s
expenses associated with the terminated transaction (see Note 1A ); and income of $116 million from resolution of a contract disagreement.

The asset impairment charges included in Other (income)/deductions––net are based on estimates of fair value.

The following table provides additional information about the intangible assets that were impaired during 2018 in Other (income)/deductions––net :

(MILLIONS OF DOLLARS)

Intangible assets––Developed technology rights (b)

  $

Intangible assets––Licensing agreements and other (b)

Intangible assets –– IPR&D (b)

Fair Value (a)

Amount

Level 1

Level 2

Level 3

665   $
150

—   $
—

—   $
—

Total
(a)  The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.
(b)

  $

95
910   $

—
—   $

—
—   $

Reflects intangible assets written down to fair value in 2018 . Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow
method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant
estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the
product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Year Ended December
31,

2018

Impairment

2,647

242

214

3,103

665   $
150

95
910   $

2018 Financial Report

97

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 5 . Tax Matters

A. Taxes on Income from Continuing Operations

The following table provides the components of Income from continuing operations before provision/(benefit) for taxes on income :

(MILLIONS OF DOLLARS)

United States

International

Income from continuing operations before provision/(benefit) for taxes on income ( a), (b)

Year Ended December 31,

2018
(4,403)   $
16,288
11,885   $

2017
(6,879)   $
19,184
12,305   $

2016

(8,534)

16,886

8,351

  $

  $

(a)

(b)

2018 v. 2017 –– The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on investments in
equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the SIP portfolio. The decrease in international income was primarily
related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to
Ibrance and Eliquis.
2017 v. 2016 –– The decrease in the domestic loss was primarily due to lower restructuring charges and certain acquisition-related costs, the non-recurrence of the 2016 impairment on the remeasurement of HIS
net assets, lower certain asset impairments and lower certain legal matters, partially offset by higher net losses on early retirement of debt, and higher amortization of intangible assets. The increase in international
income was primarily due to the non-recurrence of the 2016 impairment on the remeasurement of HIS net assets, lower restructuring charges and certain acquisition-related costs, and lower certain asset
impairments.

The following table provides the components of Provision/(benefit) for taxes on income  based on the location of the taxing authorities:

(MILLIONS OF DOLLARS)

United States

Current income taxes:

Federal

State and local

Deferred income taxes:

Federal

State and local

Total U.S. tax provision

TCJA (a)

Current income taxes

Deferred Income taxes

Total TCJA tax provision

International

Current income taxes

Deferred income taxes

Total international tax provision

Provision/(benefit) for taxes on income

Year Ended December 31,

2018

2017

2016

  $

668   $
9

1,267   $
45

(1,663)
16
(970)

(3,035)
2,439
(596)

2,831
(558)
2,273

  $

706   $

(2,064)
(304)
(1,055)

13,135
(23,795)
(10,660)

2,709
(42)
2,667
(9,049)   $

342

(52)

(419)

(106)

(235)

—

—

—

1,532

(175)

1,358

1,123

(a)

The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion
below and Note 5C .

In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the
U.S. Federal corporate tax rate from 35% to 21% , (ii) the impact on valuation allowances and other state income tax considerations, (iii) the $15.2 billion repatriation tax liability
on accumulated  post-1986  foreign  earnings  for  which  we  plan  to  elect,  with  the  filing  of  our 2018  U.S.  Federal  Consolidated  Income  Tax  Return,  payment  over  eight  years
through 2026 that is reported in Other taxes payable in our consolidated balance sheet as of December 31, 2017 and (iv) deferred taxes on basis differences expected to give
rise  to  future  taxes  on  global  intangible  low-taxed  income.  In  addition,  we  had  provided  deferred  tax  liabilities  in  the  past  on  foreign  earnings  that  were  not  indefinitely
reinvested. As a result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to
the territorial tax system.

In 2018, we finalized our provisional accounting for the tax effects of the TCJA, based on our best estimates of available information and data, and have reported and disclosed
the impacts within the applicable measurement period, in accordance with guidance issued by the SEC, and recorded a favorable adjustment of approximately $100 million to
Provision/(benefit) for taxes on income . The amounts recorded may change in the future due to uncertain tax positions. With respect to the aforementioned repatriation tax
liability, our revised estimate is approximately $15 billion . The first installment, due in April 2019, is reported in Income taxes payable , and the remaining liability is reported in
Other taxes payable in our consolidated balance sheet as of December 31, 2018. We believe that there may be additional interpretations, clarifications and guidance from the
U.S.  Department  of  Treasury.  Any  change  to  our  calculations  resulting  from  such  additional  interpretations,  clarifications  and  guidance  would  be  reflected  in  the  period  of
issuance.  In  addition,  our  obligations  may  vary  as  a  result  of  changes  in  our  uncertain  tax  positions  and/or  availability  of  attributes  such  as  foreign  tax  and  other  credit
carryforwards.

The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5,
Accounting for Global Intangible Low-Taxed Income , states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis
differences expected to reverse as global intangible low-taxed income in future

98

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

years or provide for the tax expense related to such income in the year the tax is incurred. We have elected to recognize deferred taxes for temporary differences expected to
reverse as global intangible low-taxed income in future years. In 2017, we provided a provisional deferred tax liability of approximately $1.0 billion based on the evaluation of
certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. In 2018, this estimate was finalized
and we have provided for an additional deferred tax liability of approximately $200 million , resulting in a deferred tax liability of approximately $1.2 billion .

In 2018 , the Provision/(benefit) for taxes on income was impacted by the following:

• estimated U.S. net tax benefits of approximately $600 million associated with the enactment of the TCJA (see discussion above), primarily reflecting:

◦ approximately $500 million of tax benefits associated primarily with certain current year tax initiatives;

◦ approximately $100 million of tax benefits associated with adjustments to our provisional accounting for the tax effects of the TCJA, reported and disclosed within the

applicable measurement period, in accordance with guidance issued by the SEC, primarily consisting of:

◦ $160 million of tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries; and

◦ $140 million of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities,

partially offset by:

◦ $200 million of tax expense related to future taxes on global intangible low-taxed income;

•

•

tax benefits of approximately $700 million representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various
foreign tax authorities, and the expiration of certain statutes of limitations; and

tax benefits of approximately $740 million related to certain asset impairments.

In 2017 , the Provision/(benefit) for taxes on income was impacted by the following:

• estimated U.S. net tax benefits of $10.7 billion associated with the enactment of the TCJA (see discussion above), primarily reflecting:

◦ $22.8 billion tax benefit associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see Note 5C );

◦ $1.6 billion tax benefit associated with the remeasurement of other U.S. deferred tax liabilities, primarily associated with intangibles (see Note 5C );

◦ $12.9 billion tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries;

◦ $1.0 billion tax expense related to future taxes on global intangible low-taxed income (see Note 5C ); and

◦ approximately $100 million tax benefit primarily associated with certain tax initiatives;

• U.S. tax expense of approximately $1.3 billion related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries;

•

•

•

tax benefit of approximately $370 million related to net losses on early retirement of debt;

tax benefits of approximately $150 million representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various
foreign tax authorities, and the expiration of certain statutes of limitations; and

the non-deductibility of a $307 million fee payable to the federal government as a result of the U.S. Healthcare Legislation.

In 2016 , the Provision/(benefit) for taxes on income was impacted by the following:

• U.S. tax expense of approximately $1.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely

reinvested overseas, virtually all of which were earned in 2016;

•

tax benefits of approximately $460 million , representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various
foreign tax authorities, and from the expiration of certain statutes of limitations;

• benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which

resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position;

• net tax benefits of $89 million , related to the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, requiring excess tax benefits or

deficiencies of share-based compensation to be recognized as a component of the Provision/(benefit) for taxes on income (see Notes to Consolidated Financial
Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in Pfizer’s 2016 Financial Report);

•

•

the non-deductibility of a $312 million fee payable to the federal government as a result of the U.S. Healthcare Legislation; and

the permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015.

In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision/(benefit) for taxes on
income (see Note 2A ).

2018 Financial Report

99

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

B. Tax Rate Reconciliation

The reconciliation of the U.S. statutory income tax rate to our effective tax rate for Income from continuing operations  follows:

U.S. statutory income tax rate

TCJA impact (a)

Taxation of non-U.S. operations  (b), (c), (d)

Tax settlements and resolution of certain tax positions (e)

U.S. Healthcare Legislation (e), (f)

U.S. R&D tax credit and manufacturing deduction (e)

Certain legal settlements and charges (e)

All other, net (g)

Effective tax rate for income from continuing operations

Year Ended December 31,

2018
21.0 %

2017
35.0 %

(5.0)

(6.1)

(5.8)

(0.4)

(0.7)

(0.1)

(86.6)

(17.0)

(1.2)

0.9

(0.7)

0.1

3.1
5.9 %

(3.9)
(73.5)%

2016

35.0 %

—

(13.8)

(5.5)

1.3

(1.0)

(2.9)

0.3

13.4 %

(a)  For a discussion about the enactment of the TCJA, see Note 5A.
(b)

For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions,
which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in Note 5A , changes in uncertain tax positions not included in the reconciling item called “Tax
settlements and resolution of certain tax positions,” as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year,
and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other
U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the
jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our
effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation
costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as
restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and Provision/(benefit) for taxes on income, which is based
on the location of the taxing authorities, and for information about settlements and other items impacting Provision/(benefit) for taxes on income .
In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other
incentives associated with our subsidiaries in Puerto Rico and Singapore. 2016 also includes incentives in Costa Rica and the Dominican Republic related to the Hospira infusion systems business, which was sold
to ICU Medical in February 2017. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit
from incentive tax rates effective through 2031 on income from manufacturing and other operations.
The favorable rate impacts in 2018 and 2017 also reflect lower repatriation costs associated with the estimated income of our foreign subsidiaries. The favorable rate impact in 2016 also includes the non-
recurrence of the non-deductibility of a foreign currency loss related to Venezuela.
For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and manufacturing deduction and the impact of certain legal
settlements and charges, see Note 5A.

(c)

(d)

(e)

(f)  The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well

(g)

as certain tax initiatives.
All other, net in 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax
initiatives in the normal course of business.

C. Deferred Taxes

Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.

The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:

(MILLIONS OF DOLLARS)

Prepaid/deferred items

Inventories

Intangible assets (a)

Property, plant and equipment

Employee benefits

Restructurings and other charges

Legal and product liability reserves

Net operating loss/tax credit carryforwards (b), (c)

Unremitted earnings

State and local tax adjustments

All other

Valuation allowances

Total deferred taxes

Net deferred tax liability (d)

2018 Deferred Tax*

2017 Deferred Tax*

Assets

(Liabilities)

Assets

(Liabilities)

  $

  $

1,655   $
280
532
160
2,292
266
415
2,512
—
264
200
8,576
(2,068)
6,508   $
  $

(325)

  $

(10)

(7,620)

(1,011)

(134)

—
—
—

(83)
—

(274)

(9,456)

—

(9,456)

  $

(2,948)

1,837   $
405
685
124
2,346
240
480
4,502
—
178
492
11,289
(2,203)
9,086   $
  $

(132)

(3)

(10,808)

(755)

(109)

(8)

—

—

(85)

—

(424)

(12,325)

—

(12,325)

(3,238)

* For 2018 and 2017, the deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See Note 5A . 2018 excludes deferred tax assets and

liabilities associated with fully dedicated consumer healthcare subsidiaries. For additional information, see Note 2C .

100

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

(a)  The decrease in 2018 is primarily the result of amortization of intangible assets and certain impairment charges.
(b)  The decrease in 2018 is primarily a result of the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See Note 5A .
(c)

The amounts in 2018 and 2017 are reduced for unrecognized tax benefits of $3.3 billion and $3.4 billion , respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit
carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.
In 2018 , Noncurrent deferred tax assets and other noncurrent tax assets ( $0.8 billion ), and Noncurrent deferred tax liabilities ( $3.7 billion ). In 2017 , Noncurrent deferred tax assets and other noncurrent tax
assets ( $0.7 billion ), and Noncurrent deferred tax liabilities ( $3.9 billion ).

(d)

We have carryforwards, primarily related to net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and/or state, as well
as international, income taxes payable with either an indefinite life or expiring at various times from 2018 to 2038. Certain of our U.S. net operating losses are subject to
limitations under IRC Section 382.

Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that
incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.

As of December 31, 2018, we have not made a U.S. tax provision on approximately $31.0 billion of unremitted earnings of our international subsidiaries. As these earnings are
intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2018 is not practicable.

D. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax
positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the
resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been
deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation
from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete
items in the period of resolution.

For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1P. For a description of the risks associated with estimates and
assumptions, see Note 1C.

Uncertain Tax Positions

As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2018 we
had approximately $5.1 billion in net unrecognized tax benefits, excluding associated interest and as of December 31, 2017 we had approximately $5.4 billion in net
unrecognized tax benefits, excluding associated interest.

• Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of
income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize
double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon
the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2018 we had
approximately $1.1 billion in assets associated with uncertain tax positions. These amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets
( $1.0 billion ) and Noncurrent deferred tax liabilities ( $128 million ). As of December 31, 2017 , we had approximately $1.2 billion in assets associated with uncertain tax
positions. These amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ( $1.0 billion ) and Noncurrent deferred tax liabilities ( $118
million ).

• Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs
from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues
common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.

The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:

(MILLIONS OF DOLLARS)

Balance, beginning

Acquisitions (a)

Increases based on tax positions taken during a prior period (b)

Decreases based on tax positions taken during a prior period (b), (c)

Decreases based on settlements for a prior period (d)

Increases based on tax positions taken during the current period (b)

Impact of foreign exchange

Other, net (b), (e)

Balance, ending (f)
(a)  For 2017 and 2016, primarily related to the acquisitions of Medivation and Anacor. See also Note 2A .
(b)  Primarily included in Provision/(benefit) for taxes on income.
(c)  Primarily related to effectively settling certain tax positions primarily with foreign tax authorities. See also Note 5A.
(d)  Primarily related to cash payments and reductions of tax attributes.

2018
(6,558)   $
—
(192)
561
123
(370)
56
121
(6,259)   $

2017
(5,826)   $
10
(49)
28
35
(753)
(121)
118
(6,558)   $

2016

(5,919)

(83)

(11)

409

126

(489)

(5)

146

(5,826)

  $

  $

2018 Financial Report

101

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

(e)  Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
(f)  In 2018 , included in Income taxes payable ( $11 million ), Current tax assets ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $47 million ), Noncurrent deferred tax liabilities (
$3.2 billion ) and Other taxes payable ( $3.0 billion ). In 2017 , included in Income taxes payable ( $1 million ), Noncurrent deferred tax assets and other noncurrent tax assets ( $123 million ), Noncurrent
deferred tax liabilities ( $3.3 billion ) and Other taxes payable ( $3.2 billion ).

•

Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in Provision/(benefit) for taxes on
income in our consolidated statements of income. In 2018 , we recorded a net increase in interest of $103 million . In 2017 , we recorded a net increase in interest of $208
million ; and in 2016 , we recorded a net increase in interest of $72 million . Gross accrued interest totaled $1.1 billion as of December 31, 2018 (reflecting a decrease of
approximately $16 million as a result of cash payments) and gross accrued interest totaled $975 million as of December 31, 2017 (reflecting a decrease of approximately $4
million as a result of cash payments). In 2018 , this amount was included in Income taxes payable ( $6 million ) and Other taxes payable ( $1.1 billion ). In 2017 , this amount
was included in Other taxes payable ( $975 million ). Accrued penalties are not significant. See also Note 5A.

Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:

• With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing

certain disputed issues. Tax years 2011-2015 are currently under audit. Tax years 2016-2018 are open, but not under audit. All other tax years are closed.

• With respect to Hospira, the federal income tax audit of tax year 2014 through short-year 2015 was effectively settled in the second quarter of 2018. All other tax years are

closed.

• With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer.

In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2018), Japan (2017-2018), Europe (2011-2018,
primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2018, primarily reflecting Brazil) and Puerto Rico (2011-2018).

Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within
the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $75 million , as a result of settlements with taxing authorities or
the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates
of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial
statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the
relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to
our uncertain tax positions, and such changes could be significant.

E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

The following table provides the components of the Tax provision/(benefit) on other comprehensive income/(loss) :

  $

(MILLIONS OF DOLLARS)

Foreign currency translation adjustments, net (a)

Unrealized holding gains/(losses) on derivative financial instruments, net

Reclassification adjustments for (gains)/losses included in net income

Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b)

Unrealized holding gains/(losses) on available-for-sale securities, net

Reclassification adjustments for (gains)/losses included in net income

Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings (c)

Benefit plans: actuarial losses, net

Reclassification adjustments related to amortization

Reclassification adjustments related to settlements, net

Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b)

Other

Benefit plans: prior service (costs)/credits and other, net

Reclassification adjustments related to amortization

Reclassification adjustments related to curtailments, net

Reclassification adjustments of certain tax effects from AOCI to Retained earnings (b)

Other

Tax provision/(benefit) on other comprehensive income/(loss)
(a)  Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
(b)  For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Note 1B.
(c)  For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Note 1B .

  $

102

2018 Financial Report

Year Ended December 31,

2018

94   $
21
27
1
50
(23)
16
(45)
(53)
(141)
55
33
637
29
612
2
(39)
(4)
(144)
—
(185)
518   $

2017
(215)   $
72
(224)
—
(152)
102
(60)
—
42
(59)
192
42
—
(39)
137
—
(67)
(7)
—
—
(74)
(262)   $

2016

(15)

(75)

158

—

83

49

(15)

—

34

(535)

186

45

—

36

(269)

67

(64)

(10)

—

(1)

(7)

(174)

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following table provides the changes, net of tax, in Accumulated other comprehensive loss :

(MILLIONS OF DOLLARS)

Balance, January 1, 2016

Other comprehensive income/(loss) (a)

Balance, December 31, 2016

Other comprehensive income/(loss) (a)

Balance, December 31, 2017

Other comprehensive income/(loss) due to the
adoption of new accounting standards (b)

Other comprehensive income/(loss) (a)

Net Unrealized Gain/(Losses)

Benefit Plans

Foreign
Currency
Translation
Adjustments

Derivative Financial
Instruments

Available-For-
Sale Securities

Actuarial
Gains/(Losses)

Prior Service
(Costs)/ Credits
and Other

Accumulated Other
Comprehensive
Income/(Loss)

  $

(5,863)

  $

421   $

(227)

  $

(4,733)

  $

880   $

(797)

(6,659)
1,479

(5,180)

(2)

(893)

(73)
348

(378)

(30)

(1)
198
167   $

96

(131)
532
401

(416)

(53)

(740)

(5,473)

211

(5,262)

(637)

(128)

(68)

  $

(6,027)

  $

(1)
879

(129)
750

144

(166)
728   $

(9,522)

(1,514)

(11,036)

1,715

(9,321)

(913)

(1,041)

(11,275)

Balance, December 31, 2018

  $

(6,075)

  $

(a)  Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $20 million loss in 2018 , $14 million income in 2017 and $3 million loss in 2016 .
(b)

Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax
effects from AOCI. For additional information, see Note 1B.

As of December 31, 2018 , we estimate that we will reclassify into 2019 income the following pre-tax amounts currently held in Accumulated other comprehensive loss : $258
million of unrealized pre-tax net gains on derivative financial instruments (which is expected to be offset primarily by net losses resulting from reclassification adjustments
related to net losses related to foreign currency exchange-denominated forecasted intercompany inventory sales and available-for-sale debt securities); $242 million of
actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and $186 million of prior service credits, primarily related to benefit plan
amendments.

2018 Financial Report

103

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 7 . Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

On January 1, 2018, we adopted a new accounting and disclosure standard related to accounting for the recognition of financial assets and liabilities. For additional information
see Note 1B .

The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level
as defined in Note 1E :

(MILLIONS OF DOLLARS)

Total

Level 1

Level 2

Total

Level 1

Level 2

December 31, 2018

December 31, 2017

Financial assets measured at fair value on a recurring basis:

Short-term investments

Classified as equity securities:

Money market funds

Equity (a)

Classified as available-for-sale debt securities:

Government and agency—non-U.S.

Corporate and other

Total short-term investments

Other current assets

Derivative assets:

Interest rate contracts

Foreign exchange contracts

Total other current assets

Long-term investments

Classified as equity securities:

Equity (a)

Classified as trading securities:

Equity

Classified as available-for-sale debt securities:

Government and agency—non-U.S.

Corporate and other

Total long-term investments

Other noncurrent assets

Derivative assets:

Interest rate contracts

Foreign exchange contracts

Total other noncurrent assets

Total assets

Financial liabilities measured at fair value on a recurring basis:

Other current liabilities

Derivative liabilities:

Interest rate contracts

Foreign exchange contracts

Total other current liabilities

Other noncurrent liabilities

Derivative liabilities:

  $

1,571

  $

—   $

1,571

  $

2,115

  $

29

1,600

9,609

5,482

15,091

16,691

97

477

574

17

17

—
—
—

17

—
—
—

11

1,583

9,609

5,482

15,091

16,674

97

477

574

35

2,150

12,242

3,120

15,362

17,512

104
234
337

—   $
16
16

—
—
—
16

—
—
—

1,223

1,193

30

1,440

1,398

50

1,273

94

397

491

50

1,243

—
—
—

1,764

1,243

335

232

566

—

—

—

—

30

73

73

1,514

1,472

94

397

491

521

335

232

566

387

4,702

5,090

6,603

477
7
484

—
36
36

1,507

—
—
—

2,115

19

2,134

12,242

3,120

15,362

17,496

104

234

337

42

—

42

387

4,667

5,054

5,096

477

7

484

  $

19,595

  $

1,260

$

18,335

  $

24,937

  $

1,523

  $

23,414

  $

  $

5

78

82

—   $
—
—

  $

5

78

82

1   $

201
201

—   $
—
—

1

201

201

Interest rate contracts

Foreign exchange contracts

Total other noncurrent liabilities

Total liabilities

378

564

942

  $

1,024

  $

—
—
—
—   $

378

564

942

1,024

  $

177
313
490
691   $

—
—
—
—   $

177

313

490

691

(a)

As of December 31, 2018 , short-term equity securities of $11 million and long-term equity securities of $29 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. As of
December 31, 2017 , short-term equity securities of $19 million and long-term equity securities of $42 million are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.

104

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market
approach:

(MILLIONS OF DOLLARS)

Financial Liabilities

December 31, 2018

December 31, 2017

Carrying Value

Estimated Fair Value

Carrying Value

Estimated Fair Value

Total

Level 2

Total

Level 2

Long-term debt, excluding the current portion

  $

32,909

  $

35,260

  $

35,260

  $

33,538

  $

37,253

  $

37,253

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term
borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2018 or December 31, 2017 . The fair value measurements of our held-to-
maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments
in the life sciences sector, are based on Level 3 inputs using a market approach.

In addition, as of December 31, 2018 and 2017 , we had long-term receivables whose fair value is based on Level 3 inputs. As of December 31, 2018 and 2017 , the
differences between the estimated fair values and carrying values of these receivables were not significant.

Total Short-Term and Long-Term Investments

The following table represents our investments by classification type:

(MILLIONS OF DOLLARS)

Short-term investments

Equity securities

Available-for-sale debt securities

Held-to-maturity debt securities

Total Short-term investments

Long-term investments

Equity securities

Trading equity securities

Available-for-sale debt securities

Held-to-maturity debt securities

Private equity investments carried at equity-method or cost

Total Long-term investments

Held-to-maturity cash equivalents

Fair Value Methodology

As of December 31,

2018

2017

  $

  $

  $

  $
  $

1,600   $
15,091
1,003
17,694   $

1,223   $
50
491
59
944
2,767   $
199   $

2,150

15,362

1,138

18,650

1,440

73

5,090

4

408

7,015

719

The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities:

• Trading debt securities—quoted market prices.

• Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted

interest rate yield curves.

• Equity securities—quoted market prices and observable net asset value prices.

• Derivative assets and liabilities (financial instruments)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data.
Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices
for currencies. The credit risk impact to our derivative financial instruments was not significant.

• Money market funds—observable net asset value prices.

We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other
third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial
instruments.

2018 Financial Report

105

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

B. Investments

At December 31, 2018 and 2017, the investment securities portfolio consisted of debt securities that were virtually all investment-grade.
Information on investments in debt and equity securities at December 31, 2018 and December 31, 2017 is as follows, including, as of December 31, 2018, the contractual
maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:

(MILLIONS OF DOLLARS)

Amortized
Cost

Gains

Losses

Fair Value

Within 1

Over 1
to 5

Over 5

Total

Amortized
Cost

Gains

Losses

  Fair Value

December 31, 2018

Gross Unrealized

Maturities (in Years)

December 31, 2017

Gross Unrealized

Available-for-sale debt securities

Government and agency –– non-U.S.

  $

Corporate and other (a)

Held-to-maturity debt securities

  $

9,754

5,905

  $

7
—

  $

(58)

(27)

9,703

5,878

  $

9,609

5,482

  $

94

  $

—   $

394

3

Time deposits and other

Government and agency –– non-U.S.

668

592

—
—

—
—

668

592

610

592

24
—

35
—

9,703

5,878

668

592

  $

12,616

  $

7,859

1,091

770

  $

61

15

(48)

(52)

  $

12,629

7,823

1,091

770

—
—

—
—

Total debt securities

  $

16,920

  $

8

  $

(85)

  $

16,842

  $

16,293

  $

512

  $

38

  $

16,842

  $

22,337

  $

77

  $

(100)

  $

22,313

Available-for-sale equity securities (b)

Money market funds

  $

2,115

  $

—   $

—   $

2,115

Equity
Total available-for-sale equity securities
(a)   Primarily issued by a diverse group of corporations.
(b)   Upon the 2018 adoption of a new accounting standard related to financial assets and liabilities, available-for-sale equity securities were classified as equity securities. For additional information see Note 1B .

  $

  $

  $

  $

2,843

(124)

(124)

586

586

728

1,190

3,304

The following table presents the net unrealized gains and losses for the period that relate to equity securities still held at the reporting date, calculated as follows:

(MILLIONS OF DOLLARS)
Net gains recognized during the period on investments in equity securities (a)

Less: Net gains recognized during the period on equity securities sold during the period
Net unrealized gains during the reporting period on equity securities still held at the reporting date

December 31, 2018

586

(109)

477

  $

  $

(a)

The net gains on investments in equity securities are reported in Other (income)/deductions –– net and, for 2018 , include unrealized net gains on equity securities reflecting the adoption of a new accounting
standard in the first quarter of 2018. For additional information, see Note 4 .

C. Short-Term Borrowings

Short-term borrowings include:

(MILLIONS OF DOLLARS)

Commercial paper

Current portion of long-term debt, principal amount (a)

Other short-term borrowings, principal amount (b)

Total short-term borrowings, principal amount

Net fair value adjustments related to hedging and purchase accounting

Net unamortized discounts, premiums and debt issuance costs

  $

As of December 31,

2018

2017

3,100   $
4,781
966
8,847
(5)
(11)
8,831   $

6,100

3,532

320

9,951

14

(12)

9,953

Total Short-term borrowings, including current portion of long-term debt , carried at historical proceeds, as adjusted
(a)   For additional information, see Note 7D .
(b)   Other short-term borrowings primarily include cash collateral. For additional information, see Note 7F .
The weighted-average effective interest rate on commercial paper outstanding was approximately 2.42% as of December 31, 2018 and 1.36% as of December 31, 2017 .

  $

On June 24, 2016, we acquired Anacor and assumed its short-term debt with an acquisition date fair value of $698 million , which was redeemed in the second and third
quarters of 2016.

As of December 31, 2018 , we had access to a $7.0 billion U.S. revolving credit facility expiring in 2023, which may be used to support our commercial paper borrowings. In
addition to the U.S. revolving credit facility, our lenders have provided us an additional $553 million lines of credit, of which $502 million expire within one year. Of these total
lines of credit, $7.5 billion were unused as of December 31, 2018.

106

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

D. Long-Term Debt

New Issuances

In 2018, we issued the following senior unsecured notes:

(MILLIONS OF DOLLARS)

Maturity Date

September 2021

September 2023

September 2023

September 2028

September 2038

September 2048

Total long-term debt issued (c)

Interest Rate

Principal

3.000% notes (a)   $

Floating rate notes (LIBOR plus 0.33%) (b)
3.200% notes (a)
3.600% notes (a)
4.100% notes (a)
4.200% notes (a)

  $

1,000

300

1,000

1,000

700

1,000

5,000

(a)   Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.
(b)   Floating rate notes may not be redeemed by their terms prior to maturity.
(c)  The weighted-average effective interest rate for the notes at issuance was 3.56% .
In March 2017, we completed a public offering of $1.065 billion principal amount of senior unsecured notes due 2047 with an interest rate of 4.20% , and also in March 2017,
we completed a public offering of € 4.0 billion principal amount of senior unsecured notes with a weighted-average effective interest rate of 0.23% .

On November 21, 2016, we completed a public offering of $6.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of
3.10% .

On June 3, 2016, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% .

Retirements

In January 2019, we repurchased all €1.1 billion principal amount outstanding of the 5.75% euro-denominated debt that was due June 2021 before the maturity date at a
redemption value of €1.3 billion . As a result, we recorded a net loss of approximately $138 million , which included the related termination of cross-currency swaps, and that
was recorded in Other (income)/deductions––net in the consolidated statement of income in the first quarter of 2019.

In December 2017, we exchanged approximately £833 million and repurchased £197 million principal amount of the outstanding 6.50% debt before the maturity date at a
redemption value of £1.7 billion , leaving £470 million principal amount of the 6.50% debt due 2038 outstanding. Also, in December 2017, we repurchased approximately €834
million principal amount of the outstanding 5.75% debt before the maturity date at a redemption value of €1.0 billion , leaving approximately €1.2 billion of the 5.75% euro-
denominated debt due 2021 outstanding as of December 31, 2017. As a result, we recorded a net loss of approximately $846 million and $153 million upon the exchange and
early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a net loss on early retirement of debt of $999
million . which included the related termination of cross-currency swaps, and that were recorded in Other (income)/deductions––net in the consolidated statement of income
(see Note 4 ).

In November 2016, we repurchased $3.4 billion carrying value of outstanding debt before the maturity date at a redemption value of $3.7 billion . The debt repurchased
included $3.27 billion carrying value of 6.20% senior notes due March 2019. As a result, we recorded a total net loss of approximately $312 million upon the early redemption
of debt, which included the related termination of interest rate swaps, and which was recorded in Other (income)/deductions––net in the consolidated statement of income (see
Note 4 ).

2018 Financial Report

107

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2018 and 2017 by maturity:

(MILLIONS OF DOLLARS)

Notes due 2019 (1.3%) (a)

Notes due 2020 (1.2% and 1.1%)

Notes due 2021 (3.4% and 3.5%)

Notes due 2022 (0.3%)

Notes due 2023 (3.6% and 4.3%)

Notes due 2024 (4.4%)

Notes due 2026-2028 (3.3% and 3.2%)

Notes due 2034 (6.5%)

Notes due 2036-2039 (6.0% and 6.2%)

Notes due 2040-2044 (3.8%)

Notes due 2046-2048 (4.2%)

Total long-term debt, principal amount

Net fair value adjustments related to hedging and purchase accounting

Net unamortized discounts, premiums and debt issuance costs

Other long-term debt

Total long-term debt, carried at historical proceeds, as adjusted

Current portion of long-term debt, carried at historical proceeds (not included above (1.3% and 2.4%))
(a)  At December 31, 2018, the debt issuances have been reclassified to the current portion of long-term debt.

As of December 31,

2018

—   $

  $

1,474
4,459
1,145
2,892
1,500
5,718
750
7,301
4,004
3,315
32,558
479
(136)
7

  $
  $

32,909   $
4,776   $

2017

4,848

1,528

3,550

1,199

1,592

1,500

4,759

750

6,636

4,106

2,315

32,783

872

(125)

8

33,538

3,546

Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.

E. Other Noncurrent Liabilities

Mylotarg (gemtuzumab ozogamicin)

In April 2018, the EU approved Mylotarg for the treatment of acute myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixed
annual payments over a ten -year period aggregating $301 million related to an R&D arrangement. We recorded the estimated net present value of $240 million as a liability
and an intangible asset in Developed technology rights as of the approval date. In June 2018, we entered into a transaction with the obligee to buyout the remaining liability for
the fixed annual payments for a lump sum payment of $224 million . As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash
$17 million pre-tax gain in Other (income)/deductions––net in the second quarter of 2018 (see Note 4 ).

Bosulif (bosutinib)

In December 2017, the U.S. FDA approved Bosulif for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we
incurred an obligation to make guaranteed fixed annual payments over a ten -year period aggregating $416 million related to an R&D arrangement. We recorded the estimated
net present value of $364 million as of the approval date as an intangible asset in Developed technology rights . In August 2018, we entered into a transaction with the obligee
to buyout a portion of the remaining liability for the fixed annual payments for a lump sum payment of $71 million . As a result of the buyout transaction, the liability was reduced
and we recognized a non-cash $9 million pre-tax gain in Other (income)/deductions––net in the third quarter of 2018 . The present value of the remaining future payments as of
December 31, 2018 is $209 million , of which $23 million is recorded in Other current liabilities and $186 million is recorded in Other noncurrent liabilities .

Besponsa (inotuzumab ozogamicin)

In August 2017, the U.S. FDA approved Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-
positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine -
year period aggregating $296 million related to an R&D arrangement. We recorded the estimated net present value of $248 million as of the approval date as an intangible
asset in Developed technology rights . The present value of the remaining future payments as of December 31, 2018 is $243 million , of which $7 million is recorded in Other
current liabilities and $235 million is recorded in Other noncurrent liabilities . In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual
payments over a nine -year period aggregating $148 million related to an R&D arrangement. We recorded the estimated net present value of $123 million as of the approval
date as an intangible asset in Developed technology rights . The present value of the remaining future payments as of December 31, 2018 is $122 million , of which $3 million
is recorded in Other current liabilities and $119 million is recorded in Other noncurrent liabilities .

The differences between the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of these obligations were not significant as
of December 31, 2018 .

108

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

F . Derivative Financial Instruments and Hedging Activities

We adopted a new accounting standard in the first quarter of 2018, as of January 2018. For additional information, see Note 1B.

Foreign Exchange Risk

A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk,
in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency
liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of
derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency,
or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.

All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet.
The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona and Chinese Renminbi . Changes in fair value
are reported in earnings or in Other comprehensive income/(loss) , depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the
effectiveness of the hedge relationships, as follows:

• Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair
value of the hedged risk. Upon the adoption of the new standard in 2018, for certain foreign exchange contracts, we exclude an amount from the assessment of hedge
effectiveness and recognize that excluded amount through an amortization approach. We also recognize the offsetting foreign exchange impact attributable to the hedged
item in earnings.

• Generally, we record in Other comprehensive income/(loss) gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those

amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. Upon the adoption of the new standard in 2018,
for certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization
approach.

• Upon the adoption of the new standard in 2018, for foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that

excluded amount through an amortization approach. We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-
denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of
our net investments. Historically, as part of our net investment hedging program, we recognized the gain and loss impact on foreign exchange contracts designated as
hedges of our net investments in earnings in three ways: over time –– for the periodic net swap payments; immediately –– to the extent of any change in the difference
between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments –– to the extent of change in the foreign exchange
spot rates.

• For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to
offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially
take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.

As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted euro, Japanese yen, Chinese renminbi, Canadian
dollar, U.K. pound and Australian dollar -denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge.

For 2017, any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for 2017.

Interest Rate Risk

Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis
position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. Historically, we strove to borrow
primarily on a floating-rate basis; but in recent years we borrowed on a long-term fixed-rate basis. From time to time, depending on market conditions, we will change the profile
of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed
interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.

All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair
value are reported in earnings, as follows:

• We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the

hedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk in earnings.

For 2017, any ineffectiveness is recognized immediately into earnings. There is no significant ineffectiveness for 2017.

2018 Financial Report

109

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as
hedging instruments and those that are not designated as hedging instruments:

(MILLIONS OF DOLLARS)

December 31, 2018

December 31, 2017

Fair Value

Fair Value

Notional

Asset

Liability

Notional

Asset

Liability

Derivatives designated as hedging instruments:

Foreign exchange contracts (a)

Interest rate contracts

  $

22,984   $
11,145

654   $
432
1,085

586   $
383
968

18,723   $
12,430

179   $
581
760

Derivatives not designated as hedging instruments:

Foreign exchange contracts

  $

15,154

55

55   $

14,300

62

Total
(a)   As of December 31, 2018 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was $5.8 billion .

  $

1,140   $

1,024

  $

822   $

459

178

637

54

691

The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:

(MILLIONS OF DOLLARS)

Derivative Financial Instruments in Cash Flow Hedge

Relationships:

Amount of
Gains/(Losses)
Recognized in OID (a), (b)

Amount of Gains/(Losses)
Recognized in OCI (a), (c)

As of December 31,

Amount of Gains/(Losses)
Reclassified from
OCI into OID and COS (a), (c)

2018

2017

2018

2017

2018

2017

Foreign exchange contracts (d)
Amount excluded from effectiveness testing recognized

in earnings based on an amortization approach

  $

—   $

—

Derivative Financial Instruments in Fair Value Hedge

Relationships:

Interest rate contracts

Hedged item gain

Foreign exchange contracts

Hedged item gain/(loss)

Derivative Financial Instruments in Net Investment Hedge

Relationships:

Foreign exchange contracts
The portion of gains/(losses) on foreign exchange

contracts excluded from the assessment of hedge
effectiveness

Non-Derivative Financial Instruments in Net Investment

Hedge Relationships:

Foreign currency short-term borrowings

Foreign currency long-term debt (e)

Derivative Financial Instruments Not Designated as

Hedges:

Foreign exchange contracts

All other net

(348)
348
5

(5)

—

—

—
—

136
—
136   $

  $

(6)   $

80   $

(12)   $

(182)   $

520

140

—
—
—
—

(60)
60
(19)
19

—
—
—
—

—

175

—

77

68
149

—
(1)
688   $

—
(580)

—
2
(591)   $

—
—

(87)
—
(93)   $

153

—
—
—
—

—

68

—
—

—
2
41   $

—

—

—

—

—

—

—

—

1

520

(a)

OID = Other (income)/deductions—net,   included in Other (income)/deductions—net in the consolidated statements of income . COS = Cost of Sales, included in Cost of sales in the consolidated statements of
income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income .

(b)  For 2017, there is no significant ineffectiveness.
(c)

For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in Other comprehensive income/(loss)––Unrealized holding gains/(losses) on derivative financial instruments,
net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive
income/(loss)––Foreign currency translation adjustments, net.
Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $156 million within the next 12 months into Cost of sales. The maximum length of time over which we
are hedging future foreign exchange cash flow relates to our $1.8 billion U.K. pound debt maturing in 2043.
Short-term borrowings include foreign currency short-term borrowings with carrying values of $1.4 billion as of December 31, 2018 , which are used as hedging instruments in net investment hedges. Long-term
debt includes foreign currency long-term borrowings with carrying values of $3.2 billion as of December 31, 2018 , which are used as hedging instruments in net investment hedges.

(d)

(e)

110

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides the total amount of each income and expense line in which the results of fair value or cash flow hedges are recorded:

(MILLIONS OF DOLLARS)

Cost of sales

Other (income)/deductions—net

  $

December 31, 2018

11,248

2,116

The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:

(MILLIONS OF DOLLARS)

Long-term investments

Short-term borrowings, including current portion of long-term debt

Long-term debt

  $

Carrying Amount of Hedged

Assets/Liabilities
December 31, 2018

Cumulative Amount of Fair Value
Hedging Adjustment Gains/(Losses)
Included in the Carrying Amount of the
Hedged Assets/Liabilities

December 31, 2018

45   $

1,499
9,952

(1)

5

45

Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both
counterparties’ exposure to risk of defaulting on amounts owed by the other party. As of December 31, 2018 , the aggregate fair value of these derivative instruments that are
in a net liability position was $472 million , for which we have posted collateral of $544 million in the normal course of business. If there had been a downgrade to below an A
rating by S&P or the equivalent rating by Moody’s, we would not have been required to post any additional collateral to our counterparties.

As of December 31, 2018 , we received cash collateral of $881 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative
contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt.

G. Credit Risk

On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from
failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual
counterparty, except for certain significant customers. For additional information, see Note 18C . As of December 31, 2018 , we had amounts due from a well-diversified, high
quality group of banks ( $4.4 billion ) from around the world. For details about our investments, see Note 7B above .

In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the
ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see Note 7F above.

Note 8. Inventories

The following table provides the components of Inventories :

(MILLIONS OF DOLLARS)

Finished goods

Work in process

Raw materials and supplies

Inventories (a)

Noncurrent inventories not included above (b)
(a)

As of December 31,

2018
2,262   $
4,701
546
7,508   $
618   $

2017

2,883

3,908

788

7,578

683

  $

  $
  $

The change from December 31, 2017 primarily reflects the reclassification of $538 million to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and a decrease due to foreign exchange, partially
offset by increases for certain products to meet targeted levels in the normal course of business, primarily for inventory build for supply recovery, new product launches and the movement of products within our
manufacturing network.

(b)   Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

2018 Financial Report

111

Useful Lives
(Years)

-   $

33-50
8-20
3-12 1/2
-

  $

As of December 31,

2018
500   $

9,920
11,871
4,693
2,992
29,977
16,591
13,385   $

2017

540

10,254

11,902

4,661

2,680

30,037

16,172

13,865

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 9 . Property, Plant and Equipment

The following table provides the components of Property, plant and equipment :

(MILLIONS OF DOLLARS)

Land

Buildings

Machinery and equipment

Furniture, fixtures and other

Construction in progress

Less: Accumulated depreciation

Property, plant and equipment (a)
(a)

Note 10. Identifiable Intangible Assets and Goodwill

A. Identifiable Intangible Assets

Balance Sheet Information

The following table provides the components of Identifiable intangible assets :

The decrease in total property, plant and equipment is primarily due to depreciation, the reclassification of $675 million to Assets held for sale during the fourth quarter of 2018 (see Note 2C ), reductions due to
asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see Note 3 ), and the impact of foreign exchange, partially offset by capital additions.

(MILLIONS OF DOLLARS)

Finite-lived intangible assets

Developed technology rights (a)

Brands (a)

Licensing agreements and other

Indefinite-lived intangible assets

Brands and other (a)

IPR&D (a)

Identifiable intangible assets (b)
(a)

December 31, 2018

December 31, 2017

Gross
Carrying
Amount

Accumulated
Amortization

Identifiable
Intangible
Assets, less
Accumulated
Amortization

Gross
Carrying
Amount

Accumulated
Amortization

Identifiable
Intangible
Assets, less
Accumulated
Amortization

  $

  $

89,430   $
923
1,436
91,788

1,994
2,171
4,165
95,954   $

(58,895)   $
(708)
(1,140)
(60,743)

30,535   $
215
296
31,045

89,550   $
2,134
1,911
93,595

(54,785)   $
(1,152)
(1,096)
(57,033)

1,994
2,171
4,165
35,211   $

6,929
5,249
12,179
105,774   $

(57,033)   $

(60,743)   $

34,765

982

815

36,562

6,929

5,249

12,179

48,741

The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held
for sale during the fourth quarter of 2018 (see Note 2C ), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-
metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A ), (iii) $240 million of Developed technology rights recorded in connection with the EU
approval of Mylotarg (see Note 7E ), as well as impairments of $ 2.9 billion of Developed technology rights ( see Note 4) .
The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to the reclassification of $5.8 billion of intangible assets, net, ( $6.3 billion total gross carrying amount) to Assets held
for sale during the fourth quarter of 2018 (see Note 2C ) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with
the EU approval of Mylotarg (see Note 7E ).

(b)

Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:

Developed technology rights

Brands, finite-lived

Brands, indefinite-lived

IPR&D

112

2018 Financial Report

December 31, 2018

IH

EH

WRD

76%
—
—
65%

24%
100%
100%
18%

—

—

—

17%

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Developed Technology Rights

Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to
develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes
that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized
products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi,
Prevnar 13/Prevenar 13 Infant, Eucrisa, Premarin, Prevnar 13/Prevenar 13 Adult, Enbrel and, to a lesser extent Tygacil, Pristiq, Refacto AF and Bosulif. Also included in this
category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.

Brands

Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. The more
significant components of indefinite-lived brands are the following (in order of significance): Xanax, Medrol and Depo-Medrol. The more significant components of finite-lived
brands are the following (in order of significance): Depo-Provera and Zavedos.

IPR&D

IPR&D assets represent R&D assets that have not yet received regulatory approval in a major market. A significant component of IPR&D at December 31, 2018 is the program
for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition. IPR&D assets are
required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&D effort. Accordingly, during the development period
after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries,
subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&D and begin
amortization. If the associated R&D effort is abandoned, the related IPR&D assets will likely be written-off, and we will record an impairment charge.

For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical
business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future.

Amortization

The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately 9 years. Total
amortization expense for finite-lived intangible assets was $5.0 billion in 2018 , $4.8 billion in 2017 and $4.1 billion in 2016 .

The following table provides the annual amortization expense expected for the years 2019 through 2023:

(MILLIONS OF DOLLARS)

Amortization expense

B. Goodwill

  $

2019
4,581   $

2020
3,552   $

2021
3,467   $

2022
3,217   $

2023

2,920

The following table provides the components of and changes in the carrying amount of Goodwill :

(MILLIONS OF DOLLARS)

Balance, January 1, 2017

Additions (a)

Other (b)

Balance, December 31, 2017

Other (c)

Balance, December 31, 2018
(a)

  $

  $

IH
30,134   $
572
435
31,141
(2,264)
28,877   $

EH
24,315   $
92
404
24,811
(277)
24,534   $

Total

54,449

664

840

55,952

(2,541)

53,411

IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see
Note 2A ).

(b)   Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.
(c)

Primarily reflects the impact of the reclassification of $ 2.0 billion to Assets held for sale during the fourth quarter of 2018 (see Note 2C), foreign exchange and the contribution of the allogeneic CAR T
developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B ).

2018 Financial Report

113

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 11 . Pension and Postretirement Benefit Plans and Defined Contribution Plans

The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we
sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of
the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on
discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to
certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans.

A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Loss

The following table provides the annual (income)/cost and changes in Other comprehensive income/(loss)  for our benefit plans:

Year Ended December 31,

Pension Plans

(MILLIONS OF DOLLARS)

Service cost (b)

Interest cost

  $

U.S.
Qualified (a)
2017
269   $
634

2018

—   $

598

Expected return on plan assets

(1,040)

(1,005)

2018

2016
257   $ —   $
646
(958)

55
—

2016

18   $
53
—

International
2017
171   $
204
(345)

2018
136   $
212
(360)

Postretirement
Plans
2017

2018

39   $
72
(37)

42   $
90
(36)

2016
165   $
233
(381)

U.S.
Supplemental
(Non-Qualified)
2017

Amortization of:

Actuarial losses (b)

Prior service cost/(credits)

Curtailments

Settlements

Special termination benefits
Net periodic benefit

costs/(income) reported in
Income (c)

(Income)/cost reported in Other

comprehensive income/(loss) (d)

120
2
12
113
6

393
3
13
75
—

395
5
10
90
—

13
(1)
1
26
10

(189)

382

444

103

166

137

361

141

253

(189)

23

121

101
(4)
(4)
4
—

84

84

116
(4)
—
4
1

93
(3)
(2)
9
1

7
(178)
(17)
—
2

31
(182)
(19)
—
—

147

115

(111)

(75)

(301)

640

105

(8)

(Income)/cost recognized in
Comprehensive income

  $

171   $

523   $

697   $ (86)   $ 189   $

258   $

168   $

(154)   $

755   $

(6)   $ (83)   $

(56)

(a)

(b)

(c)

(d)

In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan
participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the
recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Other (income)/deductions — net (see Note 3 ).
Effective January 1, 2018, we froze two significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the
plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average
amortization period in prior years utilized the expected future service period of plan participants.
We adopted a new accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in Other (income)/deductions––net on the
consolidated statements of income. For additional information, see Note 1B and Note 4 .
In 2017 and 2016, the changes to Other comprehensive (income)/loss for the international plans was impacted by foreign currency movements. For details of the changes in Other comprehensive (income)/loss,
see the benefit plan activity in the consolidated statements of comprehensive income.

The following table provides the amounts in Accumulated other comprehensive loss  expected to be amortized into 2019 net periodic benefit costs:

(MILLIONS OF DOLLARS)

Actuarial losses (a)

Prior service credits and other

Total

  $

  $

U.S.
Qualified

Pension Plans

U.S. Supplemental
(Non-Qualified)

(148)   $
3
(145)   $

International

Postretirement Plans

(9)

1

(9)

  $

  $

(81)

  $

3

(78)

  $

(4)

178

175

(a)

Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected
life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for 2019 are 24.2 years for our U.S.
qualified plans, 25.3 years for our U.S. supplemental (non-qualified) plans, 20 years for our international plans, and 9.3 years for our postretirement plans.

114

2018 Financial Report

24   $
54
—

50
(1)
1
39
—

37
(1)
1
28
—

2016

41

101

(34)

32

(174)

(26)

—

—

(59)

3

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

B. Actuarial Assumptions

The following table provides the weighted-average actuarial assumptions of our benefit plans:

(PERCENTAGES)

Weighted-average assumptions used to determine benefit obligations

Discount rate:

U.S. qualified pension plans

U.S. non-qualified pension plans

International pension plans

Postretirement plans

Rate of compensation increase:

U.S. qualified pension plans (a)

U.S. non-qualified pension plans (a)

International pension plans

Weighted-average assumptions used to determine net periodic benefit cost

Discount rate:

U.S. qualified pension plans

U.S. non-qualified pension plans

International pension plans interest cost (b)

International pension plans service cost (b)

Postretirement plans

Expected return on plan assets:

U.S. qualified pension plans

International pension plans

Postretirement plans

Rate of compensation increase:

U.S. qualified pension plans

U.S. non-qualified pension plans

International pension plans

2018

2017

2016

4.4%
4.3%
2.5%
4.3%

—

—
1.4%

3.8%
3.7%
2.3%
3.7%

2.8%
2.8%
2.5%

3.8%
3.7%
2.0%
2.3%
3.7%

4.3%
4.2%
2.1%
2.3%
4.2%

7.5%
4.4%
7.5%

8.0%
4.7%
8.0%

2.8%
2.8%
2.5%

2.8%
2.8%
2.6%

4.3%

4.2%

2.4%

4.2%

2.8%

2.8%

2.6%

4.5%

4.5%

2.7%

3.0%

4.5%

8.0%

5.2%

8.0%

2.8%

2.8%

2.6%

(a)

(b)

Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members’ accrued benefits to that date no longer increase in line with future compensation increases. The
rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation.
Effective January 1, 2016, the Company changed the approach used to measure service cost and interest costs for certain international pension plans and other postretirement benefits. In accordance with this
change, the effective rate for interest on the benefit obligations and effective rate for service cost, respectively, are reported for international pension plans.

The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the
assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit
obligations are established at each fiscal year-end.

The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based
on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.

The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a
portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international
plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve
approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2018 resulted
in higher discount rates as compared to the prior year.

The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:

Healthcare cost trend rate assumed for next year (up to age 65)

Healthcare cost trend rate assumed for next year (age 65 and older)

Rate to which the cost trend rate is assumed to decline

Year that the rate reaches the ultimate trend rate

2018

5.8%
6.5%
4.5%

2037

2017

6.1%

7.0%

4.5%

2037

The following table provides the effects as of December 31, 2018 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement
benefits:

(MILLIONS OF DOLLARS)

Effect on total service and interest cost components

Effect on postretirement benefit obligation

  $

Increase

Decrease

3   $
35

(2)

(27)

2018 Financial Report

115

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily
on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see Note 1C .

C. Obligations and Funded Status

The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:

Year Ended December 31,

U.S. Qualified (a)
2018

2017

Pension Plans

U.S. Supplemental
(Non-Qualified)
2018

2017

International (b)
2018

Postretirement
Plans (c)

2017

2018

2017

16,702   $
—
598
—

(22)

(1,219)

—
—
11

(391)

6

(546)
15,141

14,284

(796)
500
—
—
—

(391)

(546)
13,051

15,547   $
269
634
—
—
1,614
—
—
11
(842)
—
(530)
16,702

12,556
2,005
1,095
—
—
—
(842)
(530)
14,284

1,495   $
—
55
—
—
(152)
—
—
1
(72)
10
(58)
1,280

—
—
129
—
—
—
(72)
(58)
—

1,450   $
24
54
—
—
110
—
—
—
(98)
—
(45)
1,495

10,607   $
136
212
7
29
(169)
(457)
(2)
(3)
(34)
—
(373)
9,952

9,691   $
171
204
6
2
135
760
26
—
(31)
1
(357)
10,607

—
—
143
—
—
—
(98)
(45)
—

8,863
(77)
209
7
(380)
—
(34)
(373)
8,215

7,683
811
160
6
561
30
(31)
(357)
8,863

2,028   $
39
72
102
2
(122)
(4)
—
(1)
—
2
(249)
1,870

494
(22)
145
102
—
—
—
(249)
469

2,254

42

90

94

—

(177)

5

1

1

—

—

(280)

2,028

458

39

183

94

—

—

—

(280)

494

(MILLIONS OF DOLLARS)

Change in benefit obligation (d)

Benefit obligation, beginning

  $

Service cost

Interest cost

Employee contributions

Plan amendments

Changes in actuarial assumptions and other

Foreign exchange impact

Acquisitions/divestitures/other, net

Curtailments

Settlements

Special termination benefits

Benefits paid

Benefit obligation, ending (d)

Change in plan assets

Fair value of plan assets, beginning

Actual gain/(loss) on plan assets

Company contributions

Employee contributions

Foreign exchange impact

Acquisitions/divestitures, net

Settlements

Benefits paid

Fair value of plan assets, ending
Funded status—Plan assets less than benefit

obligation

  $

(2,089)

  $

(2,418)   $

(1,280)   $

(1,495)   $

(1,738)   $

(1,745)   $

(1,401)   $

(1,534)

(a) The favorable change in the funded status of our U.S. qualified plans was primarily due to an increase in the discount rate at the end of 2018, partially offset by a decrease in actual return on plan assets.
(b)   The favorable change in the international plans’ funded status was primarily due to favorable currency movements, partially offset by a decrease in the actual return on plan assets.
(c)  The favorable change in the funded status of our postretirement plans was primarily due to an increase in the discount rate at the end of 2018, partially offset by a decrease in actual return on plan assets.
(d)

For the U.S. and international pension plans, the benefit obligation is the PBO. For the postretirement plans, the benefit obligation is the ABO. The ABO for all of our U.S. qualified pension plans was $15.1 billion in
2018 and $16.7 billion in 2017 . The ABO for our U.S. supplemental (non-qualified) pension plans was $1.3 billion in 2018 and $1.5 billion in 2017 . The ABO for our international pension plans was $9.5 billion in
2018 and $10.1 billion in 2017 .

116

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides information as to how the funded status is recognized in our consolidated balance sheets:

As of December 31,

(MILLIONS OF DOLLARS)

Noncurrent assets (a)

Current liabilities (b)

Noncurrent liabilities (c)

U.S. Qualified

2018

2017

  $

—   $

(1)

(2,088)

—   $
—

(2,418)

Funded status
(a)   Included primarily in Other noncurrent assets .
(b)   Included in Accrued compensation and related items .
(c)  Included in Pension benefit obligations, net and Postretirement benefit obligations , net, as appropriate.

(2,418)

(2,089)

  $

  $

  $

Pension Plans

U.S. Supplemental
(Non-Qualified)
2018

2017

—   $

—   $

(167)
(1,113)
(1,280)   $

(160)
(1,336)
(1,495)   $

International
2018
401   $
(28)
(2,111)
(1,738)   $

2017
454   $
(26)
(2,172)
(1,745)   $

Postretirement
Plans

2018

—   $
(29)
(1,371)
(1,401)   $

2017

—

(31)

(1,504)

(1,534)

The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss :

As of December 31,

U.S. Qualified

2018

  $

(5,061)

  $

1

  $

(5,060)

  $

2017
(4,677)   $
(23)
(4,699)   $

Pension Plans

U.S. Supplemental
(Non-Qualified)
2018
(370)   $
1
(370)   $

2017
(561)   $
1
(559)   $

International
2018
(2,372)   $
—
(2,372)   $

2017
(2,322)   $
34
(2,288)   $

Postretirement
Plans

2018
(202)   $
994
792   $

2017

(293)

1,190

897

(MILLIONS OF DOLLARS)

Actuarial losses (a)

Prior service (costs)/credits

Total
(a)

The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the
expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the
average remaining service period for active participants for plans that are not frozen or the expected life expectancy of plan participants for frozen plans, using the corridor approach.

The following table provides information related to the funded status of selected benefit plans:

(MILLIONS OF DOLLARS)

Pension plans with an ABO in excess of plan assets:

Fair value of plan assets

ABO

Pension plans with a PBO in excess of plan assets:

Fair value of plan assets

PBO

As of December 31,

Pension Plans

U.S. Supplemental (Non-
Qualified)

2017

2018

2017

U.S. Qualified
2018

International
2018

2017

  $

13,051   $
15,141

14,284   $
16,702

—   $

—   $

1,280

1,495

4,514   $
6,286

13,051
15,141

14,284
16,702

—
1,280

—
1,495

5,432
7,571

882

2,724

1,626

3,825

All of our U.S. plans and many of our international plans were underfunded as of December 31, 2018 .

2018 Financial Report

117

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

D. Plan Assets

The following table provides the components of plan assets:

(MILLIONS OF DOLLARS)

U.S. qualified pension plans

Fair Value (a)

Fair Value (a)

As of
December 31,
2018

Level 1

Level 2

  Level 3

Assets
Measured at
NAV (b)

As of
December 31,
2017

  Level 1

Level 2

Level 3

Assets
Measured at
NAV (b)

Cash and cash equivalents

  $

443

  $

53

  $

390   $ —   $

—   $

655   $

115   $

540   $

—   $

Equity securities:

Global equity securities

Equity commingled funds

Fixed income securities:

Corporate debt securities

Government and agency

obligations

Fixed income commingled funds

Other investments:

Partnership investments (c)

Insurance contracts

Other commingled funds (d)

Total

International pension plans

Cash and cash equivalents

Equity securities:

Global equity securities

Equity commingled funds

Fixed income securities:

Corporate debt securities

Government and agency

obligations (e)

Fixed income commingled funds

Other investments:

Partnership investments (c)

Insurance contracts (f)

Other (d), (f)

Total

U.S. postretirement plans (g)

Cash and cash equivalents

Equity securities:

Global equity securities

Equity commingled funds

Fixed income securities:

Corporate debt securities

Government and agency

obligations

  $

  $

  $

  $

Fixed income commingled funds

Other investments:

Partnership investments (c)

Insurance contracts

Other commingled funds (d)

Total

  $

3,156

933

4,654

1,391

96

1,165

192

1,021

3,119

—

37
634

1

—
—

—
—
—

4,650

1,391

—

—
192
—

13,051

  $

3,173

  $

7,294

  $

—
—

3

—
—

—
—
—
3   $

—
299

—

—
96

1,165

—

1,021

2,581

  $

4,157

4,118

1,194

4,250

1,316

94

1,197

215

1,206

—

5

—
—

—
—
—

38
802

4,242

1,316

—

—
215
—

14,284

  $ 4,238

  $

7,153

  $

1
—

3

—
—

—
—
—
4   $

246

  $

39

  $

208   $ —   $

—   $

385   $

48   $

337   $

—   $

2

1,876

727

1,305

1,770

57

759

1,473

8,215

2
—

—

—
—

—
—
—

—

1,413

727

1,305

1,007

—
—

—

—
—

4
74
71

—
684
382

—
463

—

—
762

53
1

1,020

  $

40

  $

4,809

  $ 1,065

  $

2,300

  $

154

2,897

146
—

8

1,594

588

716

2,181

—

—
—

588

716

1,340

—
—

—

—
—

42
496

1,404

8,863

  $

—
—
—
194   $

7
75
408

5,073

  $

—
420
468
887   $

—   $

—   $

—   $ —   $

—   $

—   $ —   $

—   $

—   $

—
—

—

—
—

—
—

—

—
—

—
—

—

—
—

—
—

—

—
—

—

469
—

469

  $

—
—
—
—   $

—
—
—

—
469
—
469   $ —   $

—
—

—

—
—

—
—
—
—   $

—
—

—

—
—

—
—

—

—
—

—
—

—

—
—

—
—

—

—
—

—
—
—

—
494
—
494   $ —   $

—
494
—
494   $

—
—
—
—   $

—

—

392

—

—

94

1,197

—

1,206

2,889

—

—

1,303

—

—

841

35

1

528

2,709

—

—

—

—

—

—

—

—

—

—

(a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1 E).
(b) Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the

fair value hierarchy to the amounts presented for the total pension benefits plan assets.

(c )  Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.
(d)   Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
(e)   Government and agency obligations are inclusive of repurchase agreements.

(f)   See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.
(g)   Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.

118

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:

(MILLIONS OF DOLLARS)

Fair value, beginning

Actual return on plan assets:

Assets held, ending

Assets sold during the period

Purchases, sales, and settlements, net

Transfer into/(out of) Level 3

Exchange rate changes

Fair value, ending

Year Ended December 31,

International Pension Plans

Insurance contracts

2018
420   $

2017
254   $

Other

2018
468   $

1
—
188
107
(31)
684   $

1
—
138
—
27
420   $

15
—
(31)
(51)
(20)
382   $

  $

  $

2017

324

18

1

94

—

30

468

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a
description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and
assumptions, see Note 1C.

Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in
the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as
appropriate for lagged reporting of up to three months.

The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:

• Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include

short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.

• Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are

traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published
NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted,
suspended, or illiquid and are typically valued using their last available price.

• Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they
are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2
investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or
quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment
managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.

• Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are

traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments.

Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.

2018 Financial Report

119

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:

(PERCENTAGES)

U.S. qualified pension plans

Cash and cash equivalents

Equity securities

Fixed income securities

Other investments (a)

Total

International pension plans

Cash and cash equivalents

Equity securities

Fixed income securities

Other investments

Total

U.S. postretirement plans

Cash and cash equivalents

Equity securities

Fixed income securities

Other investments

Total

Target
Allocation Percentage

Percentage of Plan Assets

As of December 31,

2018

2018

2017

0-10%
35-55%
28-53%
5-20%
100%

0-10%
20-40%
35-60%
10-35%
100%

0-5%
—
—
95-100%
100%

3.4%
31.3%
47.1%
18.2%
100%

3.0%
22.9%
46.3%
27.9%
100%

—
—
—
100%
100%

4.6%

37.5%

39.6%

18.3%

100%

4.3%

34.4%

39.3%

21.9%

100%

—

—

—

100%

100%

(a)

Actual percentage of plan assets in Other investments for 2018 includes $192 million , as compared to $215 million in 2017 , related to a group fixed annuity insurance contract that was executed by legacy Wyeth
for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $177 million in 2018 , as compared to $253 million in 2017 , related to an investment in a partnership whose
primary holdings are public equity securities.

Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit
costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return
expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification,
active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our
targets accordingly and our asset allocations may vary from the target allocations.

Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans’ long-term benefit
obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset
classes and our liability profile.

Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and
associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set
on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target
allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls.

The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative
securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing
agreement.

E. Cash Flows

It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and
local tax laws.

120

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table provides the expected future cash flow information related to our benefit plans:

(MILLIONS OF DOLLARS)

U.S. Qualified

Expected employer contributions:

2019   $

11   $

Expected benefit payments:

2019

2020

2021

2022

2023

2024–2028

  $

1,387   $
1,089
1,058
1,020
1,018
4,837

Pension Plans

U.S. Supplemental
(Non-Qualified)

International

Postretirement Plans

167   $

167   $
121
114
113
103
445

177   $

354   $
372
380
385
387
2,068

160

166

171

171

168

165

777

The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions
used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.

F. Defined Contribution Plans

We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their
salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires
and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the defined
contribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each
employee’s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans
transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of $622 million in 2018
, $380 million in 2017 and $317 million in 2016 .

Note 12 . Equity

A. Common Stock

We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of
the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On October 23, 2014, we announced that the Board of
Directors had authorized an $11 billion share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a
new $11 billion share repurchase program (the December 2015 Stock Purchase Plan), which was exhausted in the third quarter of 2018. In December 2017, the Board of
Directors authorized an additional $10 billion share repurchase program, to be utilized over time, and share repurchases commenced thereunder in the third quarter of 2018
(the 2017 program). In December 2018, the Board of Directors authorized a new $10.0 billion share repurchase program to be utilized over time. This new program is in
addition to the $4.2 billion remaining under the company’s 2017 program authorization as of December, 31 2018.

On March 8, 2016, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase $5 billion of our common stock. Pursuant to the terms of the
agreement, on March 10, 2016, we paid $5 billion to GS&Co. and received an initial delivery of approximately 136 million shares of our common stock from GS&Co. based on
a price of $29.36 per share, which represented, based on the closing share price of our common stock on the NYSE on March 8, 2016, approximately 80% of the notional
amount of the accelerated share repurchase agreement. On June 20, 2016, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of
the agreement, resulted in GS&Co. owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 18
million shares of our common stock from GS&Co. on June 20, 2016. The average price paid for all of the shares delivered under the accelerated share repurchase agreement
was $32.38 per share. The common stock received is included in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase
authorization.

On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase $5 billion of our common stock. Pursuant to the terms of the
agreement, on February 6, 2017, we paid $5 billion to Citibank and received an initial delivery of approximately 126 million shares of our common stock from Citibank at a price
of $31.73 per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately 80% of the notional amount of the
accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the
agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 24
million shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement
was $33.31 per share. The common stock received is included in Treasury Stock . This agreement was entered into pursuant to our previously announced share repurchase
authorization.

On March 12, 2018 , we entered into an accelerated share repurchase agreement with Citibank to repurchase $4.0 billion of our common stock. Pursuant to the terms of the
agreement, on March 14, 2018 , we paid $4.0 billion to Citibank and received an initial delivery of approximately 87 million shares of our common stock from Citibank at a price
of $36.61 per share, which represented, based on the closing

2018 Financial Report

121

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

price of our common stock on the NYSE on March 12, 2018 , approximately 80% of the notional amount of the accelerated share repurchase agreement. On September 5,
2018, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of
shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 21 million shares of our common stock from Citibank on September 7,
2018. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $36.86 per share. The common stock received is included
in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization.

Open market purchases totaled $8.2 billion in 2018 under our publicly announced share-purchase plans.

The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including
our accelerated share repurchase agreements:

(SHARES IN MILLIONS, DOLLARS IN BILLIONS)

Shares of common stock purchased

2018 (a)

2017 (b)

307
12.2   $

150
5.0   $

2016 (c)

154

Cost of purchase

5.0
( a)  Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on March 12, 2018, as well as other share repurchases. See above for additional information.
(b)   Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on February 2, 2017. See above for additional information.
(c)  Represents shares purchased pursuant to the accelerated share repurchase agreement entered into on March 8, 2016. See above for additional information.

  $

After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through December 31, 2018 , our remaining share-purchase
authorization was approximately  $14.2 billion at December 31, 2018 .

On February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. This
agreement was entered into pursuant to our previously announced share repurchase authorization. For additional information, see Note 19 .

B. Preferred Stock

The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25% , which
are accumulated and paid quarterly. The per-share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights.
Each share is convertible, at the holder’s option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and
requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the
Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share.

C. Employee Stock Ownership Plans

We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).

Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated
preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of December 31, 2018 , the Preferred ESOP held preferred shares convertible
into approximately 1 million shares of our common stock, and the Common ESOP held approximately 49 million shares of our common stock. As of December 31, 2018 , all
shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the
Common ESOP was $19 million in 2018 , $11 million in 2017 and $9 million in 2016 .

Note 13. Share-Based Payments

Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in
competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of RSUs, PPSs,
TSRUs, stock options, PSAs, PTSRUs and PTUs, as determined by the Compensation Committee.

The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Plan, as amended and restated. The 2014 Plan provides for 520 million shares to be authorized for
grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 Plan provides that the number of
stock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36-
month period is limited to 20 million shares, and that RSUs, PPSs and PSAs count as three shares, while TSRUs, PTSRUs and stock options count as one share, toward the
maximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one
individual during any 36-month period was limited to 8 million shares. As of December 31, 2018 , 195 million shares were available for award.

Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.

122

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

A. Impact on Net Income

The following table provides the components of share-based compensation expense and the associated tax benefit:

(MILLIONS OF DOLLARS)

TSRUs (a)

RSUs

PPSs

PSAs

Stock options

Directors’ compensation

Share-based payment expense

Tax benefit for share-based compensation expense (b)

Share-based payment expense, net of tax
(a)   Includes $7.0 million of expense for PTSRUs.
(b)   2018 and 2017 include the impact of the TCJA on income taxes.
Amounts capitalized as part of inventory cost were not significant for any period presented.

B. Total Shareholder Return Units

Year Ended December 31,

2018
302   $
286
276
62
12
10
949
(180)
769   $

2017
221   $
301
209
47
55
7
840
(163)
677   $

2016

134

299

135

13

106

4

691

(205)

486

  $

  $

TSRUs are awarded to senior and other key management, and, beginning in 2016, to certain other employees. TSRUs entitle the holders to receive a number of shares of our
common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five -year or seven -
year term, if and to the extent the total value is positive. The settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or
seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. The TSRUs are automatically settled on the
fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture.

On October 26, 2016, the Compensation Committee approved the modification of current outstanding grants of TSRU awards, effective November 1, 2016, to permit a holder
who is "retiree eligible" (at least age 55 with at least 10 years of service), to elect to exercise and convert his/her TSRUs when vested, into PTUs. The value received upon the
election and conversion is calculated by taking the change in stock price ( 20 trading day average ending on the exercise date (Election Price) less the grant price) plus
accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will
be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs original settlement date (i.e., the fifth or
seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. This modification applied to
approximately 2,900 employees, including members of senior management. There was no incremental compensation cost resulting from the modification. Beginning in 2017,
TSRUs were granted with the right for retirement-eligible employees to elect to exercise and convert their TSRUs, when vested, into PTUs. We measure the value of TSRU
grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis
over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as appropriate.

The following table provides the weighted-average assumptions used in the valuation of TSRUs:

Expected dividend yield (a)

Risk-free interest rate (b)

Expected stock price volatility (c)

Contractual term (years)
(a)   Determined using a constant dividend yield during the expected term of the TSRU.
(b)   Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
(c)  Determined using implied volatility, after consideration of historical volatility.

Year Ended December 31,

2018
3.73%
2.60%
20.00%

5.12

2017
3.69%
1.98%
18.39%

5.11

2016

3.85%

1.31%

21.64%

5.12

2018 Financial Report

123

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table summarizes all TSRU activity during 2018:

Nonvested, December 31, 2017

Granted

Vested (a)

Forfeited

Nonvested, December 31, 2018
(a)

TSRUs
(Thousands)

103,906   $
47,755
(7,203)
(5,512)
138,945   $

Weighted-Average
Grant-Date
Fair Value
Per TSRU

Weighted-Average
Grant Price
Per TSRU

6.07   $
7.42
6.67
6.55
6.48   $

32.47

35.75

34.49

33.88

33.44

Includes the modification of approximately 1.7 million TSRUs to approximately 260 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified
to permit the vesting upon termination. The impact to compensation expense was immaterial.

The following table summarizes TSRU and PTU information as of December 31, 2018 (a), (b) :

TSRUs
(Thousands)

PTUs
(Thousands)

TSRUs Outstanding

TSRUs Vested (c)

TSRUs Expected to vest (d)

156,534
17,588
133,878
—

—   $
—
—
1,385   $

Weighted-
Average
Grant Price
Per TSRU
33.09
30.30
33.38
—

Weighted-Average
Remaining
Contractual Term

(Years)

Aggregate
Intrinsic
Value
(Millions)

3.1   $
1.5
3.2
0.5   $

2,073

332

1,688

60

TSRUs exercised and converted to PTUs
(a)   In 2018 , we settled 7,643,846 TSRUs with a weighted-average grant price of $23.13 per unit.
(b)   In 2018 , 2,809,652 TSRUs with a weighted-average grant price of $27.86 per unit were converted into 1,408,622 PTUs.
(c)

Includes the modification of approximately 1.7 million TSRUs to approximately 260 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified
to permit the vesting upon termination. The impact to compensation expense was immaterial.
(d)   The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.

The following table provides data related to all TSRU activity:

(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)

Weighted-average grant-date fair value per TSRU

Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax

Weighted-average period over which TSRU cost is expected to be recognized (years)

C. Performance Total Shareholder Return Units

  $
  $

Year Ended December 31,

2018
7.42   $
246   $
1.6

2017
6.23   $
232   $
1.7

2016

5.83

164

1.9

In December 2017, PTSRUs were awarded to the then Chairman and Chief Executive Officer and the then Group President, Pfizer Essential Health. These awards were
granted in connection with our Board’s succession planning for the Chairman and Chief Executive Officer and our announcement on November 13, 2017 that our then Group
President, Pfizer Innovative Health had been appointed Chief Operating Officer of Pfizer effective January 1, 2018. We also announced that effective January 1, 2018, the then
Group President, Pfizer Essential Health, had been appointed Group President, Pfizer Innovative Health. In addition to having the same characteristics of TSRUs, PTSRUs
require special service and performance conditions. On December 29, 2017, 1,372,213 PTSRUs were granted to the Chairman and Chief Executive Officer and 343,053
PTSRUs were granted to the new head of Innovative Health at a grant price of $36.22 and a grant-date fair value of $5.83 .

We measure the value of PTSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are
amortized on a straight-line basis over the vesting term into Selling, informational and administrative expenses as appropriate.

D. Restricted Stock Units

RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock, including shares resulting from
dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after three years of continuous service from
the grant date.

We measure the value of RSU grants as of the grant date using the closing price of our common stock. The values determined through this fair value methodology generally
are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses
, as appropriate.

124

2018 Financial Report

Includes the modification of approximately 150 thousand RSUs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were
modified to permit vesting upon termination. The impact to the compensation expense was immaterial.

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table summarizes all RSU activity during 2018:

Nonvested, December 31, 2017

Granted

Vested (a)

Reinvested dividend equivalents

Forfeited

Nonvested, December 31, 2018
(a)

The following table provides data related to all RSU activity:

(MILLIONS OF DOLLARS)

Total fair value of shares vested (a)

Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax

Weighted-average period over which RSU cost is expected to be recognized (years)
(a)

32.64

35.90

34.02

38.96

33.85

33.70

2016

293

262

1.7

36.22

35.74

37.31

38.23

43.65

Shares
(Thousands)

Weighted-Average
Grant-Date Fair Value
Per Share

22,241   $
9,083
(3,701)
974
(1,321)
27,276   $

  $
  $

Year Ended December 31,

2018
146   $
256   $
1.7

2017
584   $
254   $
1.7

20,973   $
6,769
(7,483)
(998)
19,261   $

  $
  $

Year Ended December 31,

2018
169   $
102   $
1.8

2017
131   $
94   $
1.7

2016

118

93

1.8

2018 Financial Report

125

2018 includes modification of approximately 150 thousand RSUs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were
modified to permit vesting upon termination. The impact to the compensation expense was immaterial. 2017 includes the modification for a commitment to pay approximately 6.4 million RSUs to approximately
9,900 employees, including senior and key management employees, for 6.6 million RSUs. These shares were paid in the first quarter of 2018.

E. Portfolio Performance Shares

PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible
range of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards
vest after three years of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s
long-term product portfolio during a five -year performance period from the year of the grant date. The number of shares that may be earned over the performance period
ranges from 0% to 200% of the initial award.

We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized
on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as
appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of
being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved and/or changes in management’s
assessment of the probable vesting term.

The following table summarizes all PPS activity during 2018, with the shares representing the maximum award that could be achieved:

Shares
(Thousands)

Weighted-Average
Intrinsic Value
Per Share

Nonvested, December 31, 2018 (b)
(a) Includes the modification of approximately 200 thousand PPSs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were

Nonvested, December 31, 2017

Granted

Vested (a)

Forfeited

modified to permit the vesting upon termination. The impact to compensation expense was immaterial.
(b)   Vested and non-vested shares outstanding, but not paid as of December 31, 2018 were 33.9 million .

The following table provides data related to all PPS activity:

(MILLIONS OF DOLLARS)

Total fair value of shares vested (a)

Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax

Weighted-average period over which PPS cost is expected to be recognized (years)
(a)

Includes the modification of approximately 200 thousand PPSs to approximately 140 employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified
to permit the vesting upon termination. The impact to compensation expense was immaterial.

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

F. Performance Share Awards

PSAs are awarded to senior and other key management. PSAs vest after three years of continuous service from the grant date. The number of shares paid, if any, including
shares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to two measures: (i) operating
income (for performance years through 2018) or net income (for 2019 and later years) over three one -year periods; and (ii) TSR as compared to the NYSE ARCA
Pharmaceutical Index (DRG Index) over the three -year performance period. The number of shares paid from awards granted in 2014 depends upon the achievement of
predetermined goals related to Pfizer's TSR as compared to an industry peer group, for the three-year performance period from the year of the grant date. The number of
shares that are earned over the performance period ranges from 0% to 200% of the initial award.

We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized
on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and development expenses , as
appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of
being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved.

The following table summarizes all PSA activity during 2018, with the shares granted representing the maximum award that could be achieved:

Shares
(Thousands)

Weighted-Average
Intrinsic Value
Per Share

4,024   $
1,833
(112)
(463)
5,282   $

36.22

35.74

39.58

37.12

43.65

Nonvested, December 31, 2017

Granted

Vested (a)

Forfeited

Nonvested, December 31, 2018
(a)

Includes the modification of a few PSAs to a few employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified to permit the vesting upon
termination. The impact to compensation expense was immaterial.

The following table provides data related to all PSA activity:

(MILLIONS OF DOLLARS)

Total fair value of shares vested (a)

Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax

Weighted-average period over which PSA cost is expected to be recognized (years)
(a)

Year Ended December 31,

2018

2017

2016

  $
  $

4   $
41   $
1.8

58   $
34   $
1.8

9

30

1.8

Includes the 2018 modification of a few PSAs to a few employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified to permit the vesting upon
termination. The impact to compensation expense was immaterial. Includes the 2017 modification for a commitment to pay 1.1 million PSAs to approximately 90 employees, including senior and key
management employees, for 1.1 million PSAs. These shares were paid in the first quarter of 2018.

G. Stock Options

Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of our common stock at a price per share equal
to the closing market price of our common stock on the date of grant.

Beginning in 2016, only a limited set of overseas employees received stock option grants. No stock options were awarded to senior and other key management in any period
presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted vest after three years of continuous service from
the grant date and have a contractual term of 10 years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In the
event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period of three months following the
date employment is terminated or through their remaining term, depending on various conditions.

We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value
methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses , and/or Research and
development expenses , as appropriate.

The following table provides the weighted-average assumptions used in the valuation of stock options:

Expected dividend yield (a)

Risk-free interest rate (b)

Expected stock price volatility (c)

Expected term (years) (d)
(a)   Determined using a constant dividend yield during the expected term of the option.
(b)   Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
(c)  Determined using implied volatility, after consideration of historical volatility.
(d)   Determined using historical exercise and post-vesting termination patterns.

126

2018 Financial Report

Year Ended December 31,

2018
3.73%
2.85%
20.02%

6.75

2017
3.69%
2.23%
18.39%

6.75

2016

3.85%

1.55%

21.64%

6.75

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

The following table summarizes all stock option activity during 2018:

Outstanding, December 31, 2017

Granted

Exercised

Forfeited

Expired

Outstanding, December 31, 2018 (b)

Vested and expected to vest, December 31, 2018 (c )

Exercisable, December 31, 2018
(a)   Market price of our underlying common stock less exercise price.
(b)

Shares
(Thousands)

Weighted-Average
Exercise Price

Per Share

Weighted-Average
Remaining Contractual
Term
(Years)

Aggregate
Intrinsic Value (a)
(Millions)

150,757   $
1,372
(47,740)
(219)
(379)
103,791
103,621
100,078   $

27.27
35.74
26.59
33.96
24.69
27.69
27.68
27.47

4.4   $
4.4
4.2   $

1,657

1,655

1,619

Includes the modification of approximately 190 thousand stock options to a few employees, including management employees, in connection with our Organizing for Growth initiative. The terms were modified to
permit a longer exercise term after termination.

(c)  The number of options expected to vest takes into account an estimate of expected forfeitures.

The following table summarizes data related to all stock option activity:

(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)

Weighted-average grant-date fair value per stock option

Aggregate intrinsic value on exercise

Cash received upon exercise

Tax benefits realized related to exercise

Total compensation cost related to nonvested stock options not yet recognized, pre-tax

Weighted-average period over which stock option compensation cost is expected to be recognized (years)

Note 14. Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders

The following table provides the detailed calculation of Earnings per common share  (EPS) :

(IN MILLIONS)

EPS Numerator––Basic

Income from continuing operations

Less: Net income attributable to noncontrolling interests

Income from continuing operations attributable to Pfizer Inc.

Less: Preferred stock dividends––net of tax

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations––net of tax

Less: Discontinued operations––net of tax, attributable to noncontrolling interests

Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders

Net income attributable to Pfizer Inc. common shareholders

EPS Numerator––Diluted

  $

  $

Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions

  $

Net income attributable to Pfizer Inc. common shareholders and assumed conversions

EPS Denominator

Weighted-average number of common shares outstanding––Basic (a)

Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible

preferred stock and accelerated share repurchase agreements (a)

Weighted-average number of common shares outstanding––Diluted
Stock options that had exercise prices greater than the average market price of our common stock issuable

under employee compensation plans (b)

Cash dividends declared per share

  $

  $

Year Ended December 31,

2018
5.06   $
625   $
1,259   $
115   $
5   $

1.7

2017
4.01   $
331   $
862   $
95   $
10   $
0.8

2016

3.89

389

1,019

112

58

1.1

  $
  $
  $
  $
  $

Year Ended December 31,

2018

2017

11,179   $
36
11,143
1
11,142
10
—
10
11,152   $

11,143   $
10
11,153   $

5,872

105
5,977

2
1.38   $

21,353   $
47
21,306
1
21,305
2
—
2

21,307   $

21,306   $

2

21,308   $

5,970

89
6,058

36
1.30   $

2016

7,229

31

7,198

1

7,197

17

—

17

7,214

7,197

17

7,214

6,089

70

6,159

63

1.22

(a)

(b)

2017 includes the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first
quarter of 2018.
These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive
effect.

2018 Financial Report

127

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 15 . Lease Commitments

We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other
operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $301 million in 2018 , $314 million in 2017 and
$292 million in 2016 .

The future minimum rental commitments under non-cancelable operating leases follow:

(MILLIONS OF DOLLARS)

Lease commitments

Note 16. Insurance

2019
300   $

2020
252   $

2021
210   $

2022
267   $

2023
248   $

  $

After 2023

2,040

Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-
insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost
and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or
substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the
period in which the amounts are paid and/or accrued (see Note 17 ).

Note 17 . Contingencies and Certain Commitments

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of
our tax contingencies, see Note 5D. For a discussion of our legal contingencies, see below.

A . Legal Proceedings

Our legal contingencies include, but are not limited to, the following:

• Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the

majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from
that drug or impairment of the value of associated assets.

• Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims,

among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual,
provable injury and other matters.

• Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will

vary from matter to matter.

• Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S.

and in other jurisdictions.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.

We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We
do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our
expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the
amounts are accrued and/or our cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore,
determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in
excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process
relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to
change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on
estimates and assumptions.

The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and
qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such
damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if
not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been
transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be
important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information
that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters
in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative
factors in our determination of

128

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is
remote.

A1 . Legal Proceedings––Patent Litigation

Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve
claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug
manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to
certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed
below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to
which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing
and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. We also are often
involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the
European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be
invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several
of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the United States. In June 2018, the Patent
Trial and Appeal Board ruled on one patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision.
Challenges to other patents remain pending before the U.S. Patent and Trademark Office. The invalidation of these patents could potentially allow a competitor pneumococcal
vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for
alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their
attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third
party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event
that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.

Actions In Which We Are The Plaintiff

Bosulif (bosutinib)
In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals,
Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S.
District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to
market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic
myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action
against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an
abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering
polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action
against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, which expire in 2025 and 2026,
respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia.

EpiPen
In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of
New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is
challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.

Precedex Premix
In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to
market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which
expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against
Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and
infringement of the patent. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material
to Pfizer.

In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic
version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in
2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement
of the patents that are the subject of the lawsuit. In January 2018, the District Court ruled that one of the four patents was valid and infringed, and that the other three patents
were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit.

In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a
generic version of Hospira’s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which
expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the
validity and infringement of those patents. In

2018 Financial Report

129

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

December 2018, the District Court ruled that the asserted patents were invalid. Hospira has appealed the District Court’s decision to the U.S. Court of Appeals for the Federal
Circuit.

In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic
version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in
2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement
of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals).

In December 2017, Gland Pharma Limited (Gland) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic
version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which expire in
2032, were invalid or not infringed. In February 2018, Hospira filed suit against Gland in the U.S. District Court for the District of Delaware asserting the validity and
infringement of four patents that are the subject of the lawsuit.

In December 2017, Jiangsu Hengrui Medicine Co., Ltd. (Hengrui) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market
a generic version of Hospira’s premix version of Precedex and containing allegations that six patents relating to the Precedex premix formulations and their use, all of which
expire in 2032, were invalid or not infringed. In February 2018, Hospira filed suit against Hengrui in the U.S. District Court for the District of Delaware asserting the validity and
infringement of four patents that are the subject of the lawsuit.

In February 2018, Baxter Healthcare Corporation (Baxter) filed a declaratory judgment action against Hospira in the U.S. District Court for the District of Delaware seeking a
declaration of non-infringement of four patents relating to the Precedex premix formulations and their use. One of the patents included in the action expires in 2019 and the
other three patents expire in 2032. In March 2018, Hospira filed a counterclaim for infringement of the patent expiring in 2019. In November 2018, the case was dismissed by
mutual agreement of the parties.

Xeljanz (tofacitinib)
In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of
Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version
of tofacitinib 5 mg tablets. In November 2018, we settled all of our claims against MicroLabs on terms not material to Pfizer.

Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware
asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in
its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional
patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another
patent challenged by Sun Pharmaceutical Industries Ltd, which covers the active ingredient and expires in December 2025. In October 2018, we brought a third patent
infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent
covering the extended release formulation of tofacitinib, which expires in 2034.

In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for
the District of Delaware asserting the infringement and validity of three patents: the patent covering the active ingredient expiring in December 2025, the patent covering an
entiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug
application seeking approval to market a generic version of tofacitinib 5 mg tablets.

Also, in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical
Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively, Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr.
Esteve, S.A. (collectively, Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective
abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action
against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of
which expire in December 2020 and one of which expires in December 2025. In March 2018, we brought another patent infringement action against Prinston in the U.S. District
Court for the District of Delaware asserting the infringement and validity of an additional patent, which had been subsequently challenged by Prinston and which expires in
December 2025. In May 2018, we settled all of our claims against Breckenridge on terms not material to Pfizer. In January 2019, we settled all of our claims against Prinston
on terms not material to Pfizer.

In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware
asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application
seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.

Inlyta (axitinib)
In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc.
asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May 2018, we filed suit against Apotex Inc. in the U.S. District Court
for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.

Kerydin (tavaborole)
In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of
Kerydin. The generic companies   assert the invalidity and non-infringement of methods of use and

130

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary , filed infringement
lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.

Matters Involving Our Collaboration/Licensing Partners

Toviaz (fesoterodine)––Inter-Partes Reviews
In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews
of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent
covering salts of fesoterodine that expires in 2022. The patents are owned by UCB Pharma GmbH, and we have an exclusive, worldwide license to market Toviaz from UCB
Pharma GmbH. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all five patents. Amerigen Pharmaceuticals Limited (Amerigen),
Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions
upholding all five patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal
Circuit . In January 2018, Mylan withdrew its appeal. Amerigen’s appeal of the decision upholding the patent covering salts of fesoterodine that expires in 2022 was the only
pending appeal. In January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. Patent and Trademark Office’s decision upholding the validity of the patent
covering salts of fesoterodine that expires in 2022.

Xtandi (enzalutamide)
In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma
US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against
Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’
respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents,
which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane
Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of
enzalutamide. In June and July 2018, we settled all of our claims against Actavis and Apotex, respectively, on terms not material to Pfizer.

Eliquis
In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug
applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis.
The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and
Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia,
asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the
2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. We and BMS have settled with certain of the generic
companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future.

Actions In Which We Are The Defendant

Inflectra (infliximab-dyyb)
In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira,
Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents
relating to infliximab, its manufacture and use. Claims with respect to four of the patents were dismissed by the plaintiffs, leaving two patents at issue: the infliximab antibody
patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the
U.S. District Court for the District of Massachusetts granted defendants’ motion for summary judgment and ruled that the patent relating to cell culture media was not infringed.
Janssen has appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit.

Bavencio (avelumab)
In July 2017, BMS, E.R. Squibb & Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of
Delaware against Pfizer, Merck KGaA, and EMD Serono, Inc., alleging that Bavencio (avelumab) infringes one patent relating to methods for treating tumors with anti-PD-L1
antibodies, which expires in 2023. In February 2019, we settled this matter on terms not material to Pfizer.

A2. Legal Proceedings––Product Litigation

Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other
products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.

Asbestos
Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos
safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-
related and other claims. As of December 31, 2018 , approximately 46,400 claims naming American Optical and numerous other defendants were pending in various federal
and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in
2000

2018 Financial Report

131

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.

Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing
asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.

There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned
by Pfizer or its subsidiaries.

Effexor
Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and
certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class
consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR
from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of
generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of
certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR
and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the
individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its
territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey.

In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct
purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct
purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit
reversed the District Court’s decisions and remanded the claims to the District Court.

Lipitor

• Antitrust Actions

Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in
most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide
classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic
Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the
launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant
to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets
beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things,
treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition,
individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially
similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a
Multi-District Litigation ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey.

In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with
prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of
Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their
complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded
the claims to the District Court.

Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on
behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described
above.

• Personal Injury Actions

A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly
as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages.

In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales
Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation
were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases
pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the
U.S. Court of Appeals for the Fourth Circuit affirmed the District Court’s decision.

Viagra
A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the
exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Plaintiffs seek compensatory and punitive damages.

132

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In Re: Viagra (Sildenafil Citrate) Products Liability
Litigation, MDL-2691 ) in the U.S. District Court for the Northern District of California. In December 2016, federal actions filed against Lilly and filed against both us and Lilly,
were transferred for coordinated pre-trial proceedings to the Multi-District Litigation ( In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-
2691 ).

Intravenous Solutions
Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and
certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent a class consisting of all persons and entities in the U.S. who directly purchased
intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that the
defendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of
federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges
for intravenous saline solution in the U.S. since January 1, 2013. All of these actions have been consolidated in the U.S. District Court for the Northern District of Illinois. In July
2018, the District Court granted defendants’ motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in
September 2018. On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, which includes intravenous saline solution, to ICU Medical. The
litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.

Hormone Therapy Consumer Class Action
A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its
hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth’s hormone-replacement
products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a
full refund of the purchase price.

Eliquis
A number of individual and multi-plaintiff lawsuits have been filed against us and BMS in various federal and state courts pursuant to which plaintiffs seek to recover for
personal injuries, including wrongful death, due to bleeding allegedly as a result of the ingestion of Eliquis. Plaintiffs seek compensatory and punitive damages.

In February 2017, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In Re: Eliquis (Apixaban) Products Liability Litigation
MDL-2754 ) in the U.S. District Court for the Southern District of New York. In July 2017, the District Court dismissed substantially all of the actions that were pending in the
Multi-District Litigation. In August 2017, certain plaintiffs appealed the District Court’s dismissal to the U.S. Court of Appeals for the Second Circuit.

EpiPen
Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian,
and/or various entities affiliated with Mylan N.V., and Mylan N.V. Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide
classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants’ allegedly
unlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of New Jersey on behalf of a purported class of direct purchaser plaintiffs
against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. Against Pfizer and/or its affiliates, plaintiffs generally allege that Pfizer’s and/or its
affiliates’ settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust or consumer
protection laws. At least one lawsuit also alleges that Pfizer and/or Mylan N.V. violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed
various consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan Pharmaceuticals regarding EpiPen. Plaintiffs seek treble
damages for alleged overcharges for EpiPen since 2009. In August 2017, the actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation ( In re:
EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation , MDL-2785) in the U.S. District Court for the District of Kansas with other EpiPen-
related actions against Mylan N.V. and/or its affiliates to which Pfizer, King and Meridian are not parties.

Nexium 24HR and Protonix
A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and
state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against us involve
Nexium 24HR and/or Protonix and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal
actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In re: Proton-Pump Inhibitor Products Liability Litigation (No. II)) in the U.S.
District Court for the District of New Jersey.

Docetaxel

• Personal Injury Actions

A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed
permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek
compensatory and punitive damages.

In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In re Taxotere (Docetaxel) Products Liability Litigation ,
MDL-2740) in the U.S. District Court for the Eastern District of Louisiana.

• Mississippi Attorney General Government Investigation

In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers
including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer
Protection Act. The action seeks civil penalties and injunctive relief.

2018 Financial Report

133

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

A3 . Legal Proceedings––Commercial and Other Matters

Average Wholesale Price Litigation
Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided
average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to
determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but one of those actions have been
resolved through settlement, dismissal or final judgment. The plaintiff state, Illinois, in the one remaining action, claims that the alleged spread between the AWPs at which
purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The action alleges, among other
things, fraud and violation of the state’s unfair trade practices and consumer protection statutes and seeks monetary and other relief, including civil penalties and treble
damages.

Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and
spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations
to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by
Pfizer in 2003 and is a wholly-owned subsidiary of Pfizer.

In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former
agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural
business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.

In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of
its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited
to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia
for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New
Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical
businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated
biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical
businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.

Environmental Matters
In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia’s discontinued industrial chemical
facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy
in late 2011 under an Updated Administrative Order on Consent with the EPA.

Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation’s (formerly, American Cyanamid Company) discontinued industrial
chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement with the EPA and Order on Consent
for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim
remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound
Brook facility’s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings
Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering
design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a
complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy
for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. We have
accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities. In September 2018, the EPA issued a final remediation plan for the two
adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study.

We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other
state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.

Contracts with Iraqi Ministry of Health
In October 2017, a number of United States service members, civilians, and their families brought a complaint in the Federal District Court for the District of Columbia against a
number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-
Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical
device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.S. Department of Justice requested documents related to this matter, which are
being provided.

Allergan Complaint for Indemnity
In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, a Pfizer subsidiary, filed by Allergan Finance LLC (Allergan) in a
Multi-District Litigation ( In re National Prescription Opiate Litigation MDL 2804 ) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserts claims for
indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed
the lawsuit.

134

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

A4. Legal Proceedings––Government Investigations

Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in
which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, substantial fines and/or civil penalties, limitations on our
ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the
matter could result from government investigations. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the
recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.

Phenytoin Sodium Capsules
In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In
May 2013, the U.K. Competition & Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market.
In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust
laws. In December 2016, the CMA imposed a £84.2 million fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA decision to The Competition Appeal Tribunal in February
2017 . On June 7, 2018, the Competition Appeal Tribunal overturned the CMA decision as well as the associated fine. The CMA has appealed the judgment to the Court of
Appeal.

Greenstone Investigations
Since July 2017, the U.S. Department of Justice’s Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing antitrust
investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone. In April 2018, Greenstone received requests for
information from the Antitrust Department of the Connecticut Office of the Attorney General. We have been providing information pursuant to these requests.

Subpoena relating to Manufacturing of Quillivant XR
In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York seeking records relating to our relationship with another drug
manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We are producing records pursuant to the subpoena.

Civil Investigative Demand relating to Meridian Medical Technologies
In February 2019, we received a civil investigative demand from the U.S. Attorney’s Office for the Southern District of New York (SDNY).  The civil investigative demand seeks
records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site.  We will be producing records in response to this civil
investigative demand.

Intravenous Solutions

See Note 17A5. Contingencies and Certain Commitments Legal Proceedings –– Matters Resolved During 2018 –– Intravenous Solutions Government Investigation below for
information regarding government investigations related to sales of intravenous solution products.

Contracts with Iraqi Ministry of Health
See Note 17A3. Contingencies and Certain Commitments : Legal Proceedings––Commercial and Other Matters––Contracts with Iraqi Ministry of Health above for information
regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.

Docetaxel –– Mississippi Attorney General Government Investigation
See Note 17A2. Contingencies and Certain Commitments : Legal Proceedings –– Product Litigation –– Docetaxel –– Mississippi Attorney General Government Investigation
above for information regarding a government investigation related to Docetaxel marketing practices.

A5. Legal Proceedings––Matters Resolved During 2018

During 2018, certain matters, including the matters discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-
principle.

Celebrex
Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to
Celebrex. The plaintiffs sought to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly
purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants’ allegedly
unlawful conduct. The plaintiffs alleged delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various
other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation and prolonging the impact of sham litigation
through settlement activity that further delayed generic entry. Each of the actions sought treble damages on behalf of the putative class for alleged price overcharges for
Celebrex since May 31, 2014. In December 2014, the District Court granted the parties’ joint motions to consolidate the direct purchaser and end-payer cases, and all such
cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers’ and end-payers’ amended complaints,
respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers’ amended complaint. In February 2016, the
District Court denied in part and granted in part our motion to dismiss the end-payers’ amended complaint, and in August 2016, the District Court dismissed substantially all of
the end-payers’ remaining claims. In February 2017, the District Court dismissed with prejudice all of the end-payers’ claims. In March 2017, the end-payers appealed the
District Court’s order dismissing their claims with prejudice to the U.S. Court of Appeals for the Fourth Circuit. In August 2017, the District Court granted the direct purchasers’
motion for class certification. In November 2017, Pfizer and the direct purchasers entered into an agreement to resolve the direct purchasers’ class action for $94 million . In
April 2018, the court approved the agreement. In November 2017, Pfizer and the end-payers entered into an agreement to resolve the claims of the end-payer plaintiffs on
terms not material to Pfizer.

2018 Financial Report

135

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Subpoenas relating to Copayment Assistance Organizations
In December 2015 and July 2016, Pfizer received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts requesting documents related to the Patient
Access Network Foundation and other IRC 501(c)(3) organizations that provide financial assistance to Medicare patients. In May 2018, Pfizer entered into a civil settlement to
resolve the matter. Pfizer paid $23.85 million to the United States, and entered into a five -year Corporate Integrity Agreement with the Office of the Inspector General of the
Department of Health and Human Services.

Civil Investigative Demand relating to Pharmacy Benefit Managers
In March 2016, Pfizer received a civil investigative demand from the U.S. Attorney’s Office for the SDNY related to Pfizer’s contractual relationships with pharmacy benefit
managers with respect to certain pharmaceutical products over the period from January 1, 2006 to the present. We have provided information to the government in response to
this civil investigative demand. In July 2018, Pfizer was served with a qui tam complaint that appears to be related to the SDNY investigation. The complaint was unsealed
following the government’s decision not to intervene in the case.

Intravenous Solutions Government Investigation
In April 2017, Pfizer, Hospira and two employees of Pfizer received grand jury subpoenas issued by the United States District Court for the Eastern District of Pennsylvania, in
connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoenas seek documents related to the sale, manufacture, pricing and shortages
of intravenous solutions, including saline, as well as communications among industry participants regarding these issues. The Department of Justice investigation is also the
subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement. In addition, in August 2015, the New York Attorney General issued a
subpoena to Hospira for similar information. Hospira has produced records to the New York Attorney General and coordinated with ICU Medical to produce records to the U.S.
Department of Justice. In December 2018, the U.S. Department of Justice informed Pfizer that it had closed its investigation.

B. Guarantees and Indemnifications
In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain
liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a
successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions
and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2018 , the estimated fair value of these indemnification
obligations was not significant.

In addition, in connection with our entry into certain agreements, our counterparties agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to
co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc.
and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has
acknowledged that it is obligated to satisfy any award of damages.

Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.

C. Certain Commitments

• As of December 31, 2018 , we had agreements totaling $3.7 billion to purchase goods and services that are enforceable and legally binding and include amounts relating to

advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.

• As of December 31, 2018 , we have obligations to make guaranteed fixed annual payments over an eight -year period in connection with the U.S. and EU approvals for
Besponsa ( $422 million ) and an obligation to make guaranteed fixed annual payments over a nine -year period for Bosulif ( $240 million ), both associated with R&D
arrangements.

• As of December 31, 2018 , in connection with the TCJA, we have an estimated $15 billion repatriation tax liability on accumulated post-1986 earnings of foreign subsidiaries
for which we plan to elect, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. The first installment, due in April
2019, is reported in Income taxes payable and the remaining installments are reported in Other taxes payable in our consolidated balance sheet as of December 31, 2018.
Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. See Note 5A
for additional information.

Note 18. Segment, Geographic and Other Revenue Information

A. Segment Information

We regularly review our segments and the approach used by management to evaluate performance and allocate resources. At the
beginning of our fiscal year 2019, we reorganized our commercial operations. Prior to the reorganization effective January 1, 2019, we managed our commercial operations
through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH operating segments were each led by a single manager.
Each operating segment had responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line
products that generally have achieved proof-of-concept. Each business had a geographic footprint across developed and emerging markets. Our chief operating decision
maker used the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. As described in Note 1A ,
acquisitions and divestitures have impacted our results of operations in 2018 , 2017 and 2016 .

136

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Some additional information about our business segments and other costs and business activities as of December 31, 2018 (prior to our new 2019 commercial organizational
re-alignment) follows:

Operating Segments

IH focused on developing and commercializing novel, value-creating medicines and
vaccines that significantly improve patients’ lives, as well as products for consumer
healthcare.

Key therapeutic areas included internal medicine, vaccines, oncology, inflammation &
immunology, rare disease and consumer healthcare.

EH included legacy brands that have lost or will soon lose market exclusivity in both
developed and emerging markets, branded generics, generic sterile injectable
products, biosimilars and select branded products including anti-infectives. EH also
included an R&D organization, as well as our contract manufacturing business.
Through February 2, 2017, EH also included HIS.

Leading brands included:
- Prevnar 13/Prevenar 13
- Xeljanz
- Eliquis
- Lyrica  (U.S., Japan and certain other markets)
- Enbrel (outside the U.S. and Canada)
- Ibrance
- Xtandi
- Chantix/Champix
- Several OTC consumer healthcare products (e.g., Centrum  and Advil )

Leading brands included:
- Lipitor
- Norvasc
- Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries)
- Celebrex
- Viagra*
- Inflectra/Remsima
- Sulperazon
- Several other sterile injectable products

* Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH

(which reported all other Viagra revenues excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH.

The following organizational change impacted our operating segments in 2018:

• Effective in the first quarter of 2018, certain costs for Pfizer’s StratCO group, which were previously reported in the operating results of our operating segments and

Corporate, are reported in Other Unallocated. StratCO costs primarily include headcount costs, vendor costs and data costs largely in support of Pfizer’s commercial
operations. The majority of the StratCO costs reflect additional amounts that our operating segments would have incurred had each segment operated as a standalone
company during the periods presented. The reporting change was made to streamline accountability and speed decision making. In 2017, we reclassified approximately
$468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from Corporate to Other unallocated costs to conform to
the current period presentation, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43
million of costs from Corporate to Other unallocated costs to conform to the current period presentation.

Other Costs and Business Activities

Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:

• WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment
via the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The
WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the
various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all
safety-event activities.

• GPD, which is generally responsible for the operational execution of clinical trials for both early-stage assets in the WRD portfolio as well as late-stage assets in the

Innovative portfolio. GPD also provides technical support and other services to Pfizer R&D projects.

• Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs,

compliance and worldwide procurement), the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities,
clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations, as well
as certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of 2018, certain
costs for StratCO, which were previously reported in the operating results of our operating segments and Corporate, are reported in Other Unallocated. For additional
information, see note below on Other unallocated costs.

• Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating

segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). In connection with the
StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of
costs from Corporate to Other unallocated costs to conform to the current period presentation, and in 2016, we reclassified approximately $312 million of costs from IH,
approximately $167 million of costs from EH and approximately $43 million of costs from Corporate to Other unallocated costs to conform to the current period presentation.

• Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to

inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the

2018 Financial Report

137

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in
some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or
size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring
costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.

Segment Assets

We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled
(such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any
asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $159 billion as of
December 31, 2018 and approximately $172 billion as of December 31, 2017 .

Selected Income Statement Information

As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2018 , 2017 and 2016 .

The following table provides selected income statement information by reportable segment:

(MILLIONS OF DOLLARS)

Reportable Segments:

IH (c)

EH (c)

Total reportable segments

Other business activities (d), (e)

Reconciling Items:

Corporate (c), (e)

Purchase accounting adjustments (e)

Acquisition-related costs (e)

Certain significant items (f)

Other unallocated (c) , (e)

Revenues

Earnings (a)

Depreciation and Amortization (b)

Year Ended December 31,

Year Ended December 31,

Year Ended December 31,

2018

2017

2016

2018

2017

2016

2018

2017

2016

  $

33,426   $
20,221
53,647
—

31,422   $
21,124
52,546
—

29,197   $
23,627
52,824
—

20,258   $
10,712
30,970

18,809   $
11,460
30,269

16,166   $
13,065
29,231

(2,977)

(3,137)

(3,020)

—
—
—
—
—
53,647   $

—
—
—
—
—
52,546   $

—
—
—
—
—
52,824   $

  $

(5,096)

(4,786)

(318)

(5,452)

(4,758)

(456)

(5,448)

(4,185)

(785)

(4,305)

(2,647)

(5,888)

(1,603)
11,885   $

(1,514)
12,305   $

(1,554)
8,351   $

629   $
547
1,175
93

363
4,620
12
38
82
6,384   $

534   $
579
1,113
90

337
4,565
39
52
72
6,269   $

583

600

1,183

85

356

3,890

7

200

35

5,757

(a)

Income from continuing operations before provision/(benefit) for taxes on income . IH’s earnings include d ividend income from our investment in ViiV of $253 million in 2018 and $266 million in 2017 . For
additional information, see Note 4.

(b)   Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c)

In connection with the StratCO reporting change, in 2017, we reclassified approximately $468 million of costs from IH, approximately $176 million of costs from EH and approximately $70 million of costs from
Corporate to Other unallocated costs, and in 2016, we reclassified approximately $312 million of costs from IH, approximately $167 million of costs from EH and approximately $43 million of costs from Corporate
to Other unallocated costs to conform to the current period presentation.

(d)   Other business activities includes the costs managed by our WRD and GPD organizations.
(e)   For a description, see the “Other Costs and Business Activities” section above.
(f)   Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as

part of our normal business on a regular basis.
For Earnings in 2018 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $977 million ,
(ii) net charges for certain legal matters of $157 million , (iii) income of $1 million , representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv)
certain asset impairment charges of $3.1 billion , (v) charges for business and legal entity alignment of $4 million , (vi) net losses on early retirement of debt of $3 million and (vii) other charges of $65 million ,
which includes, among other things, a non-cash $343 million pre-tax gain in Other (income)/deductions––net associated with our transaction with Bain Capital to create a new biopharmaceutical company,
Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, a $119 million charge, in the aggregate, in Selling,
informational and administrative expenses , for a special one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected
positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA, $59 million of incremental costs associated with the design, planning and implementation of the new
organizational structure, effective in the beginning of 2019, and primarily including consulting, legal, tax, and advisory services and a non-cash $50 million pre-tax gain in Other (income)/deductions––net as a
result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see Note 2B , Note
3 and Note 4 .
For Earnings in 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $204 million ,
(ii) charges for certain legal matters of $237 million , (iii) charges of $55 million , representing adjustments to amounts previously recorded to write-down the HIS net assets to fair value less costs to sell, (iv)
certain asset impairment charges of $379 million , (v) charges for business and legal entity alignment of $71 million , (vi) net losses on early retirement of debt of $999 million and (vii) other charges of $700 million
. For additional information, see Note 2B , Note 3 and Note 4.
For Earnings in 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.4 billion ,
(ii) charges for certain legal matters of $494 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.7 billion , (iv) certain asset impairment
charges of $1.4 billion , (v) charges for business and legal entity alignment of $261 million , (vi) net losses on early retirement of debt of $312 million and (vii) other charges of $294 million . For additional
information, see Note 3 and Note 4 .

138

2018 Financial Report

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Equity in the net income of investees accounted for by the equity-method is not significant for any of our operating segments.

The operating segment information does not purport to represent the revenues, costs and Income from continuing operations before provision/(benefit) for taxes on income that
each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.

B. Geographic Information

As described in Note 1A , the February 3, 2017 sale of HIS impacted our results of operations in 2018 , 2017 and 2016 .

The following table provides revenues by geographic area:

(MILLIONS OF DOLLARS)

United States

Developed Europe (a)

Developed Rest of World (b)

Emerging Markets (c)

Revenues

Year Ended December 31,

2018
25,329   $
9,116
6,551
12,651
53,647   $

2017
26,026   $
8,508
6,612
11,399
52,546   $

2016

26,369

9,306

6,729

10,420

52,824

$

$

(a)

Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $7.3 billion in 2018 , $6.8 billion in 2017 and $7.2 billion in
2016 .

(b)   Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c)  Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Revenues exceeded $500 million in each of 11 countries outside the U.S. in 2018 , 2017 and 2016 . The U.S. is the only country to contribute more than 10% of total revenue
in 2018 , 2017 and 2016 . As a percentage of revenues, our two largest national markets outside the U.S. were Japan, which contributed 8% of total revenue in each of 2018,
2017 and 2016, and China, which contributed 8% of total revenue in 2018, 7% of total revenue in 2017 and 6% of total revenues in 2016.

The following table provides long-lived assets by geographic area:

(MILLIONS OF DOLLARS)

Property, plant and equipment, net

United States

Developed Europe (a)

Developed Rest of World (b)

Emerging Markets (c)

Property, plant and equipment, net

As of December 31,
2017

2018

  $

  $

7,089   $
4,204
490
1,602
13,385   $

6,971   $
4,345
632
1,917
13,865   $

2016

6,649

4,228

643

1,797

13,318

(a)   Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
(b)   Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c)  Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.

C. Other Revenue Information

Significant Customers

We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2018 , sales to our three largest U.S. wholesaler customers represented
approximately 15% , 11% and 10% of total revenues, respectively, and, collectively, represented approximately 34% of total trade accounts receivable as of December 31,
2018 . In 2017 , sales to our three largest U.S. wholesaler customers represented approximately 16% , 12% and 10% of total revenues, respectively, and, collectively,
represented approximately 36% of total trade accounts receivable as of December 31, 2017 . In 2016 , sales to our three largest U.S. wholesaler customers represented
approximately 16% , 12% and 10% of total revenues, respectively, and, collectively, represented approximately 29% of total trade accounts receivable as of December 31,
2016 . For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses.

2018 Financial Report

139

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Significant Product Revenues

As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2018 , 2017 and 2016 .

The following table provides detailed revenue information for several of our major products:

(MILLIONS OF DOLLARS)

PRODUCT

TOTAL REVENUES

PFIZER INNOVATIVE HEALTH (IH) (a)

Internal Medicine

Lyrica IH (b)

  PRIMARY INDICATION OR CLASS

Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic

pain due to spinal cord injury

Eliquis alliance revenues and direct

Atrial fibrillation, deep vein thrombosis, pulmonary embolism

sales

Chantix/Champix

BMP2

Toviaz

Viagra IH (c)

All other Internal Medicine

Vaccines

Prevnar 13/Prevenar 13

FSME/IMMUN-TicoVac

Trumenba

All other Vaccines

Oncology

Ibrance

Sutent

Xtandi alliance revenues

Xalkori

Inlyta

Bosulif

All other Oncology

Inflammation & Immunology (I&I)

  An aid to smoking cessation treatment in adults 18 years of age or older
  Development of bone and cartilage
  Overactive bladder
  Erectile dysfunction
  Various

  Vaccines for prevention of pneumococcal disease
  Tick-borne encephalitis vaccine
  Meningococcal Group B vaccine
  Various

  Advanced breast cancer

Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression
on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor

  Castration-resistant prostate cancer
  ALK-positive and ROS1-positive advanced NSCLC
  Advanced RCC
  Philadelphia chromosome–positive chronic myelogenous leukemia
  Various

Enbrel (Outside the U.S. and Canada)

RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing

spondylitis and nonradiographic axial spondyloarthritis

Xeljanz

Eucrisa

All other I&I

Rare Disease

Genotropin

BeneFIX

Refacto AF/Xyntha

Somavert

All other Rare Disease

Consumer Healthcare

  RA, PsA, ulcerative colitis
  Mild-to-moderate atopic dermatitis (eczema)
  Various

  Replacement of human growth hormone
  Hemophilia
  Hemophilia
  Acromegaly
  Various

PFIZER ESSENTIAL HEALTH (EH) (d)

Legacy Established Products (LEP) (e)

Lipitor

Norvasc

Premarin family

Xalatan/Xalacom

Effexor

EpiPen

Zoloft

  Reduction of LDL cholesterol
  Hypertension
  Symptoms of menopause
  Glaucoma and ocular hypertension
  Depression and certain anxiety disorders
  Epinephrine injection used in treatment of life-threatening allergic reactions
  Depression and certain anxiety disorders

  $
  $
  $

  $

  $

Year Ended December 31,

  $
  $
  $

2018

53,647

33,426

9,996

4,622

3,434

1,085

279

271
—

  $
  $
  $

2017

52,546

31,422

9,684

4,511

2,523

997
261
257
823
312

306

6,332

5,802

184

116

230

7,202

4,118

1,049

699

524

298

296

219

  $

6,001

  $

5,601

134
88
177

  $

6,056

  $

3,126

1,081

590
594
339

233
93

  $

4,080

  $

3,968

  $

2,112

1,774

147

46

2,452

1,345

67
103

  $

2,211

  $

2,240

  $

  $
  $
  $

  $
  $
  $

558

554

514

267

318

3,605

20,221

10,540

2,062

1,024

832

318

311

303

298

532
604
551
254
300

  $
  $
  $

3,472

21,124

10,894

1,915

926
977
335
297
290
291

2016

52,824

29,197

8,858

4,165

1,713

842

251

258

1,181

447

6,071

5,718

114

84

155

4,563

2,135

1,095

140

561

401

167

63

3,928

2,909

927

—

93

2,369

579

712

554

232

292

3,407

23,627

11,197

1,758

962

1,017

363

278

386

304

Zithromax

Xanax

Sildenafil Citrate

All other LEP

  Bacterial infections
  Anxiety disorders
  Erectile dysfunction
  Various

140

2018 Financial Report

290

223

56

4,822

270
225
56

5,313

272

222

—

5,636

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

(MILLIONS OF DOLLARS)

PRODUCT

PRIMARY INDICATION OR CLASS

Sterile Injectable Pharmaceuticals (SIP) (f)

Sulperazon

Medrol

Fragmin

Tygacil

Zosyn/Tazocin

Precedex

All other SIP

Peri-LOE Products (g)

Celebrex

Viagra EH (c)

Vfend

Lyrica EH (b)

Zyvox

Revatio

Pristiq

All other Peri-LOE Products

Biosimilars (h)

Inflectra/Remsima

All other Biosimilars

Pfizer CentreOne (i)

  Treatment of infections
  Steroid anti-inflammatory
  Slows blood clotting
  Tetracycline class antibiotic
  Antibiotic
  Sedation agent in surgery or intensive care
  Various

  Arthritis pain and inflammation, acute pain
  Erectile dysfunction
  Fungal infections
  Epilepsy, neuropathic pain and generalized anxiety disorder
  Bacterial infections
  Pulmonary arterial hypertension
  Depression
  Various
  Various
  Inflammatory diseases
  Various

Hospira Infusion Systems (HIS) (j)

  Various

Total Lyrica (b)

Total Viagra (c)

Total Alliance revenues

Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic

pain due to spinal cord injury

  Erectile dysfunction
  Various

Year Ended December 31,

  $

2018

5,214

  $

2017

5,673

  $

613

427

293

249

229

213

471
483
306
260
194
243

  $

3,191

2,944

  $

3,715

3,223

  $

686

636

392

347

236

227

206

213

769

642

127

  $

  $
755
—   $

4,970

636

3,838

  $
  $
  $

775
382
421
553
281
252
303
257
531   $
419
112
706   $
97   $

5,065

1,204

2,927

  $
  $
  $

  $

  $
  $

  $
  $
  $

2016

6,014

396

450

318

274

146

264

4,166

4,220

733

383

590

801

421

285

732

276

319

192

127

718

1,158

4,966

1,564

1,746

(a)

(b)

(c)

The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant
(recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to
align these products with our management of the women’s health portfolio within EH.
Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of
worldwide revenues from Lyrica IH and Lyrica EH.
Viagra lost exclusivity in the U.S. in December 2017. In 2018, revenues for Viagra in the U.S. and Canada, which were reported in IH through 2017, were reported in EH (which reported all other Viagra revenues
excluding the U.S. and Canada through 2017). Therefore, in 2018, total Viagra worldwide revenues were reported in EH. Total Viagra revenues in 2017 and 2016 represented the aggregate of worldwide revenues
from Viagra IH and Viagra EH.

(d)   The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017).
(e)

Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share
in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets
within Pfizer CentreOne.
Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products
with our management of the women’s health portfolio within EH. See note (a) above.

(f)   Sterile Injectable Pharmaceuticals includes branded and generic injectables (excluding Peri-LOE Products). In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first

(g)

(h)

quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.
Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; and
worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra; and in 2018, Viagra revenues for all countries (and Viagra revenues for all countries other than the U.S. and Canada in 2017 and 2016),
see note (c) above.
Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and in the
U.S. and Retacrit (biosimilar epoetin zeta) in the U.S. and certain European and Africa/Middle Eastern markets.

(i)   Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our
manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related
revenues, previously reported in emerging markets within All Other LEP and All Other SIP, are reported in emerging markets within Pfizer CentreOne.

(j)   HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV

solutions and their associated administration sets.

2018 Financial Report

141

Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Note 19. Subsequent Event

A. Accelerated Share Repurchase Agreement

On February 7, 2019 , we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock. Pursuant to
the terms of the agreement, on February 12, 2019 , we paid approximately $6.8 billion to GS&Co. and received an initial delivery of approximately 130 million shares of our
common stock from GS&Co. , which represented, based on the closing price of our common stock on the NYSE on February 7, 2019 , approximately 80% of the notional
amount of the accelerated share repurchase agreement. As of February 28, 2019, the common stock received is included in Treasury Stock . At settlement of the agreement,
which is expected to occur during or prior to the third quarter of 2019, GS&Co. may be required to deliver additional shares of common stock to us, or, under certain
circumstances, we may be required to deliver shares of our common stock or may elect to make a cash payment to GS&Co. , with the number of shares to be delivered or the
amount of such payment, as well as the final price per share, based on the volume-weighted average price, less a discount, of Pfizer’s common stock during the term of the
transaction. This agreement was entered into pursuant to our previously announced share repurchase authorization. After giving effect to the accelerated share repurchase
agreement and other share repurchases through February 28, 2019, our remaining share-purchase authorization was approximately  $5.3 billion on February 28, 2019.

142

2018 Financial Report

Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies

(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)

First

Second

Third

Fourth

Quarter

2018

Revenues

Costs and expenses (a)

Restructuring charges and certain acquisition-related costs (b)

Income/(loss) from continuing operations before provision for taxes on income/(loss)

Provision/(benefit) for taxes on income/(loss) (c)

Income/(loss) from continuing operations

Discontinued operations—net of tax

Net income/(loss) before allocation to noncontrolling interests

Less: Net income attributable to noncontrolling interests

Net income/(loss) attributable to Pfizer Inc.

Earnings/(loss) per common share—basic:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders

Earnings/(loss) per common share—diluted:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders

  $

  $

  $

  $

  $

  $

12,906   $
8,736
43
4,127
556
3,571

(1)
3,570
9
3,561   $

0.60   $
—
0.60   $

0.59   $
—
0.59   $

13,466   $
8,895
44
4,527
648
3,879
—
3,879
7
3,872   $

0.66   $
—
0.66   $

0.65   $
—
0.65   $

13,298   $
9,035
85
4,177
66
4,111
11
4,122
8
4,114   $

0.70   $
—
0.70   $

0.69   $
—
0.69   $

13,976

14,051

872

(946)

(563)

(383)

—

(383)

11

(394)

(0.07)

—

(0.07)

(0.07)

—

(0.07)

(a)

(b)

(c)

The fourth quarter of 2018 historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The fourth quarter of 2018 includes $3.1
billion in certain asset impairments recorded in Other (income)/deductions––net . For additional information, see Notes to Consolidated Financial Statements— Note 4 . Other (Income)/Deductions—Net .
In the fourth quarter of 2018, includes restructuring charges that were primarily related to employee termination costs and asset write downs. The employee termination costs are associated with our improvements
to operational effectiveness as part of the realignment of our organizational structure effective at the beginning of 2019. For additional information, see Notes to Consolidated Financial Statements— Note 3.
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives .
The third and fourth quarters of 2018 reflect the impact of t he TCJA on the Provision/(benefit) for taxes on income . For additional information, see Notes to Consolidated Financial Statements— Note 5A. Tax
Matters: Taxes on Income from Continuing Operations .

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the
year.

2018 Financial Report

143

Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies

(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)

First (a)

Second

Third

Fourth

Quarter

2017

Revenues

Costs and expenses (b)

Restructuring charges and certain acquisition-related costs

Income from continuing operations before provision/(benefit) for taxes on income

Provision/(benefit) for taxes on income (c)

Income from continuing operations

Discontinued operations—net of tax

Net income before allocation to noncontrolling interests

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

Earnings per common share—basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income attributable to Pfizer Inc. common shareholders

Earnings per common share—diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income attributable to Pfizer Inc. common shareholders

  $

  $

  $

  $

  $

  $

12,779   $
8,744
84
3,951
821
3,130
—
3,130
9
3,121   $

0.52   $
—
0.52   $

0.51   $
—
0.51   $

12,896   $
9,011
70
3,815
739
3,077
2
3,078
5
3,073   $

0.52   $
—
0.52   $

0.51   $
—
0.51   $

13,168   $
9,469
114
3,585
727
2,858
—
2,858
18
2,840   $

0.48   $
—
0.48   $

0.47   $
—
0.47   $

13,703

12,665

84

953

(11,335)

12,289

1

12,290

15

12,274

2.06

—

2.06

2.02

—

2.02

(a)

(b)

In accordance with our international reporting period, our consolidated statement of income for the first quarter of 2017 reflects approximately two months of the small molecule anti-infectives business acquired
from Astra Zeneca.
The fourth quarter of 2017 historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The fourth quarter of 2017 includes a net
loss on early retirement of debt of $999 million , inclusive of the related termination of cross currency swaps.

(c)  The fourth quarter of 2017 reflects the impact of the TCJA. For additional information, see Notes to Consolidated Financial Statements — Note 5A. Tax Matters: Taxes on Income from Continuing Operations .

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the
year.

144

2018 Financial Report

Financial Summary
Pfizer Inc. and Subsidiary Companies

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

Revenues

Income from continuing operations

Total assets

Long-term obligations (b)

Earnings per common share—basic

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income attributable to Pfizer Inc. common shareholders (c)

Earnings per common share—diluted

Income from continuing operations attributable to Pfizer Inc. common shareholders

Discontinued operations—net of tax

Net income attributable to Pfizer Inc. common shareholders

Cash dividends declared per common share
(a)

Year Ended/As of December 31, (a)

2018
53,647   $
11,179
159,422
63,807

2017
52,546   $
21,353
171,797
69,714

2016
52,824   $
7,229
171,615
80,660

2015
48,851   $
6,975
167,381
72,985

2014

49,605

9,119

167,473

74,265

1.90   $
—
1.90   $

1.86   $
—
1.87   $
1.38   $

3.57   $
—
3.57   $

3.52   $
—
3.52   $
1.30   $

1.18   $
—
1.18   $

1.17   $
—
1.17   $
1.22   $

1.13   $
—
1.13   $

1.11   $
—
1.11   $
1.14   $

1.43

0.01

1.44

1.41

0.01

1.42

1.06

  $

  $

  $

  $

  $
  $

2017 reflects the February 3, 2017 sale of HIS to ICU Medical. 2017 and 2018 reflect the acquisition of the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business,
primarily outside of the U.S. on December 22, 2016. 2016, 2017 and 2018 reflect the acquisition of Medivation on September 28, 2016 and the acquisition of Anacor on June 24, 2016, and 2015, 2016, 2017 and
2018 reflect the acquisition of Hospira on September 3, 2015.

(b)   Defined as Long-term debt, Pension benefit obligations, net, Postretirement benefit obligations, net, Noncurrent deferred tax liabilities, Other taxes payable and Other noncurrent liabilities.
(c)

2018 and 2017 reflect the impact of the TCJA on the Provision/(benefit) for taxes on income . For additional information, see Notes to Consolidated Financial Statements — Note 5A. Tax Matters: Taxes on
Income from Continuing Operations.

2018 Financial Report

145

Peer Group Performance Graph
Pfizer Inc. and Subsidiary Companies

The following graph assumes a $100 investment on December 31, 2013, and reinvestment of all dividends, in each of the Company’s Common Stock, the S&P 500 Index, and
a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: Abbott Laboratories (for 2012 only), AbbVie Inc. (beginning in 2013),
Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly & Co., GlaxoSmithKline plc, Johnson & Johnson, Merck and Co., Inc., Novartis AG, Roche Holding AG
and Sanofi SA.

Five Year Performance

PFIZER

PEER GROUP
S&P 500

2013

$100.0

$100.0

$100.0

2014

$105.3

$112.4

$113.7

2015

$112.8

$114.1

$115.2

2016

$117.8

$114.7

$129.0

2017

$136.4

$134.3

$157.2

2018

$170.3

$145.4

$150.3

146

2018 Financial Report

The following is a list of subsidiaries of the Company as of December 31, 2018, omitting some subsidiaries which, considered in the aggregate,
would not constitute a significant subsidiary.

EXHIBIT 21

Company Name

Agouron Pharmaceuticals, LLC

AH Robins LLC

AHP Holdings B.V.

AHP Manufacturing B.V.

Alacer Corp.

Alpharma Pharmaceuticals LLC

American Food Industries LLC

Anacor Pharmaceuticals, Inc.

Ayerst-Wyeth Pharmaceuticals LLC

Bamboo Therapeutics, Inc.

Bioren, LLC

Blue Whale Re Ltd.

C.P. Pharmaceuticals International C.V.

CICL Corporation

COC I Corporation

Coley Pharmaceutical GmbH

Coley Pharmaceutical Group, Inc.

Continental Pharma, Inc.

Covx Technologies Ireland Limited

Cyanamid de Argentina S.A.

Cyanamid de Colombia, S.A.

Distribuidora Mercantil Centro Americana, S.A.

Encysive Pharmaceuticals Inc.

Excaliard Pharmaceuticals, Inc.

Farminova Produtos Farmaceuticos de Inovacao, Lda.

Ferrosan A/S

Ferrosan International A/S

Ferrosan S.R.L.

FoldRx Pharmaceuticals, Inc.

Fort Dodge Manufatura Ltda.

G. D. Searle & Co. Limited

G. D. Searle International Capital LLC

G. D. Searle LLC

Genetics Institute, LLC

GenTrac, Inc.

GI Europe, Inc.

GI Japan, Inc.

Greenstone LLC

HBAF Ltd.

Where Incorporated or Organized

California

Delaware

Netherlands

Netherlands

California

Delaware

Delaware

Delaware

Delaware

Delaware

Delaware

Vermont

Netherlands

Delaware

Delaware

Germany

Delaware

Belgium

Ireland

Delaware

Delaware

Delaware

Delaware

Delaware

Portugal

Denmark

Denmark

Romania

Delaware

Brazil

United Kingdom

Delaware

Delaware

Delaware

Wisconsin

Delaware

Delaware

Delaware

Bahamas

1

Hospira (China) Enterprise Management Co. Ltd.

People’s Republic of China

Hospira Adelaide Pty Ltd

Hospira Australia Pty Ltd

Hospira Benelux BVBA

Hospira Enterprises B.V.

Hospira France SAS

Hospira Holdings (S.A.) Pty Ltd

Hospira Ireland Holdings Unlimited Company

Hospira Ireland Sales Limited

Hospira Limited

Hospira NZ Limited

Hospira Philippines, Inc.

Hospira Pte. Ltd.

Hospira Pty Limited

Hospira Puerto Rico, LLC

Hospira Singapore Pte Ltd

Hospira UK Limited

Hospira Worldwide, LLC

Hospira Zagreb d.o.o.

Hospira, Inc.

InnoPharma, Inc.

International Affiliated Corporation LLC

JMI-Daniels Pharmaceuticals, Inc.

John Wyeth & Brother Limited

Kiinteistö oy Espoon Pellavaniementie 14

King Pharmaceuticals Holdings LLC

King Pharmaceuticals LLC

King Pharmaceuticals Research and Development, LLC

Korea Pharma Holding Company Limited

Laboratoires Pfizer, S.A.

Laboratorios Parke Davis, S.L.

Laboratorios Pfizer Ltda.

Laboratórios Pfizer, Lda.

Laboratorios Wyeth LLC

Laboratorios Wyeth S.A.

Mayne Pharma IP Holdings (Euro) Pty Ltd

Medivation Field Solutions LLC

Medivation LLC

Medivation Neurology LLC

Medivation Prostate Therapeutics LLC

Medivation Services LLC

Medivation Technologies LLC

Meridian Medical Technologies, Inc.

Monarch Pharmaceuticals, LLC

MTG Divestitures LLC

Neusentis Limited

Australia

Australia

Belgium

Netherlands

France

Australia

Ireland

Ireland

Hong Kong

New Zealand

Philippines

Singapore

Australia

Delaware

Singapore

United Kingdom

Delaware

Croatia

Delaware

Delaware

Delaware

Florida

United Kingdom

Finland

Delaware

Delaware

Delaware

Hong Kong

Morocco

Spain

Brazil

Portugal

Pennsylvania

Venezuela

Australia

Delaware

Delaware

Delaware

Delaware

Delaware

Delaware

Delaware

Tennessee

Delaware

United Kingdom

2

PAH USA IN8 LLC

Parke Davis Limited

Parke, Davis & Company LLC

Parkedale Pharmaceuticals, Inc.

P-D Co., LLC

Peak Enterprises LLC

PF Asia Manufacturing B.V.

PF Consumer Healthcare 1 LLC

PF Consumer Healthcare B.V.

PF Consumer Healthcare Canada ULC

PF Consumer Healthcare New Zealand Limited

PF Healthcare Australia Pty Ltd

PF OFG (Thailand) Limited

PF OFG Australia Pty Ltd

PF OFG HELLAS L.T.D.

PF OFG Hong Kong Limited

PF OFG New Zealand ULC

PF OFG South Korea 1 B.V.

PF PR Holdings C.V.

PF PRISM C.V.

PF PRISM Holdings S.a.r.l.

PF Prism S.á.r.l.

PFE Holdings G.K.

PFE Pfizer Holdings 1 LLC

PFE PHAC Holdings 1 LLC

PFE Wyeth Holdings LLC

PFE Wyeth-Ayerst (Asia) LLC

Pfizer

Delaware

Hong Kong

Michigan

Michigan

Delaware

Delaware

Netherlands

Delaware

Netherlands

Canada

New Zealand

Australia

Thailand

Australia

Greece

Hong Kong

New Zealand

Netherlands

Netherlands

Netherlands

Luxembourg

Luxembourg

Japan

Delaware

Delaware

Delaware

Delaware

France

Pfizer (China) Research and Development Co. Ltd.

People’s Republic of China

Pfizer (Malaysia) Sdn Bhd

Pfizer (Perth) Pty Ltd

Pfizer (Thailand) Limited

Malaysia

Australia

Thailand

Pfizer (Wuhan) Research and Development Co. Ltd.

People’s Republic of China

Pfizer AB

Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products & Chemicals
S.A.E.

Pfizer Afrique de L'Ouest

Pfizer AG

Pfizer Anti-Infectives AB

Pfizer ApS

Pfizer AS

Pfizer Asia Manufacturing Pte. Ltd.

Pfizer Asia Pacific Pte Ltd.

Pfizer Atlantic Holdings S.a.r.l.

Pfizer Australia Holdings B.V.

Pfizer Australia Holdings Pty Limited

Sweden

Egypt

Senegal

Switzerland

Sweden

Denmark

Norway

Singapore

Singapore

Luxembourg

Netherlands

Australia

3

Pfizer Australia Investments Pty Ltd

Pfizer Australia Pty Ltd

Pfizer B.V.

Pfizer Baltic Holdings B.V.

Pfizer Biofarmacêutica, Sociedade Unipessoal Lda

Pfizer Biologics (Hangzhou) Co. Ltd

Pfizer Biologics Ireland Holdings Limited

Pfizer Biotech Corporation

Pfizer Bolivia S.A.

Pfizer Brazil Holding SARL

Pfizer Canada ULC

Pfizer CentreSource Asia Pacific Pte. Ltd.

Pfizer Chile S.A.

Pfizer Cia. Ltda.

Pfizer Colombia Spinco I LLC

Pfizer Commercial Holdings Coöperatief U.A.

Pfizer Commercial Holdings TRAE Kft.

Pfizer Commercial TRAE Trading Kft.

Pfizer Consumer Healthcare AB

Pfizer Consumer Healthcare GmbH

Pfizer Consumer Healthcare Limited

Pfizer Consumer Manufacturing Italy S.r.l.

Pfizer Corporation Austria Gesellschaft m.b.H.

Pfizer Corporation Hong Kong Limited

Pfizer Corporation S. de R.L.

Pfizer Croatia d.o.o.

Pfizer Deutschland GmbH

Pfizer Development LP

Pfizer Development Services (UK) Limited

Pfizer Domestic Ventures Limited

Pfizer Dominicana, S.R.L

Pfizer East India B.V.

Pfizer Eastern Investments B.V.

Pfizer Egypt S.A.E.

Pfizer Enterprise Holdings B.V.

Pfizer Enterprises LLC

Pfizer Enterprises SARL

Pfizer ESP Pty. Ltd.

Pfizer Europe Finance B.V.

Pfizer Export B.V.

Pfizer Export Company

Pfizer Export Holding Company B.V

Australia

Australia

Netherlands

Netherlands

Portugal

People’s Republic of China

Ireland

Taiwan

Bolivia

Luxembourg

Canada

Singapore

Chile

Ecuador

Pennsylvania

Netherlands

Hungary

Hungary

Sweden

Germany

United Kingdom

Italy

Austria

Hong Kong

Panama

Croatia

Germany

United Kingdom

United Kingdom

Jersey

Dominican Republic

Netherlands

Netherlands

Egypt

Netherlands

Delaware

Luxembourg

Australia

Netherlands

Netherlands

Ireland

Netherlands

Pfizer Finance Share Service (Dalian) Co., Ltd.

People’s Republic of China

Pfizer Financial Services

Pfizer France International Investments

Pfizer Free Zone Panama, S. de R.L.

Belgium

France

Panama

4

Pfizer GEP, S.L.

Pfizer Global Holdings B.V.

Pfizer Global Supply Japan Inc.

Pfizer Global Trading

Pfizer Group Luxembourg SARL

Pfizer Gulf FZ-LLC

Pfizer H.C.P. Corporation

Pfizer Health AB

Pfizer Health Solutions Inc.

Pfizer Healthcare India Private Limited

Pfizer Healthcare Ireland

Pfizer Hellas, A.E.

Pfizer Himalaya Holdings Coöperatief U.A.

Pfizer Holding France

Pfizer Holding Ventures

Pfizer Holdings Corporation

Pfizer Holdings Europe Unlimited Company

Pfizer Holdings G.K.

Pfizer Holdings International Corporation

Pfizer Holdings International Luxembourg (PHIL) SARL

Pfizer Hungary Holdings TRAE Kft.

Pfizer Ilaclari Limited Sirketi

Pfizer Innovations AB

Pfizer Innovations LLC

Pfizer Innovative Supply Point International BVBA

Pfizer International LLC

Pfizer International Markets B.V.

Pfizer International Operations

Pfizer International S. de R.L.

Pfizer International Trading (Shanghai) Limited

Pfizer Investment Capital Unlimited Company

Pfizer Investment Co. Ltd.

Pfizer Investment Holdings S.a.r.l.

Pfizer Ireland Investments Limited

Pfizer Ireland PFE Holding 1 LLC

Pfizer Ireland Pharmaceuticals

Pfizer Ireland Ventures Unlimited Company

Pfizer Italia S.r.l.

Pfizer Italy Group Holding S.r.l.

Pfizer Japan Inc.

Pfizer Laboratories (Pty) Limited

Pfizer Laboratories Limited

Pfizer Laboratories PFE (Pty) Ltd

Pfizer Leasing Ireland Limited

Pfizer Leasing UK Limited

Spain

Netherlands

Japan

Ireland

Luxembourg

United Arab Emirates

New York

Sweden

Delaware

India

Ireland

Greece

Netherlands

France

Ireland

Delaware

Ireland

Japan

Delaware

Luxembourg

Hungary

Turkey

Sweden

Russia

Belgium

New York

Netherlands

France

Panama

People’s Republic of China

Ireland

People’s Republic of China

Luxembourg

Ireland

Delaware

Ireland

Ireland

Italy

Italy

Japan

South Africa

Kenya

South Africa

Ireland

United Kingdom

5

Pfizer Limited

Pfizer Limited

Pfizer Limited

Pfizer LLC

Pfizer Luxco Holdings SARL

Pfizer Luxembourg Global Holdings S.à r.l.

Pfizer Luxembourg SARL

Pfizer Manufacturing Austria G.m.b.H.

Pfizer Manufacturing Belgium N.V.

Pfizer Manufacturing Deutschland GmbH

Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG

Pfizer Manufacturing Holdings LLC

Pfizer Manufacturing Ireland Unlimited Company

Pfizer Manufacturing LLC

Pfizer Manufacturing Services

Pfizer MAP Holding, Inc.

Pfizer Medical Technology Group (Belgium) N.V.

Pfizer Medicamentos Genericos e Participacoes Ltda.

Pfizer Mexico Luxco SARL

Pfizer Mexico, S.A. de C.V.

Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals S.A.E.

Pfizer New Zealand Limited

Pfizer Norge AS

Pfizer North American Holdings Inc.

Pfizer OFG Germany GmbH

Pfizer OTC B.V.

Pfizer Overseas LLC

Pfizer Oy

Pfizer Pakistan Limited

Pfizer Parke Davis (Thailand) Ltd.

Pfizer Parke Davis Sdn. Bhd.

Pfizer PFE ApS

Pfizer PFE AsiaPac Holding B.V.

Pfizer PFE Australia Holding B.V.

Pfizer PFE Australia Pty Ltd

Pfizer PFE B.V.

Pfizer PFE Baltic Holdings B.V.

Pfizer PFE Belgium SPRL

Pfizer PFE Brazil Holding S.à r.l.

Pfizer PFE CIA. Ltda.

Pfizer PFE Colombia Holding LLC

Pfizer PFE Colombia S.A.S

Pfizer PFE Croatia Holding B.V.

Pfizer PFE Eastern Investments B.V.

6

India

Taiwan

United Kingdom

Russia

Luxembourg

Luxembourg

Luxembourg

Austria

Belgium

Germany

Germany

Delaware

Ireland

Delaware

Ireland

Delaware

Belgium

Brazil

Luxembourg

Mexico

Egypt

New Zealand

Norway

Delaware

Germany

Netherlands

Delaware

Finland

Pakistan

Thailand

Malaysia

Denmark

Netherlands

Netherlands

Australia

Netherlands

Netherlands

Belgium

Luxembourg

Ecuador

Delaware

Colombia

Netherlands

Netherlands

Pfizer PFE Finland Oy

Pfizer PFE France

Pfizer PFE Global Holdings B.V.

Pfizer PFE İlaçları Anonim Şirketi

Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V.

Pfizer PFE Limited

Pfizer PFE Luxembourg S.à r.l.

Pfizer PFE Mexico Holding 3 LLC

Pfizer PFE New Zealand Holding B.V.

Pfizer PFE Norway Holding S.à r.l.

Pfizer PFE Peru Holding LLC

Pfizer PFE Peru S.R.L.

Pfizer PFE Pharmaceuticals Israel Holding LLC

Pfizer PFE Pharmaceuticals Israel Ltd.

Pfizer PFE PILSA Holdco S.à r.l.

Pfizer PFE Private Limited

Pfizer PFE Service Company Holding B.V.

Pfizer PFE Singapore Holding B.V.

Pfizer PFE Singapore Pte. Ltd.

Pfizer PFE Spain B.V.

Pfizer PFE Spain Holding, S.L.

Pfizer PFE Switzerland GmbH

Pfizer PFE Turkey Holding 1 B.V.

Pfizer PFE Turkey Holding 2 B.V.

Pfizer PFE UK Holding 4 LP

Pfizer PFE US Holdings 4 LLC

Pfizer PFE US Holdings 5 LLC

Pfizer PFE, spol. s r.o.

Pfizer Pharm Algerie

Pfizer Pharma GmbH

Pfizer Pharma PFE GmbH

Finland

France

Netherlands

Turkey

Netherlands

Taiwan

Luxembourg

Delaware

Netherlands

Luxembourg

Delaware

Peru

Delaware

Israel

Luxembourg

Singapore

Netherlands

Netherlands

Singapore

Netherlands

Spain

Switzerland

Netherlands

Netherlands

United Kingdom

Delaware

Delaware

Czech Republic

Algeria

Germany

Germany

Pfizer Pharmaceutical (Wuxi) Co., Ltd.

Pfizer Pharmaceutical Enterprises Global Management Co.,Ltd.

People’s Republic of China

People’s Republic of China

Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer
LLC)

Hungary

Pfizer Pharmaceuticals Global B.V.

Pfizer Pharmaceuticals Israel Ltd.

Pfizer Pharmaceuticals Korea Limited

Pfizer Pharmaceuticals LLC

Pfizer Pharmaceuticals Ltd.

Pfizer Pharmaceuticals Tunisie Sarl

Pfizer Pigments Inc.

Pfizer Polska Sp. z.o.o.

Pfizer Private Limited

Pfizer Production LLC

Netherlands

Israel

Republic of Korea

Delaware

People’s Republic of China

Tunisia

Delaware

Poland

Singapore

Delaware

7

Pfizer Products Inc.

Pfizer Products India Private Limited

Pfizer R&D Holding B.V.

Pfizer R&D Japan G.K.

Pfizer R&D UK Limited

Pfizer Research (NC), Inc.

Pfizer Romania SRL

Pfizer S.A.

Pfizer S.A. (Belgium)

Pfizer S.A.S.

Pfizer S.G.P.S. Lda.

Pfizer S.R.L.

Pfizer S.r.l.

Pfizer Saidal Manufacturing

Pfizer Santé Familiale

Pfizer Saudi Limited

Pfizer Seiyaku K.K.

Pfizer Service Company BVBA

Pfizer Service Company Ireland Unlimited Company

Pfizer Services 1

Pfizer Services LLC

Pfizer Shared Services Unlimited Company

Pfizer Shareholdings Intermediate SARL

Pfizer Spain Holdings B.V.

Pfizer Specialties Limited

Pfizer SRB d.o.o.

Pfizer Strategic Investment Holdings LLC

Pfizer Trading Polska sp.z.o.o.

Pfizer TRAE Holdings Kft.

Pfizer Transactions LLC

Pfizer Tunisie SA

Pfizer Vaccines LLC

Pfizer Venezuela, S.A.

Pfizer Venture Investments LLC

Pfizer Ventures (US) LLC

Pfizer Ventures LLC

Pfizer Worldwide Services Unlimited Company

Pfizer Zona Franca, S.A.

Pfizer, Inc.

Pfizer, S.A.

Pfizer, S.A. de C.V.

Pfizer, S.L.

Pfizer, spol. s r.o.

Pharmacia & Upjohn Company LLC

Pharmacia & Upjohn LLC

Pharmacia & Upjohn, S.A. de C.V.

Connecticut

India

Netherlands

Japan

United Kingdom

Delaware

Romania

Peru

Belgium

Colombia

Portugal

Argentina

Italy

Algeria

France

Saudi Arabia

Japan

Belgium

Ireland

France

Delaware

Ireland

Luxembourg

Netherlands

Nigeria

Serbia

Delaware

Poland

Hungary

Delaware

Tunisia

Delaware

Venezuela

Delaware

Delaware

Delaware

Ireland

Costa Rica

Philippines

Costa Rica

Mexico

Spain

Czech Republic

Delaware

Delaware

Mexico

8

Pharmacia Brasil Ltda.

Pharmacia Hepar LLC

Pharmacia Holding AB

Pharmacia Inter-American LLC

Pharmacia International B.V.

Pharmacia Limited

Pharmacia LLC

PHILCO Holdings S.à r.l.

PHIVCO Corp.

PHIVCO Holdco S.à r.l.

PHIVCO Luxembourg S.à r.l.

PIMB OFG Spain Holding, S.L.

PT. Pfizer Indonesia

Renrall LLC

Rinat Neuroscience Corp.

Roerig S.A.

Searle Laboratorios, Lda.

Servicios P&U, S. de R.L. de C.V.

Shiley LLC

Sinergis Farma-Produtos Farmaceuticos, Lda.

Solinor LLC

Sugen LLC

Tabor LLC

Treerly Health Co., Ltd

Upjohn Global Holdings B.V.

Upjohn Laboratorios Lda.

Upjohn South Africa (Pty) Ltd.

Upjohn US 1 LLC

Upjohn US 2 LLC

Vesterålens Naturprodukter A/S

Vesterålens Naturprodukter AB

Vesterålens Naturprodukter AS

Vesterålens Naturprodukter OY

Vicuron Holdings LLC

Warner Lambert del Uruguay S.A.

Warner-Lambert Company AG

Warner-Lambert Company LLC

Whitehall International Inc.

W-L LLC

Wyeth (Asia) Limited

Wyeth (Thailand) Ltd.

Wyeth AB

Wyeth Australia Pty Limited

Wyeth Ayerst Inc.

Wyeth Ayerst S.à r.l.

Brazil

Delaware

Sweden

Pennsylvania

Netherlands

United Kingdom

Delaware

Luxembourg

Delaware

Luxembourg

Luxembourg

Spain

Indonesia

Wyoming

Delaware

Chile

Portugal

Mexico

California

Portugal

Delaware

Delaware

Delaware

People’s Republic of China

Netherlands

Portugal

South Africa

Delaware

Delaware

Denmark

Sweden

Norway

Finland

Delaware

Uruguay

Switzerland

Delaware

New York

Delaware

Delaware

Thailand

Sweden

Australia

Delaware

Luxembourg

9

Wyeth Consumer Healthcare LLC

Wyeth Europa Limited

Wyeth Farma, S.A.

Wyeth Holdings LLC

Wyeth Industria Farmaceutica Ltda.

Wyeth KFT.

Wyeth Lederle S.r.l.

Wyeth LLC

Wyeth Pakistan Limited

Wyeth Pharmaceutical Co., Ltd.

Wyeth Pharmaceuticals Company

Wyeth Pharmaceuticals FZ-LLC

Wyeth Pharmaceuticals India Private Limited

Wyeth Pharmaceuticals LLC

Wyeth Puerto Rico, Inc.

Wyeth Subsidiary Illinois Corporation

Wyeth Whitehall Export GmbH

Wyeth-Ayerst (Asia) Limited

Wyeth-Ayerst International LLC

Wyeth-Ayerst Promotions Limited

Pennsylvania

United Kingdom

Spain

Maine

Brazil

Hungary

Italy

Delaware

Pakistan

People’s Republic of China

Puerto Rico

United Arab Emirates

India

Delaware

Puerto Rico

Illinois

Austria

Delaware

Delaware

Delaware

10

Consent of Independent Registered Public Accounting Firm

EXHIBIT 23

To the Board of Directors and the Shareholders of Pfizer Inc.:

We consent to the incorporation by reference in this 2018 Annual Report on Form 10-K of Pfizer Inc. of our reports dated February 28, 2019 , with respect to the consolidated
balance sheets of Pfizer Inc. and Subsidiary Companies as of December 31, 2018 and 2017 , and the related consolidated statements of income, comprehensive income,
equity and cash flows for each of the years in the three-year period ended December 31, 2018 , and the effectiveness of internal control over financial reporting as of
December 31, 2018 , which reports appear in the 2018 Annual Report on Form 10-K of Pfizer Inc.

We also consent to the incorporation by reference of our reports in the following Registration Statements:

-Form S-8 dated October 27, 1983 (File No. 2-87473),
-Form S-8 dated March 22, 1990 (File No. 33-34139),
-Form S-8 dated January 24, 1991 (File No. 33-38708),
-Form S-8 dated November 18, 1991 (File No. 33-44053),
-Form S-8 dated May 27, 1993 (File No. 33-49631),
-Form S-8 dated May 19, 1994 (File No. 33-53713),
-Form S-8 dated October 5, 1994 (File No. 33-55771),
-Form S-8 dated December 20, 1994 (File No. 33-56979),
-Form S-8 dated March 29, 1996 (File No. 333-02061),
-Form S-8 dated September 25, 1997 (File No. 333-36371),
-Form S-8 dated June 19, 2000 (File No. 333-39606),
-Form S-8 dated April 27, 2001 (File No. 333-59660),
-Form S-8 dated April 16, 2003 (File No. 333-104582),
-Form S-8 dated November 18, 2003 (File No. 333-110571),
-Form S-8 dated December 18, 2003 (File No. 333-111333),
-Form S-8 dated April 26, 2004 (File No. 333-114852),
-Form S-8 dated March 1, 2007 (File No. 333-140987),
-Form S-4 dated March 27, 2009 (File No. 333-158237),
-Form S-8 dated October 16, 2009 (File No. 333-162519),
-Form S-8 dated October 16, 2009 (File No. 333-162520),
-Form S-8 dated October 16, 2009 (File No. 333-162521),
-Form S-8 dated March 1, 2010 (File No. 333-165121),
-Form S-8 dated March 2, 2015 (File No. 333-202437),
-Form S-4 dated September 3, 2015 (File No. 333-206758), and
-Form S-3 ASR dated February 26, 2018 (File No. 333-223221).

/s/ KPMG LLP

New York, New York February 28, 2019

Certification by the Chief Executive Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.1

I, Albert Bourla, certify that:

1.

2.

I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the

statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to

ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our

supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the

effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent

fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control

over financial reporting.

Date:  February 28, 2019

/s/ ALBERT BOURLA

Albert Bourla

Chief Executive Officer

Certification by the Chief Financial Officer Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002

EXHIBIT 31.2

I, Frank A. D'Amelio, certify that:

1.

2.

I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the

statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the

financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in

Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to

ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our

supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the

effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent

fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the

registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably

likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control

over financial reporting.

Date:  February 28, 2019

/s/ FRANK A. D'AMELIO

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President,
Business Operations and Global Supply

Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for
the year ended December 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934,
and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.

EXHIBIT 32.1

/s/ ALBERT BOURLA

Albert Bourla

Chief Executive Officer

February 28, 2019

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the

extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except to the extent that the Company specifically incorporates it by reference.

Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer
Inc. for the year ended December 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act
of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.

EXHIBIT 32.2

/s/ FRANK A. D'AMELIO

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President,
Business Operations and Global Supply

February 28, 2019

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the

extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except to the extent that the Company specifically incorporates it by reference.

